<SEC-DOCUMENT>0000950170-25-027714.txt : 20250226
<SEC-HEADER>0000950170-25-027714.hdr.sgml : 20250226
<ACCEPTANCE-DATETIME>20250226160535
ACCESSION NUMBER:		0000950170-25-027714
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250226
DATE AS OF CHANGE:		20250226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001369568
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33057
		FILM NUMBER:		25669962

	BUSINESS ADDRESS:	
		STREET 1:		355 ALHAMBRA CIRCLE
		STREET 2:		SUITE 801
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134
		BUSINESS PHONE:		(305) 529-2522

	MAIL ADDRESS:	
		STREET 1:		355 ALHAMBRA CIRCLE
		STREET 2:		SUITE 801
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST PHARMACEUTICAL PARTNERS, INC.
		DATE OF NAME CHANGE:	20110215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Catalyst Pharmaceutical Partners, Inc.
		DATE OF NAME CHANGE:	20060719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cprx-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-26T09:43:58.5025+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cprx="http://catalystpharma.com/20241231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6f442802-8468-425d-9746-5b60fb75bf18" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71">FY</ix:nonNumeric><ix:nonNumeric id="F_976ffb6e-1622-4f8b-8b42-d45554c6fd59" name="dei:AmendmentFlag" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_0ac0f068-c902-46ee-b0dd-ac58c27ab466" name="dei:EntityCentralIndexKey" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71">0001369568</ix:nonNumeric><ix:nonFraction id="F_b3227f7e-05ef-4816-b5f7-7b8eae6c5421" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_aad5c8a8-d3cc-486c-8887-82ff44fbcbeb" name="us-gaap:CommitmentsAndContingencies" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_af1f8375-788a-4903-85b9-db67fcf6e271" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_509d007d-642a-4644-91a4-d006a95ed40e" format="ixt-sec:durwordsen">three year</ix:nonNumeric><ix:nonNumeric id="F_af087444-9da2-4e54-b835-1802f923ce72" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_61b5027c-b632-4929-9a07-a51a4a172615" format="ixt-sec:durwordsen">five year</ix:nonNumeric><ix:nonNumeric id="F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_22ae25b7-7b9c-4c4c-babd-143090383ea0" format="ixt-sec:durwordsen">five year</ix:nonNumeric><ix:nonNumeric id="F_fc95014e-239d-4684-9334-a50e46b93483" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71">http://catalystpharma.com/20241231#PresidentAndChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_6d7694a8-4fef-4d34-ad3f-97f73cebc1d8" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1">6 years</ix:nonNumeric><ix:nonNumeric id="F_e02f321f-c2da-4a31-b171-0bb073d6f3b4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_af9bf51b-92c5-4e0c-beca-6ed527c2962a" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cprx-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_83103e7b-d556-4ade-a0c3-b0b5be918a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_890414d1-43e4-4730-a09e-a3e88bcc0421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a4314de-6143-4019-b113-f6c338cc4873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ad02f07-3470-4aaa-a47f-2bdce2375aba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b7f00ee-4559-46ef-9b02-67895013d0e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8be25042-7914-4b7c-bafc-23e4b7ab7fdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dddeb9f-3b04-4e8a-baf5-72e1456394e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91a9fa46-f095-4873-a0df-54c2ea98d1e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_933bcf2c-5622-4455-af40-79b259c772ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_947bd494-b761-4eb9-88a5-277a61b73354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96caeb09-9772-4554-9b52-38246d8f8c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9825031d-05c7-4f08-b508-c1c43d16f3d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98bd37e3-3099-4a59-86c5-e3462fe02fee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99496368-5345-4bb0-94b5-aed58a22c466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a4f3e35-a536-4dd5-b66f-0ae66fd2a87b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a567032-9b5a-41d1-86f5-591b8c5517a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b391f02-52d4-4024-84bb-8903cbcabfc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b84b239-460f-4343-8a55-dd9c8d160502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c7d03d5-7081-4449-bea0-40e589ce6ecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9deb4c05-1297-4d5e-8b6d-c26fba201c41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9df3359d-d215-4d6a-884d-65563f285107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e517535-208d-4e79-a8f2-94a3fbd26bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e6f3d23-def3-4cda-8382-44bd50588fd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0a9bef3-9a5a-46af-831b-722f42e564bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3c97892-bfc1-4d8c-9b02-7eb288071f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a45b1de6-43f0-4754-959c-bc894267db20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4930a59-5dbe-484a-931a-7075307c98cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5b8f9f5-4c42-49ac-89f4-7c6e0c290f71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6b7ed37-7935-4f83-a2ae-608865c7f8d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8aa9d09-9937-4de9-a389-d7a12cd901f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a964cbf4-04fb-4e05-a570-316b7877d00d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab102545-8c8a-4aa6-9552-8b80e35cb031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanThreeHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abbabfa3-211e-489a-bee1-41937cf8efae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af98f620-db18-4836-9d81-b2bf497b9325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:DydoPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0a378e6-1a77-4f91-81cb-13d89217dba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2fd37e7-0f2e-441c-ae7f-719ef52d29e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b48f2bea-3319-4b24-87f1-db81866524fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4f3694a-ca49-4caa-8b5c-bca9ff9a1642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63f6e84-f32c-44aa-b9da-315cc85f2d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:DydoPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc74c57a-97e8-4b7a-bee2-532bf391aa3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc793338-3e30-4b0a-b679-9536be9b17ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd18a35e-b683-418d-b5ad-979c716ec315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdd6ca59-0c27-40ea-814d-e69687c2f5b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be3b877f-8d5f-446a-ab53-63009d18c5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bffaa182-9732-421b-b5cc-2629dd407967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:PeriodAxis">cprx:CalendarYears2022Through2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0079872-347c-4ab4-bd66-e2c441bd5d42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2025-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0d78ce3-51fb-44f9-a661-e786541f4b0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c24bf7e7-9d65-4eec-b363-d92095897f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2b04665-c428-4f48-8bee-660378e215e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2c87252-f283-4c4a-9b97-9a9c92725e3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c653309b-c27f-47f4-9795-b45c969d5d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c664d775-b622-4767-80ce-109ca450ed44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8936189-a149-4740-8ce1-e4ecdafa4139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cabcf3fa-e7d3-462b-b114-a34b026905f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_caf83f47-b1bf-467a-bf14-8cd9ab3cfde4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb022394-9f10-4ba9-855f-2cc8eb1d4d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb97f1c1-6e70-405d-9c80-c07e31f4c5c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc17f402-b8b7-4846-b664-e84632ab2a8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd25d34a-1eeb-48ca-b321-579fd363c809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cef50498-2b2c-43e6-ac01-77fde9e03dec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1584098-3050-4148-b6a0-12eb3a9b86ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1dac2fe-3c70-41e5-b9eb-fad2c7cd29cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1efe803-2f0e-4a4d-8b0c-2027e98829a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2c50c06-f8b1-40b0-b95b-16454488f954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2ced546-d65f-4ccc-95d8-be9078a46d22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5f3bd21-522f-4b08-969f-7e84f85ab2d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6459900-9ea0-4176-84e6-0b21db75fa6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d706713c-2b5e-4983-a2c1-f8ebab1d21ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForAdditionalIndicationsAndMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d78b7fcb-31d0-4120-ac5f-6e28497af893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d81a6259-f258-4b87-b123-cf96424bc887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9995f07-a56a-4e7e-b1c2-377bebd919d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da5c0563-d56c-4b30-a42d-4fb7860e6926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db403975-e67d-4d1a-af52-cc04a99bba23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc509cd1-e714-4010-a518-68d402172ccd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de1a8f83-1949-42be-9761-1b0a53274e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfce6660-3b34-46db-9ab4-b2300eecbdd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e16b26af-4376-4363-969d-d2fd34caf5aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e44cf128-2b29-4334-ac2f-c4e3a37536a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5da14d5-3dc8-44d1-b668-b38be2324fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e84d3106-1c0a-425f-b8b4-ab83374f00fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb917612-49d0-4a60-87c6-e1340f2ed65b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed261f48-f289-44e4-80ec-cbc85f5f3076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed459907-b1e1-4660-b88b-b7b539a955c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eecd310a-1107-4709-994f-14fd984abc2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef0ad7eb-05bd-41b1-a942-fd05ddc204bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0b3fb71-5f08-4d82-8502-0d005079016d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0c5744c-d1f7-4baa-a2c2-36915bc2d3a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f33c6eaf-ab74-4de4-8b0a-b6b2d34223af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f352d976-0ef8-419c-95b8-31914f4eefcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f627f358-1fdf-4532-a83a-c7e61bed5227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f77728b5-2d78-4209-bf9a-e8743612b59d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa4b3467-673b-4bda-8917-eb88309ffa19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa8bafc8-49aa-4a6c-ba98-092b8ee3ad87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa9e4eb0-730f-4a45-9ce1-7f135b523329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc37c6a7-8bf0-4bfc-b756-982c3bbeeb03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcfa5920-3506-4ee6-bfc9-fd2b01fa5229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd78caae-6fed-4925-9427-26b866495956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cprx:SharePurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02504fb4-79e0-4668-9486-8cb310c6d004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:RegulatoryFilingMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02c41411-07f0-46c6-b493-3634436dc399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_037898a6-6cb1-4b19-b864-b48e4e232b6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_044a6030-c57f-4067-b68d-6fdc516643ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanThreeHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_048b05a5-861c-4ff4-b542-3b7c319a55ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06627fb8-dcb2-4630-a05b-d4177e6132d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08f6bfdf-0d3b-44a6-a23d-b2f184873fd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09c65af8-c1b9-4e2d-9312-ab77475df623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b737ad0-5bd1-4089-bd14-fd61307aded2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cprx:SharePurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0be61b87-8b88-4b7a-bc46-ddfbf3fee93e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d01d582-ddf7-4fdd-a777-e6d1bb59c432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanTwoHundredFiftyMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11716830-bd78-4cfa-b354-d95373de3afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cprx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-09</xbrli:startDate><xbrli:endDate>2024-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_120e4417-63cf-4ab5-a1e1-efaa73f03a30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_146fabbe-e017-4017-80bb-681752315fa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19dd38c4-484b-49fc-ad75-95d8593b80cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-10-26</xbrli:startDate><xbrli:endDate>2012-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d817031-5908-4974-887a-064c703e2a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:CollaborationAgreementAxis">cprx:MilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ed73abf-99b0-4ef1-a69d-7dabbba940c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-11</xbrli:startDate><xbrli:endDate>2025-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d5ec19-7e43-465e-bda0-2f4bd1233423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cprx:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21ec373d-d899-4e13-9fd1-cf11cc5ed214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22ae25b7-7b9c-4c4c-babd-143090383ea0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cprx:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26534ab4-73c0-4cf4-8ab2-a0597988cf75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26f2b844-3e09-4694-a82c-6a12e2562d12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a5da979-3b61-43bc-853e-709593328300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:PeriodAxis">cprx:CalendarYear2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bf89954-bfc4-463d-a62f-52908e5d72f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2de88c77-0912-47da-84f1-785b1e0068b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e484187-8b25-4de9-82f0-c8be02c5a796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e53e13a-9358-4ded-8867-b51252e1f076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e59e5b9-1570-4e88-8150-2217fe0d9951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3052145c-1aab-4286-a4b8-bb9e3ef1c2a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_322cdd05-3fc8-4285-9f49-2a475c723c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33d5f74d-1547-4288-8459-e89cc8ac7180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_345c9a15-8b88-4b16-82c6-8b06540097af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35f0b978-6b4f-4932-a291-aa7d01e6b0d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36b51e6f-78fe-4d4b-8094-ef5504c510aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37c62b10-c734-4e61-bef2-3be60f99493b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-09</xbrli:startDate><xbrli:endDate>2024-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c4dde2c-c247-4018-8dec-79047db0d397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d31896d-8a0f-4011-b088-df7fcdb2cc51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForSantheraSalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e76c130-0386-4921-9a30-01e38dfe1755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_449ab8c2-98c9-4b7f-964e-75ca3f26863f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_452b8271-91ed-43ef-8673-b266c4b29987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_465c30df-be19-4455-9dcb-aaf2927ffe62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48c77464-b5f1-4ac6-8188-839ff214c273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c43ddad-6603-484e-8db2-d46bb3b245a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ebf61f1-ea81-43ad-81d4-337230acd6fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50617df4-5ae4-4936-8bfe-fce589850662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_509d007d-642a-4644-91a4-d006a95ed40e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_517f0446-4af8-4ed4-a041-177e495d6020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52411d29-db32-4171-9a6f-695291dabbf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5402459a-da02-42fa-9a9a-d8809e5bcd3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_556226bc-36cb-4e4c-af68-b7221da14303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55e052ff-760b-4233-875b-b80e5e4fd436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_578e3acb-13d3-45de-b073-1b8543855c9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_581d19f7-26e1-4059-90f3-b147eba1d7ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_586a96db-2895-433b-86b3-59a27d4ec21f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59962491-572f-40ec-90f4-9cbf4e5124ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a58400b-bc1f-4635-913c-4ad5f983a455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ce2a22a-eacd-4fc1-b3cc-795c49539d41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d47ea25-4a27-4ac3-92dc-45b3e93e5aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f8fe6ab-7ff7-4826-aac8-a94da76c2e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61b5027c-b632-4929-9a07-a51a4a172615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e41641-345f-41a7-b190-b0f5bedca153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62b69186-a8bb-4324-acc0-f14d726a9dc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63b514b4-d04f-4c24-ae2c-3f68c86bc2cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_641f77d8-a8c4-4ee2-9594-6cbd48dc0f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64ac5d48-5a11-4212-bd0e-58e8990dba06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65b685f1-a56a-4c6a-bfd2-43a03bc5ac14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67b31110-ac66-4aed-a6af-7327aecffdff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67dce2a2-937e-4e9c-8d05-52a8de7df49a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_685da0b4-944b-4ee5-98c3-1fd7acde1f9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_699b6fb2-eaae-4c2e-8078-429b64ad536a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b652f70-c405-4c0f-89a3-daf7d3f4fbaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b7ac61d-59d7-4f79-a0f9-c3856afc6147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b9ea75b-fd6f-4b79-9eda-f78b19010cc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c1acb2b-a004-4627-8c8b-62b043c6ae4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ca67800-b7c3-4502-9b65-2de2fc4bcd0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d644c95-287a-423b-b6e2-b8baaa08fec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6de2fb61-b44d-45b0-b76c-c1b0f84e06f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e1efb3e-07db-484f-b24b-35978abd908b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanHundredMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e28630c-cb40-4a69-9fd0-0723bffc77c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanTwoHundredFiftyMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7063df84-df92-4d68-82de-908875303ee3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_712db356-621a-4482-bbbf-6e0f7cee9633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71521487-ca68-4307-8394-188717a68617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71e97608-057e-403f-bf4b-90daabc11583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b5439a-53d8-49ab-af66-1b56f6f623fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b8de51-684e-42d9-ae4d-1d3e47c58783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79793b06-4d51-4322-b5ab-725a80889edf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a13598e-80ea-44a3-bc8f-76223a604527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7da21a6a-c5cf-4df6-ba41-9a958e60d77d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e4fb7e8-86a6-44b3-8a48-c1f6087f018a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7edf969a-90c8-4fa0-819c-30ed128b4031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f8cfbeb-4cb9-4b6d-a5e6-cb932c0b7774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>cprx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>cprx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_ChfShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4" fromRefs="F_78ea662f-49ac-4435-b86f-eb83afbf77c0 F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a F_4090fec8-f07e-48d9-bf06-c1a0911f901a F_266311d6-f055-45aa-95b5-dcb4a1d901ee F_e1ed2f82-8a48-42fe-af2f-872d5813258d F_75cfea18-2c8e-42fa-9913-1a0fb70f871c"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711" fromRefs="F_d7c32d70-ab8c-43a6-9e28-15f96a90187c F_ecfad2e5-1ee6-4119-9494-9beb4590c583"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d94b260a-93b1-497f-8e6a-658b6a2becce" fromRefs="F_881659e8-6047-47a8-a6b8-49f8b69ba572"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352" fromRefs="F_f4436702-baa2-4753-b4e4-736cc652c726 F_40e080c9-fb3e-42e3-9405-9f5355bd8806 F_c7393005-53d8-43d7-905c-d6e3893fde43"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_267031a3-8c5f-4907-907e-81096734e04a" fromRefs="F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc F_47467f83-aca0-4199-b569-0a51fde6c304 F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_01910dd5-f9ee-4dbb-be39-87408e115701" fromRefs="F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_781e2edc-d82f-4caf-82fd-b49074646a3a" fromRefs="F_cb02a000-e0f2-4b6b-a266-10189165015c"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a726e936-cd79-4ad5-818b-5d331ff1d6ae" fromRefs="F_6451f60b-cda5-406d-9f2f-9f875cc67c07"/></ix:resources></ix:header></div>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:14pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5a6f12f-751b-4ccc-b3ff-819fad9f4951" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Mark One]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d760a810-9deb-4ea3-bef2-8f61df72b823" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Fiscal Year Ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_065ad739-7e82-4d47-84ff-389c8bfa5115" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_840725af-ebc6-417a-a161-6ec8d88d3d40" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c18cf5af-def4-462b-82b9-d9ee0b0c881d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c885e8e0-f239-4c2a-b520-f95cf69760b0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File No. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78d82ede-c24c-4251-a5ca-ed3860bd80fb" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-33057</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbfc45b2-a2ec-4933-b040-be7b636d54c5" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f72043d0-7c67-403a-a2fb-322920f52d03" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a54ce2e5-ac36-4b1a-8e52-5e5eef0faf22" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">76-0837053</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State of jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_265c654e-f64f-40c6-992c-38c88ffc38ec" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">355 Alhambra Circle</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_1e8c2a49-56ff-423a-9357-92bfb1e6a5ea" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 801</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0be43a8e-84ea-44a1-8eee-e71a37426933" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Coral Gables</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_514b4ddf-a04e-4ed7-bb2c-af078e644911" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c1199ee4-118f-4a36-a74a-d16521e08efe" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33134</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bce18b0-f920-46a1-83b3-ee9d54ebaec7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">305</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52170c9e-76ff-46d4-9508-103ce5510700" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">420-3200</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Registered Pursuant to Section 12(b) of the Exchange Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:41%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of Each Class</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ticker Symbol</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Exchange on Which Registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e2ba1ce6-94f0-4d76-996b-6f7ee9fd3290" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_10fbf918-e176-4614-81f9-0ad7365e092e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CPRX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_203731f4-9147-4929-8a6f-0dfe6dab04c6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NASDAQ</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Exchange Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#8195;</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a9d303d-25fd-44ab-81e9-bebe04d0837b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8195;No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if registrant is not required to file reports pursuant to Rule 13 or Section 15(d) of the Act.&#8195;Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8195;</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff2981c8-73ed-42f8-a56a-a157a7a241ce" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#8195;</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_992b9046-7306-4ec0-ad0f-1b33d31f552b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;&#8195;No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#8195;</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b1d4d9e-d1c0-421a-bc65-a7bb616c6bb2" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8195;No </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:52%;box-sizing:content-box;"/>
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_7460aeed-ff98-488b-8e86-4abf6d929e8e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_7d7ba637-02bb-4732-91fa-3acf33ccc27c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_fedf6815-883b-4270-a88e-b2e09f33138e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c309d910-3f60-4523-bd5b-e7f865957687" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746; </span></ix:nonNumeric></span><span style="font-size:7.5pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e0425172-645d-40a8-9c48-259ebb4a7bac" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#8195;Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8195;No </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_42eed31c-6f07-49f7-9cd6-598234c5d545" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2024, the last business day of the Registrant&#8217;s most recently completed second quarter, the aggregate market value of all voting and non-voting common equity held by non-affiliates was $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5fe6ad4-b7db-4c73-8f2f-25829841b832" contextRef="C_7063df84-df92-4d68-82de-908875303ee3" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,720,853,867</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e094710-234a-4e4c-b46f-5cb21e8456ce" contextRef="C_f77728b5-2d78-4209-bf9a-e8743612b59d" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">121,449,655</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, were outstanding as of February 24, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III incorporates certain information by reference from the registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders. The proxy statement with respect to the 2025 annual meeting of stockholders will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b127b13-d185-4f54-9a97-272fafc5deaf" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Definitive Proxy Statement to be filed for Catalyst Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tab</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">le of Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.16%;box-sizing:content-box;"/>
    <td style="width:80.66%;box-sizing:content-box;"/>
    <td style="width:5.18%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;1.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">51</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;2.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;3.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;4.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosure"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosure</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">53</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;5.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_common_equity"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;6.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Selected Financial Data</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">55</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;7.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion_and_analy_"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_disclo_market_risk"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;8.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statement_and_sup_data"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;9.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;10.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_and_executive_officer"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors and Executive Officers of the Registrant</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;11.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;12.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;13.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;14.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item&#8201;15.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_and_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">74</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:90%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EXHIBITS FILED WITH FORM 10-K</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 19.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider Trading Policy (certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 23.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 31.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 302 Certification of CEO</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 31.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 302 Certification of CFO</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 32.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 906 Certification of CEO</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EX 32.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 906 Certification of CFO</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You are urged to read this Annual Report on Form 10-K (Form 10-K) in its entirety. This Form 10-K contains forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from the projected results discussed in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those discussed below and in Item 1A, &#8220;Risk Factors.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;We,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us,&#8221; &#8220;Catalyst,&#8221; or the &#8220;Company,&#8221; when used herein, refers to Catalyst Pharmaceuticals, Inc., a Delaware corporation, and its wholly owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd., a corporation organized in the Republic of Ireland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221;, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations, beliefs, plans or objectives for future operations and anticipated results of operations. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, &#8220;believes&#8221;, &#8220;anticipates&#8221;, &#8220;proposes&#8221;, &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, and other similar expressions are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or other achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the section entitled &#8220;Risk Factors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continued successful commercialization of FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel) CIII, and AGAMREE&#174; (vamorolone) are highly uncertain. Factors that will affect our success include the uncertainty of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to successfully market and sell FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; while maintaining full compliance with applicable federal and state laws, rules and regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to attract and retain the qualified personnel necessary to run our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our estimates of the size of the market for FIRDAPSE&#174; for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) will prove to be accurate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether the daily dose of FIRDAPSE&#174; taken by patients changes over time and affects our results of operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will continue to be able to locate LEMS patients who are undiagnosed or are misdiagnosed with another disease;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether patients will discontinue from the use of our products at rates that are higher than historically experienced or are higher than we project; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether new FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; patients can be successfully titrated to stable therapy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we can continue to market our products on a profitable and cash flow positive basis; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to demonstrate, to the satisfaction of the U.S. Food and Drug Administration (FDA) and third party payors, whether AGAMREE&#174; offers advantages compared to other corticosteroids or competitor&#8217;s products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether DMD patients transitioning to current or future gene therapy treatments will delay initiating use of AGAMREE&#174; while waiting for access to such gene therapy, or stop their AGAMREE&#174; therapy during the course of their gene therapy treatment;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to successfully commercialize FYCOMPA&#174; after its patents expire starting in May 2025 and generic competition for FYCOMPA&#174; enters the market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether any revenue or earnings guidance that we provide to the public market will turn out to be accurate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether payors will continue to provide coverage and reimburse for our products at the price that we charge for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of our third party suppliers and contract manufacturers to continue to supply sufficient product to meet our customers&#8217; needs in a timely manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of our third party suppliers and contract manufacturers to maintain compliance with current cGMP; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of those third parties that distribute our products to maintain compliance with applicable law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to maintain compliance with applicable rules relating to our patient assistance programs for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to maintain compliance with the applicable rules that relate to our contributions to 501(c)(3) organizations that support patients in financial need; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope of our intellectual property and the outcome of challenges to our intellectual property, and, conversely, whether any third party intellectual property presents unanticipated obstacles for FIRDAPSE&#174;, FYCOMPA&#174;, or AGAMREE&#174;; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether there will be a post-closing review by antitrust regulators of our previous acquisition transactions, and the outcome of any such reviews if they occur; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to acquire additional drug products under development, complete development required to commercialize such products, and thereafter, if such products are approved for commercialization, successfully market such products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be successful in our litigation to enforce our patents against the Paragraph IV challengers who have filed Abbreviated New Drug Applications (ANDAs) seeking to introduce generic versions of FIRDAPSE&#174;;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our patents will be sufficient to prevent generic competition for FIRDAPSE&#174; and AGAMREE&#174; after our orphan drug exclusivity for each product expires; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact on our profits and cash flow of adverse changes in reimbursement and coverage policies or regulations from government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators, or the impact of pricing pressures enacted by industry organizations, the federal government or the government of any state, including as a result of increased scrutiny over pharmaceutical pricing or otherwise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in the healthcare industry and the effect of political pressure from and actions by the President, Congress and/or medical professionals seeking to reduce prescription drug costs, and changes to the healthcare industry occasioned by any future changes in laws relating to the pricing of drug products, including changes made in the Inflation Reduction Act of 2022, changes (if any) to be made by the current President and/or the current Congressional administrations, changes to the review and approval process at the FDA, or changes in the healthcare industry generally; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we and Santhera can successfully develop additional indications for AGAMREE&#174; and obtain the ability to commercialize the product for these additional indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state of the economy generally and its impact on our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope, rate of progress and expense of future clinical trials and studies, pre-clinical studies, proof-of-concept studies, and our other drug development activities, and whether any trials and studies we undertake will be successful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to complete any clinical trials and studies that we may undertake on a timely basis and within the budgets we establish for such trials and studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether FIRDAPSE&#174; can be successfully commercialized in Canada on a profitable basis through KYE Pharmaceuticals (KYE), our collaboration partner in Canada; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether AGAMREE&#174; will be approved by Health Canada for commercialization in Canada and whether, if the product is approved, KYE can successfully commercialize it in Canada;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether KYE will successfully file an application seeking to commercialize AGAMREE&#174; in Canada during the first quarter of 2025 or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Now that FIRDAPSE&#174; has been approved for commercialization in Japan and launched, whether DyDo will be successful in commercializing the product in Japan; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact on sales of FIRDAPSE&#174; in the U.S. if an amifampridine product is purchased in Canada for use in the U.S.; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our plans to expand the reach of FIRDAPSE&#174; and AGAMREE&#174; into other global regions will be successful;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">System failures or security or data breaches due to cyber-attacks, or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions whether it occurs directly to us or indirectly through third parties; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enhance our systems, processes and procedures to appropriately support the growing complexity and scale of our business. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current plans and objectives are based on assumptions relating to the continued commercialization of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; and on our plans to seek to acquire or in-license additional products. Although we believe that our assumptions are reasonable, any of our assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements we have made herein, which reflect our views only as of the date of this report, you should not place undue reliance upon such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">usiness</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We currently market three drug products, FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel), and AGAMREE&#174; (vamorolone). We are also currently seeking to further expand our drug portfolio, with a focus on acquiring the rights to late-stage products to treat orphan, rare diseases across therapeutic areas. With an unwavering patient focus embedded in everything we do, we are committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 28, 2018, we received approval from the FDA for our new drug application, (NDA) for FIRDAPSE&#174; Tablets 10 mg for the treatment of adult patients (ages 17 and above) with LEMS, and in January 2019, we launched FIRDAPSE&#174; in the U.S. Further, on September 29, 2022, the FDA approved our supplemental NDA (sNDA) to expand the indicated age range for FIRDAPSE&#174; Tablets 10 mg for the treatment of LEMS to include pediatric patients six years of age and older. Finally, on May 30, 2024, the FDA approved our sNDA increasing the indicated maximum daily dosage of FIRDAPSE&#174; tablets for the treatment of patients with LEMS from 80 mg to 100 mg. We believe that this recent sNDA approval offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell FIRDAPSE&#174; in the U.S. through a field-based force experienced in neurologic, central nervous system or rare disease products consisting at this time of approximately 41 field personnel, including sales (Regional Account Managers), thought leader liaisons and patient assistance and insurance navigation support (Patient Access Liaisons). These field personnel have also supported AGAMREE&#174; since its commercial launch in March 2024. We also have a field-based force of 10 medical science liaisons who are helping educate the medical community about scientific literature concerning LEMS and FIRDAPSE&#174;. Additionally, we use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient who also has small cell lung cancer. Further, we continue to make available at no-cost a LEMS voltage gated calcium channel antibody diagnostic testing program for use by physicians who suspect that one of their patients may have LEMS and wish to reach a definitive diagnosis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we launched AGAMREE&#174;, in March 2024, we utilized the FIRDAPSE&#174; commercial and medical field-based forces to market AGAMREE&#174; as well. In early 2025, we made a strategic decision to split each of these field-based forces into two units, one for each function expressly focused on supporting FIRDAPSE&#174; and one for each function expressly focused on supporting AGAMREE&#174;. This change is being made in an effort to allow us to better focus our sales teams on the market for each product. We expect to complete this division of our field-based forces into two units early in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, we are continuing to expand our digital and social media activities to introduce our products and services to potential patients and their healthcare providers. We also work with several rare disease advocacy organizations (including the Myasthenia Gravis Foundation of America, the National Organization for Rare Disorders, and the LEMS Family Association) to help increase awareness and level of support for patients living with LEMS and to provide education for the physicians who treat these rare diseases and the patients they treat.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting the distribution of FIRDAPSE&#174; through Catalyst Pathways&#174;, our personalized treatment support program for patients who enroll in it. Catalyst Pathways&#174; is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen required to reach an effective therapeutic dose. The program also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most drug products for ultra-orphan diseases are distributed and dispensed to patients. We believe that by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to help patients with LEMS afford their medication, we, like other pharmaceutical companies which market drug products for ultra-orphan conditions, have developed an array of financial assistance programs to reduce out-of-pocket costs that makes FIRDAPSE&#174; accessible and affordable. A co-pay assistance program has been designed to reduce commercial patients&#8217; out of pocket costs to $0 whenever possible. Our FIRDAPSE&#174; co-pay assistance program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Department of Veterans Affairs (VA), Department of Defense (DoD), or TRICARE. However, we are donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to any U.S. LEMS patients in financial need, who meet those independent organizations' guidelines. In addition, we have a safety net program in place for patients who are uninsured and underinsured. Subject to compliance with regulatory requirements, our goal is that no LEMS patient is ever denied access to their medication for financial reasons.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174; is currently marketed for the treatment of LEMS in Canada through our exclusive sublicensee, KYE. We supply product to KYE at agreed upon prices and we are also eligible to earn sales milestones and sales royalties based on net revenues from sales of the product in Canada.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, DyDo Pharma, Inc. (DyDo), our sub-licensee for FIRDAPSE&#174; in Japan, filed a NDA with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to commercialize FIRDAPSE&#174; for the treatment of LEMS in Japan. Upon acceptance of the Japan NDA by the PMDA in December 2023, our license for FIRDAPSE&#174; automatically expanded to include other key markets in Asia and Latin America, and we are currently seeking opportunities to expand FIRDAPSE&#174;&#8217;s global footprint through strategic partnerships (with the current focus on the Asia Pacific and Latin American regions). Further, in September 2024, DyDo advised us that the Ministry of Health, Labour and Welfare (MHLW) had approved DyDo's Japan NDA to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS in Japan. Finally, DyDo began commercialization of FIRDAPSE&#174; in Japan on January 21, 2025. We will generate revenue through additional milestone payments and a transfer price on the product supplied by us to DyDo, in lieu of royalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We control six U.S. patents for FIRDAPSE&#174; that are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), the earliest of which expires in 2032 and the latest of which expires in 2037. We also have orphan drug exclusivity (ODE) for the product that will not expire until November 2025, and no Abbreviated New Drug Application (ANDA) for the product can be finally approved by the FDA until the ODE exclusivity period has expired. Nevertheless, generic drug manufacturers were permitted to submit applications for the product challenging our patents starting in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In that regard, in January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva), Hetero USA, Inc. (Hetero), and Lupin Pharmaceuticals, Inc. (Lupin)) advising that they had each submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE&#174; in the U.S. The notice letters each alleged that the six patents protecting FIRDAPSE&#174; that are listed in the Orange Book in connection with FIRDAPSE&#174; are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the Federal Food, Drug, and Cosmetic Act (FDCA), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first in all cases (but not earlier than the expiration of orphan drug exclusivity on November 28, 2025). In that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions, thus triggering the stay.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, Lupin converted five of its Paragraph IV Certifications in its ANDA to Paragraph III certifications acknowledging the validity and their ANDA&#8217;s infringement of five of those patents, the latest ending in 2034. We subsequently dismissed all of our claims against Lupin related to those five patents but maintain our claims against Lupin for the remaining Paragraph IV certification for U.S. Patent No. 10,626,088, which is the patent expiring in 2037, accordingly the litigation continues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on January 8, 2025, we reached a settlement with Teva in which Teva agreed not to market a generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the settlement agreement, the parties terminated all ongoing patent litigation between us and Teva regarding FIRDAPSE&#174; patents pending in the U.S. District Court for the District of New Jersey.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for FIRDAPSE&#174;&#8217;s Orange Book-listed patents expiring in 2032, 2034 and 2037) and Lupin (only for FIRDAPSE&#174; patent expiring in 2037), remains ongoing, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there can be no assurance as to whether the currently ongoing litigation with Hetero and Lupin will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to Teva's licensed entry into the market on February 25, 2035.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer (Inventia Life Science Pty Ltd (Inventia)), and we filed a similar lawsuit against that manufacturer in November 2023 in the U.S. District Court for the District of New Jersey. On July 30, 2024, we settled this patent litigation with Inventia for FIRDAPSE&#174;. In this settlement, Inventia acknowledged both the validity of our FIRDAPSE&#174; patents and also the infringement by the ANDA filer's product of our patents. As part of the settlement, Inventia also agreed not to commercialize its product until the earlier of all FIRDAPSE&#174; patents expiration or the entry into the market of another ANDA product meeting certain conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance as to whether we will prevail in these litigations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2022, we entered into an agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA&#174; (perampanel) CIII. FYCOMPA&#174; is a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. It was the first, and still the only, drug of its class to be approved for epilepsy. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. FYCOMPA&#174; is a controlled substance and is approved with a box warning label. FYCOMPA&#174; is used to treat certain types of focal onset seizures (seizures that involve only one part of the brain) in adults and children four years of age and older. It is also used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures (also known as a &#8220;grand mal&#8221; seizure, a seizure that involves the entire body) in adults and children 12 years of age or older. Perampanel is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 24, 2023, we closed our acquisition of the U.S. rights to FYCOMPA&#174;. In connection with the acquisition, we purchased Eisai&#8217;s regulatory approvals and documentation, product records, intellectual property, inventory, and other matters relating to the U.S. rights for FYCOMPA&#174;, in exchange for an upfront payment of $160 million in cash. We also agreed to pay Eisai royalty payments after patent protection for FYCOMPA&#174; expires, which royalty payments will be reduced upon generic equivalents to FYCOMPA&#174; entering the market.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the closing of the asset purchase, we entered into two additional agreements, a Transition Services Agreement (TSA) and a Supply Agreement. Under the Supply Agreement, Eisai agreed to manufacture FYCOMPA&#174; for us for at least seven years at prices listed in the Supply Agreement (to be updated on a yearly basis), and under the TSA, a U.S. subsidiary of Eisai provided us with certain transitional services (which transition services ended on December 31, 2023).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell FYCOMPA&#174; in the U.S. through a field-based force experienced in epilepsy products consisting at this time of approximately 27 field personnel, including sales (Regional Account Managers) and payor reimbursement (National Account Managers). We also have a field-based force of four medical science liaisons who are helping educate the medical community who treat epilepsy about scientific literature regarding epilepsy and FYCOMPA&#174;. Further, since January 1, 2024, FYCOMPA&#174; is being sold and distributed through a 3PL organization under our contracts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently taking steps to prepare for the loss of exclusivity for FYCOMPA&#174;, which, assuming a timely ANDA approval of the respective generic applications, will take place on or after May 23, 2025 for the tablet version of the product and will take place on or after December 15, 2025 for the oral suspension version of the product. We expect to continue to market the product following the loss of patent exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting patients using FYCOMPA&#174; through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $5 for their FYCOMPA&#174; co-pay (with a maximum savings of $2,500 per year). The FYCOMPA&#174; Instant Savings Card Program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent protection for FYCOMPA&#174; tablets and oral solution is primarily derived from two patents listed in the FDA&#8217;s Orange Book. The first, U.S. patent no. 6,949,571 (the &#8216;571 patent), will expire on May 23, 2025, including patent term extension. The second FYCOMPA&#174; patent in the Orange Book is U.S. Patent No. 8,772,497 (the &#8216;497 patent), which will expire on July 1, 2026. The &#8216;497 patent, which covers the API used in both FYCOMPA&#174; tablets and oral solution, has been the subject of previous Paragraph IV certifications from three ANDA filers for the tablet formulation, which were not contested by Eisai prior to our acquisition of the drug. Following our acquisition of the drug, we attempted to obtain an extension of the patent term for the '571 patent, which was ultimately unsuccessful. As a result, the '571 patent will expire on May 23, 2025 and the initial ANDA filers who did not challenge this patent may seek approval of their ANDA applications on or after that date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023 we received a Paragraph IV certification for the '497 patent from an ANDA filer for two applications, one for the FYCOMPA&#174; tablets and another for the FYCOMPA&#174; oral suspension. After due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions alleging infringement of both patents. In June 2024, we settled the pending Paragraph IV litigation with the Paragraph IV filer for both ANDAs. As part of that settlement, this Paragraph IV filer agreed not to commercialize their proposed ANDA products for both the oral suspension formulation of FYCOMPA&#174; and for FYCOMPA&#174; tablets until at least December 15, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we received a Paragraph IV certification for the &#8217;571 and &#8217;497 patents from an ANDA filer for an application for the FYCOMPA&#174; oral suspension. After due diligence, we determined that the circumstances and timeline did not warrant a lawsuit against this Paragraph IV filer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 19, 2023, we entered into a License and Collaboration Agreement (AGAMREE&#174; License Agreement) and an Investment Agreement (Investment Agreement) with Santhera Pharmaceuticals Holding, Inc. (Santhera). Under the AGAMREE&#174; License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera&#8217;s investigational product candidate, AGAMREE&#174; (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both transactions closed on July 18, 2023. Under the AGAMREE&#174; License Agreement, upon closing we made a $75 million payment to Santhera in return for the exclusive North American license for AGAMREE&#174;. In addition to the rights to commercialize the product in North America, the AGAMREE&#174; License Agreement provides us with the right of first negotiation for AGAMREE&#174; in Japan should Santhera pursue partnership opportunities in that territory. Additionally, we will hold the North American rights to any future approved indications for AGAMREE&#174;. Finally, under our AGAMREE&#174; License Agreement with Santhera, we have agreed to purchase commercial supply of AGAMREE&#174; from Santhera at agreed upon prices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with the closing of the AGAMREE&#174; License Agreement, we made a strategic investment into Santhera in which we acquired 1,414,688 of Santhera&#8217;s ordinary shares (representing approximately 11.26% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction) at an investment price of CHF 9.477 per share, with the approximately $15.7 million USD in equity investment proceeds to be used by Santhera for Phase IV studies of AGAMREE&#174; in DMD and future development of additional indications for AGAMREE&#174;. On February 24, 2025, the closing price of Santhera&#8217;s common shares on the SIX Swiss Exchange was CHF 16.08 per share (approximately $17.90 USD based on then-current exchange rates).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 26, 2023, the U.S. FDA approved Santhera&#8217;s NDA for AGAMREE&#174; for use in treating DMD in patients aged two years and older. Shortly thereafter, as part of the previously described transaction, Santhera transferred the approved NDA to us. Additionally, following approval of the NDA for the drug, we became obligated to make a milestone payment of $36 million to Santhera, which we paid during the fourth quarter of 2023. We may also be obligated to pay future regulatory and commercial milestone payments to Santhera tied to calendar year sales of AGAMREE&#174;, as well as commercial royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2024, utilizing our FIRDAPSE&#174; field-based force, we launched AGAMREE&#174; for the treatment of DMD in the U.S. for patients aged two years or older. During the first quarter of 2024, in connection with our preparation for the commercial launch of AGAMREE&#174;, we incurred substantial commercialization expenses, including sales, marketing, analytical infrastructure, patient services, patient advocacy, and other commercialization related expenses. Initially, we added approximately 10 additional members to our FIRDAPSE&#174; team, and our commercial team marketed both products. However, in early 2025, we made a strategic decision to split our commercial field-based force into two units, one expressly focused on the marketing of FIRDAPSE&#174; and one expressly focused on the marketing of AGAMREE&#174;. This change is expected to allow us to better focus on the market for each product. We expect to complete this division of our field-based force into two units early in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are further supporting the distribution of AGAMREE&#174; through our Catalyst Pathways&#174; patient services program to ensure that patients have access to a dedicated, personalized support team that assists families through the AGAMREE&#174; patient journey, from answering questions to coordinating financial assistance programs for eligible patients. Finally, we have donated and intend to continue to donate funds to one or more qualified, independent charitable financial foundations who assist U.S. DMD patients in financial need for paying the costs of care including medication, to the extent permitted by each such organization's guidelines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD, the most common form of muscular dystrophy, is a rare and life-threatening neuromuscular disorder characterized by progressive muscle dysfunction, ultimately leading to loss of ambulation, respiratory failure, and fatality. Current standard treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 patients in the U.S. are affected by DMD, with approximately 70% of patients currently receiving a corticosteroid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">treatment. Steroids are expected to remain the foundation of therapy for DMD patients and dosed concomitantly with other therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174;&#8217;s unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In that regard, we have launched our SUMMIT study to evaluate data about long-term patient safety and quality of life data from the use of our product, with the hope of offering a deeper understanding of the product's potential long-term benefits for patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 13, 2023, Santhera announced that the European Union&#8217;s Committee for Medicinal Products for Human Use (CHMP) adopted a positive position in favor of AGAMREE&#174; for the treatment of DMD patients aged four and older. In its recommendation for approval, CHMP acknowledged that there was a positive benefit-risk profile of AGAMREE&#174; in such patient population, including certain safety benefits of AGAMREE&#174; compared to standard of care corticosteroids in the treatment of DMD. Further, on December 18, 2023, the European Commission (EC) granted to Santhera marketing authorization for AGAMREE&#174; for the treatment of DMD in patents ages four years and older and on January 12, 2024 Santhera announced that AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had received approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Further, on January 15, 2024, Santhera announced that AGAMREE&#174; was commercially launched in Germany. Finally, On January 16, 2025, the National Institute for Health and Care Excellence (NICE) issued positive Final Guidance that recommends AGAMREE&#174; for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of DMD in patients four years of age and older and on February 13, 2025, Santhera announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for AGAMREE&#174; (vamorolone) for the treatment of DMD. This milestone makes AGAMREE&#174; the first product to receive an agreed federal price in Germany for the treatment of DMD in patients 4 years of age and older, independent of the underlying genetic mutation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently taking the first steps to seek to expand the number of diseases that can be treated with AGAMREE&#174;. In furtherance of that objective, we are currently conducting a Phase 1 study in healthy adults comparing a single dose of vamorolone, prednisone, and deflazacort, and studying the immunosuppressive effect of multiple ascending doses of AGAMREE&#174;, which study will attempt to define the immunosuppressive dose of vamorolone for future indications and for the use of our product in conjunction with gene and cell therapies that are approved to treat DMD and require a concurrent immunosuppressive regimen of a corticosteroid when administered. We expect to have the results of this study around the middle of this year and hope that the results of this study will provide important information for use in marketing our product to healthcare practitioners in an effort to help with the treatment of patients. We have also begun a long-term project to undertake long-term research and development efforts for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we have established a joint steering committee with Santhera that is overseeing the lifecycle management and development of AGAMREE&#174;. There can be no assurance that we can develop our product for the treatment of diseases other than DMD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., AGAMREE&#174; has New Chemical Entity exclusivity that expires in October 2028. AGAMREE&#174; also has Orphan Drug Exclusivity expiring in October 2030. AGAMREE&#174; is further protected by seven Orange Book listed patents expiring as early as May 28, 2029 and as late as July 16, 2040. The Company has also requested Patent Term Extension and will update the relevant expiration date in the Orange Book upon a final determination by the USPTO. The earliest a generic manufacturer could submit an ANDA is October 26, 2027. If we were to pursue a patent infringement action if any such ANDA challenges any of AGAMREE&#174;&#8217;s Orange Book patents, then the automatic statutory 30-month stay would prevent FDA approval of such ANDA until April 26, 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, on July 23, 2024 we entered into a license, supply and commercialization agreement with KYE, which is already our sublicensee for FIRDAPSE&#174; in Canada, granting KYE the exclusive Canadian commercial rights to market AGAMREE&#174; in Canada for DMD and other indications. Under the agreement, KYE is responsible for obtaining regulatory approval of the product from Health Canada (of which there can be no assurance), and we will supply product to KYE. Further, KYE has advised us that they expect to file an application with Health Canada seeking approval to commercialize AGAMREE&#174; in Canada during the first quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any such application when and if filed will be approved, and even if such application is approved that KYE will be successful in commercializing AGAMREE&#174; in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to advance our strategic initiatives and portfolio expansion efforts, focusing on broadening and diversifying our rare (orphan) neurology product portfolio with innovative therapies that address critical unmet medical needs and expanding the geographical footprint of our existing products. In that regard, we are currently exploring clinically differentiated and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adequately de-risked opportunities, with a keen focus on orphan, rare disease products across therapeutic areas. These prospects include evaluating companies with existing commercial drug products or drugs in development, for potential partnerships, licensing, geographical expansion opportunities with our existing products, and/or asset acquisitions. We continue to employ a disciplined, comprehensive, and exhaustive approach to identifying and evaluating opportunities that we believe will add significant value to our company over the near, mid, and long term. However, other than the recent sublicense agreement described above between the Company and KYE for AGAMREE&#174; in Canada, no definitive agreements have been entered into to-date, and there can be no assurance that any of the Company's business development initiatives will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, we had cash and investments of approximately $517.6 million. Based on our current financial condition, including our profitability, cash flows generated from operations and forecasts of available cash, we believe that we have sufficient funds to support our operations for at least the next 12 months. There can be no assurance that we will continue to be successful in commercializing FIRDAPSE&#174; and AGAMREE&#174;, that our projections about the commercialization of FYCOMPA&#174; after the expiration of its patents will be correct, or that we will continue to be profitable and cash flow positive. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources&#8221; below for further information on our liquidity and cash flow.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to implement our buy-and-build strategy, acquiring and integrating high-value, orphan designated, synergistic assets. We are dedicated to making a meaningful impact on the lives of those suffering from rare diseases, and we believe in putting patients first in everything we do. Specifically, we intend to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continue to commercialize FIRDAPSE&#174; for the treatment of LEMS and improve disease awareness. We are currently commercializing FIRDAPSE&#174; in the U.S. and Canada. We are working to expand awareness of the disease, including to physicians treating LEMS patients who also have small-cell lung cancer, and helping health care providers and their patients understand the benefits of FIRDAPSE&#174;. A cornerstone of our strategy is our continuing development of Catalyst Pathways&#174;, our personalized treatment support program, and our development of the patient assistance programs that are required to further our goal that no LEMS patient be denied access to FIRDAPSE&#174; for financial reasons within existing legal restrictions. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continue to commercialize AGAMREE&#174; for the treatment of DMD and seek to develop additional indications for the product. We are currently marketing AGAMREE&#174; in the U.S. for the treatment of DMD. We are also hoping to evaluate our product for the treatment of other diseases and in furtherance of that objective we are currently taking steps that will help us in that goal, including our current Phase 1 trial to evaluate AGAMREE&#174; against other steroids in an effort to first evaluate the dose equivalence between AGAMREE&#174;, prednisone and deflazacort) and the immunosuppressive dose of AGAMREE&#174;. We are also conducting the SUMMIT study in an effort to obtain real world data about the benefits of AGAMREE&#174; over other corticosteroids.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seek to expand the market for FIRDAPSE&#174; and AGAMREE&#174;. We are continuing our efforts to expand the footprint for FIRDAPSE&#174; into Asia and Latin America and maintain our Right of First Negotiation with Santhera for rights to AGAMREE&#174; in Japan.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seek to acquire additional products. We intend to continue our efforts to broaden and diversify our product portfolio through acquisitions of early and/or late-stage products or companies or technology platforms in orphan, rare disease therapeutic categories. To accomplish these priorities, we are continuing to employ a disciplined approach to evaluating assets and we believe that this strategic expansion will better position our company to build out a broader, more diversified portfolio of drug candidates, which should add greater value to our company over the near and long-term. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174; Product Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174; is Catalyst&#8217;s registered trade name in the U.S. for amifampridine phosphate tablets. Amifampridine is the WHO (World Health Organization) registered INN (International Nonproprietary Name) and U.S. Adopted Name (USAN) for the chemical entity, 3,4-diaminopyridine, often abbreviated as 3,4-DAP or DAP. FIRDAPSE&#174; contains the phosphate salt of amifampridine, hence the name &#8220;amifampridine phosphate.&#8221; We will refer to our drug by its trade name in the U.S. (FIRDAPSE&#174;), by the INN and USAN (amifampridine), or by the specific salt in our product (amifampridine phosphate), throughout this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amifampridine has been recommended as the first-line symptomatic treatment for LEMS by the European Federation of Neurological Societies (now known as the European Academy of Neurology). In December 2009, amifampridine phosphate received marketing approval from the European Commission (with the trade name FIRDAPSE&#174;) for the symptomatic treatment of patients with LEMS. Safety data from clinical data published over the last 30 years in patients with LEMS or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neurological disorders treated with amifampridine show that amifampridine is well tolerated at doses up to 80 mg per day. Among the 1,279 patients or healthy subjects assessed in the literature, the most frequently reported adverse events (AEs) were perioral and peripheral paresthesias (unusual sensations like pins and needles), and gastrointestinal disorders (abdominal pain, nausea, diarrhea, and epigastralgia (pain around the upper part of the stomach)). These events were typically mild or moderate in severity, and transient, seldom requiring dose reduction or withdrawal from treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lambert-Eaton myasthenic syndrome (LEMS)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEMS is a rare autoimmune neuromuscular disorder characterized primarily by muscle weakness of the limbs. The disease is caused by an autoimmune reaction where antibodies are formed against voltage-gated calcium channels on nerve endings, which damages the channels. These calcium channels are responsible for the transport of charged calcium atoms that activate the biochemical machinery responsible for releasing acetylcholine. Acetylcholine is the neurotransmitter responsible for causing muscles to contract and the failure to release enough of this neurotransmitter results in muscle weakness in LEMS patients. Additionally, LEMS is often associated with an underlying malignancy, most commonly small-cell lung cancer (SCLC), and in some individuals, LEMS is the first symptom of such malignancy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEMS generally affects individuals' extremities, especially the legs. As LEMS most affects the parts of limbs closest to the trunk, difficulties with climbing stairs or rising from a sitting position are commonly reported. Physical exercise and high temperatures tend to worsen the symptoms. Other symptoms often seen include weakness of the muscles of the mouth, throat, and eyes. Individuals affected with LEMS also may have a disruption of the autonomic nervous system, including dry mouth, constipation, blurred vision, impaired sweating, and/or hypotension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEMS is managed by treating the symptoms or treating the underlying autoimmune attack on voltage gated calcium channels. Unapproved treatments include steroids, azathioprine and intravenous immunoglobulin, which work by suppressing the immune system; and pyridostigmine and amifampridine, which enhance neuromuscular transmission. Plasma exchange has also been used to attempt to remove antibodies from the body. FIRDAPSE&#174; is a symptomatic treatment and does not alter the underlying autoimmune condition. As a voltage gated potassium blocker, FIRDAPSE&#174; prevents charged potassium atoms from leaving the nerve cells, which prolongs the period of depolarization. This allows more charged calcium atoms to enter the nerves, which enables the nerves to release acetylcholine and causes muscles to contract and to restore lost muscle strength in LEMS patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on currently available information, we estimate that there are at least 3,600 LEMS patients in the U.S., approximately half of which we believe are presently diagnosed and identified and the remainder of which we believe are undiagnosed or misdiagnosed. However, until awareness of the disease is increased, it is unlikely that the total number of LEMS patients in the U.S. can be determined with better certainty (as is typical of rare diseases), and the actual number of patients in the U.S. with LEMS may be higher or lower than our estimate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the factors that affect the addressable size of the population with a rare disease such as LEMS include the number of patients actually diagnosed with the disease, the number of patients who are misdiagnosed with other diseases, and the number of patients who are simply undiagnosed. Additionally, while there is an antibody test that positively identifies patients with LEMS which we offer at no cost to health-care providers to be used to definitively determine whether a patient has LEMS, the test is not particularly well known or utilized at this time by many neurologists. Further, many LEMS patients who have small cell lung cancer (SCLC) are not currently being treated for LEMS because many oncology medical professionals who treat SCLC patients are generally unfamiliar with how to diagnose and treat LEMS. All of these factors affect the ultimate number of patients who will benefit from treatment with FIRDAPSE&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements for FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreement with BioMarin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 26, 2012, we licensed the exclusive North American rights to FIRDAPSE&#174; pursuant to a License Agreement (the License Agreement) between us and BioMarin Pharmaceutical Inc. (BioMarin). Under the License Agreement, we make the following royalty payments on our net sales of FIRDAPSE&#174;:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Royalties to the licensor for seven years from the first commercial sale of FIRDAPSE&#174; equal to 7% of net sales (as defined in the License Agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Royalties to the third party licensor of the rights sublicensed to us for seven years from the first commercial sale of FIRDAPSE&#174; equal to 7% of net sales (as defined in the License Agreement between BioMarin and the third party licensor) in any calendar year for the duration of any pending or issued patents or regulatory exclusivity within a territory and 3.5% of net sales in any calendar year in territories without pending or issued patents or regulatory exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2019, we entered into an amendment to the License Agreement. Under the amendment, we expanded our commercial territory for FIRDAPSE&#174;, which originally was comprised of North America, to include Japan. Additionally, in December 2023 our territory automatically expanded to include most of Asia, as well as Central and South America, upon the acceptance by the MHLW in Japan of an application to market our product in Japan. Under the amendment, we will pay royalties on net sales in Japan of a similar percentage to the royalties that we are currently paying under our original License Agreement for North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2020, we were advised that BioMarin had sold certain rights under the License Agreement to SERB SA.  We believe that we remain in compliance with our obligations under the License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreement with Jacobus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the FDA approved an NDA for RUZURGI&#174;, Jacobus Pharmaceuticals&#8217; version of amifampridine (3,4-DAP), for the treatment of pediatric LEMS patients (ages 6 to under 17). In June 2019 we filed suit against the FDA and several related parties challenging this approval and related drug labeling. Jacobus later intervened in the case. We ultimately prevailed in our litigation in September 2021, when U.S. Court of Appeals for the 11</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Circuit determined that the FDA&#8217;s approval of RUZURGI&#174; violated our rights to Orphan Drug Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2022, we settled our disputes with Jacobus. In connection with the settlement, we licensed the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico. Simultaneously, we purchased, among other intellectual property rights, Jacobus&#8217; U.S. patents related to RUZURGI&#174;, its NDAs in the U.S. for RUZURGI&#174;, and certain RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inventory previously manufactured by Jacobus. At the same time, we received a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#174;. Further, we settled our pending patent lawsuit against Jacobus, which has been dismissed without prejudice. Finally, Jacobus agreed that until the later of (i) the expiration of the royalty term or (ii) December 31, 2034, Jacobus and its affiliates, will not, directly or indirectly, research, develop, manufacture, commercialize, distribute, use or otherwise exploit any product competitive to FIRDAPSE&#174; or RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the U.S. and Mexico, and Laura Jacobus, the sole shareholder of Jacobus, and two of Jacobus&#8217; other officers, also signed individual non-competition agreements containing the same terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the settlement with Jacobus, we paid Jacobus $30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022, $10 million was paid on the first anniversary of the closing of the settlement, and the remainder was paid on the second anniversary of closing. We also pay Jacobus an annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between us and Jacobus) of amifampridine products in the U.S. equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst&#8217;s FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patents in the U.S., 2.5% (with a minimum annual royalty of $5 million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances. Royalties will be trued up at the end of the year to the extent that royalties on net sales are below the minimum royalty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials Supporting our NDA for FIRDAPSE&#174; for LEMS and Approval of our NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted two successful Phase 3 double-blind, placebo-controlled clinical trials evaluating FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the treatment of LEMS. The results of the first trial published in 2016 in Muscle &amp; Nerve (Muscle Nerve, 2016, 53(5):717-725). The results of the second trial were published in March 2019 in the Journal of Clinical Neuromuscular Disease (J. Clin Neuromusc Dis 2019; 20:111-119). In March 2018, we submitted an NDA seeking approval of FIRDAPSE&#174; for the treatment of LEMS. Our NDA was accepted for filing in May 2018 and, on November 28, 2018, the FDA granted approval of FIRDAPSE&#174; for the treatment of LEMS in adult patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 29, 2022, the FDA approved our sNDA to expand the indicated age range for FIRDAPSE&#174; for the treatment of LEMS to include pediatric patients, six years of age and older.  Further, on May 30, 2024, the FDA approved our sNDA increasing the indicated maximum daily dose of FIRDAPSE&#174; for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of LEMS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Required Post-Approval Studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the approval of our NDA for FIRDAPSE&#174; for LEMS, the FDA required us to conduct two studies.  The first was a clinical trial to evaluate the effect of hepatic impairment on the exposure of amifampridine after oral administration of FIRDAPSE&#174; relative to that in subjects with normal hepatic function. The second was to perform a second carcinogenicity study of amifampridine phosphate in mice. Both have been completed and submitted to the FDA which considers these commitments complete. For a third commitment, we have also established a pregnancy surveillance program to collect and analyze information for a minimum of 10 years on pregnancy complications and birth outcomes related to FIRDAPSE&#174;. Finally, in connection with the approval of our sNDA for FIRDAPSE&#174; for the treatment of children ages six through seventeen with LEMS, we are currently conducting a pediatric safety study of juvenile toxicity in a rodent.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compassionate Use Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to make FIRDAPSE&#174; available to a limited number of patients diagnosed with congenital myasthenic syndromes or Downbeat Nystagmus through investigator-sponsored compassionate use programs. Further, when we acquired the U.S. rights to RUZURGI&#174; in July 2022, we agreed to continue to supply RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to these patients with neuromuscular conditions other than LEMS who are without access to an approved drug and were being treated with RUZURGI&#174; under investigator-sponsored INDs at the time of our settlement with Jacobus. However, this program has recently been discontinued because the API for RUZURGI&#174; is no longer available and we are therefore unable to manufacture additional product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales, Marketing and Distribution</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing of FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2019, we launched FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the U.S. We currently sell FIRDAPSE&#174; in the U.S. through a field-based force experienced in neurologic, central nervous system or rare disease products consisting at this time of approximately 40 field personnel, including sales (Regional Account Managers), thought leader liaisons and patient assistance and insurance navigation support (Patient Access Liaisons). We also have a field-based force of nine medical science liaisons who are helping educate the medical community about scientific literature concerning LEMS and FIRDAPSE&#174;. Additionally, we use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient who also has small cell lung cancer. Further, we continue to make available at no-cost a LEMS voltage gated calcium channel antibody diagnostic testing program for use by physicians who suspect that one of their patients may have LEMS and wish to reach a definitive diagnosis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we launched AGAMREE&#174;, in March 2024, we utilized the FIRDAPSE&#174; commercial field-based force for AGAMREE&#174; as well. In early 2025, we made a strategic decision to split our commercial field-based force into two units, one expressly focused on the marketing of FIRDAPSE&#174; and one expressly focused on the marketing of AGAMREE&#174;. This change will allow us to better focus on the market for each product. We expect to complete this division of our field-based force into two units by early in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting the distribution of FIRDAPSE&#174; through Catalyst Pathways&#174;, our personalized treatment support program. Catalyst Pathways&#174; is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen to an effective therapeutic dose. It also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most pharmaceutical products for ultra-orphan diseases are distributed and dispensed to patients. By using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Catalyst Pathways&#174; is the gateway for our free bridge medication for patients transitioning from investigational product while they are waiting for a coverage determination or, later on, for patients whose access is threatened by the bureaucratic complications arising from a change of insurer. The Catalyst Pathways&#174; program is also the access point for our Patient Assistance Program, which provides longer-term free medication for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#174; because they may be unable to obtain coverage from their payer despite having health insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing efforts on the challenging process to identify patients and their physicians who have diagnosed LEMS, but have not had access, awareness or understanding of this treatment for their rare disease. These patients often do not see their physician frequently, have many questions about changing treatment(s), and may not perceive the need to change to a new therapy. Further, we have begun to focus our commercial efforts to locate misdiagnosed and undiagnosed LEMS patients and provide educational and sales activities to help improve the diagnosis, understanding of the treatment, and information on the prescribing process. We plan to continue to support LEMS and rare disease patient organizational groups&#8217; efforts to generate awareness and educate patients and physicians on the diagnosis of LEMS, the impact of the disease, and the support services and treatments available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to help patients afford their medication, we, like other pharmaceutical companies who are marketing drugs for ultra-orphan conditions, have developed an array of financial assistance programs that are available to reduce patient co-pays and deductibles to a nominal affordable amount. For eligible patients with commercial coverage, a co-pay assistance program designed to keep out-of-pocket costs to $10 or less per month (currently $0.00 per month) is available for all LEMS patients prescribed FIRDAPSE&#174;. We are also donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to LEMS patients in financial need. Our goal is to ensure that no LEMS patient is ever denied access to their medication for financial reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been widely covered and reimbursed by private and public payors for the indicated small population of adult and pediatric LEMS patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canadian Market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We market FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the treatment of LEMS in Canada through a sublicensee, KYE. Our product was approved for commercialization in Canada in 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Japanese Market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, we entered into an amendment to our license agreement for FIRDAPSE&#174; with BioMarin. Under the amendment, we expanded our commercial territory for FIRDAPSE&#174;, which originally was comprised of North America, to include Japan. Further, we were granted orphan drug designation in Japan for FIRDAPSE&#174; for the symptomatic treatment of LEMS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2021, we entered into a sub-license agreement with DyDo Pharma, Inc., or DyDo, pursuant to which we sub-licensed to DyDo the Japanese rights for FIRDAPSE&#174; for the treatment of LEMS. In December 2021, we announced that DyDo had initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of FIRDAPSE&#174; for the treatment of LEMS. In December 2023, DyDo submitted a Japan NDA for FIRDAPSE&#174; to the PMDA.  On September 24, 2024, DyDo informed us that the MHLW of Japan has approved their New Drug Application for FIRDAPSE&#174; for the treatment of LEMS and DyDo began commercialization of FIRDAPSE&#174; in Japan on January 21, 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Markets for FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the amendment to our license agreement that added Japan to our territory, our territory in which we have the right to seek to commercialize FIRDAPSE&#174; has automatically expanded to include several countries in Asia-Pacific and South and Central America, and we are working to expand our FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">activities into some of these.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property and regulatory exclusivity protections for FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The bulk of our patent rights related to FIRDAPSE&#174; are derived from our license agreement with BioMarin, which was transferred to SERB in 2020. In August 2020, the U.S. Patent and Trademark Office (USPTO) allowed Patent No. 10,793,893 (the &#8217;893 patent) to our licensor and thereby to us, and the patent issued on October 6, 2020. The patent is directed to the use of suitable doses of amifampridine to treat patients, regardless of the therapeutic indication, that are slow metabolizers of amifampridine. Any drug product containing amifampridine with a label that states the patented dosing regimens and doses in the Dosing and Administration section prior to May 26, 2034, the expiration date of the patent, could possibly infringe this patent. Generic drug product labels would necessarily have to do this, and we intend to take all appropriate actions to protect our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2021, the USPTO also allowed a further application in the family of licensed intellectual property, and this second patent, Patent No. 11,060,128 (the &#8217;128 patent), issued on July 13, 2021. The patent is directed to the use of suitable doses of amifampridine to treat patients suffering with LEMS that are slow metabolizers of amifampridine. Any drug product containing amifampridine with a label for the treatment of LEMS, that states the patented dosing regimens and doses in the Dosing and Administration section of a product label, including generic drug product labels, could possibly infringe this patent prior to this patent&#8217;s expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional patents claiming priority from the patents noted above issued in March 2022 as Patent Nos. 11,268,128, 11,274,332, and 11,274,331, and extended our patent coverage to include fast metabolizers of amifampridine. These patents are now listed in the Orange Book for FIRDAPSE&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our transaction with Jacobus Pharmaceuticals, we also acquired two patents. One of these patents, 10,626,088 issued by the USPTO on April 21, 2020, was suitable for listing in the Orange Book and has now been listed in further support of FIRDAPSE&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2023 and January 16, 2024, the USPTO issued Patent Nos. 11,845,977 and 11,873,525, respectively. These new patents cover methods of treating LEMS with FIRDAPSE&#174; under fasting and fed conditions of dosing. We are also pursuing additional patent applications for FIRDAPSE&#174; in an effort to further protect our drug product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we do not or will not infringe on patents held by third parties or that third parties in the future will not claim that we have infringed on their patents. In the event that our products or technologies infringe or violate the patent or other proprietary rights of third parties, we may be prevented from pursuing product development, manufacturing or commercialization of our products that utilize such technologies. For example, there may be patents or patent applications held by others that contain claims that our products or operations might be determined to infringe or that may be broader than we believe them to be. Given the complexities and uncertainties of patent laws, there can be no assurance as to the impact that future patent claims against us may have on our business, financial condition, results of operations, or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until FIRDAPSE&#174; was approved in November 2018, no drug product containing amifampridine for any indication had been approved by the FDA such that we received five-year &#8220;new chemical entity&#8221; exclusivity from the FDA. New chemical entity exclusivity provides a five-year period of marketing exclusivity for all indications and in the absence of an Orange Book listed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent, precludes a generic from submitting an ANDA until that five-year period has expired. Further, when FIRDAPSE&#174; was approved for the treatment of LEMS patients, we received seven-year orphan drug exclusivity (ODE) for our product for the treatment of LEMS, precluding a generic filer from receiving final FDA approval until the ODE exclusivity period has expired. Because we have Orange Book listed patents for FIRDAPSE&#174;, potential generic filers were permitted to submit ANDA filings to the FDA starting on the &#8220;NCE-1&#8221; date (November 28, 2022).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of currently ongoing Paragraph IV litigation related to FIRDAPSE&#174;, see &#8220;Item 1. Business &#8211; Overview &#8211; FIRDAPSE&#174;.&#8221; The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance to whether we will prevail in this litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also in-licensed the FIRDAPSE&#174; trademark, which was registered in the U.S. in March 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protection of our intellectual property and regulatory exclusivities is a strategic priority for our business. Our ability to protect and use our intellectual property rights and regulatory exclusivity in the future development and commercialization of our products, operate without infringing the proprietary rights of others, and prevent others from infringing our proprietary rights, is crucial to our future success. See Item 1A. &#8220;Risk Factors - Risks Related to Our Intellectual Property.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FYCOMPA&#174; Product Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epilepsy is a serious neurological condition that affects more than 50 million individuals globally, 80% of whom live in developing countries. An estimated 1.7% of U.S. adults have been diagnosed with the condition. From prominent historical figures to friends or family members, most people probably know someone affected by epilepsy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA approved FYCOMPA&#174; in October 2012 as an adjunctive agent for the treatment of focal onset seizures with or without secondary generalization in patients with epilepsy at least 4 years of age. In June 2015, the agency approved a second indication for primary generalized tonic-clonic seizures in patients with epilepsy who are at least 12 years of age.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FYCOMPA&#174; is a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor. In the nervous system, glutamate is known to be a major excitatory neurotransmitter, but the exact antiepileptic mechanism of perampanel in humans is unknown. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. In addition, AMPA receptor antagonists may prevent neuronal death.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of its approval, the FDA included specific significant warnings for FYCOMPA&#174; in the prescribing information that it required to be included prominently in all communications about the product. Such warnings are known as &#8220;black box&#8221; warnings because they are traditionally surrounded by a black box to emphasize their significance. For FYCOMPA&#174;, the warning addresses rare but serious behavioral changes that occur in some patients using FYCOMPA&#174; including aggression (up to and including homicidal behavior), hostility, anger, distrust and other extreme behavioral changes; visual and auditory hallucinations; and difficulty with memory. In addition, FYCOMPA&#174; was classified as a Class III controlled substance prior to its approval due to evidence of prolonged use creating a physical dependence in some patients and the possibility of abuse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Epilepsy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epilepsy is a long-term (chronic) disease that causes repeated seizures due to abnormal electrical signals produced by damaged brain cells. A burst of uncontrolled electrical activity within brain cells causes a seizure. Epilepsy is generally diagnosed after an individual suffers two seizures within a 24-hour period. Generally, cells in the brain send messages to and receive messages from all areas of the body. These messages are transmitted via a continuous electrical impulse that travels from cell to cell. Epilepsy disrupts this rhythmic electrical impulse pattern. Instead, there are bursts of electrical energy &#8212; like an unpredictable lightning storm &#8212; between cells in one or more areas of your brain. This electrical disruption causes changes in awareness (including loss of consciousness), sensations, emotions and muscle movements. In the U.S., about 3.4 million people have epilepsy. Of this number, approximately 3 million are adults and 470,000 are children. There are 150,000 new cases of epilepsy in the U.S. each year. Worldwide, about 65 million people have epilepsy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Epileptic seizures (defined by two or more unprovoked seizures separated by more than 24 hours, or one unprovoked seizure with high probability of an additional seizure in the next 10 years, or as better defined by an epileptic syndrome) are separated into two broad categories: partial-onset seizures (POS) and generalized seizures, which affect one or both hemispheres of the brain, respectively. While many risk factors (e.g., infection, genetics, prenatal injury, or structural or metabolic abnormalities) have been elucidated, more than half of all cases of epilepsy are due to unknown causes. Regardless of the causative factor, epileptic seizures result from a persistent and uncontrolled increase in hypersynchronous neuronal excitability implicating various receptors (e.g., sodium, calcium, potassium, gamma-aminobutyric acid, or glutamate) involved in normal neurotransmission. Antiepileptic drugs (AEDs) target the various receptors to reduce neuronal excitability and control seizures, thus reducing the risk of seizure-related injuries and death. Although monotherapy is ideal for treating epileptic seizures, only about 49% of patients achieve seizure freedom while using their first appropriately selected AED. Subsequently, 62% to 66% of patients might only be able to achieve seizure freedom with a second or third appropriately selected AED, respectively,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">leaving up to one-third of patients with inadequate control of their seizures. In addition, patients may have a higher risk of toxicity if AEDs with similar mechanisms of action are used concomitantly. In the last two decades, the number of agents commercially available in the armamentarium against epilepsy has risen fourfold, few with a novel mechanism of action like FYCOMPA&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Access to FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting patients using FYCOMPA&#174; through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $5 for their FYCOMPA&#174; co-pay (with a maximum savings of $2,500 per year). The FYCOMPA&#174; instant savings card program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medigap, VA, DoD, or TRICARE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition of U.S. rights to FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2022, we entered into an Asset Purchase Agreement with Eisai, pursuant to which we acquired the U.S. rights to FYCOMPA&#174;. Pursuant to the Asset Purchase Agreement entered into with Eisai for FYCOMPA&#174;, we purchased Eisai&#8217;s regulatory approvals and documentation, product records, intellectual property, inventory, and other matters relating to the U.S. rights for FYCOMPA&#174;, in exchange for an up-front cash payment of $160 million; and royalty payments on net sales post-expiration of the patents for FYCOMPA&#174;, which royalty payments will be reduced upon generic equivalents to FYCOMPA&#174; entering the market. Finally, we have agreed to pay Eisai an additional cash payment of $25 million if a patent extension for FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was approved by the USPTO (which did not occur).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the Asset Purchase Agreement, at the closing of our purchase on January 24, 2023 we entered into two additional agreements with Eisai:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	A Transition Services Agreement under which a U.S. subsidiary of Eisai provided us with certain services for certain periods, including but not limited to, FDA Post-Marketing study requirements for FYCOMPA&#174; and Transitional Services pursuant to which Eisai&#8217;s U.S. subsidiary assisted us with the transition of commercial, market asset, finance, medical information, and supply issues; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	A Supply Agreement under which Eisai has agreed to manufacture FYCOMPA&#174; for us for at least seven years at prices to be updated on a yearly basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These additional agreements became effective upon the closing of the transaction with Eisai on January 24, 2023. The transition services under the Transition Services Agreement ended on December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials Supporting FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partial Onset Seizures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy of FYCOMPA&#174; in partial-onset seizures, with or without secondary generalization, was studied in patients who were not adequately controlled with 1 to 3 concomitant AEDs in 3 randomized, double-blind, placebo-controlled, multicenter trials (Studies 1, 2, and 3) in adult and pediatric patients (12 years of age and older). All trials had an initial 6-week Baseline Period, during which patients were required to have more than five seizures in order to be randomized. The Baseline Period was followed by a 19-week Treatment Period consisting of a 6-week Titration Phase and a 13-week Maintenance Phase. Patients in these 3 trials had a mean duration of epilepsy of approximately 21 years and a median baseline seizure frequency ranging from 9 to 14 seizures per 28 days. During the trials, more than 85% of patients were taking 2 to 3 concomitant AEDs with or without concurrent vagal nerve stimulation, and approximately 50% were on at least one AED known to induce CYP3A4, an enzyme critical to the metabolism of FYCOMPA&#174; (i.e., carbamazepine, oxcarbazepine, or phenytoin), resulting in a significant reduction in FYCOMPA&#174;&#8217;s serum concentration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each study evaluated placebo and multiple FYCOMPA&#174; dosages. During the Titration period in all 3 trials, patients on FYCOMPA&#174; received an initial 2 mg once daily dose, which was subsequently increased in weekly increments of 2 mg per day to the final dose. Patients experiencing intolerable adverse reactions were permitted to have their dose reduced to the previously tolerated dose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint in Studies 1, 2, and 3 was the percent change in seizure frequency per 28 days during the Treatment Period as compared to the Baseline Period. The criterion for statistical significance was p&lt;0.05. A statistically significant decrease in seizure rate was observed at doses of 4 to 12 mg per day. Dose response was apparent at 4 to 8 mg with little additional reduction in frequency at 12 mg per day.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary Generalized Tonic-Clonic Seizures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy of FYCOMPA&#174; as adjunctive therapy in patients 12 years of age and older with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic seizures was established in one multicenter, randomized, double-blind, placebo-controlled study (Study 4), conducted at 78 sites in 16 countries. Eligible patients on a stable dose of 1 to 3 AEDs experiencing at least 3 primary generalized tonic-clonic seizures during the 8-week baseline period were randomized to either FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or placebo. Efficacy was analyzed in 162 patients (FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N=81, placebo N=81) who received medication and at least one post-treatment seizure assessment. Patients were titrated over 4 weeks up to a dose of 8 mg per day or the highest tolerated dose and treated for an additional 13 weeks on the last dose level achieved at the end of the titration period. The total treatment period was 17 weeks. Study drug was given once per day.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint was the percent change from baseline in primary generalized tonic-clonic seizure frequency per 28 days during the treatment period as compared to the baseline period. The criterion for statistical significance was p&lt;0.05. A statistically significant decrease in seizure rate was observed with FYCOMPA&#174; compared to placebo.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Protections for FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent protection for FYCOMPA&#174; is primarily from two patents listed in the Orange Book. The first, U.S. patent no. 6,949,571 (the '571 patent) will expire no earlier than May 23, 2025, inclusive of patent term extension. A request for reconsideration of patent term extension to extend the period until June 8, 2026 was denied. The second FYCOMPA&#174; patent in the Orange Book is U.S. Patent No. 8,772,497 (the '497 patent), which expires on July 1, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expiration of Patent Protection for FYCOMPA&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the anticipated loss of exclusivity for FYCOMPA&#174; tablets on May 23, 2025 and for the FYCOMPA&#174; oral suspension on December 15, 2025, we expect that one or more generic versions of each FYCOMPA&#174; formulation will come onto the market in 2025. We are currently executing our strategy in preparation for the patent expiry of the solid dose of FYCOMPA&#174; in the face of generic competition. The level of generic competition we will face is uncertain and we are currently exploring our options for future commercialization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AGAMREE&#174; Product Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; is a structurally unique steroidal anti-inflammatory drug to treat children and adults living with DMD. In clinical studies, AGAMREE&#174; showed evidence of inhibition of pro-inflammatory NF-kB (nuclear factor kappa light chain enhancer of activated B cells) pathways, which are, a family of highly conserved transcription factors that regulate many important cellular behaviors, in particular, inflammatory responses and cellular growth.  This inhibition is achieved through high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties. It is hoped that AGAMREE&#174; will demonstrate similar efficacy to traditional corticosteroids with reduced negative downstream impacts and side effects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA approved AGAMREE&#174; for the treatment of DMD in patients aged 2 and older on October 26, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials Supporting AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A randomized, double-blind, placebo and prednisone-controlled trial of vamorolone was carried out in patients with DMD. The trial met the primary (time to stand velocity after 24 weeks for vamorolone, 6 mg/kg per day vs placebo) and first 4 sequential secondary motor function endpoints. Study participants receiving vamorolone, 2 mg/kg per day, and vamorolone, 6 mg/kg per day, showed improvements in multiple functional endpoints over the 24-week treatment period as compared to placebo. The statistical thresholds for the primary outcome and first 4 secondary outcomes for vamorolone treatment were met, and vamorolone demonstrated efficacy across both dose ranges. The differences in time to stand from supine velocity (TTSTAND) were clinically meaningful. The differences in 6-minute walk test (6MWT)  were also clinically meaningful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trial validated previous open-label findings where a more normal growth trajectory was observed over 18-month and 30-month periods in vamorolone treated boys with DMD. Furthermore, bone turnover markers supported the improved profile of vamorolone on bone health.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Access to AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting AGAMREE&#174; through our Catalyst Pathways&#174; Program, which includes a dedicated, personalized support team that assists families through the AGAMREE&#174; treatment journey, from answering questions to coordinating financial assistance programs for eligible patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition of AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 19, 2023, we entered into a License and Collaboration Agreement (License Agreement) and an Investment Agreement (Investment Agreement) with Santhera. Under the License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera&#8217;s investigational product candidate, AGAMREE&#174; (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both transactions closed on July 18, 2023. Under the License Agreement, upon closing, we made a $75 million payment to Santhera in return for the exclusive North American license for AGAMREE&#174;. Additionally, following approval of the NDA for the drug, on October 26, 2023, we became obligated to make milestone payments of $36 million to Santhera, $26 million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of which will be used by Santhera to make milestone payments to third parties. This payment were made in the fourth quarter of 2023. We may also be obligated to pay future regulatory and commercial milestone payments to Santhera tied to calendar year sales of AGAMREE&#174;, as well as commercial royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the rights to commercialize the product in North America, the License Agreement provides us with the right of first negotiation for AGAMREE&#174; in Japan should Santhera pursue partnership opportunities in that region. Additionally, we will hold the North American rights to any future approved indications for AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the closing of the License Agreement, we made a strategic investment into Santhera in which we acquired 1,414,688 of Santhera&#8217;s post-reverse split ordinary shares (representing approximately 11.26% of Santhera&#8217;s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume weighted average price prior to signing), with the approximately $15.7 million investment to be used by Santhera for Phase IV studies of AGAMREE&#174; in DMD and future development of additional indications for AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Protections for AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; is protected by multiple patents with expiration dates from August 2028 to July 2040. The Orange Book listed patents granted by the USPTO are as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.216%;box-sizing:content-box;"/>
    <td style="width:2.539%;box-sizing:content-box;"/>
    <td style="width:52.729%;box-sizing:content-box;"/>
    <td style="width:2.599%;box-sizing:content-box;"/>
    <td style="width:20.916%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">U.S. Patent No.</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Indication</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,857,161</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-hormonal steroid modulators of NF-kB for treatment of disease</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 28, 2029</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,334,279</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-hormonal steroid modulators of NF-kB for treatment of disease</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 28, 2029</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,471,471</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aqueous oral pharmaceutical suspension compositions</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 17, 2040</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,382,922</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aqueous oral pharmaceutical suspension compositions</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 16, 2040</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,690,853</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-hormonal steroid modulators of NF-&#954;B for treatment of disease</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2033</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,833,159</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-hormonal steroid modulators of NF-&#954;B for treatment of disease</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 28, 2029</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,201,639</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aqueous oral pharmaceutical suspension compositions</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 17, 2040</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Duchenne Muscular Dystrophy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is the most common of four conditions known as dystrophinopathies, with the others being Becker Muscular Dystrophy, or BMD, a mild form of DMD; an intermediate clinical presentation between BMD and DMD, and DMD-associated dilated cardiomyopathy (heart disease), with little or no clinical skeletal, or voluntary, muscle disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD symptom onset is in early childhood, usually between the ages of 2 and 3. The disease primarily affects boys, but in rare cases can affect girls. For girls who are carriers, about 2.5 to 20 percent may have mild symptoms. In the U.S., the incidence of DMD is estimated to be about 1 in 3,600 live male births.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD causes muscle weakness that worsens over time, and common symptoms include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progressive muscle weakness and atrophy that begins in the legs and pelvis, occurring less severely in the arms, neck, and other areas of the body.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calf muscle hypertrophy (increase in muscle size).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Difficulty climbing up stairs. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Difficulty walking that gets worse over time. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frequent falls.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waddling gait (walk).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Toe walking.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fatigue.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other common symptoms of DMD include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiomyopathy.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breathing difficulties and shortness of breath.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cognitive impairment and learning difficulty.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delayed speech and language development.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developmental delay.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scoliosis.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short stature.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD is caused by a mutation in the gene that gives instructions for a protein called dystrophin. Dystrophin is a critical part of the dystrophin-glycoprotein complex (DGC), which plays an important role as a structural unit of muscle. In DMD, both dystrophin and DGC proteins are missing, which ultimately leads to the death of muscle cells. People with DMD have less than 5% of the normal quantity of dystrophin needed for healthy muscles. As people with DMD age, their muscles can't replace dead cells with new ones, and connective and adipose (fat) tissue gradually replace muscle fibers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD has X-linked recessive inheritance, but about 30% of cases happen spontaneously with no family history of the condition. X-linked diseases are located on the X chromosome. Recessive inheritance means that when there are two copies of the responsible gene, both copies must have a pathogenic variant or mutation in order for a person to have the condition. Since males only have one X chromosome, any mutation on that chromosome will cause DMD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are licensed in Florida as a virtual drug manufacturer, which means that we have no in-house manufacturing capacity and we are obligated to rely on contract manufacturers and packagers. We have no plans to build or acquire the manufacturing capability needed to manufacture any of our research materials or commercial products, and we expect that our drug products and drug substances will be prepared by contractors with suitable capabilities for these tasks and that we will enter into appropriate supply agreements with these contractors at appropriate times in the development and commercialization of our products. Because we will use contractors to manufacture and supply our products, we will be reliant on such contractors. Further, the contractors selected would have to be inspected by the FDA and found to be in substantial compliance with federal regulations in order for an application for one of our drug candidates to be approved, and there can be no assurance that the contractors we select would pass such an inspection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into agreements with a supplier of the active pharmaceutical ingredient (API) contained in FIRDAPSE&#174; for future requirements and we have contracted with third party contract manufacturers who are manufacturing FIRDAPSE&#174; tablets for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our Supply Agreement with Eisai, Eisai has agreed to manufacture and supply to us finished bulk FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tablets for us for a seven-year period that will run through at least the end of 2029. In addition, Eisai has assigned to us third party manufacturing contracts related to final packaging of bulk FYCOMPA&#174; tablets and also the manufacture of the oral solution formulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our License and Collaboration Agreement with Santhera, we have agreed to purchase supplies of AGAMREE&#174; from Santhera until January 1, 2026, after which we have the right, but not an obligation, to contract with outside, third party manufacturers for the manufacture and supply of AGAMREE&#174;. In that regard, we have begun the process of preparing to add additional third party manufacturers for the manufacture and supply of AGAMREE&#174;.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Changes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any significant change that we make for any of our drug products must be approved by the FDA in an sNDA. If the manufacturing plan and data are insufficient, any sNDA we submit will not be approved. Before an sNDA can be approved,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our manufacturers must also demonstrate compliance with FDA&#8217;s cGMP regulations and policies. Further, even if we receive approval of any sNDAs for our drug product(s), if our manufacturers do not follow cGMPs in the manufacture of our products, it may delay product launches or shipments and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we contract with third parties to manufacture our products, our contract manufacturers are required to comply with all applicable environmental laws and regulations that affect the manufacturing process. As a result, we do not believe that we will have any significant direct exposure to environmental issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by us would likely compete with currently marketed and potentially new drugs and therapies even though they are not indicated for these conditions. We also may face generic competition upon the loss of exclusivity and/or patent protection for our products. There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations that compete with us in developing various approaches to the treatment of orphan diseases. Many of these organizations have substantially greater financial, technical, marketing and manufacturing resources than we have.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before the approval of FIRDAPSE&#174;, LEMS was generally treated with unapproved drugs and therapies including steroids, azathioprine, other immunosuppressants and intravenous immunoglobulin, which work by suppressing the immune system, and pyridostigmine. Plasma exchange has also been used in an attempt to remove antibodies from the body. Further, one other product, guanidine HCl tablets, was approved many years ago (during a period when drugs were not required to be reviewed by the FDA for both safety and effectiveness) for use in the treatment of LEMS. However, this drug has significant side effects and is not currently viewed as an effective treatment for LEMS. Notwithstanding, drugs may be prescribed by physicians for the treatment of LEMS whether or not they are considered effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, we are aware that amifampridine has been available in the past from compounding pharmacies and may remain available, even though FIRDAPSE&#174; has been approved and is commercially marketed in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FYCOMPA&#174; is the first and only AED that targets a specific receptor in the brain called &#8220;AMPA&#8221;. The receptor plays a role in allowing seizures to occur. Seizures have historically been treated with benzodiazepines such as clonazepam (Klonopin) and lorazepam (Ativan), GABA inhibitors such as gabapentin (Neurontin), phenobarbital (Luminal), and pregabalin (Lyrica), and sodium channel blockers such as carbamazepine (Tegretol) and lacosamide (Vimpat). Additionally, surgical options such as deep brain stimulation have been used in patients who have failed polypharmacy. Finally, there are multiple compounds that have been recently approved or are in late-stage development for focal epilepsy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the expiration of patent protection for FYCOMPA&#174;, we expect that we will also face competition from generic manufacturers. At this time, we are not yet aware of the scope of this competition, including the identity of such manufacturers and pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market for DMD treatment is highly competitive, with multiple lines of treatment and medications, both name brand and generic. The first-line treatment has long been and continues to be corticosteroids. On February 9, 2017, the FDA approved Emflaza (deflazacort), a corticosteroid marketed by PTC Therapeutics for the treatment of DMD in patients 5 years old and older.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are many companies which have announced plans for pre-clinical candidates and clinical development for the treatment of DMD, including gene transfer and/or gene editing therapies. One of those gene therapy treatments, Sarepta&#8217;s Elevidys has been approved for the treatment of DMD and, in June 2024, received an expanded label for treatment of DMD patients over age five, even though the drug failed the primary endpoint in a Phase 3 clinical trial in that population. Since the drug was only evaluated with co-treatment with prednisone as an immunosuppressant, we expect that DMD patients transitioning to Elevidys may (in the short-term) delay initiating use of AGAMREE&#174; while waiting for access to such gene therapy, or stop their AGAMREE&#174; therapy during the course of their gene therapy treatment. We believe that patients are likely to return to a differentiated steroid like AGAMREE&#174; post the immunosuppression period due to its potential superior clinical profile.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we believe that in the long term, corticosteroids like AGAMREE&#174;, will continue to be the foundational therapy for the treatment of DMD.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factors affecting competition generally</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, our ability to compete depends in large part upon:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;     our ability to complete clinical development and obtain regulatory approvals for our drug candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the demonstrated efficacy, safety and reliability of our drug candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the timing and scope of regulatory approvals;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	product acceptance by physicians and other health care providers;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the willingness of payors to reimburse for our product;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	protection of our proprietary rights and the level of generic competition;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the speed at which we develop drug candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	our ability to supply commercial quantities of a product to the market;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.733%;text-indent:-3.783%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	our ability to obtain reimbursement from private and/or public insurance entities for product use in approved indications;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	our ability to recruit and retain skilled employees; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the availability of capital resources to fund our development and commercialization activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following our acquisition of the U.S. rights to FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the North American rights for AGAMREE&#174;, we are continuing to work to broaden and diversify our product portfolio through acquisitions of early and/or late-stage products or companies or technology platforms in rare disease therapeutic categories. To accomplish these priorities, we are continuing to employ a disciplined approach to evaluating assets, and we believe that this strategic expansion will better position our company long term to build out a broader more diversified portfolio of drug candidates (which should add greater value to our company over the near and long-term). In that regard, we are currently exploring several additional potential opportunities to acquire companies with commercial drug products and/or drug products in development or to in-license or acquire commercialized drug products or drug products in development. However, other than the recent License Agreement with KYE for AGAMREE&#174;, no additional definitive agreements have been entered into to date and there can be no assurance that our efforts to continue to broaden and diversify our product portfolio will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the U.S., at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, record-keeping, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Our drugs must be approved by the FDA through the NDA process before they may be legally marketed in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., drugs are subject to rigorous regulation by the FDA under the FDCA and implementing regulations, as well as other federal and state statutes. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the U.S. generally involves the following: completion of pre-clinical laboratory tests, animal studies and formulation studies according to the FDA&#8217;s good laboratory practice (GLP) regulations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	submission of an investigational new drug application (IND) which must become effective before human clinical trials may begin and which must include approval by an institutional review board, or IRB, at each clinical site before the trials are initiated;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use conducted in compliance with federal regulations and good clinical practice</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(GCP), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	submission to, and acceptance by, the FDA of an NDA;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP regulations to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	potential FDA audit of the non-clinical and clinical trial sites that generated the data in support of the NDA; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	FDA review and approval of the NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a pharmaceutical candidate is identified for development it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. Prior to beginning human clinical trials, an IND sponsor must submit an IND to the FDA. The IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some pre-clinical or non-clinical testing may continue even after the IND is submitted. In addition to including the results of the pre-clinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated, if the trial lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30&#8211;day time period, raises concerns or questions about the conduct of the trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may, at any time, impose a clinical hold on ongoing clinical trials. If the FDA imposes a clinical hold, clinical trials cannot commence or recommence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of one or more qualified investigators in accordance with federal regulations and GCP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials must be conducted under protocols detailing the objectives of the trial and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. Further, an Institutional Review Board (IRB) at each institution participating in the clinical trial must review and approve each protocol before any clinical trial commences at that institution. All research subjects must provide informed consent, and informed consent information must be submitted to the IRB for approval prior to initiation of the trial. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if adverse events or other certain types of other changes occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three phases. A fourth, or post-approval, phase may include additional clinical studies. These phases generally include the following, and may be sequential, or may overlap or be combined:</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Phase 1 clinical trials involve the initial introduction of the drug into human subjects. These studies are designed to determine the safety of usually single doses of the compound and determine any dose limiting intolerance, as well as evidence of the metabolism and pharmacokinetics of the drug in humans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Phase 2 clinical trials usually involve studies in a limited patient population to evaluate the safety and efficacy of the drug for specific, targeted indications, to determine dosage tolerance and optimal dosage, and to identify possible adverse effects and safety risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	In Phase 3, if a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 (or occasionally Phase 1) studies, the Phase 3 studies will be conducted to further confirm clinical efficacy, optimal dosage and safety within an expanded population which may involve geographically diverse clinical trial sites. Generally, but not always, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Phase 4 clinical trials are studies required of or agreed to by a sponsor that are conducted after the FDA has approved a product for marketing. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials where necessary could result in withdrawal of approval for products approved under accelerated approval regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While Phase 1, Phase 2, and Phase 3 tests are generally required for approval of an NDA, certain drugs may not require one or more steps in the process depending on other testing and the situation involved. Additionally, the FDA, an IRB, or the sponsor may stop testing at any time if results show patients being exposed to unnecessary health risks or overly dangerous side effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other requirements, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA approval of an NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of product development, pre-clinical studies and clinical studies, together with other detailed information, including information on the chemistry, manufacture and composition of the product. The FDA has 60 days from its receipt of the NDA to review the application to ensure that it is sufficiently complete for substantive review before filing it. The FDA may request additional information rather than file an NDA. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review. The submission of an NDA is also subject to the payment of a substantial application fee (for FDA fiscal year 2025 this fee is $4,310,002), although a waiver of such fee may be obtained under certain limited circumstances, including when the drug that is subject of the application has received Orphan Drug Designation for the indication sought. Further, the sponsor of an approved NDA is subject to an annual program fee, which for FDA fiscal year 2025 is $403,889 per prescription drug product. User fees typically increase annually. The approval process is lengthy and difficult, and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured to determine whether its manufacturing is cGMP&#8211;compliant to assure and preserve the product&#8217;s identity, strength, quality, purity and stability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA&#8217;s evaluation of the NDA submission or manufacturing facilities is not favorable, the FDA will issue a complete response letter. The complete response letter outlines the deficiencies in the submission and often requires additional testing or information in order for the FDA to reconsider the application. Even after submitting this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. With limited exceptions, the FDA may withhold approval of an NDA regardless of prior advice it may have provided or commitments it may have made to the sponsor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA is approved, changes to the conditions of approval, including additional indications, are made by the submission of a supplement to the NDA. The supplemental NDA (sNDA) must contain all of the information necessary to support the change. In the case of a new indication, that information usually consists of at least one clinical trial, and often more. Like an NDA, FDA determines whether the sNDA is sufficiently complete to permit review before it files the sNDA. FDA then reviews the sNDA. Like an NDA, FDA can either approve the sNDA or issue a complete response letter outlining the deficiencies in the sNDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. As a condition of NDA approval, the FDA may also require a risk evaluation and mitigation strategy (REMS), to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for the healthcare professionals, and other Elements To Assure Safe Use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or sNDA before the change can be implemented. An sNDA for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled Substance Regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug product approved by FDA may be subject to scheduling as a controlled substance under the Controlled Substances Act (CSA) depending on the drug&#8217;s potential for abuse. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements administered by the U.S. Drug Enforcement Administration (DEA). The DEA classifies controlled substances into five schedules. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted medical use&#8221; in the U.S., lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse. FYCOMPA&#174; is a Schedule III drug (DEA Controlled Substance Code 2261), which means that the DEA has determined that (i) it has a potential for abuse less than the drugs or other substances in Schedules I and II, (ii) it has a currently accepted medical use in treatment in the U.S., and (iii) abuse may lead to moderate or low physical dependence or high psychological dependence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule III drugs are subject to certain DEA import volume limits and state regulations relating to manufacturing, storage, distribution and physician prescription procedures, including limitations on prescription refills. In addition, the third parties who perform our clinical and commercial manufacturing, distribution, and dispensing for FYCOMPA&#174; are required to maintain necessary DEA registrations and state licenses. The DEA periodically inspects facilities for compliance with its rules and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orange Book Listing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims covering the applicant&#8217;s product or approved methods of using the product. Upon approval of a drug, each of the patents listed in the application for the drug are then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon NDA approval of a new chemical entity (NCE), which is a drug product that contains an active moiety that has never been approved by FDA in any other NDA, that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug. A drug may obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for the previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. During this period of exclusivity, FDA cannot approve an ANDA for a generic drug that includes the change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there cannot be a Paragraph IV certification, and, thus, no ANDA can be filed before the expiration of the exclusivity period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 505(b)(2) NDAs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most drug products obtain FDA marketing approval pursuant to an NDA or an ANDA. A third alternative is a special type of NDA, commonly referred to as a Section 505(b)(2), or 505(b)(2), NDA, which enables the applicant to rely, in part, on FDA&#8217;s previous approval of a similar product, or published literature, in support of its application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#8217;s prior findings of safety and effectiveness or published literature is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical or clinical studies of the new product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the Section 505(b)(2) applicant is relying on studies conducted on previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications with respect to any patents for the approved product on which the application relies that are listed in the FDA&#8217;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. Specifically, the applicant must certify for each listed patent that either: (1) the required patent information has not been filed; or (2) the listed patent has expired; or (3) the listed patent has not expired but will expire on a particular date, and approval is not sought until after patent expiration; or (4) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product&#8217;s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the applicant does not challenge one or more listed patents through a Paragraph IV certification, the FDA will not approve the Section 505(b)(2) NDA application until all the listed patents claiming the referenced product have expired. Further, the FDA also will not approve, as applicable, a Section 505(b)(2) NDA application until any non-patent exclusivity has expired, for example: five-year exclusivity period for obtaining approval of an NCE; or three-year exclusivity period for an approval based on new clinical trials; or pediatric exclusivity, listed in the Orange Book for the referenced product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A section 505(b)(2) NDA applicant must send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. If the relevant patent holder elects to initiate litigation, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its product, only to be subject to significant delay and patent litigation before its product may be commercialized. Alternatively, if the NDA applicant or relevant patent holder does not file</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a patent infringement lawsuit within the specified 45-day period, the FDA may approve the Section 505(b)(2) application at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANDAs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generic drugs may enter the market after the approval of an ANDA. The ANDA development process typically does not require new pre-clinical or clinical studies, but it does typically require one or more bioequivalence studies to show that the ANDA drug is bioequivalent to the previously approved brand name reference listed drug. Bioequivalence studies compare the bioavailability of the proposed drug product with that of the approved listed product containing the same active ingredient. Bioavailability is a measure of the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. A demonstration of bioequivalence means that the rate and extent of absorption of the ANDA drug is not significantly different from the rate and extent of absorption of the brand name reference listed drug when administered at the same molar dose under similar experimental conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As noted above, generic drug products are generally introduced to the marketplace at the expiration of patent protection and non-patent market exclusivity for the reference listed drug. However, if an ANDA applicant is the first ANDA applicant to submit an ANDA containing a Paragraph IV certification, that ANDA may be eligible for a period of generic marketing exclusivity on approval. This exclusivity, which under certain circumstances must be shared with other ANDA applicants with Paragraph IV certifications, lasts for 180 days, during which the FDA cannot grant final approval to other ANDA sponsors of an application for a generic equivalent to the same reference drug. Under certain circumstances, eligibility for 180-day exclusivity may be forfeited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various types of changes to an approved ANDA must be requested in a prior approval supplement. In addition, some changes may only be approved after new bioequivalence studies are conducted or other requirements are satisfied. In addition, the ANDA applicant must demonstrate that manufacturing procedures and operations conform to FDA cGMP requirements. Facilities, procedures, operations, and/or testing of products are subject to periodic inspection by the FDA and other authorities. In addition, the FDA conducts pre-approval and post-approval reviews and inspections to determine whether the systems and processes are in compliance with cGMP and other FDA regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also user fees for ANDA applicants, sponsors, and manufacturers. For fiscal year 2025, the application fees are $321,920 per ANDA application and the facility fees are $231,952 per domestic finished dosage form facility, $246,952 per foreign finished dosage form facility, $41,580 per domestic active pharmaceutical ingredient facility, and $56,580 per foreign active pharmaceutical ingredient facility. In addition, there is a new annual program fee based on the size of the generic drug applicant. These user fees typically increase each fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Regulatory Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulation by the FDA and certain state regulatory agencies, we are also subject to a variety of foreign regulations governing clinical trials and the marketing of other products. Outside of the U.S., our ability to market a product depends upon receiving a marketing authorization from the appropriate regulatory agencies. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. In any country, however, we will only be permitted to commercialize our products if the appropriate regulatory agency is satisfied that we have presented adequate evidence of safety, quality and efficacy. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing of the product in those countries. The regulatory approval and oversight process in other countries includes all of the risks associated with regulation by the FDA and certain state regulatory agencies as described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the European Union regulatory system, applications for drug approval may be submitted either in a centralized or decentralized manner. Under the centralized procedure, a single application to the European Medicines Agency leads to an approval granted by the European Commission which permits marketing of the product throughout the European Union. The decentralized procedure provides for mutual recognition of nationally approved decisions and is used for products that do not comply with requirements for the centralized procedure. Under the decentralized procedure, the holders of national marketing authorization in one of the countries within the European Union may submit further applications to other countries within the European Union, who will be requested to recognize the original authorization based on an assessment report provided by the country in which marketing authorization is held.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical pricing and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In both the U.S. and foreign markets, our ability to commercialize our products successfully, and to attract commercialization partners for our products, depends in significant part on the availability of adequate financial coverage and reimbursement from third party payors, including, in the U.S., governmental payors such as Medicare and Medicaid, managed care organizations, private commercial health insurers and PBMs. Third party payors are increasingly challenging the prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic or other studies in order to further demonstrate the value of our products. Even with the availability of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies, our products may be considered less safe, less effective or less cost-effective than alternative products, and third party payors may not provide coverage and reimbursement for our drug candidates, in whole or in part.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Political, economic and regulatory influences are subjecting the health care industry in the U.S. to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system in ways that could significantly affect our business, including the Patient Protection and Affordable Care Act of 2010 (the Affordable Care Act) and the Inflation Reduction Act of 2022 (IRA).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that in the U.S., Congress, state legislatures, and private sector entities will continue to consider and may adopt healthcare policies intended to curb rising healthcare costs. These cost-containment measures could include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	public transparency on qualifying price increases and/or discounting to better inform purchasers;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	additional controls on government-funded reimbursement for drugs;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	controls on healthcare providers;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	reform of drug importation laws;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	entering into contractual agreements with payors; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	expansion of use of managed-care systems in which healthcare providers contract to provide comprehensive healthcare for a fixed cost per person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare industry or third party coverage and reimbursement may be enacted in the future or what effect such legislation, regulations or policies would have on our business. Any cost containment measures, including those listed above, or other healthcare system reforms that are adopted may have a material adverse effect on our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the pricing of pharmaceutical products generally, and particularly the pricing of orphan drugs, has received scrutiny from the press, and from members of Congress in both parties. Some members of the medical community and some politicians have also made statements in the press on the potential pricing of orphan drugs generally and on the pricing of our product specifically. The impact of this scrutiny on us and on the pricing of orphan drugs and other pharmaceutical products generally cannot be determined at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Reimbursement in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by third party payors, such as state and federal governments, including Medicare and Medicaid, managed care providers, private commercial insurance plans and pharmacy benefit management (PBM) plans. Decisions regarding the extent of coverage and the amount of reimbursement are expected to be made on a plan-by-plan, and in some cases, on a patient-by-patient basis. Particularly given the rarity of LEMS and DMD, our experience has been that securing coverage and appropriate reimbursement from third party payors requires targeted education and highly skilled insurance navigation experts that have experience with rare disease launches and medical exception processes at insurance companies to provide patient coverage for important rare disease therapies. To that end, we have engaged a dedicated team of field-based market access account managers and reimbursement experts as well as a patient service center staffed with experienced personnel focused on ensuring that clinically-qualified patients have access to our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance, however, as to whether payors will continue to cover our products, and if so, at what level of reimbursement. In that regard, we have advised payors that we will provide free medication to support titration and confirm patient therapeutic benefit. Further, when necessary, we provide patients with access to therapy at no charge while those patients are awaiting coverage decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some jurisdictions, including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983 (ODA), the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for this type of disease or condition will be recovered from sales in the U.S. for that drug. In the U.S., Orphan Drug Designation must be requested before submitting an application for marketing approval. An Orphan Drug Designation does not shorten the duration of the regulatory review and approval process. The grant of an Orphan Drug Designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and efficacy of a compound must be established through adequate and well-controlled studies. If a product which has been granted Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to an orphan drug exclusivity period, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as where an alternative product demonstrates clinical superiority to the product with orphan exclusivity. In addition, holders of exclusivity for orphan drugs are expected to assure the availability of sufficient quantities of their orphan drugs to meet the needs of patients. Failure to do so could result in the withdrawal of marketing exclusivity for the drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan drug exclusivity contained in the ODA has been the subject of recent scrutiny from the press, from some members of Congress and from some in the medical community. There can be no assurance that the exclusivity granted in the ODA to orphan drugs approved by the FDA will not be modified in the future, and as to how any such change might affect our products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The European Orphan Drug Regulation is considered for drugs intended to diagnose, prevent or treat a life-threatening or very serious condition afflicting five or fewer per 10,000 people in the EU, including compounds that for serious and chronic conditions would likely not be marketed without incentives due to low market return on the sponsor&#8217;s development investment. The medicinal product considered should be of significant benefit to those affected by the condition. Benefits of being granted Orphan Medicinal Product Designation are significant, including eight years of data exclusivity, two years of marketing exclusivity and a potential one-year extension of both. The EU Community and Member States may not accept or grant for ten years a new marketing authorization or application for another drug for the same therapeutic indication as the orphan drug, although the ten-year period can be reduced to six years if, after the end of the fifth year, available evidence establishes that the product is sufficiently profitable not to justify maintenance of the marketing exclusivity. A supplementary protection certificate may extend the protection six months beyond patent expiration if that is later than the orphan drug exclusivity period. To apply for the supplementary protection, a pediatric investigation plan, or PIP, must be included in the market application. In Europe all drugs now seeking marketing authorization need to have a PIP agreed with the European Medicines Agency (EMA) before it can be approved, even if it is a drug being developed specifically for a pediatric indication. If a product is developed solely for use in the pediatric population, then a Pediatric Use Marketing Authorization, or PUMA, may provide eight years of data exclusivity and ten years of marketing exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Therapy Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the fast track program features (see below for more details on fast track designation), as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an organizational commitment to involve senior management in such guidance. Actions taken to expedite development may include the following actions, as appropriate holding meetings with the sponsor and review team throughout the development of the drug;</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the non-clinical and clinical data necessary for approval is as efficient as possible;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the cross-discipline members of the review team (i.e., clinical, pharmacology-toxicology, chemistry, manufacturing and control (CMC), compliance) for coordinated internal interactions and communications with the sponsor through the review division&#8217;s Regulatory Health Project Manager; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track Designation and Accelerated Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA must determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the fast track program and FDA&#8217;s accelerated approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by FDA. The Food and Drug Omnibus Reform Act (FDORA) included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. FDORA enables the FDA to initiate enforcement action for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections of a fast track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under FDA policies, a drug candidate is eligible for priority review, or review within a six to eight-month time frame from the time a complete NDA is submitted, if the drug candidate is intended for the treatment, diagnosis, or prevention of a serious or life-threatening condition, demonstrates the potential to address an unmet medical need, or provides a significant improvement compared to marketed drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure of Clinical Trial Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-Kickback, False Claims Laws &amp; the Prescription Drug Marketing Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to FDA restrictions on marketing of drug products, other state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and patients, prescribers, purchasers and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Centers for Medicare &amp; Medicaid Services (CMS) has issued a final rule that requires manufacturers of approved prescription drugs to collect and report information on payments or transfers of value to physicians, physician assistants, certain types of advanced practice nurses and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The information reported each year is made publicly available on a searchable website. Failure to submit required information may result in civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products, to report gifts and payments to individual physicians in these states and to report certain pricing information, including price increases. Other states prohibit various other marketing-related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prescription drug advertising is subject to federal, state and foreign regulations. In the U.S., the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act (DSCSA), has imposed &#8220;track and trace&#8221; requirements on the distribution of prescription drug products by manufacturers, distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization) on prescription drug products in order to eventually establish an electronic interoperable prescription product to system to identify and trace certain prescription drugs distributed in the U.S. and preempts existing state drug pedigree laws and regulations on this topic. The DSCSA also establishes new requirements for the licensing of wholesale distributors and third party logistic providers, although FDA regulations addressing wholesale distributors and third party logistics providers have not yet been promulgated. We serialize our product at both the package and homogeneous case level, pass serialization and required transaction information to our customers, and believe that we comply with all such requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Programs for Marketed Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Medicaid, the 340B Drug Pricing Program, and Medicare</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal law requires that a pharmaceutical manufacturer, as a condition of having its products receive federal reimbursement under Medicaid and Medicare Part B, must pay rebates to state Medicaid programs for all units of its covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program under either a fee-for-service arrangement or through a managed care organization. This federal requirement is effectuated through a Medicaid drug rebate agreement between the manufacturer and the Secretary of Health and Human Services (HHS). CMS administers the Medicaid drug rebate agreements, which provide, among other things, that the drug manufacturer will pay rebates to each state Medicaid agency on a quarterly basis and report certain price information on a monthly and quarterly basis. The rebates are based on prices reported to CMS by manufacturers for their covered outpatient drugs. For innovator products, that is, drugs that are marketed under approved NDAs, the basic rebate amount is generally the greater of 23.1% of the average manufacturer price (AMP) for the quarter or the difference between such AMP and the best price for that same quarter. The AMP is the weighted average of prices paid to the manufacturer (1) directly by retail community pharmacies and (2) by wholesalers for drugs distributed to retail community pharmacies. The best price is essentially the lowest price available to non-governmental entities. Innovator products are also subject to an additional inflation rebate that is based on the amount, if any, by which the product&#8217;s current AMP has increased over the baseline AMP, which is the AMP for the first full quarter after launch, adjusted for inflation. To date, the rebate amount for a drug has been capped at 100% of the AMP; however, effective January 1, 2024, this cap was eliminated, which means that a manufacturer could pay a rebate amount on a unit of the drug that is greater than the average price the manufacturer receives for the drug. For non-innovator products, generally generic drugs marketed under approved ANDAs, the basic rebate amount is 13% of the AMP for the quarter. Non-innovator products are also subject to an additional inflation rebate. The additional rebate is similar to that discussed above for innovator products, except that the baseline AMP quarter is the fifth full quarter after launch (for non- innovator multiple source drugs launched on April 1, 2013 or later) or the third quarter of 2014 (for those launched before April 1, 2013). The terms of participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in additional or lesser rebate liability, depending on the direction of the correction. In addition to retroactive rebates, if a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturer were found to have knowingly submitted false information to the government, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information. CMS may also impose penalties against a manufacturer that is notified by CMS about a &#8220;misclassification&#8221;, defined as an incorrectly reported drug attribute (for example, an erroneous classification of non-innovator rather than innovator), and fails to correct the error within 30 days.  The penalties include monetary penalties and/or suspension of the drug from Medicaid coverage until the error is corrected. CMS may also suspend a manufacturer&#8217;s Medicaid rebate agreement if a manufacturer fails to submit the required pricing reports or fails to correct a misclassification within 90 calendar days after receiving notice from CMS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A manufacturer must also participate in a federal program known as the 340B drug pricing program in order for federal funds to be available to pay for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. Under this program, the participating manufacturer agrees to charge certain federally funded clinics and safety net hospitals no more than an established discounted price for its covered outpatient drugs. The formula for determining the discounted price is defined by statute and is based on the AMP and the unit rebate amount as calculated under the Medicaid drug rebate program, discussed above. Manufacturers are required to report pricing information to the Health Resources and Services Administration (HRSA) on a quarterly basis. HRSA has also issued regulations relating to the calculation of the ceiling price as well as imposition of civil monetary penalties for each instance of knowingly and intentionally overcharging a 340B covered entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal law also requires that manufacturers report data on a quarterly basis to CMS regarding the pricing of drugs that are separately reimbursable under Medicare Part B. These are generally drugs, such as injectable products, that are administered &#8220;incident to&#8221; a physician service and are not generally self-administered. The pricing information submitted by manufacturers is the basis for reimbursement to physicians and hospital outpatient departments for drugs covered under Medicare Part B. Under the IRA, manufacturers are also required to provide quarterly rebates for certain single-source drugs and biologics (including biosimilars) covered under Medicare Part B with prices that increase faster than the rate of inflation, and in November 2024, CMS finalized regulations pertaining to the Medicare Part B inflation rebates. As with the Medicaid drug rebate program, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicare Part D provides prescription drug benefits for individuals at least 65 years of age and certain people with disabilities. Enrollees in Part D plans, after they meet a deductible, pay a co-insurance of 25% until they reach the out-of-pocket limit, after which they have no co-insurance.  The out-of-pocket limit is $2,000 in 2025 and is to be adjusted for inflation thereafter.  Each manufacturer of a drug approved under an NDA. in order for the drugs to be reimbursed by Medicare Part D, is required to enter into a manufacturer discount agreement with HHS and provide a discount on those drugs dispensed to Medicare enrollees. The discount is 10% of Part D enrollees&#8217; prescription costs for brand drugs above the deductible and below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached.  The IRA also requires manufacturers to provide annual Medicare Part D rebates for single-source drugs and biological products with prices that increase faster than the rate of inflation, and in November 2024, CMS finalized regulations pertaining to Medicare Part D inflation rebates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA also allows HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source drugs (excluding drugs and biologics that are designated and approved for only one rare disease or condition) that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, 20 Part B or Part D drugs will be selected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Contracting/Pricing Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers are also required to make their covered drugs, which are generally drugs approved under NDAs, available to authorized users of the Federal Supply Schedule (FSS), which is administered by the VA. The law also requires manufacturers to offer deeply discounted FSS contract pricing for purchases of their covered drugs by the VA, the DoD, the Coast Guard, and the Public Health Service (including the Indian Health Service) in order for the manufacturer&#8217;s covered drugs to be eligible for purchase by these agencies and also in order for federal funding to be available for reimbursement of the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. FSS pricing to those four federal agencies for covered drugs must be no more than the Federal Ceiling Price (FCP), which is at least 24% below the Non-Federal Average Manufacturer Price (Non-FAMP) for the prior government fiscal year. The Non-FAMP is the average price for covered drugs sold to wholesalers or other middlemen, net of any price reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accuracy of a manufacturer&#8217;s reported Non-FAMPs, FCPs, or FSS contract prices may be audited by the government. Among the remedies available to the government for inaccuracies is recoupment of any overcharges to the four specified federal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agencies based on those inaccuracies. If a manufacturer were found to have knowingly reported false prices, in addition to other penalties available to the government, the law provides for civil monetary penalties of $100,000 per incorrect item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, manufacturers are required to disclose in FSS contract proposals all commercial pricing that is equal to or less than the proposed FSS pricing, and subsequent to award of an FSS contract, manufacturers are required to monitor certain commercial price reductions and extend commensurate price reductions to the government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is recoupment of any FSS overcharges that may result from such omissions, and civil penalties under the Federal False Claims Act if such failures are knowing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tricare Retail Pharmacy Network Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DoD provides pharmacy benefits to current and retired military service members and their families through the Tricare healthcare program. When a Tricare beneficiary obtains a prescription drug through a retail pharmacy, the DoD reimburses the pharmacy at the retail price for the drug rather than procuring it from the manufacturer at the discounted FCP discussed above. In order for the DoD to realize discounted prices for covered drugs (generally drugs approved under NDAs), federal law requires manufacturers to pay refunds on utilization of their covered drugs sold to Tricare beneficiaries through retail pharmacies in DoD&#8217;s Tricare network. These refunds are generally the difference between the Non-FAMP and the FCP and are due on a quarterly basis. Absent an agreement from the manufacturer to provide such refunds, DoD will designate the manufacturer&#8217;s products as Tier 3 (non-formulary) and require that beneficiaries obtain prior authorization in order for the products to be dispensed at a Tricare retail network pharmacy. However, refunds are due whether or not the manufacturer has entered into such an agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Branded Pharmaceutical Fee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A branded pharmaceutical fee is imposed on manufacturers and importers of branded prescription drugs, generally drugs approved under NDAs. In each year between 2011 and 2018, the aggregate fee for all such manufacturers ranged from $2.5 billion to $4.1 billion, and has remained at $2.8 billion in 2019 and subsequent years. This annual fee is apportioned among the participating companies based on each company&#8217;s sales of qualifying products to or utilization by certain U.S. government programs during the preceding calendar year. The fee is not deductible for U.S. federal income tax purposes. Utilization of generic drugs, generally drugs approved under ANDAs, is not included in a manufacturer&#8217;s sales used to calculate its portion of the fee. Further, orphan drugs with only one indication are generally exempt from this fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dedicated to making a meaningful impact on the lives of those suffering from rare diseases, and we believe in putting patients first in everything we do. To facilitate talent attraction and retention, we strive to make Catalyst an inclusive, safe, and healthy workplace, with opportunities to grow and develop in their careers, supported by strong compensation, benefits, health and welfare programs. Our goal in selecting employees is to retain high quality personnel with substantial prior experience who understand and support our mission as a company to develop and commercialize innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases and who are willing to work hard and in a collaborative manner to further that mission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Profile</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 24, 2025, we had 181 employees, 127 of whom are in our commercial organization, 11 of whom are in our R&amp;D organization, and the rest of whom are in our G&amp;A organization. We also utilize the services of several full-time consultants who primarily work with our commercial organization. None of our employees are covered by a collective bargaining agreement. We believe our relationship with our employees and consultants is good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation and Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation philosophy is to provide pay and benefits that are competitive in the biotechnology and pharmaceutical industry where we compete for talent. We monitor our compensation programs closely and review them at least annually to provide what we consider to be a very competitive mix of compensation and health, welfare and retirement benefits for all our employees. Our compensation package includes market-competitive base salaries, annual performance bonuses and stock option grants. Our benefits programs include company sponsored medical, dental and vision health care coverage, life and AD&amp;D insurance, and a 401(k) plan with a matching employer contribution, among others benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Workforce Goals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe a diverse workforce is critical to our success and we are fundamentally committed to creating and maintaining a work environment in which employees are treated fairly, with dignity, decency, respect and in accordance with all applicable laws. We strive to create a professional work environment that is free from all forms of harassment, discrimination and bullying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the workplace, including sexual harassment and any form of retaliation. We are an equal opportunity employer and we strive to administer all human resources actions and policies without regard to race, color, religion, sex, national origin, ethnicity, age, disability, sexual orientation, gender identification or expression, past or present military or veteran status, marital status, familial status, or any other status protected by applicable law. Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace. All employees must adhere to a code of business conduct and ethics and our employee handbook, which combined, define standards for appropriate behavior and are annually trained to help prevent, identify, report, and stop any type of discrimination and harassment. Our recruitment, hiring, development, training, compensation, and advancement is based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Communication and Engagement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus on engagement with our employees as we believe an engaged workforce is key to our success and to the success and wellbeing of our employees. In addition, we are always looking for new and different ways to engage our staff further as a team and individually.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health, Wellness and Safety</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Culture</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are committed to instilling a company culture that is focused on integrity, transparency, quality and respect. We expect our employees to observe the highest levels of business ethics, integrity, mutual respect, tolerance and inclusivity. Our Code of Business Conduct and Ethics sets forth policies reflecting these values and provide direction for registering complaints in the event of any violation of our policies. We maintain an &#8220;open door&#8221; policy at all levels of our organization and any form of retaliation against an employee is strictly prohibited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make available free of charge on or through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (SEC). Our Internet address is </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.catalystpharma.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The content on our website is not, nor should it be deemed to be, incorporated by reference into this report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;1A. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">isk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from our recent results or from our anticipated future results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to the Marketing of Approved Products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our success depends on the successful commercialization of our products. To the extent that our drug products are not commercially successful, our business, financial condition and results of operations will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our drug products may fail to receive the degree of market acceptance by physicians, patients, third party payers or others in the medical community necessary for commercial success, which would negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our strategy of seeking to acquire or in-license innovative technical platforms or earlier stage drug development programs outside of the neuromuscular disease space may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Because the target patient populations for FIRDAPSE&#174; and AGAMREE&#174; are small, we must achieve significant market share and obtain relatively high per-patient prices for our products to achieve meaningful gross margins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Because of risks associated with taking FYCOMPA&#174;, potential patients may be reluctant to start treatment with FYCOMPA&#174; or may discontinue use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to the Development of Additional Drug Products and Indications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Failure can occur at any stage of our drug development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We rely on third parties to conduct our pre-clinical studies and clinical studies and trials, and if they do not perform their obligations to us we may not be able to obtain approval for additional indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We will need to continue to develop and maintain distribution and production capabilities or relationships to be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We could be impacted by the viability of our suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We are dependent on our licensing partners for supplies of FYCOMPA&#174; and AGAMREE&#174;.</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We may encounter difficulties in managing our growth, which would adversely affect our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Pressure on drug product third party payor coverage, reimbursement and pricing may impair our ability to be reimbursed at prices or on terms sufficient to provide a viable financial outcome.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our internal computer systems, or those of our contract research organizations and other key vendors or consultants, may fail or suffer security breaches, which could result in a material disruption of our business and/or our product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our employees, sales agents and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="margin-left:6.733%;text-indent:-3.783%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We may face significant delays in our clinical studies and trials due to an inability to recruit patients for our clinical studies and trials or to retain patients in the clinical studies and trials we may perform.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	The healthcare industry is highly regulated, subject to stringent regulatory standards and other applicable laws, and we may be the subject of unexpected changes in interpretation or enforcement, any of which may adversely impact our business.</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	The regulatory approval process is lengthy, and we may not be able to obtain all of the regulatory approvals required to manufacture and commercialize our drug products in which we are licensed to them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	If our pre-clinical studies or our clinical studies and trials are unsuccessful or significantly delayed, our ability to commercialize our products will be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	If our third party suppliers or contract manufacturers do not maintain appropriate standards of manufacturing in accordance with cGMP and other manufacturing regulations, our development and commercialization activities could suffer significant interruptions or delays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our drug products are subject to continuing regulatory review. If we fail to comply with continuing U.S. and applicable foreign regulations, we could lose those approvals, and our business would be severely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Enacted and future legislation or judicial action may increase the difficulty and cost for us to market our approved products or commercialize any other drug candidates we may acquire or license and affect the prices we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	If we fail to obtain or subsequently maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE&#174;, AGAMREE&#174;, and any other orphan drug candidates we may acquire or license, our competitors may sell products to treat the same conditions at greatly reduced prices, and our revenues would be significantly adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products, or such authorities do not grant our products sufficient periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Changes to the Orphan Drug Act or successful legal challenges to the FDA&#8217;s interpretation of the Orphan Drug Act may affect our ability to obtain or subsequently maintain orphan drug exclusivity or may affect the scope orphan drug exclusivity for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our operations and relationships with healthcare providers, healthcare organizations, customers and third party payors are subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:10.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We are subject to environmental, health, and safety laws and regulations, which could increase our costs or restrict our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	There is a risk that our patents may not protect our products from generic competition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Our success will depend significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also general risk factors relating to us that you should consider that relate to our business and to our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves a high degree of risk. You should carefully consider the risks and uncertainties described below, and all of the other information contained in this Form 10-K in assessing the risks relating to ownership of our common stock. The risks described below could cause our business, results of operations, financial condition and prospects to materially suffer and the market price of our stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success depends on the successful commercialization of our products. To the extent that our drug products are not commercially successful, our business, financial condition and results of operations will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received approval for FIRDAPSE&#174; for the treatment of LEMS from the FDA in November 2018; in January 2023, we completed our acquisition of FYCOMPA&#174; for the treatment of (i) partial-onset seizures with or without secondary generalized seizures in people with epilepsy four years of age and older, and (ii) for the treatment of primary generalized tonic-clonic seizures in people with epilepsy twelve years of age and older from Eisai; and in October 2023, we received approval for AGAMREE&#174; for the treatment of DMD. We invest a significant amount of effort and financial resources in the commercialization of these drug products in the U.S., and, in the case of FIRDAPSE&#174;, Canada and now Japan and in the case of AGAMREE&#174;, Canada. The ability for us to generate net product revenues from our drug products will depend on the size of the markets, the numbers of competitors in such markets and numerous other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	successfully establishing and maintaining effective sales, marketing, and distribution systems in jurisdictions in which our drug products are approved for sale;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	successfully establishing and maintaining commercial third party manufacturers and having adequate commercial quantities of our drug products manufactured at acceptable cost and quality levels, including maintaining cGMP and quality systems regulation standards required by various regulatory agencies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	broad acceptance of our drug products by physicians, patients and the healthcare community;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the acceptance of pricing and placement of our drug products on payers&#8217; formularies and the associated tiers;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	effectively competing with other approved or used medicines and future compounds in development;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	continued demonstration of safety and efficacy of our drug products in comparison to competing products; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	obtaining, maintaining, enforcing, and defending intellectual property rights and claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our drug products may fail to receive the degree of market acceptance by physicians, patients, third party payers or others in the medical community necessary for commercial success, which would negatively impact our business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug products may fail to gain sufficient market acceptance by physicians, patients, third party payers, or others in the medical community. If any of our drug products do not achieve an adequate level of acceptance, we may not generate significant net product revenue or become profitable. The degree of market acceptance of our drug products is dependent on a number of factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the efficacy and potential advantages compared to alternative treatments, including the convenience and ease, or duration of administration;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the competition pressure from other products can be particularly pronounced at launch when having to establish market share against older, more established products;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	a separate competitive pressure also occurs at loss of exclusivity when drug products like ours to face significant price erosion and loss of market share upon the launch of generic alternatives &#8211; with the effect typically being more severe the greater the number of generic entrants;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the prevalence and severity of any side effects;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the acceptability of the price of our drug products relative to other treatments;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the content of the approved product labels and our ability to make compelling product claims;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the effectiveness and adequacy of our and our collaboration partner&#8217;s sales and marketing efforts;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the patients&#8217; out-of-pocket costs in relation to alternative treatments;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the breadth and cost of distribution support;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the effectiveness of our patient assistance and support programs;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the availability of third party payer coverage and adequate reimbursement; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	any restrictions on the use of our drug products together with other medications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to substantial competition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are highly competitive. Many of our competitors have substantially greater financial and other resources, larger research and development staffs and more experience developing products, obtaining FDA and other regulatory approvals of products and manufacturing and marketing products than we have. We compete against pharmaceutical companies that are developing or currently marketing therapies that will compete with us. In addition, we compete against biotechnology companies, universities, government agencies, and other research institutions in the development of pharmaceutical products. Our business could be negatively impacted if our competitors&#8217; present or future offerings are more effective, safer or less expensive than ours, or more readily accepted by regulators, healthcare providers or third party payors. Further, we may also compete with respect to manufacturing efficiency and marketing capabilities. For all of these reasons, we may not be able to compete successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our strategy of seeking to acquire or in-license innovative technical platforms or earlier stage drug development programs may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to seek to broaden and diversify our product portfolio through acquisitions of both early and late-stage products or companies or technology platforms in orphan, rare disease therapeutic categories. To accomplish these priorities, we are employing a disciplined approach to evaluating assets and we believe that this strategic expansion will better position our company to build out a broader more diversified portfolio of drug candidates, which should add greater value to our company over the near-term and the long-term. However, there can be no assurance that whatever product candidates or technology platforms we acquire, if any, will be successfully developed or commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate is lengthy and complex, and we may be unable to in-license or acquire the rights to any such products, product candidates or technologies from third parties for several reasons. Further, even if we identify acquisition or in-licensing targets, we may not be able to close those deals or we may determine after diligence not to pursue identified targets. The success of this strategy depends partly upon our ability to identify, select and acquire or in-license promising product candidates and technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, acquisitions and in-licenses may entail numerous operational, financial and legal risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	exposure to known and unknown liabilities, including possible intellectual property infringement claims, violations of laws, tax liabilities and commercial disputes;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	higher than expected acquisition and integration costs;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	difficulty in combining the operations and personnel of any acquired businesses with our operations and personnel;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	inability to maintain uniform standards, controls, procedures and policies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	restructuring charges related to eliminating redundancies or disposing of assets as part of any such combination;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	large write-offs and difficulties in assessing the relative percentages of in-process research and development expense that can be immediately written off as compared to the amount that must be amortized over the appropriate life of the asset;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	increased amortization expenses or, in the event that we write down the value of acquired assets, impairment losses;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	potential failure of the due diligence process to identify significant problems, liabilities or other shortcomings or challenges of an acquired or licensed product candidate or technology, including problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, partner disputes or issues and other legal and financial contingencies and known and unknown liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	entry into therapeutic modalities, indications or markets in which we have no or limited direct prior development or commercial experience and where competitors in such markets have stronger market positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because the target patient population for certain of our products is small, we must achieve significant market share and obtain relatively high per-patient prices for our products to achieve meaningful gross margins.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our products target diseases with a small patient population. A key component of the successful commercialization of a drug product for these indications includes identification of patients and a targeted prescriber base for the drug product. Due to small patient populations for certain of our products, we believe that we would need to have significant market penetration to achieve meaningful revenues and identifying patients and targeting the prescriber base are key to achieving significant market penetration. Typically, drugs for conditions with small prevalence have higher prices in order to generate a return on investment, and as a result, the per-patient prices at which we sell our products are relatively high in order for us to generate an appropriate return for the investment in these product development programs and achieve meaningful gross margins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will be successful in achieving a sufficient degree of market penetration and/or obtaining or maintaining high per-patient prices for FIRDAPSE&#174; and AGAMREE&#174; for diseases with small patient populations. Further, even if we obtain significant market share for FIRDAPSE&#174; and AGAMREE&#174;, because the potential target populations are very small, we may not be able to maintain profitability despite obtaining such significant market share. Additionally, patients who discontinue therapy or do not fill prescriptions are not easily replaced by new patients, given the limited patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because of risks associated with taking FYCOMPA&#174;, potential patients may be reluctant to start treatment with FYCOMPA&#174; or may discontinue use.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;'s labeling has a boxed warning noting that some people taking the drug have undergone serious psychiatric and behavioral changes. These events occurred in people who had no history of such issues, as well as people who had such a history. The psychiatric changes included mood changes like euphoric mood, anger, irritability, aggression, belligerence, agitation, and anxiety, as well as psychosis (acute psychosis, hallucinations, delusions, paranoia) and delirium (delirium, confusional state, disorientation, memory impairment). Behavioral changes included physical assault and homicidal ideation and/or threats. While these side effects are rare, their existence may cause reluctance on the part of patients or providers to start or continue treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other serious side effects include suicidal thoughts or behavior (like all anti-epileptic drugs), dizziness and gait disturbance, somnolence and fatigue, risk of falls, and increased risk of seizures if the drug is quickly withdrawn. In clinical trials, dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech were the side effects that most commonly led people to leave the trial. Use of FYCOMPA&#174; is also contraindicated in women who are pregnant or breastfeeding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development of Drug Products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure can occur at any stage of our drug development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will only obtain regulatory approval to commercialize our future drug candidates if we can demonstrate to the satisfaction of the FDA (or the equivalent foreign regulatory authorities) in adequate and well-controlled clinical studies and trials that the drug is safe and effective for its intended use, that the clinical and other benefits outweigh the safety risks and that it otherwise meets approval requirements. As we have experienced in the past, a failure of one or more pre-clinical or clinical trials or studies can occur at any stage of drug development. We may experience numerous unforeseen events during, or as a result of, testing that could delay or prevent us from obtaining regulatory approval for, or commercializing our drug candidates, including but not limited to:</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	regulators or Institutional Review Boards (IRBs) may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	conditions may be imposed upon us by the FDA regarding the scope or design of our clinical trials, or we may be required to resubmit our clinical trial protocols to IRBs for review due to changes in the regulatory environment;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the number of subjects required for our clinical trials may be larger, patient enrollment may take longer, or patients may drop out of our clinical trials at a higher rate than we anticipate;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	we may have to suspend or terminate one or more of our clinical trials if we, regulators, or IRBs determine that the participants are being subjected to unreasonable health risks;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	our third party contractors, clinical investigators or contractual collaborators may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the FDA may not accept clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially different from the U.S.;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	our tests may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional testing; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the costs of our pre-clinical and/or clinical trials may be greater than we anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical studies and trials, and if they do not perform their obligations to us we may not be able to obtain approval for additional indications.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the ability to independently conduct pre-clinical studies or clinical studies and trials, and we rely on third parties, such as third party contract research and governmental organizations, medical institutions and clinical investigators (including academic clinical investigators), to conduct studies and trials for us. Our reliance on third parties for development activities reduces our control over these activities. These third parties may not complete activities on schedule or may not conduct our pre-clinical studies and our clinical studies and trials in accordance with regulatory requirements or our study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be adversely affected, and our efforts to obtain regulatory approvals for and commercialize our product candidates may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we conduct studies with other parties, we may not have control over all decisions associated with that trial. To the extent that we disagree with the other party on such issues as study design, study timing and the like, it could adversely affect our drug development plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we also rely on third parties to manage the data from our studies and trials, we are responsible for confirming that each of our studies and trials is conducted in accordance with its general investigational plan and protocol. Moreover, the FDA and foreign regulatory agencies will require us to comply with applicable regulations and standards, including Good Laboratory Practice (GLP) and Good Clinical Practice (GCP), for conducting, recording and reporting the results of such studies and trials to assure that the data and the results are credible and accurate and that the human study and trial participants are adequately protected. Our reliance on third parties does not relieve us of these obligations and requirements, and we may fail to obtain regulatory approval for any additional indications if these requirements are not met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to continue to develop and maintain distribution and production capabilities or relationships to be successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are licensed in Florida as a virtual drug manufacturer, which means we have no in-house manufacturing capacity and we will be obligated to rely on contract manufacturers and packagers. We cannot be sure that we will successfully manufacture any product, either independently or under manufacturing arrangements, if any, with third party manufacturers. Moreover, if any manufacturer should cease doing business with us or experience delays, shortages of supply or excessive demands on their capacity, we may not be able to obtain adequate quantities of product in a timely manner, or at all. Manufacturers, and in certain situations their suppliers, are required to comply with current NDA commitments and cGMP requirements enforced by the FDA, and similar requirements of other countries. The failure by a manufacturer to comply with these requirements could affect its ability to provide us with product. Although we intend to rely on third party contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP. In addition, if, during a preapproval inspection or other inspection of our third party manufacturers&#8217; facility or facilities, the FDA determines that the facility is not in compliance with cGMP, any of our marketing applications that lists such facility as a manufacturer may not be approved or approval may be delayed until the facility comes into compliance with cGMP and completes a successful re-inspection by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any manufacturing problem, natural disaster, or epidemic, affecting manufacturing facilities, or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we will be reliant on third parties to supply the raw materials needed to manufacture our products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quality. Any unanticipated disruption to future contract manufacture caused by problems at suppliers could delay shipment of products, increase our cost of goods sold and result in lost sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our suppliers were to be unable to supply us with adequate supply of our drugs, it could have a material adverse effect on our ability to successfully commercialize our drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be impacted by the viability of our suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We source FIRDAPSE&#174; from more than one supplier, and we have entered into contracts with our suppliers that contractually obligate them to meet our requirements. However, if our suppliers cannot or will not meet our requirements (for whatever reason), our business could be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on our licensing partners for supplies of FYCOMPA&#174; and AGAMREE&#174;.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through our agreements with Eisai for FYCOMPA&#174; and Santhera for AGAMREE&#174;, we have agreed to purchase our supplies of each product through such companies. If either company were unable to supply sufficient supplies of drug product, our business would be adversely impacted, whether we would be required to work with these companies to resume supplies or whether we would be required to search for a sufficient third party supplier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter difficulties in managing our growth, which would adversely affect our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To manage future growth, we will likely need to hire, train, and manage additional employees. Concurrent with expanding our operational and marketing capabilities, we will also need to increase our product development activities. We may not be able to support, financially or otherwise, future growth, or hire, train, motivate, and manage the required personnel. Our failure to manage growth effectively could limit our ability to achieve our goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success in managing our growth will depend in part on the ability of our executive officers to continue to implement and improve our operational, management, information and financial control systems, and to expand, train and manage our employee base, and particularly to expand, train and manage a specially-trained field-based force to market our products. We may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions. Our inability to manage growth effectively could cause our operating costs to grow at a faster pace than we currently anticipate and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pressure on drug product third party payor coverage, reimbursement and pricing may impair our ability to be reimbursed at prices or on terms sufficient to provide a viable financial outcome.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our drug products will depend substantially on the extent to which the cost of those products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities (such as Medicare and Medicaid), private health coverage insurers and other third party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to continue to successfully commercialize our products. Even if coverage is provided, the approved reimbursement amount may not be high enough to establish and maintain pricing sufficient to realize a meaningful return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The healthcare industry is acutely focused on cost containment, both in the U.S. and elsewhere. Government authorities and third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products as cost-effective, and coverage and reimbursement may not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues. If the prices for our products decrease or if governmental and other third party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, increasingly, third party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. An inability to promptly obtain coverage and adequate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pricing of pharmaceutical products, in general, and of specialty drugs, in particular, has been a topic of concern in the U.S. Congress, where hearings have been held on the topic, and several bills have been introduced proposing a variety of actions to restrain the prices of drugs. Healthcare reform proposals culminated in the enactment of the IRA, which eliminates, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached. The IRA also allows the Department of Health and Human Services (HHS) to negotiate the selling price of certain drugs and biologics that the CMS reimburses under Medicare Part B and Part D (excluding drugs and biologics that are designated and approved for only one rare disease or condition), although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, 20 Part B or Part D drugs will be selected. Beginning in October 2022 for Medicare Part D and January 2023 for Medicare Part B, the IRA began penalizing drug manufacturers that increased prices of Medicare Part D and Part B drugs at a rate greater than the rate of inflation. There have also been indications by some, including President Trump&#8217;s</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretary of HHS, that the government should seize the patents of &#8220;high priced drugs&#8221; and transfer them to other manufacturers to lower drug prices. It is unclear to what extent other statutory, regulatory, and administrative initiatives will be enacted and implemented in the future and to what extent these or any future legislation or regulations will have on our business, including market acceptance, and sales, of our products and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict how any such laws or regulations, or new laws or regulations that have yet to be proposed, will affect the pricing of our product, of orphan drugs generally, or of pharmaceutical products generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our contract research organizations and other key vendors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal computer systems and those of our contract research organizations and other key vendors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our drug candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, sales agents and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, sales agents or consultants. Misconduct could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The healthcare industry is highly regulated, subject to stringent regulatory standards and other applicable laws, and we may be the subject of unexpected changes in interpretation or enforcement, any of which may adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The healthcare industry is highly regulated. We, and our customers, are subject to various local, state, federal, national, and transnational laws and regulations, which include the operating, quality, and security standards of the FDA, the DEA, various state boards of pharmacy, state health departments, similar bodies of the U.K., the E.U. and its member states, and other comparable agencies around the world, and, in the future, any change to such laws and regulations or the interpretation or application thereof could adversely affect us. Among other rules affecting us, we are subject to laws and regulations concerning cGMP and drug safety. New public health orders or best practice guidelines may increase our costs to operate or reduce our productivity, thereby affecting our business, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts of our employees, agents, contractors, or collaborators that turn out to violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Failure by us or by our customers to comply with the requirements of applicable laws and regulations or requests from regulatory authorities could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture or distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, permits, or registrations, including those relating to products or facilities. In addition, any such failure relating to the products or services we provide could expose us to contractual or product liability claims as well as claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, which cost could be significant. Our business activities outside the U.S. are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Anti-Bribery Act, and other anti-bribery or anti-corruption laws, regulations, or rules. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations may have a material adverse impact on our business, prospects, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any new offering or product classified as a pharmaceutical or medical device must undergo lengthy and rigorous clinical testing and other extensive, costly, and time-consuming procedures mandated by the FDA, the EMA, and other equivalent local, state, federal, national, and transnational regulatory authorities in the jurisdictions that regulate our offerings and products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results depend on our ability to execute and improve when necessary our quality management strategy and systems, and effectively train and maintain our workforce with respect to quality management. Quality management plays an essential role in determining and meeting customer requirements, preventing defects, and improving our offerings, and, despite our network of quality systems, a quality or safety issue, including with respect to a high-revenue product, could have an adverse effect on our business, financial condition, stock price, or results of operations and may subject us to regulatory action, including a product recall, product seizure, injunction to halt manufacture or distribution, or restriction on our operations; monetary fines; or other civil or criminal sanctions. In addition, such an issue could subject us to adverse publicity and costly litigation, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients or other related losses, the cost of which could be significant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval process is lengthy, and we may not be able to obtain all of the regulatory approvals required to manufacture and commercialize our drug products in which we are licensed to them.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will not be able to commercialize our products in other countries or for additional indications until we have obtained the requisite regulatory approvals from applicable governmental authorities. To obtain regulatory approval of a drug candidate for an indication, we must demonstrate to the satisfaction of the applicable regulatory agency that such drug candidate is safe and effective for that indication. The type and magnitude of the testing required for regulatory approval varies depending on the drug candidate and the disease or condition for which it is being developed. In addition, in the U.S. we must show that the facilities used to manufacture our drug candidates are in compliance with cGMP requirements. We will also have to meet similar regulations in any foreign country where we may seek to commercialize our drug candidates. In general, these requirements mandate that manufacturers follow elaborate design, testing, control, documentation, and other quality assurance procedures throughout the entire manufacturing process. The process of obtaining regulatory approvals typically takes several years and requires the expenditure of substantial capital and other resources. Despite the time, expense and resources invested by us in the approval process, we may not be able to demonstrate that our drug candidate is safe and effective for such indications, in which event we would not receive the regulatory approval required to market it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our pre-clinical studies or our clinical studies and trials are unsuccessful or significantly delayed, our ability to commercialize our products will be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can obtain future regulatory approval for the sale of our drug candidates for an indication, we may have to conduct, at our own expense, pre-clinical tests in animals in order to support the safety of our drug candidates. Pre-clinical testing is expensive, difficult to design and implement, can take several years to complete, and is uncertain as to outcome. Our pre-clinical tests may produce negative or inconclusive results, and on the basis of such results, we may decide, or regulators may require us, to halt ongoing clinical trials or conduct additional pre-clinical testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In other countries where FIRDAPSE&#174;, FYCOMPA&#174;, AGAMREE&#174;, or any other product we may acquire or license may be marketed, we will also be subject to regulatory requirements governing human clinical studies, trials and marketing approval for drugs. The requirements governing the conduct of clinical studies, trials, product licensing, pricing and reimbursement varies widely from country to country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may face significant delays in our clinical studies and trials due to an inability to recruit patients for our clinical studies and trials or to retain patients in the clinical studies and trials we may perform.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter difficulties in our current and future clinical studies and trials recruiting patients, particularly since the conditions we are studying are rare, orphan conditions. The availability of approved therapies can also make enrollment difficult. We compete for study and trial subjects with others conducting clinical trials testing other treatments for the indications we are studying for our drug candidates. Further, unrelated third parties and investigators in the academic community have in the past and we expect will continue in the future to test our drug products and/or drug candidates. If these third party tests are unsuccessful, or if they show significant health risk to the test subjects, our development efforts may also be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials in orphan diseases are often difficult to enroll given the small number of patients with these diseases. Completion of orphan clinical trials may take considerably more time than other trials, sometimes years, depending on factors such as type, complexity, novelty and intended use of a product candidate. As a result of the uncertainties described above, there can be no assurance that we will meet timelines that we establish for any of our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our third party suppliers or contract manufacturers do not maintain appropriate standards of manufacturing in accordance with cGMP and other manufacturing regulations, our development and commercialization activities could suffer significant interruptions or delays.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely, and intend to continue to rely, on third party suppliers and contract manufacturers to provide us with materials for our clinical trials and commercial-scale production of our products. These suppliers and manufacturers must continuously adhere to cGMP as well as any applicable corresponding manufacturing regulations outside of the U.S. In complying with these regulations, we and our third party suppliers and contract manufacturers must expend significant time, money and effort in the areas of design and development, testing, production, record-keeping, and quality control to assure that our products meet applicable specifications and other regulatory requirements. Failure to comply with these requirements could result in an enforcement action against us, including warning letters, the seizure of products, suspension or withdrawal of approvals, shutting down of production, and criminal prosecution. Any of these third party suppliers or contract manufacturers will also be subject to inspections by the FDA and other regulatory agencies. If any of our third party suppliers or contract manufacturers fail to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize our products could suffer significant interruptions and delays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third party manufacturers entails risks to which we would not be subject if we manufactured the product ourselves, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	reliance on the third party for regulatory compliance and quality assurance;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	reliance on the continued financial viability of the third parties;</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	limitations on supply availability resulting from capacity and scheduling constraints of the third parties;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	impact on our reputation in the marketplace if manufacturers of our products fail to meet the demands of our customers;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the possible breach of the manufacturing agreement by the third party because of factors beyond our control; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the possible termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our contract manufacturers fail to achieve and maintain appropriate manufacturing standards, patients using our products could be injured or die, resulting in product liability claims. Even absent patient injury, we may be subject to product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously harm our business or profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our drug products are subject to continuing regulatory review. If we fail to comply with continuing U.S. and applicable foreign regulations, we could lose those approvals, and our business would be severely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are and will continue to be subject to continuing regulatory review for our approved products, including the review of our required nonclinical and clinical post-marketing studies, and other clinical results which are reported after our drug candidates become commercially available approved drugs. As greater numbers of patients use a drug following its approval, side effects and other problems may be observed after approval that were not seen or anticipated during preapproval clinical studies and trials. In addition, the manufacturer, and the manufacturing facilities we use to make any approved drugs, will also be subject to periodic review and inspection by the FDA. The subsequent discovery of previously unknown problems with the drug, manufacturer or facility may result in restrictions on the drug, manufacturer or facility, including withdrawal of the drug from the market. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, suspension, or withdrawal of regulatory approval, product recalls and seizures, operating restrictions, and criminal prosecutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product promotion and advertising are also subject to regulatory requirements and continuing regulatory review. In particular, the marketing claims we will be permitted to make in labeling or advertising regarding our marketed products will be limited by the terms and conditions of the FDA-approved labeling and available scientific data. We must submit copies of our advertisements and promotional labeling to the FDA at the time of initial publication or dissemination. If the FDA believes these materials or statements promote our products for unapproved indications, or with unsubstantiated claims, or if we fail to provide appropriate safety related information, the FDA could allege that our promotional activities misbrand our products. Specifically, the FDA could issue an untitled letter or warning letter, which may demand, among other things, that we cease such promotional activities and issue corrective advertisements and labeling to all recipients of the misbranded materials. The FDA also could take enforcement action including seizure of allegedly misbranded product, injunction, or criminal prosecution against us and our officers or employees. If we repeatedly or deliberately fail to submit such advertisements and labeling to the agency, the FDA could withdraw our approvals. Moreover, the Department of Justice can bring civil or criminal actions against companies and executives that promote drugs or biologics for unapproved uses, based on the FDCA, the False Claims Act, and other federal laws governing the marketing and reimbursement for such products under federally supported healthcare programs such as Medicare and Medicaid. Monetary penalties in such cases have often been substantial, and civil penalties can include costly mandatory compliance programs and potential exclusion of a company&#8217;s products from federal healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future legislation or judicial action may increase the difficulty and cost for us to commercialize FIRDAPSE&#174;, FYCOMPA&#174;, AGAMREE&#174;, or any other drug candidates we may acquire or license and affect the prices we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., there have been a number of court cases, legislative and regulatory changes, and other potential changes relating to the healthcare system that restrict or regulate post-approval activities, which may affect our ability to profitably sell FIRDAPSE&#174;, AGAMREE&#174;, or any other drug candidates for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements, restrict sales and promotional activities for pharmaceutical products, and with respect to orphan drug designation and exclusivity. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may subject us to more stringent product labeling and post-marketing testing and other requirements. Delays in feedback from the FDA may affect our ability to quickly update or adjust our label in the interest of patient adherence and tolerability. We cannot predict whether other legislative changes will be adopted or how such changes would affect the pharmaceutical industry generally and specifically the commercialization of FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any other products we develop.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While it is difficult to quantify in the absence of specific proposals, we assess the risk of a material financial impact from potential new tariffs to be low due to a significant portion of our supply chain being U.S. based; however, this may not prove to be the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to obtain or subsequently maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE&#174;, AGAMREE&#174;, and any other orphan drug candidates we may acquire or in-license, our competitors may sell products to treat the same conditions at greatly reduced prices, and our revenues would be significantly adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user fee waivers. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated disease or condition for a period of seven years, with an additional six months of exclusivity if the product also qualifies for pediatric exclusivity. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective, a subsequent product is deemed clinically superior, or if the manufacturer is unable to deliver sufficient quantity of the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the extent and scope of patent protection for some of our drug products may be particularly limited, orphan drug designation &#8211; and ultimately, orphan drug exclusivity &#8211; is especially important for our products that are eligible for orphan drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designation. For eligible drugs, we plan to rely on the orphan exclusivity period to maintain a competitive position. However, if we do not obtain orphan drug exclusivity for our drug candidates or we cannot maintain orphan exclusivity for our drug candidates, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced. Also, without strong patent protection, competitors may sell a generic version upon the expiration of orphan exclusivity if our patent position is not upheld.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain orphan drug designation for our future drug candidates, we may not fulfill the criteria for exclusivity or we may not be the first to obtain marketing approval for any orphan indication. Further, even if we obtain orphan drug exclusivity for a particular product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition, and FDA can approve the same drug for a different patient population. Even after an orphan drug is approved, the FDA can subsequently approve a drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. The FDA can discontinue orphan drug exclusivity after it has been granted if the orphan drug cannot be manufactured in sufficient quantities to meet demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, there can be no assurance that the exclusivity provisions currently in the law may not be changed in the future and the impact of any such changes (if made) on us. The orphan drug exclusivity contained in the Orphan Drug Act has been the subject of recent scrutiny from the press, from some members of Congress and from some in the medical community. There can be no assurance that the exclusivity granted in the Orphan Drug Act to orphan drugs approved by the FDA will not be modified in the future, and as to how any such change might affect our products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products, or such authorities do not grant our products sufficient periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA is approved, the product covered becomes a "reference listed drug" in the FDA's publication, "Approved Drug Products with Therapeutic Equivalence Evaluations", commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the U.S. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The U.S. Federal Food, Drug, and Cosmetic Act (FDCA) provides a period of five years of non-patent exclusivity for a new drug containing a new chemical element (NCE). Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent protection for FYCOMPA&#174; will expire during 2025, and the FDA may approve an ANDA for a generic version at any time after that patent expires. Additionally, while we believe that FIRDAPSE&#174; and AGAMREE&#174; are protected both by patent and NCE, manufacturers may seek to launch generic versions of these products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for such product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition that FYCOMPA&#174; or our other products may face from generic versions could materially and adversely affect our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on investment for such products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes to the Orphan Drug Act or successful legal challenges to the FDA&#8217;s interpretation of the Orphan Drug Act may affect our ability to obtain or subsequently maintain orphan drug exclusivity or affect the scope of orphan drug exclusivity for our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the designation and/or exclusivity provisions currently in the law may not be changed in the future and the impact of any such changes (if made) on us. For example, the U.S. Congress could pass, and the President could sign, legislation to effectively overturn the decision of the U.S. Court of Appeals for the 11th Circuit overturning the FDA&#8217;s approval of RUZURGI&#174;, and such legislation, if passed and signed into law, could retroactively affect the outcome of the 11th Circuit&#8217;s decision. Notwithstanding, since we now hold the U.S. rights to RUZURGI&#174;, these legislative efforts will have no effect on our FIRDAPSE&#174; business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In that regard, in January 2023, the FDA reported that while it is complying with the 11</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Circuit decision in Catalyst&#8217;s favor with respect to FIRDAPSE&#174;, going forward the FDA intends to continue to apply its regulations tying the scope of orphan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">drug exclusivity to the uses or indications for which a drug is approved with respect to other orphan drugs. We will not be affected by the FDA&#8217;s position, as the FDA&#8217;s announcement confirms the FDA&#8217;s previous decision to set aside the approval of RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as a result of the 11</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Circuit&#8217;s decision.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan drug exclusivity contained in the Orphan Drug Act has been the subject of scrutiny from the press, from some members of Congress and from some in the medical community. Furthermore, the FDA&#8217;s interpretations of the Orphan Drug Act have been successfully challenged in court and future court decisions could continue that trend. There can be no assurance that the exclusivity granted in the Orphan Drug Act to orphan drugs approved by the FDA will not be modified in the future, and as to how any such change might affect our products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations and relationships with healthcare providers, healthcare organizations, customers and third party payors are subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and future arrangements with healthcare providers, healthcare organizations, third party payors, customers, and patients expose us to broadly applicable anti-bribery, fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our drug candidates. In addition, we may be subject to patient data privacy and security regulation by the U.S. federal government and the states and the foreign governments in which we conduct our business. Restrictions under applicable federal and state anti-bribery and healthcare laws and regulations include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the Federal health care program Anti-Kickback Statute, which prohibits individuals and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal and state healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be imposed through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	HIPAA, as amended by HITECH, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced care practice nurses and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof;</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	certain state and local laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures; require manufacturers to report price increases that exceed a statutory threshold, as well as information on the reasons for the price increase; require manufacturers to report the introduction into the market of costly drugs; require the registration of pharmaceutical sales representatives; and govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, not only civil and criminal penalties, but also exclusion from participation in government-funded healthcare programs, and exclusion from eligibility for the award of government contracts for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that government authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA or other comparable foreign regulatory authorities may also slow the time necessary for new products to be reviewed and/or approved, which would adversely affect our business. In addition, there is substantial uncertainty regarding the new Administration&#8217;s initiatives and how these might impact the FDA, its implementation of laws, regulations, policies and guidance and its personnel.  These initiatives could prevent, limit or delay development and regulatory approval of our product candidates, which would adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA or other comparable foreign regulatory authorities may also slow the time necessary for new products to be reviewed and/or approved, which would adversely affect our business. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant shutdown of the federal government. For example, in 2024, the U.S. government was on the verge of a shutdown and has previously shut down several times, and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, FDA-regulated industries, such as ours, face substantial uncertainty in regard to the regulatory environment we will face as we proceed with research and development efforts following the inauguration of President Trump in January 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of these efforts have manifested to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and retain key personnel, which could result in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite regulatory approvals in the future. There remains general uncertainty regarding future activities. The new Administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the new Administration, there could be a material adverse effect on us and our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to environmental, health, and safety laws and regulations, which could increase our costs or restrict our operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the EPA, OSHA, and equivalent local, state, and national regulatory agencies in the jurisdictions in which we operate. Any failure by us to comply with environmental, health, and safety requirements could result in the limitation or suspension of production or subject us to monetary fines, civil or criminal sanctions, or other future liabilities in excess of our reserves. In particular, we are subject to laws and regulations governing the destruction and disposal of raw materials, byproducts of our manufacturing operations, and non-compliant products, the handling of regulated material included in our offerings, and the disposal of our products or their components at the end of their useful lives. In addition, compliance with environmental, health, and safety requirements could restrict our ability to expand our facilities or require us to acquire costly environmental or safety control equipment, incur other significant expenses, or modify our manufacturing processes. Our manufacturing facilities may use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us. In the event of the discovery of new or previously unknown contamination either at our facilities, facilities we acquire in the future, or at third party locations, including facilities we formerly owned or operated, the issuance of additional requirements with respect to existing contamination, or the imposition of other cleanup obligations for which we are responsible, we may be required to take additional, unplanned remedial measures for which we have not recorded reserves. We are conducting monitoring and cleanup of contamination at certain facilities currently or formerly owned or operated by us, and such activities may result in unanticipated costs or management distraction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to our drug development programs, products, and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our drug candidates. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent applications that we own or have licensed may fail to result in issued patents with claims that protect our drug products in the U.S. or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover our drug products, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our development programs, products, and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future drug products or candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a materially adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, many countries restrict the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patentability of methods of treatment of the human body. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we may be subject to a third party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (USPTO) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success will depend significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our products, product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. Also, there may be third party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products or product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our products or product candidates may infringe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon rights. If any third party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such products or product candidates unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable products or product candidates unless we obtained a license or until such patent expires. In either case, such a license may not be available on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products or product candidates, and we may do so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our products or product candidates, which could harm our business significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, enablement, written description, or patentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may also raise similar validity claims before the USPTO in post-grant proceedings, such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our products, or current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business may require additional capital.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need to raise additional capital in the future in order to fund our business (particularly to fund potential company or product acquisitions that are intended to expand our product offerings). If necessary, we would likely raise additional funds in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the future through public or private equity offerings, debt financings, corporate collaborations, or other means. We may also seek governmental grants to support our clinical and pre-clinical trials. However, there is no assurance that any such funding will be available, and, even if it is available, whether it will be available on terms that are favorable to us. We may also seek to raise additional capital to fund additional product development efforts, even if we have sufficient funds for our planned operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any sale by us of additional equity or debt securities convertible into additional equity could result in dilution to our stockholders. Further, to the extent that we raise funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are not favorable to us. If we are not able to secure funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, which could have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The obligations incident to being a public company place significant demands on our management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public reporting company, we are required to comply with the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC, including periodic reports, disclosures and more complex accounting rules. As directed by Section 404 of the Sarbanes-Oxley Act, the SEC adopted rules requiring public companies to include a report of management on a company&#8217;s internal control over financial reporting in their Annual Report on Form 10-K. Based on current rules, we are required to annually report under Section 404(a) of the Sarbanes-Oxley Act regarding our management&#8217;s assessment as to the effectiveness of our internal control over financial reporting. Further, under Section 404(b) of the Sarbanes-Oxley Act, our auditors are required to report on their assessment as to the effectiveness of our internal control over financial reporting. If we or our auditors are unable to conclude that we have effective internal control over our financial reporting, investors could lose confidence in the reliability of our consolidated financial statements, which could result in a decrease in the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations could suffer in the event of system failures or security or data breaches due to cyber-attacks, or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, cybersecurity threats have become a greater risk and focus for companies. In particular, ransomware attacks, where a hacker locks and threatens to delete or disclose the victim&#8217;s data unless a ransom is paid, has become a major risk. We and our third party service providers are at risk of cyber-attacks or cyber intrusions via the Internet, computer viruses, break-ins, malware, ransomware, phishing attacks, hacking, denial-of-service attacks or other attacks and similar disruptions from the unauthorized use of, or access to, computer systems (including from internal and external sources). These types of incidents continue to be prevalent and pervasive across industries, including in our industry. In addition, we expect information security risks to continue to increase due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state actors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, process, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. The size and complexity of our information technology systems, and those of third party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware, phishing, and other cyber-attacks. Our information security systems and those of our third party vendors are subject to laws and regulations, or may become subject to new laws and regulations, requiring that we enact certain measures to protect the privacy and security of certain information we collect or use in our business. A security breach or privacy violation that leads to disclosure or modification of, or prevents access to, personal information or other protected information, whether caused by internal or external parties, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to notification requirements under certain agreements with third parties, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal information, resulting in increased costs or loss of revenue. Similarly, the loss or unauthorized disclosure of clinical trial data from completed, ongoing or planned clinical trials could prevent us from obtaining regulatory approval or delay our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer negative impact to our reputation, financial loss and be subject to regulatory fines and penalties. In addition, breaches and other unauthorized data access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the reliance on remote working technologies by our employees and third party partners due to COVID-19 and related public health safety measures and the prevalent use of mobile devices that access confidential and personal information increases the risk of data security breaches, which could lead to the loss of confidential information, personal information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on our small number of key personnel and advisors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on our executive officers and key employees, and on our Board of Directors. The loss of the services of one or more of these individuals could significantly impede the achievement of our scientific and business objectives. We have no employment or retention agreements with any of our other officers or key employees. If we lose the services of any of our existing executive officers or key employees, or if we were unable to recruit qualified replacements on a timely basis for persons who leave our employ, our efforts to develop our drug candidates might be significantly delayed. We do not carry key-man insurance on any of our personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face a risk of product liability claims and may not be able to obtain adequate insurance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to potential risks that may arise from the clinical testing, manufacture, and/or sale of our pharmaceutical products. Patients have received substantial damage awards in some jurisdictions against pharmaceutical companies based on claims for injuries allegedly caused by the use of pharmaceutical products used in clinical trials or after FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liability claims may be expensive to defend and may result in large judgments against us. We currently carry liability insurance that we believe to be adequate. Our insurance may not reimburse us for certain claims or the coverage may not be sufficient to cover claims made against us. We cannot predict all of the possible harms or side effects that may result from the use of our current drug candidates, or any potential future products we may acquire and use in clinical trials or after FDA approval and, therefore, the amount of insurance coverage we currently hold may not be adequate to cover all liabilities we might incur. If we are sued for any injury allegedly caused by our products, our liability could exceed our ability to pay the liability. Whether or not we are ultimately successful in any adverse litigation, such litigation could consume substantial amounts of our financial and managerial resources, all of which could have a material adverse effect on our business, financial condition, results of operations, prospects and stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad-based business or economic disruptions could adversely affect our ongoing or planned research and development activities. Global health concerns could also result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical trial sites, regulators and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. It is also possible that global health concerns could disproportionately impact the hospitals and clinical sites in which we conduct any of our clinical trials, which could have a material adverse effect on our business and our results of operation and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We anticipate being subject to increasing focus by our investors, regulators, customers, and stakeholders on environmental, social &amp; governance (ESG) matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investors, regulators, and other stakeholders have in the last few years increasingly focused on ESG matters. Certain investors, particularly institutional investors, may use third party benchmarks or scores to measure our ESG practices, and to decide whether to invest in our shares, engage with us regarding our practices, or engage or continue to use our services. If our ESG scores or practices do not meet desired standards, we may face reputational challenges. There can be no assurance that we will be able to accomplish any particular ESG goal or commitment, including any additional or revised commitment that we may announce in the future, as statements regarding such goals and commitments reflect our plans and aspirations at the time of announcement and do not guarantee achievement of such plans and aspirations within the timelines we announce or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Different stakeholder groups have divergent views on ESG matters, which increases the risk that any action or lack thereof with respect to ESG matters will be perceived negatively by at least some stakeholders and adversely impact our reputation and business. Anti-ESG sentiment has gained some momentum across the U.S., with several states having enacted or proposed &#8220;anti-ESG&#8221; policies or legislation, or issued related legal opinions. If we do not successfully manage ESG-related expectations across these varied stakeholder interests, it could erode stakeholder trust, impact our reputation, and constrain our business. Globally, a lack of harmonization in relation to ESG legal and regulatory reform across the jurisdictions in which we may operate may affect our future implementation of, and compliance with, rapidly developing ESG standards and requirements. Generally, we expect stakeholder demands and the prevailing legal environment to require us to devote additional resources to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ESG matters in our review of prospective acquisitions. Additionally, collecting, measuring, and reporting ESG information and metrics can be costly, difficult, and time-consuming, are subject to evolving reporting standards, and can present numerous operational, reputational, financial, legal, and other risks. Compliance with ESG-related rules and efforts to meet investor expectations on ESG matters may place strain on our personnel, systems, and resources, and we may incur significant compliance costs. Additionally, failure to comply with such rules or meet investor expectations may have a material adverse impact on our business, prospects, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock has been and could in the future be highly volatile.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock has fluctuated in the past and is likely to fluctuate in the future. Market prices for biopharmaceutical companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	developments concerning our clinical studies and trials and our pre-clinical studies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	status of regulatory requirements for approval of our drug candidates;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	adverse publicity regarding the pricing our drug products;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	announcements of product development successes and failures by us or our competitors;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	new products introduced or announced by us or our competitors;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	adverse changes in the abilities of our third party manufacturers to provide drug or product in a timely manner or to meet FDA requirements;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	challenges to our intellectual property which could affect our products, such as the currently pending litigation involving Paragraph IV challenges to FIRDAPSE&#174;;</span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in reimbursement levels;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in financial estimates by securities analysts;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	actual or unanticipated variations in operating results;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in laws regarding FDA approval;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	expiration or termination of licenses (particularly our License Agreement for FIRDAPSE&#174;), research contracts, or other collaboration agreements;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	conditions or trends in the regulatory climate and the biotechnology and pharmaceutical industries;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	intellectual property, product liability or other litigation against us;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in the market valuations of similar companies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in pharmaceutical company regulations or reimbursements for pharmaceutical products as a result of healthcare reform or other legislation;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	changes in economic conditions; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	sales of shares of our common stock, particularly sales by our officers, directors and significant stockholders, or the perception that such sales may occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, equity markets in general, and the market for emerging pharmaceutical and life sciences companies in particular, have experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies traded in those markets. Further, changes in economic conditions in the U.S., Europe, or globally could impact our ability to grow profitably. Adverse economic changes are outside our control and may result in material adverse impacts on our business or financial results. These broad market and industry factors may materially affect the market price of our shares, regardless of our own development and operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any such litigation that we become involved in could cause us to incur substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware law and our certificate of incorporation and by-laws contain provisions that could delay and discourage takeover attempts that stockholders may consider favorable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain provisions of our certificate of incorporation and by-laws, and applicable provisions of Delaware corporate law, may make it more difficult for or prevent a third party from acquiring control of us or changing our Board of Directors and management. These provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the ability of our Board of Directors to issue preferred stock with voting or other rights or preferences;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	limitations on the ability of stockholders to amend our charter documents, including stockholder supermajority voting requirements;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	the inability of stockholders to act by written consent or to call special meetings;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	requirements that special meetings of our stockholders may only be called by the Board of Directors; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	advance notice procedures our stockholders must comply with in order to nominate candidates for election to our Board of Directors or to place stockholders&#8217; proposals on the agenda for consideration at meetings of stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Section 203 of the Delaware General Corporation Law generally prohibits us from engaging in a business combination with any person who owns 15% or more of our common stock for a period of three years from the date such person acquired such common stock, unless Board or stockholder approval is obtained. These provisions could make it difficult for a third party to acquire us, or for members of our Board of Directors to be replaced, even if doing so would be beneficial to our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay or prevention of a change of control transaction or changes in our Board of Directors or management could deter potential acquirers or prevent the completion of a transaction in which our stockholders could receive a substantial premium over the then current market price for their shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales of our common stock may cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 24, 2025, we had 121,449,655 shares of our common stock outstanding, of which 7,642,725 shares were held by our executive officers and directors. We also had outstanding: (i) stock options to purchase an aggregate of 13,077,867 shares at exercise prices ranging from $2.11 to $22.90 (7,582,868 of which are currently exercisable); and (ii) restricted stock units for 575,049 shares of common stock (none of which are currently vested).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of shares, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay cash dividends on our common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock or other securities, and we currently do not anticipate paying any cash dividends in the foreseeable future. Accordingly, investors should not invest in our common stock if they require dividend income. Our stockholders will not realize a return on their investment unless the trading price of our common stock appreciates, which is uncertain and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;1B. Un</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resolved Staff Comments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_f0243950-fca9-4165-b731-4d4a48419984" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_f0243950-fca9-4165-b731-4d4a48419984_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;1C. Cybe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rsecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><div><ix:nonNumeric id="F_02e736a0-8c14-4da0-aab0-ef6588b0ebda" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true" continuedAt="F_02e736a0-8c14-4da0-aab0-ef6588b0ebda_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cfb89a2-d5cf-4560-9d56-d8b277c1fc76" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are a part of our decision-making processes at every level. Our risk management team works closely with our Information Technology (IT) team including our IT and cybersecurity vendors to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Engage Third Parties on Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recognizing the complexity and evolving nature of cybersecurity threats, we </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68c28609-501c-44e1-9d8e-d86b77f5de4f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a range of external experts in evaluating and testing our risk management systems. These partnerships enable us to leverage specialized knowledge and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0243950-fca9-4165-b731-4d4a48419984_1" continuedAt="F_f0243950-fca9-4165-b731-4d4a48419984_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_02e736a0-8c14-4da0-aab0-ef6588b0ebda_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insights, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third parties includes regular audits, threat assessments, and consultation on security enhancements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oversee Third Party Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_367e7154-f62c-46a0-98c2-3617ba0b9707" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are aware of the risks associated with third party service providers, we implement stringent processes to oversee and manage these risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We conduct thorough security assessments of all third party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes quarterly assessments by our Chief Legal and Compliance Officer (CLCO) and our Chief Operating Officer (COO) and on an ongoing basis by our IT professionals. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54540c53-1bee-4b55-a27e-e231190fb534" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41db1c65-efde-4b4d-b6e3-09f8ffdcba0c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not encountered, to date, cybersecurity challenges that have materially</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impaired our operations or financial standing.</span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats. The Board has established robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats because we recognize the significance of these threats to our operational integrity and stakeholder confidence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><div><ix:nonNumeric id="F_f7f0079b-9de0-4ee5-86da-4967e9e88bf1" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with our CLCO, our COO, and our IT personnel. In their time with our company, our CLCO and our COO have become increasingly involved in investigating, responding to, and mitigating cybersecurity incidents and intrusion attempts. Their in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CLCO and our COO oversee our governance programs, test our compliance with standards, remediate known risks, and oversee or lead our employee training program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0ab7ba8-4dd2-4927-ba4d-72f55cb8c1a4" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO regularly inform our CEO and CFO of all aspects related to cybersecurity risks and incidents.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This ensures that the highest levels of management are kept abreast of the cybersecurity posture and potential risks facing our company. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitor Cybersecurity Incidents</span></p><div><ix:nonNumeric id="F_f54c55b4-77bf-468d-85c1-2dd8e48d364b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CLCO, our COO, and our IT personnel are periodically informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CLCO and COO implement and oversee processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the CLCO and COO, along with our IT personnel, are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a218015-8410-4f76-a941-7e5b883ccd3c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_469be272-d0dd-4810-a448-3db29258a44a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b2d3229-e6b8-4ce8-96fd-614762bcbf06" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These briefings encompass a broad range of topics, including:</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Current cybersecurity landscape and emerging threats;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Status of ongoing cybersecurity initiatives and strategies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Incident reports and learnings from any cybersecurity events; and</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Compliance with regulatory requirements and industry standards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, at regular meetings of the Board, the Board members, including the CEO, and the CLCO and COO maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The Board members actively participate in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives. The Board of Directors conducts an annual review of the company&#8217;s cybersecurity posture and the effectiveness of its risk management strategies. This review helps in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f0243950-fca9-4165-b731-4d4a48419984_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7eb19572-d924-4bb7-aa2f-413474b28ce6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b36162df-abf9-4ee2-913d-b179304ebf35" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board has delegated to the Audit Committee the primary responsibility of overseeing risk management relating to cybersecurity.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8fb02df-f02b-49a8-95ae-77ed21a9b78e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently operate our business in 10,700 square feet of leased office space in Coral Gables, Florida. Our current annual rent in the new space is approximately $0.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;3. L</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">egal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Paragraph IV Patent Litigation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of currently ongoing Paragraph IV litigation related to FIRDAPSE&#174;, see &#8220;Item 1. Business &#8211; Overview &#8211; FIRDAPSE&#174;.&#8221; The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance as to whether we will prevail in this litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Litigation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time we may become involved in legal proceedings arising in the ordinary course of business. Other than as set forth above, we believe that there is no litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;4. Mi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne Safety Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT II</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;" id="item_5_market_for_common_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;5. Ma</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rket for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares of the Company's common stock are traded on the Nasdaq Capital Market under the symbol "CPRX". There were 17 holders of record of the Company's common stock as of February 24, 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has never paid dividends on its common stock and does not anticipate that it will do so in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Repurchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Graph</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing. The graph compares the cumulative 5-year total return to stockholders on the Company&#8217;s common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The Company selected the Nasdaq Biotechnology Index because it believes the index reflects the market conditions within the industry in which the Company primarily operates. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on January 1, 2020, in each of the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img136052313_0.jpg" alt="img136052313_0.jpg" style="width:523px;height:434px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.86%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/19</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/20</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/21</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/22</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/23</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12/24</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">89.07</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">180.53</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">496.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">448.27</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">556.53</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NASDAQ Composite</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144.92</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">177.06</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">119.45</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">172.77</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">223.87</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Russell MicroCap</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">120.96</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144.35</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">112.66</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">123.17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">140.05</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NASDAQ Biotechnology</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">126.42</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">126.45</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">113.65</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">118.87</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">118.20</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information as of December 31, 2024 with respect to compensation plans under which shares of our common stock may be issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.229%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.303%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.4%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.763%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.303%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>securities to<br/>be issued upon<br/>exercise<br/>of outstanding<br/>options,<br/>warrants, and<br/>rights</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average<br/>exercise price of<br/>outstanding<br/>options,<br/>warrants, and<br/>rights</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>securities<br/>remaining<br/>available<br/>for equity<br/>compensation<br/>plans</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by<br/>&#160;&#160;&#160;security holders </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,076,789</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,254,102</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by<br/>&#160;&#160;&#160;security holders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">13,076,789</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2,254,102</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes our 2014 Stock Incentive Plan and our 2018 Stock Incentive Plan </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remaining shares are only under our 2018 Stock Incentive Plan </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;6. S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">elected Financial Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_management_discussion_and_analy_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;7. Managem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ent&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties that could cause actual results to differ materially from those implied or described by the forward-looking statements. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, as well as those described in future reports filed with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is intended to provide an understanding of our financial condition, changes in financial condition and results of operations. The discussion and analysis is organized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section provides a general description of our business and information about our business that we believe is important in understanding our financial condition and results of operations. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section provides information about key accounting estimates and policies that we followed in preparing our consolidated financial statements for the 2024 fiscal year. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section discusses those accounting policies that are both considered important to our financial condition and results of operations and require significant judgment and estimates on the part of management in their application. All of our significant accounting policies, including the critical accounting policies, are also summarized in the notes to our accompanying consolidated financial statements. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section provides an analysis of our results of operations for the three fiscal years presented in the accompanying consolidated statements of operations and comprehensive income. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section provides an analysis of our cash flows, capital resources, off-balance sheet arrangements, and our outstanding commitments, if any. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This section discusses how certain forward-looking statements made throughout this MD&amp;A and in other sections of this report are based on management&#8217;s present expectations about future events and are inherently susceptible to uncertainty and changes in circumstance. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We currently market three drug products, FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel), and AGAMREE&#174; (vamorolone). We are also currently seeking to further expand our drug portfolio, with a focus on acquiring the rights to late-stage products to treat orphan, rare diseases across therapeutic areas. With an unwavering patient focus embedded in everything we do, we are committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 28, 2018, we received approval from the FDA for our new drug application, (NDA) for FIRDAPSE&#174; Tablets 10 mg for the treatment of adult patients (ages 17 and above) with LEMS, and in January 2019, we launched FIRDAPSE&#174; in the U.S. Further, on September 29, 2022, the FDA approved our supplemental NDA (sNDA) to expand the indicated age range for FIRDAPSE&#174; Tablets 10 mg for the treatment of LEMS to include pediatric patients six years of age and older. Finally, on May 30, 2024, the FDA approved our sNDA increasing the indicated maximum daily dosage of FIRDAPSE&#174; tablets for the treatment of patients with LEMS from 80 mg to 100 mg. We believe that this recent sNDA approval offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell FIRDAPSE&#174; in the U.S. through a field-based force experienced in neurologic, central nervous system or rare disease products consisting at this time of approximately 41 field personnel, including sales (Regional Account Managers), thought leader liaisons and patient assistance and insurance navigation support (Patient Access Liaisons). These field personnel have also supported AGAMREE&#174; since its commercial launch in March 2024. We also have a field-based force of 10 medical science liaisons who are helping educate the medical community about scientific literature concerning LEMS and FIRDAPSE&#174;. Additionally, we use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient who also has small cell lung cancer. Further, we continue to make available at no-cost a LEMS voltage gated calcium channel antibody diagnostic testing program for use by physicians who suspect that one of their patients may have LEMS and wish to reach a definitive diagnosis.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we launched AGAMREE&#174;, in March 2024, we utilized the FIRDAPSE&#174; commercial and medical field-based forces to market AGAMREE&#174; as well. In early 2025, we made a strategic decision to split each of these field-based forces into two units, one for each function expressly focused on supporting FIRDAPSE&#174; and one for each function expressly focused on supporting AGAMREE&#174;. This change is being made in an effort to allow us to better focus our sales teams on the market for each product. We expect to complete this division of our field-based forces into two units early in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, we are continuing to expand our digital and social media activities to introduce our products and services to potential patients and their healthcare providers. We also work with several rare disease advocacy organizations (including the Myasthenia Gravis Foundation of America, the National Organization for Rare Disorders, and the LEMS Family Association) to help increase awareness and level of support for patients living with LEMS and to provide education for the physicians who treat these rare diseases and the patients they treat.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting the distribution of FIRDAPSE&#174; through Catalyst Pathways&#174;, our personalized treatment support program for patients who enroll in it. Catalyst Pathways&#174; is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen required to reach an effective therapeutic dose. The program also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most drug products for ultra-orphan diseases are distributed and dispensed to patients. We believe that by using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to help patients with LEMS afford their medication, we, like other pharmaceutical companies which market drug products for ultra-orphan conditions, have developed an array of financial assistance programs to reduce out-of-pocket costs that makes FIRDAPSE&#174; accessible and affordable. A co-pay assistance program has been designed to reduce commercial patients&#8217; out of pocket costs to $0 whenever possible. Our FIRDAPSE&#174; co-pay assistance program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Department of Veterans Affairs (VA), Department of Defense (DoD), or TRICARE. However, we are donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to any U.S. LEMS patients in financial need, who meet those independent organizations' guidelines. In addition, we have a safety net program in place for patients who are uninsured and underinsured. Subject to compliance with regulatory requirements, our goal is that no LEMS patient is ever denied access to their medication for financial reasons.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174; is currently marketed for the treatment of LEMS in Canada through our exclusive sublicensee, KYE. We supply product to KYE at agreed upon prices and we are also eligible to earn sales milestones and sales royalties based on net revenues from sales of the product in Canada.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, DyDo Pharma, Inc. (DyDo), our sub-licensee for FIRDAPSE&#174; in Japan, filed a NDA with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to commercialize FIRDAPSE&#174; for the treatment of LEMS in Japan. Upon acceptance of the Japan NDA by the PMDA in December 2023, our license for FIRDAPSE&#174; automatically expanded to include other key markets in Asia and Latin America, and we are currently seeking opportunities to expand FIRDAPSE&#174;&#8217;s global footprint through strategic partnerships (with the current focus on the Asia Pacific and Latin American regions). Further, in September 2024, DyDo advised us that the Ministry of Health, Labour and Welfare (MHLW) had approved DyDo's Japan NDA to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS in Japan. Finally, DyDo began commercialization of FIRDAPSE&#174; in Japan on January 21, 2025. We will generate revenue through additional milestone payments and a transfer price on the product supplied by us to DyDo, in lieu of royalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We control six U.S. patents for FIRDAPSE&#174; that are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), the earliest of which expires in 2032 and the latest of which expires in 2037. We also have orphan drug exclusivity (ODE) for the product that will not expire until November 2025, and no ANDA for the product can be finally approved by the FDA until the ODE exclusivity period has expired. Nevertheless, generic drug manufacturers were permitted to submit applications for the product challenging our patents starting in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In that regard, in January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva), Hetero USA, Inc. (Hetero), and Lupin Pharmaceuticals, Inc. (Lupin)) advising that they had each submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE&#174; in the U.S. The notice letters each alleged that the six patents protecting FIRDAPSE&#174; that are listed in the Orange Book in connection with FIRDAPSE&#174; are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the Federal Food, Drug, and Cosmetic Act (FDCA), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first in all cases (but not earlier</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than the expiration of orphan drug exclusivity on November 28, 2025). In that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions, thus triggering the stay.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, Lupin converted five of its Paragraph IV Certifications in its ANDA to Paragraph III certifications acknowledging the validity and their ANDA&#8217;s infringement of five of those patents, the latest ending in 2034. We subsequently dismissed all of our claims against Lupin related to those five patents but maintain our claims against Lupin for the remaining Paragraph IV certification for U.S. Patent No. 10,626,088, which is the patent expiring in 2037, accordingly the litigation continues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on January 8, 2025, we reached a settlement with Teva in which Teva agreed not to market a generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the settlement agreement, the parties terminated all ongoing patent litigation between us and Teva regarding FIRDAPSE&#174; patents pending in the U.S. District Court for the District of New Jersey.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for FIRDAPSE&#174;&#8217;s Orange Book-listed patents expiring in 2032, 2034 and 2037) and Lupin (only for FIRDAPSE&#174; patent expiring in 2037), remains ongoing, and there can be no assurance as to whether the currently ongoing litigation with Hetero and Lupin will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to Teva's licensed entry into the market on February 25, 2035.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer (Inventia Life Science Pty Ltd (Inventia)), and we filed a similar lawsuit against that manufacturer in November 2023 in the U.S. District Court for the District of New Jersey. On July 30, 2024, we settled this patent litigation with Inventia for FIRDAPSE&#174;. In this settlement, Inventia acknowledged both the validity of our FIRDAPSE&#174; patents and also the infringement by the ANDA filer's product of our patents. As part of the settlement, Inventia also agreed not to commercialize its product until the earlier of all FIRDAPSE&#174; patents expiration or the entry into the market of another ANDA product meeting certain conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance as to whether we will prevail in these litigations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2022, we entered into an agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA&#174; (perampanel) CIII. FYCOMPA&#174; is a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. It was the first, and still the only, drug of its class to be approved for epilepsy. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. FYCOMPA&#174; is a controlled substance and is approved with a box warning label. FYCOMPA&#174; is used to treat certain types of focal onset seizures (seizures that involve only one part of the brain) in adults and children four years of age and older. It is also used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures (also known as a &#8220;grand mal&#8221; seizure, a seizure that involves the entire body) in adults and children 12 years of age or older. Perampanel is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 24, 2023, we closed our acquisition of the U.S. rights to FYCOMPA&#174;. In connection with the acquisition, we purchased Eisai&#8217;s regulatory approvals and documentation, product records, intellectual property, inventory, and other matters relating to the U.S. rights for FYCOMPA&#174;, in exchange for an upfront payment of $160 million in cash. We also agreed to pay Eisai royalty payments after patent protection for FYCOMPA&#174; expires, which royalty payments will be reduced upon generic equivalents to FYCOMPA&#174; entering the market.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the closing of the asset purchase, we entered into two additional agreements, a Transition Services Agreement (TSA) and a Supply Agreement. Under the Supply Agreement, Eisai agreed to manufacture FYCOMPA&#174; for us for at least seven years at prices listed in the Supply Agreement (to be updated on a yearly basis), and under the TSA, a U.S. subsidiary of Eisai provided us with certain transitional services (which transition services ended on December 31, 2023).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell FYCOMPA&#174; in the U.S. through a field-based force experienced in epilepsy products consisting at this time of approximately 27 field personnel, including sales (Regional Account Managers) and payor reimbursement (National Account Managers). We also have a field-based force of four medical science liaisons who are helping educate the medical community who treat epilepsy about scientific literature regarding epilepsy and FYCOMPA&#174;. Further, since January 1, 2024, FYCOMPA&#174; is being sold and distributed through a 3PL organization under our contracts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently taking steps to prepare for the loss of exclusivity for FYCOMPA&#174;, which, assuming a timely ANDA approval of the respective generic applications, will take place on or after May 23, 2025 for the tablet version of the product and will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">take place on or after December 15, 2025 for the oral suspension version of the product. We expect to continue to market the product following the loss of patent exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are supporting patients using FYCOMPA&#174; through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $5 for their FYCOMPA&#174; co-pay (with a maximum savings of $2,500 per year). The FYCOMPA&#174; Instant Savings Card Program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent protection for FYCOMPA&#174; tablets and oral solution is primarily derived from two patents listed in the FDA&#8217;s Orange Book. The first, U.S. patent no. 6,949,571 (the &#8216;571 patent), will expire on May 23, 2025, including patent term extension. The second FYCOMPA&#174; patent in the Orange Book is U.S. Patent No. 8,772,497 (the &#8216;497 patent), which will expire on July 1, 2026. The &#8216;497 patent, which covers the API used in both FYCOMPA&#174; tablets and oral solution, has been the subject of previous Paragraph IV certifications from three ANDA filers for the tablet formulation, which were not contested by Eisai prior to our acquisition of the drug. Following our acquisition of the drug, we attempted to obtain an extension of the patent term for the '571 patent, which was ultimately unsuccessful. As a result, the '571 patent will expire on May 23, 2025 and the initial ANDA filers who did not challenge this patent may seek approval of their ANDA applications on or after that date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023 we received a Paragraph IV certification for the '497 patent from an ANDA filer for two applications, one for the FYCOMPA&#174; tablets and another for the FYCOMPA&#174; oral suspension. After due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions alleging infringement of both patents. In June 2024, we settled the pending Paragraph IV litigation with the Paragraph IV filer for both ANDAs. As part of that settlement, this Paragraph IV filer agreed not to commercialize their proposed ANDA products for both the oral suspension formulation of FYCOMPA&#174; and for FYCOMPA&#174; tablets until at least December 15, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we received a Paragraph IV certification for the &#8217;571 and &#8217;497 patents from an ANDA filer for an application for the FYCOMPA&#174; oral suspension. After due diligence, we determined that the circumstances and timeline did not warrant a lawsuit against this Paragraph IV filer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AGAMREE&#174;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 19, 2023, we entered into a License and Collaboration Agreement (AGAMREE&#174; License Agreement) and an Investment Agreement (Investment Agreement) with Santhera Pharmaceuticals Holding, Inc. (Santhera). Under the AGAMREE&#174; License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera&#8217;s investigational product candidate, AGAMREE&#174; (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both transactions closed on July 18, 2023. Under the AGAMREE&#174; License Agreement, upon closing we made a $75 million payment to Santhera in return for the exclusive North American license for AGAMREE&#174;. In addition to the rights to commercialize the product in North America, the AGAMREE&#174; License Agreement provides us with the right of first negotiation for AGAMREE&#174; in Japan should Santhera pursue partnership opportunities in that territory. Additionally, we will hold the North American rights to any future approved indications for AGAMREE&#174;. Finally, under our AGAMREE&#174; License Agreement with Santhera, we have agreed to purchase commercial supply of AGAMREE&#174; from Santhera at agreed upon prices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with the closing of the AGAMREE&#174; License Agreement, we made a strategic investment into Santhera in which we acquired 1,414,688 of Santhera&#8217;s ordinary shares (representing approximately 11.26% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction) at an investment price of CHF 9.477 per share, with the approximately $15.7 million USD in equity investment proceeds to be used by Santhera for Phase IV studies of AGAMREE&#174; in DMD and future development of additional indications for AGAMREE&#174;. On February 24, 2025, the closing price of Santhera&#8217;s common shares on the SIX Swiss Exchange was CHF 16.08 per share (approximately $17.90 USD based on then-current exchange rates).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 26, 2023, the U.S. FDA approved Santhera&#8217;s NDA for AGAMREE&#174; for use in treating DMD in patients aged two years and older. Shortly thereafter, as part of the previously described transaction, Santhera transferred the approved NDA to us. Additionally, following approval of the NDA for the drug, we became obligated to make a milestone payment of $36 million to Santhera, which we paid during the fourth quarter of 2023. We may also be obligated to pay future regulatory and commercial milestone payments to Santhera tied to calendar year sales of AGAMREE&#174;, as well as commercial royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2024, utilizing our FIRDAPSE&#174; field-based force, we launched AGAMREE&#174; for the treatment of DMD in the U.S. for patients aged two years or older. During the first quarter of 2024, in connection with our preparation for the commercial launch of AGAMREE&#174;, we incurred substantial commercialization expenses, including sales, marketing, analytical infrastructure, patient services, patient advocacy, and other commercialization related expenses. Initially, we added approximately 10 additional members to our FIRDAPSE&#174; team, and our commercial team marketed both products. However, in early 2025, we made a strategic decision to split our commercial field-based force into two units, one expressly focused on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing of FIRDAPSE&#174; and one expressly focused on the marketing of AGAMREE&#174;. This change is expected to allow us to better focus on the market for each product. We expect to complete this division of our field-based force into two units early in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are further supporting the distribution of AGAMREE&#174; through our Catalyst Pathways&#174; patient services program to ensure that patients have access to a dedicated, personalized support team that assists families through the AGAMREE&#174; patient journey, from answering questions to coordinating financial assistance programs for eligible patients. Finally, we have donated and intend to continue to donate funds to one or more qualified, independent charitable financial foundations who assist U.S. DMD patients in financial need for paying the costs of care including medication, to the extent permitted by each such organization's guidelines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DMD, the most common form of muscular dystrophy, is a rare and life-threatening neuromuscular disorder characterized by progressive muscle dysfunction, ultimately leading to loss of ambulation, respiratory failure, and fatality. Current standard treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 patients in the U.S. are affected by DMD, with approximately 70% of patients currently receiving a corticosteroid treatment. Steroids are expected to remain the foundation of therapy for DMD patients and dosed concomitantly with other therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174;&#8217;s unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In that regard, we have launched our SUMMIT study to evaluate data about long-term patient safety and quality of life data from the use of our product, with the hope of offering a deeper understanding of the product's potential long-term benefits for patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 13, 2023, Santhera announced that the European Union&#8217;s Committee for Medicinal Products for Human Use (CHMP) adopted a positive position in favor of AGAMREE&#174; for the treatment of DMD patients aged four and older. In its recommendation for approval, CHMP acknowledged that there was a positive benefit-risk profile of AGAMREE&#174; in such patient population, including certain safety benefits of AGAMREE&#174; compared to standard of care corticosteroids in the treatment of DMD. Further, on December 18, 2023, the European Commission (EC) granted to Santhera marketing authorization for AGAMREE&#174; for the treatment of DMD in patents ages four years and older and on January 12, 2024 Santhera announced that AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had received approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Further, on January 15, 2024, Santhera announced that AGAMREE&#174; was commercially launched in Germany. Finally, On January 16, 2025, the National Institute for Health and Care Excellence (NICE) issued positive Final Guidance that recommends AGAMREE&#174; for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of DMD in patients four years of age and older and on February 13, 2025, Santhera announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for AGAMREE&#174; (vamorolone) for the treatment of DMD. This milestone makes AGAMREE&#174; the first product to receive an agreed federal price in Germany for the treatment of DMD in patients 4 years of age and older, independent of the underlying genetic mutation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently taking the first steps to seek to expand the number of diseases that can be treated with AGAMREE&#174;. In furtherance of that objective, we are currently conducting a Phase 1 study in healthy adults comparing a single dose of vamorolone, prednisone, and deflazacort, and studying the immunosuppressive effect of multiple ascending doses of AGAMREE&#174;, which study will attempt to define the immunosuppressive dose of vamorolone for future indications and for the use of our product in conjunction with gene and cell therapies that are approved to treat DMD and require a concurrent immunosuppressive regimen of a corticosteroid when administered. We expect to have the results of this study around the middle of this year and hope that the results of this study will provide important information for use in marketing our product to healthcare practitioners in an effort to help with the treatment of patients. We have also begun a long-term project to undertake long-term research and development efforts for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we have established a joint steering committee with Santhera that is overseeing the lifecycle management and development of AGAMREE&#174;. There can be no assurance that we can develop our product for the treatment of diseases other than DMD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., AGAMREE&#174; has New Chemical Entity exclusivity that expires in October 2028. AGAMREE&#174; also has Orphan Drug Exclusivity expiring in October 2030. AGAMREE&#174; is further protected by seven Orange Book listed patents expiring as early as May 28, 2029 and as late as July 16, 2040. The Company has also requested Patent Term Extension and will update the relevant expiration date in the Orange Book upon a final determination by the USPTO. The earliest a generic manufacturer could submit an ANDA is October 26, 2027. If we were to pursue a patent infringement action if any such ANDA challenges any of AGAMREE&#174;&#8217;s Orange Book patents, then the automatic statutory 30-month stay would prevent FDA approval of such ANDA until April 26, 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, on July 23, 2024 we entered into a license, supply and commercialization agreement with KYE, which is already our sublicensee for FIRDAPSE&#174; in Canada, granting KYE the exclusive Canadian commercial rights to market AGAMREE&#174; in Canada for DMD and other indications. Under the agreement, KYE is responsible for obtaining regulatory approval of the product from Health Canada (of which there can be no assurance), and we will supply product to KYE. Further, KYE has advised us that they expect to file an application with Health Canada seeking approval to commercialize AGAMREE&#174; in Canada during the first quarter of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any such application when and if filed will be approved, and even if such application is approved that KYE will be successful in commercializing AGAMREE&#174; in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to advance our strategic initiatives and portfolio expansion efforts, focusing on broadening and diversifying our rare (orphan) neurology product portfolio with innovative therapies that address critical unmet medical needs and expanding the geographical footprint of our existing products. In that regard, we are currently exploring clinically differentiated and adequately de-risked opportunities, with a keen focus on orphan, rare disease products across therapeutic areas. These prospects include evaluating companies with existing commercial drug products or drugs in development, for potential partnerships, licensing, geographical expansion opportunities with our existing products, and/or asset acquisitions. We continue to employ a disciplined, comprehensive, and exhaustive approach to identifying and evaluating opportunities that we believe will add significant value to our company over the near, mid, and long term. However, other than the recent sublicense agreement described above between the Company and KYE for AGAMREE&#174; in Canada, no definitive agreements have been entered into to-date, and there can be no assurance that any of the Company's business development initiatives will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, we had cash and investments of approximately $517.6 million. Based on our current financial condition, including our profitability, cash flows generated from operations and forecasts of available cash, we believe that we have sufficient funds to support our operations for at least the next 12 months. There can be no assurance that we will continue to be successful in commercializing FIRDAPSE&#174; and AGAMREE&#174;, that our projections about the commercialization of FYCOMPA&#174; after the expiration of its patents will be correct, or that we will continue to be profitable and cash flow positive. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources&#8221; below for further information on our liquidity and cash flow.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal year ended December 31, 2024, we generated revenues from product sales of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174;. We expect these revenues to fluctuate in future periods based on our sales of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received approval from Health Canada on July 31, 2020, for FIRDAPSE&#174; for the symptomatic treatment of LEMS and as of December 31, 2020, our sub-licensee KYE launched FIRDAPSE&#174; in Canada. During the fiscal year ended December 31, 2024, revenues generated under our collaboration agreement with KYE were immaterial. During the year ended December 31, 2024, we announced that we had entered into a collaboration agreement with KYE for the launch of AGAMREE&#174; in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 24, 2024, we were informed by DyDo that it had received approval of its New Drug Application for the sale of FIRDAPSE&#174; in Japan. Further, DyDo informed us that they had launched FIRDAPSE&#174; in Japan in January 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect revenues from both the KYE and DyDo agreements to be immaterial in 2025 as distribution ramps up in each jurisdiction and KYE begins the process of seeking approval to market AGAMREE&#174; in Canada.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Sales</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales consists of third party manufacturing costs, freight, royalties, milestone payments, and indirect overhead costs associated with sales of our products. Cost of sales may also include period costs related to certain inventory manufacturing services, inventory adjustments charges, unabsorbed manufacturing and overhead costs and manufacturing variances.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as support for selected investigator-sponsored research. The major components of research and development costs include acquired IPR&amp;D, preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials, consulting, and other third party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials, and allocations of various overhead costs related to our product development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to January 2023, all of our research and development resources had been devoted to the development of FIRDAPSE&#174;, and until we acquire or license new products we currently expect that our future development costs will be attributable principally to the continued development of FIRDAPSE&#174;, and AGAMREE&#174;.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cost accruals for clinical studies and trials are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical study and trial sites and clinical research organizations (CROs). In the normal course of our business we contract with third parties to perform various clinical study and trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar conditions. The objective of our accrual policy is to match the recording of expenses in our consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to preclinical and clinical studies or trials are recognized based on our estimate of the degree of completion of the event or events specified in the specific study or trial contract. We monitor service provider activities to the extent possible; however, if we underestimate activity levels associated with various studies or trials at a given point in time, we could be required to record significant additional research and development expenses in future periods. Preclinical and clinical study and trial activities require significant up-front expenditures. We anticipate paying significant portions of a study or trial&#8217;s cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2019, we began to commit funds to developing our commercialization program for FIRDAPSE&#174; and we have continued to incur substantial commercialization expenses, including sales, marketing, patient services, patient advocacy and other commercialization related expenses as we have continued our sales program for FIRDAPSE&#174;. We are also now incurring substantial commercialization expenses for FYCOMPA&#174; and AGAMREE&#174; as we continue commercialization of both products. We expect that such expenses for FYCOMPA&#174; may begin to decline as a result of a potential decline in sales upon the expiration of patent protection and the commencement of generic competition during 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general and administrative expenses consist primarily of salaries and personnel expenses for accounting, corporate, compliance, and administrative functions. Other costs include administrative facility costs, regulatory fees, insurance, and professional fees for legal including litigation cost, IT, accounting, and consulting services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amortization of Intangible Assets</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization of intangible assets consists of the amortization of the FYCOMPA&#174; product rights, which are amortized using the straight-line method over its estimated useful life of 5 years, the RUZURGI&#174; product rights, which are amortized using the straight-line method over its estimated useful life of 14.5 years, and the milestone payment made to Santhera relating to the approval of AGAMREE&#174; in the U.S. in October 2023, which is amortized using the straight-line method over its estimated useful life of 10.5 years.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our effective income tax rate is the ratio of income tax expense over our income before income taxes. As of December 31 2024, 2023, and 2022, we had no federal net operating loss carry-forwards. Additionally, we had no state net operating loss carry-forwards in any such year.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For discussion of recently issued accounting standards, please see Note 2, "Basis of Presentation and Significant Accounting Policies,": in the consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, our expected course of development, historical experience and other factors we believe are reasonable based on the circumstances, the results of which form our management&#8217;s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts of assets and liabilities reported in our consolidated balance sheets and the amounts reported in our consolidated statements of comprehensive income are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, valuation of intangible assets, stock-based compensation and valuation allowance for deferred tax assets. The accounting policies described below are not intended to be a comprehensive list of all of our accounting policies but represent the accounting estimates which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. GAAP. There are also areas in which our management&#8217;s judgment in selecting any available alternative would not produce a materially different result. Our consolidated financial statements and the notes thereto included elsewhere in this report contain accounting policies and other disclosures as required by U.S. GAAP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts with our customer, payors, and other indirect customers relating to the sale of our products. These reserves are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Our analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates as of December 31, 2024, 2023 and 2022 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Refer to Note 2, &#8220;Basis of Presentation and Significant Accounting Policies,&#8221; in the consolidated financial statements included in this report for further details on revenue recognition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation of Intangible Assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have acquired and continue to acquire significant intangible assets that we record at fair value at the acquisition date. Transactions involving the purchase or sale of intangible assets are usually based on a discounted cash flow analysis. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, cost of capital and market participants. Each of these factors can significantly affect the value of the intangible asset. We engage independent valuation experts who review our critical assumptions and calculations for acquisitions of significant intangibles. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, we would estimate the fair value of the assets and record an impairment loss. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest group level for which cash flows are identifiable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize stock-based compensation for the fair value of all share-based payments, including grants of stock options and restricted stock units. For stock options, we use the Black-Scholes option valuation model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of our common stock. The estimated expected option life is based upon the simplified method. Under this method, the expected option life is presumed to be the mid-point between the vesting date and the end of the contractual term. We will continue to use the simplified method until we have sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the expected life of our stock option awards. For the years ended December 31, 2024 and 2023, the assumptions used were an estimated annual volatility of 54.1% to 61.5% and 68.0% to 71.0%, expected holding periods of 4.5 to 5.0 years and 4.5 to 5.2 years, and risk-free interest rates of 3.70% to 4.70% and 3.55% to 4.92%, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Years Ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended December 31, 2024, we recognized total revenues of approximately $491.7 million,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which included approximately $489.3 million in net revenue from product sales primarily in the U.S.,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compared to approximately $398.2 million in total revenues, which included approximately $396.5 million in net revenues from product sales primarily in the U.S., for the fiscal year ended December 31, 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174; net sales were approximately $306.0 million for the fiscal year ended December 31, 2024, compared to approximately $258.4 million for the fiscal year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net sales were approximately $46.0 million for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FYCOMPA&#174; net sales were approximately $137.3 million for the fiscal year ended December 31, 2024, compared to approximately $138.1 million for the period between January 24, 2023 (date of acquisition) and December 31, 2023. FYCOMPA&#174; net sales for the fiscal year ended December 31, 2024 were affected by differences in variable consideration (gross-to-net) compared to the 2023 period when revenues were booked under Eisai&#8217;s more favorable cost arrangements with distributors and government authorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase of approximately $92.8 million in net product revenues when comparing the fiscal year ended December 31, 2024 and 2023 was primarily due to the commercialization of AGAMREE&#174;, and related product sales, and increases in FIRDAPSE&#174; sales volumes of approximately 12.4% and net price increases. Net revenues from product sales of FIRDAPSE&#174; increased by 18.4% from 2023 to 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the first quarter of each calendar year, like many companies in our industry, we are also impacted by the reset of patient insurance deductibles.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beginning in May 2025, product revenue for FYCOMPA&#174; will be affected by the expiration of FYCOMPA&#174; patent protection, which we expect will decrease our net product revenue for this product.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended December 31, 2024, we recognized $2.4 million in license and other revenue, as compared to $1.7 million during the fiscal year ended December 31, 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended December 31, 2024, license and other revenue consisted primarily of a milestone payment of $2.1 million earned upon DyDo receiving product approval to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS in Japan. For the fiscal year ended December 31, 2023, such revenue consisted of the $1.4 million payment achieved as a result of DyDo submitting a Japan NDA for FIRDAPSE&#174; to the PMDA on December 18, 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales was approximately $68.8 million for the fiscal year ended December 31, 2024, compared to $52.0 million for the fiscal year ended December 31, 2023. Cost of sales in both periods consisted principally of royalty payments, which are based on net revenue as defined in the applicable license agreements.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For FIRDAPSE&#174;, royalties are payable on the terms set forth below in Liquidity and Capital Resources&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and increase by 3% when net sales (as defined in the applicable license agreement) exceed $100 million in any calendar year.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales for FYCOMPA&#174; for the fiscal year ended December 31, 2024 consisted of product costs and excludes the amortization of the FYCOMPA&#174; intangible assets.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales for AGAMREE&#174; for the fiscal year ended December 31, 2024 consisted of royalties payable on the terms set forth below in Liquidity and Capital Resources&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, product costs and excludes the amortization of the AGAMREE&#174; intangible asset. Royalties on sales of AGAMREE&#174; in future years may increase as a percentage if net sales exceed certain amounts over $100 million. See Note 9 of the Notes to Consolidated Financial Statements included elsewhere in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amortization of Intangible Assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization of intangible assets was approximately $37.4 million for the fiscal year ended December 31, 2024 compared to $32.6 million for fiscal year ended December 31, 2023. Amortization of intangible assets consists of the amortization of the FYCOMPA&#174; rights, which are amortized using the straight-line method over its estimated useful life of 5 years, the RUZURGI&#174; rights, which are amortized using the straight-line method over its estimated useful life of 14.5 years and the AGAMREE&#174; rights, which are amortized using the straight-line method over its estimated useful life of 10.5 years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each fiscal quarter, we review the value of our intangible assets to determine if they are impaired. If we determine one or more of our intangible assets are impaired during a future period we would record a charge in the amount of that impairment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the years ended December 31, 2024 and 2023 were approximately $12.6 million and $93.2 million, respectively, and represented approximately 4% and 30% of total operating costs and expenses, respectively. Research and development expenses for the years ended December 31, 2024 and 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.942%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.662%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Salary and benefit expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,905</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,119</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">786</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.2</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,779</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,481</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.1</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and clinical trial expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,813</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,513</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(81,513</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional research and development expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,151</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,704</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(553</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32.5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,648</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,150</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,502</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86.4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses decreased approximately $80.5 million during year ended December 31, 2024 when compared to the same period in 2023. The decrease is primarily attributable to the $81.5 million IPR&amp;D purchase consideration for the acquisition of the license in North America for AGAMREE&#174; during the third quarter of 2023. During 2024, research and development expenses consisted of costs for company-sponsored research and development activities, support for selected investigator-sponsored research, and support for our commercial activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that research and development activities may become more significant in the future if we seek to execute on the development of additional indications for FIRDAPSE&#174; and AGAMREE&#174; and on our portfolio expansion efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were approximately $177.7 million and $133.7 million, respectively, and represented approximately 60% and 43% of total operating costs and expenses for the years ended December 31, 2024, and 2023, respectively. Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.36%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.940000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,344</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,689</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,655</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.4</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,924</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,252</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,672</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.1</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,472</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,769</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,703</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total selling, general and administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177,740</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,710</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,030</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, selling, general and administrative expenses increased approximately $44.0 million when compared to the same period in 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This was primarily attributable to an approximately $18.1 million increase in employee compensation and stock-based compensation related to annual merit increases and an increase in headcount resulting from the acquisitions of FYCOMPA&#174; and AGAMREE&#174;, an approximately $24.7 million increase in commercialization expenses related to the launch of AGAMREE&#174; and to the timing of our commitments to make contributions to 501(c)(3) organizations supporting LEMS patients of approximately $1.3 million. Further, an approximately $3.9 million increase in stock-based compensation expense is related to the retirement of two former executive officers, which was recorded during the first quarter of 2024 upon lapse of the applicable revocation periods under the respective separation agreements with these former executives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that selling, general, and administrative expenses will continue to be substantial in future periods as we continue to sell FIRDAPSE&#174; and AGAMREE&#174; and as we take other steps in an effort to continue to expand our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation for the years ended December 31, 2024 and 2023 was $22.3 million and $14.3 million, respectively. In 2024 and 2023, grants were principally for stock options and restricted stock units related to year-end bonus awards and grants to new employees. For 2024, stock-based compensation included stock option and restricted stock unit grants to our new Chief Executive and Chief Financial Officers, each of which began employment at the beginning of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We reported other income, net in all periods, primarily relating to interest on our investment of our cash and cash equivalents of approximately $21.1 million and $7.7 million for the fiscal years ended December 31, 2024 and 2023, respectively. The increase in other income, net for the fiscal year ended December 31, 2024 when compared to the same period in 2023 was primarily due to increases in cash and cash equivalents partially a result of our underwritten public offering that we completed in January 2024 and an increase in the share price of our investment in Santhera, partially offset by lower interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since Santhera&#8217;s shares are traded on the SIX Swiss Exchange, they have a readily determinable fair value, and as a result the investment is measured quarterly, at fair value, with changes reported in other income, net.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of other income, net were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,064</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,675</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net gains recognized during the period on equity<br/>&#160;&#160;&#160;securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,075</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,139</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,699</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our effective income tax rate was approximately 24.2% and 24.4% for fiscal years ended December 31, 2024 and 2023, respectively. Differences in our effective tax and the statutory federal income tax of 21% are driven by state income taxes and anticipated annual permanent differences offset by equity compensation deductions. Our effective tax rate is affected by many factors, including the number of stock options exercised in any period, and our effective tax rate is likely to fluctuate in future periods (and may be higher than it was in the 2024 fiscal year).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had no material uncertain tax positions as of December 31, 2024 and 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net income was approximately $163.9 million in the year ended December 31, 2024 ($1.38 per basic and $1.31 per diluted share) as compared to approximately $71.4 million in the year ended December 31, 2023 ($0.67 per basic and $0.63 per diluted share).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Years Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information comparing results of operations for the year ended 2023 compared to 2022 was included in our Annual Report on Form 10-K for 2023 filed with the SEC on February 28, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have financed our operations primarily through revenues from product sales and multiple offerings of our securities. At December 31, 2024 we had cash and cash equivalents aggregating $517.6 million and working capital of $502.9 million. At December 31, 2023, we had cash and cash equivalents aggregating $137.6 million and working capital of $143.3 million. At December 31, 2024, substantially all of our cash and cash equivalents were deposited with two financial institutions, and such balances were in excess of federally insured limits. Further, as of such date, substantially all such funds were invested in money market accounts and U.S. Treasuries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 8, 2023, we filed a shelf registration statement with the SEC to sell up to $500 million of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the 2023 Shelf Registration Statement). The 2023 Shelf Registration Statement (file no. 333-274427) became effective upon filing. On January 9, 2024, we completed a public offering of 10 million shares of our common stock under the 2023 Shelf Registration Statement, raising net proceeds of approximately $140.7 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current financial condition, including our profitability, cash flows generated from operations and forecasts of available cash, we believe that we have sufficient funds to support our operations for at least the next 12 months from the date of this report. There can be no assurance that we will remain profitable or that we will be able to obtain any additional funding that we may require in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may require additional working capital to support our operations depending on our future success with FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; sales, or the products we may acquire and continue to develop and whether our results continue to be profitable and cash flow positive. There can be no assurance as to the amount of any such funding that will be required for these purposes or whether any such funding will be available to us if and when it is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In that regard, our future funding requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of diligence in seeking potential acquisitions and of the completion of such acquisitions, if any future acquisitions occur; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future clinical trial results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress and cost of our clinical trials and other product development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of net revenues that we report from sales of FIRDAPSE&#174;, FYCOMPA&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and AGAMREE&#174;; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competition and market developments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in other products. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. We also may seek governmental grants for a portion of the required funding for our clinical trials and preclinical trials. We may further seek to raise capital to fund additional product development efforts or product acquisitions, even if we have sufficient funds for our planned operations. Any sale by us of additional equity or convertible debt securities could result in dilution to our stockholders. There can be no assurance that any such required additional funding will be available to us at all or available on terms acceptable to us. Further, to the extent that we raise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are not favorable to us. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, which could have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities was $239.8 million and $143.6 million, respectively, for the years ended December 31, 2024 and 2023.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash provided by operating activities was primarily attributable to our net income of $163.9 million,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases of $1.8 million in accounts payable and $53.8 million in accrued expenses and other liabilities,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$22.3 million in stock-based compensation and $37.8 million in amortization of intangible assets and depreciation. This was partially offset by increases of $12.0 million in accounts receivable, net, $3.9 million in inventory and $8.5 million prepaid expenses and other current assets, a decrease of $0.4 million in operating lease liability, $9.4 million in deferred taxes and $5.6 million in non-cash expenses. During the year ended December 31, 2023, net cash provided by operating activities was primarily attributable to our net income of $71.4 million, increases of $10.8 million in accounts payable and $5.8 million in accrued expenses and other liabilities, $81.5 million in acquired IPR&amp;D, $14.3 million in stock-based compensation and $32.9 million in amortization of intangible assets and depreciation.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This was partially offset by increases of $43.1 million in accounts receivable, net, $4.7 million in inventory and $5.8 million prepaid expenses and other current assets, a decrease of $0.3 million in operating lease liability, $17.8 million in deferred taxes and $1.3 million in non-cash expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities during the year ended December 31, 2024 was $0.6 million and consisted of purchases of property and equipment.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities during the year ended December 31, 2023 was $293.5 million and consisted primarily of payments in connection with asset acquisitions of $198.3 million, acquired IPR&amp;D of $81.5 million and the purchase of equity securities of $13.5 million.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities during the year ended December 31, 2024 was $140.7 million, consisting primarily of proceeds from the issuance of common stock. </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in financing activities during the year ended December 31, 2023 was $10.9 million, consisting primarily of payment of liabilities arising from asset acquisition of $12.7 million, partially offset by proceeds from the exercise of stock options of $2.8 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into the following contractual arrangements with respect to sales of FIRDAPSE&#174;:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payments due under our license agreement for FIRDAPSE&#174;. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently pay the following royalties under our license agreement: </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties to our licensor for seven years from the first commercial sale of FIRDAPSE&#174; equal to 7% of net sales (as defined in the FIRDAPSE&#174; License Agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties to the third party licensor of the rights sublicensed to us from the first commercial sale of FIRDAPSE&#174; equal to 7% of net sales (as defined in the FIRDAPSE&#174; License Agreement between BioMarin (since transferred to SERB) and the third party licensor) in any calendar year for the duration of regulatory exclusivity within a territory and 3.5% for of net sales in any territory in which we do not enjoy regulatory exclusivity. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, we recognized an aggregate of approximately $47.3</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$39.5 million, respectively, of royalties payable under these license agreements, which is included in cost of sales in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we will pay royalties to our licensor on net sales in Japan equal to a similar percentage to the royalties that we are currently paying for non-U.S. sales under our original FIRDAPSE&#174; License Agreement for North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payments due to Jacobus. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our July 2022 settlement with Jacobus, we agreed to pay the following consideration to Jacobus: </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022, $10 million was paid on the first anniversary of closing and $10 million was paid on the second anniversary of closing; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An annual royalty on Catalyst&#8217;s net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the U.S. equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst&#8217;s FIRDAPSE&#174; patents in the U.S., 2.5% (with a minimum annual royalty of $5 million per year); </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, we recognized an aggregate of approximately $4.4 million and $3.7 million, respectively, of royalties payable to Jacobus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into the following contractual arrangements with respect to sales of FYCOMPA&#174;:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payments due under our asset purchase agreement for FYCOMPA&#174;. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our asset purchase agreement with Eisai Co., Ltd. (Eisai), we agreed to pay the following consideration to Eisai:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid at closing a $160 million upfront cash payment, plus $1.6 million for reimbursement of certain prepayments.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to 12% on net sales greater than $10 million and less than $100 million, 17% on net sales of greater than $100 million and less than $125 million and 22% on net sales greater than $125 million prior to the date of generic entry. Royalties equal to 6% on net sales greater than $10 million and less than $100 million, 8.5% on net sales of greater than $100 million and less than $125 million and 11% on net sales greater than $125 million after the date of generic entry. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the acquisition, the parties entered into two related agreements: (i) a short-term TSA for commercial and manufacturing services (to which transition services ended on December 31, 2023) and (ii) a long-term Supply Agreement for the manufacturing of FYCOMPA&#174;. Under the TSA, Eisai provided certain commercial and manufacturing services to the Company for a transition period following the closing of the acquisition. Further, under the Supply Agreement, Eisai will manufacture FYCOMPA&#174; for the Company for a period of seven years (or such longer period as is set forth in the Supply Agreement) following the closing of the acquisition. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into the following contractual arrangements with respect to AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vamorolone):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payments due under our license agreement for AGAMREE&#174;. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our recent acquisition from Santhera: </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At closing we paid a $75 million initial cash payment. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the fourth quarter of 2023, following regulatory approval of Santhera&#8217;s NDA for AGAMREE&#174; by the FDA, we paid a regulatory milestone payment of $36 million. We are also obligated to pay additional regulatory </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestone payments upon regulatory approval by the FDA in the U.S. of an NDA for the product for the first, second, and third additional indications in the amounts of $50 million, $45 million, and $45 million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to pay royalties and/or sales-based milestone payments if the applicable amount of net sales of all products in the territory in a single calendar year fall within the range of one or more of the net sales threshold levels set forth in the AGAMREE&#174; License Agreement. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until January 1, 2026, we are obligated to purchase all of the requirements for product solely from Santhera, and Santhera is required to manufacture, supply, and sell product to us at an agreed upon supply price. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simultaneously with entering into the license agreement, we made a strategic equity investment into Santhera by acquiring 1,414,688 of Santhera&#8217;s ordinary shares (representing approximately 11.26% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the approximately $15.7 million USD in equity investment proceeds, inclusive of the approximately $13.5 million USD fair value of the investment in Santhera and approximately $2.2 million USD of transaction costs included in acquired in-process research and development, to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE&#174;. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, we recognized an aggregate of approximately $5.1 million of royalties payable under this license agreement, which is included in cost of sales in the accompanying consolidated statement of operations and comprehensive income. No royalties were recognized during the year ended December 31, 2023 under this agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have entered into the following contractual arrangements:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase commitment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have entered into a purchase commitment with a contract manufacturing organization for approximately $0.5 million per year. The agreement expires in December 2025. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease for office space</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We operate our business in leased office space in Coral Gables, Florida. We lease approximately 10,700 square feet of office space and we pay annual rent of approximately $0.5 million. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any off-balance sheet arrangements as such term is defined in rules promulgated by the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This report contains &#8220;forward-looking statements&#8221;, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations, beliefs, plans or objectives for future operations and anticipated results of operations. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, &#8220;believes&#8221;, &#8220;anticipates&#8221;, &#8220;proposes&#8221;, &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, and other similar expressions are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or other achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the section entitled &#8220;Item 1A &#8211; Risk Factors.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continued successful commercialization of FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel) CIII, and AGAMREE&#174; (vamorolone) are highly uncertain. Factors that will affect our success include the uncertainty of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to successfully market and sell FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; while maintaining full compliance with applicable federal and state laws, rules and regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to attract and retain the qualified personnel necessary to run our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our estimates of the size of the market for FIRDAPSE&#174; for the treatment of LEMS will prove to be accurate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether the daily dose of FIRDAPSE&#174; taken by patients changes over time and affects our results of operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will continue to be able to locate LEMS patients who are undiagnosed or are misdiagnosed with another disease;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether patients will discontinue from the use of our products at rates that are higher than historically experienced or are higher than we project; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether new FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; patients can be successfully titrated to stable therapy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we can continue to market our products on a profitable and cash flow positive basis; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to demonstrate, to the satisfaction of the FDA and third party payors, whether AGAMREE&#174; offers advantages compared to other corticosteroids or competitor&#8217;s products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether DMD patients transitioning to current or future gene therapy treatments will delay initiating use of AGAMREE&#174; while waiting for access to such gene therapy, or stop their AGAMREE&#174; therapy during the course of their gene therapy treatment;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to continue to successfully commercialize FYCOMPA&#174; after its patents expire starting in May 2025 and generic competition for FYCOMPA&#174; enters the market; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether any revenue or earnings guidance that we provide to the public market will turn out to be accurate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether payors will continue to provide coverage and reimburse for our products at the price that we charge for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of our third party suppliers and contract manufacturers to continue to supply sufficient product to meet our customers&#8217; needs in a timely manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of our third party suppliers and contract manufacturers to maintain compliance with current Good Manufacturing Practices (cGMP); </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of those third parties that distribute our products to maintain compliance with applicable law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to maintain compliance with applicable rules relating to our patient assistance programs for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to maintain compliance with the applicable rules that relate to our contributions to 501(c)(3) organizations that support patients in financial need; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope of our intellectual property and the outcome of challenges to our intellectual property, and, conversely, whether any third party intellectual property presents unanticipated obstacles for FIRDAPSE&#174;, FYCOMPA&#174;, or AGAMREE&#174;; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether there will be a post-closing review by antitrust regulators of our previous acquisition transactions, and the outcome of any such reviews if they occur; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be able to acquire additional drug products under development, complete development required to commercialize such products, and thereafter, if such products are approved for commercialization, successfully market such products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we will be successful in our litigation to enforce our patents against the Paragraph IV challengers who have filed ANDAs seeking to introduce generic versions of FIRDAPSE&#174;;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our patents will be sufficient to prevent generic competition for FIRDAPSE&#174; and AGAMREE&#174; after our orphan drug exclusivity for each product expires; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact on our profits and cash flow of adverse changes in reimbursement and coverage policies or regulations from government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators, or the impact of pricing pressures enacted by industry organizations, the federal government or the government of any state, including as a result of increased scrutiny over pharmaceutical pricing or otherwise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in the healthcare industry and the effect of political pressure from and actions by the President, Congress and/or medical professionals seeking to reduce prescription drug costs, and changes to the healthcare industry occasioned by any future changes in laws relating to the pricing of drug products, including changes made in the Inflation Reduction Act of 2022, changes (if any) to be made by the current President and/or the current Congressional administrations, changes to the review and approval process at the FDA, or changes in the healthcare industry generally; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether we and Santhera can successfully develop additional indications for AGAMREE&#174; and obtain the ability to commercialize the product for these additional indications; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state of the economy generally and its impact on our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope, rate of progress and expense of future clinical trials and studies, pre-clinical studies, proof-of-concept studies, and our other drug development activities, and whether any trials and studies we undertake will be successful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to complete any clinical trials and studies that we may undertake on a timely basis and within the budgets we establish for such trials and studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether FIRDAPSE&#174; can be successfully commercialized in Canada on a profitable basis through KYE, our collaboration partner in Canada; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether AGAMREE&#174; will be approved by Health Canada for commercialization in Canada and whether, if the product is approved, KYE can successfully commercialize it in Canada;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether KYE will successfully file an application seeking to commercialize AGAMREE&#174; in Canada during the first quarter of 2025 or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Now that FIRDAPSE&#174; has been approved for commercialization in Japan and launched, whether DyDo will be successful in commercializing the product in Japan; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The impact on sales of FIRDAPSE&#174; in the U.S. if an amifampridine product is purchased in Canada for use in the U.S.; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether our plans to expand the reach of FIRDAPSE&#174; and AGAMREE&#174; into other global regions will be successful;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">System failures or security or data breaches due to cyber-attacks, or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions whether it occurs directly to us or indirectly through third parties; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.398%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.6457662761254888%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enhance our systems, processes and procedures to appropriately support the growing complexity and scale of our business. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current plans and objectives are based on assumptions relating to the continued commercialization of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; and on our plans to seek to acquire or in-license additional products. Although we believe that our assumptions are reasonable, any of our assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements we have made herein, which reflect our views only as of the date of this report, you should not place undue reliance upon such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_disclo_market_risk"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;7A. Quanti</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market risk represents the risk of changes in the value of market risk-sensitive instruments caused by fluctuations in interest rates, foreign exchange rates and commodity prices. Changes in these factors could cause fluctuations in our results of operations and cash flows.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our exposure to interest rate risk is currently confined to our cash and cash equivalents that are from time to time invested in highly liquid money market funds and U.S. Treasuries. The primary objective of our investment activities is to preserve our capital to fund acquisitions and operations. We also seek to maximize income from our investments without assuming significant risk. We do not use derivative financial instruments in our investment portfolio. Our cash and investments policy emphasizes liquidity and preservation of principal over other portfolio considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statement_and_sup_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;8. Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Statements and Supplementary Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the list of financial statements filed with this report under Item 15 below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;9. Ch</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">anges in and Disagreements with Accountants on Accounting and Financial Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;9A. C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ontrols and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules 13a-15(e) and 15(d)-15(e) under the Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act of 1934 (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2024, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports filed or submitted by us under the Securities Exchange Act of 1934, as amended, was recorded, processed, summarized or reported within the time periods specified in the rules and regulations of the SEC, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports was accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management's Annual Assessment of Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our principal executive officer and our principal financial officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024 based on the 2013 framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and in accordance with the interpretive guidance issued by the SEC in Release No. 34-55929. Based on that evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter of 2024, there were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities and Exchange Act of 1934 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, Grant Thornton LLP, has issued a report on our internal control over financial reporting, which is included in Item 15 of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;9B. O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ther Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4da62ba-83f6-4a39-b05d-307494796743" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_5d1f462e-214a-47bc-b531-cbcfe8ae6531" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_162e521a-204f-43a5-8a55-405b6e5479c8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_302c3710-6486-495f-9b5e-aa3db0142e2d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9c_foreign_jurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT III</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_and_executive_officer"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;10. Direc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tors and Executive Officers of the Registrant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be contained in our definitive proxy statement, or Proxy Statement, to be filed with the SEC in connection with our 2025 Annual Meeting of Stockholders. Our Proxy Statement for the 2025 Annual Meeting of Stockholders is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2024 and is incorporated into this report by this reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of ethics that applies to our chief executive officer, chief financial officer, and to all of our other officers, directors, employees and agents. The code of ethics is attached to this Annual Report on Form 10-K as Exhibit 14.1 and is available on our website at </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.catalystpharma.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within five business days following the date of such amendment or waiver.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;11. Exec</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;12. Secur</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ity Ownership of Certain Beneficial Owners and Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;13. Ce</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rtain Relationships and Related Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;14. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incipal Accounting Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT IV</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_15_exhibits_and_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Exhibits and Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents filed as part of this report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following financial statements of Catalyst Pharmaceuticals, Inc. and Reports of Grant Thornton LLP, independent registered public accounting firm, are included in this report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reports of Grant Thornton LLP, Independent Registered Public Accounting Firm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of financial statement schedules. All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of exhibits required by Item 601 of Regulation S-K. See part (b) below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:33.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:11.66%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:10.66%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">File Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of<br/>Filing</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed<br/>Herewith</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated August  14, 2006, between the</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Company and Catalyst Pharmaceutical Partners, Inc., a Florida</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">corporation</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-136039</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/1/2006</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement by and between Eisai Co., Ltd. and the Company, dated as of December 17, 2022</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/2022</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-136039</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/25/2006</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-136039</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/25/2006</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312515111873/d862051ddef14a.htm#tx862051_19"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/30/2015</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annex A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520227098/d67771dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Incorporation</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/21/2020</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">By-Laws</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-136039</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/1/2006</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312519302591/d841417dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to By-Laws</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/27/2019</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014406009063/g02464a2exv4w1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Stock Certificate for Common Stock</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-136039</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/1/2006</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312522077228/d159262dex45.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of the Company&#8217;s Capital Stock</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/16/2023</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(a)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between the Company and Richard J. Daly*</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(a)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(b)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between the Company and Michael W. Kalb*</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(b)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:33.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:11.66%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:10.66%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">File Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of<br/>Filing</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed<br/>Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(c)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement between the Company and Patrick J. McEnany*</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(c)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(d)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101d.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement between the Company and Alicia Grande*</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1(d)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.2(a)+</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518119932/d558293ddef14a.htm#toc558293_20"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2018 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;DEF 14A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;001-33057</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;4/17/2018</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Annex A</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(b)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520188818/d932120ddef14a.htm#tx932120_21"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to 2018 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;7/7/2020</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annex A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(c)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312521308040/d249150ddef14a.htm#tx249150_20"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to 2018 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/25/2021</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annex A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(d)+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1369568/000119312523185962/d500830ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3 to 2018 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/12/2023</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annex A</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.2(e)+</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1369568/000119312524091926/d762054ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4 to 2018 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;DEF 14A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;001-33057</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/10/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Annex A</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Severance and Change in Control Plan</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095014407004805/g07390exv10w1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement between the Company and 355 Alhambra Plaza, Ltd.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/14/2007</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312511223174/dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/15/2011</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312514060790/d678177dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/2014</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(d)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312515109517/d897752dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/27/2015</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(e)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518251807/d610816dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/17/2018</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(f)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520141636/d931443dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fifth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2020</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated as of December  13, 2011, among New York</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">University, the Feinstein Institute for Medical Research, and the</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Company</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/30/2012</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312512442533/d429885dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated as of October 26, 2012, between the Company and BioMarin</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/31/2012</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312514147816/d712457dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to License Agreement, dated as of April  8, 2014,</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312514147816/d712457dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">between the Company and BioMarin</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/17/2014</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Settlement Agreement, dated effective as of July  26, 2018, by and</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">among (i)  Aceras BioMedical, LLC, in its capacity as Stockholder</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Representative for the</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/17/2018</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:33.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:11.66%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:10.66%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">File Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of<br/>Filing</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed<br/>Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Former stockholders of Huxley</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Pharmaceuticals, Inc., (ii) BioMarin, and (iii) the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(d)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/d755191dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to License Agreement, dated May  29, 2019,</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/d755191dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">between the Company and BioMarin</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/30/2019</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312518358175/d666131dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Development, License and Commercialization Agreement, dated effective as of December  18, 2018, by and between Endo Ventures Limited and the Company</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/26/2018</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/d811529dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Supply Agreement, dated as of August  14, 2020, by and</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/d811529dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">between KYE Pharmaceuticals, Inc. and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312521204754/d187873dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Supply Agreement, dated as of June 28, 2021, by and between DyDo Pharma, Inc. and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/28/2021</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312522191772/d329751dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Settlement Agreement, dated July  11, 2022, by and between the Company and SERB SA, on the one hand, and Jacobus Pharmaceutical Company, Inc., PantherRx Specialty LLC, and Panther Specialty Holding Co., on the other hand</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/12/2022</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312522191772/d329751dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Asset Purchase Agreement, dated as of July  11, 2022, by and between Jacobus Pharmaceutical Company, Inc. and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/12/2022</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition Services Agreement between Eisai, Inc. and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/2022</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312523207344/d524408dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Transition Services Agreement, dated as of July 31, 2023, made by and between the Company and Eisai</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/9/2023</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Supply Agreement between Eisai Co., Ltd. and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/22/2022</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312523173863/d499888dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Collaboration Agreement, executed and delivered as of June  19, 2023, by and between Santhera, its wholly-owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/23/2023</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001369568/000119312523173863/d499888dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Investment Agreement, dated as of June 19, 2023, by and between Santhera and the Company</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/23/2023</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000095017024092745/cprx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License, Supply and Commercialization Agreement, made as of July 23, 2024, between the Company and KYE Pharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;001-33057</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;8/7/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:33.44%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:1.56%;box-sizing:content-box;"/>
    <td style="width:11.66%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:10.66%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">File Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of<br/>Filing</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed<br/>Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider Trading Policy (certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed)</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312520075048/d838851dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/16/2020</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cprx-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Grant Thornton LLP</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cprx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 302 CEO Certification</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cprx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 302 CFO Certification</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cprx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 906 CEO Certification</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="cprx-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 906 CFO Certification</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex971.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clawback Policy</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-33057</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2/28/2024</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;97.1</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document&#8211;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Certain identified information has been excluded from these exhibits because it is both (i) not material, and (ii) would likely cause competitive harm to the Company if publicly disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this Annual Report on Form 10-K to be signed by the undersigned, thereunto duly authorized, this 26</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of February, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:90%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard J. Daly</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard J. Daly,</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and CEO</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons, in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:32%;box-sizing:content-box;"/>
    <td style="width:51.68%;box-sizing:content-box;"/>
    <td style="width:16.32%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard J. Daly</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard J. Daly</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Officer (Principal Executive Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael W. Kalb</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael W. Kalb</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Patrick J. McEnany</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patrick J. McEnany</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Charles B. O&#8217;Keeffe</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Charles B. O&#8217;Keeffe</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David S. Tierney, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David S. Tierney, M.D.</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Donald A. Denkhaus</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald A. Denkhaus</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Molly Harper</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Molly Harper</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Tamar Thompson</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tamar Thompson</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:86.667%;text-indent:50.001%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reports of Independent  Registered Public Accounting Firm (PCAOB ID Number </span><span><ix:nonNumeric id="F_9bf538da-0d39-4a2a-b5ca-ba180369a17f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">248</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidate_operations_comp_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Income</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_to_consolidated_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPOR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors and Stockholders</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86670336-559f-4511-9c99-d392af708c7f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on internal control over financial reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Catalyst Pharmaceuticals, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by COSO.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the Company as of and for the year ended December 31, 2024, and our report dated February 26, 2025 expressed an unqualified opinion on those financial statements.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Assessment of Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and limitations of internal control over financial reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efe92fcd-6d33-4d76-9ee4-2a7d8919550e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GRANT THORNTON LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:9.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a92a76fc-bdbb-4476-9f74-f52367efc4b8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miami, Florida</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2025</span><span style="color:#ff0000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the financial statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Catalyst Pharmaceuticals, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income, changes in stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical audit matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicated below is a</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matter</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arising from the current period audit of the financial statements that was</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicated or required to be communicated to the audit committee and that: (1) relates</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below, providing a separate opinion</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on the critical audit matter or on the accounts or disclosures to which it</span><span style="color:#0000ff;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relates.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue adjustments for government rebates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 2 to the financial statements, the Company estimates reductions to its revenues for amounts due under various government rebate programs, including Medicaid and Managed Care, in the period in which the related sales occur. We identified the revenue adjustments for Medicaid and Managed Care as a critical audit matter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal considerations for our determination that the revenue adjustments for Medicaid and Managed Care is a critical audit matter are that auditing the Company&#8217;s reductions to revenue for Medicaid and Managed Care rebates are complex and involved significant judgment, particularly in assessing the reasonableness of estimated payor mix applied to sales during the year. This estimate relies heavily on historical data that is adjusted for changes in payor mix expectations over time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to the revenue adjustments for Medicaid and Managed Care included the following, among others. We evaluated and tested the design and operating effectiveness of internal controls over the Company&#8217;s estimates of the revenue adjustment for Medicaid and Managed Care rebates, including assumptions over payor mix. Our test of details procedures included, among others, performing a comparison of actual rebate claims received against the amounts recorded by management, performing a sensitivity analysis on the rebate amount and payor mix used in the estimates, analytically evaluating management&#8217;s estimates and evaluating evidence contrary to the estimated amounts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ GRANT THORNTON LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2006.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miami, Florida</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2025</span><span style="color:#ff0000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ASSETS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8f61f4-21b3-4a32-86fc-3aa20d18735d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,553</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74f9db9a-ca72-48ff-a973-e13f7ab069c6" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,636</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c718ec8-adf2-4d81-8d65-978c6d68909c" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,476</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4646e103-93e0-487c-ae76-d35965d209c2" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2dd1ceb-3cee-4ec5-a4f2-c3a1b5be45d8" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,541</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23d8557e-7610-4c33-a4e8-d58175acce8b" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,644</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d0ad7a-9378-4d47-938b-d1ba8426f659" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,039</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d77b3dd7-513c-4b7f-9fd2-cf7fd3c46d29" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,535</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfbd13b0-e282-4498-bd4b-f6f3ab1493fa" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9987dba-d676-4a74-af34-12179bc2ef11" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,329</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f03a24-24ee-4b78-b52f-43647c79d68a" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,230</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11aa4101-d764-4d02-a6b2-03c8e297d3ef" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,508</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cb2bc01-2851-475d-8ef7-4e44e219b4ab" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,354</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0d9092f-05e1-4f11-ac3a-30f1513cbcae" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,195</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3e4fa4b-bff7-4420-a323-90ea290a61ad" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,672</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cd7a551-2227-42b2-be92-14ffcc3f09a6" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,049</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c72821-5ff1-4c6e-8066-2c422a0b2914" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,982</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c231c7b3-9e3f-4071-aa54-db1bd746c861" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,544</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in equity securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f8f767b-6506-4a3c-94f6-1c3d908034e7" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,564</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5789ed-611a-4f82-b461-e913a26854ec" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ecee4a4-1ad4-4691-963d-af4891bb7339" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">851,411</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9784148-63f2-494a-8843-1de77d5b5231" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470,114</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cee26d8f-5233-4fc3-85aa-f359d61f8bbb" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,593</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42b6457-0abd-4e0e-b9f0-0d1485f255d1" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,795</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4bb061b-9f4c-43f3-ade4-91cd71f9a13d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b6f8d5-cba5-43d2-b5fc-dc247f12a6d1" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,268</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_590956e0-8ec1-4a09-b1c7-fd0124485f7e" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,678</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feebfd3d-16ab-480d-92db-12c88f443c77" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,063</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b469d3d-f8ca-4911-ba0a-163b698b5c4b" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8337f159-0423-49b4-b6d0-a9acaf3797da" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,188</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac71413a-aecf-40f0-bad0-771ba51f2726" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4eb36ca-8375-4a59-9be9-8649bcd76033" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,982</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89033a6f-e720-4f8f-8083-43e797e9c767" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,779</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d250cb3b-06bc-41b1-b893-1c5722f9c7aa" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,233</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="-sec-ix-hidden:F_b3227f7e-05ef-4816-b5f7-7b8eae6c5421;"><span style="-sec-ix-hidden:F_aad5c8a8-d3cc-486c-8887-82ff44fbcbeb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 12)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4b145ec-62c4-442c-a36f-5970e1c7cef4" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f859dd2b-51d8-4ec3-9ff1-43c4741727ad" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2257958-8b13-40e4-b769-034d5b963381" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_efdad824-02ef-4d2e-8442-865bee88f55a" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93179275-28b1-4c3f-b037-9d5ea00580de" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b162b43a-ad3e-479b-8503-fefee4c6d33a" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d436d2a7-f541-40bb-9486-ffc2bd719976" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42edb062-8b7a-4d5d-956c-3bfe8b972139" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and<br/>&#160;&#160;&#160;outstanding at December 31, 2024 and 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeed3a0d-6ae6-4b4f-83e9-0565100df9c5" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a5d6722-3b76-4508-b4f3-f3b28ebea50e" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23b02162-bcda-497c-88d8-6294cd2b6423" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ad9af219-d1eb-4418-81f9-9a84223470f6" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3f13661-7693-48b6-af0c-564f80bffe56" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ab0e594d-1d0e-46b4-aec2-2cfc5222f879" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b2b45a7-8b40-43cd-be73-ec1c27921083" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d75aec02-6757-468a-9566-d355d57a8eb2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">120,879,099</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f66958d3-65eb-4177-86eb-788feb1cafb4" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_eb652236-a973-4cbd-80ca-db120e6ba943" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">107,121,549</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024<br/>&#160;&#160;&#160;and 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_630e3887-c9a3-4588-901b-a9c94f248ed6" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86c5f227-2a50-4043-b7e4-4096e1237e9a" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a47861d-8f27-4a88-bdbf-88f0567fe8e6" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442,286</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23274f95-0336-4e8b-81af-8525bdb755c5" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,488</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retained earnings</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_942f954e-99ee-4ae9-907f-d06801b7898b" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,161</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79d45dff-d314-48f0-9b8c-14f5e316f1b9" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income (Note 4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d776a50e-32e5-4f9a-a842-2222066697b0" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eadf7cb-2b15-4fa5-8181-d9fa0f919ae2" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0479fa45-8683-4b5a-aa3c-dfcd56163631" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2a1c2d0-7b3b-4af2-afa0-01971762aad2" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387,881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_447152b4-f0c5-45f3-8e26-e1e9855d901f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">851,411</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1044fa63-bd80-47e8-b845-eeb627be8978" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470,114</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidate_operations_comp_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED ST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d84f130-0ab2-4d0d-80a7-cf65bee8a739" contextRef="C_9b84b239-460f-4343-8a55-dd9c8d160502" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b964b3e0-8459-409d-8e48-919fe26f5a9a" contextRef="C_76b5439a-53d8-49ab-af66-1b56f6f623fd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c820fe1-5663-4d92-8dbd-6606831639fb" contextRef="C_b48f2bea-3319-4b24-87f1-db81866524fe" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and other revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3675dbd-9cf6-4e2e-9399-bbd0bc553a66" contextRef="C_120e4417-63cf-4ab5-a1e1-efaa73f03a30" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,407</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d886aec-fb83-40b9-8d04-4673cd793c6c" contextRef="C_3c4dde2c-c247-4018-8dec-79047db0d397" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,702</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1903216b-edfc-454c-bead-03541967507a" contextRef="C_bc793338-3e30-4b0a-b679-9536be9b17ee" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b80566b-682b-4d24-912c-29d44fd48e94" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491,734</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d16489d-ec9e-43d3-9ce3-c8f1ff7c90f9" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,204</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f1ff7e-296e-41a6-ac23-30bf116ee8bb" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,203</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating costs and expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales (a)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ed2f82-8a48-42fe-af2f-872d5813258d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,967</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4090fec8-f07e-48d9-bf06-c1a0911f901a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d7bcec3-1fee-418e-b3c1-ba9969689260" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,648</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c10a8b95-2022-44bd-920a-d67d0528455f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d249fca2-2d41-41fa-aa9d-d85acd64557a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative (a)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75cfea18-2c8e-42fa-9913-1a0fb70f871c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,740</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78ea662f-49ac-4435-b86f-eb83afbf77c0" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,710</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_266311d6-f055-45aa-95b5-dcb4a1d901ee" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,085</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_031f85ad-c0bb-4cfc-a82c-d201e112aaa0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AmortizationExpensesOfIntangibleAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,377</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6c38add-4acf-40c1-9a27-e56bcb8cff33" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:AmortizationExpensesOfIntangibleAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,565</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d9450a1-2497-48a3-9107-8500b63abb7f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:AmortizationExpensesOfIntangibleAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81f01372-76fd-4b6f-b82a-24c96989417c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:OperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,610</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ba873a8-ed0a-434c-856e-ee3ca263eaa8" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:OperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_524fdb93-7595-453e-b461-bde90f8e2e23" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:OperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,365</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd86fc2f-e228-4517-b797-17456e62fba0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,124</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f59ab16-1d8e-4ee6-ac8b-defc21d45854" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_366642d8-9eca-4994-8d03-591c0c7fe190" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b3198ce-8876-4bfe-95c1-4620bf8d3a15" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,139</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e1297ac-d75c-4a3f-ae2c-b1b0b66dbb61" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389bb83e-3a01-4cc0-9d9a-6849f9ce100d" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income before income taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d737d514-29e3-435f-82f7-ab84839f838f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,263</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abd90bb1-b752-4c64-be3a-3609e0281a3f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,511</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_326bd90e-bb1a-4fd8-aa57-fd8294984ca2" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1891ea1-1f1d-43f7-af44-e0a6de57c395" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01aaa8d7-122f-41d4-9d0c-b9534774910d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,101</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_339c90f1-f237-4be5-ad04-0985c9e0826e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,640</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dbdadad-2c28-47aa-9b8a-b2aa30115307" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0020963-13dd-4fdb-bfb3-dee998e9615f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676d591d-a320-4790-b439-fbcde2afa393" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income per share:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d239254c-94a0-43af-b9d6-3e50a26a7532" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.38</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd91cce6-38fa-4a58-9e1e-cc872ca57027" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e942226c-f203-4963-bddf-11b5443f2058" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.80</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65dda079-ac6e-4346-80a9-0e6ed10cd0e0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.31</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d74d96d-4c9b-4920-b2d2-28b5bfd8d6f2" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.63</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a34421-4d19-42ca-b326-bb11d613ddc4" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares outstanding:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b059198f-ec07-4e35-9d88-388e1df40318" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">118,457,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_241019d1-ee22-4ae5-b4ce-7483b4ed06fa" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,279,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d69fe632-c8d5-40b5-857c-9a55ed0bdc7a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">103,374,606</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f1ea5c3-ad62-4a49-9868-e2ebca964fa1" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">124,943,603</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a8de5ee-6cdf-4e2c-b7cb-eed1c3d3f083" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,753,154</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3457157f-10fc-4c18-8f01-a42ee8b5b9e3" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">111,375,631</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b62ebb3f-f55a-402a-b97c-fdd44718cb1d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5693295c-0886-41a9-b94f-2aac834b3091" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f3f39e-32bc-4ab4-a46b-1fa6aa6b3485" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (Note 4):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities, net of tax of<br/>&#160;&#160;&#160;($</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e62c929-8868-4d2d-a8e1-95b4bbd534f6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">), $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14939732-c473-440d-9df2-577f48e3f37e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and ($</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39dbcc16-a04a-4ee1-b611-462d52a4ec08" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">), respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_714cf9f6-8fb3-462d-853b-2a24e6e3b8e8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4b6ca6b-c291-4f17-8962-35910bca0c3b" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bf5e0e3-b348-407a-8c8f-d2ace8234d18" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5919c02-3834-45df-8dea-e2dd41ee0703" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e96c7e57-c162-4ae5-86b8-22e14a23af42" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0faf0998-ac38-4fb4-99a5-8813f952e83e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets </span></ix:footnote></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.86%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Retained<br/>Earnings<br/>(Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29cae9c2-fb7f-45f0-a1a1-5676d94e9a11" contextRef="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">102,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_995203ea-3fd1-4cf7-9331-2647975cddc2" contextRef="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45ee5290-d92e-4f03-afcc-4ab6261261c7" contextRef="C_d5f3bd21-522f-4b08-969f-7e84f85ab2d2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_593d37d8-a234-41e7-97c6-aa6222219982" contextRef="C_7e4fb7e8-86a6-44b3-8a48-c1f6087f018a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,310</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e0aaf2-c8ba-4937-81b1-72b867c52da5" contextRef="C_5a58400b-bc1f-4635-913c-4ad5f983a455" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e4c098-ccc6-4a22-9306-57605860b8e6" contextRef="C_c24bf7e7-9d65-4eec-b363-d92095897f82" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206,831</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e75c4524-5e20-464d-9769-2a0bc6ebd203" contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb71450-020f-401c-a8a6-600b38a39e5a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options for<br/>&#160;&#160;&#160;common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78799b1-3c1a-49f9-a2ce-c69d326c2c94" contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eb11a22-564d-4885-ba6e-2b54feef21e9" contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675fd159-b575-49c7-b87e-631c131b5111" contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,567</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b7f3915-7e57-4f41-bbac-a26774cd2e93" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,569</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon<br/>&#160;&#160;&#160;vesting of restricted stock units, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c732d32a-376d-439f-b674-89f8b8e14994" contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629cd6cd-c44e-42ac-96f3-21c6092a0179" contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3203f47c-91cf-4e0d-acec-610d9c57bc9e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c661528-4c5f-4ead-9ba7-471be9e28c17" contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f2278e6-5f4d-4846-a3fc-8d007c71f68f" contextRef="C_da5c0563-d56c-4b30-a42d-4fb7860e6926" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d09fbc89-668c-4a07-98cf-da395a1386c6" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_990f9984-3329-4043-84f0-d0ca28daff6e" contextRef="C_9a567032-9b5a-41d1-86f5-591b8c5517a5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_897dc2de-5754-40bc-8b29-d4105f8d54db" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c9228d0-d2f2-4c29-8dc0-fc3f6792cee1" contextRef="C_da5c0563-d56c-4b30-a42d-4fb7860e6926" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_affbc5e7-3c4a-4830-8428-a1f9de569bb5" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc35ccf7-3ef3-4600-959c-8c4558956e17" contextRef="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">105,263</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5957310-0cb0-47d0-8a69-ad09eebd3fb0" contextRef="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c6c0a21-db44-4133-8656-625cdf92962f" contextRef="C_eb917612-49d0-4a60-87c6-e1340f2ed65b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,430</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_330a0651-f75c-40d0-a95e-680d48cc335e" contextRef="C_63b514b4-d04f-4c24-ae2c-3f68c86bc2cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,862</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17f5ee2-02b7-495a-8483-053b69ad104d" contextRef="C_146fabbe-e017-4017-80bb-681752315fa3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66061dac-b317-4099-b4a6-7277ff759377" contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,421</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d72b149-2779-4f17-8010-52224283e1b8" contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eb4010b-e679-4c06-a9a7-4636b95e4b20" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options for<br/>&#160;&#160;&#160;common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c768b748-620e-4b21-9327-4df525a85264" contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,652</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cd34d37-7234-47cb-8f86-ce1bcd907a99" contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e968a474-5157-40c2-bb74-f399728e76ba" contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,790</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f59245e-270b-43af-88a1-40c9b151d4b4" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon<br/>&#160;&#160;&#160;vesting of restricted stock units, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a7559a-ec01-4289-a139-7f0fc000cd14" contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_060029bc-138e-4999-b508-4e41de532269" contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3afa04f3-1208-46d6-bd7d-60a48fa62f12" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ebd6de2-f020-44af-983c-47eb340d9692" contextRef="C_e84d3106-1c0a-425f-b8b4-ab83374f00fa" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2216e08e-0812-4ccb-a869-ca09ec7ba2f4" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9fcf92e-a2af-4f53-b81d-35fbc53d4f8a" contextRef="C_09c65af8-c1b9-4e2d-9312-ab77475df623" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd98324-a31d-41a2-ab97-ef3f46d4a7b5" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fca285ce-17c3-4e1e-888a-0d2c968ffd4a" contextRef="C_586a96db-2895-433b-86b3-59a27d4ec21f" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">107,122</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd412172-c214-4fb6-b2b1-76ec9116f811" contextRef="C_586a96db-2895-433b-86b3-59a27d4ec21f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94292cd2-a377-451d-9523-9aa3c1c887ed" contextRef="C_cb022394-9f10-4ba9-855f-2cc8eb1d4d2e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,488</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06118ec1-c1ba-48f1-833a-67fd13ae5ed9" contextRef="C_9a4f3e35-a536-4dd5-b66f-0ae66fd2a87b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3973b4a-8fd2-42c3-81f8-58330ea095a0" contextRef="C_8dddeb9f-3b04-4e8a-baf5-72e1456394e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cc9f91e-cae6-43ca-8db6-6609ed7efc26" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">387,881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0a11324-8102-4fd1-af54-8cad212281f0" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7a86ce3-bad6-48fd-9950-d3ef15425dcf" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd5e3b3-b0ce-4735-a9e8-efcf08835632" contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,704</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b1af070-4ccf-4f96-9a60-0e3ce8f76c1f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4513717e-12d9-4a48-a59a-59cdce3618a9" contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15d75696-50cd-47f0-99fb-a83bac4c785d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options for<br/>&#160;&#160;&#160;common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc80dbec-0645-48c0-88d9-529d96369f2e" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,429</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1935635-56e1-40e9-bb85-29d7eff5f13d" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aabc5493-2d2b-4a81-a8da-6d9d865e40f0" contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,511</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fbcc1d3-5e5f-44aa-ae33-8290b03137d3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon<br/>&#160;&#160;&#160;vesting of restricted stock units, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88580a19-ea62-442e-ad7b-b271837b4cd1" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6831634f-2310-4144-9ef0-74e53538709c" contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c2af574-5ce5-42d3-b6ae-dd1765e7dc12" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61a3964-0946-4307-9c08-273de1aa8105" contextRef="C_449ab8c2-98c9-4b7f-964e-75ca3f26863f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b612d1b7-7a89-462b-b97a-d7a59c7ad080" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2715388-892b-4336-8d9c-e08bf4f83bac" contextRef="C_322cdd05-3fc8-4285-9f49-2a475c723c0a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad3c79c7-fe23-43af-b903-bb791ee82696" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7505a09-56d7-4a47-afe2-9b35c8face5c" contextRef="C_345c9a15-8b88-4b16-82c6-8b06540097af" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">120,879</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ac4d197-c604-44ed-9956-e8bcb370453c" contextRef="C_345c9a15-8b88-4b16-82c6-8b06540097af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ce233f8-f2f9-4395-8802-f5e378a8223b" contextRef="C_048b05a5-861c-4ff4-b542-3b7c319a55ea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442,286</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_634015bc-ceb3-4126-890a-b711f8fb3c6d" contextRef="C_d6459900-9ea0-4176-84e6-0b21db75fa6e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285,161</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb9dabbb-7026-4dc0-98e6-1eab338a22e7" contextRef="C_a6b7ed37-7935-4f83-a2ae-608865c7f8d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0604e773-3c7b-4b60-9d16-45ec8cbaa365" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NSOLIDATED STATEMENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1844fa84-68ba-4d45-aed7-a67bd467e33d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6039807c-58f4-431b-bb85-5f50d64af615" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,410</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3842b3f-7633-4028-9206-b80ca17ac26f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income to net cash provided by (used in)<br/>&#160;&#160;&#160;operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d75c07f9-d51f-488b-a863-99b2fb35b645" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04261232-5e9f-45bf-9e47-27ec018e521e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_955556a8-3575-49a8-ba21-759c1a1d7b0a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1072a55-b409-4831-ac2f-5a8bc4c2b60f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5433cf88-4a01-42f9-a31d-38ade1467961" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12984851-b2a1-432b-ba20-65494d7d7ad3" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4c4d1f-233e-4aa7-9fbb-d55a28b18f8c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,377</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea450243-9b95-4f15-b311-f8fe934c8084" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,565</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5e555e2-cf0a-4b37-bdea-f80cb5b8861d" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,098</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred taxes</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e5e3e72-df19-4870-b748-a3d5e6ac3725" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,388</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76f1b685-3c91-44f2-80a1-3ccb7769ce16" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a7f04dc-28b6-4751-8bc2-90da6bfe6cfe" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,937</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_240ed2fe-ce95-4e59-a16a-22b02377ad8d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AccretionOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">835</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2fe4116-8973-4cc3-9a85-329f228f41c7" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:AccretionOfDiscount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,320</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88038fec-ba8b-48b0-b0e5-6c4674f67d1a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:AccretionOfDiscount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reduction in the carrying amount of right-of-use asset</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c0414b2-0c7d-478a-acde-c3cb8ba74edd" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:NonCashChangeInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_983f8e54-a417-44c9-af4d-09d5ad07dcab" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:NonCashChangeInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c01e411-d642-41ab-a69e-0f71f9590a68" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:NonCashChangeInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Realized loss on sale of available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436bd015-a7fa-4607-8990-8c34398b6765" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69feb187-b6b7-4ec2-a845-16023ce43c58" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab9e4d9a-7c16-40c2-ab17-69905ebebccc" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">762</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired research and development inventory expensed from asset<br/>&#160;&#160;&#160;acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e2f3dd-50ca-44b1-9fb9-9383f86cbf1f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1a47c84-a47d-4b86-bbce-7acf965f6759" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_425d81cb-acd7-4eb7-861f-c3b3359d1767" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired inventory samples expensed from asset acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b6a240f-ccec-411e-830d-2e865744ae92" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_584bda6a-660e-48f8-8e68-85e58f5a2035" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b74b6f4-7090-47b4-9993-3c6cb357f447" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45709ed8-2617-40b9-aa5e-1bba891fa637" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85aa3e86-9c48-4100-872a-752c82becd43" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d523daa-0001-4a21-acaa-9209291f711e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:AcquiredInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of equity securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93bcf038-e723-4830-a450-c2f27e03df1e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ddf755e-9815-4060-a58f-5bc815fe000e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,024</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5436104f-150b-42b6-bc6e-f5cbdec485a8" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Increase) decrease in:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4048c0f-8dae-4651-80ef-ad5513f510e7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86169d8a-0e56-4d2f-befb-2452a18c709b" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,075</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58e67829-bdfb-4c0c-a625-eb941cda0bad" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,820</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7419ad70-0c56-4458-ad71-689f46a725ba" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,897</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e979fdb-7162-46fa-a22d-3d094d0202cb" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,739</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89768cc6-e40c-4932-b649-8a0f2342cd57" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_711a6a9f-75c3-454d-ac82-dfa2a5ca56b9" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,504</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dba83fa-46b3-4d81-bf22-c99682c1cb66" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dd94b15-2b40-494e-b1a4-a6bf6328d62a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">807</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase (decrease) in:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c6c078e-cef6-4a43-8451-2e1d2ee5bcc8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa9d4d16-e99e-472f-b300-002d7cb0fb3b" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,820</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9158f862-b674-45cd-9f04-5a51c7754f68" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,207</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6df11b9b-1cd2-4c34-ba94-1a2b3c1457b6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,848</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_940c171b-2824-4f8a-b299-6c739943bea0" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,800</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3379355-7c8a-474b-a1f7-c30e9456981f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,391</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a779198-971a-4f57-b1a6-f92c8d4cbbf9" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f7e619b-3b70-4919-9bc4-158677e57220" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5754f629-5b20-4a1f-98ee-17ec5322e32f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b56090c-3b06-4243-b8e0-79117ab335a7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,808</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ff47a10-a924-4b8b-a7a4-b974f79b527e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,600</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a1ce94-52dc-4338-9ab8-8ef74096867e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,047</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing Activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93a1357e-8f57-4963-b092-c32b5a33b196" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_932082ca-1cfe-4503-8acf-d3f7976f18e4" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_557891ac-f6ee-4530-af36-cbe60ef0bea6" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e2d5ed4-f59c-4366-a674-9a4dec478614" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faa881d1-ee96-47b4-9b47-4cd35c45e01d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_325b9058-65d6-4129-b112-f7e37d505db3" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,238</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments in connection with asset acquisitions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21983441-3cb6-488a-9ee7-c09022ebdd1f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:PaymentInConnectionWithAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aac34b99-7f9d-41ca-a8e8-84de3b77bc0d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:PaymentInConnectionWithAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198,293</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7129c5a8-c663-449a-b463-6078b2337150" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:PaymentInConnectionWithAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of in-process research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50f3235a-820d-4212-90cc-65911cc0bb11" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_510e449f-9a0c-43b7-a0af-662df03246e5" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d091eac1-2dc2-473e-9961-3fb7ff4a91a9" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of equity securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_213fbdd4-4736-4b6a-b3c8-3600ef47450f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bcf1675-bff5-4143-b2bb-7b9380e99ca5" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,465</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_315bdf3b-4bdb-4e15-9f2a-cac0dd12048e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c9d9a1-58e7-4f16-986a-04e9257e676b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6ff9f0-366c-4c46-9bd8-abb4c8d3e9a4" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">293,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_890f9626-8912-4fc2-851f-fb7cd782714a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,209</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing Activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of employee withholding tax related to stock-based<br/>&#160;&#160;&#160;compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94534026-2b02-4d0f-8e40-e30a4212df14" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b7b19a-3ef3-4307-9e1f-c98ee842671f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6e8b7a8-e121-4156-ba5e-4febc75c6cff" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_011a3f93-df58-408c-b106-3d8cdf695279" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe199fe-9397-436c-be7b-fca67c714364" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c05173d6-109b-4bc7-9b34-a597cc3e4f60" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,569</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d56118fc-e87e-4a8b-9b8c-ac6b627cffba" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63e85cd3-f7d9-4438-aece-38c0e8a0c1aa" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db1319c4-c481-4261-bbf3-fa60b67e5f1e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of liabilities arising from asset acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a109b77a-d2f9-4be5-986c-6b374802623a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,886</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b48af94f-9788-4707-96bf-42c81eadc89d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,667</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a048760-abd6-4ea6-a2f3-370031c89746" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52fb793a-c2b2-4eaf-999b-10ded39f5e99" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of fees in connection with issuance of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13a7245d-dff0-4320-972f-62dc8c410808" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5697f370-b9cb-4c26-bb6c-5d0e680b6ed8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,665</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a798c0c5-d808-4826-9134-560c47b86fb7" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,857</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c364b8-356b-41e2-aa36-b1db2d27093b" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,694</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99e4c05c-8f97-4fac-ade1-239dc11dad77" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,917</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1281410-4379-4097-b190-b900473d782e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,759</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3e65930-929b-4816-b8cf-4f4b40d7fe22" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,950</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents &#8211; beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f503dc1e-ab49-4c22-b859-437f6e50a5a9" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,636</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850d61f4-7734-433e-80b0-d9d176bd6e12" contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37ef5ecd-b479-48e6-8b7f-96d2d3596ed8" contextRef="C_c24bf7e7-9d65-4eec-b363-d92095897f82" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,445</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents &#8211; end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8c485ce-1bbb-4713-89d6-12b84df2ab18" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,553</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0bc677-9f53-4383-afc6-439c7ad3b744" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,636</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e308ec81-8b0c-47d1-bf96-20564a4a89d3" contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Supplemental disclosures of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for income taxes, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b188c8d2-a282-41b8-a1ae-6e0f16a4add0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,451</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a11dc4-824d-40eb-9e42-9237e47bf5ad" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad0b57c3-5a9f-44a7-901e-334317ae9f37" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,667</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b395b61-4cc1-42bf-9e45-15298d10d905" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,395</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07518736-45bc-4679-8d82-3d539d1fffab" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c67ac53e-843a-4eea-ac05-bbc3150ec228" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities arising from asset acquisition</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d71edce-295f-444d-88d5-587952c3e9ee" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:LiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8c0245e-c40c-4331-8bc5-f8ee51df1d7d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:LiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,915</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b174a279-6743-4ec7-b264-3ebc53a9bf17" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:LiabilitiesArisingFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="note_to_consolidated_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_c1566db8-5b9a-4ec7-80a6-9f65122f690e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NatureOfOperations" escape="true" continuedAt="F_c1566db8-5b9a-4ec7-80a6-9f65122f690e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company currently markets three drug products, FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel), and AGAMREE&#174; (vamorolone). The Company is currently seeking to further expand its drug portfolio, with a focus on acquiring the rights to late-stage products to treat orphan, rare disease across therapeutic areas. With an unwavering patient focus embedded in everything it does, the Company is committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s New Drug Application (NDA) for FIRDAPSE&#174; (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food &amp; Drug Administration (FDA), and FIRDAPSE&#174; is commercially available in the U.S. as a treatment for adults with LEMS. Further, Canada&#8217;s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE&#174; for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE&#174; is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals, Inc. (KYE). In the third quarter of 2022, the FDA approved the Company&#8217;s supplemental New Drug Application approving an expansion of the FIRDAPSE&#174; label to include pediatric patients (ages six and older). In the second quarter of 2024, the FDA approved the Company&#8217;s supplemental New Drug Application increasing the indicated maximum daily dose of FIRDAPSE&#174; (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of LEMS.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA&#174; (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of the U.S. rights to FYCOMPA&#174; on January 24, 2023 and is now marketing FYCOMPA&#174; in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company completed its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an exclusive license for North America for AGAMREE&#174; (vamorolone), a treatment for patients suffering from Duchenne muscular dystrophy (DMD). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in that jurisdiction. Additionally, the Company holds the North American rights for any future approved indications of AGAMREE&#174;. AGAMREE&#174; previously received FDA Orphan Drug and Fast Track designations and on October 26, 2023, the FDA approved AGAMREE&#174; oral suspension 40 mg/ml for the treatment of DMD in patients aged two years and older. On March 13, 2024, the Company commercially launched AGAMREE&#174; in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has devoted substantially all its efforts since inception to selling its products, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and research and development. The Company has been able to fund its cash needs to date through profits generated from sales of its products and offerings of its securities. See Note 15 (Stockholders&#8217; Equity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Company's current financial condition, including its profitability, cash flows generated from operations and forecasts of available cash, the Company believes it has sufficient funds to support operations for at least the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c1566db8-5b9a-4ec7-80a6-9f65122f690e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business (continued).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#8217;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 9, 2024, the Company completed a public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f385ce9-3dd6-44b9-bb08-efca2a9db265" contextRef="C_11716830-bd78-4cfa-b354-d95373de3afc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, raising net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0263344-b780-446d-8678-8fb78d96984a" contextRef="C_11716830-bd78-4cfa-b354-d95373de3afc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The proceeds of the offering will be used to acquire new products and for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e0bd480-23a8-4b40-ab05-03ea49652432" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRINCIPLES OF CONSOLIDATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The consolidated financial statements include the Company&#8217;s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.</span></div></div></ix:nonNumeric></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd8fa3f7-f05b-4e26-8a82-d8d6bceaa7ad" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:UseOfEstimates" escape="true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF ESTIMATES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc789707-9c93-4134-879c-5f062456f71b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CASH AND CASH EQUIVALENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company primarily invests in high credit-quality instruments in order to obtain higher yields on its cash equivalents. The Company considers all highly liquid instruments, purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80d75849-92b4-4257-a24d-b293e7ed355d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:MaximumMaturityPeriodOfCashAndCashEquivalent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has its cash and cash equivalents deposited with two financial institutions.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37d75c48-6e30-4f99-8b01-0ab0e8590dcd" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:InvestmentPolicyTextBlock" escape="true" continuedAt="F_37d75c48-6e30-4f99-8b01-0ab0e8590dcd_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At December 31, 2024 and 2023, investments consisted of U.S. Treasuries and an investment in equity securities. Such investments are not insured by the U.S. Federal Deposit Insurance Corporation.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Treasuries held at December 31, 2024 and 2023 were classified as available-for-sale securities. The Company classifies U.S. Treasuries with stated maturities of greater than three months and less than one year in short-term investments. U.S. Treasuries with stated maturities greater than one year are classified as non-current investments in its consolidated balance sheets.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (in stockholders&#8217; equity). Realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statements of operations and comprehensive income. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of its available-for-sale securities are judged to be as a result of a credit loss. The Company considers various factors in determining whether to recognize an allowance for credit losses including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. If the unrealized loss of an available-for-sale debt security is determined to be a result of a credit loss the Company would recognize an allowance and the corresponding credit loss would be included in the consolidated statements of operations and comprehensive income. The Company has not recorded an allowance for credit loss on its available-for-sale securities. See Note 3 (Investments).</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company made a strategic equity investment into Santhera by acquiring </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b80c94d-f884-40f4-9193-1774de86ceec" contextRef="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c" name="cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,414,688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Santhera&#8217;s  ordinary shares (representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b4a33eb-9a51-4ca1-a89b-928f26707931" contextRef="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c" name="cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction). The investment is denominated in Swiss Francs. The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera&#8217;s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes resulting from movements in foreign exchange rates, in other income, net in the consolidated statements of operations and comprehensive income.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_1" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_2"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_37d75c48-6e30-4f99-8b01-0ab0e8590dcd_1"><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc25b986-982e-42d3-af6a-0a3aeb6cb475" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCOUNTS RECEIVABLE, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounts receivable are recorded net of customer allowances for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed. At December 31, 2024 and 2023, the Company determined that an allowance for expected credit losses was not required. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d9c27e4-ff1b-45e4-bcc3-ace8dd046bae" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2042e2e3-ece0-4663-a828-748e7e623613" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts were written off during the periods presented.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0697907b-9bb1-41bb-a761-1bd65b74884e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:InventoryPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVENTORY</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; are also used in clinical programs to assess the safety and efficacy of the products for usage in treating diseases that have not been approved by the FDA or other regulatory authorities. The forms of FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; utilized for both commercial and clinical programs are identical and, as a result, the inventories have an &#8220;alternative future use&#8221; as defined in authoritative guidance. Raw materials associated with clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221;.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, and patient usage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7e477f2-c544-485d-bec9-c6435f61314f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PREPAID EXPENSES AND OTHER CURRENT ASSETS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements, and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company&#8217;s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing costs consist of advances for the Company&#8217;s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. </span></div></div></ix:nonNumeric></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">h.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_703ca658-c6b2-47ce-94f6-d49fc13062bf" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROPERTY AND EQUIPMENT,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af1f8375-788a-4903-85b9-db67fcf6e271;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daa7bfa4-20db-4163-8534-ad53d70f1dc3" contextRef="C_517f0446-4af8-4ed4-a041-177e495d6020" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computer equipment and software, from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af087444-9da2-4e54-b835-1802f923ce72;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb036f14-81e0-407c-9ed3-79cbc9712152" contextRef="C_6c1acb2b-a004-4627-8c8b-62b043c6ae4f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment, and from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f2e1209-d796-4a49-b827-fc1504335963" contextRef="C_578e3acb-13d3-45de-b073-1b8543855c9c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_2" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_3"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7633232e-9a4a-4cf3-a99b-84c53c0d3bf8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:BusinessCombinationsPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion of the Company&#8217;s exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico, which the Company accounted for as an asset acquisition under ASC 805-50. See Note 13 (Agreements) for further discussion on the Company&#8217;s acquisitions of the U.S. rights to FYCOMPA&#174; from Eisai, and on the exclusive license for North America acquired from Santhera for AGAMREE&#174;, both of which the Company accounted for as asset acquisitions under ASC 805-50.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0d2ca7c-cc2c-46f8-a631-8576e3c74337" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">j.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTANGIBLE ASSETS, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89a06719-2093-49f5-b3ac-9c17e66466c0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">k.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE OF FINANCIAL INSTRUMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and certain components of accrued expenses and other liabilities. At December 31, 2024 and December 31, 2023, the fair value of these instruments approximated their carrying value as a result of their respective short-term duration. </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">l.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE MEASUREMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity&#8217;s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). </span></div></div></ix:nonNumeric></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e_1" continuedAt="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity&#8217;s own assumptions, as there is little, if any, related market activity.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_3" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_4"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e_2"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_988d19f3-86a8-4466-ad73-3b20009287e5" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.984%;box-sizing:content-box;"/>
          <td style="width:1.479%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.436%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.479%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.436%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.479%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.436%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.479%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:11.791%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using (in thousands)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd654fd-13e5-4a20-8b48-7b6a8e7dedd5" contextRef="C_556226bc-36cb-4e4c-af68-b7221da14303" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,947</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c1218a-86a0-438d-b0e5-942ebf99c3e1" contextRef="C_36b51e6f-78fe-4d4b-8094-ef5504c510aa" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,947</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bfdbfdf-491e-4f32-99be-b721eca088b8" contextRef="C_be3b877f-8d5f-446a-ab53-63009d18c5b5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,457</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc205fea-d817-424d-9ffb-417692743bd4" contextRef="C_641f77d8-a8c4-4ee2-9594-6cbd48dc0f85" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,457</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3e62045-09fe-46e4-b7c0-83bcc9562e17" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,564</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9658a8d2-3066-41a1-a3a0-039a996968ea" contextRef="C_de1a8f83-1949-42be-9761-1b0a53274e18" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,564</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.188%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.594999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.594999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.594999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:11.943999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of<br/>December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2cfe5ff-3f1a-489e-aa4b-e80f97b3c329" contextRef="C_685da0b4-944b-4ee5-98c3-1fd7acde1f9b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,256</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_879e66c5-cc22-4a34-85b0-c417c3134b1b" contextRef="C_5f8fe6ab-7ff7-4826-aac8-a94da76c2e7b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,256</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_270e7833-c226-4aad-9a73-182bfe627026" contextRef="C_f33c6eaf-ab74-4de4-8b0a-b6b2d34223af" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,523</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a0ba6ee-3944-4543-9727-8b93c351b11e" contextRef="C_3052145c-1aab-4286-a4b8-bb9e3ef1c2a9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,523</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff2e2217-c088-4f62-9f30-3cfff5ef481d" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,489</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_babac47e-4e30-4e82-a1f9-4d1fab47268b" contextRef="C_a0a9bef3-9a5a-46af-831b-722f42e564bd" name="us-gaap:EquitySecuritiesFVNINoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,489</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2419c74a-d34c-4d8d-86bd-4ef4acf8067b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">m.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OPERATING LEASES. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, net, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately.</span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2c645bf-ecf2-4bcb-91d0-1e40bdefd2c3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:ShareRepurchases" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">n.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHARE REPURCHASES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In March 2021, the Company&#8217;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4e231ed-dc19-4830-85ae-9a92752a49b7" contextRef="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c" name="srt:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock. The share repurchase program currently expires in March 2025. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock&#8217;s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_4" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_5"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE RECOGNITION. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenues:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (ASC) Topic 606 &#8211; Revenue from Contracts with Customers (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue when its customers obtain title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. For FIRDAPSE&#174; and AGAMREE&#174;, subsequent to receiving FDA approvals, the Company entered into an arrangement with one distributor (the Customer), which is the exclusive distributor of FIRDAPSE&#174; and AGAMREE&#174; in the U.S. The Customer subsequently resells FIRDAPSE&#174; and AGAMREE&#174; to a small group of exclusive specialty pharmacies (SPs) whose dispensing activities for patients with specific payors may result in government-mandated or privately negotiated rebate obligations for the Company with respect to the purchase of FIRDAPSE&#174; and AGAMREE&#174;.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; in the U.S. commercial market through a Transition Service Agreement with a U.S. subsidiary of Eisai to major wholesalers and specialty pharmaceutical distributors. These sales are often subject to contracts held with managed care organizations and government agencies. The distribution services under the Transition Services Agreement ended on December 31, 2023, and beginning on January 1, 2024, the Company commenced direct sales of FYCOMPA&#174; in the U.S.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Revenue, Net:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company recognizes revenue on product sales when its customers obtain control of the Company&#8217;s products, which occur at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company&#8217;s payment terms range between 15 and 60 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, substantially all of the Company&#8217;s product revenues were from sales to customers in the U.S.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_5" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_6"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_1" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c65f616-7cf6-4de2-b929-51ed569a5b95" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net product revenue disaggregated by product (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_527373f0-fe09-4389-814b-2c1e7f6a378f" contextRef="C_cc17f402-b8b7-4846-b664-e84632ab2a8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,035</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec06c76-37e7-46d8-a932-efdea2ba7b2d" contextRef="C_a3c97892-bfc1-4d8c-9b02-7eb288071f27" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,426</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5036a41-7b9d-42b6-97f7-bfd841abc0c9" contextRef="C_4ebf61f1-ea81-43ad-81d4-337230acd6fc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,938</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;+</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7c32d70-ab8c-43a6-9e28-15f96a90187c" contextRef="C_a964cbf4-04fb-4e05-a570-316b7877d00d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,251</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecfad2e5-1ee6-4119-9494-9beb4590c583" contextRef="C_c0d78ce3-51fb-44f9-a661-e786541f4b0f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,076</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AGAMREE&#174;*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_881659e8-6047-47a8-a6b8-49f8b69ba572" contextRef="C_d9995f07-a56a-4e7e-b1c2-377bebd919d0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,041</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c5d0700-7421-4049-b16a-80c252f66e08" contextRef="C_9b84b239-460f-4343-8a55-dd9c8d160502" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,327</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_563bce81-0e82-4a35-be19-58b53bd70d2d" contextRef="C_76b5439a-53d8-49ab-af66-1b56f6f623fd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,502</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a70d6518-5059-43f9-b4b9-a4a34893c8c1" contextRef="C_b48f2bea-3319-4b24-87f1-db81866524fe" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,938</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711" xml:lang="en-US"><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#174; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:footnote><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><ix:footnote id="FNT_d94b260a-93b1-497f-8e6a-658b6a2becce" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></ix:footnote></p></ix:nonNumeric></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves for Variable Consideration:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, prompt payment discounts, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers relating to the Company&#8217;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to its customers) or a current liability (if the amount is payable to a party other than its customers).</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2024 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Discounts, Allowances and Wholesaler Fees:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with a discount that is explicitly stated in its contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. To the extent the services received are distinct from the sale of products to its customers, these payments are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income. However, if the Company has determined such services received are not distinct from the Company&#8217;s sale of products to its customers, these payments have been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive income through December 31, 2024, 2023 and 2022, as well as a reduction to accounts receivable, net on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prompt Payment Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual invoice sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_6" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_7"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_2" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_3"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funded Co-pay Assistance Program:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company contracts with a third party to manage the co-pay assistance program intended to provide financial assistance to qualified commercially-insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with its products, that have been recognized as revenue, but remains in the distribution channel at the end of each reporting period. These payments are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution or master agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. Return payments related to the sale of products are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provider Chargebacks and Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to the customer, who directly purchases the product from the Company. The customer charges the Company for the difference between what they paid for the product and the ultimate selling price to the qualified healthcare providers. The Company also participates in programs with government entities and other parties, including covered entities under the 340B Drug Pricing Program, whereby pricing on FYCOMPA&#174; is extended below wholesaler list price to participating entities (the FYCOMPA&#174; Participants). These entities purchase FYCOMPA&#174; through wholesalers at the lower program price and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue, net and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by the customer or at the time of a resale to a FYCOMPA&#174; Participant by a wholesaler, and the Company generally issues credits for such amounts within a few weeks of the customer or wholesalers&#8217; notification to the Company of the resale. Reserves for chargebacks consist primarily of chargebacks that the customer or wholesalers have claimed, but for which the Company has not yet issued a credit, as well as an estimate of chargeback claims that the Company expects to receive associated with its products, that have been recognized as revenue but remains in the distribution channel at the end of each reporting period.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Rebates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company is subject to discount obligations under state Medicaid, Medicare and other government programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For reserves related to the sale of its products, there is an establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the coverage gap program is sunsetting in 2024 and is being replaced with the Inflation Reduction Act (IRA) program. While most components of this program will begin 2025, the inflation penalty portion is effective as of 2024. Specifically, the program imposes manufacturer rebates on certain Part B and Part D drugs when prices rise faster than the rate of inflation. The Company has estimated this potential impact and has accounted for these inflation-related rebates as a reduction of product revenue in 2024 to the extent they apply to its drug portfolio. Similar to the coverage gap rebates, the associated reserve is accrued for as a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_7" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_8"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_3" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_4"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payor Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balances sheets.</span></p></ix:continuation></div><div><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_4" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_5"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bridge and Patient Assistance Programs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides FIRDAPSE&#174; and AGAMREE&#174; free of charge to uninsured patients who satisfy pre-established criteria for either the Bridge Program or the Patient Assistance Program. Patients who meet the Bridge Program eligibility criteria and are transitioning from investigational product while they are waiting for a coverage determination, or later, for patients whose access is threatened by the complications arising from a change of insurer may receive a temporary supply of free FIRDAPSE&#174; or AGAMREE&#174; while the Company is determining the patient&#8217;s third party insurance, prescription drug benefit or other third party coverage for FIRDAPSE&#174; or AGAMREE&#174;. The Patient Assistance Program provides FIRDAPSE&#174; or AGAMREE&#174; free of charge for longer periods of time for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#174; or AGAMREE&#174; because they are unable to obtain coverage from their payor despite having health insurance, to the extent allowed by applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company provides FYCOMPA&#174; free of charge to uninsured patients who satisfy pre-established criteria through a Patient Assistance Program. In addition, Catalyst provides programs to assist patients through the process for obtaining reimbursement approval for their FYCOMPA&#174; prescriptions from their insurers. Catalyst also provides support for patients using FYCOMPA&#174; through an Instant Savings Card Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues from Collaboration and Licensing Arrangements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration (Topic 808), to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. Revenue is included in product revenue, net in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_8" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_9"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_5" continuedAt="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_6"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes sales-based royalties or net profit-sharing when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d_6"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments to and from the collaborator are presented in the statements of operations based on the nature of the Company&#8217;s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 11 (Collaborative and Licensing Arrangements), for further discussion on the Company&#8217;s collaborative and licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbce71a2-04aa-4911-9cef-5c8a3f5b09f8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">p.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESEARCH AND DEVELOPMENT.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research-related services for the Company.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records upfront and milestone payments made to third parties under licensing and collaboration arrangements that occur before a compound receives regulatory approval as acquired in-process research and development (IPR&amp;D). IPR&amp;D acquired as part of an asset acquisition with no alternative future use is expensed immediately to research and development. Milestone payments made after regulatory approval are capitalized as a developed asset and unless the asset is determined to have an indefinite life, the Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">q.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17a19bba-8ad7-4f72-bf88-d96a21a877b3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADVERTISING EXPENSE. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5573d2a4-5bdc-416d-8289-3ca90ab77489" contextRef="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b0813a6-ba6f-4652-8269-e424cf51dab9" contextRef="C_96caeb09-9772-4554-9b52-38246d8f8c0e" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91adc952-2099-4122-9cf2-47f573877621" contextRef="C_d2c50c06-f8b1-40b0-b95b-16454488f954" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in advertising costs during the years ended December 31, 2024, 2023 and 2022, respectively, which are included in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4af32751-f5e0-41a9-818c-d554f8eeeefa" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">r.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK-BASED COMPENSATION. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3cdd42e-bab3-4c40-b1fc-16720c714e44" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_9" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_10"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43fb9923-93c1-4a5e-ae6c-31970646798a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_43fb9923-93c1-4a5e-ae6c-31970646798a_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">s.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONCENTRATION OF RISK. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sells its products, FIRDAPSE&#174; and AGAMREE&#174;, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to these products. The Company sells its product, FYCOMPA&#174;, directly to major wholesalers and specialty pharmaceutical distributors and indirectly to managed care organizations and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE&#174;. The Company expects sales of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; to constitute virtually all of the Company&#8217;s product revenue for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_43fb9923-93c1-4a5e-ae6c-31970646798a_1"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE&#174;. The Company relies on the same third party manufacturers for FYCOMPA&#174; as utilized by Eisai prior to the Company&#8217;s acquisition of the U.S. rights to the product in January 2023. It also relies on Santhera and its supplier as its sole source of supply for AGAMREE&#174;. If the Company is unable to continue its relationships with one or more of these third party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third party contractors to manufacture the commercial supply of its drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7404b0b-9e2d-4158-9d74-9f99092cd454" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates the approximate percentage of the Company&#8217;s total net product revenue attributed to the Company&#8217;s largest customers for the periods presented:</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"/>
          <td style="width:1.2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.72%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8908ec4d-2383-4836-8dcd-80320f5e65ad" contextRef="C_947bd494-b761-4eb9-88a5-277a61b73354" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0c538b0-cfea-4451-8254-55093e56403c" contextRef="C_c2c87252-f283-4c4a-9b97-9a9c92725e3f" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">65.2</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5e1ce43-d1b7-468c-b054-fbe2ce905ded" contextRef="C_b4f3694a-ca49-4caa-8b5c-bca9ff9a1642" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4436702-baa2-4753-b4e4-736cc652c726" contextRef="C_99496368-5345-4bb0-94b5-aed58a22c466" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7393005-53d8-43d7-905c-d6e3893fde43" contextRef="C_fa8bafc8-49aa-4a6c-ba98-092b8ee3ad87" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">34.8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e080c9-fb3e-42e3-9405-9f5355bd8806" contextRef="C_8b7f00ee-4559-46ef-9b02-67895013d0e5" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_867ff943-6113-4987-8b30-5d5fe1321be2" contextRef="C_7edf969a-90c8-4fa0-819c-30ed128b4031" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">72.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_090701e8-fa71-4bb0-8e45-228ef6ca16b6" contextRef="C_67dce2a2-937e-4e9c-8d05-52a8de7df49a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd68d0cc-15b6-4c99-a1e1-fee5d2dd1c04" contextRef="C_e5da14d5-3dc8-44d1-b668-b38be2324fa8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><ix:footnote id="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</span></ix:footnote><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76e3bc2d-e130-41ed-b91e-a22e8f02cddf" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:RoyaltiesExpensePolicyTextBlock" escape="true" continuedAt="F_76e3bc2d-e130-41ed-b91e-a22e8f02cddf_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">t.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROYALTIES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Royalties incurred in connection with the Company&#8217;s license agreement for FIRDAPSE&#174; and AGAMREE&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. </span></div></div></ix:nonNumeric></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_76e3bc2d-e130-41ed-b91e-a22e8f02cddf_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties incurred in connection with the Company&#8217;s license agreement for RUZURGI&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized for any royalties in excess of the minimum annual royalty payment from July 11, 2022 (the Effective Date) through 2025. The minimum royalty payment that exists annually for calendar years from the Effective Date through 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ad1668-9b29-45c7-b3a4-2ec072b4ebb3" contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a2ba0ac3-ff5f-4bd6-bdc3-c6bdb52c1f0a" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal"><ix:nonFraction id="F_69e1ea1d-55a8-4a61-85be-38d4109950b7" contextRef="C_465c30df-be19-4455-9dcb-aaf2927ffe62" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">3</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are included in the purchase price of the agreement.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_10" continuedAt="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_11"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2108d1f7-3f04-4790-80ec-75e342b4deda" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">u.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCOME TAXES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2021. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2defd399-c51a-41b3-980d-0b6038a8f47a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">v.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPREHENSIVE INCOME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders&#8217; equity. The Company&#8217;s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2024, 2023 and 2022, and is comprised of net unrealized gains (losses) on the Company&#8217;s available-for-sale securities.</span></div></div></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cb2b66d-96e8-4793-9970-891557c5efed" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">w.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET INCOME PER COMMON SHARE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4c2d510-2468-4841-8807-304dc18adb5e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles basic and diluted weighted average common shares:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.726%;box-sizing:content-box;"/>
          <td style="width:1.683%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.056999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.407%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.056999999999999%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.43%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.642%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6ef366-0b1b-4908-9e8b-40c9d6698d72" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">118,457,673</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3262111-397f-45a9-b321-fd067fffbbbf" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,279,736</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d1da843-5ee0-4eb3-a91a-7fd514c67cc2" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">103,374,606</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of dilutive securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_539d46e9-9abf-4388-91c3-caa8d62a5bd0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,485,930</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f05a079-d164-43dc-a530-def693f091a6" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,473,418</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c896b767-ff37-4362-9cfa-36d3678ce571" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,001,025</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eb8bfec-3c19-4904-8cb8-75e2e0b77ec1" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">124,943,603</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b546c6f8-8347-4d1d-9f52-3ab375dc1735" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,753,154</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76f82f3a-47cc-4f2d-bbd8-ba1ab8c79c3f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">111,375,631</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding common stock equivalents totaling approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1038229d-d94e-4c6c-8d0e-a5df5b0b1a1c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c1b411-8104-42a3-8b38-f6c60f93f316" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dea675f7-a616-4e76-a2de-00845537edee" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were excluded from the calculation of diluted net income per common share for the years ended December 31, 2024, 2023 and 2022, respectively, as their effect would be anti-dilutive. Potentially dilutive options to purchase common stock as of December 31, 2024, 2023 and 2022 had exercise prices ranging from</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b251cbf9-0aa1-4c79-b133-5f199fbc5b0e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a9e9e1-38fd-4a38-8858-3de1a219f9ce" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">14.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cfa0353-3610-4c89-a4d5-fa1ef61a0478" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ced02898-031d-4787-9537-faa3ebf09601" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1a18e2-2dda-4073-a268-2e5f93e4f6b1" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c2a79f2-cc6c-4587-a177-958b2cc152d8" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a_11"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div><ix:nonNumeric id="F_37aac078-d9ee-4e9d-92b7-745043d79426" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_37aac078-d9ee-4e9d-92b7-745043d79426_1"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">x.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEGMENT INFORMATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management has determined that the Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcbca938-e9c6-4aa2-a8a9-e2e94c0bf6d3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is the development and commercialization of drug products. The Company's chief operating decision maker (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fc95014e-239d-4684-9334-a50e46b93483;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">president and chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who reviews financial information presented on a consolidated basis.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa879947-85b8-4e47-82c9-2c689588da85" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These financial metrics are used by the CODM t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating margin and the allocation of budget between cost of revenues, selling, research and development, and general and administrative expenses.</span></div></div><p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</span><span><ix:nonNumeric id="F_4863c748-930f-4527-b4a7-da7852f1b269" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_4863c748-930f-4527-b4a7-da7852f1b269_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates information about significant segment expenses:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4863c748-930f-4527-b4a7-da7852f1b269_1" continuedAt="F_4863c748-930f-4527-b4a7-da7852f1b269_2">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.26%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47328395-c4f5-425e-bb09-324a5ab788d2" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,648</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f81251e-b40d-4bb2-82f1-a6adb05c1e9e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,150</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcbf119a-b622-4420-8a6f-74ce61be9e81" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,789</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85ab21a8-799b-4419-bd5b-239ca0c0f306" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SellingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,746</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4026ab61-faa8-4cdc-a928-6a4591a5603f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:SellingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,500</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ed55be4-b8ef-4d9d-8e0a-9f0a159e4bc9" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:SellingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,044</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative (a)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,994</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,210</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47467f83-aca0-4199-b569-0a51fde6c304" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,041</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_528907b0-46ca-4b1a-8a8c-c3e72ac6a5b9" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,388</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f793012c-28ba-4338-8950-71ad3ca54999" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,860</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59bdc1c3-9499-448d-b279-f0147ab5a2fe" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,874</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4863c748-930f-4527-b4a7-da7852f1b269_2"><span><ix:continuation id="F_37aac078-d9ee-4e9d-92b7-745043d79426_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     (a)     </span><ix:footnote id="FNT_267031a3-8c5f-4907-907e-81096734e04a" xml:lang="en-US" continuedAt="F_267031a3-8c5f-4907-907e-81096734e04a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</span></ix:footnote></ix:continuation></span></ix:continuation></span><ix:continuation id="F_267031a3-8c5f-4907-907e-81096734e04a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6dc836d-a789-4812-86ea-9ee5e179f012" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">y.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECLASSIFICATIONS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_733dd2ce-a4b1-48fe-a0d1-138664c9cf76" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">z.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECENTLY ISSUED ACCOUNTING STANDARDS. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ASU 2023-07) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 during the year ended December 31, 2024. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires significant disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance will be applied prospectively and is effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the impact of the standard on the Company&#8217;s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income&#8212; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a843c46-dc1e-424a-a8f9-00e320b22e68" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f306df02-b09c-4dad-b5aa-63059ed63440" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments by security type were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a65adb53-a039-4e2c-8283-c26880d4eac8" contextRef="C_3e76c130-0386-4921-9a30-01e38dfe1755" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,457</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4fa20d4-0e63-43e0-a8ef-8066f455d26d" contextRef="C_cef50498-2b2c-43e6-ac01-77fde9e03dec" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a45a72d-29bc-41b7-9624-e71c2410eba8" contextRef="C_cef50498-2b2c-43e6-ac01-77fde9e03dec" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256f2d8c-84dd-4e4b-b9cb-145c2e99f1d1" contextRef="C_3e76c130-0386-4921-9a30-01e38dfe1755" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,373</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dc3705c-5bd6-408e-8be4-9b73835c084c" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,457</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e448836-14ca-4923-a976-0625645098da" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_431f588f-b724-44dd-8093-aa0273c81afa" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0278696e-47cb-4d2b-a5a1-7e2150fea8f8" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,373</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0276b4b7-1019-4ef2-ac4d-efebcbb31cc5" contextRef="C_02c41411-07f0-46c6-b493-3634436dc399" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fa7d420-687c-4858-892f-38d8c6dcdcb7" contextRef="C_dc509cd1-e714-4010-a518-68d402172ccd" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0108b4c7-0eac-4d8c-a45f-3f7ed9b80329" contextRef="C_dc509cd1-e714-4010-a518-68d402172ccd" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba24fda-9cdb-4674-a069-9b34d11cae15" contextRef="C_02c41411-07f0-46c6-b493-3634436dc399" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,505</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0e4a5bc-3bce-4a66-8a76-5773e926c8cd" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,523</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23b9b961-b95d-43c0-b691-1314e518b0ba" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8072bd19-e049-4eb2-82ad-62725490e256" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf2f9f07-7a29-4c79-b99c-97e68e3ead85" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,505</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebc9756d-2a7a-477e-9bea-c31661dbb676" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a20942c1-a52b-4a98-9ed7-b5dda0f622d6" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses from available-for-sale securities for the years ended December 31, 2024 or 2023. There were realized losses from sale of available-for-sale securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ded9671-2bb2-4056-839b-ce5b77acac98" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">762</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61d619b5-9fa6-4229-9a8a-5b638bc83a01" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair values of available-for-sale securities at December 31, 2024, by contractual maturity, are summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3492c3cd-0010-4f7a-987e-b8b4c457460f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329,457</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73ee862e-61ec-4678-ab2a-d5379af6cfb3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:GainLossOnInvestmentsTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net gains (losses) recognized during the period on<br/>&#160;&#160;&#160;equity securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a276d4e2-7e44-4143-a755-b8a7aa1c68d3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,075</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d3ba64f-3f4f-4dae-b922-79a15aa72b44" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,024</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_251e05d4-6df5-4b73-9b19-64161c8286de" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized net gains (losses) recognized during the<br/>&#160;&#160;&#160;period on equity securities still held at the reporting<br/>&#160;&#160;&#160;date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fab98bf8-9b3e-4c87-b8ff-ab03992db07b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,075</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ba4da10-38d0-4844-9a86-db83813231ab" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,024</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74816607-e4d9-431c-a23d-4413efc2a3fc" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no sales of equity securities during the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_5cf18c36-fe7d-4c49-8c09-15091b7de8ee" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ComprehensiveIncomeNoteTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Income. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes in accumulated other comprehensive income, net of tax from unrealized gains (losses) on available-for-sale securities, the Company&#8217;s only component of accumulated other comprehensive income for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount reclassified out of accumulated other comprehensive income, net of tax and into net income during the year ended December 31, 2022, was solely due to a realized loss from sale of available-for-sale securities. </span><span><ix:nonNumeric id="F_52d5b900-3755-4f80-8421-4e081b39e418" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" escape="true" continuedAt="F_52d5b900-3755-4f80-8421-4e081b39e418_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no reclassifications out of accumulated other comprehensive income during the years ended December 31, 2024 or 2023. </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_52d5b900-3755-4f80-8421-4e081b39e418_1" continuedAt="F_52d5b900-3755-4f80-8421-4e081b39e418_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"/>
        <td style="width:2.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.099999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c53a2c0-943e-468a-bf4b-06b08f90802d" contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42eeb380-9665-41f1-b5ab-a9c3c4f0f8ac" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdf799e9-a892-4565-a856-2e37b7d498a5" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f261079-9206-4e8a-a15c-61f240834707" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d2a5277-95db-486c-9256-00ef2caafd87" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2daf9a2-e277-480b-8231-cbb56936f32f" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_519632fa-a949-4952-8f1e-e60cbe4e3444" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_52d5b900-3755-4f80-8421-4e081b39e418_2"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_16ba1629-bcaf-4a12-b926-b8ce14dfdf75" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:InventoryDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4a39a54-1dff-45c0-9178-3b18d5dab1c9" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true" continuedAt="F_d4a39a54-1dff-45c0-9178-3b18d5dab1c9_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f88f268-5885-40ca-9fa9-49966a60e7ea" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b63dd53-a2c6-4cb6-a08e-4efe8fdb8bc4" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,910</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db7817a2-e1dd-4500-9330-fadae57e9bd2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,445</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_052519f6-4fa4-446b-8a49-be1d9649a40e" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,573</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662c472b-84b2-4a4d-b4d3-6913e788559d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,578</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40368b01-6b8f-4aab-945c-cac14188e956" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,161</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d6379a3-f281-44ff-9a2e-ee3c508771ff" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,541</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd30948e-0165-4163-b5ba-ec3101e0df26" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,644</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_d4a39a54-1dff-45c0-9178-3b18d5dab1c9_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_9ce7cae7-0dab-414e-a5b2-5a60d15efaa0" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b7ddfd1-cc5f-4c59-902f-d99e3852738b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true" continuedAt="F_3b7ddfd1-cc5f-4c59-902f-d99e3852738b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e132074-ea47-47a3-aaef-6e643a559c4c" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidManufacturingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9623a4-5849-4824-9e69-2a1981d57bca" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidManufacturingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9843bc0-fad9-4e6c-9440-27112a3b5ac6" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e26ab8-29f4-490c-a837-2df3e4a24641" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d66996a-ddf6-4d03-93c9-bfd9a54e1b02" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66c803da-f8b9-4b67-9c3b-ceda150e181b" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb86897-637b-4b0d-b162-7d35dfe05a72" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidSubscriptionFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24596bb4-28b7-4882-a688-4ee2675dd66c" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidSubscriptionFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,299</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be785ae2-5099-4e1b-8ee4-7d42b6a470e0" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidResearchFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81a51d74-ec3e-4999-a5df-21b893541116" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidResearchFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b5f0340-776e-4298-bb28-41e7509825c5" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidCommercialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,957</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40ccef85-44c7-4387-8d14-1695aa41cf30" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidCommercialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,038</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due from collaborative and licensing arrangements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da113539-3b13-4db6-9923-2fd853158489" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:DueFromCollaborativeAndLicencingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fa13f15-d8eb-4de1-90c1-b24b5ab9aba5" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:DueFromCollaborativeAndLicencingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid conference and travel expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e60f4796-0018-42d0-801c-2b6d27d53a13" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidConferenceAndTravelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_975f3bb3-ab3c-4a66-96e5-3e03e9466c97" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidConferenceAndTravelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">771</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid co-pay assistance program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72606b51-e171-4db1-923f-9206bfa2ad3e" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:PrepaidCopayAssistanceProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,561</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de1a7ed7-44b9-4ae3-b1a6-b32dce50eef4" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:PrepaidCopayAssistanceProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">863</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c761f971-3b5f-4606-abeb-15826f8512d2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,030</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97131aa3-e44f-4bb7-a8fa-0ccdf1d9d0b6" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fda468e7-f362-4390-9728-10fe950d0283" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,039</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7db3d015-3778-4285-963d-b650d2fba1fa" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,535</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_3b7ddfd1-cc5f-4c59-902f-d99e3852738b_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1217525a-830f-4218-b1d9-66cb0231b78c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Leases. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease agreement for its corporate office. The lease includes an option to extend the lease for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01ff7144-37b2-4380-8791-4d225c3f2d2a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and options to terminate the lease within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6d7694a8-4fef-4d34-ad3f-97f73cebc1d8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a9c9230-93ec-448f-91e1-23981a825942" contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bcf7c57-e542-473c-9ea7-4b3750e7fee1" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> obligations under finance leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement in May 2020 that amended its lease for its office facilities. Under the amended lease, the Company&#8217;s leased space increased from approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd68f933-d891-43ab-8b41-e4575e5e31ee" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:BeforeAgreementOfCompanyLeasedSpaces" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">7,800</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf52e313-84a4-4fce-a410-309ea189f103" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AfterAgreementOfCompanyLeasedSpaces" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">10,700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space. The amended lease commenced in March 2021 when construction of the asset was completed and space became available for use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d1ef844-0842-4a44-a87e-18b4e52b84dc" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77052ced-25bd-4e0c-b542-dc5ec51cca0e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6738010-894f-4185-905e-dc1ed93cc16c" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_560fce43-d991-466a-ba09-de4cdbfe5fe7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c2bac6f-e112-4959-bff1-d70e7cabbbcc" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd8553e5-d317-48b7-b717-40c0f52592ac" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for lease<br/>&#160;&#160;&#160;obligations:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68b033a5-ef96-4999-a12d-d40cdcc7fc44" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2df50425-d007-4d54-9432-e592360edaed" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0416301c-deb8-4032-9118-715a37b185f8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental balance sheet information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c876b0c-2634-4df2-bb49-a6d0516c6638" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dc8674b-fb7b-4b34-a351-885e72b25197" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21a3de6d-dd63-426d-8792-9eac3aaf6b81" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13ac50da-f17d-4e87-891e-cc0343cecd7f" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="-sec-ix-hidden:F_e02f321f-c2da-4a31-b171-0bb073d6f3b4;"><span style="-sec-ix-hidden:F_af9bf51b-92c5-4e0c-beca-6ed527c2962a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;liabilities, net of current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaedfc00-ab29-4be0-a259-c8c8ae74d580" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a78092b-ce24-4471-8b25-50593e5b3b60" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3177b4a3-a949-4a38-89eb-04ad32f70b0d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f18ff05-b040-4fd4-b757-cd3cc661a682" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_694c5d1f-825d-4f23-a5d6-b42284bbceae" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b3aaaf9-1223-4556-8d69-561f1686a855" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The weighted average discount rate used to determine the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80cbe385-d130-4137-8d1b-e5b6a8e6e8de" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as of December 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_570934e5-4138-4723-8ec3-a1b1f5eb430d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remaining payments of lease liabilities as of December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_235ebffc-272e-44c6-a0dd-de27a47d84b3" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78144d54-1808-4153-b82c-3e67a2650fbb" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">553</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114bf220-2310-4112-a2b9-80d281beda41" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c823eeb2-828e-48d2-aeaa-3e5f6c59c4cc" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479f1861-744a-40bf-b509-96a8c0b21005" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4958980f-bda3-433d-9345-77a945a672b7" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">835</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d6810e6-2711-4597-bda1-e72090d923a2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,687</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_339f0073-f878-42a1-b043-6e0db92d48a5" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b514792-f2b6-4f72-882c-d79283acf0f8" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74fef29d-efe0-4fe6-adb4-e3eca0bd9171" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2ddf6c3c-72b5-437e-984d-5641fc26cc59" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_44a67fa3-e784-4d9a-b355-72bc19f9079f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ca2413e-4e40-419f-8e3d-a6bc5a5a3c6b" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43b2f010-f632-43f4-8b10-5c2314b89740" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e144b8bf-0e0c-4993-8fcb-d89a96ae4a6d" contextRef="C_08f6bfdf-0d3b-44a6-a23d-b2f184873fd1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c408b1-6acc-4c73-a279-a0fd14555064" contextRef="C_21ec373d-d899-4e13-9fd1-cf11cc5ed214" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c275858-f32e-4b28-a94f-c90071542bab" contextRef="C_71521487-ca68-4307-8394-188717a68617" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_989cc69f-32f4-4b26-8339-ff7088e76dbc" contextRef="C_c653309b-c27f-47f4-9795-b45c969d5d1f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">991</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e6c0787-42ed-44a0-883e-49076309eae1" contextRef="C_8be25042-7914-4b7c-bafc-23e4b7ab7fdf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce233c55-0c83-4fb4-88e2-e8fc43b1edb1" contextRef="C_bdd6ca59-0c27-40ea-814d-e69687c2f5b3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d653073f-0351-4a50-b69d-5235f2e0b915" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daab077e-40c8-4486-9280-c845081aeee4" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcd6c46a-6afc-48bb-becf-7b64e75112d3" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,354</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd1cfa4b-4f4c-4a79-bbf2-f8fa3050e3ca" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,195</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_efe74631-ec21-41ce-9fe0-57f70792b8bf" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="F_efe74631-ec21-41ce-9fe0-57f70792b8bf_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Acquired Intangibles, Net. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bf1fa46-ae4d-4568-b5f8-e4dfdab0be9a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae9fd2db-4b2c-4ab6-8746-52180f83eb9e" contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,569</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d86d01-741d-422f-8db4-a1940731865c" contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c5096bf-ff54-44c6-a719-8e6de79f8198" contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88cca80e-3509-430c-89df-b0d75b686919" contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7887ebd-b730-4587-8ef6-65cc659eb6f8" contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,301</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a662cfa6-4dc8-4988-8331-80463c6b5877" contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,842</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74bb9ba1-2b6f-46b7-80da-049b87167c3d" contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9613bff9-0fb4-4944-b761-477164e65a21" contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34589d9e-ff85-4f86-9106-55a7b675a9d4" contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37aff173-00f9-4685-a0af-86a088422d8d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_231ede08-c006-413e-8af9-e4dfc63c3ad2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,040</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7faaec86-6ff2-42df-8702-6e8b5a94c90b" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,672</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f18caf-278d-4cee-8ae0-11512e7e3d27" contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,569</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_453b59f9-ebd6-4225-a11b-5a79afb9c116" contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,418</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81e6638c-e38d-4e1a-95db-dcfc3496c2e5" contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1de6a19d-94d1-495c-923a-bce9724461ed" contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21dcc5b7-8766-40d8-8a2d-b4ee35886d10" contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,673</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb4465b5-5d42-4d75-90d3-cd3b6f531d0b" contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,470</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2de23ca-a7a7-4f12-9db7-cf098cd326b8" contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c01b316f-418e-4226-9ac6-00d8f3bd5c72" contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8367d4f3-f264-4628-a028-19e13dc8df14" contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8e83007-f262-40c6-8846-970f69ed2d57" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_574589ce-a61f-49bc-9420-e53242143385" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_330f3f51-1913-4cb5-9d08-c20765c51e31" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,049</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life. The estimated useful life used for this purpose for RUZURGI&#174;, FYCOMPA&#174; and AGAMREE&#174; was approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_609a8380-432b-4b35-8ba5-f919334b1c23" contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9ae7620-9f8d-469a-807c-c8ffd02cca87" contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c81ea64-1b2d-4ba2-b258-39a130b9719d" contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_640a033f-9a92-43a4-842a-481a90de7932" contextRef="C_6de2fb61-b44d-45b0-b76c-c1b0f84e06f6" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4edf6304-ae53-4e85-a935-f478684b7b05" contextRef="C_6b7ac61d-59d7-4f79-a0f9-c3856afc6147" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f7c0d80-6bac-4407-9ff7-e7cf72afc8fb" contextRef="C_fcfa5920-3506-4ee6-bfc9-fd2b01fa5229" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in amortization expense related to the licensed and acquired intangibles for RUZURGI&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within selling, general and administrative expenses in the consolidated statements of operations and comprehensive income. The Company recorded approximately</span><span style="color:#ed7d31;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff50103f-e46f-4365-903d-b7fc0528f1c4" contextRef="C_9e6f3d23-def3-4cda-8382-44bd50588fd1" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_248e6a6c-3a72-4978-8b3f-349c3baebb55" contextRef="C_ed459907-b1e1-4660-b88b-b7b539a955c9" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c10a7ba-6303-415f-9927-e92ba65fb877" contextRef="C_d78b7fcb-31d0-4120-ac5f-6e28497af893" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in amortization expense related to the licensed and acquired intangibles for FYCOMPA&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income. The Company recorded approximately</span><span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_696a1060-0a8a-4460-a927-b233cc6abc15" contextRef="C_6b9ea75b-fd6f-4b79-9eda-f78b19010cc0" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5472ca6b-f374-4371-9c07-15b1a65d41bc" contextRef="C_48c77464-b5f1-4ac6-8188-839ff214c273" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6185ff-e4cf-4c79-b96c-d32d042fb598" contextRef="C_0be61b87-8b88-4b7a-bc46-ddfbf3fee93e" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in amortization expense related to the licensed and acquired intangibles for AGAMREE&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_efe74631-ec21-41ce-9fe0-57f70792b8bf_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Acquired Intangibles, Net (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec5a0627-5502-4885-839f-22ae0d94e9a7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future amortization expense the Company expects for its intangible assets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff6b273-0e96-43d4-bcf3-5112bb1f5296" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,378</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c864a89-f214-48cd-9f73-e7f8252a7cca" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,378</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbba7dd4-be0b-4675-8962-aa4c8cd598b6" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,378</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37a2b0f9-fc96-43fb-a16e-e46137dfbbb3" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,705</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a83bb874-f800-4fe5-9cef-beb1a10eee8d" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,750</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8e96971-9a4d-4273-9153-ea2b5e54cf59" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,083</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1bef222-ccf9-4529-a74e-92f51b02281e" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,672</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and December 31, 2023, the weighted average amortization period remaining for intangible assets was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f64f14c7-0871-466b-9b0d-5c8dcca04b8f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a39c75a8-418b-45ba-a3b1-6d034fcefbe2" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3430f3f-db57-45f1-80cf-45d844523f2e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7bc202a5-4aac-4c70-83ca-4217230d5fd6" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f9316b60-4a48-4e6b-9d0c-86d2c61b77db" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges recognized on definite-lived intangibles for the years ended December 31, 2024, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5395198-7823-4618-a4ed-c702ab3d0136" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Liabilities. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_412ecaaa-f2c9-4503-a1bb-05979ba0c282" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5f1971-cbc0-4ec9-9775-b27a1c53d321" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AccruedNonClinicalAndClinicalTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e46ad2e1-2570-4947-b194-b1b50c7dff35" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AccruedNonClinicalAndClinicalTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c59ffd0-7e18-4496-ba95-591f7031e416" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,011</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_251a5adb-2828-409c-ab16-fa8227563372" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,730</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f0c76db-7a78-4463-9bbb-aa2298f9dca9" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,746</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_163698d9-4dfa-4939-a37d-7491f36ce34c" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,883</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_901aaf1a-70a7-4737-b3b8-1ef569307147" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AccruedLicenseFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,991</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c81c52d5-c6d8-4058-a433-c6ebe1045b23" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AccruedLicenseFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,437</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued purchases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7d563d3-5fdb-4d1f-9a54-4facf8df0895" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AccruedPurchasesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">447</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a85707e-d519-43b7-8732-d5ae3e7c5cf3" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AccruedPurchasesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3282b4a-6209-4060-909f-75f1002f1451" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f3da23-c08f-451c-9668-35fbc8359508" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net revenue liabilities*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a00bcef-013e-4b81-9338-670783a1df9f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AccruedGrossToNetRevenueLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,939</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f6c9bc4-0cf1-4bc8-a3ff-9c89dd62711b" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AccruedGrossToNetRevenueLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d02dfbce-a4b4-4d65-8153-552d739faa9f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b31ba04c-8e97-40d7-8160-0f2ead673482" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">729</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790cc8d5-32b2-4ab4-b88d-6c704e443363" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AssetAcquisationDueToLicensorCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,582</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a508d1-ca60-4889-ad0e-9fe41b3ff428" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AssetAcquisationDueToLicensorCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,540</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb9067a7-76e2-4145-b663-be14d96eb30e" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18298d8c-cf43-4de9-9ada-289b7b026449" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,031</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf93f9f5-ac2e-4f82-aa55-dea4c17dc153" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">417</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a019909a-f88d-44d2-a203-a21e1f561a37" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2ea52a6-03f9-4225-b94f-1e01314968d0" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,085</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67e4e0d-5a3a-4f2b-8d5e-d31a5f2be4a7" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,268</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00f9d681-789f-42eb-92fb-2598a4eed137" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edbef13e-563e-46a3-b2ec-5780356c9c1d" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c5205a-ba53-4d8d-b2b6-709519827b02" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:AssetAcquisationDueToLicensorNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c305b37c-1da2-49fe-a9fc-7876006f0222" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:AssetAcquisationDueToLicensorNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,497</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0369414-ffe2-4451-ac19-6e7f18de8434" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eced8d9e-9d86-4022-84f1-cb780e477e11" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eeaefa7-0e31-49ad-890f-28c584a665f2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,101</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2356d10-450a-40a6-85ed-d99dfdae71e6" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e0e0a60-a13d-40ec-a0f7-38fc61c32de1" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6de6f62-7aff-47fd-9d10-744197206c2f" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a 3PL organization under the Company's contracts.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_54a18074-6b89-4d72-ad56-c15f5cf9002e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_54a18074-6b89-4d72-ad56-c15f5cf9002e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative and Licensing Arrangements. </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Endo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, the Company entered into a collaboration and license agreement (Collaboration) with Endo, Inc. (formerly, Endo International plc) (Endo), for the further development and commercialization of generic Sabril&#174; (vigabatrin) tablets through Endo&#8217;s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical, Inc. (Par). Under the Collaboration, Endo assumed all development, manufacturing, clinical, regulatory, sales and marketing costs under the collaboration, while the Company was responsible for exercising commercially reasonable efforts to develop, or cause the development of, a final finished, stable dosage form of generic Sabril&#174; tablets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, a termination and mutual release agreement was finalized between Endo and the Company that discontinued work on the collaboration for development and commercialization of vigabatrin. The end of the collaboration does not have a material impact on the Company's consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KYE Pharmaceuticals Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, the Company entered into a collaboration and license agreement with KYE, for the commercialization of FIRDAPSE&#174; in Canada.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, Catalyst granted KYE an exclusive license to commercialize and market FIRDAPSE&#174; in Canada. KYE assumes all selling and marketing costs under the collaboration, while the Company is responsible for supply of FIRDAPSE&#174; based on the collaboration partner&#8217;s purchase orders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company received an up-front payment, has received payment upon transfer of Marketing Authorization and delivery of commercial product, received payment for supply of FIRDAPSE&#174;, and will receive milestone payments and a sharing of defined net profits upon commercialization from KYE consisting of a mid-double-digit percent of net sales of FIRDAPSE&#174;. The Company has also agreed to the sharing of certain development expenses. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the date that is ten years following the commercial launch of the product in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collaborative agreement included a nonrefundable upfront license fee that was recognized upon transfer of the license based on a determination that the right is provided as the intellectual property existed at the point in time in which the license was granted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into a license, supply and commercialization agreement with KYE, for the commercialization of AGAMREE&#174; in Canada granting KYE the exclusive Canadian commercial rights to market AGAMREE&#174; in Canada for DMD and other indications.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, KYE will be responsible for obtaining regulatory approval of the product from Health Canada and the Company will supply product to KYE. Further, the Company received an upfront payment from KYE and will be eligible to receive further reimbursement, sales milestones and sales royalties for AGAMREE&#174;.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These agreements are in form identified as collaborative agreements and the Company has concluded for accounting purposes that they also represent contracts with a customer. This is because the Company grants to KYE a license and provides supply of FIRDAPSE&#174; and AGAMREE&#174; in exchange for consideration, which are outputs of the Company&#8217;s ongoing activities. Accordingly, the Company has concluded that these collaborative arrangements will be accounted for pursuant to Topic 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sales by KYE is recognized in the quarter in which the sales occurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from the arrangements with KYE for the years ended December 31, 2024, 2023 and 2022 were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a095fd07-dde1-4ed2-8bdf-31a24b47d3a7" contextRef="C_9c7d03d5-7081-4449-bea0-40e589ce6ecc" name="cprx:ExpensesIncurredInConnectionWithCollaborationAgreement" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8ac63f63-f422-44ba-a265-75cfc41f79ea" contextRef="C_55e052ff-760b-4233-875b-b80e5e4fd436" name="cprx:ExpensesIncurredInConnectionWithCollaborationAgreement" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_667628a2-4e81-41d5-a01f-8c17e2915c9a" contextRef="C_b2fd37e7-0f2e-441c-ae7f-719ef52d29e9" name="cprx:ExpensesIncurredInConnectionWithCollaborationAgreement" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material. Revenue is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income. Expenses incurred, net have been included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_54a18074-6b89-4d72-ad56-c15f5cf9002e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative and Licensing Arrangements (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DyDo Pharma, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2021, the Company entered into a license agreement with DyDo Pharma, Inc. (DyDo), for the development and commercialization of FIRDAPSE&#174; in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, DyDo has joint rights to develop FIRDAPSE&#174;, and exclusive rights to commercialize the product, in Japan. DyDo is responsible for funding all clinical, regulatory, marketing and commercialization activities in Japan, while the Company is responsible for clinical and commercial supply based on purchase orders, as well as providing support to DyDo in its efforts to obtain regulatory approval for the product from the Japanese regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company has earned an up-front payment and certain regulatory milestones and may earn sales-based milestones for FIRDAPSE&#174;, as well as revenue on product supplied to DyDo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that this license agreement will be accounted for pursuant to Topic 606. The agreement included a nonrefundable upfront license fee that was recognized upon the effective date of the agreement as the intellectual property existed at the point in time in which the right to the license was granted. The Company determined the granting of the right to the license is distinct from the supply of FIRDAPSE&#174; and represents a separate performance obligation in the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement includes milestones that are considered a sales-based royalty in which the license is deemed to be the predominant item to which these milestones relate. Revenue will be recognized when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty has been allocated has been satisfied. Additionally, the agreement includes regulatory milestone payments which represent variable consideration, and due to uncertainty are fully constrained and only recognized when the uncertainty is subsequently resolved. For clinical and commercial supply of the product, the Company will recognize revenue when the Customer obtains control of the Company&#8217;s product, which will occur at a point in time which is generally at time of shipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were revenues of</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34dd8cce-71ba-461f-98da-760b3fb58605" contextRef="C_b63f6e84-f32c-44aa-b9da-315cc85f2d23" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the arrangement with DyDo for the year ended December 31, 2024, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1376436c-f727-464e-91cf-a8d7bd3890ff" contextRef="C_f352d976-0ef8-419c-95b8-31914f4eefcf" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fdd39d0-f23e-43d7-95d4-6be18ca9cfea" contextRef="C_1d817031-5908-4974-887a-064c703e2a44" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to a milestone payment earned upon DyDo receiving regulatory approval to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS in Japan, which is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cd16f00-f8b3-4320-8d4d-1b693dd41e6c" contextRef="C_af98f620-db18-4836-9d81-b2bf497b9325" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the arrangement with DyDo for the year ended December 31, 2023, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f4b8b50-9090-4844-a56d-0edcd08f8581" contextRef="C_7f8cfbeb-4cb9-4b6d-a5e6-cb932c0b7774" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fedefc4-fa9f-431d-8990-839eea233b76" contextRef="C_02504fb4-79e0-4668-9486-8cb310c6d004" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to a regulatory filing milestone in Japan, which was included in licensing and other revenue in the accompanying consolidated statements of operations and comprehensive income. There were revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6710541-64cf-4639-b80a-8bf1d23e6642" contextRef="C_61e41641-345f-41a7-b190-b0f5bedca153" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the arrangement with DyDo for the year ended December 31, 2022, which was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, on September 24, 2024, DyDo advised the Company that the Ministry of Health, Labour and Welfare (MHLW) had approved DyDo's Japan NDA to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS. See Note 18 (Subsequent Events).</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_9b1ead07-346b-4987-9f19-c6cc7386d442" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_9b1ead07-346b-4987-9f19-c6cc7386d442_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the FDA approved a NDA for RUZURGI&#174;, Jacobus Pharmaceuticals&#8217; version of amifampridine (3,4-DAP), for the treatment of pediatric LEMS patients (ages 6 to under 17). In June 2019 the Company filed suit against the FDA and several related parties challenging this approval and related drug labeling. Jacobus later intervened in the case. The Company ultimately prevailed in its litigation in September 2021 when the U.S. Court of Appeals for the 11th Circuit determined that the FDA's approval of RUZURGI&#174; violated the Company's rights to Orphan Drug Exclusivity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2022, the Company settled certain of its disputes with Jacobus. In connection with the settlement, the Company licensed the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico (the Territory). Simultaneously, the Company purchased, among other intellectual property rights, Jacobus&#8217; U.S. patents related to RUZURGI&#174;, its new drug applications in the U.S. for RUZURGI&#174;, and certain RUZURGI&#174; inventory previously manufactured by Jacobus. At the same time, the Company received a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#174;. Further, the Company settled its patent case against Jacobus, which was dismissed without prejudice. Finally, Jacobus agreed that until the later of (i) the expiration of the royalty term or (ii) December 31, 2034, Jacobus and its affiliates, will not, directly or indirectly, research, develop, manufacture, commercialize, distribute, use or otherwise exploit any product competitive to FIRDAPSE&#174; or RUZURGI&#174; in the Territory, and Laura Jacobus, the sole shareholder of Jacobus, and two of Jacobus&#8217; other officers, also signed individual non-competition agreements containing the same terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the settlement with Jacobus, the Company paid the following consideration to Jacobus:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dff6a5a-1fe3-4e71-8b8f-65c124f74821" contextRef="C_ed261f48-f289-44e4-80ec-cbc85f5f3076" name="cprx:PurchasePriceOfAnAssetAcquisition" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42cfc8cd-03a5-43e7-9890-190f7715d13c" contextRef="C_4c43ddad-6603-484e-8db2-d46bb3b245a3" name="cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid at the closing of the settlement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_118aa0a9-5667-49f4-af7d-156fbb9e95ee" contextRef="C_712db356-621a-4482-bbbf-6e0f7cee9633" name="cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid on the first anniversary of the closing, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06a0849e-7c40-4d14-8883-cc724f7c9db6" contextRef="C_d1efe803-2f0e-4a4d-8b0c-2027e98829a4" name="cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid on the second anniversary of the closing; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An annual royalty on the Company's net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the U.S. equal to: (a) for calendar years 2022 through 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_291ed5a9-a811-4d20-bbf7-fa7a088cdbd2" contextRef="C_bffaa182-9732-421b-b5cc-2629dd407967" name="cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (with a minimum annual royalty of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f9d0795-226e-4005-a3a1-d1362d338ffd" contextRef="C_bffaa182-9732-421b-b5cc-2629dd407967" name="cprx:MinimumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year), and (b) for calendar years 2026 through the expiration of the last to expire of the Company&#8217;s FIRDAPSE&#174; patents in the U.S., </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a043cd66-5a7b-418b-99f5-3c042f68a520" contextRef="C_2a5da979-3b61-43bc-853e-709593328300" name="cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (with a minimum annual royalty of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64daa2d4-1afd-467d-b781-75ba203e0336" contextRef="C_2a5da979-3b61-43bc-853e-709593328300" name="cprx:MinimumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva), Hetero USA, Inc. (Hetero), and Lupin Pharmaceuticals, Inc. (Lupin)) advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE&#174; in the U.S. The notice letters each alleged that the six patents listed in the FDA Orange Book covering FIRDAPSE&#174; are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, the Company had 45 days from receipt of the notice letters to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court to trigger a stay precluding the FDA from approving any ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, the Company filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified the Company of their ANDA submissions, thus triggering the stay.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, Lupin converted five of its Paragraph IV Certifications in its ANDA to Paragraph III certifications acknowledging the validity and their ANDA&#8217;s infringement of five of those patents, the latest ending in 2034. The Company subsequently dismissed all of its claims against Lupin related to those five patents but maintains its claims against Lupin for the remaining Paragraph IV certification for U.S. Patent No. 10,626,088 which is the patent expiring in 2037, so the litigation continues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_9b1ead07-346b-4987-9f19-c6cc7386d442_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on January 8, 2025, the Company reached a settlement with Teva in which Teva agreed not to market a generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the settlement agreement, the parties terminated all ongoing patent litigation between the Company and Teva regarding FIRDAPSE&#174; patents pending in the U.S. District Court for the District of New Jersey. See Note 18 (Subsequent Events).</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#174;&#8217;s Orange Book-listed patents) and Lupin (only for FIRDAPSE&#174; patent expiring in 2037), remains ongoing, and there can be no assurance as to whether the currently ongoing litigation with Hetero and Lupin will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to February 25, 2035.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, in October 2023, the Company received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer (Inventia Life Science Pty Ltd (Inventia)), and the Company filed a similar lawsuit against that manufacturer in November 2023. On July 30, 2024, the Company settled its patent litigation with Inventia for FIRDAPSE&#174;. In that settlement, Inventia acknowledged both the validity of the Company's FIRDAPSE&#174; patents and also the infringement by the ANDA filer's product of the Company's patents. As part of the settlement, Inventia also agreed not to commercialize its product until the earlier of all FIRDAPSE&#174; patents expiration scheduled for February 2037, or the earlier entry into the market of another ANDA product meeting certain conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance that the Company will prevail in these litigations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 20, 2023, the Company received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA&#174;. The same company sent a similar letter to the Company later in February with a similar certification for the tablet formulation for FYCOMPA&#174;. Similar to the actions with the FIRDAPSE&#174; Paragraph IV Certifications described above, after due diligence the Company filed lawsuits on April 5, 2023, in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified the Company of their ANDA submissions for both FYCOMPA&#174; formulations, thus triggering the 30-month stay for each application. This lawsuit was settled in June 2024. As part of this settlement, this Paragraph IV filer agreed not to commercialize their proposed ANDA products for both the oral suspension formulation of FYCOMPA&#174; and for FYCOMPA&#174; tablets until at least December 15, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, from time to time the Company may become involved in legal proceedings arising in the ordinary course of business. Except as set forth above, the Company believes that there is no other litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition, or cash flows.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:AgreementsDisclosureTextBlock" escape="true" continuedAt="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b00eaf97-d1fb-43ce-a461-608b1a1cb41c" contextRef="C_19dd38c4-484b-49fc-ad75-95d8593b80cf" name="cprx:LicenseAgreementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 26, 2012</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to FIRDAPSE&#174;. Under the license agreement, the Company pays: (i) royalties to the licensor for seven years from the first commercial sale of FIRDAPSE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1fb8b83-80f5-4fa5-9874-8139157d2a84" contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_070b75dc-91cc-487a-aa03-088ecf6b9c92" contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0ae4ed-ca73-4234-b7ab-8d4f57f9e345" contextRef="C_caf83f47-b1bf-467a-bf14-8cd9ab3cfde4" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales in North America in any calendar year in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15a1d1c-f0aa-4f11-a8bd-14090d440202" contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60bfb03a-56ee-4ac7-947c-122f8f9e7e70" contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20" name="cprx:RoyaltyAgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the first commercial sale of FIRDAPSE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5aec280-2d11-437f-bdb2-cb0ee1d79ba2" contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement between BioMarin and the third party licensor) in any calendar year for the duration of any regulatory exclusivity within a territory and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f14e60-3503-4081-a497-fd492dc9d673" contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for territories in any calendar year in territories without regulatory exclusivity.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2019, the Company and BioMarin entered into an amendment to the Company&#8217;s license agreement for FIRDAPSE&#174;. Under the amendment, the Company has expanded its commercial territory for FIRDAPSE&#174;, which originally was comprised of North America, to include Japan. Additionally, the Company&#8217;s commercial territory was expanded under the license agreement in December 2023 to include most of Asia, as well as Latin America, upon the acceptance by the Pharmaceuticals and Medical Devices Agency (PMDA) of a Japan MAA for FIRDAPSE&#174; for LEMS. Under the amendment, the Company will pay royalties to its licensor on net sales in Japan of a similar percentage to the royalties that the Company is currently paying under its original license agreement for North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2020, the Company was advised that BioMarin has transferred substantially all of its rights under the license agreement to SERB S.A. (SERB), and SERB is now the Company&#8217;s licensor under the license agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d6be30b-075a-44c4-b12d-004ed8006121" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:LicenseAgreementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 11, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the Effective Date), the Company entered into an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the license agreement, the Company paid Jacobus a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6ea8c60-c397-4f74-be92-58a361ef9071" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million up-front payment on the Effective Date, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3feedd31-f415-4f7b-ba7e-7bcdd3e21a00" contextRef="C_465c30df-be19-4455-9dcb-aaf2927ffe62" name="cprx:AssetAcquisitionPurchasePriceConsideration" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the first annual anniversary of the Effective Date (July 11, 2023), and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ce49bbc-ed5f-4d37-a50a-18c5ad7793ec" contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527" name="cprx:AssetAcquisitionPurchasePriceConsideration" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the second annual anniversary of the Effective Date (July 11, 2024). The Company is also obligated to pay tiered royalty payments on net sales (as defined in the license agreement) of all of the Company&#8217;s amifampridine products in the U.S. that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d74e456-709e-4f0b-ba39-3e89acf2db34" contextRef="C_6d644c95-287a-423b-b6e2-b8baaa08fec1" name="cprx:PercentageOfMinimumRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86083284-ae6c-42ea-9a4c-7a47fb624052" contextRef="C_f0b3fb71-5f08-4d82-8502-0d005079016d" name="cprx:PercentageOfMinimumRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on whether there is a competing product or generic version of FIRDAPSE&#174; being marketed or sold in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A minimum royalty payment exists annually for calendar years from the Effective Date through 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c59b25-f94e-44b5-bff3-fbcf11c7c669" contextRef="C_1ed73abf-99b0-4ef1-a69d-7dabbba940c1" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d6ab4f4-74f5-4db2-91dd-4dfea837258d" contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal"><ix:nonFraction id="F_315e2a6a-03ba-4335-97c8-a7e4c63b696d" contextRef="C_c0079872-347c-4ab4-bd66-e2c441bd5d42" name="cprx:MinimumRoyalty" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">3</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, provided that such minimum annual royalty payment shall be prorated in the first calendar year of the agreement. As these minimum payments are both probable and estimable, they are included in the purchase price of the agreement and any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. A minimum royalty payment exists annually for calendar years from 2026 through the expiration of the royalty term (which ends when there is no valid claim under the Company&#8217;s FIRDAPSE&#174; patents in the U.S.) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f686e9a-76fa-48d3-add4-04b776c64b67" contextRef="C_e16b26af-4376-4363-969d-d2fd34caf5aa" name="cprx:AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unless a competing product or generic version of FIRDAPSE&#174; is being marketed or sold in the U.S. If these minimum payments become probable in the future, the Company would recognize a contingent liability at that time with an offset to the value of the intangible asset acquired. Any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. Royalties over the minimum, if any, will be paid based on the agreement terms on a quarterly basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets acquired as part of the license agreement include among other intellectual property rights, Jacobus&#8217; U.S. patents related to RUZURGI&#174;, its new drug applications in the U.S. for RUZURGI&#174;, its U.S. Trademark for RUZURGI&#174;, the Orphan Drug Designation for RUZURGI&#174; and a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company also purchased from Jacobus approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_461fde90-42c2-4809-bb1c-53c057584c61" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of RUZURGI&#174; inventory previously manufactured by Jacobus, which was recorded as an expense in research and development expenses in the consolidated statements of operations and comprehensive income for 2022.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_1" continuedAt="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_2"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under business combination guidance, the screen test states that if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and is accounted for as an asset acquisition. The Company has determined that the screen test was not met. However, the Company determined that the acquisition did not meet the definition of a business under ASC 805, Business Combination. The Company believes that the licensing agreement and other assets acquired from Jacobus are similar and considered them all to be intangible assets with the exception of the inventory acquired. As the screen test was not met, further determination was required to determine that the Company had not acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business, and therefore, determined that this was an asset acquisition. The Company accounted for the Jacobus license agreement as an asset acquisition under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a8533fc-3bf1-48f2-b1a6-83eb3d52bee6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a8f7fcb-6225-49b7-838e-8a32f23c0792" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,569</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired research and development inventory expensed<br/>&#160;&#160;&#160;from asset acquisition</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ddc68d5-85a1-460f-bf99-3e91cf10fbc0" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,130</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4871974-ebca-4c20-a465-331072168ca1" contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076" name="cprx:AssetAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,699</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACQUISITION OF U.S. RIGHTS FOR FYCOMPA&#174;. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b7d4364-0e0a-4003-9f81-dd51271b4497" contextRef="C_c2b04665-c428-4f48-8bee-660378e215e7" name="cprx:LicenseAgreementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 24, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired the U.S. Rights for FYCOMPA&#174; (perampanel) CIII a commercial stage epilepsy asset, from Eisai. The aggregate consideration for the acquisition was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55548250-9aa2-4003-a3f4-86b4ead88eb1" contextRef="C_d81a6259-f258-4b87-b123-cf96424bc887" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">164.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash, including the reimbursement of certain liabilities and the payment of transaction costs.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eisai was eligible to receive a contingent payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f8ebc3-f074-493b-9bd8-e226198b56a6" contextRef="C_8ad02f07-3470-4aaa-a47f-2bdce2375aba" name="cprx:ContingentConsiderationArrangementsContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million if a certain regulatory milestone was met. As meeting the regulatory milestone was not probable, the Company did not recognize any amount related to the milestone payments in the purchase price. Additionally, after the loss of patent exclusivity for FYCOMPA&#174;, the Company may be obligated to pay certain royalties to Eisai on net sales of FYCOMPA&#174;. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize the royalty payments in cost of sales as revenue from product sales is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e660084c-c4f0-4415-8466-af156f42d836" contextRef="C_abbabfa3-211e-489a-bee1-41937cf8efae" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0d73838-9023-425a-88e6-bcfbcac5faff" contextRef="C_b0a378e6-1a77-4f91-81cb-13d89217dba7" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f349287-a878-441d-9236-834de96f5fee" contextRef="C_91a9fa46-f095-4873-a0df-54c2ea98d1e7" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab5149ae-dcaa-4e61-967e-7f4cef089589" contextRef="C_fa9e4eb0-730f-4a45-9ce1-7f135b523329" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales of greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cec9de70-84ee-475f-b820-a9794d129a0e" contextRef="C_9e517535-208d-4e79-a8f2-94a3fbd26bfb" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4adf30d6-39a8-49dd-b5df-e079bd8f8735" contextRef="C_a8aa9d09-9937-4de9-a389-d7a12cd901f2" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_480c3203-49c1-4482-b19b-4a0e2f9a55b0" contextRef="C_452b8271-91ed-43ef-8673-b266c4b29987" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7c8a8bf-b58f-4aff-bc98-571c47db12a5" contextRef="C_dfce6660-3b34-46db-9ab4-b2300eecbdd6" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million prior to the date of generic entry. Royalties equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b3cd620-46ca-47e6-b156-86f12672ed15" contextRef="C_a5b8f9f5-4c42-49ac-89f4-7c6e0c290f71" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa557829-eb9b-4eb9-b3e3-826b9b7d53c3" contextRef="C_79793b06-4d51-4322-b5ab-725a80889edf" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8e8de32-0fe4-457c-9275-98cb368a50d1" contextRef="C_2e484187-8b25-4de9-82f0-c8be02c5a796" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e3cacae-4946-4efd-a037-a4f7f14a417c" contextRef="C_62b69186-a8bb-4324-acc0-f14d726a9dc6" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales of greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9565c2e2-0959-478e-858a-cdc63e6193f4" contextRef="C_26f2b844-3e09-4694-a82c-6a12e2562d12" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a09bf57-1019-4654-a52b-07262a8442b5" contextRef="C_d1dac2fe-3c70-41e5-b9eb-fad2c7cd29cc" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ba2035f-dfe6-4bae-9fbc-64bc59a83b1b" contextRef="C_933bcf2c-5622-4455-af40-79b259c772ba" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03c28bd-f2ca-4df5-b8d9-4ade11f126d2" contextRef="C_933bcf2c-5622-4455-af40-79b259c772ba" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after the date of generic entry.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6600b942-c426-460f-b603-ca278e462938" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:AssetAcquisitionTableTextBlock" escape="true" continuedAt="F_6600b942-c426-460f-b603-ca278e462938_1"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA&#174; (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Base cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02c9f8f7-8b09-40c4-8838-e84cb634fc7b" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionBaseCashPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for pro-rated prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ef7e31-5461-4ad3-bae0-d0d12466b9d9" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionCashPaidForProRatedPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,576</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reimbursement on base purchase price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:ReimbursementOnBasePurchasePrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,238</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(ii)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb02a000-e0f2-4b6b-a266-10189165015c" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,870</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_712bb953-76ee-4940-ac07-9cdb394ae39f" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,208</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_01910dd5-f9ee-4dbb-be39-87408e115701" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </span></ix:footnote></div></div></ix:nonNumeric></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span><ix:continuation id="F_6600b942-c426-460f-b603-ca278e462938_1"><ix:footnote id="FNT_781e2edc-d82f-4caf-82fd-b49074646a3a" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_470da26c-c0c4-4afe-850a-867899488d26" contextRef="C_d81a6259-f258-4b87-b123-cf96424bc887" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</span></ix:footnote></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_2" continuedAt="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_3"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acquisition of FYCOMPA&#174; has been accounted for as an asset acquisition in accordance with FASB ASC 805-50. The Company accounted for the acquisition of FYCOMPA&#174; as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the FYCOMPA&#174; product rights. The FYCOMPA&#174; product rights consist of certain patents and trademarks, at-market contracts and regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dee76cd0-d3c8-454b-bcae-3403b1879ead" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55c221f4-fdff-4564-afec-217761f75c5f" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionInventoryCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets (samples)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c39984-c81d-410c-b8cf-56a28e9cab0d" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59c34316-81a9-428f-abd8-d9f7116966b7" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquistionPrepaidCommercializationFees" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,576</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a183fa3c-b836-44ca-a7d5-6bce801f7a64" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionPropertyAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fc3e12d-cb1d-4a4d-b7eb-5ec767b45320" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158,143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2c667bf-73be-4a9f-844d-0f0516e9cf30" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="cprx:AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45a1ee5-e48b-4b84-863b-ef688d43d5d7" contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,208</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR AGAMREE&#174; (VAMOROLONE). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company completed its acquisition from Santhera of an exclusive license for North America for AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vamorolone), a treatment for patients suffering with DMD which was approved by the FDA on October 26, 2023. On March 13, 2024, the Company announced the U.S. commercial launch of AGAMREE&#174; for the treatment of DMD in patients aged two years or older. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in those jurisdictions. Additionally, the Company will hold North American rights for any future approved indications of AGAMREE&#174;. The Company made an all-cash initial payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d8dc6bc-eeef-41d9-88ce-8470d103da5d" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at the closing of the acquisition to acquire the license.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreement, the Company pays: (i) royalties to the licensor until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff8a8ed9-fa37-4181-92ba-41e1378e95bc" contextRef="C_6e1efb3e-07db-484f-b24b-35978abd908b" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any calendar year for sales equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dcb8195-52d2-4970-8526-b7c0beb12d49" contextRef="C_db403975-e67d-4d1a-af52-cc04a99bba23" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (prior to December 31, 2025 only), </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_234467bf-e50c-4183-8097-beea939eb275" contextRef="C_890414d1-43e4-4730-a09e-a3e88bcc0421" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad62d70-a073-4881-ab0f-7ac471c0b789" contextRef="C_50617df4-5ae4-4936-8bfe-fce589850662" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a9c8d9-221b-4d5b-8653-31fd185237c3" contextRef="C_5d47ea25-4a27-4ac3-92dc-45b3e93e5aaa" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25edbee8-7cef-423b-8390-60c74514076d" contextRef="C_2e59e5b9-1570-4e88-8150-2217fe0d9951" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e75383f5-3b25-4e1f-8622-f7db2d5c687e" contextRef="C_9deb4c05-1297-4d5e-8b6d-c26fba201c41" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6b6adfc-3d95-4e50-b94d-755876b7369f" contextRef="C_f0c5744c-d1f7-4baa-a2c2-36915bc2d3a4" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">300</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c36d27-a1f0-49e8-b87e-e066dfb0115a" contextRef="C_ab102545-8c8a-4aa6-9552-8b80e35cb031" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e12e4035-39b4-4181-aded-d7e4f3e3fab7" contextRef="C_044a6030-c57f-4067-b68d-6fdc516643ad" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">300</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a825508-a2aa-4f8f-8a14-36a5e1ec8210" contextRef="C_6e28630c-cb40-4a69-9fd0-0723bffc77c0" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any single calendar year for sales equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_665ad2b9-dede-4449-bb03-82c4a72f8585" contextRef="C_0d01d582-ddf7-4fdd-a777-e6d1bb59c432" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3e62f3b-87bb-450a-92b2-7444ca127c2c" contextRef="C_cb97f1c1-6e70-405d-9c80-c07e31f4c5c3" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_970026cf-2f5e-4c9b-bf79-12d7c9af51b6" contextRef="C_fc37c6a7-8bf0-4bfc-b756-982c3bbeeb03" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f300b32-9c4f-4c60-8030-36a5e39b4a24" contextRef="C_5ce2a22a-eacd-4fc1-b3cc-795c49539d41" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff7767e-e730-4ed8-92d7-a7456ab6ba07" contextRef="C_06627fb8-dcb2-4630-a05b-d4177e6132d5" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d2d20c-159f-4599-a9a0-0e228b63da59" contextRef="C_cabcf3fa-e7d3-462b-b114-a34b026905f8" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccaaf0d7-97ae-4731-bc14-6175e2b3ef7c" contextRef="C_98bd37e3-3099-4a59-86c5-e3462fe02fee" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50417ad8-c333-41a6-b00c-04a7fc14fe63" contextRef="C_64ac5d48-5a11-4212-bd0e-58e8990dba06" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_364f53ff-6f6f-4e53-a19b-ee31740d029c" contextRef="C_bc74c57a-97e8-4b7a-bee2-532bf391aa3d" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3441a6fa-ae24-469a-a492-d447d60d1937" contextRef="C_bd18a35e-b683-418d-b5ad-979c716ec315" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="9" decimals="-9" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75452f91-3720-499a-82bd-1f98949ff78a" contextRef="C_76b8de51-684e-42d9-ae4d-1d3e47c58783" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffee60d9-b142-4e5e-a9b8-6eb1c3de24d9" contextRef="C_e44cf128-2b29-4334-ac2f-c4e3a37536a9" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="9" decimals="-9" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c45ff59-6d69-4098-82d1-f15026d0a538" contextRef="C_fa4b3467-673b-4bda-8917-eb88309ffa19" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="9" decimals="-9" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c8c573-533c-45a6-b387-302b1e051254" contextRef="C_83103e7b-d556-4ade-a0c3-b0b5be918a24" name="cprx:PercentageOfRoyaltyPayableToNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e77b5972-985d-4c63-b3e7-0a6d249afa3e" contextRef="C_9b391f02-52d4-4024-84bb-8903cbcabfc3" name="cprx:NetSalesRoyaltyThreshold" unitRef="U_USD" scale="9" decimals="-9" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Furthermore, the Company may be obligated to pay Santhera sales-based milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5df5b6-6aa9-4550-80fc-3a7ba084d3d7" contextRef="C_3d31896d-8a0f-4011-b088-df7fcdb2cc51" name="cprx:NetSalesBasedMilestoneToRoyaltyThreshold" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as well as up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afa39628-d26a-4ba3-8ca6-abc9fe1a9fd6" contextRef="C_cd25d34a-1eeb-48ca-b321-579fd363c809" name="cprx:PercentageOfRoyaltyPayableToSalesBasedMilestone" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% percent royalties for all additional indications and milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_995c8603-e7fa-4b6c-93fb-a24f4166d817" contextRef="C_d706713c-2b5e-4983-a2c1-f8ebab1d21ee" name="cprx:ContingentConsiderationArrangementsContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the first three additional indications.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simultaneously, the Company made a strategic equity investment into Santhera by acquiring </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c615a6a-3262-4af0-81d7-0c3ce9549031" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,414,688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Santhera&#8217;s post reverse-split ordinary shares (representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d0057d7-d1b7-43f4-9473-0f9b63c7ce22" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction), which are traded on the SIX Swiss Exchange, at an investment price of CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f619cff-8561-428d-8736-165c7326349e" contextRef="C_fd78caae-6fed-4925-9427-26b866495956" name="cprx:AssetAcquisitionInvestmentSharePrice" unitRef="U_ChfShares" scale="0" decimals="3" format="ixt:num-dot-decimal">9.477</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the funds invested into Santhera to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE&#174;.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_3" continuedAt="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_4"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82c75c8e-f361-4743-9da8-d0f419c02d39" contextRef="C_fd78caae-6fed-4925-9427-26b866495956" name="us-gaap:AssetAcquisitionTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the strategic equity investment (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b209c392-3dc8-4d8f-a620-c1aa9645b385" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b55390-ac60-4d72-9aae-2df3aa121181" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:AssetAcquisitionConsiderationTransferredInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f5a955a-292c-475b-8cbd-58b1f00f9255" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,513</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b514e827-cbec-48dc-859f-0046c78b0ef5" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,978</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction has been accounted for as an asset acquisition in accordance with ASC 805-50. The Company accounted for the transaction as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the rights to develop, commercialize and manufacture AGAMREE&#174;. The AGAMREE&#174; rights consist of certain licenses and regulatory approvals and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. Additionally, the Company did not acquire a substantive process. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-financial assets based on relative fair values.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7ca89fb-fe6d-4e58-9407-3d305a765cf8" contextRef="C_fd78caae-6fed-4925-9427-26b866495956" name="cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" escape="true"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174; (vamorolone) (IPR&amp;D)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d29b7040-4178-4624-a8ac-3f383837d6cf" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,513</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6451f60b-cda5-406d-9f2f-9f875cc67c07" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:AssetAcquisitionConsiderationTransferredInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c08d4f9-e455-44c6-9c8e-6d56cc762e10" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,978</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_a726e936-cd79-4ad5-818b-5d331ff1d6ae" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the investment in Santhera was determined based on the closing market price (CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cab325f-2e82-456b-ae65-fe5913f85674" contextRef="C_9df3359d-d215-4d6a-884d-65563f285107" name="cprx:ClosingMarketPrice" unitRef="U_ChfShares" scale="0" decimals="2" format="ixt:num-dot-decimal">8.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of Santhera shares and the exchange rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_798f1321-88b0-4562-837e-847c0094b9e6" contextRef="C_6b652f70-c405-4c0f-89a3-daf7d3f4fbaa" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">1.1537</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of CHF to USD on the date the shares were transferred, July 19, 2023. </span></ix:footnote></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with FASB ASC 730-10-25, as AGAMREE&#174; (vamorolone) had not achieved regulatory approval when acquired, the portion of the purchase price allocated to the IPR&amp;D asset acquired (which includes all transaction costs related to the transactions with Santhera) was immediately expensed to research and development. Milestone payments made are either expensed as research and development or capitalized as a developed asset based on when regulatory approval is obtained. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize all sales-based milestone and royalty payments in cost of sales as revenue from product sales is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the approval of the NDA for AGAMREE&#174; on October 26, 2023, the Company became obligated to make a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_668b91ad-483a-4d07-bc4f-ccf6665b265c" contextRef="C_35f0b978-6b4f-4932-a291-aa7d01e6b0d2" name="cprx:CollaborativeArrangementMilestonePaymentObligation" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">36</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Santhera. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e2b05b0-a74f-4de4-92e6-e5332069dc31" contextRef="C_c664d775-b622-4767-80ce-109ca450ed44" name="cprx:PaymentOnMilestonePayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">36</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment was made during the fourth quarter of 2023. The Company capitalized the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fd1c12-855a-4218-8202-c996464eff7c" contextRef="C_c664d775-b622-4767-80ce-109ca450ed44" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">36</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment which is being amortized using the straight-line method over the product&#8217;s estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0bff39c7-75ee-4043-9637-f3bd7de2de75" contextRef="C_7da21a6a-c5cf-4df6-ba41-9a958e60d77d" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strategic equity investment in Santhera is accounted for as an investment in equity securities, and is recognized as a non-current asset, as the Company does not intend to sell the shares within 12 months. Since Santhera shares have a readily determinable fair value, the investment will be measured quarterly at fair value with changes reported in earnings in other income, net in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225_4"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has entered into agreements with contract manufacturers for the manufacture of commercial drug and drug and study placebo for the Company&#8217;s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company&#8217;s trials and studies and with various entities for laboratories and other testing related to the Company&#8217;s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. </span></div></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_f6bafff0-5734-4519-8a32-03e781d4cce1" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_f6bafff0-5734-4519-8a32-03e781d4cce1_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to income taxes in the U.S. federal jurisdiction and various states jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01ce9ec0-b578-40d0-829f-53c95f0315ad" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax expense for the years ended December 31, 2024, 2023 and 2022 consists of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63e54a92-2f76-41f1-a5d9-a16f8f3e652a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,876</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9658b5d5-ba65-49c2-885a-30380dbc39c0" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f04d18-a68b-4755-892e-4971c7cd7928" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e29b9ac9-f7b6-4004-9679-472559cae5d2" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,951</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f05060cd-d4ec-41b0-95b8-8b444b8bc764" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,931</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47836630-8d43-4636-8a2d-38986db06331" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6f67c17-7eb3-44ae-92f2-1956c77de188" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,442</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36033ce0-53a4-4f9f-be3f-6e3e045edca7" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,093</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ba13cd-daa2-4bfe-92fe-28ad046ee85c" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f82724-eb58-439e-80f8-8e9b09d0081a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,011</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_150a3f2f-bf06-4d65-bafb-95fea0a0e523" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,712</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d6a3c9d-0efe-47e8-a769-a6a1e522cefd" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c111e530-8061-4a58-824b-eec6368e32d3" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,374</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_940c19ac-8731-4689-8423-2426d175db64" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,101</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81321662-2726-46e4-9aca-e0451657f67f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,640</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0435e11a-5aae-4829-8c63-9f993a497f28" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of income tax expense computed at the statutory federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b004fb18-aa0b-4990-b7aa-57e2a63c7e10" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to amounts included in the statements of operations is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c1654a8-cc03-43cb-b2fd-bf878ff79fcd" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee97cd14-4220-4626-9758-2ad2d7d19537" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fd8b2f-7d3c-4878-8871-2c253db5a0a0" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44eef232-2cb8-4cf3-aa61-b196bd2a7d9d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e0a02ba-8840-4f55-9d54-c1155e663418" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec73657a-66f5-4b05-9c37-36b050091cd7" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5709391-a530-4eea-86b4-1c6937b583d8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd786fa-ce45-4f73-ac05-29dbee793565" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a5bddc-b470-4f69-b6a2-21482f0ab367" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7107d0c1-6767-4b26-bbb4-33eb30e5ae54" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:EffectiveIncomeTaxCreditsRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a6d0b0e-9ad7-47e4-a703-049725ad597e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:EffectiveIncomeTaxCreditsRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9baeefa-6e4d-49e6-8ed0-e059515e306d" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:EffectiveIncomeTaxCreditsRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation windfall</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1d0192-05cf-42f7-8298-85fa7b3d02d2" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ce9120e-180a-4efa-af21-5f2044a6bc02" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4b630d-6d81-4038-982b-609f94578db6" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df5c4512-885f-483d-af76-86aed1980443" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4705057a-b3a5-4e05-9e07-55c89e7faf72" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6986a28-813f-47e3-bb17-a48f1cf1ea1c" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39276a87-c98c-47ed-ba07-e05351090917" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">24.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436b54af-171b-4f43-89c1-4c07dee41a0b" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">24.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400fbe75-ca2e-4ae2-bc38-58357c506c65" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">20.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_f6bafff0-5734-4519-8a32-03e781d4cce1_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryovers and the temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets/(liabilities) as of December 31, 2024 and 2023 are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26ddc9f3-caeb-42dc-a34d-a46b3d616c15" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d31b189-09fb-400c-a68e-9f4666782bc8" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,950</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33751ae9-9799-4405-ba7c-3ef5b85f9f90" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93deef35-a662-4d2c-888c-b25c80e36295" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e578d66d-6559-439f-ae7b-fdf2eabbb9c8" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0d0153d-ea98-47a5-a64b-20c76a125d51" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6d54e1d-fa12-4148-bfa0-fddea0da952b" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7d2b41-de6a-4f77-895b-f3b249d1f0f0" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,863</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a1cb43-facd-4934-ae93-ca6b00f22096" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbd13139-b895-4c31-b1d8-e0bf6d75d7e1" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">762</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70bc5fd6-7723-47ed-8775-372907148607" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="cprx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">854</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92979a5b-3501-4401-9a2e-8c34f0e83fc3" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,755</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c3c0d2a-dacb-4428-be87-e8c94e019dcc" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,927</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_175ad65c-e78e-4160-9302-5949af8eb6c2" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,058</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bec3bfd-3269-4afc-902b-2b37db9ee14f" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de51a725-4d04-45c6-bd5b-f314e5926a0a" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3c667d7-7815-4957-9080-b4e181917534" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,023</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eeb9b43-1d1f-4529-9a23-eccbe705aef1" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599a806b-f08a-458a-ace3-1775fdb1a368" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38bb70e0-54c4-4cf7-a1ed-1c61b2cbdd35" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3272d849-7764-4f87-9406-dd130a370f94" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50efe6a6-d9a5-49d7-9674-51bed7db2959" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,076</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a9aabe-d1ce-4fa3-ba90-0e09b4ee6bc5" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29006600-76e4-4dd5-8369-8d3858201e69" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,982</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ac8d8c9-6d2f-4cdb-b9bf-803bc1258f1f" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,544</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December 31, 2024, the Company determined that there is sufficient positive evidence to conclude that it is more likely than not that the above deferred taxes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12e509a3-5e64-4016-9a52-2826d0170324" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">46</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are realizable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has received several orphan drug designations by the FDA for products currently under development. The orphan drug designations allow the Company to claim increased federal tax credits for certain research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An immaterial amount of interest and penalties were accrued through December 31, 2024 and 2023. The Company&#8217;s policy is to recognize any related interest or penalties in income tax expense. The Company is not currently under income tax examinations by any tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_f005b099-0914-4a81-8f26-a2478d8442a6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_f005b099-0914-4a81-8f26-a2478d8442a6_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a7c8fa5-764c-45b7-91df-e8a9f95be610" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of authorized preferred stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9bf7d8d-119b-4b8f-8426-9e3a241d82f5" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value per share. At December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f2c9f7-ba76-4803-a9a3-5b33f7d2436e" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e7c0cf6f-e019-4b91-9f32-86413e942c5c" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock were outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6266a51a-5726-4488-9372-4599560231b4" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of authorized common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_786d6106-03d8-4cf4-b3b6-bb95179be543" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. At December 31, 2024 and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bc084a0-7f09-495e-9db2-c26bf8dfa1bf" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cae69244-9ced-49c6-879c-a052521f96ad" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">120,879,099</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f09e2468-3d6e-4773-841f-ed092623fdb3" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_58136856-4d09-4bc0-b832-5e2ccb9ba909" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">107,121,549</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of common stock were issued and outstanding. Each holder of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feb5e85e-e3b7-42a0-9344-4e91fff4438f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="cprx:NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" unitRef="U_Vote" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote of each share of common stock held of record on all matters on which stockholders generally are entitled to vote.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Repurchases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, the Company&#8217;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac82fd8-d47f-4335-bb0b-2364a796e976" contextRef="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c" name="srt:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock, pursuant to a repurchase plan under Rule 10b-18 of the Securities Act. The share repurchase program commenced on March 22, 2021 and currently expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6984d8de-e4fa-4b13-8841-bb4b0fbacf3b" contextRef="C_0b737ad0-5bd1-4089-bd14-fd61307aded2" name="srt:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 22, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f53d71f-7688-45a0-bc94-da725903a1d3" contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7f2cfa10-d945-4b3d-8ff1-054242820721" contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were repurchased during the years ended December 31, 2024 and 2023. During the year ended December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc7fcbd2-5329-4344-ad5f-4aa918130527" contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were repurchased for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d53c1037-ab00-4d65-8192-12ec0d1c3f6a" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b320ab89-d402-4fda-ba09-8b7a2322e127" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> average price per share).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f005b099-0914-4a81-8f26-a2478d8442a6_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 8, 2023, the Company filed a shelf registration statement with the SEC to sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4cce59-d277-43c9-85a1-c29965b9d189" contextRef="C_6ca67800-b7c3-4502-9b65-2de2fc4bcd0d" name="cprx:MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the 2023 Shelf Registration Statement). The 2023 Shelf Registration Statement (file no. 333-274427) became effective upon filing. On January 9, 2024, the Company completed a public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78d8cd64-80bb-43e3-970d-090e87487fee" contextRef="C_37c62b10-c734-4e61-bef2-3be60f99493b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, raising net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98894ca2-26bb-4ba3-9965-284cdff9d79c" contextRef="C_37c62b10-c734-4e61-bef2-3be60f99493b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Company&#8217;s 2023 Shelf Registration Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_c62a25de-26ef-42c8-b6d2-dd247863be8e" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_c62a25de-26ef-42c8-b6d2-dd247863be8e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7dcee78-81c0-4134-8c64-8ef572a07ac1" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bbf1a15-e776-40f1-9791-d428d9b3234a" contextRef="C_52411d29-db32-4171-9a6f-695291dabbf1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,779</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_614633d6-c809-48f1-9eb4-431a22a4226b" contextRef="C_f627f358-1fdf-4532-a83a-c7e61bed5227" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ac9b2f-cde9-4d70-86df-73842ce651c9" contextRef="C_eecd310a-1107-4709-994f-14fd984abc2a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,729</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe5c65c6-f5d6-4b9b-a57a-1b70fc15efda" contextRef="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c222fb97-522a-4367-8745-76f4b8150a89" contextRef="C_96caeb09-9772-4554-9b52-38246d8f8c0e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,769</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19a80902-6bae-4510-ab6f-6efd0d3e449b" contextRef="C_d2c50c06-f8b1-40b0-b95b-16454488f954" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,178</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51709493-9e71-4138-a4e9-f0bb87ec1d51" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,251</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4b41ce-3704-473e-ac96-b577ccc124b7" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,250</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5d89a9e-fc6f-4511-8661-9d71f4d9bb33" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may issue stock options, restricted stock, stock appreciation rights and restricted stock units (collectively, the Awards) to employees, directors, and consultants of the Company under the 2014 and 2018 Stock Incentive Plans (the 2014 Plan and the 2018 Plan or collectively, the Plans). At December 31, 2024, no shares remain available for future issuance under the 2014 Plan. Under the 2018 Plan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53651961-217e-4497-907d-32cc5e4e3fe2" contextRef="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,000,000</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares are reserved for issuance and as of December 31, 2024,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3727b0-0da6-4d4b-b47a-5c1a2a969319" contextRef="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,254,102</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares remain available for future issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted stock options to employees, officers, directors, and consultants generally at exercise prices equal to the market price of the common stock at grant date. Option awards generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce97501c-17da-4c9f-8cf0-88aca3640058" contextRef="C_699b6fb2-eaae-4c2e-8078-429b64ad536a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f52d6b72-3723-4051-a1ce-54b6db741c57" contextRef="C_a4930a59-5dbe-484a-931a-7075307c98cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of continuous service and have contractual terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_892b426c-124c-4e9b-a30d-cdb81a2ea86a" contextRef="C_ef0ad7eb-05bd-41b1-a942-fd05ddc204bc" name="cprx:ContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Certain awards provide for accelerated vesting if there is a change in control. The Company issues new shares as shares are required to be delivered upon exercise of outstanding stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, options to purchase</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32cacc4e-a0b4-452e-aa73-2581c5769f65" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,429,184</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f1a7ef7-6d4e-4808-a91a-72e6ffbce9a0" contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,651,345</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33e9fbb9-5652-472e-87a5-ffd0c06724e7" contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,172,342</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company&#8217;s common stock were exercised with gross proceeds to the Company of approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb1a8d42-fac5-4f5e-9c8c-9aeb9cbf14ae" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec9ff6f6-a76e-49c9-8803-5bfb1f796acf" contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b5ab9f3-bce9-4bca-8bdd-0fadd4791b7a" contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. During the years ended December 31, 2024, 2023 and 2022, no options to purchase shares of the Company&#8217;s common stock were exercised on a &#8220;cashless&#8221; basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022 the Company recorded non-cash stock-based compensation expense related to stock options totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11fa4ac0-347e-4ae4-a358-d06ded222f65" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_903c980a-67bc-45fe-b5db-03f137b01f7c" contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19827f42-7bf0-4ba7-9dcb-ca3a8925f015" contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6eb63435-ad31-4c87-b6f4-e52566b84180" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_248b2427-a6c3-4d83-85b8-42d4b532f4b9" contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_ab1e33bb-853d-4135-8f40-e239a8e52204" contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-year</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options to purchase an aggregate</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9725914d-fefa-401b-b2f9-3ff6c66488ea" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,476,946</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf904b3e-b743-453e-9dac-59464df034cf" contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,598,535</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ac534e5-4943-48da-82f9-bfbd1ec3cba1" contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,386,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company&#8217;s common stock to certain of the Company&#8217;s officers, employees, directors, and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c62a25de-26ef-42c8-b6d2-dd247863be8e_1" continuedAt="F_c62a25de-26ef-42c8-b6d2-dd247863be8e_2"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e14b7748-122c-486f-a8ac-c2facdbf2c45" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the Company&#8217;s Plans for the year ended December 31, 2024 is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.352%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.258%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.658000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.258%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.798%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bebd2bb-50c3-4275-af09-918b5bcde7ff" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,177,488</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_285df4be-1c7e-4ec4-ae78-8d8acb12b9ef" contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.73</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_500a6574-4d14-40ee-9dc7-adc1d6ab95e6" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,476,946</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b7c8a2-161f-4858-be7e-da4817781278" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.95</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised or released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47a0d939-85f1-420f-94c2-288a0eaf6343" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,429,184</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e6eea53-585e-481a-9c25-3823dc7c3728" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7717876e-538a-433e-9a2b-0f48ae67790c" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">137,337</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_263943b9-9a30-4cae-bf18-4598d46a0518" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.29</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d78f2354-8444-4a61-a8fd-14c0176693b7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,124</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c79c5e2-4de5-40a6-a79d-286a32924334" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.47</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2245bdcc-3713-465b-ad28-1b57f7982892" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,076,789</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_000a5d00-07d6-4093-8b3c-f2b454c8d74f" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.76</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_a0b5778c-e71f-4d9a-a53c-2bd9176dcd13" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7151bcff-5e41-4e86-b6cf-aa88ab9406b9" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80a03a72-f380-49f3-851d-77f34c899a4b" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,353,893</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cbc5751-2671-452d-9665-520e257fb56b" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_b6d4f13d-723f-4050-9745-39095f0b72ae" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.93</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_565b7d5d-1474-44c8-ab45-3f60573a0a7c" contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,449</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_737e0f76-a318-4b86-9922-017ac218a2dc" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information pertaining to stock option activity during the years ended December 31, 2024, 2023 and 2022 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted&#8211;average fair value of granted stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_705e5b3e-4e27-49bb-868f-0204d978534a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_839b82f8-9218-4343-8301-8a948b0e233b" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_953f1b21-155b-4384-a664-345001b59cb0" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of vested stock options (in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88518ae7-6c82-4ee4-b4b4-865b7e86e4f7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1adf263-da42-4378-beaf-98904cb56d35" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d4b720-c91c-449b-9812-56e69c23147f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intrinsic value of exercised stock options<br/>&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c99e1af-d214-4515-9ce8-8ef9403e7123" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,230</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c4d0077-de0f-48c1-8b04-a1beb497fcaa" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,265</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5a88b40-c9d7-4750-8aba-fc6a840a2696" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,881</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e83966b-1c4b-42b2-a2e1-79a87ba1b5d6" contextRef="C_65b685f1-a56a-4c6a-bfd2-43a03bc5ac14" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation expense related to non-vested stock option awards granted under the Plans. That cost is expected to be recognized over a weighted average period of approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc33afd0-c4ac-433a-aca8-0c33d25168bb" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.72</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to the expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of the Company&#8217;s common stock. The Company estimates the expected option life for options granted to employees and directors based upon the simplified method. Under this method, the expected life is presumed to be the mid-point between the vesting date and the end of the contractual term. The Company will continue to use the simplified method until it has sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the estimated life of the stock option awards. The expected dividend rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a3a7e8-d663-4372-891f-62ebc1af6b39" contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d654b1a7-2d5e-4267-a9db-9369417f83c7" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumptions used during the years ended December 31, 2024, 2023 and 2022 were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.928%;box-sizing:content-box;"/>
        <td style="width:1.68%;box-sizing:content-box;"/>
        <td style="width:18.344%;box-sizing:content-box;"/>
        <td style="width:1.68%;box-sizing:content-box;"/>
        <td style="width:18.344%;box-sizing:content-box;"/>
        <td style="width:1.68%;box-sizing:content-box;"/>
        <td style="width:18.344%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ab28df6-c655-4774-86d8-d30376bfb697" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0946551-3712-4f3d-ac1f-a731dad29fce" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_937cc3b5-0c5c-4ef0-a20a-b5d44334d8f4" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e13da491-1f9d-4942-8c42-476b99ae792f" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdadbba7-db9e-452d-9b00-b616adf6f81f" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ed2d206-dc0a-4416-a614-9e9802fea308" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_a19e6922-e38e-49d1-a4a8-fa2808df348c" contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_f04a540d-b613-43c6-ae95-c060bcf838a7" contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_71c4c17c-739c-4c50-94af-02f96cac4ec6" contextRef="C_67b31110-ac66-4aed-a6af-7327aecffdff" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_bea5f8e4-7b54-43c7-8e12-b49427c2f617" contextRef="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_4ad8aa32-d6f0-4f33-8a41-93ef542c0b6c" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bca5aa8-d64f-40fb-accb-f677c4f0a0d7" contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">54.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fea209d-fc01-44f3-b8e4-3b96bcd74693" contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">61.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e8db7ed-e78f-432d-bc39-8c338adddd5f" contextRef="C_67b31110-ac66-4aed-a6af-7327aecffdff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c811a4f6-00ec-4e9a-8052-650dcc422aca" contextRef="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19888765-1a7b-40e4-a703-ca324e8b77da" contextRef="C_26534ab4-73c0-4cf4-8ab2-a0597988cf75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd4574c9-b147-4009-9003-1a252251ba56" contextRef="C_5402459a-da02-42fa-9a9a-d8809e5bcd3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">69.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddf7f9e3-fe67-42c9-b8e4-266c4b5a407d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4471de0d-4020-452d-a7f7-34a5d912f47d" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5872b98-5425-40e9-bc5c-96c2339e7cd9" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected forfeiture rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df61dfe-552d-4174-b081-ca65992801b8" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90e8283f-9420-4c28-98a0-21e401928f40" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9ae8fb4-899f-45f7-95cb-f96793aba92e" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;display:inline-block;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c62a25de-26ef-42c8-b6d2-dd247863be8e_2"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation (continued). </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2018 Plan, participants may be granted restricted stock units, each of which represents a conditional right to receive shares of common stock in the future. The restricted stock units granted under this plan generally vest ratably over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ca6025-9a8a-4923-8e2d-91c295c60e70" contextRef="C_21d5ec19-7e43-465e-bda0-2f4bd1233423" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. Upon vesting, the restricted stock units will convert into an equivalent number of shares of common stock. The amount of expense relating to the restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant and is amortized on a straight-line basis over the requisite service period. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_546ce7a2-dfad-4984-8a09-d617ca9f057d" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_546ce7a2-dfad-4984-8a09-d617ca9f057d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity for the year ended December 31, 2024 was as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_546ce7a2-dfad-4984-8a09-d617ca9f057d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e18d29-eb08-419e-b3da-3745242067e7" contextRef="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">854,459</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3da288af-e8e1-4e1c-bfaa-5580102159c6" contextRef="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49e28e93-f63d-4cee-850d-dcbbde347c81" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">228,029</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f80696c3-e58d-4b0b-8af6-bb15ce9838cd" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746ad4c5-70d6-444d-a0b9-e2e1c583788d" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">364,861</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef69929d-c66b-4193-946c-677546bf2920" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.19</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f40ac3-5bf0-447e-8ba8-68ac4695478e" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,667</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_152d88f7-00e0-447e-bf5e-5ae1084382c6" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb997e9-d419-41ac-97b8-5df6e61bb5da" contextRef="C_59962491-572f-40ec-90f4-9cbf4e5124ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">708,960</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99631b34-ec72-4319-a7d0-d040e7d389a0" contextRef="C_59962491-572f-40ec-90f4-9cbf4e5124ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.63</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded non-cash stock-based compensation expense related to restricted stock units totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bdd6088-cfd4-4a76-8e1f-288741535c20" contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5865d1d6-066d-435a-8198-883bb13f21cf" contextRef="C_71e97608-057e-403f-bf4b-90daabc11583" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0053bf52-a8fa-4319-b0fd-d13477e2da30" contextRef="C_581d19f7-26e1-4059-90f3-b147eba1d7ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ba3be93-3e2f-4f62-9535-eb30dfc5e454" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit Plan. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code covering all eligible employees. Subject to certain dollar limits, eligible employees may contribute up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46c82d5d-b899-4b38-b5a0-8dfae46e68a4" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their pre-tax annual compensation to the plan. The Company has elected to make discretionary matching contributions of employee contributions up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07518972-d9be-4966-9feb-d5d12dcea13a" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s gross salary. For the years ended December 31, 2024, 2023 and 2022, the Company&#8217;s matching contributions were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f803f7f-c1ae-44c0-a58b-8cecabde8ce9" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b82a050-b5d9-463f-8577-62c378f73e4e" contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad6fee86-91c3-486f-b3cb-e03bf2e7fcaa" contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45a9b073-1255-43fc-9ed0-0e737e586c46" contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent Events. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company announced that it and its licensor, SERB have entered into a Settlement Agreement with Teva. This agreement resolves the patent litigation brought by the Company and SERB in response to Teva&#8217;s ANDA seeking approval to market a generic version of FIRDAPSE&#174; (amifampridine) 10 mg tablets prior to the expiration of the applicable patents.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the settlement agreement, Teva has agreed not to market its generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of settlements occur. In accordance with the Agreement, the Company/SERB and Teva have terminated all ongoing patent litigation between them that is currently pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#174;&#8217;s Orange Book-listed patents) and Lupin (only for Catalyst&#8217;s FIRDAPSE&#174; patent expiring in 2037) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to February 25, 2035.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 17, 2025, Charles B. O&#8217;Keeffe, an independent member of the Board of Directors (Board) of the Company, advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company&#8217;s stockholders. Mr. O&#8217;Keeffe will continue to serve as a member of the Board until the 2025 annual meeting, when his current term will expire. Mr. O&#8217;Keeffe has been a member of the Board since December 2004 and currently serves as the Board&#8217;s Lead Independent Director. Mr. O&#8217;Keeffe&#8217;s intention to retire from the Board was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 21, 2025, the Company reported that its sub-licensee in Japan, DyDo, has launched FIRDAPSE&#174; Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with LEMS.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>cprx-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                                                                                                                          Exhibit 19.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***]</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CATALYST PHARMACEUTICALS, INC.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING POLICY</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy (&#x201c;Policy&#x201d;) summarizes the policies of Catalyst Pharmaceuticals, Inc. (&#x201c;Catalyst&#x201d;) and its subsidiaries (collectively, the &#34;Company&#34;) with respect to transactions in Catalyst&#x2019;s securities by employees, officers, and directors of, and consultants and contractors to, the Company. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicability of Policy </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all transactions in Catalyst&#x2019;s securities, including common stock, options for common stock and any other securities Catalyst may issue from time to time, such as preferred stock, warrants and convertible debentures, as well as to derivative securities relating to the Catalyst's stock (collectively, &#34;Catalyst's Securities&#34;). It applies to all executive and non-executive officers of the Company, all members of the Company's Board of Directors, and all employees of, and consultants and contractors to, the Company and its subsidiaries, who receive or have access to Material Nonpublic Information (defined below) regarding the Company. This group of people, members of their immediate families, and members of their households are sometimes referred to as &#34;Insiders.&#34; This Policy also applies to any person who receives Material Nonpublic Information from any Insider. Any person who possesses Material Nonpublic Information regarding the Company is an Insider for so long as the information is not publicly known. Any employee can be an Insider from time to time, and at those times is subject to this Policy. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">StatemenT of General Policy </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the policy of the Company to (i) oppose the unauthorized disclosure of any nonpublic information acquired in the workplace, (ii) prohibit the misuse of Material Nonpublic Information in trading of Catalyst&#x2019;s Securities, (iii) prohibit trades in Catalyst&#x2019;s Securities by an Insider while the Insider possesses Material Nonpublic Information concerning the Company, and (iv) prohibit Insider trades in the Catalyst&#x2019;s Securities during a Trading Window (as defined below). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific Policies </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tradin</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on Material Nonpublic Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No director, officer or employee of, or consultant or contractor to, the Company, and no member of the immediate family or household of any such person, shall engage in any transaction involving a purchase or sale of the Company's Securities, including any offer to purchase or offer to sell, during any period commencing with the date that he or she possesses Material Nonpublic Information concerning the Company, and ending at the beginning of the second Trading Day following the date of public disclosure of that information, or at such time as such nonpublic information is no longer material. As used herein, the term &#34;Trading Day&#34; shall mean a day on which national stock exchanges are open for trading. A &#34;Trading Day&#34; begins at the time trading begins on such day. This restriction on trading does not apply to transactions made under a trading plan adopted pursuant to Securities and Exchange Commission Rule 10b5-l(c) (17 C.F.R. &#167; 240.10b5-1(c)) (&#34;Rule 10b5-l(c)&#34;) and approved in writing by the Company (an &#34;approved Rule 10b5-1 trading plan&#34;). In addition, no Insider may trade in any interest or position relating to the future price of the Company's Securities, such as a put, call or short sale. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider shall disclose (&#34;tip&#34;) Material Nonpublic Information to any other person (including family members, analysts, individual investors, and members of the investment community and news media), where such information may be used by such person to his or her profit by trading in the Company's Securities, nor shall such Insider or related person make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in the Company's Securities, unless required as part of that Insider's regular duties for the Company and authorized by the Chair of the Nominating and Corporate Governance Committee.  In any instance in which such information is disclosed to outsiders, the Company will take such steps as are necessary to preserve the confidentiality of the information, including requiring the outsiders to agree in writing to comply with the terms of this policy and/or to sign a confidentiality agreement.  All inquiries from outsiders regarding Material Nonpublic information about the Company must be forwarded to the Chief Executive Officer and/or the Chair of the Nominating and Corporate Governance Committee. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality of Material Nonpublic Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Material Nonpublic Information is the Property of the Company, and the unauthorized disclosure of such information is forbidden. In the event any officer, director or employee of the Company receives any inquiry from outside the Company, such as from a stock analyst broker, for information (particularly financial results and/or projections, or clinical trial results or analysis of such results) the inquiry should be referred to the Chief Executive Officer, the Chief Financial Officer, and/or the designated Investor Relations personnel who are collectively responsible for coordinating and overseeing the release of such information to the investing public, analysts and others in compliance with applicable laws and regulations. No Company employee, other than designated executive officers or those employees expressly designated by the Chief Executive Officer, should discuss Company business with anyone outside the company whether or not it is Material Nonpublic Information. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advice Concerning Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may give trading advice of any kind about the Company or Catalyst&#x2019;s Securities to anyone while possessing Material Nonpublic Information about the Company. Insiders should always advise others, preferably in writing or electronically, not to trade in Catalyst&#x2019;s Securities if doing so might violate the law or this policy. The Company strongly discourages all Insiders from giving trading advice Catalyst&#x2019;s Securities or the Company to third parties even when the Insiders do not possess Material Nonpublic Information about the Company or Catalyst&#x2019;s Securities. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential Criminal and Civil Liability and/or Disciplinary Action </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liability for Insider Trading</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pursuant to federal and state securities laws, Insiders may be subject to criminal and civil fines and penalties as well as imprisonment for engaging in transactions in Catalyst&#x2019;s Securities at a time when they have knowledge of Material Nonpublic Information regarding the Company. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liability for Tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Insiders may also be liable for improper transactions by any person (commonly referred to as a &#34;tippee&#34;) to whom they have disclosed Material Nonpublic Information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in Catalyst&#x2019;s Securities. The Securities and Exchange Commission (the &#34;SEC&#34;) has imposed large civil penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges and FINRA use sophisticated electronic surveillance techniques to uncover securities trading on Material Nonpublic Information. In recent years, criminal prosecution of Insiders has become much more common, particularly when Insiders were aware of their obligations under the securities laws and elected to ignore those obligations in acting on, or in tipping others concerning, Material Nonpublic Information. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC can also seek substantial civil penalties from any person who, at the time of an insider trading violation, &#x201c;directly or indirectly controlled the person who committed such violation,&#x201d; which would apply to the Company and/or management and supervisory personnel.  The control persons may be held liable for up to the greater of $1 million or three times the amount of profits gained, or losses avoided.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even for violations that result in small or no profit, the SEC can seek penalties from a company and/or its management and supervisory personnel as control persons.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible Disciplinary Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Employees of the Company who violate this Policy shall also be subject to disciplinary action by the Company, which may include ineligibility for future participation in the Company's equity incentive plans or termination of employment. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Guidelines and Requirements </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Black-Out Periods and Trading Windows. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Information Black-Out Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The period beginning at the close of market on [***] is a particularly sensitive period of time for transactions in Catalyst&#x2019;s securities from the perspective of compliance with applicable securities laws. This sensitivity is due to the fact that certain Insiders will, during that period, possess Material Nonpublic Information about the expected financial results for the quarter. Accordingly, the periods of time referred to above with respect to financial information are referred to as &#34;financial blackout&#34; periods. All directors and officers (and those other employees identified by the Company from time to time and who have been notified that they have been so identified) are prohibited from trading in Catalyst&#x2019;s Securities during financial black-out periods. The specific Insiders whose roles require them to be within this category shall be reassessed at least annually. Insiders within this category will also be notified prior to the Black Out Periods beginning and ending each quarter.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Information Black-Out Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is common for pharmaceutical companies to come into possession of information concerning (i) the early results of clinical trials of product candidates, (ii) reported results of clinical trials of product candidates from Company personnel or from contractors, and/or (iii) information that results from the analyses of clinical trial results pertaining to product candidates. This information is highly sensitive due to the fact that certain Insiders may possess Material Nonpublic Information concerning the early results of the clinical trials, the yet- unreported results of the clinical trials, or the scientific or medical inferences or conclusions that can be drawn from the early results or yet-unreported results of clinical trials. The periods of time referred to above during which the Company has received (i) information concerning the early results of clinical trials of product candidates, (ii) reported results of clinical trials of product candidates from Company personnel or contractors, and/or (iii) information that results from the analyses of clinical trial results pertaining to product candidates, are referred to as &#34;clinical information black-out periods.&#34; All directors and officers (and those other employees identified by the Company based on the circulation of the relevant clinical information and who have been notified that they have been so identified) are prohibited from trading in the Company's Securities during each specific Clinical Information Black-Out Period upon their notification of the initiation of one. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:8.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:10.353073744835358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope of employees identified for inclusion in a Clinical Information Black-Out Period will be determined by the level of information available to individual employees regarding both the results and the underlying clinical activity that generated the results.  The goal will be to define the scope of individuals included in such a Black-Out to be those concerned with the clinical activity and the results.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Black-Out Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, from time-to-time, Material Nonpublic Information regarding the Company may be pending such as, for example, potential merger or acquisition activity. While such information is pending, the Company may impose a special &#34;black-out&#34; period during which the same prohibitions and recommendations shall apply. These restrictions on trading do not apply to transactions made under a Rule 10b5-l trading plan previously approved in writing by the Company.  All officers, directors, and employees identified for </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inclusion in these Special Black-Out Periods will be notified in writing at or before the beginning of any Special Black-Out Period.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Trading Window Related to Financial Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To ensure compliance with this Policy and applicable federal and state securities laws, the Company requires that all directors and officers and those certain Identified Employees of the Company refrain from conducting transactions involving the purchase or sale of Catalyst&#x2019;s Securities other than during the period (the &#34;Trading Window&#34;) commencing at the open of market on [***] and continuing until [***]. During the Trading Window, if the Company is either in a Special Black-Out Period or a Clinical Black-Out Period, the Company requires that all directors and officers of the Company and those certain identified employees specific to the parameters of the specific Black Out Period in place refrain from conducting transactions involving the purchase or sale of Catalyst Securities even though the Trading Window may otherwise be open. These restrictions on trading do not apply to transactions made under an effective Rule 10b5-l trading plan previously approved by the Company. The prohibition against trading during any black-out period encompasses the fulfillment of &#34;limit orders&#34; by any broker for a director, officer, employee, or consultant, as applicable, and the brokers with whom any such limit order is placed shall be so instructed by the Insider not to execute on any such instructions immediately after the Insider is advised that a black-out period has become effective. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Full Company Black-Out Period due to Financial Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the end of the first month of each quarter, there will be a standard, company-wide trading blackout for all employees that will last until [***].  This is due to the sensitivity of the pending financial results. While the Company will try to remind people of these periods, it is an employee&#x2019;s responsibility to observe these Full Company Black-Out Periods due to Financial Information pending release.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Developments Not Yet Disclosed</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  From time to time, the Company may also prohibit directors, officers and potentially a larger group of employees, consultants and contractors from trading in Catalyst&#x2019;s Securities because of material developments known to the Company and not yet disclosed to the public. In such event, directors, officers and such employees, consultants and contractors may not engage in any transaction involving the purchase or sale of Catalyst&#x2019;s Securities and should not disclose to others the fact of such suspension of trading. Any employees affected by these sorts trading black-outs will be notified in writing at or before the commencement of the black-out.  This restriction on trading does not apply to transactions made under an effective Rule 10b5-1 trading plan previously approved by the Company. The Company will re-open the Trading Window at the beginning of the second Trading Day following the date of public disclosure of the information, or at such time as the information is no longer material. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Safe Harbor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It should be noted that even during the Trading Window, any person possessing Material Nonpublic Information concerning the Company, whether or not subject to the financial and clinical information black-out periods and Trading Window, should not engage in any transactions in Catalyst&#x2019;s Securities until such information has been known publicly for at least one Trading Day, whether or not the Company has recommended a suspension of trading to that person. This restriction on trading does not apply to transactions made under an effective Rule 10b5-l trading plan previously approved by the Company. Trading in Catalyst&#x2019;s Securities during the Trading Window should not be considered a &#34;safe harbor,&#34; and all directors, officers, employees, and other persons must use good judgment at all times in deciding whether to trade in the Company's Securities. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance of Trades</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No executive officer or director may trade in Catalyst Securities until (i) the person trading has notified the Chief Executive Officer, or the Chief Executive Officer&#x2019;s designees, of the amount of the proposed trade(s), and (ii) the person trading has certified to the Chief Executive Officer, or the Chief Executive Officer&#x2019;s designees, in writing no earlier than one business day prior to </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proposed trade(s) both that (a) he or she possession of Material Nonpublic information concerning the Company, and (b) the proposed trade(s) do not violate the trading restrictions of Section 16 of the Exchange Act or Rule 144 of the Securities Act. Although an Insider wishing to trade pursuant to an effective and previously approved Rule 10b5-1 trading plan need not seek preclearance from the Company's Chief Executive Officer before each trade takes place, such an Insider must obtain the Company's prior written approval of the proposed Rule 10b5-1 trading plan before it is adopted.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20.13%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:8.269%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:10.353073744835358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Executive Officer currently designates [***], as the primary designee for Pre-Clearance of Trades as outlined in Section 6.2. Further, the Company's Chief Executive Officer currently designates [***], as his secondary designee for the same purpose if [***] cannot be reached or is otherwise unavailable.  In the absence of both the primary and the secondary designees, notices can be provided to the Company's Chief Executive Officer.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual Responsibility</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Every officer, director and other employee, consultant and contractor has the individual responsibility to comply with this Policy against insider trading. An Insider may, from time to time, have to forego a proposed transaction in the Company's Securities even if he or she planned to make the transaction before learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated profit by waiting. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicability of Policy to Inside Information Regarding Other Companies  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy and the guidelines described herein also apply to Material Nonpublic Information relating to other companies, including the Company's contractors and consultants (&#34;Business Partners&#34;), when that information is obtained in the course of employment with, or the performance of services on behalf of, the Company. Civil and criminal penalties, and termination of employment, may result from trading on inside information regarding the Company's Business Partners. All officers, directors, employees, consultants and contractors should treat Material Nonpublic Information about the Company's Business Partners with the same care required with respect to information related directly to the Company. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Material Non-Public Information </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> It is not possible to define all categories of Material Nonpublic Information. However, information is not limited to historical facts but may also include projections and forecasts.  With regard to a future event, such as a merger, acquisition or introduction of a new product, the point at which negotiations or product development are determined material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on the Company&#x2019;s operations or stock price should it occur.  Thus, information concerning an event that would have a large effect on the stock price, such as a merger, may be material even if the possibility that the event will occur is relatively small.  When in doubt about whether nonpublic information is material, you should presume that it is material.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are unsure whether the information is material, you should contact any of the individuals referenced in Section 11 before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which the information relates or assume that the information is material.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered material unless publicly announced. Examples of such information may include, but are not limited by the following, at least until the initiation of trading on the second day after the information is publicly announced: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial results;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Known but unannounced future earnings or losses;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early indications of clinical trial results;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Known but unannounced clinical trial results;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Known but unannounced analyses of clinical trial results;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">News of pending or proposed transactions, even if not definite, including mergers, acquisitions, divestitures, recapitalization, strategic alliances, collaborative arrangements, licensing arrangements, or purchases/sales of substantial assets;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant developments related to intellectual property;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in dividend policy;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New product candidate announcements of a significant nature;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock splits;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New equity or debt offerings; and/or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant exposure due to actual or threatened litigations or significant developments (whether positive or negative) in pending litigation.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either positive or negative information may be material. Nonpublic information is information that has not been previously disclosed to the general public and is otherwise not available to the general public. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Exceptions </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, the Company considers that the exercise of stock options entirely with cash under the Company's stock option plan is exempt from this Policy.  Furthermore, any form of exercise that does not involve any sale of the exercised shares to a third-party, such as netting the shares issued by the Company for tax withholding purposes, is also exempt, but only if such netting has been approved by the Company's Chief Executive Officer. However, any transaction resulting in the sale of any shares issued upon such exercise is not exempt from this Policy and therefore prevented by any Black Out Periods or due to possession of non-public material information. In addition, for purposes of this Policy, the Company considers that bona-fide gifts of the Company's Securities to immediate family members are exempt from this Policy. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Information - Directors and Officers </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors and officers of the Company and holders of more than ten percent of Catalyst Securities must also comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16 of the Securities Exchange Act of 1934, as amended. The practical effect of these provisions is that officers, directors and holders of more than ten percent of Catalyst Securities who purchase and sell the Catalyst&#x2019;s Securities within a six-month period must disgorge all profits to the Company whether or not they had knowledge of any Material Nonpublic Information. Under these provisions, and so long as certain other criteria are met, neither the receipt of an option under the Company's option plans, nor the exercise of that option is deemed a purchase under Section 16; however, the sale of any such shares is a sale under Section 16. Section 16 further prohibits executive officers and directors from ever making a short sale of the Company's stock. A short sale is a sale of securities not owned by the seller or, if owned, not delivered. Transactions in put and call options for the Securities may in some instances constitute a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">short sale or may otherwise result in liability for short swing profits. All executive officers and directors of the Company must confer with Catalyst&#x2019;s Outside Securities Counsel before effecting any such transaction. The Company does not permit short sale transactions by any executive officer, director and employee.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While employees who are not executive officers and directors are not prohibited by law from engaging in short swing transactions of Catalyst Securities, the Company believes it is inappropriate for employees to engage in such transactions and therefore strongly discourages all employees from such activity. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.720495141324946%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.0</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please direct your questions as to any of the matters discussed in this Policy to [***].</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cprx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have issued our reports dated February 26, 2025, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Catalyst Pharmaceuticals, Inc. on Form 10-K for the year ended December 31, 2024. We consent to the incorporation by reference of said reports in the Registration Statements of Catalyst Pharmaceuticals, Inc. on Form S-3ASR (File No. 333-274427) and on Forms S-8 (File No. 333-275962, File No. 333-275963 and File No. 333-279886).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ GRANT THORNTON LLP</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Miami, Florida</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cprx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Richard J. Daly, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Catalyst Pharmaceuticals, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s Board of Directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard J. Daly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard J. Daly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cprx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Michael W. Kalb, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Catalyst Pharmaceuticals, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s Board of Directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael W. Kalb</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael W. Kalb</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cprx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification Required by 18 U.S.C. Section 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Richard J. Daly, as Principal Executive Officer of Catalyst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (the &#x201c;Report&#x201d;), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p></td>
   </tr>
   <tr style="height:12.25pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard J. Daly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard J. Daly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cprx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification Required by 18 U.S.C. Section 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Michael W. Kalb, as Principal Financial Officer of Catalyst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (the &#x201c;Report&#x201d;), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p></td>
   </tr>
   <tr style="height:12.25pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael W. Kalb</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael W. Kalb</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img136052313_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img136052313_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ?H"84# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:/JMC<*'@O=.U.PFN+*^M)T(>&YMIY89%(9'8<T :M%%<IXY\>>!_AAX/\
M$?Q"^)?C+PI\// /@_2KK7?%OCCQSXBTCPEX/\+:)8IYE[K/B/Q+K]YI^BZ)
MI5G'\]UJ&IWMK:6Z?-+,B\T =717P=IG_!4[_@F)K>I:=HVC?\%&_P!@[5]8
MU>^M-,TG2=,_:]_9]O\ 4M3U*_N([2QT[3K&T^(<MU>WU[=2Q6UI:6T4MQ<W
M$L<,,;R.JG[QH ***^$-6_X*F?\ !,?0-5U/0M=_X*,_L(:+K>BZA>Z3K&CZ
MM^UY^S]IVJZ3JNG7,EGJ&F:GI]Y\0H;NPU"PNX9K6]LKJ&*YM;F*2">..6-E
M !]WT5\ ?\/8O^"67_22S]@#_P 3(_9U_P#GC5HZ5_P5*_X)D:]?0Z7H?_!1
MC]A'6=3N!*;?3M*_:[_9^U&^G$,3SS&&TL_B%-<2B*&.2:4I&PCB1Y'PBL0
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M=C&SQI)<*\D:M\K>#_\ @O\ _P#!&KQQJR:+HO\ P4'^ ME>/J$>F+-XPO\
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MQI^IV5M=P,0)85)H ^TZ*^4/A#^WG^PU^T'XR@^'/P$_;._90^-_Q"N=/O\
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MZKJ5Y.Z0VMC8VL]U<2LL<,3NP!^H: "BBB@ HHKYU^./[8'[)7[,=]X?TO\
M:3_:C_9T_9[U/Q9:7U_X5T[XX_&WX:?">^\36.ES6]OJ=[X?M/'OB;0+C6;3
M3KB[M8+ZYTZ.YAM)KFWBN'C>:-6 /HJBOF[X(?ME?L@_M,ZOK?A_]F[]JO\
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M-M<:=H^HV.IWD<-E=V\\GSA_P]B_X)9?])+/V /_ !,C]G7_ .>-0!]_T5\
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M9'[.O_SQJ /O^BOE;X7_ +=?[$7QOU:UT#X+?MC_ +*WQ>UV]N&M++1?A?\
MM"_"/Q_JUW=HULKVMKIWA3Q?JUY<7"M>6:M#%"\BM=6P*@SQ;OJF@ HKR_XO
M?&_X+_L^>#9_B-\>_B]\+_@A\/;;4+#2;GQW\7O'_A3X:^#;?5=5D>+3-,G\
M4>,]6T71(M0U&6-X["RDOEN;R1'2WCD92!\H?\/8O^"67_22S]@#_P 3(_9U
M_P#GC4 ??]%? '_#V+_@EE_TDL_8 _\ $R/V=?\ YXU'_#V+_@EE_P!)+/V
M/_$R/V=?_GC4 ??]%>/_  F_:%^ 7Q\\#WWQ.^!7QQ^#_P :?AKIFH:GI.I?
M$+X3?$OP7\1O ^GZKHMI:W^LZ9?>+/!^M:SH%IJ&DV%[97NIV5QJ$=S86EW:
MW-U'%#<1._S!_P /8O\ @EE_TDL_8 _\3(_9U_\ GC4 ??\ 17P!_P /8O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!X7_ &D?#'[KS?L7_"KOVA/A3_PG=_P"\?V?X1:Y\1OWJ8V;_P!X1 9: /\
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MCW=WH^KVUS"^I::O^M7_ ,$/O^"DTO\ P5+_ ."?_P ._P!HKQ+9:5I7Q?\
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ME^+E '^NU1110 5_!K_P<V_\'#/Q,^#GQ \6?\$XOV%/&^H> O%_AJUAT_\
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M:&_\%?\ X5^";SQCX?T/]GGXXW.GZ5_:UWX)^#WQ=U&7QLL<<%U<7EC9Z?\
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MOC;X1\=^-KK0OC%H^MZQ!H&C7,DM[)IVDP:?%-J%TJ,/+MHY$:0\!A7]I?\
MP^M_X)'_ /21K]D#_P /AX)_^6E?4'[-W[:_[(_[87_"9_\ #+'[1OP?_: _
MX5W_ ,([_P )W_PJCQQHGC/_ (1+_A+O[=_X1C^WO[&NKG^S?[>_X1CQ#_9?
MVG9]L_L;4?)W?99=H!]/T444 ?GG_P %:/C</V=/^"9?[=GQACO!8:GX6_9A
M^+EGX9O"X00>-?%WA/4/!7@5\E'R3XQ\1:&HCVYE+",,A<.O^,C^S9^RQ^T-
M^V#\2/\ A4/[,GPE\6_&?XE_V!JGBD^#O!EI!>:NGAW1)+.+5=7D2YN+6".R
ML9=0L8II7F7$MW!&H9Y%4_Z=O_!WS\;?^%6_\$?_ !!X AO/(O/VC/V@/@S\
M*&MHWVW$^F>'K_6/C??R;5(D%G%<?"/3K:ZEQY0>^M;:4_Z6B2?PP?\ !"+_
M (*F?!3_ ()&?'CXY_M*?$GX.>//C9XZ\5_ \_!_X7>%?"6K>'?#>D6O_"0^
M//"?B[QAJ?B?Q5K;7]UH*K:^!M$L]+ET;PIXDN[LW>H6LZ:?:O)-. >8_P##
M@C_@LE_TCV_: _\ !/H?_P O:_MQ_P"#1[]A/]KS]A_X=_MOZ5^UG\ _'GP)
MU'XB>-/@9J'@FT\<VEE:2^)++PYH?Q-MM<N-.%E?7H>/39]7TR*Y,AC*M>0[
M0P)(\$^ ?_![C^SEXP\8:=HO[1O[$GQ0^!OA._U""RG\:?#GXO:'\>1HMM<-
M'&=6UCP[J/PZ^#.IMI]E([2W\6AR:YJHLHGET[3-3O#'I\G]EOP.^.7PC_:5
M^$_@?XY_ GQ]X>^)WPG^)&B0>(/!OC;PQ=_:]*U?3I7D@E0JZ17>GZGIM[!=
M:7K>B:I;66LZ#K-E?Z-K5A8:I8W=I" >KUY7\<?@K\-OVC?@_P#$KX#_ !A\
M,V?C#X8?%KP;KO@3QOX<OAB/4=!\06,MC=_9YU'G6&I6GF)?:1JMHT=_I&JV
MUEJFGSP7UG;S1^J44 ?XBO\ P4W_ &!?BK_P2Z_;7^)?[,?C6YU.9?"&JVWB
M_P"#WQ%BCETT_$'X5:U=W-Y\/OB#I4]L(4M]1:*SFTGQ!'I\C1:#XYT#Q'HD
M%S*VD^>_^HE_P;X_\%3K3_@J%^PEX8\0>-M<M;S]I[X"+H_PI_:/T\O&FHZQ
MKEKI[CP?\66M46-4L?BSH6GS:O=S6]O;:?%XXTSQSH^FV\5CH]ON\8_X.5/^
M"2*?\%)_V,[OXB_";PVE_P#M<?LM6&M^.OA,NGVV=8^)7@@P+>?$/X+.T2/+
M?7>NV%DGB/P#;-%/,OCS0]/T.SFTRP\8>(;M_P#/*_X(@_\ !3;Q!_P2N_;P
M\!?&;4[K5)/@=XW:+X5_M+>%;5+FX.H_"W7=1M3<^);32HPS7/BCX::Q#9>-
M-!2&%=0O4TS5O"L-S:V?BC4BX!_I._\ !PC_ ,%1[;_@F%^P5XM\1>"=<@L?
MVFOCT-4^$?[.5G&ZMJ.C:]J&G@>+_BLD(<.EI\*?#EX=9L+N2&ZLF\=ZAX%T
MC4;:6QUBX*_YA_\ P2@_X)V_$C_@JA^V]\.?V;O#EQJUEX8U&^E\>?'KXCQH
M]Y+X!^$&AZA9R^-O%,MS<1W$<OB+5I+ZT\,>$8KU9(=1\;>(]#AU!HM/>_O+
M;VO_ (+E_P#!3'7_ /@JO^WYXV^)WABXU:Z^!G@*XD^#_P"R_P"%1#>B5_AY
MI&JSQIXM;1F1)8_%'Q7U^6Z\7W\#6:ZK:6%_X=\(W4EXOA>RE/\ HJ?\&ZG_
M  26MO\ @F!^Q5INH?$G0+>U_:S_ &D+?0?B)\?+JX@B.J^";064DW@;X))<
MINVP_#K3]2O)?$J0R30W/Q!USQ6T%[?Z/::%)  ?(W_!TQ\*?A]\"O\ @@[9
M_!GX4>&-.\%_#3X7?%']FKP+X&\*Z2C)8:%X8\,W5[I6D:?"TC23SO%:6T9N
M+RZEGO;ZY::]O;BXNYYII/\ ./\ V%/V%/C]_P %%OC]IW[-7[-6G>%]4^)^
MJ>%_$OB^TM/%_B6V\)Z,VC>$[:&[U=WU>[AGA2X2&>,P0&/=.V54@BO]+/\
MX.\O^4-OC3_LX#X$_P#I\U6OX=_^#;+]K7]G?]BG_@IWX5^.7[4/Q-TOX2?"
MFP^#GQ<\-WGC'6-+\1ZQ90:WXBTBPM]&L&LO"VC:[JS27TT4D<<B:>T$94F>
M6)2"0#Z+_P"(0[_@LE_T)7P _P##[:%_\K*/^(0[_@LE_P!"5\ /_#[:%_\
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M'U/Q!K^LZC,MOI^D:)HUE/J.JZG?7#_+!9V%C;3W=S,WRQ0Q.YX4T ?P!?\
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MH?LI:/\ &#XNZNK":/2]=\!^!YI_C.0^X>:NA^*O#/BZW+N8WD^Q$R)$Y9%
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M_P##??'#_P"=?1_Q$A?\$2O^C]_A_P#^&^^.'_SKZ /Q\_X-J/\ @B!^W?\
M\$O?VK/CQ\7/VK/#_P --(\'?$']GR7X<>'9_!/Q&T[QGJ$OB9_B/X'\3+%=
MV%E9V\EK9_V7H.H.;MV9!,L4.W=*"/[0:^2OV0/VZ_V3OV]_!'B;XC_LB?&7
M1?C5X*\&^*F\$^)=>T31?%NAV^E>*5TC3==;2)K?QAX?\.WTTPTG5].O?.M;
M6>UV72)]H\Y)8T^M: "O\[?_ (+'?\&V7_!3O]M;_@I9^U5^U#\#?"OP<O\
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MI\2;@ A8SXR$(5&B9%^3/^#L#_E"5^T;_P!E _9W_P#5X>"* /X@_P#@T_\
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M,\L2D$@'T7_Q"'?\%DO^A*^ '_A]M"_^5E'_ !"'?\%DO^A*^ '_ (?;0O\
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MK_P<<?&W_@JS_P %!/'WP*\8_L[>%?@Q\ IO@[XJ\2?"MO"Y\6^.O$^G>/\
MPSKGA^^&E?$KXF7,.E>%[E=9\#S^);S3(=/\'>$(X=0T9+4?VM+?P/;_ -=]
M?C9_P0C_ &W_ (@_M[?\$]?A=\7_ (H_L\ZM^S]XTTG=X-U-;;P*? GPM^+:
M:196;6_QA^"U@EEI]G)X%\7K.QNK73K7^S=#\56?B#0]+NM1TFQT_4;O]DZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!XZ^&WBJUVH_VGPWXY^(O@#PQKEOLD!C?SM,U2ZCVN"C;L,"":_I>_X/"_\
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M8EFU34O%'A3PGJEY\7?C#>:M=W#2RW5[K7A'PQXJFOKZZ,K/<W4ES<"4EU<
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M/$GCCX5W&H^'C;^*=4G ?5/$G@GQ1X4;5;RXOM>\3:3XGUZ[GOI?Y#/VF_\
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M=50S?M3_ ,&K'_*<;]D;_L7_ -I'_P!9E^+E '^NU1110!\.?\%.],U+6_\
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M:5X0\62>-_B'I_@N[AUG6=);6K)+&UO;2X:]MVL49I)T95CD_=D$G-?T;?\
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M(O?$]Q=P7VF?H[_P76_X+S_$;_@C;XZ^!GA32_V.=+^.GA;X[^#?$OB#P_\
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M (A_^EL5?[%?[,WPWOO@Y^S?^S[\(M3V?VE\*_@A\*/AOJ'ER>;']N\#^ ]
M\,7?ERAY!(GVC2Y-LGF2;UPV]L[C_CJ?\%T_^4P/_!1+_LY_XA_^EL5 '[O?
M\'.'[-W_ !@+_P $/OVOM+L/^;0/A9^S=XXU3RO^J,> _B?\++#SE'_98KCR
MI&_VX1_KS7%?L?\ _!3%_AW_ ,&J'[=?[/#Z\EK\0_"GQULOV8/A_9&ZP?\
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M%?/_ /P8Z?\ )5/^"B7_ &3_ /9Q_P#4C^+]?0'_  ?%_P#)*_\ @G;_ -E
M_:._]1SX05\__P#!CI_R53_@HE_V3_\ 9Q_]2/XOT ?TK_\ !R;^Q@?VT/\
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M_P":.@#\>?\ @W>_X)2?M#_\$DOV8_C;\%OVCO&?P7\:^*?B3\=Y?BAH5_\
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M]LGP;^S!^T[^RK^UK^SI\9_C7\,=:UOX*_$+P=\-?B9X5\3^,M8^%'BN"_\
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M)HOC/XI?#O7;.SOEA=T@U33DO?[/U:S+>;9:E:W=G,J302(H!_''_P &G_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6-"%_;W!C;3=;\+>'=:D@:X633FMXY7K_7WHH _R&?@E_P $ O\ @M[_ ,%
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M&/Q#UCPQX7>2">*:)=6,L;JR!A_.=_P0G_X.&?VG?^"@G[7GB7]D3]NCX2_
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M5LO^$"^&.K:'X[\1?8O#>J:UJ_V;P[JMG<VW]G?VA<N]A:7<,@!]OT5\(?\
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MQ,FN[BVF\+Z>NFOID^D1PQS7@NHKQI(7MP#^E6BBOX;O^"CG_!TY^U%^RO\
M\%!?CC\'OV?O@3\"OBC^QA^RS\9?A;\&/CG\2=?\(_$S6/B2?%VH)>O\4O#^
MB^)] ^+OAGP5X;UF'5?"?Q+\%>"&USP3K%FGB#P/>7^J?VK;W,6E@ _N1HKE
M_!'C3PO\2/!?A#XB>!]:L_$?@KQ[X7T#QIX0\0Z<[2:?KWA?Q3I-IKGA_6K%
MV5&>SU32;ZTOK9V16:&="54D@><?M)?M%?"3]DKX$_%#]I#X[>*(O!OPF^$/
MA:[\6^,]?>WGO9X+&"6"TLM/TS3[97NM5UW7=6N]/T'P]H]HCW>KZ[J>G:9:
MJUQ=Q@@'M]%?PMZ#_P %R_\ @X!_X*=ZKXL\5?\ !(S_ ()U^$?#O[.&BZ]>
MZ/X?^)/Q4M_#MYK>NR:7(JW%O=?$KXK_ !-^%OP3NM<\J-9];\&^#=,\2ZAX
M2DU*'2[OQ'JDAL=5O8O$G_!=?_@OQ_P2_P!5\'^(?^"NG_!.KP9K_P"S[XAU
MVVT;4_B1\+QH&FZUIMUJ)FDAL;7XE_"KXE?%CX(PZ^MJ)KK1?!7BG2O#.J^*
M$TJ[L[?7K QW^JV0!_=317A/[,G[2/PD_:^^ 7PL_:6^!/B/_A*_A/\ &'PK
M:^+/!^L26SV-Y]FDFN+#4M)U?3Y2TNF>(/#FMV6I>'?$>E2.\FEZ[I6HZ>\D
MC6Q=OXKM$_X.$O\ @O-^T7^V3^UQ^RY^PO\ L3?L9_'N3]FCXJ_%?PY-:S>#
M_B=IWB:T^'W@GXIZS\.] U_Q%J.O?M>>!M#U#4[UK/3H]2?1;*TCEU"XFGMM
M)L;,K%" ?WCT5_$AXD_X*Q_\'9OP[>74?&O_  1O^!VNZ/IMJ+_4;'X;_"7X
MS>-=9NK:0O#'%I1\!_M:?$.>YODGV22V-EH>JWZVZLSV<4<BW"?HS_P1_P#^
M#D'X*?\ !2/XGW_[*_QN^%&I?LA_MBZ:NJQZ7\-O$WB!]6\)_$F[\.*P\2:/
MX.U?6M'\+>(-%^(&C"WO[_4OAAXDT,ZK!I%E=W>D:]XD?3-<CTD _I6HHK\F
M_P#@M9_P4BF_X)8_L"_$7]I[PWIOA#Q%\69?$?@_X:_ _P (>.X-6N_"?BKX
ME^+]3>?[)KEGH.M^&]:O-,T'P/HWC7QG?6>F:[I-W>VWAF2RBU"T>X$Z 'ZR
M45_-3_P0'_X+7?'3_@ICXJ_:M_9^_;-^&GPM^"G[5?[..M:-J\/@/X9^&_''
M@^RU3X=7L\OACQ%)?Z#X]\?_ !(UD^(/ OCFTM;/Q!J,&MV>E7&G^./!\=AI
MK2Q7M]=?TK4 %%?D9_P5N_X+)?LQ_P#!(GX1Z7XO^+D>H?$/XP^/[?51\&/V
M?O"=_!I_BKX@W.D-;0ZAJVKZ[<6>HV'@3P'I%S?6<.M>,-3L-1G#3/:^&O#_
M (IU>"72E_G>\ ?\%*?^#L+]NC1K;XQ_LF_L _!7X/\ P-\46Q\1_#ZX\=:5
MX3\-:CKGAEK.6723%JO[0/QC\)ZMXOMO$.8Y]+\4>'_ >@:!J<<UC?VDUEHT
MLEW( ?W*45_$UX"_X.4OV_OV$_CIX3^ _P#P75_8%7X$>'_&6K/8:;\?O@[I
M&O6VBZ9I\,D46H:]:Z3#XG^*_@3XUZ/H5S?6)\2WGPC^(]IJ?A_2666W\,>)
M=8EM=-U#^S;X?^/_  5\5O W@_XF_#?Q/HWC7X?_ ! \-:+XQ\%>+_#M[%J.
MA>)O"_B+3[?5=$UO2;Z$M%=6&I:==6]U;2J1NCE7<JL&4 '7T455OKZRTRRO
M-2U*\M=/T[3[6XOK^_OKB*TLK&RM(GN+J\O+JX>."VM;:".2:XN)I$BAB1Y)
M'5%9@ 6J*_C0_:-_X.9?VC_VD?V@O$_[)G_!"W]C6Z_;$\5^&9&L]8_:#\6Z
M/XFU7X<@I>M87>O:-X4TN_\ !5CH7@-+B,V>C?%#XI?$;PGH.L:E*BV_AJXT
M[^SKS6_./&?[>G_!WA^R=X=U#XX_'K]@']GWXM?"31 /$/CCPOX(L? _C?Q)
MX5\.PR7EQJ]E8Z7\!/V@=?\ 'MNFFZ5!+=S^*/\ A'/B!H>@VL5MJ&N7%W%'
M?6TP!_;M17X]_P#!'_\ X+-?LY_\%>_@_K?BOX;Z?=?"_P"-?PZ:R@^,?[/_
M (CUJVUOQ!X-74WG31O$WAW7H+'2(O&W@'7&MY[>Q\26^D:3=V.IVUQI6OZ)
MI%RVFOJ?["4 %%%% !1110 4444 %%%% !1110 4444 %%%% !117X8_\$8O
MVX_^"EW[9>J_M=VO_!0[]C__ (93L?A'XP^'VC_ 6Y_X9_\ C[\#/^%G:!X@
MN?B?'XJU3SOCAXM\40^-/[$A\,>#)/MO@Q=-LM-_X2'=J44RZMI0MP#]SJ*_
M'[]C+_@L'\)OVYOV^/VQ/V*/@_\ #KQ=I^G_ +%UCJ6C^/OBIXNNK+34\7?$
MG0_B1?\ PY\2>'_"'A&U2\NHO"N@ZEH^I"'Q5K6JVE_X@N"!;>&=-T^V@U'5
M_P!@: "BBB@ HHKQS]HKXAZU\(_V??CK\5_#=KI=[XB^&/P<^)WQ#T"RUR"[
MN=%N]:\%^"=;\2:7:ZO;6%[IM]<:7<7VFP1:A!9:CI]W+:/-';7MK,R3Q@'L
M=%?S\_\ !N]_P5;_ &A_^"MO[,?QM^-/[1W@SX+^"O%/PV^.\OPOT*P^"7AW
MQQX<T"[T!/A]X,\5B\U:U\=_$7XDZC/K!U'Q%>PFXL]5L++[%%:QC3Q.DUS/
M_0-0 4444 %%%?S\_P#!Q#_P5;_:'_X))?LQ_!+XT_LX^#/@OXU\4_$GX[Q?
M"_7;#XV^'?''B/0+30'^'WC/Q6;S2;7P)\1?AMJ,&L#4?#ME"+B\U6_LOL4M
MU&=/,[PW, !_0-17!_"SQ1J'CCX8_#CQKJT-G;ZKXO\  ?A#Q1J=OIT<\6GP
M:AX@\/:=JUY#8Q7-Q=W,5G%<W<B6T=Q=W,Z0*BRW$T@:1N\H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-Y<?';]G:SGNXE6.YFLX_P!L_P"'HCM9IT EDMD%_?!('=HE%Y=A4'VB;?\
M7O\ P>4>,?%/AG_@DGX4T3P^UPFD?$3]L/X.^#_'/DG$4GA>Q\!?&/Q_9Q78
M!R83XU\#^$)DR-GVF& E@_EJP!\T?"O_ (+2_P#!>K_@JIK/C?QQ_P $GOV"
MO@A\._V4_"NMMHND?%G]I>^>YU_Q)JVFFY-QI47B74_B3X%\%ZOJ-_"L#:YX
M9^'_ (*\9+X NI;:PU[XA9U#3KN^^B?V/_\ @X#_ &KOA9^VCX0_X)V_\%L?
MV3?#?[*'QQ^*6K:'H?P>^,WPQEN(?@UXIO\ Q%,VE^%EUO\ M?QU\0-)O-%\
M5ZY&F@6?Q$\ ^/\ 7M#L?&%['X:\1>$_":6>L7^D?N=_P2A^%?@?X+_\$SOV
M#/A]\.[#2;'PUI_[*'P-UPS:+#Y%CKOB/QK\/M"\;>-?&!7:F^^\;^,O$.O>
M+]4G*(;G4];NY_+C$@C7^<;_ (/7OAOX,N_V$?V5?C5+;:9;?$[P/^UQIOP^
M\,:Z(?+\0+X1^('PC^*?B?Q3I>GW\"&YCM#KOPR\&:I-'(\=K'/80RI/%>/;
MPW8!^PW_  7V_P""DOQS_P""5W[#.D_M-?L^>%/A/XQ\>7_QW\ ?"^;2?C+H
M7B_Q#X170/%7AWQWJ^H7D=AX)\=?#S61K$-SX7L$LKAM?>RC@FO%GT^XDDAE
MM_Q^L?\ @LA_P75_X*2^'G\9_P#!'W]@KX<K\ O#&EV6AZW^T;\=9M#\-1_%
M?XF:5I4<7C9/@[H?Q0^*W@'1;7P?:^*TU;1-+M'C^(^H6*:=92>-?$_A+6+R
M]\-6#/\ @YV\<:W\3?\ @WK_ &2/B3XE2:/Q'\0?B%^QQXXU]+EF>X36_%GP
M%\>:]JJ3N_SM,M]?SB5F^9G#%N2:_HC_ ."0G@'0/AG_ ,$L/^"=_A+PW8V=
MAI\?[&W[/'B*ZCL;2"Q@NO$/C?X8>&_&_B[5FM[=$3[5KGBOQ%K6M7T[[[B[
MOK^XNKJ:>ZFFFD /Q'_X))?\%]_VI_C5^W5XC_X)=?\ !4K]G'PC^SK^UI;V
M_B%?!.L>"[75_#&DZUXB\,>'V\977@KQ+X6U[Q1XVLIKS7_!%OJ7B[P7X]\&
M^,;OPGXLTZRMK;2M)D35M+U6\_6W_@L%_P %:/@W_P $B?V:+;XT_$'0+OXC
M?$;QYK=UX+^!_P '-*U:VT34/'_B^UTV35-0O-5UB>"_D\.^!/"UF+6X\7>)
MX-(UB;3Y=4T+2;33;O5-?TV"3^;O_@IW9VMA_P '>_\ P2VNK*WBM+C5?A3\
M"[S4Y[=!%+?W7_"9_M+:1]HNG3#32G2["RT\O(239VL%N<QQJHJ_\%\88OC'
M_P '(7_!%O\ 9X^*5LNH_ ^UM?@#XGA\/:[!!>>&?$.O^.OVH?&]GXRTB2T)
MDBN;?Q99_"[X>>%M9L[O8US;K!%+;?9)8)KH ]U^'_[>W_!VGXR^'0_:QTO_
M ()V?LM:C\']7TN7Q;H7[/NM6-[X9^,NH> [@W.I0:AI'A#4/CYIOQ,3Q)!I
M,*166BZ[8P^*M>DEM)M&^&NJS:A:6LG=_P#!-'_@Y)^-?_!1[_@J[X1_9 T/
MX#^ OA'^SSKOPD\3Z]XDT?QMX;\:']HSP3\6? 'PW&J>//"5YXLC^(D/@?4?
M#VF_$6RUC3M*NKCX3Z#KMYX72Q&K:;H6OF]M[;^P"OX0_@1\-O!?PM_X/5_C
MWH?@6UTO3-*\0?#WQ5\1M5TC2H/(33_&/Q._9(\"^/?'-Q>H$2-M2\2^+O$&
ML^-+R6,$2OXE$DC-.TQ(!_=Y7\S_ /P=B?M9>*_V8O\ @DKXO\+^!=2U#1O$
MW[5/Q6\%_LVSZQI-[)8ZEI7@G7-&\6_$/XALDT4D3MI_B7PI\.;[X=ZS OF&
MXTOQQ=0-'Y<DDL7],%?Q]_\ !Z1\-==\4_\ !-/X(?$+1[*[O;'X6_M=>$)O
M%+6[2&#2?#WC/X9?%'P[#K-]&'6'R%\5?\(QH44SH\T=WK]O%"5CN+@D _3S
M_@W<_8?^'_[%?_!+/]F=M!\/:?:_$S]HWX:^"_VC_C/XL-A:P^(_$GB+XK:!
M;>,?#.A:Q?QQBYET_P"'?@[7M)\'Z-ICS-9V,MEJ^I0PQZCKNL7%W^Y%?!G_
M  2T^).@_%W_ ()L_L&_$+PW/#/INO?LD? %)4@6)$L=9T7X9^'- \2Z.R0(
MD"3:'XCTO5=&N$@184N+"58@(PM?>= 'X5?LJ_\ !"'X'_L>_P#!3?XW_P#!
M2#X+?&/XA^#4^,Z>,X+S]FCPKH'A+P]\([.P^(MII.H^,=&U6=+2_P!5U70F
M^(^EQ_$CPMI6AQ^#K?POJEMI&CQG4='TR6#4,;_@M5_P6XTS_@EVWP:^"'P>
M^#=Y^TU^VO\ M*7"P?![X*V-WJ,-CI^F7FLIX4T7Q/XHL] M+_Q3KTGBCQC*
M?#/@;P7X<MK34?&>IZ7XCA7Q!H7]BJU_^DEU_P %"OV*[#]K&?\ 87U+]HSX
M>:5^UI!;:)<I\$=7O-0TGQ5?GQ'X97QGHUEH]QJ.GVNA:[J][X4>/Q -$T;5
M[_6(-+EAN[FQACFB+_E'_P %E?V[/^"17_!.KXR?!+]HG]JWX"^&?CM^WIHV
MCV^H_L\:3X#\&>&M<^/>C>'_  ]J.NV^@ZUJOBW5;_2H/!'@&T\1^)_$:^'K
MK7[N^GOM:?Q!>^"/#7B#5?#NJ'3 #X2\<?M*?\'AMIX6/QIL?V+?V(-,TK3M
M-N=8N?@)X5ETOQ1XVETQ;2WO56[TNX_:+U?6]8URW@BDB&A^$_&Z:W>ZA/=V
MEKX?DG-A9V_Z2_\ !"+_ (+51?\ !7+X7?%?2_B1\,-+^"7[4'[.NL:!HWQ>
M^'^C7^IR^'=8L/$B:M!I7C3PGI?B,'Q/X>LSK7A[Q#H&O>$=9OO$-_X4U&PL
M!>^([\:Y9I%^<^G?\%YO^"UG[330VG[%W_! KXLZ#::NB#PSX_\ VD?$7CG2
M/!&JI<,\%MJ4FH^)O _[/7@Z.R6XEMS<+;?$V[MHH;>ZDEU:%'>2Q^"?^#37
M4?B3J?\ P5*_X*[7_P 8-$\/>%OBQJ?]OZC\5/"W@YB?!_A_XDW'[1/BR;QI
MHGA@?VKK@;P]HOB2XU?3M!8ZUK!&EQ08U6_#-=S 'YZ_MZ?$W_@L;J/_  <%
M_L;^,?BS^SM^RWH'[?F@>%_ EG^S#\*/#6MWTWP6\;^ [/QS\<'\ :K\0M1?
MXZ:U<VFLZM>W?C:/6HXOB5X16.+3-(*Z;IOF-)J']K/C_P#X*7_&G_@GO_P2
MO7]M#_@K1\,?AUX"_:8TG4]?\+ZA\"/V>M8CE\,^-?'NM>-O%%A\'_!7@;5M
M6\=_$Z.WN=?\!Z;IGBWQEJD_BSQ /#NEZ?XPUN+2I3I">&S^!_\ P5&_Y6\/
M^"4W_9(/@7_ZL3]J*OZ7_P#@KAXU_P"";7PT_9'U?XB?\%1/!GPX^(/P!\(>
M)].OO#7A#QSX3M/&VOZ[\3]0TO6M"T'3?A7X;=XM5O/B'=Z-JOB&&UNM%NM/
MET;0&U_7=6U71_#NEZOJUB ?@=\,O^"@G_!TW^WE\*M(_:"_95_8<_8\^ /P
M-\;6?_"6?"F;XI:O,_Q&\=^$KBYAO-&N+8>//BQIB7NDZYI@B&D>)K_X9_#[
M2_$FFW,OB#0KM=-O]&O(?8O^"7'_  7K_:^\??M^7O\ P2Q_X*O_ +,O@O\
M9U_:FU"UUAOA_P"*O HU3P[X?US6=(\,R^,K3POK?A_6/%'CW1M57Q?X4LM5
MUKP9\0O!'CF3PSKT]E9Z#8Z#-=ZI!J \9\$?\'+'[5OQS\.:-X>_X)C_ /!"
MO]IWXN_"G2[6W\)_#SXAZW/XFTOX=Z3H6AQ-H/A[3KNQ^'GPH\2^ M$M;"&Q
M@M9++_A=$%GID>G7&G1WLRQM>VWX]S_%;]O;XQ?\'/'_  37\??\%$?V?/AU
M^R_\=M67X4IH/PL^&NK0ZQ#9?"9KGXP-X0U+Q=J-K\0/B*DOC/49[GQ!:ZQ
M^K:3<6^FVFE65[X7T2ZBN+9P#]&_^#SO_D:O^"1'_98/V@?_ $X_LQ5^[G_!
M?+]OK]LK_@FA^QEI'[6?[(_@3X&_$.U\*_%+PUX4^-6D_&SPE\0?$]EH7@?Q
MO#>:-X=\7Z))X!^)_P -)M/:S\?'PYX8U)-3GU:*\/B_3I+:.R:QG:Z_"/\
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MW'@GX_\ [1WQ]N9H?#.G>+['7-:\,W_]A1W/CWX?:%HV@#Q/X9\3Z#X<,O\
MPGWB;XA0>'=:\2^'/#UCX>TZ>^KPOQ9_P70_X+)?\$JOB_\ "'P[_P %IOV/
M/@QJ'[-WQ8UN/PU9?'_]G*:5=5T^XLUM(=<U>*ZT?QUXS\(:UJ>DV6_Q)-\.
M-9\+_#;Q+KEC_:EYX=U%K&R%G:_/7QC_ ."??_!<;_@BQ^W1^UA^US_P2D\"
M>'/VG?V8OVG?'^L_$?Q1\([71X?'EW!8ZMXI\2^,]$\">./A OB3PO\ %35M
M1^'>I>*O$VA^$?&/P>\0ZCJFI^&;\2ZS?Z5?:WJ.@V_?>!/^#I#X _$[QKX)
M_9S_ ."U_P#P3!E^#FHZ)XKTS6%\1^-OAN/B;X3^'WBZ:UU'PS'\0=5^ _QM
M\"V/Q!\!6VD:/KOB+3KS7O">H?$/Q=#HNI:OIVGZ5>Q7U[:S 'T?_P ':?Q'
M_;JU#]A;Q7H_P<^&_P #/%O_  3=\:> O@CXF^.7QNU#5YG^,.@_$*?]H#PU
M?_#VP^'=K!\2]+LM0\):[<P?#@WUX?AGXIS9:WK$L>M6(1)M,]8_X-E_B)_P
M5=UC]F_]FWP1\>O@/^S=X5_X)QZ-^R_J,_[/OQB\&:Q>7'QV\6^)+?QIHL7A
M2R\;:7)\9O$EK;6%_HUYX]N=2>+X6>&2EWI6C*MW9"1H-2]R_P"#FKQ!X*\6
M?\$ /VAO%7PVU/P_K?PZ\2V?[)GB#P#K/A.:RN/"NK^"M9_:"^"^H^%M3\,W
M&F_\2Z?P_?Z%<V%WHTUA_H4NG2VSVO[AHZ^R_P#@@/\ \H;/^">W_9 -(_\
M3[KU 'Z_U^8'_!:W_E$?_P %&O\ LT#XX?\ J$ZI7Z?U^8'_  6M_P"41_\
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MQ=H4'QR^*.L^(IO!]WX!\2Z-JD_Q U/X>^(/"FKQVNH7VIZ5?>)]/\;Z??\
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M)-,\GSY-5_(O_@[C_P"3T/\ @A]_V5_XH?\ JUOV4*_=_P#X.0O^4)7[>_\
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MWQ)^)_Q%\=W&E3W5K<PZAYWQ#UK0&^WB281/)\/$0K(T7[K]_?B[_P %,_\
M@X-^-OPI^)?P:\>_\$!H=5\$?%?P#XO^''B[3;CQ'XBN8KWPWXUT#4/#FM6S
MV]WJ<UM+YNG:E<*JSPR1%BI=& Q0!_5=^R!^UC\&_P!N+]F_X4_M3? 36KG6
MOAA\7/#B:[HHU*&VM-?T*^M[FXTSQ!X2\5:?9WNHVVF>*_"6O66H^'O$5A;:
MA?VD&JZ=<_8-0U"P>UOKCZ4K^57_ (-//V8?VSOV.OV1OVD/@;^U[\#?B'\$
M3_PT':?$CX::;X_2VB;5M/\ %_P^\/:#XH_L."VU"_C@LK'4/ ^G3W4:^0C7
MNK2SA'EFF<_U54 ?Q1?\'N/_ "9?^QO_ -G/Z]_ZJGQ+7YH>,/"OQ$_X-CO^
M"CW[-W[:/PLTOQ)K7_!-[]NCX?\ @JT^*?@[33/J5MH$>N:'H>N_$CX?)'+(
M(?\ A,/AEK5\_P 6/@;/>R6-UK/A.?5OAW#K%Q:VGCW49?TO_P"#W'_DR_\
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MT;3-=M=%L;'POX"USQ)H\4W^BWD5Q_HT_M,?MD_LK_L:^'-#\6_M3_'KX:?
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M/KU[IOA7XR?"B3PYI.N^(KFUL/(T[PCKGPWT#0O$5[MM+[7K&*X$! /ZZ_\
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M.YDDL(-$N-3O_$_QUU/1LW&G:CX]BNEU.SU.QU?55D_T*  H"J JJ %4
M8  '  '  X K_/W_ .#8J5_V>O\ @M[_ ,%8?V4_'JIHOC:^@^+R:5!KS06^
ML:Q=_"']HQK6XMM*FN9#/J;ZOX>\:MXMC73Y;I-4T+39-?C:XT^R^UI_H$T
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MQ0E8[BX) /T\_P"#=S]A_P"'_P"Q7_P2S_9G;0?#VGVOQ,_:-^&O@O\ :/\
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M]?@1_P $VOV7_'/[4_[0>HW\?A+PL]IHOAWPQH4=O<>+/B-X]UJ.Z/ACX?\
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M[X>U PV%_K'@G7+O3-;TZPN]7T70==TS6]!US0]8T>$V5CJ6K_D+_P /@O\
M@XY_Z0+?^75XI_\ EO7R?_P1*_9R_P""F/AC_@NC\?\ ]MC]H/\ 8$\>_LB_
M"/\ :W^'7QA_X61ID/DGX;^'/&GB34/!7Q!%RDS:BUW>7OB7Q[X/O]1AFN;%
M[B#4/%6I1B8I-/-* ?W75\P?MN_\F7_M=_\ 9L'Q]_\ 54^+*^GZ^8/VW?\
MDR_]KO\ [-@^/O\ ZJGQ90!_+#_P9+_\F"_M7_\ 9W]Q_P"J8^%U>!?LU?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPT?3[33+)992#+*MK90P0"20@&1Q&&<@%B2* /XEO^#A?_E/K_P;Y_\ 9?\
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M0_%7AW5(UAU/0/$FDV&N:+J,22),D5]I6IV]U8W<:31QRJEQ!(JR1I( &52
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M[L-0MH+RRNHB03%<6MRDD$\9(!*2QLI(!QD"@#\#?^#7'_E!1^PS_P!W,_\
MK8?[05?RL?\ !)/]K/X6?\&_7_!2K_@H)\)/^"I'P\^(7@SQ=\7-2L;3P)^T
MB/ 6L>,[D^'_  _XU\=>(+O6[)=+@N_$.N_#WXZVGB/PUXH?Q'X,L]<9=?\
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M_AKX \+^%]3E6?4O#?AWP;X=T30=0G5UD6:^T?3=.MM/NY5D5762XMY'#JK
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MUO!'9M'=^;)]I0PE9_,?S0^]L@'\G7_!F%_RB@^*'_9[_P 7/_5/_L]UY_\
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M_A/[!444 ?Q1?\'N/_)E_P"QO_V<_KW_ *JGQ+7]?O[/7_) ?@=_V1_X9_\
MJ%Z)7HNN>&?#GB:"&V\2>']$\0VUM*9[>WUS2K#5H()RAC,T,5_;W$<4IC9D
M,B*KE"5)VDBMB...&..**-(HHD6.**-52..-%"I'&B@*B(H"JJ@*J@    4
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M7D9AN[#4+:"\LKJ(D$Q7%K<I)!/&2 2DL;*2 <9 JIHOA_0?#=H]AX=T32-
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M7WPZO?$'@SQGX'\6:GXCEUD6NJWVI^'X?T[^/'_!YI^PAHW@::W_ &5O@/\
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MOB2X\/R:ROEW-I:W$>+T;)[:WE7$D,;+[I0 5\P?MN_\F7_M=_\ 9L'Q]_\
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M.7;(!_%3\<_^"Q_[=W_!:']M+X&_LP_\$+=2^-/P1^!OP\UN75/V@?VLM?\
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MF_XG^!/&LFA_8(_&7B1?/\-OH]S=?VEF\FN&L[ VH!_3?\+O@]\)/@=X5M_
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M7/#FW0_%OB"Q\_PGJ>A7)_M#[2TQO+2RN+8 _JVHHHH **** "BBB@ HHHH
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MBMOXBU+PK_:B"& 92&5@"K @@@C(((X((Y!'!% "T45_+#_P=-_\%'OVSO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GO
MQ;TOXB:Y\*?B;HGPA\3:;X*^+&L?#WQII?PP\8ZS8VVIZ1X2^(FH>&]2M/!7
MB;5=-O-+UNTU#3=!\2S:9JE]8W6BZO;7=K:2P3Z7J$4C6DW^9+\)?@1_P6*O
M_P#@XR^/7PC\'?MN_!?1/^"E^E^ 9KKX@_M57OPO\&W7PO\ $OAT? ?X6ZH^
MF:=X"F^!E]X8LKEOA]>^$_#8GM_A-ID@U'1KR]^U"XN9M3O?]1ROX8OV=?\
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M]0G5*_3^OS _X+6_\HC_ /@HU_V:!\</_4)U2@#^<O\ X-;O^"D'[!'[+?\
MP2ZM_A=^T9^U]^S_ /!/XBK^T-\7/$3>"OB3\2_#7A3Q(-"U>T\'II>K'2M5
MOK>Z%A?M9W2VMSY?ES&WE",=C8_H3\5_\%T_^"0'@WP[J_B?5/\ @H?^S#?Z
M?HME-?W5GX4^(VG>-_$5S%"I9H=(\*>#EUSQ-KEZ_P!V&PT?2;Z\F8@1PMR1
M_*!_P;H?\$)O^";7_!0W_@G5!^T+^U/\(/%?C;XI/\<OB?X(;6]'^+?Q+\%V
M9\.^&;;PM)I%I_8OA3Q+I6E"6W?5+PR78M?M,_F*)I'$:;>%_P""V_\ P;<?
M#O\ X)Y>#=,_X*$?L!^#;OXK_"#X+ZW8>)/V@OV5/CA)JOQ3\,:5X.@GCC?Q
MGI5W976@>-]?^&6FOY4/Q*\.ZMXCO_$6AZ9>7'C2R\66?AW2M7BT( V_^"87
MB?7/^"OG_!S]\0?^"G?P(^&OBKP5^RW\%[?5]<UWQ7KMD-(O;ZVL?V9[G]F?
MX<6&N75F;_2U\>?$B^EA\8W/A&*^GN+'P-I>NVEQ>7#Z0UY=_L3_ ,'-G_!2
MC]M7_@GMK_\ P3FLOV0/C1_PJ*U^/'Q(^,.@?%>+_A7/PG\??\)5I/A:]^!,
M.@VF_P")_@3QK)H?V"/QEXD7S_#;Z/<W7]I9O)KAK.P-K^CO_!"K]MG]C7]M
M;]A3P5XD_9 ^%7PU_9SA\ R0^%_C+^S/\-_#VA>%-.^$'Q1N+1;G56BTK0['
M3H=8\/\ C?R9?$GA;QU-;27GBRPDN%UVY3QAH_BC2]+_ )]?^#T:=+'6O^"2
MNJ7 D6QT_P"+7[0L]W<+$\B1)'=_LTW!!V*<R-#;3O'$/GE$,FQ6V-@ _NBK
M^4G]FG_@I1^VM\0/^#FC]K/_ ()\>+OC1_:_[(/PS^''B+7O!'PB_P"%<_":
MP_L35K'X:_!CQ!:W?_"?:9X$LOB?J7E:OXL\07?D:OXTO[9_M_V>2%[6ULH;
M;^K:OX8?V-B&_P"#S7]N\J01_P *A\7#(((ROP=_9W5AD=U8%2.H((/(H _0
M/_@LA_P5$_;KLOV\_P!G7_@CO_P2ND\ ^"_VK_CMX1_X6%XR^//Q)M= U70_
MAYX=DTSQMXABT/2;'Q)HGBS0].NM,\%_#WQ'XX\8ZWJG@KQ?J#Z)=^'-'\#:
M%?>*-0=8?BC]J'X0?\'2O_!-_P""WC/]LNU_X*2?"']KOP=\'M$G^)'QK^#U
M_P##?PW<_P#%&:)9V]UXRU#2--\0?"CP_+?>$O#.D:6VLZ\WA'QC\.O%,.D6
M^L:GH5DU_<ZE%=?>G_!<+_@A%\:_V\/CY\(/V]?V%/VAK']G3]M/X)^$]+\)
M6=QK.H^(?"&B^+-/\*:QX@\1>$->T?X@^![#4_$G@WQ]HTWB36O#\UW>:'KV
MC^*/#]UHNCZA<^'+'0)9-6_)C5O^"H7_  =(_P#!*K2;K6_V\_V/_#W[6?P'
M\&(MQXJ^+<7A3PWJ!L/">GLBMJUW\7OV8[P^'/!%HULJP2>)?C!\,;V_,K1W
M&LQ3:C.\ER ?TH_LS?\ !7/P]\5/^"06K_\ !4?XM_"O7OAW>?#3X0_$WQA\
M6_@_#%?:;?#QW\)CJUAJ'AGP9=>)X;9VTWXA:GI^ES^!;S4Y+A+.S\5Z39ZQ
M?SWEAJ,U?@3^R5J/_!RI_P %FOA6/VX?AG^WM\$/V%OV<_B+XD\6R? CX3>&
MO!FD:I?R67@3QIJOA:Y&H30?#/Q)XIG\.Q^)?#.I:)<ZKXX\>:OJGB&73=4N
MD\#V/A/4]-BU#^@/]D/]K[]E'_@O]_P3@^*SZ#I/B?PYX&^,'A+QY^S?\?OA
MMK$NG-XX^%/C'Q#X(LX_$%AI.LFTN-*U=]-T[Q7I7BGX=>/;;3$M;YAINH7.
MD:/K^F:SX<T?^8?PK_P2H_X.5O\ @C')KVA_\$T/V@/"7[4W[,J^(=4\1VGP
MHCN? C-<6MS<;[J[U;X,?'86]IX0U_55@M;K65^!7Q)OM9UB= 7U&X:2>V8
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M\9_A#<A_#_P!_P""K7@*]\>^#UE/V?1#\2_&\NH^/K2^;8%MSJ8^.G@SXO\
M@#0=/@W?9;3XF:4LD$4=U#,H!]=?\'6WQD\9>)_V=OV4O^"9GP:N!<?&7_@I
M#^TQX%^'\>E0RR2/)\/O _BGPO=R_P!H06C"XM+*\^*WB/X57!O;D"RDT?0O
M%"E9%M+B6T_)[]@_X+>#?V</^#O;Q;^S_P##VU%GX&^"G[.7AGX6^%(?+6*5
MM"\"_P#!/SX+>&]/N;H*SF2_O8-.2\U&XDDEGNKZ>XN;B::>:25_T0^"4?\
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MRV_B'P?X(\&:<; Z[XMGU+P_KNB:'\^Z_P"+_P#@[[_:7\+>*)]>\"_L._\
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MP5XJTKQ6D\23POX:U#0K^TUU9H9 T<T3:7-="2*1621"48%217\6'_!D)?\
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M"5XXI?#\7[,?Q9UFV2\1719[8>*M(\,R)%(LJ"\CM9P@DA22, \P_96\9_\
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M>^\0_8HCXF^%&J:E<&..W\-?%;3=.L])>6>YM;/2?%^F^#?$U].VGZ%>V=X
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M+,D<DD6L?#^Y\*ZU;S;/+D@U&)H7E@\N60 _>NOX@O\ @]Y_Y-9_8>_[+_\
M$3_U75O7]OM?Q!?\'O/_ ":S^P]_V7_XB?\ JNK>@#]=/@O_ ,'$_P#P1?\
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M]^'VJ)::SX*UKQUXELO@A\4-5N[CQ5X<DT[47'BWQ'86^I7=Q.;GX:> ]%U
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ME:-I$'AT?$/PM\./!OCKQNFA:1>W.B1ZAXRU&_N+^-%O[VTCU$EX_2?V _\
M@IG^W-X$_P""^/[6_P#P2F_;W^-I^*?@76+#QKKW['>HZG\-/A#X!U&"PTV.
MW^+O@&PCU/X:> O TOB<^)/@!J>MOXANM9N=>>S\6?#]K#3TMKBXUES\:_\
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M1"W6C7GBC5_VUOB-;ZG83:?.9+65-7DT+P+INJI+;^5>V<MM;W1G@B$<8!]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^ K_ (*5WO[8
M'_!*#_@XO\7_ /!4[PG^Q=\1_P!I_P" /QU^'7AG0=&A^'=IK]OI=Y(/V?/
M?P>\8:%>>,?"_@[Q[!X/\=Z-XE\ /XSM=)\1^'=WBK0;AOL,B1W-[K&D?WZT
M4 ?P5?\ !R?)^T+_ ,%%?V._^".G[0/PR_9)^/UEXA\::K\3?'_Q!^$&A?#K
MX@>/_%?P9O/$&D_"*.;P_P"-&TKP1I>IVB6NHZ9JEII^L:QX:\.1ZY;V+W]K
M80Q,8X_[U:** /XUOA+\"_C;9?\ !XQ^U!\<KSX._%2T^"FK_ SP_IVD_&"Y
M^'OBV#X6ZGJ$7[&?[/&A26.G?$"72$\)WMY'KFF:EHSVUMJ\LR:KI]]IS(+N
MTN(8_6O^#@G_ ()5_M:_$#]H+]G+_@K7_P $T--;6_VP?V58](7QG\.K&[4:
MY\1_"7@/5KSQ-X/U7PGH4\UC9^+M8TR'5?%?A+QMX$.H1:K\2/ VM6'AW0[?
M4-0TR/1M9_K/HH _C;M_^#KGXI:5X&B\%^+O^"/'[;%G^V$F@6L1^%-OX8\1
M:;X&U+Q2T-E9/>Q7FI^#9?BCI.@7FLW<;6NEGX=:[J-O#=66E'5[Z[F747]\
M_P"" _[%'_!3(?&W]H;_ (*6_P#!3OQ]\4?!WCO]HM_$'_"MOV2-;\8^+;/P
MYX&@\6:SI>LZIXZU[X4MXDO/#O@*?1]'TG3_ (??#+P3J]G<^*_#?A8Z[+XE
M@TW4I=*>;^JBB@ K\WO^"POA7Q/XX_X)9?\ !0#P?X*\.:]XO\6^)?V4OC+H
MWASPMX7T?4/$'B/7]7O_  =J4%CI6BZ)I-O=ZGJNI7D[I#:V-C:SW5Q*RQPQ
M.[ '](:* /YH?^#3WX4?%+X-?\$HK?P;\7_AKX_^%/B\?M(?&/53X5^)/@[Q
M%X&\2#3+ZT\%K9:D=#\3Z=I>J"PO&@G%K>&U^SW!AE$,CF-]O])6N:)HWB;1
M=7\-^(])TW7O#WB#2]0T37M"UFQMM3TC6M&U:TFL-4TG5=-O(YK/4--U&QN)
M[.^L;N&6VN[6:6">.2*1U.I10!_G:>$OV:_VNO\ @W/_ ."WE]XG_9V^!'[0
M7QU_X)S?M%/;GQ/9?"7X:?$+XK6^D_ OQAXAN'DT'6$\):1KXC^*/[-GB<7%
M_P"%'U1UU[Q;X)@6!+NSC^(VM_9OW%_X.BO^":WQO_X*,_L7?![XB?LJ>']7
M^(/QB_9D\<ZQ\1M)^'6CR?8O$7C?X:>./"]O#XQ3PAIUY]CN]3\>Z/>^'?!F
MMZ%X<C:'6-6L+;Q!I6CVE]XEN-(TF]_J&HH _BP^%?\ P=&_M<ZK\-?#?P3U
M+_@CS^UOX^_;_M?#.D^'-3\*:7X8\6:%X"\0^-ULVTR7QSJ6A'X?R_$#PGH>
MI:E;2^(+[PDV@R6NFP?;]&7QS;6MF?$,?RQ_P1?_ &3?^"A_PI_X.*?B]\9/
MVZ?A7XLM?B'\5/@!\1?BC\4OB1X=\%>(I/@CHWC_ .-FA?#+XBK\,/#WQ%M[
M.\\!WU]X!M];7P%<:5H'B?6[#3]4\+:GHNDZOKMII2:O>?W[44 ?QY_\%B_A
M9_P5/_8>_P""FWPJ_P""N'[%'A[XS?M@_L]0>&+70?CE^R1H/BWXA^)-&\)C
M3?",/@3Q6NF_#/2KGQ%_8GA;QUX1MM+\4:9XT\#^"=9B\%?$[P_JGBOQIX>N
M;6ZM_P#A(_./C=_P= _$;]HKX0>/_P!GG]D__@DU^VCXG_:D^)_@?7?A_:>$
MO&_@:XUKPIX/O_&WA^[TEM<U#2?"FBZWXH\8Z?I5KJ#ZFFCZIX>\$V&L6L/_
M !,=7TG3WGF7^U.B@#^1C_@E=_P0M_:;_9__ .")?[4?[*WCGXIZY^SM^V%^
MV1J%W\3M.U;P-XXUK2+SX"^(O#VG>%#\)_"6M^,OAQJZ7TTUUJ7A$/\ %6;P
MGJ=_9R^'O%NI^$8XM?ATN?\ M;XA_8<_X+:?MU?\$??@S:?L3?\ !5#_ ()V
M?M@>/+_X*WNMV'@+]H+P/8W7B^Y\5^$-4\0WMY8Z;K/B3Q&1X)\>V6C:MJ4^
ME^'OB#X8^)E[#>:'+H_AV\T&'4]#EU'6/[Q:* /X"]5\#_MI?\'(O_!4/]CG
M]IBZ_8P^)7[&7[!_['6M>'=;E^)GQDT^\T;Q?\1M+T'Q]I_Q$U?3= O=0TC0
M#XF\0>,=1\/Z7X5TC2O!=OXG\-?#2$ZQXDU[Q9=7NI0:1=_I+_P<$_\ !*O]
MK7X@?M!?LY?\%:_^":&FMK?[8/[*L>D+XS^'5C=J-<^(_A+P'JUYXF\'ZKX3
MT*>:QL_%VL:9#JOBOPEXV\"'4(M5^)'@;6K#P[H=OJ&H:9'HVL_UGT4 ?QMV
M_P#P=<_%+2O T7@OQ=_P1X_;8L_VPDT"UB/PIM_#'B+3? VI>*6ALK)[V*\U
M/P;+\4=)T"\UF[C:UTL_#K7=1MX;JRTHZO?7<RZB_OG_  0'_8H_X*9#XV_M
M#?\ !2W_ (*=^/OBCX.\=_M%OX@_X5M^R1K?C'Q;9^'/ T'BS6=+UG5/'6O?
M"EO$EYX=\!3Z/H^DZ?\ #[X9>"=7L[GQ7X;\+'79?$L&FZE+I3S?U444 ?Q=
M:1\!_CBG_!Y/XH^.C_!GXKI\$IOA1;V4/QB;X=^+U^%DMX/V#_#OATVD?Q".
MCCPD]R/$$4NA&!=7,HUF.32RGVU&@!_P=V_ ?XX_&OQ-_P $K)?@U\&?BO\
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MT6DGQ"&CGPDER?$$L6A"!M7$IUF2/2PGVUU@.E_P5X_8/_;A_8B_X*@^#/\
M@NC_ ,$U/@]??M"R3:'::3^UA^SUX>&KZOXH\0I%X5C^&^OZMIO@W0+>37M=
M\)^+_A_:>'?MC^$['Q)KO@GXC>&;;XDWWAS5M*>^?3_[,Z* /XJ_CK_P<K?M
M6?M/_"?Q5^S;^P=_P2G_ &TM#_;)^)&D7_P[-_XZ\'WEWX>^">H^*;-]-?Q=
M!_9FA+=:IJ>BV=X]_IMYX]LOAQX7T&[%MXB\1W%]HNFW>E:A]M_\$Z?^"2_C
M;_@F5_P0T_;"^"7C"TC\6?M1?M _ +]H[XE?%31/!MN?$4^F^-/$OP"U;PKX
M/^#?AJXT9[\^+YO"=EI]O8"YT9;JVUCQKK_B4^'Y-0TJYTNYN/Z>:* /YA/^
M#2;X2?%;X+_\$LO$'@_XQ?#+XA?";Q;+^U;\6]9C\+?$OP7XD\">(Y-(O?!W
MPI@L]531/%.FZ5J;Z;=SV=Y#;7RVIM9Y;6YCBE=X)0GV+_P7L_X)53_\%7_V
M(K_X5^!;S1]&_:%^%'B:#XJ? #6=?OIM,T"\\3VMC<Z3XB\"^(KZ*WN_LFB^
M.O#5Y=V$-ZUOY6F>*;+PMJUY-'IFGZA'-^VU% '\0_[-O_!Q'^VS^P1\(?#'
M[+7_  5 _P""87[8GB+X]?"&RL?A1X?^+?@3PY=7.G_&F?PY:V6C>&;G6-2U
MRS?P_P"(?$>I6-NAU/Q_\//%WCK2O'-T8_$&FZ5$VI3"N._9F_9'_P""A/\
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MZ9I?BJTTW4M!TBY+V$C+-I6OZ/J=G]HM[NX:U_#GP)X__;L^!W_!QQ_P4_\
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M^&FB7%GX+^,MO=P:OX[L]&F\+:;-:SWUC#<17NJPO!+>6L<JJ]Q"K_VQT44
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M\-?V'-:_88_8IO?'&A>)OBW\2?B&GC2Z\/:DGA[4X;FQF\0_$SQEX3^&EO\
M$.S\'M<V.OZ9\+OAAX*.O:KXHM],UC7;J+3+.RNM!_T,J* /Q@_;<_9*TG]G
MS_@A%^TG^QI^SYX9\4>+[+X9?L%>/?A#\/= T;2M0\1>-?&NI:9\.[S35NHM
M&TB"]O\ 5O%7B_63=:Q>66E6LAN=7U2XCL+5(C% G\<__!)+_@JQ_P %,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_\ ZMKQY7W97PG_ ,$T/^3)?@K_ -U'_P#5M>/*^[* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\1?^"BO_!P
M1_P3N_X)D?&/3O@!^T!XA^*7B?XNW'AG3?%^M>#_ (/^ K?Q?/X-T/7?.;P]
M)XLU36?$/A/0['4-=M[>:_L=$L=3U+6X-+-EJNJ:?I^G:QHEUJ0!^W5%?RA?
M\1DG_!(__H7/VO\ _P ,UX)_^>_1_P 1DG_!(_\ Z%S]K_\ \,UX)_\ GOT
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M )-E\"_]EV\,_P#JO_B?7ZQ5^3O_  6+_P"39? O_9=O#/\ ZK_XGT >[?\
M!-#_ ),E^"O_ '4?_P!6UX\K[LKX3_X)H?\ )DOP5_[J/_ZMKQY7W90 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7^8Y_P6:^$?P]^/O_  ==_#'X'_%KP_\
M\)9\+OB[\9_V OAO\0_"_P#:VN:%_P )#X+\9>%_A-H'B31O[:\,ZEHWB+2?
M[2TF_N[3^T=#U;3-5L_-\^POK6Y2.9/]..O\V3_@IS_RN)_LT_\ 9S__  3;
M_P#3?\&Z /ZG?^(7'_@A1_T8S_YLS^V'_P#1!4?\0N/_  0H_P"C&?\ S9G]
ML/\ ^B"J+_@H?_P<H_\ !,_]@(:[X0B^)8_:?^.NDFZL_P#A3W[/-]I/BR/2
M-8MR\+6/C[XF"Z_X5]X+-G>HUIK>EIJVO^.-(=)"_@FY=#$?G'_@@K_P7\^.
MO_!8#X__ +1GPQ\?_LEZ'\)OAY\-/ </Q&\(?$KP%K?BKQ)H7AYKGQ?I7AW2
M_A3\1]=US3X-+UCQYXFTO6+[Q)X9U;1[;PA%J.F^ ?&LH\)>4B2Z< ?SB_\
M!U1_P2D_8%_X)N> /V,=;_8N^ O_  IG4_BQXP^-6E>/[G_A:7QH^(G]OV'A
M+1?AQ=^'H/)^*_Q%\=6^E?V?<:]JTGFZ+%ILUW]KV7TERD%LL/\ ?9_P3*_Y
M1N?\$^?^S(/V4/\ U0W@&OY(O^#XO_DE?_!.W_LH'[1W_J.?""OZW?\ @F5_
MRC<_X)\_]F0?LH?^J&\ T ?;]%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5^3O_  6+_P"39? O_9=O#/\ ZK_XGU^L5?D[_P %B_\ DV7P+_V7;PS_
M .J_^)] 'NW_  30_P"3)?@K_P!U'_\ 5M>/*^[*^$_^":'_ "9+\%?^ZC_^
MK:\>5]V4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%5;Z^LM,LKS4M2O+73].T^UN+Z_O[
MZXBM+*QLK2)[BZO+RZN'C@MK6V@CDFN+B:1(H8D>21U168 %JJM]?66F65YJ
M6I7EKI^G:?:W%]?W]]<16EE8V5I$]Q=7EY=7#QP6UK;01R37%Q-(D4,2/)(Z
MHK,/Y?/^"D?_  =;?\$_?V,?[>^'_P"SQ=_\-M_'73_M-C_9WPNUVVL?@AX:
MU2/?%CQ1\:OLNJZ7KOV>0K+]@^&.E^.([AXI],U+6O#=U^^C_DJUSXP?\' /
M_!RYXQU#PIX,T[Q3;?LVG6_L>J>&_!0U'X)_L9^!5BG280>./%=_=W5S\3];
MT=7COAI&OZU\4/'EL'>X\.>'+:V=;9 #^N3_ (**?\'6?_!.O]C)]?\  GP+
MU&Y_;:^-VEFYLO[#^$&M6=C\&]$U6'<OD^)_CE/::KH5_$K@;A\,M'^(Q69)
M++4)=(G5WC_SG_VN_P!K/XY?\%<_^"@%U\<_'-K\*OAE\5OVAO%OPX^'>AVM
MAK__  KGX5^"K*SL=#^&WA!M<\:>.?$%W%H>D:;I=G97/C#QEX@URWT])!JV
MKM!I.FB+3+/^][_@G#_P:"_L:?LX)H?Q"_;@\1/^V1\6[46U\? L<.I>$?V=
M/#6HIME\A?#D5Q!XK^)YM)PT?VSQKJ&E^%]8M6V:A\-8FYKM_P#@J?\ \&I/
MP,_X*#_M!:1\>_@S^T-:_L8^7\/?"7@#7OAEX6_9ZT/Q_P##>:#P+8'0_#-_
MX+\/:)\3/@]:> 8X/#L6G:1?:+81:GI%TVF0:A:V^G7ESJ#7@!^1_P#P3R_X
M-UO^"1OPW_L+Q_\ \%&/^"G/[)?[0'BR$6U[<? OX/?M2?#7P-\&K*Y"*9M-
M\2?$!O&6D?$_Q[;+(=T<OA^+X3(DB>5<1ZM:LPD_L@^"?[1__!)K]F[P!I/P
MK^ '[17[ 'P:^'.AJ1IG@SX;_&S]G_PCH$,SJJSWTMAHWBJTCO=4O602ZCJU
M]]IU/4KDO=7]W<W,CRM_(Y_Q Q_]91?_ #2;_P#*XH_X@8_^LHO_ )I-_P#E
M<4 <S_P>;?M&_L]?';X9_L#6GP0^._P9^,EUX;\=?M W'B*V^%7Q0\$?$.XT
M&WU+P_\ "F+3I]:A\(ZYJ\FEPZA)9WD=E+?+ ET]K<I TC02A/[0_P#@F5_R
MC<_X)\_]F0?LH?\ JAO -?QYZ1_P8SZ3#JNG3:]_P4WU'4M$BO;:35M/TC]C
MJVT35;W3DF1KRUT[6+W]J#Q!::7>SP!X[:_N="UB"TF9)Y=-O40V\G]T7P:^
M%GA?X%_"#X4_!+P0MZO@OX._#;P-\+/""ZE<_;-17PO\/?#&E^$M 6_N]D?V
MJ]&DZ1:"ZN=B>?.))=B[L  ])HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OR=_X+%_\FR^!?\ LNWAG_U7_P 3Z_6*OR=_X+%_\FR^!?\ LNWAG_U7
M_P 3Z /=O^":'_)DOP5_[J/_ .K:\>5]V5\)_P#!-#_DR7X*_P#=1_\ U;7C
MRONR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\$T/^3)?@K_W4?\ ]6UX\K[LKX3_ .":'_)DOP5_[J/_ .K:\>5]V4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<WXR\7^&?A[
MX0\5>/O&FLV?AWP=X'\-ZYXO\6>(-19TT_0O#/AK3+K6M>UF^>-))$L]+TNR
MNKVY9(W=88'*HS *>)^!?QV^$/[3'PJ\)?'#X"^/M!^*'PE\=PZK<>$/'?AF
M6>?0]?AT37=4\,ZM)82W,%M.ZV.O:+JNES^9!&1=6,ZJ&4*S 'K5%%% !111
M0 4444 %%%% !1110 5^3O\ P6+_ .39? O_ &7;PS_ZK_XGU^L5?D[_ ,%B
M_P#DV7P+_P!EV\,_^J_^)] 'NW_!-#_DR7X*_P#=1_\ U;7CRONROA/_ ()H
M?\F2_!7_ +J/_P"K:\>5]V4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNC2^(]!^(WARVL[JWT[Q'::LFNW)MO%WAZ+VO_@L-_P3!_X*(?\ !)W]MO\
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MIJI\#:-KZ6GA.7Q;X*\!:;::S<26]A=ZGK^BQ6MS.UPJ/_*1^P3^SS_P=.?
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M!7CWQC^S;\9RX99%%A'JQ;PEI9F,<9W?\+ACVS(N_"(LU>5'_@H]_P '1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !117Y#_\%)/^"X'_  3_ /\ @F!I>H:9\=/BK#XN^-:Z?]LT3]G'X4-8
M>+_B_J+SP>=ITFOZ9'?6VC_#K1[Y2LT&M_$'5_#MO?VB7$F@0Z[=P?89 #]>
M*_G2_P""G_\ P<P?L _\$[6\0_#GPCKR?M9?M+Z2+FR;X1?![7M.E\*^$=:A
M9X39_%;XMQQ:MX9\(SVMQ#<6VI>'= M?&GCO2[R*.WUCPEI-O<QWZ?Q^_M-_
M\%IO^"RW_!>;XG:G^RO^P]\,?'WPQ^$WB)9K6[^"?[.5WJ,GB#4/"E[.UJ-2
M_:(_:#N8_#J:?X7G2633-7\^]^%_PLU""YBTK7=$UF],%S<?M)_P3"_X,YOA
M-\.!X=^+'_!3/QK;?&GQI$;?4[?]FWX7:MJ^D?"/1)P%G@M?B%\0(%T?Q?\
M$*[@8Q_;=%\+IX-\,6][;36=QJWCO0[DF8 _!/Q=\=/^"[G_  <V_$R\\!>!
M=%\0)^SYIVO0Q:CX(\"MJGPG_8\^& 66*YM+OXG>+]1N[L>/O%6F6DJ:G;6?
MB75?'GCUD-]/X"\(VEK/)IB_U=?\$O?^#3S]BS]CG_A'/BC^UQ)I?[:7[0.G
M_9]1CTWQ1HIMOV=?!.JI^\$>@?#+46N&^(=Q9%WMAKGQ0;4M)OS%;:MI_@#P
MMJ<49B_J(^'?PV^'GPA\%^'_ (;_  I\"^$/AK\/O"=A'I?A?P/X#\.:1X2\
M)>'M.B+,EEHWA[0K2PTK3;8.SR&*TM8D:1WD8-([,>UH KVEI:6%K;6%A;6]
ME8V5O#:6=G:0QVUK:6EM&L-O;6UO"J0P6\$*)%##$B1Q1HJ(JJH L444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S>;Y4OD>7Y_EOY/G;
MO*\W:?+\W9\_E[]N_9\VW.WG%244 ?P=P_\ !T1J_P"T%K'_  4!_86_;?\
M@1\-_P!CFZD_9:_;"^%'@W55\9^*-?NQ^T3X=\%>(_"^G_"WQ;JWB#2?#^F:
M8OB1X?$NFZ)J<VDZ6+SQ7;^']!"1W&MP*W\XO[;MA^P9#_P0^_X))WW@H?#.
M'_@H1=Z]\=!\58_ L>@#QS>_ N/XN_&^*SN_CDVB?\3'^UK;7(O 5I\+)/&(
M_M:?PP?%$6BN^B6.R+^XS_@MK_P;N?L??MX:%\</VPO"^A_%#X>_M?\ A_X2
M>-_%4)^",%EJ]G^T%XR\$^"+J[\%:#XU^&MUH6M7/B+Q9JDNAZ=X3TS5/ EQ
MX:\5:PM];VVK-XGN+31X+/X,_P""!?\ P;5?LMZ'\#OV=/VX?VV?A-\;]4_:
MCNY_%?B*\_9H_:&\.MX'\ ?"S7O"WQ(\4^'O!^I:_P#!W7O!^A^,M;U>XT+0
M-&\76%K\1-4U#PQ=1:W9ZC%X3N(DTV_(!]N_$W_@II\2_P#@AQ_P1?\ ^"7G
MCOXR_LP>,_CSKVJ? CX%?!3QQI/_  G4?PMO?A;XUMO@5I_B'PKX4\9W6I>"
M_&]S'?QZ=X?U?PI?YT^.6QU+PO>,R7<T\-J?O?\ 8J_X+D?L(_M8_L3:/^V/
MXP^-OP:_9Z.E>'-7U'XU?"7QQ\8?#=YXN^#?B+P_+=1ZKX:O8M0LO"?B+Q4+
MZ.W@O?!NHZ7X,M)O&]IJ>F)H6DR:G='3(_TB_:._9P^"?[6_P6\=_L]?M$>
M-(^)OP@^).E+I'BWPAK+WMM%>0P74&H6%]8:GI5U8:SH>MZ/J=I9ZKH>OZ)J
M&GZSHNJV=KJ.F7UK=V\4J_R-^./^#)?]BO6/&TVK^ _VN/VD?!/@2YU"YNY/
M!>K:%\.O&6KV5G/-)+%I>D>,CI?ASR;>R1TM[6XU?PYKE\T$2F]N;RY:2Y<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M**XB\'>$;'PYX.M[B*.\30SJ)GOIP#^%7XZ?\&]'_!0_P9^Q'^T[_P %/_\
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M/'7P5T3QM?1>(O$N@^(?$C_$W]K_ .)1E$/[SQ/K'B2X\0:%\,FN[(QK#?\
MC&\\8^,=->U;2M5^&^E 0W,0!RG[;O\ P<\?\%(?^"E7C\_LM_\ !+WX4?$?
MX$^%_&UW<Z'H5K\*]-O?'G[7'Q&T^<?9WGF\2>&K6^M_A59"-H[^Z'PWCBUO
MPUMFDN_BI>Z2)P/IO_@F[_P9Y?$WXE:IIWQS_P""K?Q1U7PJFMWY\3ZE^SM\
M-/%%MXE^)_B.^OK@W]X/C!\:!+K.B:'<ZA=F5M<TSP%)XPUG5+6^DFC^(7A?
M6XY$B_M4_8B_X)R_L9_\$[/A^OP\_9*^!OA/X9V]W:V\'BCQDMN^N?$[Q]-;
MD2?:_'?Q&UIKSQ9XD_TKS;NTTNZU)?#VB2SS0^'=&T>Q*6B?;M 'SY^S1^RA
M^S?^QO\ #+3/@Y^R_P#!KP+\%/ASI>R1/#_@K2$LI-4O4B6%M9\3ZW<O=>(?
M&'B*>)42\\2^*]6UG7[Y43[9J4^U<?0=%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7Y._\%B_^39? O\ V7;PS_ZK_P")]?K%7Y._\%B_^39? O\ V7;P
MS_ZK_P")] 'NW_!-#_DR7X*_]U'_ /5M>/*^[*^$_P#@FA_R9+\%?^ZC_P#J
MVO'E?=E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$W5U'!:I),G\*O[??_!X7^T/\<=;NO@A_P $L_@EJOPQ@\2ZB/#/A[XP>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0=?LEE=M,\0Z'<:?KFE3$7.FZA:W"I*OME% '\)G_!17_@S&^'OBDZ[\1/\
M@FG\7S\,]8<37T?[.WQXU/6/$/@*=E$DC:?X'^+MM;:QXU\-CRXT@T[2_'>D
M^.UO=0N"VH>-]!T]=T/XP_";_@J/_P %Z/\ @@!X[T'X&?M2^#OB!XG^$.G7
M T[1OA!^U#;ZEXY^'NKZ%IC&VGB^ WQ]T74=2EL[&PM Z:7;>"/&_B;P)HUP
M89=2\$WK1O9O_JHUYQ\6/@]\*/CQX$USX7?&SX;>!OBU\./$L'V?7O WQ%\+
MZ-XP\+:K&N?*:\T37K.^L))[=V\VTNO(%S9SA+BUFAG1)% /P,_X)U?\'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKJ.L7<NB:IJ^K7.HZ/;Z;>:+#IE_'K8!_9+17^:)_P /7O\ @\"_Z-@_:_\
M_%5^M?\ S@J/^'KW_!X%_P!&P?M?_P#BJ_6O_G!4 ?Z7=%?Y>'Q?_P""[?\
MP=&_LW^%K;XB?M#> ?C'\$? #:YI^@IXO^-7_!/73_A=X,O-=OXKN[L/#O\
MPDWB_P"#_AW36U34[73M0EMM-MM3CU*YMK.]FM%Q:RR1?WX?\$BOVQO'/[?W
M_!.3]EW]KGXFZ#X=\-_$+XN>$?$LGC+2_"4-[:^&O^$B\$?$3QC\-]3U+1++
M4;[4[W3]/URY\'OKD&FW&HW[Z:NH_8/MERMNLS@'Z/T444 %%4-4U72]#TZ]
MUC6M2L-'TC3;:6]U'5-4O+?3].T^S@0R3W=[?7<D-M:VT* O+//+'%&@+.Z@
M$U^*7[67_!Q7_P $B/V0FU72O%G[6/A7XM^-]+\Z-OA]^S=;3?'#7)[RW %S
MIDOB/PB\WPRT/5+:0_9[FP\5>/\ P_<6]TLMK*B3V]S'" ?MY17^>Q^U?_P>
MV>-=2:_T+]A[]CG0O#D+B2+3_B)^TWXEN_$VJ3"9S&CK\)OACJ&AZ=I=[;1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445_*5_P ',?\ P7)7_@GI\('_ &2_V9_%<</[:/QS\,R27_B/1[N-K[]G
M7X4:NMQ8W/CAY8B[V/Q*\7I'=Z7\-;0>3>:';KJ/Q!GELY-,\*0>(P#\K_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Y._P#!8O\ Y-E\"_\ 9=O#/_JO_B?7ZQ5^3O\ P6+_
M .39? O_ &7;PS_ZK_XGT >[?\$T/^3)?@K_ -U'_P#5M>/*^[*^$_\ @FA_
MR9+\%?\ NH__ *MKQY7W90 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%>.?M!_'SX5?LM_!/XF_M#?&_Q
M79>"OA3\(O"6I^,_&OB.^.X6FEZ;&!'9V%JI$^J:[K5_+::)X<T.R674M?\
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M*".*&&*,+'%%%&JI'&BJB(H50% %2T44 %%%% !1110 4444 %%%% !1110
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M_#IW_@EE_P!(T_V /_$-_P!G7_YW-'_#IW_@EE_TC3_8 _\ $-_V=?\ YW-
M'^>;_P %J_\ @Y3\$?\ !67]CS3/V6_#W[)?BKX)W^G_ !F\%?%5O&.L_%W2
M/'%G+;^$M"\9:/)HHT6Q\ ^&9EFOF\51SI>G462!;)XVMI3.KQ_VP?\ !M-I
MNH:5_P $0/V#;74[&[T^YE\)?%O4HH+VWEMII-/UG]HGXOZOI-\D<R([6FIZ
M5?66I6%P 8KNQN[:Z@>2":-V^U$_X)0?\$M(W62/_@FK^P$CHRNCI^QQ^SLK
MHZD,K*R_#D%64@%6!!! (.17W5HNBZ-X;TC3/#_AW2=,T'0=$L+32M&T31;"
MUTO2-(TRP@2VL=-TS3;&*"RL+"SMHX[>TL[6&*WMX(TBAC2-54 &G1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7Y._P#!8O\ Y-E\"_\ 9=O#/_JO_B?7
MZQ5^3O\ P6+_ .39? O_ &7;PS_ZK_XGT >[?\$T/^3)?@K_ -U'_P#5M>/*
M^[*^$_\ @FA_R9+\%?\ NH__ *MKQY7W90 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YF/_!Q1_P50^)G
M_!6#]L'P3_P2V_81&J_$'X-^"_BSIO@6.W\%7*SQ?M+_ +1QU"703J$-_%-'
M8W7PL^&MU/>Z9X;U"YN(O#-YJ$'B7XF:AJ%[X=M?!^K:-^[_ /P=/_\ !9\_
ML7_ V7]AC]G?Q9]C_:E_:.\)S_\ "P?$6AWC1ZM\$/@1K7VK3-0O8;RW8-I?
MC[XI+#?^'?#'EN-3T#PLGB+Q7&=(U*?P1J=WYK_P:E?\$6(_V9OA3IW_  4;
M_:2\(^1^T+\;_#+K\ /"NOV3"_\ @]\$O$%JI_X3*6SNX4;3/'WQ@T^07$,R
M*][H?PQGT^PCN[6Y\:^+M&M@#]S_ /@C1_P2L^&O_!)S]D'P[\%=!_LKQ)\9
M_&8T[QI^TA\5+.V(F\>?$J2R9#IFF75Q%#?+X \ P75SX:\ Z=-%: 6(U'Q+
M=Z?:^(O%7B)[G]:J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K\G?^"Q?_)LO@7_ ++MX9_]5_\ $^OUBK\G
M?^"Q?_)LO@7_ ++MX9_]5_\ $^@#W;_@FA_R9+\%?^ZC_P#JVO'E?=E?"?\
MP30_Y,E^"O\ W4?_ -6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#_/1_X+%_\ !?#]NW]JS]IS]J/_ ()M_P#!,CPOI^F_"'X6^#_C
MUX"^._C^U\+>&?%/CGXE>#OAMX-UVT_:4UN?4O']C=^%OAG\+?"FFZ=XO\/:
M7JNC6O\ PF&O+9V^OZ#XMM]6\3^'/#.G?G)_P2R_X+N_\% _^"1_@S]CSX>_
MM"^#(?B'_P $VOBGHOB3Q#\*]!O/"?A6S\4:7\,KGXR^,=$^)WC'X0>/_#$.
MG:MK7B;PI\2K7QK<ZEX$^*%]K+72R0Z=;KX3TGQ#X7\26_D7[=_AG]J__@A!
M_P %2?VV]6C^'4.M_"[]LCP/^UA\./ ?BOQ5I^K#PC\3OV>OVHFFU/4#X8\3
MV5T!%\0OA5JNJ>&H-?MIY+BXL?$_AI&U31I_#?B32[K4/Z)/^#<C_@K1_P $
ML-9_9 _8X_8 _:#U#PKX,_:L^#/_  L_PEX&U7X\_#GP^W@SQ%JGQ-^,'C+X
M@6^G?"OXL7JZ]I&@7FN:=KWAS2;K2?%5YX"U+Q#XFTR'1]'L]?ECT>6\ /[;
M="US1_$^B:-XE\/:C::QH'B'2M.US0]7L)EN+'5='U:TAO\ 3-1LIT)2>TOK
M*X@N;:9"5DAE1U.&%?S"_P#!RM_P7#\0_P#!,CX2>#_@-^RUXNTG2_VVOC4M
MGXDTW6YM%\.>+!\$?A#INJ217WCW4/#?BS2M?\,:EKWCG5M,N_!O@K2?$&B:
MEISV5MXS\0W$45SX?T>'4_W"_;\_;=^#G_!.C]DWXJ_M5_&:[CC\+_#C0]GA
MWPI:7=M9:W\1/'>I*UEX)^&WA2.57$FM>*-7\FT$L=O/!H>CQ:KXFU..+0]"
MU2ZM_P#,,^(G[*'[0W_!0?\ 8-_X*@_\%_?VR=2U1=1O/%'PH\-_LZ:=%]KL
M=+\0>)O$'[37P4^%OB[4= MKF9Y(_A+\'_AOJ]_\'_!5@?ML&J:]+JC3:BNK
M_#^].J ']S7_  ;(_MU_M4_\%"O^"?'CSXX?M?\ Q3_X6[\4=%_:G^(OPWTW
MQ1_PA'PY\ _9O!>A?#?X.:_I6C?V+\,/"'@KP[-]EU;Q5K]W_:-QI,NJS_;_
M "+F^FMK6RAM_CG_ (."_P#@XB^)G_!/OXN>&/V'?V(/!7A[QM^U9K^E>%=?
M\=>,?$VAW_C+3_AS#XTF5_!7@+PGX L'MW\6_$SQE926&KJ^H2W>DZ+H6KZ+
M;VNA>(=9\1I)X8O_ /!F%_RB@^*'_9[_ ,7/_5/_ +/=?S2^$]3M_P!HW_@\
M"O;CQS_Q.(="_P""F_CG1[5;AWNE5OV8-1\0:#X"B)ND!\O2)?A)X<BCA"F*
MWCLD@MBT,43$ ^Q] _X.(/\ @NS_ ,$S/CQ\+=,_X*Y? B^\6?"/XHPW/B(^
M%_%7PC\ _"+Q[=>"[FYLGU&^^%'C+X:Z=HGA&\\2?#]=5TQ-2\'^,;+5M4CC
MN+7P_P",+GPUK&L6GB6Q_NN^,?[<_P"SY\&?V(O$O_!0+5_%1UW]G71?@EI?
MQWT7Q#H=O(UWXR\)^*-%TW5? =EX?L[X6CC6_'5SKGA_0]!LM2^P[-8UNRMM
M2>Q5;AX?Y>/^#VOP;HE]^PK^R/\ $*>VC;Q'X7_:SF\&Z5>&-3+!HGCOX/?$
M'6]?MDE/SI'=WWPY\-2RQK\LK6<+-S"E?E3^U%^T-XHO?^#,_P#8?T2ZU6:6
M;QK^U'#^SSKS->W+M>>%_AQ\5OVFOB!X3TJ9-A5H=,T_X3^"TM[*:1K:*+2;
M6XA=)(K:VC )+#_@O]_P<8?\%!?$OQC^,W_!/?X&_P!@?L_?!74I-;\0^"_A
M9\"_!WQ?AT#PRUI/)I?A3Q;XV^(VB:OX@\>>,IM-B_MS5=/^&5EX<\0W;Q2Z
MGIOAG1_#Q%DO]$__  ;Q?\%]+O\ X*Q:'XZ^!?Q_\+^&? W[77P<\*V?C2_N
M?!JW=GX,^,OPZ?5H- U#QOH&@WDM]<>$]>\*:QJ?AS2_&GA]]5OM.NYO$FD:
M]X9D@L;K5- \+Y7_  :"^#=#\,_\$=/#&NZ5:I!J/Q$_:'^./BWQ+.$4/>:O
MI^I:'X#M97< ,XB\/^"]%MDWD[?)8+@&OY3O^"--]!^S]_P=1ZQ\,O!K#2O!
M<O[4W[?WP,?3(':RMIO".EZ/\>5\-:6T4(>,P6>N>$?"EY!:,K0F?3K=%:)E
MCGB /]3JBBB@ K\G?^"Q?_)LO@7_ ++MX9_]5_\ $^OT(^+7QU^$_P "M.TC
M5OBQXRLO!NGZ]>SZ=I-S>V6KWJ7M[;0"YG@1=)T_4)$:. B0M,D:$<*Q;BOQ
MV_X*:_M3_ 'XX? ;PEX3^%?Q(TSQAXAT_P"+F@^(KS3++3/$%G+!HUIX-\>Z
M;<7S2ZKI%A;M'%?:MIUN8TF:<M=(RQ,BR,@!][_\$T/^3)?@K_W4?_U;7CRO
MNROA/_@FA_R9+\%?^ZC_ /JVO'E?=E !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%?D__P %E_\ @I[X&_X)4_L5^-_C
MUJ;Z5K/Q>\2BX\ _LZ?#V_D+GQI\6-6L+A].N[^SADBN9/!W@BT2;Q=XUN$E
MM$?2M.CT&WO[;7/$.B1W !_-'_P=P_\ !8F7PSHC_P#!*7]F_P 222>+O&=G
MHVL?M>>(O#UPS7FC^%M16VU;P?\  .UFMU:<:IXUBDTWQ;\08;5X9%\)MX9\
M+22:A9>,/%6EVGZS_P#!M5_P1XA_X)J_LHK\7_C'X:BM/VQ?VG]$T7Q#\2%U
M"V!U?X3?#EUCU;P;\%('FC6;3M3M?-B\2?$Z& 0_:_&DMKH-ZVI6O@30;]OY
MK/\ @V&_X)?>-O\ @H5^UKXW_P""KG[94>J^/?A_\,OBKJWC#PA?>-8GN9/C
MQ^U9?ZF/%5]XSOC,BQZGX:^$^H7T'B6\\J*+3+_X@7OAC2K62YL?"_BO1%_T
MJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9(S)'(ZQO,R(S+%&8
MQ)*RJ2(XS+)%$'<@*IEECC#$%Y$7+!]% '\C?BW_ (+V_P#!.K_@K-\)/V]O
MV*[+X'_$OPUXV\(_L7_M2?$CPEI7[6O@'X.VNG>(?'OPJ^'GB/[7I'@W0M.^
M(/Q*>+XD^$'DD\8Z(?*M-8M--\-^(=8M6L+C0G#_ ,8W[8O_  3_ /V:/A1_
MP1._X)<?M]>!M7N?#?[1G[2/C7XV_#WXM^"+SQ/?:I;?$C2?"/Q&^+]II?Q-
MT#P]JDUTWAT^ ]-\'>$_!7BA= DL] OG\6^%KJ;2H-:EO]0U7^HC_@NI_P &
MP'AOXA^)_P!H[_@HM^QU\8- ^"FKVO@[XF?'[XU_!3Q7I.J0^$M:\0^&?#&J
M>,/&WB3X8>*?"=O<:GX5U7QNFFZMJ6K>&-8T/5M*O?%VL7U_:>(/#^D7HTFQ
M^"?^"'__  ;5K^W]\#?V6OVW?VR/VE=6\3_LQW%OXOE^&?[+_A=_$M[K$GAS
MPC\5/&6AW_A/6_&?B"^ATKX<^$=<\<Z'XCU[7?#7P^T#4KC7+'6I[F#Q-X<U
M[4[R]M #P7_@N6G_  4M_:^_9N_X(T>$K?X6_M(_'#X?K_P30_9]^.7C0_#O
MX6_$/X@Z+JOQZ\?:?KV@ZIXS\=:QX4\.:A:7?Q U#X=Z!X2U%K+6)/MWAW_A
M*O$$NGPVL7BK49+[Y?\ VN_^"FO_  6(\6_\$V_$7["OQH_82TW]G7]B+2/"
M/P@\#WNI:3^Q_P#'?X5V7@CP[\-OB/X!\2> ;8>/?&WB'4-"TZZU?QOX7\,:
M=J&I:]%>:AXHU#5[J&:YFU[6UO&_UE],TS3=$TW3M&T;3K'2-'TBQM-,TG2=
M,M+>PTW3--L+>.TL=.TZQM(XK6RL;*UBBMK2TMHHK>VMXHX88TC15'YW?\%<
M/V(?%7_!1W_@GM^T#^QEX)\<>'_AOXG^,G_"J?[,\:>*=.U'5=!T;_A7GQN^
M&WQ5O?MUAI++J%Q_:.G^!KO2K7[.P\J\OK>:7,$<@H _AN_X-.OVV_V^_ _Q
MF^#G[%?P_P#@K_;?[!GQ4^.GQF\9_&#XS_\ "F?B!K7_  BWCJ+]G\W\6C_\
M+CT[48_ /AC=J/@#X;P?V/K.G3W[?V]Y D\W7=-,7SKK%O8?L;_\'>=YJ/Q,
MDB\.:'J__!2"]\8R:IJJKIFG6ND?M9W%SXB\,ZY=74A6WATJ-?C'IEY=ZK-(
MEI%!'<7E[-#''<M'_<]_P0M_X)@>//\ @DM^QUXM_9F^(GQ1\(_%O7?$?Q^\
M:?&&#Q/X+T?6=$TFVTWQ1X)^&OA6WT:6TUQGO'OK6X\"W=W-.A^SO#?VZ(-\
M<M?*'_!<G_@W=^%__!6C5?#GQU^''Q"M/@'^UKX2T+3?!\OC74='N-:\ ?$W
MP1IEY>W>FZ)\0='TN2WU:S\0^')-1NQX:\=:.]U?Q:6[>&]=TC7=-M_#<WA4
M _.+_@]Q^*/AS3?V/?V-_@M-=VW_  EWC3]I37_BCIUA]HC^V?\ ".?#'X7^
M)/">M79M0WF_9O[3^+F@PBX*B/S08U8MN"_ G[6/[)_C+1O^#,_]B^]OM&O4
MU'X;_&?PK^UAKT;:?^\A\&_&SXJ_'7P_X-UDJ$\V*RN_"WQ_\#7*:@[2^=;7
MB2!X[*X2.'W/]G/_ (,]OVE_B#\<?!OCC_@IY^VQX?\ C!\+O!"VFG'PA\+_
M !G\7?'_ (Z\7^$?#S[/#?@-?B!\6?#GA67X<^%9(@J:G:^'M-UZXT_3A=:/
MX;N--O+RW\2:7_<%\3?V<O@K\7OV??%?[+'CKX?Z#J/P%\9?#.Y^$&K?#FTM
M1I.AVW@"70U\/6>B:%'IOV:3P]_8>FQ6H\-7NC/9WOAR\T_3=0T:XLKW3[2>
M$ _G"_X,_/BOX2\5_P#!(@^#;/5M/CUOX*?M#?&'P_XRL9;N**YTN+Q'_8?Q
M&TC5KV&5T>WTN^TOQ/)#::BX%E//H^K01S-/IM\D'\O'_!">Q7]K+_@YV\0?
M'WP- ^I> M/^-?[=G[4-[>V<:WEO:^"/&MG\6-"\):E)<%9(HK27Q7\6? UK
M'=E3ODOH(H'BN+B&:/\ 0KXJ_P#!G-^VE\.OB%\0M*_8;_;Z\&^&_P!GWXF7
M%SHFOZ%\3?$OQ<^''CJ[^'%P[75MX3\=VOPG\+>(O!_Q9;39G-K(-2B\(:-K
M C_M7^Q]'EG;38?Z3_\ @B+_ ,$-?A!_P1[^'/BZ_3Q>?C)^TS\7K#2;'XK_
M !>ETA-%T:QT+1[NYO\ 3?A_\--$FDN]1T/PA;WMQ'?:Y>:AJ-QJWC76K'3]
M7U2+3;/2] T#0@#]V:*** /E?]J?]D[P;^UAH'A7P]XR\2>)_#EMX3UB]UFR
MG\,G2A/<SWMD+&2*Z_M73]0C\E(QO3RDC??]YBO%?BK^W7^P'\-_V5OA'X=^
M(7@_QGXW\1:GK/Q&TCP;/9>)6T$V,5CJ'AGQ?K<MU$-+TC3[C[6EQX=M88]\
MS0^3//NB9_+=/Z4J_)W_ (+%_P#)LO@7_LNWAG_U7_Q/H ]V_P"":'_)DOP5
M_P"ZC_\ JVO'E?=E?"?_  30_P"3)?@K_P!U'_\ 5M>/*^[* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0W%O;WEO/:7<$-U:W4,MO<VUQ$D]O<6\Z-%-
M!/#*K1S0S1LT<L4BLDB,R.I4D&MIFE:7HEC;Z7HVFV&D:9:B06NG:99V]A8V
MPEE>>46]I:1Q6\(DFEDFD$<:AY9'D;+NQ-^B@ HHHH **** "BBB@ HHHH *
M*** "OR=_P""Q?\ R;+X%_[+MX9_]5_\3Z_6*OR=_P""Q?\ R;+X%_[+MX9_
M]5_\3Z /=O\ @FA_R9+\%?\ NH__ *MKQY7W97PG_P $T/\ DR7X*_\ =1__
M %;7CRONR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\G?^"Q?_)LO@7_LNWAG_P!5_P#$^OUBK\G?^"Q?
M_)LO@7_LNWAG_P!5_P#$^@#W;_@FA_R9+\%?^ZC_ /JVO'E?=E?"?_!-#_DR
M7X*_]U'_ /5M>/*^[* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBOBW_@H3^W!\*O^"=7[(OQ@_:S^+LR3Z)\-] ;_ (1KPK%>16>K
M?$7XAZP_]F^!?AYH+.DTG]H^*/$$UK:W-W%:W::#HD>K^)]0@_LC0]1FB /Y
MD/\ @[?_ ."NG_#/'P0M_P#@G!\"_$_V?XT?M&^&_P"U/V@-8T>[_P!,^'W[
M/E^\]HG@N66 AK/Q!\:KJ"YL+V S-/:_#73/$$&H6"VWCOP_J*_3_P#P:U?\
M$C#^P=^R>?VI?C1X8&G?M4_M;^'M'UN6SU2U,>M?"GX#3_9M;\#_  ^>*=/M
M&E:_XOD^R>/O']I_HUQ'</X/\,ZO90:KX(G:7^97_@A%^PY\5?\ @N/_ ,%/
M?BQ_P41_;.A?QI\'OA?\3;;XN_%>?4[24^&OB9\9;^X34_A=\#=$L;XW%K)X
M \%Z7IVG:CXA\.QR7UEHOP]\/>$O VH6T5CXVTVZ3_4,H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K\G?^"Q?_)LO@7_ ++MX9_]5_\ $^OUBK\G?^"Q?_)LO@7_
M ++MX9_]5_\ $^@#W;_@FA_R9+\%?^ZC_P#JVO'E?=E?"?\ P30_Y,E^"O\
MW4?_ -6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OR=_P""Q?\ R;+X%_[+MX9_]5_\3Z_6*OR=_P""Q?\ R;+X%_[+MX9_
M]5_\3Z /=O\ @FA_R9+\%?\ NH__ *MKQY7W97PG_P $T/\ DR7X*_\ =1__
M %;7CRONR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_)W_@L7_P FR^!?^R[>&?\ U7_Q/K]8J_)W
M_@L7_P FR^!?^R[>&?\ U7_Q/H ]V_X)H?\ )DOP5_[J/_ZMKQY7W97PG_P3
M0_Y,E^"O_=1__5M>/*^[* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7Y._\ !8O_ )-E\"_]EV\,_P#JO_B?
M7ZQ5^3O_  6+_P"39? O_9=O#/\ ZK_XGT >[?\ !-#_ ),E^"O_ '4?_P!6
MUX\K[LKX3_X)H?\ )DOP5_[J/_ZMKQY7W90 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?D[_ ,%B_P#DV7P+_P!EV\,_^J_^)]?K%7Y.
M_P#!8O\ Y-E\"_\ 9=O#/_JO_B?0![M_P30_Y,E^"O\ W4?_ -6UX\K[LKX3
M_P"":'_)DOP5_P"ZC_\ JVO'E?=E !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO@OPC?D6]V/!UGXKU")KS1?'FGW%?W4T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\-)/!EEXCO8E-^M@/"LKQVS&"*"\6+^T)?Z\?^"@_P#P29_9*_X*6?!3X7_
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M3[:[F=-,NM7U.73HHFU?5'F^3OVK/VR?'>L?\&:'[)<EYK6J2:[\6?'7@O\
M8^UW4%G1;O\ X0SX*_%[XN3:#IDMT-D[6-QX(_9X\,:+<I$PFNK"XET^]:XM
M)[X3 'I/QR_X/7M87XF^*+']E7]@]/'7P7\'7\TK>./BA\1]<TCQ=XI\*VUY
M!:'Q->>%O"7@[4M,^&%M?3SQV]E%JWB#QH81/937[6][=OHUK_2?_P $<_\
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M?^"Q?_)LO@7_ ++MX9_]5_\ $^@#W;_@FA_R9+\%?^ZC_P#JVO'E?=E?"?\
MP30_Y,E^"O\ W4?_ -6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S2I!%+-)N$
M<,;RR%$>5]D:EVVQQ*\DC;0=J1H[N<*BLQ ,E% '\LO[>GQE_P""%W_!:?X$
M_M8>$?"WBOX3?M0_M,_LL?L>_'[XX^ O$>@^'OBEX,^('P]TSP!X?U.ZM-6\
M._$I_#W@RW\2>&-.\?2>'Y]4\%P^(O$7A^^_M."_U/P[<Z;JGVN?^#[XN?\
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MQ<^&?CS7[_2/#-AXRT/1]'T#0M3L/$/B#PO!;VGA+P[K&B:K/J?VZSE &?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D[
M_P %B_\ DV7P+_V7;PS_ .J_^)]?K%7Y._\ !8O_ )-E\"_]EV\,_P#JO_B?
M0![M_P $T/\ DR7X*_\ =1__ %;7CRONROA/_@FA_P F2_!7_NH__JVO'E?=
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 A(4%F(55!+,2   ,DDG@ #DD\ 5_ER_\%Q?V
MX/BO_P %W/\ @J+\*_\ @G]^Q?/)XS^"_P -OB1=?"+X-0Z;=NWAKXD_%&=Y
M;7XK_M ZU=6:SV[> _"^EZ9JUOX?U\MJ%GIOPP\+:UXYL9+5/&FK:?'_ $B_
M\'5/_!7\?L6?LTG]BOX&^*7L/VG_ -JKPM?VWB?5M%O?(UCX1?L^7TMUHWB3
M7UN('%QIGB?XG2P:GX'\(31*EU9:/#XV\16EWI>K:3X=N+KR[_@TP_X)!?\
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MY,E^"O\ W4?_ -6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR=_P""Q?\ R;+X
M%_[+MX9_]5_\3Z_6*OR=_P""Q?\ R;+X%_[+MX9_]5_\3Z /=O\ @FA_R9+\
M%?\ NH__ *MKQY7W97PG_P $T/\ DR7X*_\ =1__ %;7CRONR@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_5?_ !/K]8J_)W_@L7_R;+X%_P"R[>&?_5?_ !/H ]V_X)H?\F2_!7_NH_\
MZMKQY7W97PG_ ,$T/^3)?@K_ -U'_P#5M>/*^[* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Y._P#!8O\ Y-E\"_\ 9=O#/_JO_B?7ZQ5^3O\ P6+_
M .39? O_ &7;PS_ZK_XGT >[?\$T/^3)?@K_ -U'_P#5M>/*^[*^$_\ @FA_
MR9+\%?\ NH__ *MKQY7W90 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&7[2_Q"B,+2:/X0T/PW#K-WX<NM;M?/\#?"ZVUO7KNTTK6?%GB?2(_]"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:E\/+WXVZYJ_B/PU#965_)J&E:]-X2\+/K_BV?P\T5QJ%CH-IK6BZE>?'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HKX$_:[_X*E?\ !/G]@[48M"_:R_:K^%_PA\57&CQ^((/ U]=ZMXI^(LVA
MSR2Q6VK1?#KP)I/BCQS)I]Y+!<16%TGA]HK^2WN$LVG:"8)^('Q*_P"#QO\
MX)+^"_%&E^'_  =H_P"U)\8-)N]5M[74_''@SX2:%H'A?2=*>:.*ZU8VGQ+\
M>^!O&E^]NDGVF+3K?P@LMQ#!<JTT%P+:"Z /ZNJ*_)O_ (*S_MJ_M'?LN_\
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MWXH:WXR\5Z!=:C87=YI]]<:'JVG27.G7EUILA.GW$MJWZ7T4 %%%% !1110
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MPVECI]C;P6EI;1106\,<4:H-BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*(IY8]2^-6K?!K3=0MK7F22YTJ[OX+B)2VG/>ED#_JW\>OV[)M._X)H>-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y._\%B_^39? O_9=O#/_
M *K_ .)]?K%7Y._\%B_^39? O_9=O#/_ *K_ .)] 'NW_!-#_DR7X*_]U'_]
M6UX\K[LKX3_X)H?\F2_!7_NH_P#ZMKQY7W90 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !163KFOZ%X8TJ\UWQ+K6D^'M$T^,37^L:
MYJ-GI.E6,194$MYJ%_-;VEM&794#S3(I9E7.2!7SKX*_;>_8N^)/Q-MO@I\.
MOVO?V7_'WQEO1J1L_A)X*^/WPH\4_$V[&C6-UJ>KFV\!:%XLO_%4XTK3;&]U
M#4C%I3BQL;.ZN[KRH+>61 #Z@HK\K?\ @IU_P6+_ &-?^"2^@?#C5/VH]1^(
M>I^(/BT_B@_#[X>_"?PE9^+?&FOV7@V+26\1:JR:UK_A/PQH^F6-SKVAZ=%<
M:]XGTMK^^U)8].BNX;#5Y]._FW^+/_![_P# #2C=1_ O]@_XQ>.Q^_2QN_BS
M\6_!7PG(^:);:XNM/\'^'/C1NPK3S3V<.IKEH8K:.^ N7NK0 _N:HK\PO^"8
M_P#P47O/^"E__!/_ ,,?MG>#O@GJWP]\5^(;?XCZ-#\)M8\2P:EINH^.?AYJ
M.J:&;+PYX[GTK0X-4\+^(=8L(;6UUZ[T33&TNZEU#3K^V:?1[BXG_AD\>_\
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M-V\5K]DNDG:.2WE1/X-/ '_!CEXFG\BX^*7_  48T+2M@C-SI/@#]FG4-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBD)"@LQ"JH)9B0  !DDD\  <DG@"@!:*
M\5\$_M*?LZ?$OQ_XD^$_PX^/OP4^('Q3\&Z<FL>+_AKX)^*G@7Q7X_\ "NDR
M7*V4>J>)/!NA:[?^(M#TZ2\=+1+W4].M;9[EE@64RL$/XE_\%@/^#C#]F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=!U:VDLM5T37-.M-6TC4[.7'FVFH:;?PW%G>VTF!YD%S#)$^!N0XK\B?B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+JWK^P3_ (B0O^")7_1^_P /_P#PWWQP_P#G7U^8'_$%3_P2R_Z+Y^W_ /\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR=_X+%_\FR^!?\
MLNWAG_U7_P 3Z_6*OR=_X+%_\FR^!?\ LNWAG_U7_P 3Z /=O^":'_)DOP5_
M[J/_ .K:\>5]V5\)_P#!-#_DR7X*_P#=1_\ U;7CRONR@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLZIXJ^%VC^();(20A+B?PU::OKFG6]TT37#M9Q^++F%)(H8A?.L[S6WX[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?D[_ ,%B_P#DV7P+_P!EV\,_^J_^)]?K%7Y._P#!8O\
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MT"0>9)JT=G]I60 _U$J\4^*_[2G[.GP'MWN_CC\??@I\&;6*"6ZDN?BO\5/
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M ,8_V[^T[\6;NX\#Z;J,FH>#/@9X&2Z\*?!7P,S>8L,FC^#(;VZ.LZS!%-+
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M<RI.WA/]IC0?&CQV8@5H)XDUCX)^ A-<R7):*6U>2"*& +<)>3R,;9?Z /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUHFJV]WINJ:==PLT5S97MM/;SQL4DC93BOQ__P""U'P=_;A_;-_X)W1^'/\
M@EE\:HO"?Q/\9>+_ (<>.X_$_@CXGGX=W?Q6^!5[HNMW=_X>\!_%G2M0L+;1
M4\2W>L>"_%2:I'K^EZ7XD\*Z+JN@2ZG)9:^UK>?FS_P;N_\ !-+_ (+ _L4?
M&/XY_$G_ (*&?'_5O$7PL^(?PQM]%T/X+Z]\>_$?QUU>Y^+%QXI\-:Q#\2KN
MZN[W6O#?AVZ\/>%]+\1^%+V?2]=N[_Q-)XHA-T);+P_87# '\W/_  63_9*U
M+_@W?_X*R?LS_MF?L0IJ'A7X-?$;5K_XM_#GP&VIZE'I.B:MX.UG3-+^/7[/
MDVI,;B[OOAGXF\,>+-&BM8KJXGU'3O#?C^XT% [^&[#5[W_3;^'7COP_\4?A
M]X$^)OA*XDN_"OQ%\&^&/'?AFZFC\F6Y\/\ B[1+'Q!HUQ+%EO*DFT[4+:1X
M]QV,Q7)QFO\ /U_X/:/C]X.\9_%S]AG]D[PG-'KWQ,^'/A_XJ?%+QMI>FH;^
M_P!(MOB]?> O"_PXT,16@EE36-;/P_\ %.IS:.RB_:PE\,WRVYM]5LI9O[M/
MV0OAGK?P6_9-_9?^#GB8$>)/A-^SO\%/AGX@#7!NV&M^!/AKX9\+:J#=$DW)
M%_I5P#<$DS']YGYJ /HBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
M)W_@L7_R;+X%_P"R[>&?_5?_ !/K]8J_)W_@L7_R;+X%_P"R[>&?_5?_ !/H
M ]V_X)H?\F2_!7_NH_\ ZMKQY7W97PG_ ,$T/^3)?@K_ -U'_P#5M>/*^[*
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MLY//MO$>A^(_BQX@\::AH.O6UT3=6.I:%)IL^E3;!I)L(H8(HOU;H _R[?\
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MZF58Y[^&[N?.DF_5K]C#_@VY_P""4_[#OQ2\$?''X;?![QCX^^,/PVU5-?\
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M_%W]NW1O#'AR)I?+N6!^&V@?&34+_2V#" R*/ UH!)'%#R]HT=O)_P .T_\
M@\D_Z*-^W_\ ^+8O W_T9%'_  [3_P"#R3_HHW[?_P#XMB\#?_1D4 ==X+_X
M,PO^"E_C_4#K_P :_P!IO]E3PA<:EL:^N8_%OQA^*?C(-;P3VT7]I)<?#+PY
MI%PRI;:=%;&#QA?!;&5M[02V265Q]_\ PR_X,=_ =H8+CXR?\%"_%WB!696N
MM(^&7[/NC>$#"BR,&B@\1>*OBEXX%TTD01UGD\+V@@D9HS;W"QB63\TO^':?
M_!Y)_P!%&_;_ /\ Q;%X&_\ HR*/^':?_!Y)_P!%&_;_ /\ Q;%X&_\ HR*
M/])']G#X"> ?V6?@%\&_V;_A;%JD?P[^!_PW\(_##P>VN7J:EKESH?@[1;31
M;._US4([>TAO=:U);4ZAJUU;V=E:S:A<W,EK96=NT5M%[57^8)_P[3_X/)/^
MBC?M_P#_ (MB\#?_ $9%(/V5O^#R30Q_8P\4?\% )_[))TWSC^V1X'\0&4V1
M-L9/[>;XXZD=:#F,L-5_M&_&H BZ6\N5E$S@'^B??_L'_L.ZK\0?$/Q:U/\
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M-TG76^U?Z;;?;M/T_P ;:#:6^+2YMQ:^3I5KYMF+>:3SY9'N9C_B,5_X+"^
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M]\-^.$T[QMHMM<V?A_\ P72_86_8._9&_:"_9*;_ ()\^-/$?CW]F_\ :F^
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M -H;_@X-_P""//[-)O[3QK^W%\)_&>NV/F1_\(W\#)-:^/FI3WL3,DFFF_\
MA'I?B[PUI=]$Z21SQZ_K^CQ6LT;074T$^(SZS\//V;/VDOVI/^"35C^RG_P4
M)\7?\(W^TI\;?V7-?^#_ .T)XU^&EWI,]_H_B+Q;H6J^'_[<2?1I%\+ZOXHM
M-'N=)N/&]KHLG_"%:_XE7Q%9:23X7O[8'^<GX&_\&1O[*_AB_2Z_:+_;5^.?
MQBM8;D3QZ9\*/AWX)^ MK<PHRM'9ZC-XEU?X^7\T$A!2[?3KO2;J2%F6UN+&
M;;.H!^VG_!-3_@X$_8/_ ."J'QQ\>_L]_LZZ?\<_"_Q$\$>#+WX@VD/QB\#>
M%_"VE>.O".E:SI>A:UJO@N]\,>/_ !O,[Z/>:[HDEYIGBJS\*ZM+9ZI'=:?8
M7T=EJW]G?BK_ ,%\_P#@H9_P7V^&O[;TO[)/_!/?X(?%[PQ\%]2\"^$]9^'W
MQ0^!G[/DGQO\9_&<ZOHFF7/CO4I?%EUX.\>:9\/X? GBVZU#PA=:/I=EX<\1
M:/9:3;^,-:U?^P_%NA/%_1Y^P)_P2#_X)_?\$SI?$&K_ +)'P*L_!OCKQ?H<
M'AOQ=\4O$WB7Q1X^^)'B#0HKNUU"31CXD\7:MJG_  CVAWVH:?IFHZKX=\&6
MGAKP]JVI:5I.HZCI5S>Z98W%O^E] '^8?X _X((_\''O_!0/QIX2^(?[6WQD
M\?\ PHLK?Q#I7B+2_&W[4_[3_B'Q3XI\)1V=]#=?VWX&^&G@#7_B!K_A/Q#H
MYCFG\.Z!?V/PU5=3@MD_M#0+"X36(O\ 0P^/7[$GP3_:Z_92M_V2/VOM'?\
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MNI+B36O@_P#%C1-2O[?P]X;\6ZA>ZWJGA>+Q;H'B*.]T%M%UC6O]&K_@F/\
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MX;\2ZAXQA)U"XBM8"MQX1TG7+=ECEF1KUUE*:;;B6\U%K6T@GGC_ )7O"_\
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MJ%G."K#[D]M<1-%=V-Y#;WUC/;7MM!/'W]% 'X^^$O\ @@)_P1K\%M;MH_\
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MFSL[[48_ 7Q"M=/TZVUBXT^VN+S1-;TGPUXG@L]431+C1-6_:^OQ9_X+._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6O&<_@7PCJ.O0>%O#NG:;9QP3^(->BT>'0=%C^S2EKNXLX%C9 L= '^;F/\
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MYX)^(?AOX6^!-9\2?#SQ;_PC'B'Q%X7\-Z3XYN);!O 7C[QCJOABUM?'>L_
M[Q%HLLNL6.M^ M1T/4Y+37O"GBV2]G\+V>MZ;>?VC?M4?\&I_P#P3,_;;^%7
MP2\0_P#!-[XI_#[]E#P;IUQXFUW5_B?\/+?QS^V3H_QJT3Q);:++X=@M_%'B
M_P#::L8;"T\-2V^IWEI>:;K6KB_AUQ;5DM+?3K56 /\ .V_94_:*\._LV?$?
M4/%7BS]G[X(_M-^!_$7A;6?"/BGX9?'7P99:WIUQ8:U82VRZYX/\20J_B;X=
M>./#]W(NH^'?%OA?4()X;JWB35;#5=.DETUOZ%_^#1'PO\)/BE_P4+^*_P &
MOC+^R]\,?VA_"'B_]G;Q#XILM?\ B3\)/ GQ0A^#FO\ @;Q1X<6P\0QW_C30
M=6?PKI/BO3O$VK^#=3GT5[2?6M<U'PG:7D%S:VXDLOU?_P""T^O_ /!$W_@F
MO_P3>/[ '@GX#_L;?M#_ +?>K_!7P/\ !VZ\<?#3X/\ PY\-?%/PGXV\+Z!I
MFE:Y^TS\7_B%X)&K^,O 7C8ZO!?^,_#_ ,/=;^(6K^)?$>KZW;Z'K$&L?#BY
M\2:C-VG_  9\_P#!+O\ :+^"]EXR_P""CGQ2\0ZO\-/AQ\>?AM/\.OA-\')M
M(L!JWQ6\&2Z_I.OI\7?%<FK:=/J/AOPE'J6BQ)\,X=&GT_6?&,,VI>);NX@\
M$3:"OC8 _L5T3]BK]C;PU;RVGAS]DK]F7P_:SS?:)[;1/@-\+-*MYK@HD1GE
MAL/"L$<DWEQQQ^:ZL^Q$3=M4 ?E'_P %U/V2?V_?B;^QYX4\._\ !(-M*^%/
MQOT'XHZ!=>+[#X4:[X$^ ?Q/\1?"M?#^O:5-H_PZ^+^HZAX,M_ \^CZ[<^']
M4U.SL/%W@^\UG0+.\L;3772"3PUXC_?6B@#_ "^H?^#:K_@XF_:#41_&_P"*
MVGZ5'=QA+E/CU^V?XE\?HJ-#!8&*Z7P7<?%L2J+*^NX66(7"&SM+^W4L)K.&
M^]R^'/\ P9&?MBZF8?\ A;?[9W[-'@@,!]H_X5SX7^*7Q2,1Q-D0CQ-HWP>^
MT ,MN 7-L2)9F(!@1;C_ $DZ* /X;/AO_P &/_[.VEF#_A;_ .WE\:?'*J?]
M*'PW^$/@;X5&89FR(&\3^)_C(+8X:WYD6Z ,4QP?/06WZ!?#?_@S]_X(\>!_
M(_X2?1OVE/C)Y./,_P"%D?'%]+^U8WY\_P#X5#X3^%>W.Y<_9OL_^K3&,R>9
M_4C10!\3?L6?\$Y/V)O^"=_AOQ5X6_8U_9_\*_!/3O'-UI=WXSOM-U3Q9XL\
M4^*Y-"2_30X?$/C?X@>(?%GC/6+'1!JNK-HVFW^OSZ=I4NJZI-86MO+J-Z\_
MVS110 4444 %%%% !1110 4444 %%%% !152_O['2K&\U/5+VTTW3=/MI[V_
MU"_N8;.QL;.VC::YN[R[N'C@MK:WB1Y9YYI$BBC5GD=54D?B]^UI_P '#/\
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M?!SP'>+9K!$\D4UR/ WQD\:.T=XZ+!;BT6ZE665#=Q6L DFC_2#Q+_P;O?\
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MHVF:?I%@DDTR66F65M86BRW$K37$JVUI'%"LD\SO+,X0-+*[2.6=B3_BP_\
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M:G\#FX417?\ P@UW\)?BC8P&5%5][Z]XS^%=S<6JNTBRLE@9C N^.TEE?[,
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M[PS_ ,$^O^":?Q&_9@^-7@7Q?\5OC'\$IM5F_8TMH6!\)>)] \:ZB]\WP_\
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MO"^LCQ%!XZT#4['4XO"/AZYM6%E;:IH>JV%M=VUXUA<ZOI.K_E_X6_X-@_\
M@WO\/M$=6_;,^)GCD1WING7Q3^V-^SE:+- 8XD_LV7_A"?AIX.860:-YA)"T
M6H^9/*#?F(010@']2/[&7[<O[-G[?7[/6C_M/_LS>.9/&/PIU2\US2;R\U'1
MM4\/:]X:\0^&"@\1>&_%'A[5+>'4=*UK24FMKF2'RY[:^TZ\T_5M)N]0TK4;
M"]N?Y2/C#_P>W?LJ>&M:\0:=\$/V,?C=\6=,TV^U"ST/Q!XX^(7@_P"$%EXD
M@M/M4=GJB65CH7Q1U;2=/U2:*VE@2_L1JEOI]T9[W3+>_@?2G_H]_8H\)_\
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MVHK2\6"X51+"MW:6MRL;J)[>"4/$H!_7M17\8TW_  >S_L ++*L'[*G[8<D
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M#K'A:V@N;+[/=BWCNOAMX"T..QNPDMO)=K;R07%S;SHMYYUO/M>_\'?VR_\
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M5_$,?A>.]T+25\4R0ZGJ5I/JNHF]UBZM1=V%M+<06ILH%_:;_B"I_P""IO\
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MS3-(2^NK?2+#1O#6C1&]UF^DG^UW=Z''W_\ \/"?V!?^CX?V0/\ Q);X,?\
MS:U_"CIG_!D%^TI+?6\>L_MV? ZPTQC)]JN],^%?CW5[Z$")S$;?3KO6]$M[
MDO,(XY!)JEJ(XG>93*\:P2]C_P 0.GQ4_P"DB7P__P#$<?$?_P ]^@#^J/\
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M_P#P(TF.YDB5ECDN$L/%MNLSQJS*C2!F168*0"0?XG_^('3XJ?\ 21+X?_\
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M:)J&EZI??3M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU[K$5O="QLM4TK2KSPU;:)"L]H?Z(?VO/^"P?Q,F_P"#8+P9^WAX<UV;P_\
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MJ:$Z/9^#_AQ\0OCG\58/FCA+V\NK^(Y?"^HA998@H;X6D"62-'+[U0_VR?\
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MO@6NL63K.L7CF^UJ]U#Q7\5]$CN4CF31)M/^'^AZ@L;6/B?1?$6D75UIDO\
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MMI+6L-Q]HU*QCTK4[+4;*73+ZXG6^M;+XF_X<I?\%</^D<O[7_\ X8_QM_\
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M6^8PB3Q+^Q_:B4QAVG^,GCAA;AR-QF^S?!^X9A#DF3[.LY(4^4)3M#>DV/\
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MM87RK/ S7$ME+<+#.WB7X<^);6ZO_P#2\^ WQG\)?M%_!7X5_'GP%9^*M/\
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M_:<^*_@&Y43S->2#_BJ?AW\,XXI/M6GV,URJ7#QM=O8RQRW'V>:>T8/V!/\
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MVBOEWX??MP_L5_%KR?\ A5?[7_[+OQ,^TE5M_P#A7W[0'PG\9^>S/=1J(?\
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MM5OK/3-.LXS-=W^H7,%G96L0(!EN+JY>."",$@%Y9%4$@9R17^7Q_P -*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:V-F/%GPY^'?C,P(J1B[6Y;1[KP$+MIW$K6S1+9BU1XTE2\,;22@']3OA?\
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MMFO_  Y\'?@=JGB8W(89NX;3QIXU\>^$OL1B8>7;7$W@+4!.&\V6UMRGDO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K\G?^"Q?_ ";+X%_[+MX9_P#5?_$^
MOUBK\G?^"Q?_ ";+X%_[+MX9_P#5?_$^@#W;_@FA_P F2_!7_NH__JVO'E?=
ME?"?_!-#_DR7X*_]U'_]6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O#_VE/V=OA3^UK\!OBI^S;\</#[>)_A3\8O".H>#?&6D0W<VG
MWKZ?>^7-;:AI6HV_[_3-<T34[>QUO0=3A#2:;K.G6-\B.T 1O<** /Y!9/\
M@RK_ ."6#R2.OQX_;\A5W9EBC^*G[/)CB5F)$<9E_99EE*("%4RRR2%0"\CM
MEBS_ (@J?^"67_1?/V__ /PZ?[.O_P!"K7]?M% '\@7_ !!4_P#!++_HOG[?
M_P#X=/\ 9U_^A5K]8_\ @EM_P0H_8D_X)(>)OB1X[_9QOOC-XW^(?Q/\/VO@
M_6_'OQP\7^%/$_B#3/!MMJ=GK<OA3P]#X'\ _#CP_IVDZCK6FZ9JNIR3:'>:
MK>W6EZ<LNI?9K."W3]FJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR=_X+%_\
MFR^!?^R[>&?_ %7_ ,3Z_6*OR=_X+%_\FR^!?^R[>&?_ %7_ ,3Z /=O^":'
M_)DOP5_[J/\ ^K:\>5]V5\)_\$T/^3)?@K_W4?\ ]6UX\K[LH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OR=_X+%_\FR^!?\ LNWAG_U7_P 3Z_6*OR=_X+%_\FR^
M!?\ LNWAG_U7_P 3Z /=O^":'_)DOP5_[J/_ .K:\>5]V5\)_P#!-#_DR7X*
M_P#=1_\ U;7CRONR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_)W_ (+%_P#)LO@7
M_LNWAG_U7_Q/K]8J_)W_ (+%_P#)LO@7_LNWAG_U7_Q/H ]V_P"":'_)DOP5
M_P"ZC_\ JVO'E?=E?"?_  30_P"3)?@K_P!U'_\ 5M>/*^[* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K\G?^"Q?_ ";+X%_[+MX9_P#5?_$^OUBK\G?^"Q?_ ";+
MX%_[+MX9_P#5?_$^@#W;_@FA_P F2_!7_NH__JVO'E?=E?"?_!-#_DR7X*_]
MU'_]6UX\K[LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OR=_X+%_\FR^!?^R[>&?_
M %7_ ,3Z_6*OR=_X+%_\FR^!?^R[>&?_ %7_ ,3Z /=O^":'_)DOP5_[J/\
M^K:\>5]V5\)_\$T/^3)?@K_W4?\ ]6UX\K[LH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7QIXZ\$?#?P]?>+O
MB'XQ\*^ O"FF*'U+Q/XT\0Z1X6\/:>A#,&OM:UR\L=-M%*H[!I[F,$(QSA3C
MJJ_S0O\ @IA>_&7_ (+>_P#!QA;_ /!,OQK\;=:^$'[._P +_B9XG^$W@;1'
M:XN=$\,VOPG^%VN^//B?XWTKP;J.HZ5I'B#XJ?$J^\/^)-&\.^(9K>2XCT.]
M\)6+MJ7AW0'%V ?W5_\ !.S_ (*B_LF_\%//A7>?%7]FKQ1J<,&G>(];\.:C
MX ^(3>%?#WQ4TY]#33WFUJ_\#:-XK\3:A9^'+_\ M&)=*U>XECAOGAN515\G
MYOT2K_(S_P""?'_!%S_@H3^T+^R_^SM_P44_X)D>*-<NOCGHO[0?Q2\ ^*M,
MTWXA>"?A%K'PF;X>V'AS5?!_Q&\-^,_%/BSPT->TGQ(-9U/POXH\*0VVI7T,
MJV#R6FL^'-=UN'0/[_/^"HO_  4&_:%_X)V_\$8]6_:8^).E^%?#/[;E]\+?
MA9\+ETW1)--\0^#-"_:?^(UAIGA_Q7XC\.[DO-(U;0?!=RGC3XC>&=.O[>\T
M_5+;PWINC:O:RV]U=QT ?LIXG^*?PQ\$ZOI/A_QG\1_ ?A'7M>_Y >B>)_%_
MA[0=7UK]YY7_ !*=-U74;2]U']Z1'_H<,W[SY/O<5WE?Y7'_  30_P"#?#]H
M7_@MI^S;\>/^"@7Q._:_U+PO\3_%WQ&\=:+\/V^(/A+5/BAK7QI\>^&],TS4
M=;\3_$/Q[?\ CC1M0\.>']3\0:BO@JUOK/2_%&I6$VGZKJS::]AHVGZ+K?ZD
M?\&@?_!2?XY/\8/BG_P2S_: \6Z_XC\,>$O &N>-?V?;#Q9>S:KJGPOUOX:Z
M_8:'\0_A#H]_(UU<Q^%K[2M8_P"$DT70GNQHGA:X\&Z[%HD< \120. ?W_T4
M44 %?D[_ ,%B_P#DV7P+_P!EV\,_^J_^)]?K%7Y._P#!8O\ Y-E\"_\ 9=O#
M/_JO_B?0![M_P30_Y,E^"O\ W4?_ -6UX\K[LKX3_P"":'_)DOP5_P"ZC_\
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MD7[$)[UM!A2XC!\N-;B0Q\JM 'ZF4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445^6?[$/_!0'QA^U9\5_$'P\\0?#[PUX3LM&^'N
MK>,XM1T;4]4O;J:ZT[Q)X3T-+*2*]41+!)%XBFG:13Y@DMHE'RN] 'ZF4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB=M#LY_#NK>,=-TOQ)=+>7&G>._"T&G2^)],M]+LP#\,_P#@C[_P<*_M6_\
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M_:OW/G?9XO=O^'UG_5M/_F9/_P 55?K%_P ,M_LR_P#1NGP)_P##1?#_ /\
MF>H_X9;_ &9?^C=/@3_X:+X?_P#S/4 ?D[_P^L_ZMI_\S)_^*JC_ (?6?]6T
M_P#F9/\ \55?K%_PRW^S+_T;I\"?_#1?#_\ ^9ZC_AEO]F7_ *-T^!/_ (:+
MX?\ _P SU 'Y._\ #ZS_ *MI_P#,R?\ XJJ/^'UG_5M/_F9/_P 55?K%_P ,
MM_LR_P#1NGP)_P##1?#_ /\ F>H_X9;_ &9?^C=/@3_X:+X?_P#S/4 ?D[_P
M^L_ZMI_\S)_^*JC_ (?6?]6T_P#F9/\ \55?K%_PRW^S+_T;I\"?_#1?#_\
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M_P#,R?\ XJJ/^'UG_5M/_F9/_P 55?K%_P ,M_LR_P#1NGP)_P##1?#_ /\
MF>H_X9;_ &9?^C=/@3_X:+X?_P#S/4 ?D[_P^L_ZMI_\S)_^*JC_ (?6?]6T
M_P#F9/\ \55?K%_PRW^S+_T;I\"?_#1?#_\ ^9ZC_AEO]F7_ *-T^!/_ (:+
MX?\ _P SU 'Y._\ #ZS_ *MI_P#,R?\ XJJ/^'UG_5M/_F9/_P 55?K%_P ,
MM_LR_P#1NGP)_P##1?#_ /\ F>H_X9;_ &9?^C=/@3_X:+X?_P#S/4 ?D[_P
M^L_ZMI_\S)_^*JC_ (?6?]6T_P#F9/\ \55?K%_PRW^S+_T;I\"?_#1?#_\
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M_P#,R?\ XJJ/^'UG_5M/_F9/_P 55?K%_P ,M_LR_P#1NGP)_P##1?#_ /\
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M,G_XJJ_6+_AEO]F7_HW3X$_^&B^'_P#\SU'_  RW^S+_ -&Z? G_ ,-%\/\
M_P"9Z@#\G?\ A]9_U;3_ .9D_P#Q54?\/K/^K:?_ #,G_P"*JOUB_P"&6_V9
M?^C=/@3_ .&B^'__ ,SU'_#+?[,O_1NGP)_\-%\/_P#YGJ /R=_X?6?]6T_^
M9D__ !54?\/K/^K:?_,R?_BJK]8O^&6_V9?^C=/@3_X:+X?_ /S/4?\ #+?[
M,O\ T;I\"?\ PT7P_P#_ )GJ /R=_P"'UG_5M/\ YF3_ /%51_P^L_ZMI_\
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M !54?\/K/^K:?_,R?_BJK]8O^&6_V9?^C=/@3_X:+X?_ /S/4?\ #+?[,O\
MT;I\"?\ PT7P_P#_ )GJ /R=_P"'UG_5M/\ YF3_ /%51_P^L_ZMI_\ ,R?_
M (JJ_6+_ (9;_9E_Z-T^!/\ X:+X?_\ S/4?\,M_LR_]&Z? G_PT7P__ /F>
MH _)W_A]9_U;3_YF3_\ %51_P^L_ZMI_\S)_^*JOUB_X9;_9E_Z-T^!/_AHO
MA_\ _,]1_P ,M_LR_P#1NGP)_P##1?#_ /\ F>H _)W_ (?6?]6T_P#F9/\
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MW_A]9_U;3_YF3_\ %51_P^L_ZMI_\S)_^*JOUB_X9;_9E_Z-T^!/_AHOA_\
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M\/\ _P"9ZC_AEO\ 9E_Z-T^!/_AHOA__ /,]0!^3O_#ZS_JVG_S,G_XJJ/\
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M\/\ _P"9ZC_AEO\ 9E_Z-T^!/_AHOA__ /,]0!^3O_#ZS_JVG_S,G_XJJ/\
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M  ^L_P"K:?\ S,G_ .*JC_A]9_U;3_YF3_\ %57ZQ?\ #+?[,O\ T;I\"?\
MPT7P_P#_ )GJ/^&6_P!F7_HW3X$_^&B^'_\ \SU 'Y._\/K/^K:?_,R?_BJH
M_P"'UG_5M/\ YF3_ /%57ZQ?\,M_LR_]&Z? G_PT7P__ /F>H_X9;_9E_P"C
M=/@3_P"&B^'_ /\ ,]0!^3O_  ^L_P"K:?\ S,G_ .*JC_A]9_U;3_YF3_\
M%57ZQ?\ #+?[,O\ T;I\"?\ PT7P_P#_ )GJ/^&6_P!F7_HW3X$_^&B^'_\
M\SU 'Y._\/K/^K:?_,R?_BJH_P"'UG_5M/\ YF3_ /%57ZQ?\,M_LR_]&Z?
MG_PT7P__ /F>H_X9;_9E_P"C=/@3_P"&B^'_ /\ ,]0!^3O_  ^L_P"K:?\
MS,G_ .*JC_A]9_U;3_YF3_\ %57ZQ?\ #+?[,O\ T;I\"?\ PT7P_P#_ )GJ
M/^&6_P!F7_HW3X$_^&B^'_\ \SU 'Y._\/K/^K:?_,R?_BJH_P"'UG_5M/\
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M  ^L_P"K:?\ S,G_ .*JC_A]9_U;3_YF3_\ %57ZQ?\ #+?[,O\ T;I\"?\
MPT7P_P#_ )GJ/^&6_P!F7_HW3X$_^&B^'_\ \SU 'Y._\/K/^K:?_,R?_BJH
M_P"'UG_5M/\ YF3_ /%57ZQ?\,M_LR_]&Z? G_PT7P__ /F>H_X9;_9E_P"C
M=/@3_P"&B^'_ /\ ,]0!^3O_  ^L_P"K:?\ S,G_ .*JC_A]9_U;3_YF3_\
M%57ZQ?\ #+?[,O\ T;I\"?\ PT7P_P#_ )GJ/^&6_P!F7_HW3X$_^&B^'_\
M\SU 'Y._\/K/^K:?_,R?_BJH_P"'UG_5M/\ YF3_ /%57ZQ?\,M_LR_]&Z?
MG_PT7P__ /F>H_X9;_9E_P"C=/@3_P"&B^'_ /\ ,]0!^3O_  ^L_P"K:?\
MS,G_ .*JC_A]9_U;3_YF3_\ %57ZQ?\ #+?[,O\ T;I\"?\ PT7P_P#_ )GJ
M/^&6_P!F7_HW3X$_^&B^'_\ \SU 'Y._\/K/^K:?_,R?_BJH_P"'UG_5M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML:M>W$MUJ_B+Q%JCQ1RZQXE\0ZAJGB#6)T6XU34[N<>97N5% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?Q'_P#!:G_@ZY\4_L:_M.6?[.'_  3QT/\ 9O\
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M2%\>?$_Q&(=2U+1/#M[J4.J67AC3=(T34M4\7:EH&M:?'/H5G87FN6?Y9?\
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MHK]E6O\ 3[H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ5XSL[%F8V\?Q\^*GAKX/>%]>OBA<6Y\*:%X&^)>IB0QH]MI^IWEW-OA: J
M?L!^T;_P74L/^"<?_!+O]C+]J']M'PSI7Q)_;!_:L^$7A#QMX<^ 'PN=/A_:
MZUK_ (F\(Z7X[UV>[GUJX\6S^"_ WPZT[Q1X7\->*M<\OQ7J#>)-3TVUTO2M
M2^WSR6'\[R_\'A__  4NTG2]-^-7B3_@G/\ "-/V:M:U8Z7HWBI=#^/NB:7J
MM[!<W<5UI&F_&R_U74? -_JR8M[<PVOA&26"YMKMI+)_M"06?]-7_!53_@WR
M_9@_X*N>,?A/XY^)WQH^/_PCO_@I\+X?A-\/O"7PMO?AO_PK32O#L.JZOK#:
M@_AGQ+\/M8UX^(+N:^TC3+ZZM?&5GI<F@>%]%T^VT:TO4N=5N)/^"\GQ8_95
M_8J_X(M_M$_"'QWIWA'3/#'C;]GO4/V6?V;OA,UII:S:IX[U#PBOA?X7?\(C
MX>6*&W"_"":STOXFS7UI;6]OX<LO!*7UJT6HKI5K<@'V'_P2_P#^"HG[/7_!
M5']F*W_:/^"YU#PC/H6J7?A;XM_##QA>Z8WBKX3>,].M8[ZYTS6[NQF-AJ7A
M_4],FAUWPKXLMA;66N:'.'NK/1M=T_7_  _HO\P?[97_  =_^.[C]H37_P!G
MK_@EQ^R1I'[2C:)K^O\ A?0OB9XS@\>^.!\6=2T:6YMI-8^&7PC^%$VB^)[W
MP<[64^IZ3K-]XL_M3Q%HLD5Y)X?\.*NZ7D_^#.?]E+QSXW_8F_X*6:YXRU3Q
M_P"!?A#^U=<^$_@'X,\4>&)=*TC7;:\\+> ?BMHOQ&\=_#J^U_2M>L5U_08_
MB_X?LM)UV\\/ZMX;C\2>'Y+*]L==FT34M,L?Z!?^"3O_  01_95_X)$?$KXU
M_$[X(>/?BI\4?$/Q?\+^&_!=IJ?QD3P%J/B#P)X7T37-9US5=)T'7O!W@[P@
MTMOXNNI_"TGB.-["V@NKKP7I%TL"CRX+0 _'K_@FA_P=IO\ '/\ :;\.?LE_
M\%#OV<]%_9?\;>.?%5CX \,_$CPI=^)M*\)>&OB%J5S+9Z7X5^+'@;XC33>*
M/ UKK.H2:=HEIXECUW6(=,UN^M1XBTC2-!EOO$&C_P!I]?Y7'_!P;XL\"_\
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M];CT76M0N=5UG3=.TC1K\MJ-QIG\F<?_  >(?\%+=!T[2/C-XS_X)S_"2/\
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M[:W_ (?\16%M?ZA8IJ-A-/I6I:KI,]AJ=Y^#G_!3O_@K]^UA\!/^"P_[ ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$.W26^!OP7.CBYU"3XL7LU]%IGBSQ1I*MJO@F_N%\*>%=OC_P#M&_\ !O\
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M44 %%%% !7^7)_P58_Y6^_#W_9[_ /P2V_\ 5:?L?U_J-U_"I^WO_P $//\
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M?7?C'\!?&&FZ;)I/A#Q%J^I6]O-H/@3Q)=/J,]LEC#)9Q6TLZW%W;1R_W*4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_QMXXOXKZ+PEX=TP>+/#\3SZ?H7B;7;^XU".+3M!GMX-1OM. /V4HK\UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBO#OVD_VCO@W^R+\#/B1^T?\
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MHHH **** "BBB@ HHHH **** "BBB@ HHK\#?^#AOXZ_\%.O@!^R3\(O%?\
MP2KT/XR:]\<]6_:+T/P]X[M?@G^SKI/[2WB2+X3S_#/XGZEJ5QJ?@S6/AC\5
M;?1=#7QAIG@V.;Q/'H5A-;W\FGZ4-6B35I+.\ /WRHK\</\ @A1\7OV_/C?^
MP)X>\=_\%*=)^*&B_M/W'Q0^)6F:K8_%[X(:;^SYXR7P9IVI64?A"2?X<Z5X
M ^&MI;:?):/<&PU9?"\4FJQAY7O;PQAU_-[X[?\ !RIH4O\ P5?^"7_!+C]F
M+X03ZI>R_MA>%?V;OVCOC;\4%ELK#3;FR^(-OX2\>^&_A!X/TG4!=ZG<Q3PW
M^EKX_P#%M]865O/;W9TCP7K5I/IOB)0#^K"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNP#_ &)J*_S!/^(*G_@J;_T7S]@#_P .G^T5_P#0JT?\05/_  5-_P"B^?L
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M4M7E\.:!\7='_9H^-GPV\?2:3>6^IZ[X7U+QC\'IM>U3P_>)'>1.FE:7X_\
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M?"3_ !>^#%WXLT3X?>-;7QE\.O#7A_PAX;\=?"O7]>NM"\*ZC'J/A?PUI/\
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M+E"EM+H/BCQ!X/%RQEM-9F\I'5 #^B/_ (-O_P#@LK\2O^"M/[/WQAT[X_\
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MJS --,NK:U<-'&#R[B"WGF*C)$<4C=%)'S+_ ,&4'_*-S]I7_L]_Q;_ZH;X
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MK9YI9M,6.U^V888K>**""*."""-(88846.*&*-0D<44:!4CCC10B(BA44!5
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M7XAZ5'>>"_$*ZSXFAM;/0M=U*]2RU.>"+3[G]\O^#AG_ ()/_M:_\%8?@?\
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M=3\4_!WQ9X.M?AOIW@"?3?BMX.OM-M[DS_$R_P!/7X?^/XM5DMKC5XKGP[&
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MR1\._P!E'_@J'HOCSX,^']-\!Z'^TI\%_"_QOUG1?"]E'H.F:5\5;'Q?XO\
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M7TI2-/MOBFZMT!^SL3^!O_![A^T9XD\+_ C]BO\ 9:T6_GM= ^+_ ,0_B?\
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MO@'Q%%%J:ZAILL]OJ.G3V5 'ZN?MG?M=?!G]@#]EKXH_M1_'+5KZQ^''P?\
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M:-=:?9NR6]H^L7UQ! DVH7<]R ?SW_!;_@XY_P""SW_!+_\ :>T_X(?\%8?
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MX&YDC::9HU)*HTLA4 NQ(![;\</^"H?_  <I?\%+_!/Q*_;._P""<_P=\>_
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M+V,-O$+KQWK_ (G\1:K\1;F[:W&)[[_A.;G7X+F:8M<;X!%,5:+RT /Y7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!_BX?L"_\%#_C]_P1D_;>^,WQB\%_"/P?
MK_Q8MO#OQ0_9^\7_  ^^-6G^+;"W\-G4/B)X7UK7TO=.\/ZUX:UJR\2:1K'P
M_M=--O=W1@A2>_2>U>80R1?NI_Q&T?M]?]&H_L@?^ _QG_\ GHU_I%ZK\//
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M\;?L]W.B?L4V7A+]J;P#XY^+MA\!OBQ9?$OX>Q>+_ OQ?^(%C!XY^(<VN_\
M"#>'+*S^*.OVFAZ?+=^$] U=KO7='T2\UF>>:WW_ ))_ _PA_P %._\ @VO_
M ."B6L_$_4OV5M?^(5OH>C>,_A??:S=^#?%NJ?!?X[_!SQ)KFDR)K/@GXE^%
M['4+?0KO4M0T#PGXDTQC<2>(_"FJQ6>@^-/"Y:?5/#UU_KAT4 ?Y=O\ P5D\
M3_\ !;__ (+7? _PY^UMXX_81\>_!C]DKX":_INC?"KX)>$_"GQ"U;Q]XW\0
M_$Z3[!J_Q0LO"NI:*GCSXI6VD1:7I>BW/C>Q\'>&O!/AS1M2BM?#5K>WUYXZ
MU.3^KC_@V$B^)/A[_@CAHWP1^*GPC^*7PA^('P1^(7Q\\&W7A;XH?#KQ?\/M
M>UG3O&6OZA\6M%\0Z/IGBS2=+O-7T>]_X6+<:)#J-A!);G5-#U+3S_I%G(7_
M *6J* /\P?\ X-5/V2?VK/@[_P %;?!WC3XN?LR?M!_"SP=!\#/C7IT_BSXC
M_!CXC^"/#,.H7^B:;'86,NO>)O#>EZ7'>7LB,EI;/=":Y=66%'8$#_2D^.?P
M=\%?M#?!?XL? ;XD6']I^ /C+\.?&?PP\8V*B/S9O#GCCP_J'AS5C:O*DBP7
MT-GJ,L]A=!#):7L4%U$5EA1AZI7\B/\ P7U_X+R?MV_\$NOVF-)_9\_9^_9Q
M^%_COP?\2?@#X3\?^"OB]XO\+_$K7[S0?&OB?Q=\1? VHZ.;;P]XAT[POKNH
MZ/?>%M%U/3-#N%MKI?[5LAJEKJ5GJMDK '^<;\5_V<_C+\(?VF_B7^P_<6^I
MZU\2_"G[0M]\#KOPCHL\Z:?XR^)WA'QCK?PW\,W5AIS7/V.]GU"^U?4(?"U]
M.TKPZ?XFN5M;I+?4[IIO]K+]A;]EKPU^Q-^Q[^SE^REX4-M/IOP.^%'A7P5?
MZG:1M%#XB\66]DM]XZ\7&)DC,<_C'QM?>(?%5T@CB5;K6)@D4:@(O^?'_P &
MUW_!(S]JG]IO_@H#X>_X*._M>_#;XC^&_A%\)_%NM?'K2O&OQ;\/ZGX=UGX_
M_M%:UJ5YJWA;6O#MIXAL;'4_$.E>'?%NH7OQ.U[QOI\#:.GB;P_HNB0W=S=:
MI?)I_P#IE4 ?P$_\%\OV)O\ @MK^S_\ MNG]N[]B[XP_M=_M$?LX+\0/#?QO
M\(?#'P7\1/BE\4H/V:O'OA2XTW5=0\*W_P  Y/$6N66K?"6]UNVU/7]';PSX
M0N_!VE^&=4UCP9XMTG1]/L+6]\3?*_[3W_!R!_P56_;=_9E^+7[%FG?\$QK?
M2/'?QJ^'.K?"?XEZWX/^%GQW\=:Q#H?C_1!IFLMX0^%>JZ1J=UX<UC5M'N-4
M;P[=:[K/BV72S=V>IV"W-_ID%]+_ *3U% '\>W_!JI_P1H_:%_8 \-_&G]JK
M]K?PK-\,?B[\>_#/ASP!X!^$&I36-QXL\%?"[3M1C\5ZKKGCH:=?7MOHWB#Q
MKKD>@+;^#;DPZ[X6L?"Q/B2*TU?6)M&T;\._^#M'_@G[^U;I'_!1R^_;3\"?
M!_XB?$/X&_%GX9_"ZX/Q"\#^$-5\6Z%X#\<_#+P\O@_6/"?C-M$M-0F\.3?V
M3X6T;Q;IVH:_;V6CZU8ZU<VVE7U[=:%KMMIO^F;10!_-I_P;P_\ !4+]OS_@
MIAH'[3?B+]M[X%:1\)=+^&Z? ^W^#?B/PA\&OB7\,?!?CY/$MC\2/^%@36VL
M?$#Q#XJM_$^OZ;)H'@S4M6@T#5K>PTJW\2V#P:18VNH6X;^DNBB@#_-[_P"#
MP;]EG]ISXW_\%+O@=XK^"W[.?QW^+WA;3_V&/AIX>O\ Q+\+_A#\0?'^@6.O
MVGQ]_::U*ZT.\UGPIX>U;3K;6+;3M6TJ_N-,FN4O8;+4]/NI(%@O;:23^[K_
M ()SZ%K?A?\ X)[_ +"/AGQ-HVJ^'?$GAW]C7]F#0O$'A_7=/N](UO0M;TCX
M)>!]/U71M9TK4(;>_P!,U73+^WN++4-/O;>"[LKN":VN88IHG1?LJB@ K\%/
M^#F?X<_$+XL?\$9/VJ/ GPL\!^,_B7XXUC7?V?)-(\&_#_POKGC+Q7JD>F?M
M%_"O5-2DT[P]X=L=2U>^33],L[O4;YK:SE6TL;6YNYS';P2R+^]=% '\:W_!
MFS\"_C;\"_V:/VS-)^-OP=^*GP=U37?CGX"U'0]-^*?P]\6_#[4-9T^V\ SV
MUQ?:59^+=(TBXU&SM[@BWFN;2.:&*<B)W60[:^-?^#R[]F[]HGXZ_'+]AW4/
M@C\!/C3\8[#P_P#"CXO66OWWPK^%OCGXA6>B7E]XO\(SV5IJ]SX1T+5X=-N;
MN&"::U@O7AEN(H99(D=(W(_OSHH _!?X"_L=>.OVE?\ @W1^$O[%.L1:I\*?
MB=\3/^"='A#X5QVOCC2=:\/7_@SX@O\ #FR71;/QGHES;6NO:7:V7B:TL+;Q
M-I\MDNH0Z<;Z$V<LO^CO_"'_ ,$Z?VFO^"G7_!NI^TS\;/#7C#]A#QQXI_X6
MMI_AOP)\1/AGXV\*>,=,L/$NJ^$=0UV\\ >)OA?\6/!^B^)M"UA89]<\2V]G
M?>'AXP\,>*=+U2^BBC;4;+3]2TO_ %I** /\G_\ X+ _"?\ X+@_\%*KGX9?
M\%!_VF/V)_B?X*\ ^)Y[WX.? C]G_P"''PZ^(>M^+/AOX+TFT;Q:/$NN_#1-
M.UOQ[I%EXYOK_4)[KQ]XULM#O/%FK:6L6G:'H_A"U\%V=?UV:-9?%'XL?\&H
M-_\ #I/@Y\6-%^,?A[_@GMJGP(N?@YK/PV\9Z/\ %*3Q9\)+)_AA%96_@#4-
M(B\57=QXBM_"MMK^B+:Z9*=6TK5;*_LD:*X55_J4HH _@F_X,ROV;OV@?@5\
M4/V]M0^.'P$^,?P<B\0> O@%9>&K[XK?"WQK\/8];DL?$/Q2GU:TT.Y\7:%I
M"ZD]HL^G3:C!8/,UNLUE)<H@D@)_I^_X+D^#?%_Q"_X))?MX>"_ /A7Q)XX\
M8^(O@9JNG>'_  GX0T/4_$OB;7=0?6]$D2QT;0=%M;W5-4O'CCD=;:RM9YF1
M'8(55B/U;HH _A&_X,P?V=OV@?@1XF_X*'R_'#X%_&/X-1>)]"_9<C\-2_%;
MX9>-?AY'XADTC4/C^VK1Z&_B[1-'75GTM=2TYM16P-PUDM_9&Y$0NH#)X7_P
M>/?LS?M(?'+]KS]DK6_@G^S[\;OC#HVB_LWZWI6L:O\ "WX4>//B#IFDZG)\
M3O$-W'INIW_A+0-7M+"_>TEBNDL[J6*X:WD298S&ZL?]"VB@#X8_X)?>'M?\
M(_\ !-'_ ()W^%/%>AZQX8\4^&/V&/V2?#WB7PUXATR]T77_  ]K^B_ +X?Z
M;K.AZYHVI06VHZ3K&DZC;7-AJ>F7]M;WMA>V\]K=013Q21K_ )Z7_!M3^R+^
MU?\ "G_@ME\(?'WQ1_9A_:&^&W@2RT+]I*.]\:^/O@K\2?!WA*TDU7X5>.K/
M2X[KQ'XA\-:=H]N^I7EQ;VM@LMXC7ES/#!;B265%;_44HH _S'O^#AO_ ()L
M?MW_ +*G_!5KQ%_P4E^ ?PJ\=?%3X6>.OBM\+OVA/A]\2/ _@W5/B/:?#+XN
M>"$\+7,GA'XEZ#I4&JWND0VGC'PA!K.@7NL6%MX3\0>']9TO0]/U&?6+#6=*
ML/HSXV_\%,?^"X7_  7U_9A\9?LE?L]?L 1? [X8:OX2N]5_:/\ C-I\?Q#L
M?#OC6P\#64GBF?X=>%_&'C;3],TOP]%XXUO1K735^'&AM\0/'OB*673]#N==
MM/",GBZYO?\ 15HH _S]/^#-SX>?M"?LX?M%_ME?#'XY_LW?'[X0V/QD^$'P
MU\6^&?%GQ-^"_P 2/ OAB\U3X/\ BWQ%IUYX:B\1>)_#NEZ2-;U#3_BS)JUC
MI;3FZOK+0=4GMQML)E;A/^#C_P#X(9?M8>"?VQ[_ /X*;_\ !/?X=>/OB/HO
MCWQ-H7Q3^)OACX/:=J7B?XK?!SX^>&[RTU"?XG>&_"&D07OB?6O"OBF_TO3_
M !I=:GX>L]9N?"GC-/$MWK-MI/AVZT62/_1&HH _RV?C]_P6X_X+_?M__L^^
M(_\ @GQ>_LKZJ-<\?Z-8?#/XM^(/@[^RO\:-)^._C[0-5M8K+5/#GBZVN-:U
MOPAX0MO'5LEXGC63PWX"\'6M_I-Q>V%B- \/R:G9W?\ 4=_P;-?\$5?B#_P3
M8^ OQ9^*O[5N@Z-I_P"TE^U)::#HVN_#9I=(\0O\)OA-X9DUM[#P5K.N:3?:
MIHFI:_XYOM8;Q#XST_2KN]TNSM-.\):1/<RZKIFJQ0_U,44 ?Y=/[57_  3'
M_P""G'_! /\ X*/-^V)^P-\)?'?Q:^ &D^+?%?B+X1>,O _@GQ5\6?"NG_"_
MQ=+=V^K? C]HOPSX5\WQ%I-MIFCZA#X9G\0ZK)H^E^)S;Z)XO\&>)],\9VDE
MEX6T/VH?^"KG_!>?_@M9KOP=^!W[-O[,7Q?^ 2^#/&+^*+>;]E73OCA\/-6U
M/QM'I4_A>76OB1\;]9\1:3I/A'P=X;M];U..SL+_ %7PKH>EW6O2S>*=5UZ^
M@\/S:7_J#44 ? W_  35_9J^//[+W[%?PE^#'[6'Q^\;?M1_M VVCW^I_&'X
MH^/_ !IXF^(4VH>(_$5Q+<3>%-#\1>,II_$.I>$_"&E-8>%M-OM4,5WX@DTZ
M^\47MG8WNOW5E;_YCOCK]E;_ (*<?\&[_P#P4CC^-7PN^"_BWQ%I?PM\8^+T
M^#GQ8N?AWXJ^('P)^-GPC\5)J'AV#1?$^K^%Q8P07^N>%=9M=/\ %OA(>(/#
MWC3PGXCEM[O3;BTGC\/Z[=?Z[=% '^9-_P %*/B;_P %W/\ @MO^Q_K7QJ^)
MO[&OB3X ?LF?LU7WA'Q9X8^#O@CX:?%F+QE^T;\6O%_BOPS\,[?7?#/@[Q"-
M:^(/Q"M_ >A^+_%NOVOB'2/#FF?#[PCX=@\6V%YJ^M^*98Y;?^@?_@SQ^"_Q
MB^!__!/?]H?PS\:OA/\ $OX0>)-3_;*\4Z[IOA_XH^!/%'P_UO4-$F^"7P-T
M^'6;'2O%FE:3?W>E2W^GW]E'J%O;R6CW=C>6RS&:VF1/ZTJ* /\ *2_X+1?L
MK_MR_P#!//\ X+9?$[]N/P/\$?&GB;PG<?M1^'_VP/@'\6A\/?$'C/X1Z]K,
MOB;0/B+#X:\1W_AT+;VMUX9\</<>#O$/A?4]5T#Q#>6UG#J>G[-,UW0]8N_Z
MOO@)^V)^W/\ \%.O^" /_!3[XC?M4_L\:I\//CUKOPS_ &O/AG\+_AOX$^"_
MQ/\  ]KX[\%R?LXZ!=^#KKX<>$O&FH>+/&'C%M4\8>(O%7AB&]L-7UZ74-<T
MBYTJW;[3:FV3^J^B@#_/N_X,V?V:OVC?@9^TQ^V7JWQM^ /QL^#NE:[\"_ >
MG:)J?Q3^%7CKX?:?K.H6WC^:YN+'2KSQ;H.D6VHWD%L1<36UI)-/% 1*Z+&=
MU?2/_!T]_P $*/C7^U?XRT#_ (*!_L6_#W5OBC\4=.\(V'@?]HGX.^%(WU'Q
MSXQT7PM%Y'@?XE> /#P+7GBSQ!H^CLW@[Q1X4T/[1KVH:/IO@^\\-Z%J$]EX
MAD?^X"B@#_+KTO\ X+[_ /!PKI'[/"_L)I^SOXEN/B6GP^C^'&G_ !:N?V5_
MC@/VN;+PM):MX<MK^""#5;?PM/XM@L'M=$T[QK/\*I=;\Z/^U+FXO_&$R^(8
M_P!?_P#@VF_X-_/C=^SM9?&K]K/]M[PC?_"+XA_%WX+>-/@+\&OA-JZ6<GQ
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M,SI)!*J?U,_\'AWP7^,7QP_X)[_L\>&?@K\)_B7\7_$FF?ME>%M=U+P_\+O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0ZO_ $+T4 ?X]7[4'P!_X*1_!/\ X*X?M/?M2_L^_LF_M02>*_ '_!0#X_\
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MB;P5I.H>+-"M/%^I7::GJ6K>(/#ND^&?[9G.HZQKXO[N%[Z'_;&HH _QM_\
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M\1W'A*^U&VCEUOP5?:G=>$?$"&6#6]$OX9I(V^U0 H"J JJ %4    8  '
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MQ\(?'=W:M>6O@?XN^#FN;CPEK5_;QPW%P^A:G#>:KX0\6?8H)-3'A#Q/K_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,?!FK^'+#Q!I_A/7O$FC:5?V6D1QZB\WBB_T6'PQI36^\+K.KZ<)E6W:62,
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M+_%_A#6=&AM?!=E;7MU8O9:-$E\UQ>I<*D$BMY<;*3(,$4 ?TS4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML;_P79^$_P#P1T\2_ ?PW\2O@1\1/C)/\>-#\?:YI-SX'\2>&M!BT&+P#?\
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MEX1T>6V6?&O:WI4=Q&EI)/<VX!_6%1137=(T:21E1$5G=W8*B(H+,S,Q 55
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MAHU+<!G$952> 2">*_B0_P"(WG]EG_HQ[X__ /AQ/AU_\CT ?V^T5_$1;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXLM/C%\&=!MM=MDL[RRD6^AT?7]9T]':1D%OJ%P"A8JR_P"CE_P5B_Y19?\
M!2S_ +, _;(_]9U^(U?Y*G_!)G]F[_@I/^TU\<?B3X1_X)??$SX@_#'XX^'/
M@YJ/BWQEJ'PV_:!U?]G/Q!KGPOA\=>!=$U+0V\8Z5XE\)IJMD?%.M^$]5F\.
M:EK$5E</I<6I+'+>Z9:(0#_4$\:?\&]/_!%SQ/X4U_0=5_8.^#OA[3M2TRYA
MN]=\,W_C+P=KVCPJGFG4]+\3Z+XJL-1T>YLC&+@745TD6R-XKQ)[*2XMY?\
M-P_X)517/P+_ ."_G[,7A/\ 9B\87_BWPGX7_;XNOA)X2\:1S0?:?&GP"O\
MX@:]\-_%.O7C6ML;2:+Q-\$[W7=2O1!;16[K=N]NUGB*>#S3]O7QY_P6=_9J
M^(VL_LE?\%#_ -IW]N?0KG4]/AGU7P=\5OVG?C!\3_AYXP\#ZX]SI4GB;07'
MQ$\3>"OB'X1OH8]3L)[C1;K5+9[JTU3P]J*VVKV.I:;;?V_?\&W/_!$#]B'X
M :%X+_X*.>!OVH/#G[<GQ.\2:%K6F?#+QUX,\/R^$OAG\%CK>E#1?&&D6/A7
M6[O4/&P^+,&GWVI^'M?U+QM'X2U30=&UN]T-/ .E7,]QK&I '[+_ /!7[_@K
M3\._^"0?P2^&?QM^(_PD\:?&#2_B9\5$^%ECH?@G7-#T+4-,U!_"7B3Q:-5N
M[C74>WFLQ;^')[0PP@3>=<Q29\M'KV+_ ()@?\%"/!W_  4^_9'\*_M;^!/A
MYXF^%_AWQ5XJ\<>%;?PCXMU32]8UJTN/!&OW&@W5W-?:,J6+PWTT!N+=$7?'
M&P63+ U_.7_P>T?\F"_LH?\ 9W]O_P"J8^*-?;__  :3?\H7/@]_V6#X_P#_
M *L;4: *_P#P5*_X.9/@;_P2W_:PU?\ 9/\ 'O[,GQ7^*?B'2/ _@OQO)XL\
M(>+_  AHVC36OC2RN;VUL4LM9B>^6XLDMV2>1F\N1F!C& :_=K]HW]JWX'?L
MD_L\>,/VHOVAO&EG\.?A#X$\-V7B/Q%KE]%<7UT#JC6EMH^A:/I>GQ7&H:]X
MDUS5+ZRT70]%TRWGO=3U.[@MX(PK,Z?YB'_!WC_RF3\;?]D ^!/_ *8M3K^O
M#_@Z9_93^/G[4_\ P2+\*Q_ +P]XB\;ZC\"OBU\-/CM\0? ?A:S;4M;\0?#7
MP]\-/B'X2U_4M/TBU5M4UF;P?>>-=+\4WFG:>ERZ:'INLZJ]E.^EPRVP!\#_
M !!_X/>/V9M)\2:C8_##]AWXV^./"UO>WD&G^(?&/Q1\$_#K5-1LH9MEG?-X
M<TOP_P#$6*R-[$&F>UDUZ62U!CC9Y79Q%^OW_!*S_@XW_8?_ ."I?Q!'P*\+
MZ5X[^ 7[1,^F:IK&@?"SXLMX>EL_B#8:+!+?ZLGPS\9:#JES8^)]7TC1XI=9
MU3PWJ6F^'/$:Z79ZOJNEZ5J^C:'J^J6?\0?_  1Z_P"#AWP7_P $U/@;:?LQ
M_%G]@#X-_'CX>CQ-XDUO4?B9X<ET7P5\9]0_X274;C4+D>.9?$/@_P 8Z-\3
MY-&2YET'0(+Z[\'2Z?X;BT[2&U&:#2XUN/WR_P""1_\ Q##?M>_MNZ;\;_V>
M/!/Q3^!O[;.H?%&3XS?"GX*?&KQQXP^$FD>'?B!'?S^);RP^!.A?"GQTGPD\
M1Z-I]W#?S6/PNU+Q!KGVGPU<75A#X#_X1JTN=+TL _JX_;X_X*"_LR?\$U_@
M'J/[1/[4OC"\\.>#8M6M/#7AO0?#VF_V_P".OB!XOU""ZNK#PCX&\.BYLEU7
M6KBSL;Z_GEO;_2]%TK3K*[U+6]7TS3[>2Y7^3O6/^#X+X P:Y]G\/_L#?&'4
M_#?GHO\ :VL?&?P7H>N?9C.RR3?\(_9>#?$5AYZ6P29+?_A)O+DG9K=KJ*-1
M=/V7_!Z5^RC\??B]^S_^R9^T9\-/#OB/QE\*/V:]=^,UA\:].\/V;ZE_PA=K
M\4[;X8'PM\1M6L;)'OD\.65QX$U;P]K>N3Q3Z?H,^LZ()I+"/5+J:X_&'_@F
MQ_P<Q_ 3]F/]F'X>_L9?M4_\$S?@W\5/A'X/\%Q> -7\<_"FR\&:7XB\::$;
M<V&IZI\0_ACXZ\+:EX=^('C#Q/:2/<^+/$$WC[PNFO:I]HO+O3_,U"1[4 _M
MT_X)3?\ !<?]C'_@K=8>)]%^"-SXM^'?QI\!Z-;>(/&OP*^*EMHNG>-+?P_-
M<PZ=/XM\(WFB:QK&C^-_!EGJUS::9?ZQIEQ;:GHMUJ.BIXGT#P^VO:*E_P#:
MW[;G[=G[,7_!/'X':O\ M!?M5?$>Q^'_ (%L;H:/H=FD3:GXN\>^+9[*]U#3
MO!'@#PQ;,+_Q-XJU.VT^]N(;*W\JSL+"TO=9US4-)T'3M1U2T_FQ_P"" /P[
M_P"#<SQY\;G^,G_!.)/BEX<_:^\)Z3XNU*U^'W[07Q+^)'A_XL^%_!'B?3Y]
M)\2VNC_#^P\:2_"3XC^$;/3]:33;VXL7^)5QX:GM])U34M0T[51I6KW/X(_\
M'F/[2?C+X@_\%&?AM^S<?$5XWPT_9Z^ ?A/6++PBDA73;;XF?%C4=:\1>*_$
M\\8"F?4M1\&6?PYTB-IFE2RL]'/V,0/J.I&Y /URU+_@]\_9GB\7066C_L+?
M'6^\!M<P)<^)-2^*'@#2O%T-FTC"YG@\$VNDZSHUQ<Q1!7@M9/']K%<2%HY+
MRU51*W]1W_!/#_@I9^R?_P %/_@M+\:_V5O&UYK5AHNH6^A^/_ 7BK3XO#WQ
M,^%_B*ZMWN[31/'7AF.]U&"T;4+2.:XT;7-%U37/"NO1VU^FAZ_J$^E:K#8_
MR(?!+_@J=_P:Q_#W]B/P?^QIXK^ NI>*_#8^%NB^$_B5XCU;]DRUO_'WC+QN
M_A^VM?%7Q&O/B(2OBR#QQ>^(&O=;TGQ-IFJV-YX:N391>%SH^GZ;IME:?D)_
MP:E?M#7'P0_X+1:!\&_ 7B/6M1^$'[3WA'XW?">Z34XI;8:WIG@?PKXF^,/P
MT\5:OHL7[BV\202_#E=-M[KR/.TBW\7^(;".2"RU'4-X!Z1_P>>_\I7_ (7_
M /9D'PC_ /5P?M"5_3[_ ,%]?^59+Q'_ -D?_8*_]6I^S_7\P7_!Y[_RE?\
MA?\ ]F0?"/\ ]7!^T)7]/O\ P7U_Y5DO$?\ V1_]@K_U:G[/] 'Q!_P9#?\
M)K/[</\ V7_X=_\ JNKBO[?:_B"_X,AO^36?VX?^R_\ P[_]5U<5_;[0!_'%
M_P 'K_\ RC<_9J_[/?\ "7_JAOC]7\ ?P^MO'7[%WB7_ ()_?MP^%GO)3J?B
MI?C?X3N5801+XV_9X_:(US1]9\+Q2;0LL/\ 9?AGP;?WRS>;%-!XL>UG1H"T
M;?W^?\'K_P#RC<_9J_[/?\)?^J&^/U?S _'K]F[_ (3S_@U]_8,_:;TVP^TZ
MO^SW^VQ^T=X'UNYCBP]EX"^.OB'4H[^^N9@.;>'QQ\./ &F0QR$A9]=+1%2\
MHD /[W?^"YW[9?ASX-_\$3_VI?C]X%UU;B#XY? ;1OAU\)]3M9!!=ZM'^U%!
MI'@;3=8TF3<#%>:9X(\:ZOXS@DCD$UO#HDL]NQGBC!_R,_%/P4USPI^S_P#!
MWX\:GYUOI?QD^(WQO\$^'+.:,*MS8?!G2?@U<WNO6K[<RVM]K/Q1U'0]Q<[;
MSPS>($3;OD_?O_@HM_P4T_X:#_X((?\ !(C]DZV\1B_\8>#O%?Q3TKXR:7%>
M)+=Z58?LJ6L?PL^!=KJ9W?:FLM=^'/Q0M-4MK:8"$WWATR.CM96$YP_^"U_[
M-W_#*O\ P3E_X(%?"ZZL/[.\0:I^RO\ 'CXN>+[>6+R[^+Q7\=?&'PO^,>KV
M.JD@.^H:"_C:+PU('+BWAT6"RB=K>VAP ?Z*_P#P1OEM8/\ @CI_P3]FO8#=
M6</[%?P@EN[4,4-S:Q_#VQ>> ."I4S1!XPP8%2V01C-?S=?\$$?VUO\ @C#\
M<_\ @H1X<\!?L0_\$NO%?[*/QWN/A9\3M3T_XNZO\6]>\8V5GX9TW3+*3Q'H
M3:+J'C+6[:236[9X8([@V+/;F(LDD9.3_1U_P1^_Y0R_L%?]F0?"C_U6]I7^
M?'_P:'?\ID_!/_9 /CM_Z8M,H _TA?\ @H3_ ,%*OV2O^"8WP;7XR?M5?$ ^
M';76'U.P^'O@#P_:+KOQ,^*_B#2K:WN;OP]\/_"RW%K_ &A/:K>Z>NK:WJU[
MH_A+PX-3TV7Q-XAT>'4+.2?^6N]_X/??V:X_%2V>G?L*?'*Z\$&1PWB&]^*G
M@+3_ !4(@LQ1U\'0:+J6D-(SK KQ'QTJHLLSB:0P(EQ^#_\ P= ?%_QY^U7_
M ,%P_$O[.%UXKNG\%_!IO@/^S]\,-.N"%T7PS>?$GPCX"\:>-M6CL1)##)J%
M[XV\?WL.K:G,R7E_8>']%L)KG^S](TQ+?_0,A_X(D_\ !,RV_9&G_8YMOV2/
M@BO@2X^';>!Y?&\_PT\'7'Q=FUHZ-+IL?Q0N/B:VCKXRE^)T&H32:_!XL768
M[^VU$B"TDMM,6.Q0 ];_ ."=/_!3;]DW_@J-\&;SXS_LK^,-2U*U\/:I!H'Q
M ^'WC+3K?PY\3_AGX@NK-;^STOQIX9@U'5K:&'4K0R2Z-XAT+5M=\*:ZUGJE
MMHVO7UYHVL6UA^2/QW_X.?/V9?V=O^"D&N?\$\OB5\#O'N@S>%?C3X,^$?B[
M]H#5O'7@S2/AGX6L?%4/AR\O_B#K5K?(NIV?ACPMIWB!M1UD2RK.+73;IT8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6^@?"B^U;4]1U:Q^(/B+7M \5_\ %0-]C@\ :8YU?PQ'=>,-?LM<\'?UW_\
M!J5_P2Z_;%_8O^$GQ$_:5_::^(GC_P  Z1^U#I&E:QX5_9"U=PUMIT9GM;^P
M^.'Q2L-7MKC4O#GQ5UW2X_[+TG0-+FTG5+/PE?.?B,=2UI]&T+P3_FX?LU^-
M_C/\.?CW\)_&G[.FC?\ "0?'?0_&VB3_  CT>/X5^%/C9J%]\0)[I;/PO%H7
MPN\:^$?'?A[Q;XF75;BVE\,64_A/6;ZV\0)INHZ+!%K5GI]S!_4=_P /+/\
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MXM\<Z_X<\:_"*Y\0:I>2V6GZ/XB\=Z5#X?U'P@^H3R:=!9ZQKGA*'PO#/=7
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M%#XET#P^FL:$VL_<.F?\%[? _B'_ ()'ZE_P5S\,_LM?%37?AAX<^(%UX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[!O[-?QI^%7[)/PET[X,_#SQ-IWCWQ[K?A71_$/C+7M-N_%]]X$@T"]UU/\
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MULK*UABMK6VBC@@CCBC50 :%%%% !1110 4444 %%%% !1110 4444 %%%%
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M O#WC/PM^Q_\"_#7P1T/XAZSINO^-;70=4\5:U-XAU71K&;3M)N+[4?%^O\
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M[K?AO1KS6)[:W=+&WU/7]'LI9RBW&H6T9,J_V7>,?^#V'_@G+8^'=2N?A_\
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MPWIEW+JGA[1?":>)M&U/6)-,CU36+2QBU!!\D?\ !F3_ ,$ZOB/9?$#XO?\
M!2;XC>&]7\-_#Q_A]JGP)_9]EU:TN+!/B#JWB'Q#HVJ_$SQWHB2M;S7OA[PA
M:^%-/\%66K""[T36=:\2^*;&SN#JO@R^6U_HA^''_!K]_P $4/AKXRT[QK9_
MLB-XNO=(F^TZ?H?Q'^+OQC\=>#5NA+')'+J/A#7O'-SH'B.&)$>W_LWQ/9:U
MI$T4TC76GW$Z03P_O1X>\/:!X2T'1O"WA30]'\,^&/#FEV.A^'O#GA[3++1=
M!T'1=+MHK+3-(T;2--@MM/TO2].LX8;2QT^QMX+2TMHHH+>&.*-4 !_D^?\
M!;C_ )6;/BS_ -G/_L7?^JJ_9SK^FS_@\=_8"^)?[1'[+WP-_:_^$WAS5O%M
M[^R)JGCW3OBSH.AV\E]J-M\'_B='X6GNO'BZ="DEW=Z?X \2^#M-&NFQCD?3
M= \5:IXDU)8]$\/:C>V/[Z_&#_@C1_P3,^/O[1&J?M8?%[]E'PEXU_:%UGQ'
MX1\6ZG\2[[Q;\3['5+OQ%X$TS0-'\):F^EZ/XXT[PZDNC:;X7T&U@BBT>.VG
M33HWNX;B62X>;].'1)$:.15='5D='4,CHP*LK*P(96!(92"""01@T ?Y]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,_5M*L-<TK4]$U6#[5IFL:?>Z5J-MYLT'VFPU"VEM+R#SK:2&XA\ZWFDC\V"
M6*:/=OBD1PK#\N/V//\ @B1_P3"_8&^,"_'O]DO]F7_A4_Q93POK?@Q?%?\
MPN?]H/QWCPUXC>QDUG3?["^)?Q7\9>&C]L?3;(_;#HQO[?R<6EU ))A)^J]%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^$W[3W_!MG_P
M1^_:J\;ZU\2O%_[+T7P[\>>);VYU+Q'KWP.\;>+OA39:UJ-Y=K>WFHWG@GP_
MJG_"NHM3O;EKJ;4-4L?!]GJ6ISW]W=:E=W=W]FN+;]V:* /PF_99_P"#;7_@
MD'^R9X[TWXG^#OV9$^)/C[0;U;_PUKGQX\8^)?BSIWARZC\IX+G3/ ^OWH^'
M,NHV=U!#?Z7KFJ^#]2\0:-?1K=:-JMA(,U^QGQG^$'@+X_\ P>^*7P'^*&CO
MKGPS^,GPZ\9?"OQ[HEO>W>E3ZEX,\>>'=0\+>([&SU/39K;4-)NYM(U2[CLM
M3TVXMM0TVY,-[8W$%U!#*GIM% '\_'P1_P"#8#_@C3\#?B+IGQ-TK]FC5?B#
MK>@ZV->\.Z-\7?B=X[^('@K1[R*=+BR@E\%:GK$7ASQ/8:>Z 6UEXWL/%$,H
M.^_%Y,L<B?T"HB1HL<:JB(JHB(H5$10%5550 JJ  J@    # IU% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU]@_\$R/VQ?VY/V&O^"GFO?\$2?^"E'QK/[3</CGX?:M\7_V*_VL?%5UJ/\
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M9QRNCW5R+6VN+DP0!Y1!;SS;/+BD9;= !137=(T:21E1$5G=W8*B(H+,S,Q
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M-&CN++Q9X^\(Z)!>W]EJ&A2WO@7X?W43^(?%WB*2_P! ?P;J@!_8+17X8_\
M!M?\0O'WQ5_X(J?L7^/?BAXX\8?$CQUKW_#1?]N>-/'OB;6O&'BS6?[+_:Q^
M.VC:9_:WB/Q#>ZCK&H_V=H^G:?I-C]LO)OLFFV-G8V_EVMK!$GS-_P %]O\
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M0/&UCXHT:.XLO%GC[PCHD%[?V6H:%+>^!?A_=1/XA\7>(I+_ $!_!NJ?IO\
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MFPI<Z%\5KWPO>>./%&N7<FH^(=?\7:_I]A"E]YFJ6_AO3XP8]!\/:4T]]+>
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MR:MI4.I6VC3:GI\6KWEO-=VFE27MLFI75I;D+<7-M8M(+J>W@8A9IHHFCB)
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M&A=9 K#\U/\ @CU^P_\ M+?L _LM^)?@I^U3^U#J_P"UM\2-8^-/BOXB:?\
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M+,0 30!)15/3]1T_5K*WU+2KZSU/3KR,36E_I]S!>65U$20);>ZMGD@GC)!
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M.TR.^O;:TDU'4)59HK&Q2XDC:[O)%1VCMK<23NJL50A3C^2#]L'XV?&70_\
M@[9_X)O_  6T7XM_$[2/@[XI_92U#6?$_P )M+\>^*M/^&GB/5U\%_MKW"ZK
MKW@2TU6'PMJ^I+/H&A3+?:AI5Q="71=)D$H?3K-H0#^N^BBJ-CJ>FZH+MM,U
M&QU$6%]=:9?&QN[>[%GJ5DXCO-.NS;R2"WOK1R$NK2;9<0.0LL:$XH O4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1FO](N(LQDV^H2NL@9 K?E]_P3K_ .5P+_@KG_V:!J?_ *>_V!:_;S_@OO\
M 7Q!^TG_ ,$>OV[_ (7^%-.GU;Q'%\(K/XG:3IEFKR7^H3? KQSX2^.$]AIL
M,44TUUJ.H67P\NK&RL;>,SZC<7*:?$0]T" #N/\ @B-X8L/"/_!(K_@G/I6F
MQPQ6]W^R5\'?$\BP'*&_\;^%;/QGJLC?*G[Z;5-?O);@8.+AY1N?[[?SX_\
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MQ_+'H7P5OK6W_9Z\?>-[M_+T+P;:Z#X[\9P>(-=\1W)B\G3[73?!_P"TC?\
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M4@N;"ROHY-!M[:YMH6M3#%_:W^T+_P D!^./_9'_ (F?^H7K=?RP_P#!H_\
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M_B+19?$_A_PWX7FUGP#XBEAO+![GRT?^]"OXPO\ @HI_RN!?\$C/^S0-,_\
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MG74L$5]<^,/%&IV]J9XC/-83?'.[NA<QQ!R[Q11:IIXN'52+>6[@BF*22HK
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M/P>(3XC\*>&?"?P[M_$EMX.7QGK]U(G-?M__ /!&3X.?\$I_@#XN_P""A/\
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MII$G\B:*79Y<B,0#M*_C"_X/1/\ DUG]A+_L[^7_ -5UKE?V>U_&%_P>B?\
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MXF_&[]BN;]KSX4>,_P!D+3/BWJ>GZYXN^#%[J_[2'P)L?C3\)DURVM+.74]
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M%I[^T@@\20Z?XR33)YSX>U-(OZ\_V>O^2 _ [_LC_P ,_P#U"]$H /VA?^2
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M-5L-&\3>&7U?3M.EU6&W/Y+_ /!)7_E4?_X*P_\ 90/VG_\ U27[.U '6?\
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M/AOXG?Q9,)IET7Q)XG^'OPG\=Z]H;7:N&/[1W@VX$4HU&UM' /5;WXH_'/\
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MUW8Z9J>AVNDS:;/;:YJ6L^V?#[]EV^_X(!_\'"'[$W[.'[)GQI^*?B+]D_\
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MM)\8N5^-5E<QS7$=POD\)_P2]_Y6Q_\ @LK_ -D UG_U,_V2ZTO^"H']G_\
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M=>-_V0_B3X0MK\2RPFQG\2ZE^RYHT-X)H09HC;27JS"6(&6,INC&X"@#Y_\
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MPX_9U^%GP"\<Z;:/;QWGA?XC? GP5H7PR\6:'JNFPNTFDS2W7AR+7])MKB.
MWOAC7-!UJTB.FZK922?@#^U-\<?AY\7O^#R;_@GKX4\!:UI'B"^_9_\ V?\
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M8WIM[S3[VQOM1T+7]+UKPYJ^KZ-?_P Z4/\ P:>>&M<T[PS\'OBG_P %4O\
M@H!\3_V-_"=WI,^C_LJ:QXT,'A&TM-$N(+C3M,LVN]=UGP%I%I ;2UBBDT'X
M3Z3>6<<0?2[K3[E+:XMOZYJ* /*/@9\#_A3^S5\(?A[\!O@?X+TCX>?"?X6>
M&K'PGX'\'Z)'(MCI&CV(=OGGN))[W4M3U"[EN=4UO6]3N;S6->UJ^U#6M9OK
M[5+^\NYO5Z** /R'_8;_ .".GP._8/U']O34?AU\3_BOXPE_X* >)[GQ3\28
M_&LGA!H_!EY<S_%6=[?P/_87AK266V5OBUK07^WFUB7;INEYD)%V;CT[_@E=
M_P $QOA+_P $G?V<?$'[-/P:\?\ Q%^(_A3Q%\6_$OQ?NM>^)S^&G\0P:WXG
M\,>"?"UWIEN?"NA>'M-_LJWL_ VGW%L)+%[O[3=WGFW,D1@CB_2JB@#\KO\
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MWM]5TOPYJ/Q"N?"!NTDDUOP]KK- UO\ TDT4 ?F'_P %5_\ @E-^SY_P5L^
M&C? _P".>L>,?!=_X)\6IX[^&GQ*\ W&GQ^)?!GB?^S;K1[T/I^L6=]H^O\
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M:UKUQX?T?5_"OB'1KG7]3*7_ (BT?PUXWT7PKJMY$-17P_::Q<7^IWG]']%
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MQ-=:]%;Z=]A_>>B@#^>3]B__ (-V_@1^SW^TCX:_;+_:D_:7_:2_X*+?M3^
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M:2Z:.9YY9_ZTJ* /S[_X)S_\$R/V3O\ @ES\&+KX,?LL^#]1TZV\0:G;Z_\
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MUWX<V%E916MG'ID5I\(8TTN2V2>T12L"0?UJ44 ?.?[*'[)OP"_8C^!?@O\
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MEU:Z\/Z^NF7P\$7NF:G"8;35)]'^%GA[59IS>:G9ZC87MS;O8_JO_P $X_\
M@CI^S5_P3!^+_P"US\4OV<]<\:0:5^UIXB\*ZQ?_  PU9/#4/@/X3Z3X+UKX
M@ZMX<\)?#:#1]#T[6(M!TV#XA7NDQ?\ "1ZIKFH-8Z5IC2WLEV;RXN?UKHH
M_*[]GS_@D[\&OV=?^"D/[4O_  4P\,?$?XG:Y\5_VK?!=UX)\9> M>?PJ?AY
MX<T^[U7X;:L]WX933_#UEXD6\6;X9:3&IU77-0A\J_U',1<VS0=__P %/?\
M@FI\#_\ @JK^S,_[,OQUUGQ;X4T.S\>^%OB3X9\:^ VT./QAX3\5>%UU*P6\
MT>3Q%I&N:5LU;P]KOB#PYJ45UITP?3M9N'A,5U%;S1_HE10!\G_L-_L=?"S]
M@/\ 95^#W[(_P9DU>[\ ?!W0+W2M.UCQ$=/?Q'XDU76]=U7Q3XG\4>(9=*L=
M-T^76?$?B77-6U>^-G8VMK%)=BWMH8[>&)%^7OV?/^"3OP:_9U_X*0_M2_\
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M_P""A7[$O@'_ (*+_L?_ !=_8V^*'BSQAX'\"_&+_A ?[<\4> FT5/%FE_\
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M27D/AIO%/AB#Q9KVI>._#_V3Q-=I\.-!\/\ B/Q;J"'3P#^F6OR]_P""P?\
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MOQ%JWAF&Z5?%_C'1_$>D>*M)UW1-8%DKB7?_ ."O7_!;'QM^Q5\;/@S^P?\
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MJ7]H+XLW.L>"O@+9?&2^D_M9?AE\"/"_B;XS:/K5[>>'?".H^&+_ %W4-?\
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MV_$K3-2M?"]D'\0:_;W%GJUE8):WZ>)O%O@70EN-;T+[G_X( ?\ !67XU_\
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M_P"TQX4M]-@MUDEO+K4KS5OV,O$D#VRQ!7+XL$MECDDEEE5@(OTC_P""6_\
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M7J,=K#::1I"WD&CZ78V&AZ#I]CI>FZ;IUG$4O-1;4-5U  _T+J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6]?TL0WEYHFJ0)"U\+I&LW::WC1XFD -SX:?\&P/_!'/X2?$;P!\5O W[/\
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M^&-=LHEU/7;&2*33I'N4AADMY)?W:_X(/?L[_&;]E#_@DY^R+^S]^T)X%O\
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MM6T75;.:PU73-3L[E7M[O3[^QGGM;VVG1X9[:62*561V!_C0_P"#+"'2;?\
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M>S+#!J7B3QAIUQI4",DF\RM>_MB>%K"UD!VM%=W^K)9QLNV:"<2!1G?L<?\
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M+J^F^&-9_:3^-O\ PE.D:;>,#+:Z)!/X#^'5DMI:-]BFM-+T,+F*RL\?8_\
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MWU[_ ,$-O^":W[:G[/OQ"_::_;V_X*2?$RXUS]K[]KW5KRXO/@]X>\83^(/
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M^ =4UCPKJFH7MCXT\&Z/IOA>X34/#FO:SH:+JU];3V\*S:I&\+1EKI((RKD
M^:O^#,+PAX0TC_@EQ\5_%^CVUF_BSQC^V'\1;;QEJBVULNI;/#'PS^$%KX<\
M/W%[&#<SZ;I5AJ-SK6G6ERP2TO/%.L36\2"_EDF\V_X/4=*TBV_8I_8T\?:<
M3;_%7PK^V1::5X$U.QMLZ]8Z1KWPF^(&M>(SI%_%F[M2WB/P9\/+A[:W!^UW
MEGILS?O;""OBG_@D=^S9_P %]/\ @B7\$];^(?A?]AV/]J+X4?&CQEK\_P 7
MOV+&^)'@_P '_&3X9>+?"-II%CX8^,/@SQ3H5WX_T_5]+^(/ADOX?U&PT+1_
M%NJ-<>';&'5_"FE)IVD:WJOV]HG[$_\ P4T_X+C?MU_LY?M/_P#!3C]FW2OV
M'OV$/V0];C\:?##]DG6_&-OXT^(/Q7\6W,^FZW=)XN^QKIM_)!JFM^'O#-IX
MTUOQ=X5\!11>"=,7P;X,\'S:EKWBWQ;" ?/7_!VS<?&KQ;^T/_P1$^&WA_0/
M!L_B+Q7\2_'EQX?T;QU<S)\*?$/QJU3QQ^S'H-CH'CIQ/;8\&Z/?:A96FLW(
MOH)D\-^*-7/GPY$U?>?_  F7_!X%_P!$F_X)@_\ @RUG_P">77Z#_P#!=7_@
MDM-_P5=_9>\,>&/AQXOTSX9_M1? /QF?B;^SE\1]7O-7TW2;#6[F&TM?$_@[
M7M5T*WOM9T31/%UMIVBW\?B#1M/N]6T'Q7X4\)ZO#%<6-IJ6GW_Y@^"?^"J?
M_!Q=\%/AKIGP1^,O_!#WQ%\>_P!H31=#O?#6G?M#^"OBO:67PN\4:GH$/V"R
M\9^,_"_@_P /^-/#]S=:JJ6VI:K#IGQ;^'EGXDO)+V70-/\ #4,JZ;IP!?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"]#OO$?B+5)AD%H[#2--O+IU!!81%1R17\)_[._PA_;"_P"#K7XO?%W]H/\
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M9M'U+3]3$ILKRWGD /;Z*0D*"S$*J@EF)   &223P !R2> *^/M-_P""AW[
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M=A?V.J6=MJ.F7MIJ.GWD2SVE]87,-Y9W4#\I-;75N\D$\3CE9(G9&[$U;K^
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MBX@B>>&-X1OH ]VHKXS^*'_!1G_@G]\$?'C_  N^,7[;O[)OPN^),%Z-.O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^*/\ P<8:[XB\._\
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MG_!4+_@F'_P6M\$6-S:>%M.\>Z;^SS^TW/I=M+_IWA^V@UK'GK LAOM=\<_
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M>QL^H>,OCC8W.CV?B'PY?12>5+>>%_ #^+_B5I=Q$\D<L?A,2(LJD*W\8_\
MP5)_9)UO_@F__P $!/\ @D%H-G!)X3^.&N_M-W7[4OQ"U#[) NJZ7\7/B'\,
M-0\::+!J-I=036[:Q\/O"]EX%\#74-S#<V\ESX.)D2:.1E:;]E_X^^(_^"Y7
MC'_@@9_P3-\1MJNN^$OV//#WC#X@?MF6U[;W$NDZQX8^!?B6X\-> --\0W%S
M;(]U=WWP-^'OACP8=503LOB#XZ74%_<W=ZLLT/[.?\'H8"_LL?L(JH"JO[7T
M@50   /AUK@  '  '  X H ^]_V!?^#:K]A+]F+5OV7OVF_'MA\4_BA^VO\
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M'_P<^?MJ?#K_ ()W_L/1:Y:?\$YOV9/B18?$?]IS]K$:?<VGA[Q5K=G:ZEH
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M_B7XG?PYK7P@^'&@Z9K?A>S\83?$OP)K7A?Q3_PE]GI.B^*-/\71>''M(?\
MA(M&TCQ(=->6]T"6WE_/?_@H!_P;I?\ !"GXA?LX?$']IOP]>^'OV+_#EMX
MU+QYI/[1'P>^*[3_  66)]+>_P##>MR^#/%&N>)_AKX@\+:C<?9(X-"^'"^$
M=5\6072Z9X<UJVU>^L+R( ^@/VAOV=_V]?V"_P#@W)^.7[.O@KXW:U^T'^U-
M\#O@/JGA;PA\6?A[H_BS0_&K?".7XA:5/XFL=!235_$'B8^(/A?\"-3\8>&O
M"6LZ5<V>HII/A3PY=65OINIVS3+^&/\ P1M\-?\ !K'\;OV-O@Q\)?VB=(^!
M^B?M=ZKX1&D_'F;]J?Q?XY^'/BS7/B?JHFL=;O\ P+\4M4U_PQ\/;+P_J4^P
M?#G3/A_XHTW7-(TTZ2NJV,7CJ?5;_4?J3_@B7_P55_:5_9H_X-\?C)^V+^T/
M\./BO^U3X7_97^/NH?#KX;+-XK6Q\7ZE\#)--^%.B6K0>)?$.G:U?:KX,^%O
MC_Q?JVC7.L^3K!\/^%X-0TVVBCTSP!+9P_H!X%_X)F?\$(?^"X_[-GA#]LWP
MU^SE\.O!GB'XL^&K+Q%X^\0? 'QG<_"[QW\*OB5>:;!<^._!_P 1=)\#3Z-X
M%O\ QWX8UK[;;:SJWCCX>7__  D?E)XQLUO-,UZTU.] /HO_ ((O_P#!*KQ3
M_P $J)_VL--\+?M1Z1\8OV,?C?X[B^)W[/?PZ:#4[ZZ^#^B6=SKIM]5E\<-K
ML_ASQ'>^*/!6H>'=)\9:II&A6%KK%UX$T#7+>Y07-Y:K_*]^Q%\9_P#@G1_P
M5]_;2_:H_;^_X+7?M3?"_0O GA3XA?\ "$?L<?L<?&7XZR>!/!?ACX?/;27<
M.H-X='B#P_J-WH.BZ-%X2ANX]'AT;1/'OQ%E\9^)/%]IJ=RCZ:/L/_@WGT.\
M^ __  5H_P""E/\ P3(_9U_:#\8_M2_\$T_!GPB\5ZGI?BZ?7+#5_"F@^/=2
MUCX7Z1#=:9JVAQ/X.7QB4\5?$OX9^)-6\&6FA:3\2[WP-+XUATB&QT"ST_3O
ME/\ X-^?V0O^":^G_&[]LC_@F5_P5/\ V>/@K??MK?"/XZZC+\,;[XUR'2+W
MQ_X7M](L/#FM>"_A]JLVN:3:^(!ITWARR^)/AG3;1)[GQ1X2^(,WBOPT=5T>
MSU6XT\ M_P#!6[3?^"0G[&^D?";_ (*%_P#!#O\ :U^ WPB_;!^!'Q2\%KKG
MP?\ V?/CQ'XBT#XN?#C5]2:#6HM0^'A\5:C>7<-CJ$>BVOB[0]&EM_"WBGX?
MWOBFT\6^'M2:.TU33OK'_@Z>^..G?M-_\$O_ /@D7^T=I-A%I.G?'OXH_##X
MQVNCPW@U!-%C^)7P"_X3 Z(;T10&YET9]8;3)Y'@@E,]K()8()0\2?4W_!7#
MX5?\&\W_  2;\#^!KGQ9_P $WO@%\<?CG\2?&&B^'O!O[-O@76)]+^)>H:!?
M?:'U7QW?6DE_KMWI/AO33#;Z9IDMWI ;Q-XDU33=$TAF']J7VE?+W_!U1X7\
M.^"_^"9O_!)[POX2^$0^ /AO1_C-X&M]'^!OVF&]?X/VC_!2ZG7X:S7EL\MM
M=7/@IYG\/75Q;2R6TUSI\LEO))"R.0#W/_@OW_RG<_X-X_\ LO\ X+_]:4^#
M]?V>U_&%_P %^_\ E.Y_P;Q_]E_\%_\ K2GP?K^SV@#Q_P#:%_Y(#\<?^R/_
M !,_]0O6Z_CB_P"#27_E"]_P4&_[+_\ 'G_UE+X.5_8[^T+_ ,D!^./_ &1_
MXF?^H7K=?QQ?\&DO_*%[_@H-_P!E_P#CS_ZRE\'* /@S_@US_P""2/P#_P""
MBW[/_P 1OCM^V_:^*/CC\&/@-\8/$7P>_9]_9YU;Q9XK\/\ PI\+^--9\)^$
M?B!\7OB+J.E^%];T:77?$'B"T\7?#[2K97GMK9(M"+:ZGB 6GA:+PQ[)_P %
M*/V&O@K_ ,$3/^"S'_!'/]H#_@GUI&I?!CPW^U)\;KKX:?$'X26GBSQ=KWA9
MK'3/B-\'/ WQ'AL;KQ/K&M:U;:'\1O WQZ;3+CP[-JM]H6AZKX=M-6T32[#;
M#;+^E_\ P9A?\HH/BA_V>_\ %S_U3_[/=>/_ /!TG_R?U_P;M?\ 9W_Q#_\
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MM-?&FOW>H _SA;K]A6P_X*6?\'/G_!13]D3XC^./'7AO]FRXUJ'X\_M#^%?
M6I?V)J7Q*\/?![PM\,-%\$>%+_7$AFETW23\0?B;H%W>R^5<+Y4;2V,5GXD@
M\/:]HGZ'?\%T_P#@EQ^Q[_P3"_X(>?M=>%_V1/!&N^#=$^,O[2?[-GC3Q9!X
MC\6ZOXUO89M"\5Z9HFA>'],USQ#)=:]_PC6BQRZMJ&G6.KZGJ]Y!J?B+7;@Z
M@\5Y%;V_7_\ !+W_ )6Q_P#@LK_V0#6?_4S_ &2Z^W_^#MG_ )0N?&'_ ++!
M\ /_ %8VG4 ?D=_P5G_:5^..O?\ !.'_ ((%_P#!)_\ 9U\93^ ?%7_!1_X
M?LA^!?B9XHM9[^RD_P"$!U'X<_ GX9^&/!NJ7>GM]L_X0KQAXN\>W>K>.[>Q
M$=S?:%X"&AW<LV@Z[K6G:A^UD'_!K;_P1YA_9OA^ A_9_P!5/BF+PU'IQ_:1
MC\=^+(?CV?%R6@3_ (6%'KRZHWA:+53J(_M-?"R^$S\.T;%@/"!TX?9J_!7_
M (*U^ _&OP&_91_X-G?^"K_ASPKJ?BSP'^QA\+OV++3XTVFA G5K?2+7P?\
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MY^UK\;?B7XTMO"OP1^/OQW'ASP]\(?ASI>J&/25MOA^?%NGW=I97&H3ZY9>
M_"FI%_"'A'P%;Z$WA[0TN[T:E%[G_P $'/"?QW_:H_8+_P""[G_!-7PE\5?$
M'[17[-'@3POX^^!_[#WQ5UZ]GTWPGJ7B7Q=H?QYT#0(_!\^KW.H0Z#X/\9OH
M'PI^(]WX3M=6?1_!J>()KK9%)XMFOKAW_!MA^S#_ ,$>OVN_V:=:_9E_:Z_9
M;^!VH?\ !07]GSXE?$;PQ\1/"OQ?M[K0/BUXX\,7'BW4-5TC7++0[K7=,O\
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M_@W4TO3[:*RL--^.7@'3[*S@+&"TM+/]HWX-VUM;0E@&,4$,:11E@&V(,C-
M'WEX7_X-6/\ @ES\,_AG\1?#WPV\&^/'^)?CG]F3XG_L_GXC?$'QWJ?C)%\1
M_$/1(K*U^,LGAJZMUT/1O'WAG5+2UO-%D\'V/A_0;6SEO[1] NY;A;A/+O\
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M55OJZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#!/S]H'_@KA_P1O_X)R_\ !(3P-\+]4^%O[(?QQ\0_'K]HGQ=\#KVZ\?\
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M*TVQ?3]-T_Q5-IC3Z!XL&F6HM8--U#Q)H&J:SIUGIUAI=EJ<&CPMITGZ^T4
M?A[^Q-_P;L_\$K/V#OB1X9^,_P )_@7K'C7XR>"IH;SP=\2_C3XYU_XB:OX6
MU6##1Z_H'AN:32_AWI?B:"98KG3_ !-:>"XM>T2XB$N@:CI327'G?>W[='[
M/[+/_!1SX*O\!?VL?ARGC[P1;Z[9^*_#MW8ZMJ7AOQ9X+\6Z?;7=E9^)O"'B
M?1I[;4M(U-+&_OK"ZBWW&EZKIUY<Z=K.G:C8S/;G[,HH _&/P%_P01_X)R^
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MN_C+^TE?^%7NH&5DBN? M]\9+GP1>Z:Q0";1KSP]/I%RI9+BQE1W5@#\J/\
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MH.EIHVGZ1J6H:]-?W^M+_9T8MKJ;59[J:\0O]J>4NV?8J* /Q)_9P_X-[_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cprx-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-26T09:43:59.3961+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://catalystpharma.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cprx="http://catalystpharma.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail2" id="DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail2">
        <link:definition>100020 - Disclosure - Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome" id="ConsolidatedStatementsOfOperationsAndComprehensiveIncome">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical" id="ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies" id="BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/Investments" id="Investments">
        <link:definition>995475 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome" id="DisclosureAccumulatedOtherComprehensiveIncome">
        <link:definition>995485 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/Inventory" id="Inventory">
        <link:definition>995495 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995505 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases" id="OperatingLeases">
        <link:definition>995515 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>995525 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet" id="LicenseAndAcquiredIntangiblesNet">
        <link:definition>995535 - Disclosure - License and Acquired Intangibles, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
        <link:definition>995545 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements" id="CollaborativeAndLicensingArrangements">
        <link:definition>995555 - Disclosure - Collaborative and Licensing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995565 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/Agreements" id="Agreements">
        <link:definition>995575 - Disclosure - Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995585 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>995595 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensation" id="StockCompensation">
        <link:definition>995605 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan" id="BenefitPlan">
        <link:definition>995615 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995625 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>995635 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>995645 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables" id="InvestmentsTables">
        <link:definition>995655 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" id="DisclosureAccumulatedOtherComprehensiveIncomeTables">
        <link:definition>995665 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InventoryTables" id="InventoryTables">
        <link:definition>995675 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables" id="OperatingLeasesTables">
        <link:definition>995695 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>995705 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables" id="LicenseAndAcquiredIntangiblesNetTables">
        <link:definition>995715 - Disclosure - License and Acquired Intangibles, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
        <link:definition>995725 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables" id="AgreementsTables">
        <link:definition>995735 - Disclosure - Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>995745 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables" id="StockCompensationTables">
        <link:definition>995755 - Disclosure - Stock Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" id="OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>995765 - Disclosure - Organization and Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail" id="BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail">
        <link:definition>995785 - Disclosure - Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail">
        <link:definition>995795 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail">
        <link:definition>995805 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail" id="BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail">
        <link:definition>995815 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails">
        <link:definition>995825 - Disclosure - Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail" id="InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail">
        <link:definition>995835 - Disclosure - Investments - Summary of Available-for-Sale Investments by Security type (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail" id="InvestmentsAdditionalInformationDetail">
        <link:definition>995845 - Disclosure - Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail" id="InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail">
        <link:definition>995855 - Disclosure - Investments - Estimated Fair Values of Available for Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail" id="InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail">
        <link:definition>995865 - Disclosure - Investments - Summary Of Net Gains And Losses On Equity Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail" id="DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail">
        <link:definition>995875 - Disclosure - Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail" id="InventorySummaryOfCurrentInventoryDetail">
        <link:definition>995885 - Disclosure - Inventory - Summary of current inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" id="PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995895 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail" id="OperatingLeasesAdditionalInformationDetail">
        <link:definition>995905 - Disclosure - Operating Leases  - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail" id="OperatingLeasesOperatingLeasesDetail">
        <link:definition>995915 - Disclosure - Operating Leases - Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail" id="OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail">
        <link:definition>995925 - Disclosure - Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail" id="OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail">
        <link:definition>995935 - Disclosure - Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail" id="OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail">
        <link:definition>995945 - Disclosure - Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetPropertyAndEquipmentNetDetail">
        <link:definition>995955 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail" id="LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail">
        <link:definition>995965 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail" id="LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail">
        <link:definition>995975 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail" id="LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail">
        <link:definition>995985 - Disclosure - License and Acquired Intangibles, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" id="AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail">
        <link:definition>995995 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail" id="CollaborativeAndLicensingArrangementsAdditionalInformationDetail">
        <link:definition>996005 - Disclosure - Collaborative and Licensing Arrangements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996015 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail" id="AgreementsAdditionalInformationDetail">
        <link:definition>996025 - Disclosure - Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail" id="AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail">
        <link:definition>996035 - Disclosure - Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail" id="AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail">
        <link:definition>996045 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail" id="AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail">
        <link:definition>996055 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail" id="AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail">
        <link:definition>996065 - Disclosure - Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail" id="AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail">
        <link:definition>996075 - Disclosure - Agreements - Summary of aggregate amount paid for the assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail" id="AgreementsSummaryOfTotalPurchasePriceAllocatedDetail">
        <link:definition>996085 - Disclosure - Agreements - Summary of total purchase price allocated (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail" id="DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail">
        <link:definition>996095 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>996105 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail" id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail">
        <link:definition>996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" id="IncomeTaxesComponentsOfDeferredTaxAssetsDetail">
        <link:definition>996125 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail" id="StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail">
        <link:definition>996135 - Disclosure - Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail" id="StockholdersEquityShareRepurchasesAdditionalInformationDetail">
        <link:definition>996145 - Disclosure - Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail" id="StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail">
        <link:definition>996155 - Disclosure - Stockholders' Equity (2020 Shelf Registration Statement) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail" id="StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail">
        <link:definition>996165 - Disclosure - Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail" id="StockCompensationStockBasedCompensationExpenseDetail">
        <link:definition>996175 - Disclosure - Stock Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail" id="StockCompensationAdditionalInformationDetail">
        <link:definition>996185 - Disclosure - Stock Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail" id="DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail">
        <link:definition>996195 - Disclosure - Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail" id="StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail">
        <link:definition>996205 - Disclosure - Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail" id="StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail">
        <link:definition>996215 - Disclosure - Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail" id="StockCompensationSummaryOfRestrictedStockUnitActivityDetail">
        <link:definition>996225 - Disclosure - Stock Compensation - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail" id="BenefitPlanAdditionalInformationDetail">
        <link:definition>996235 - Disclosure - Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
        <link:definition>996245 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" xlink:href="cprx-20241231.xsd#ConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail2" xlink:href="cprx-20241231.xsd#DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome" xlink:href="cprx-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:href="cprx-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails" xlink:href="cprx-20241231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail" xlink:href="cprx-20241231.xsd#DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail" xlink:href="cprx-20241231.xsd#InventorySummaryOfCurrentInventoryDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="cprx-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail" xlink:href="cprx-20241231.xsd#OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail" xlink:href="cprx-20241231.xsd#OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail" xlink:href="cprx-20241231.xsd#LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail" xlink:href="cprx-20241231.xsd#LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:href="cprx-20241231.xsd#AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail" xlink:href="cprx-20241231.xsd#AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail" xlink:href="cprx-20241231.xsd#AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail" xlink:href="cprx-20241231.xsd#AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail" xlink:href="cprx-20241231.xsd#AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail" xlink:href="cprx-20241231.xsd#AgreementsSummaryOfTotalPurchasePriceAllocatedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail" xlink:href="cprx-20241231.xsd#DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail" xlink:href="cprx-20241231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:href="cprx-20241231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/CoverPage" xlink:href="cprx-20241231.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="cprx-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical" xlink:href="cprx-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="cprx-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="cprx-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness" xlink:href="cprx-20241231.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/Investments" xlink:href="cprx-20241231.xsd#Investments" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome" xlink:href="cprx-20241231.xsd#DisclosureAccumulatedOtherComprehensiveIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/Inventory" xlink:href="cprx-20241231.xsd#Inventory" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="cprx-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases" xlink:href="cprx-20241231.xsd#OperatingLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet" xlink:href="cprx-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet" xlink:href="cprx-20241231.xsd#LicenseAndAcquiredIntangiblesNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities" xlink:href="cprx-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements" xlink:href="cprx-20241231.xsd#CollaborativeAndLicensingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:href="cprx-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/Agreements" xlink:href="cprx-20241231.xsd#Agreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes" xlink:href="cprx-20241231.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity" xlink:href="cprx-20241231.xsd#StockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensation" xlink:href="cprx-20241231.xsd#StockCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan" xlink:href="cprx-20241231.xsd#BenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents" xlink:href="cprx-20241231.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables" xlink:href="cprx-20241231.xsd#InvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" xlink:href="cprx-20241231.xsd#DisclosureAccumulatedOtherComprehensiveIncomeTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InventoryTables" xlink:href="cprx-20241231.xsd#InventoryTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="cprx-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables" xlink:href="cprx-20241231.xsd#OperatingLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:href="cprx-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables" xlink:href="cprx-20241231.xsd#LicenseAndAcquiredIntangiblesNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="cprx-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables" xlink:href="cprx-20241231.xsd#AgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables" xlink:href="cprx-20241231.xsd#IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables" xlink:href="cprx-20241231.xsd#StockCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail" xlink:href="cprx-20241231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail" xlink:href="cprx-20241231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail" xlink:href="cprx-20241231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail" xlink:href="cprx-20241231.xsd#InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#InvestmentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail" xlink:href="cprx-20241231.xsd#InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail" xlink:href="cprx-20241231.xsd#InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#OperatingLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail" xlink:href="cprx-20241231.xsd#OperatingLeasesOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail" xlink:href="cprx-20241231.xsd#OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:href="cprx-20241231.xsd#PropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#CollaborativeAndLicensingArrangementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#AgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail" xlink:href="cprx-20241231.xsd#AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#StockholdersEquityShareRepurchasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail" xlink:href="cprx-20241231.xsd#StockCompensationStockBasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#StockCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail" xlink:href="cprx-20241231.xsd#DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail" xlink:href="cprx-20241231.xsd#StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail" xlink:href="cprx-20241231.xsd#StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:href="cprx-20241231.xsd#StockCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#BenefitPlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail" xlink:href="cprx-20241231.xsd#SubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementMember" xlink:label="cprx_LicenseAndAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AfterAgreementOfCompanyLeasedSpaces" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonRefundableUpfrontLicenseFeesMember" xlink:label="cprx_NonRefundableUpfrontLicenseFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedGrossToNetRevenueLiabilities" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInProcessResearchAndDevelopment" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DueFromCollaborativeAndLicencingArrangements" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementLineItems" xlink:label="cprx_LicenseAgreementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccretionOfDiscount" xlink:label="cprx_AccretionOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPurchasePriceConsideration" xlink:label="cprx_AssetAcquisitionPurchasePriceConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementTable" xlink:label="cprx_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementWithBioMarinMember" xlink:label="cprx_LicenseAgreementWithBioMarinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:label="us-gaap_OperatingLeasesLeaseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementAxis" xlink:label="cprx_CollaborationAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyalty" xlink:label="cprx_MinimumRoyalty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OptionsToPurchaseCommonStockMember" xlink:label="cprx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" xlink:label="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DisclosureOfOperatingLeasesAbstract" xlink:label="cprx_DisclosureOfOperatingLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedVariableConsideration" xlink:label="cprx_AccruedVariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" xlink:label="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationArrangementDisclosureAbstract" xlink:label="cprx_CollaborationArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementDate" xlink:label="cprx_LicenseAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PublicOfferingMember" xlink:label="cprx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareRepurchases" xlink:label="cprx_ShareRepurchases"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerAMember" xlink:label="cprx_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxCreditsRate" xlink:label="cprx_EffectiveIncomeTaxCreditsRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomersMember" xlink:label="cprx_CustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FycompaMember" xlink:label="cprx_FycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionValue" xlink:label="cprx_AssetAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPayment" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitDomain" xlink:label="cprx_RoyaltyThresholdLimitDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInvestmentSharePrice" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" xlink:label="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RegulatoryFilingMilestoneMember" xlink:label="cprx_RegulatoryFilingMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCommercialExpenses" xlink:label="cprx_PrepaidCommercialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidManufacturingExpense" xlink:label="cprx_PrepaidManufacturingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" xlink:label="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SharePurchaseProgramMember" xlink:label="cprx_SharePurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContractualTerm" xlink:label="cprx_ContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanHundredMillionMember" xlink:label="cprx_RoyaltyLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForSantheraSalesBasedMilestonesMember" xlink:label="cprx_RoyaltyForSantheraSalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramExpirationDate" xlink:label="srt_StockRepurchaseProgramExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyAgreementTerm" xlink:label="cprx_RoyaltyAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCopayAssistanceProgram" xlink:label="cprx_PrepaidCopayAssistanceProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesRoyaltyThreshold" xlink:label="cprx_NetSalesRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidSubscriptionFees" xlink:label="cprx_PrepaidSubscriptionFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UpFrontPayment" xlink:label="cprx_UpFrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMaximumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOnMilestonePayment" xlink:label="cprx_PaymentOnMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInventoryCurrent" xlink:label="cprx_AssetAcquisitionInventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssetsAbstract" xlink:label="us-gaap_PaymentsToAcquireProductiveAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityTable" xlink:label="cprx_ScheduleOfRestrictedStockActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_BeforeAgreementOfCompanyLeasedSpaces" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureLineItems" xlink:label="cprx_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquistionPrepaidCommercializationFees" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentInConnectionWithAssetAcquisition" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltiesExpensePolicyTextBlock" xlink:label="cprx_RoyaltiesExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageDomain" xlink:label="cprx_ThresholdNetSalesPercentageDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandEighteenStockIncentivePlanMember" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizationExpensesOfIntangibleAsset" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedPurchasesCurrent" xlink:label="cprx_AccruedPurchasesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYear2026Member" xlink:label="cprx_CalendarYear2026Member"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedAxis" xlink:label="cprx_ComponentsOfRevenueRecognizedAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitAxis" xlink:label="cprx_RoyaltyThresholdLimitAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYears2022Through2025Member" xlink:label="cprx_CalendarYears2022Through2025Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementAxis" xlink:label="cprx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementDomain" xlink:label="cprx_CollaborationAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMinimumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndOtherRevenueMember" xlink:label="cprx_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureTable" xlink:label="cprx_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" xlink:label="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborativeArrangementMilestonePaymentObligation" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedDomain" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:label="cprx_ScheduleOfRestrictedStockActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedNonClinicalAndClinicalTrialExpenses" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_KyePharmaceuticalsMember" xlink:label="cprx_KyePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceOfAnAssetAcquisition" xlink:label="cprx_PurchasePriceOfAnAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonCashChangeInRightOfUseAsset" xlink:label="cprx_NonCashChangeInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodAxis" xlink:label="cprx_PeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorNoncurrent" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsTable" xlink:label="cprx_CommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyaltyAmount" xlink:label="cprx_MinimumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MilestonePaymentMember" xlink:label="cprx_MilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementDomain" xlink:label="cprx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DydoPharmaIncMember" xlink:label="cprx_DydoPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RightOfUseAssetsObtainedAbstract" xlink:label="cprx_RightOfUseAssetsObtainedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LiabilitiesArisingFromAssetAcquisition" xlink:label="cprx_LiabilitiesArisingFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionBaseCashPayment" xlink:label="cprx_AssetAcquisitionBaseCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgamreeMember" xlink:label="cprx_AgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementsDisclosureTextBlock" xlink:label="cprx_AgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesBasedMilestoneToRoyaltyThreshold" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingExpense" xlink:label="cprx_OperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageAxis" xlink:label="cprx_ThresholdNetSalesPercentageAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPropertyAndEquipmentNet" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerBMember" xlink:label="cprx_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ReimbursementOnBasePurchasePrice" xlink:label="cprx_ReimbursementOnBasePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedLicenseFeesCurrent" xlink:label="cprx_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FirdapseMember" xlink:label="cprx_FirdapseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidResearchFee" xlink:label="cprx_PrepaidResearchFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidConferenceAndTravelExpenses" xlink:label="cprx_PrepaidConferenceAndTravelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ClosingMarketPrice" xlink:label="cprx_ClosingMarketPrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsLineItems" xlink:label="cprx_CommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorCurrent" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PresidentAndChiefExecutiveOfficerMember" xlink:label="cprx_PresidentAndChiefExecutiveOfficerMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of&#160;available-for-sale&#160;securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option exercise price range, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transaction expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition,, prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Prepaid Expenses And Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets (samples)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets (samples)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Asset Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After agreement of company leased spaces.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Agreement Of Company Leased Spaces</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After agreement of company leased spaces</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets and Liabilities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other comprehensive gain (loss) before reclassifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NonRefundableUpfrontLicenseFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront license fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NonRefundableUpfrontLicenseFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued gross-to-net revenue liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued gross to net revenue liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued gross-to-net revenue liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred&#160;- Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders' equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of trading days from receipt of the notice letter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Trading Days From Receipt Of The Notice Letter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of trading days from receipt of the notice letter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for pre-commercialization fees that provide economic benefits with a future period of one year or the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due From Collaborative And Licencing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from collaborative and licensing arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock units, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate share repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Repurchase of common stock (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire productive assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more seven hundred and fifty million and less than one billion member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price consideration for intangible assets acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Consideration For Intangible Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and acquired intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License and acquired intangibles for vamorolone (IPR&amp;D)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INVENTORY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccretionOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount represents accretion of discount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccretionOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccretionOfDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPurchasePriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition purchase price consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPurchasePriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset acquisition purchase price consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementWithBioMarinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement with BioMarin.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementWithBioMarinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement With Bio Marin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementWithBioMarinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement with BioMarin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic value, Exercisable at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liabilities arising from obtaining right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Arising From Obtaining Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for the carrying amount as of the balance sheet date of expenditures made in advance of the timing of recognition of expenses which are expected to be charged against earnings within one year or the normal operating cycle, if longer. Includes, but is not limited to, prepaid research, prepaid product development activities and prepaid insurance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COMPREHENSIVE INCOME</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesLeaseIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Lease Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition percentage of outstanding ordinary shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Percentage Of Outstanding Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition Percentage Of Outstanding Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Asset acquisition percentage of outstanding ordinary shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for expected credit losses, written off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum royalty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Royalty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum royalty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ADVERTISING EXPENSE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than five hundred million and less than seven hundred fifty million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Five Hundred Million And Less Than Seven Hundred Fifty Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DisclosureOfOperatingLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DisclosureOfOperatingLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Operating Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Outstanding at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, Outstanding at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other &#8211; non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserved for issuance under the Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of contractual term of option awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payments Award Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option granted, contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (Note 4)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INVESTMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum length of time to maturity for instruments included as cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Maturity Period Of Cash And Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum maturity period of cash and cash equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement Specific to Assets or Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, accrued preclinical and clinical trial expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Accrued Preclinical And Clinical Trial Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued preclinical and clinical trial expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued preclinical and clinical trial expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued variable consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Variable Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued variable consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net current period other comprehensive gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities, net of tax of ($20), $4 and ($54), respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Acquired Intangibles, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities by amortized cost unrealized gains or losses and fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities By Amortized Cost Unrealized Gains Or Losses And Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Values of Available for Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ACCOUNTS RECEIVABLE, NET</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Arrangement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Arrangement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Percentage of the Company's Total Net Product Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date on which strategic collaboration is entered into</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested balance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested balance at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current - Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability &#8211; non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareRepurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for share repurchases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareRepurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareRepurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHARE REPURCHASES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options for common stock (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised or released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of total purchase price was allocated to acquire assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Total Purchase Price Was Allocated To Acquire Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Purchase Price Allocated to Acquired Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of total purchase price was allocated to the acquired assets based on their relative fair values [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred - State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxCreditsRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax credits rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxCreditsRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Credits Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxCreditsRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payable to sales based milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable To Sales Based Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payable to sales based milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Votes Entitlement for Each Share Held by Common Stock Holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Votes Entitlement for Each Share Held by Common Stock Holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes entitled for each share of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ProductRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ProductRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ProductRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue, net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FYCOMPA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FYCOMPA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FYCOMPA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired research and development inventory expenses from asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Research And Development Inventory Expenses From Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired research and development inventory expensed from asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative and Licensing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible expense share based compensation cost including salary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Including Salary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive compensation limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and asset purchase agreement payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Asset Purchase Agreement Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Dilutive Weighted Average Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized loss on sale of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Realized losses from sale of&#160;available-for-sale&#160;securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Terms [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyThresholdLimitDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty threshold limit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyThresholdLimitDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Threshold Limit [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition investment share price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Investment Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition Investment Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents &#8211; end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents &#8211; beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_StockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of time in which compensation cost from stock options is amortized on a straight line basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amortization Period Of Compensation Cost On Straight Line Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amortization period of compensation cost on straight line basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Disaggregated Product Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Liability, Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabulor Disclosure of Supplemental balance Sheet Information Related To Lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Balance Sheet related To Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Supplemental Balance Sheet related To Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected remaining weighted average vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than hundred million and less than hundred and twenty five million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RESEARCH AND DEVELOPMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RegulatoryFilingMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Filing Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RegulatoryFilingMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Filing Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and asset purchase agreement payment made in third year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and asset purchase agreement payment made in third year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and asset purchase agreement payment made in third year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCommercialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid commercial expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCommercialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Commercial Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCommercialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid commercialization expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Securities, FV-NI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidManufacturingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid manufacturing expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidManufacturingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Manufacturing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidManufacturingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RECENTLY ISSUED ACCOUNTING STANDARDS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and asset purchase agreement payment made in second year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and asset purchase agreement payment made in second year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and asset purchase agreement payment made in second year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Income [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of fees in connection with issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Operating Lease Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_VamoroloneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vamorolone member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_VamoroloneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vamorolone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_VamoroloneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vamorolone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement by Arrangement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration Payment Arrangement by Arrangement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than ten million and less than hundred million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Ten Million And Less Than Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more two hundred and fifty million and less than five hundred million member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Two Hundred And Fifty Million And Less Than Five Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SharePurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SharePurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SharePurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Purchase Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition consideration transferred investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Consideration Transferred Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Santhera</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current&#160;- State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discretionary matching contributions of employee contributions of an employee's gross salary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized net gains (losses) recognized during the period on equity securities still held at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual royalty on the company's net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Annual Royalty On The Companys Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual royalty on the Company's net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyLessThanHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty less than hundred million member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyLessThanHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Less Than Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyLessThanHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Less Than Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Thousand Twenty Three Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForSantheraSalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty for santhera sales based milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForSantheraSalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty For Santhera Sales Based Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of exercised stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of employee withholding tax related to stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock unit granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRINCIPLES OF CONSOLIDATION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING LEASES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Us Treasury Bond Securities Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Us Treasury Bond Securities Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries - Cash equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase program, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized cost before unrealized gains and losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortized Cost Before Unrealized Gains And Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Information Pertaining to Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than three hundred million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Three Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty More Than Three Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The term of the royalty payments from the first commercial sale of product under the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty agreement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired research and development inventory expensed from asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Research And Development Inventory Expensed From Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired research and development inventory expensed from asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expenses Incurred In Connection With Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expenses Incurred In Connection With Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred in connection with collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of income tax expense computed at statutory federal income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCopayAssistanceProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid copay assistance program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCopayAssistanceProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Copay Assistance Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidCopayAssistanceProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid co-pay assistance program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Exchange Rate, Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Exchange Rate, Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount used to determine the percentage of royalties for the period from the first commercial sale equal to the minimum percentage of net sales in North America for any calendar year for sales up to the amount, and maximum percentage of net sales in North America in any calendar year in excess of the amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Royalty Threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales royalty threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and acquired intangibles, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTwoBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than two billion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTwoBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Two Billion [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition cash paid for pro rated prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Cash Paid For Pro Rated Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for pro-rated prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidSubscriptionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for subscription fees that provides economic benefits within a future period of one year of the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidSubscriptionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Subscription Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidSubscriptionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid subscriptions fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Net Gains And Losses On Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the consideration paid by a third party to acquire that voucher.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of The Consideration Paid By A Third Party To Acquire That Voucher</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of the consideration paid by a third party to acquire that voucher</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Reconciliation of income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential equivalent common stock excluded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Up-front&#160;payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up front payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum royalty payable to net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Royalty Payable To Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum royalty payable to net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for prepaid expenses and other current assets. This disclosure may include the types of prepaid expenses and other current assets and how these are recognize in expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOnMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment on milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOnMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment on Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOnMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment on milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Interest Issued or Issuable, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, inventory current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Inventory Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionInventoryCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Basis Of Presentation And Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges recognized on definite-lived intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCK-BASED COMPENSATION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net gains (losses) recognized during the period on equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">USE OF ESTIMATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Productive Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and acquired intangibles for RUZURGI.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Acquired Intangibles For RUZURGI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Acquired Intangibles for RUZURGI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees contribution of pre-tax annual compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INTANGIBLE ASSETS, NET</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH AND CASH EQUIVALENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfRestrictedStockActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Restricted Stock Activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfRestrictedStockActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Stock Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option exercise price range, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Before agreement of company leased spaces.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Before Agreement Of Company Leased Spaces</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Before agreement of company leased spaces</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of tax impact</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of granted stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than hundred and twenty five million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Hundred And Twenty Five Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of liabilities arising from asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Liabilities Arising From Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of liabilities arising from asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquistion, prepaid commercialization fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquistion, Prepaid Commercialization Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid commercialization expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid commercialization expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Acquired Intangibles For FYCOMPA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Acquired Intangibles for FYCOMPA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, license and acquired intangibles for FYCOMPA&#174;.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition License And Acquired Intangibles For Fycompa</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and acquired intangibles for FYCOMPA&#174;</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">License and acquired intangibles for FYCOMPA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment in connection with asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment In Connection With Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments in connection with asset acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) decrease in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltiesExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltiesExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Expense [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltiesExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ROYALTIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ThresholdNetSalesPercentageDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold net sales percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ThresholdNetSalesPercentageDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Net Sales Percentage [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during the period shares new issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than hundred million and less than two hundred million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Hundred Million And Less Than Two Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage applied to net sales to determine the amount payable as part of the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable To Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Eighteen Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Expenses of Intangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY AND EQUIPMENT, NET</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of vested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedPurchasesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued purchases current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedPurchasesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Purchases Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedPurchasesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CalendarYear2026Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calendar Year 2026 Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CalendarYear2026Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calendar Year 2026 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ComponentsOfRevenueRecognizedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components Of revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ComponentsOfRevenueRecognizedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Revenue Recognized [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyThresholdLimitAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty threshold limit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyThresholdLimitAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Threshold Limit [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CalendarYears2022Through2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calendar Years 2022 Through 2025 Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CalendarYears2022Through2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calendar Years 2022 Through 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than two hundred million and less than three hundred million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than Two Hundred Million And Less Than Three Hundred Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid expenses and other current assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborationAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Outstanding at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME PER COMMON SHARE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUE RECOGNITION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaborative Arrangement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss) Note [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reclassifications out of Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minimum royalty payable to net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minimum Royalty Payable To Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of minimum royalty payable to net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementForRuzurgiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement for ruzurgi.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAgreementForRuzurgiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For RUZURGI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity Under the Company's Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty more than one billion and less than two billion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty More Than One Billion And Less Than Two Billion [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty for additional indications and milestones of up to fifty million more.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty For Additional Indications And Milestones Of Up To Fifty Million More [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired inventory samples expensed from asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Inventory Samples Expensed From Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired inventory samples expensed from asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT INFORMATION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and other revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Other Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and other revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Interest Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amount reclassified from accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty less than two hundred fifty million.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Less Than Two Hundred Fifty Million [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Awards Based on Certain Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Exercisable at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains losses from available for sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum dollar amount of common stock to be issued under shelf registration statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Common Stock That Can Be Issued Under Shelf Registration Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum dollar amount of common stock to be issued under shelf registration statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement milestone payment obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payment Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement, milestone payment obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement, Arrangement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration Payment Arrangement, Arrangement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Components Of revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Revenue Recognized [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2024 and 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfRestrictedStockActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Restricted Stock Activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ScheduleOfRestrictedStockActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Stock Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RECLASSIFICATIONS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of basis of presentation and significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related To Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable pertaining to non clinical and clinical trial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Non Clinical And Clinical Trial Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued preclinical and clinical trial expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition equity interests issued or issuable number of shares issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition equity interests issued or issuable number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_KyePharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">KYE Pharmaceuticals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_KyePharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">KYE Pharmaceuticals [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Acquired, Average Cost Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Aggregate Amount Paid for the Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Components of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Minimum Royalty Payable Maturity Terms Not Met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of minimum royalty payable maturity terms not met.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of minimum royalty payable maturity terms not met</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings (Accumulated Deficit) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceOfAnAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of an asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PurchasePriceOfAnAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price of an asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NonCashChangeInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash change in right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NonCashChangeInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash change in right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NonCashChangeInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Authorized Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase program, authorised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed and acquired intangibles for AGAMREE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed And Acquired Intangibles For AGAMREE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Licensed And Acquired Intangibles For AGAMREE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised or released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty for additional indications and milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty For Additional Indications And Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONCENTRATION OF RISK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic value, Outstanding at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period Axis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_U.s.RightsForFycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Rights for FYCOMPA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_U.s.RightsForFycompaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. Rights for FYCOMPA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested Weighted Average Grant Date Fair Value balance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested Weighted Average Grant Date Fair Value balance at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and asset purchase agreement payment made in first year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Asset Purchase Agreement Payment Made in First Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and asset purchase agreement payment made in first year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period Domain.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisation due to licensor noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisation Due to Licensor Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to licensor &#8211; non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income (Note 4):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum royalty amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Royalty Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MinimumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_MilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of current inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DydoPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dydo pharma inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_DydoPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dydo Pharma Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RightOfUseAssetsObtainedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of Use Assets Obtained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RightOfUseAssetsObtainedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_RightOfUseAssetsObtainedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities arising from asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Arising From Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_LiabilitiesArisingFromAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities arising from asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionBaseCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition base cash payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionBaseCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Base Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionBaseCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AGAMREE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AGAMREE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgamreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGAMREE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Investment Income [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Investment Income [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, $0.001 par value, 200,000,000 shares authorized; 120,879,099 shares and 107,121,549 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaborative Arrangements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares available for future issuance under the Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived, Future Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Investments by Security type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales based milestone to royalty threshold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Based Milestone To Royalty Threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales based milestone to royalty threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating costs and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Diluted weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ThresholdNetSalesPercentageAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold net sales percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ThresholdNetSalesPercentageAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Net Sales Percentage [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating costs and expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation windfall adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Windfall Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation windfall</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, property and equipment, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Property And Equipment Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ReimbursementOnBasePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement on base purchase price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ReimbursementOnBasePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement On Base Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ReimbursementOnBasePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reimbursement on base purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FirdapseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FIRDAPSE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FirdapseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FIRDAPSE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_FirdapseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FIRDAPSE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock units, net (Share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other noncurrent accrued expenses and other liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Accrued Expenses And Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Non-current accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total purchase consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total purchase consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidResearchFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for research and product development activities that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidResearchFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidResearchFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidConferenceAndTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid conference and travel expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidConferenceAndTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Conference And Travel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PrepaidConferenceAndTravelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid conference and travel expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected forfeiture rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ClosingMarketPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing market price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ClosingMarketPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Market Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ClosingMarketPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing Market Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration Arrangements Contingent Consideration Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Arrangements Contingent Consideration Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_CommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty shelf registration statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisation due to licensor current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisation Due To Licensor Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to licensor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">President and chief executive officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cprx_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">President and Chief Executive Officer [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" xlink:to="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAssetPurchaseAgreementMember" xlink:to="cprx_LicenseAndAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AfterAgreementOfCompanyLeasedSpaces" xlink:to="cprx_AfterAgreementOfCompanyLeasedSpaces_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NonRefundableUpfrontLicenseFeesMember" xlink:to="cprx_NonRefundableUpfrontLicenseFeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccruedGrossToNetRevenueLiabilities" xlink:to="cprx_AccruedGrossToNetRevenueLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AcquiredInProcessResearchAndDevelopment" xlink:to="cprx_AcquiredInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_StockholdersEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" xlink:to="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_DueFromCollaborativeAndLicencingArrangements" xlink:to="cprx_DueFromCollaborativeAndLicencingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" xlink:to="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_LicenseAgreementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccretionOfDiscount" xlink:to="cprx_AccretionOfDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionPurchasePriceConsideration" xlink:to="cprx_AssetAcquisitionPurchasePriceConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_LicenseAgreementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAgreementWithBioMarinMember" xlink:to="cprx_LicenseAgreementWithBioMarinMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:to="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="us-gaap_OperatingLeasesLeaseIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:to="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CollaborationAgreementAxis" xlink:to="cprx_CollaborationAgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MinimumRoyalty" xlink:to="cprx_MinimumRoyalty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_OptionsToPurchaseCommonStockMember" xlink:to="cprx_OptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" xlink:to="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_DisclosureOfOperatingLeasesAbstract" xlink:to="cprx_DisclosureOfOperatingLeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" xlink:to="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" xlink:to="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccruedVariableConsideration" xlink:to="cprx_AccruedVariableConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" xlink:to="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CollaborationArrangementDisclosureAbstract" xlink:to="cprx_CollaborationArrangementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAgreementDate" xlink:to="cprx_LicenseAgreementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PublicOfferingMember" xlink:to="cprx_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ShareRepurchases" xlink:to="cprx_ShareRepurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CustomerAMember" xlink:to="cprx_CustomerAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_EffectiveIncomeTaxCreditsRate" xlink:to="cprx_EffectiveIncomeTaxCreditsRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" xlink:to="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" xlink:to="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ProductRevenueNetMember" xlink:to="cprx_ProductRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CustomersMember" xlink:to="cprx_CustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_FycompaMember" xlink:to="cprx_FycompaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionValue" xlink:to="cprx_AssetAcquisitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAssetPurchaseAgreementPayment" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementTermsMember" xlink:to="us-gaap_RoyaltyAgreementTermsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyThresholdLimitDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionInvestmentSharePrice" xlink:to="cprx_AssetAcquisitionInvestmentSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_StockholdersEquityTable" xlink:to="cprx_StockholdersEquityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" xlink:to="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" xlink:to="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RegulatoryFilingMilestoneMember" xlink:to="cprx_RegulatoryFilingMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidCommercialExpenses" xlink:to="cprx_PrepaidCommercialExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidManufacturingExpense" xlink:to="cprx_PrepaidManufacturingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="cprx_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_VamoroloneMember" xlink:to="cprx_VamoroloneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" xlink:to="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" xlink:to="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_SharePurchaseProgramMember" xlink:to="cprx_SharePurchaseProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ContractualTerm" xlink:to="cprx_ContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" xlink:to="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyLessThanHundredMillionMember" xlink:to="cprx_RoyaltyLessThanHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" xlink:to="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyForSantheraSalesBasedMilestonesMember" xlink:to="cprx_RoyaltyForSantheraSalesBasedMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" xlink:to="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramExpirationDate" xlink:to="srt_StockRepurchaseProgramExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" xlink:to="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanThreeHundredMillionMember" xlink:to="cprx_RoyaltyMoreThanThreeHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyAgreementTerm" xlink:to="cprx_RoyaltyAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" xlink:to="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidCopayAssistanceProgram" xlink:to="cprx_PrepaidCopayAssistanceProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NetSalesRoyaltyThreshold" xlink:to="cprx_NetSalesRoyaltyThreshold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanTwoBillionMember" xlink:to="cprx_RoyaltyMoreThanTwoBillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" xlink:to="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidSubscriptionFees" xlink:to="cprx_PrepaidSubscriptionFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="us-gaap_GainLossOnInvestmentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" xlink:to="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_UpFrontPayment" xlink:to="cprx_UpFrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfMaximumRoyaltyPayableToNetSales" xlink:to="cprx_PercentageOfMaximumRoyaltyPayableToNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PaymentOnMilestonePayment" xlink:to="cprx_PaymentOnMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionInventoryCurrent" xlink:to="cprx_AssetAcquisitionInventoryCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssetsAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:to="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfRestrictedStockActivityTable" xlink:to="cprx_ScheduleOfRestrictedStockActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_BeforeAgreementOfCompanyLeasedSpaces" xlink:to="cprx_BeforeAgreementOfCompanyLeasedSpaces_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" xlink:to="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" xlink:to="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="cprx_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquistionPrepaidCommercializationFees" xlink:to="cprx_AssetAcquistionPrepaidCommercializationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:to="cprx_LicenseAndAcquiredIntangiblesForFycompaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" xlink:to="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PaymentInConnectionWithAssetAcquisition" xlink:to="cprx_PaymentInConnectionWithAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltiesExpensePolicyTextBlock" xlink:to="cprx_RoyaltiesExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ThresholdNetSalesPercentageDomain" xlink:to="cprx_ThresholdNetSalesPercentageDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfRoyaltyPayableToNetSales" xlink:to="cprx_PercentageOfRoyaltyPayableToNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_TwoThousandEighteenStockIncentivePlanMember" xlink:to="cprx_TwoThousandEighteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AmortizationExpensesOfIntangibleAsset" xlink:to="cprx_AmortizationExpensesOfIntangibleAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccruedPurchasesCurrent" xlink:to="cprx_AccruedPurchasesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CalendarYear2026Member" xlink:to="cprx_CalendarYear2026Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ComponentsOfRevenueRecognizedAxis" xlink:to="cprx_ComponentsOfRevenueRecognizedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyThresholdLimitAxis" xlink:to="cprx_RoyaltyThresholdLimitAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CalendarYears2022Through2025Member" xlink:to="cprx_CalendarYears2022Through2025Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AgreementAxis" xlink:to="cprx_AgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="srt_ShareRepurchaseProgramDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" xlink:to="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CollaborationAgreementDomain" xlink:to="cprx_CollaborationAgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PercentageOfMinimumRoyaltyPayableToNetSales" xlink:to="cprx_PercentageOfMinimumRoyaltyPayableToNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAgreementForRuzurgiMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" xlink:to="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" xlink:to="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndOtherRevenueMember" xlink:to="cprx_LicenseAndOtherRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_IncomeTaxDisclosureTable" xlink:to="cprx_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" xlink:to="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:to="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CollaborativeArrangementMilestonePaymentObligation" xlink:to="cprx_CollaborativeArrangementMilestonePaymentObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ComponentsOfRevenueRecognizedDomain" xlink:to="cprx_ComponentsOfRevenueRecognizedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="cprx_ScheduleOfRestrictedStockActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccruedNonClinicalAndClinicalTrialExpenses" xlink:to="cprx_AccruedNonClinicalAndClinicalTrialExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_KyePharmaceuticalsMember" xlink:to="cprx_KyePharmaceuticalsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" xlink:to="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PurchasePriceOfAnAssetAcquisition" xlink:to="cprx_PurchasePriceOfAnAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NonCashChangeInRightOfUseAsset" xlink:to="cprx_NonCashChangeInRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:to="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_U.s.RightsForFycompaMember" xlink:to="cprx_U.s.RightsForFycompaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PeriodDomain" xlink:to="cprx_PeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisationDueToLicensorNoncurrent" xlink:to="cprx_AssetAcquisationDueToLicensorNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_CommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MinimumRoyaltyAmount" xlink:to="cprx_MinimumRoyaltyAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_MilestonePaymentMember" xlink:to="cprx_MilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AgreementDomain" xlink:to="cprx_AgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_DydoPharmaIncMember" xlink:to="cprx_DydoPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_RightOfUseAssetsObtainedAbstract" xlink:to="cprx_RightOfUseAssetsObtainedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_LiabilitiesArisingFromAssetAcquisition" xlink:to="cprx_LiabilitiesArisingFromAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionBaseCashPayment" xlink:to="cprx_AssetAcquisitionBaseCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AgamreeMember" xlink:to="cprx_AgamreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AgreementsDisclosureTextBlock" xlink:to="cprx_AgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_NetSalesBasedMilestoneToRoyaltyThreshold" xlink:to="cprx_NetSalesBasedMilestoneToRoyaltyThreshold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_OperatingExpense" xlink:to="cprx_OperatingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ThresholdNetSalesPercentageAxis" xlink:to="cprx_ThresholdNetSalesPercentageAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisitionPropertyAndEquipmentNet" xlink:to="cprx_AssetAcquisitionPropertyAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CustomerBMember" xlink:to="cprx_CustomerBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ReimbursementOnBasePurchasePrice" xlink:to="cprx_ReimbursementOnBasePurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AccruedLicenseFeesCurrent" xlink:to="cprx_AccruedLicenseFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_FirdapseMember" xlink:to="cprx_FirdapseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:to="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidResearchFee" xlink:to="cprx_PrepaidResearchFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PrepaidConferenceAndTravelExpenses" xlink:to="cprx_PrepaidConferenceAndTravelExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ClosingMarketPrice" xlink:to="cprx_ClosingMarketPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" xlink:to="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_CommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_TwoThousandTwentyShelfRegistrationStatementMember" xlink:to="cprx_TwoThousandTwentyShelfRegistrationStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_AssetAcquisationDueToLicensorCurrent" xlink:to="cprx_AssetAcquisationDueToLicensorCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cprx_PresidentAndChiefExecutiveOfficerMember" xlink:to="cprx_PresidentAndChiefExecutiveOfficerMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndOtherRevenueMember" xlink:label="cprx_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizationExpensesOfIntangibleAsset" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingExpense" xlink:label="cprx_OperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_LicenseAndOtherRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="cprx_AmortizationExpensesOfIntangibleAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="cprx_OperatingExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_14"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LiabilitiesArisingFromAssetAcquisition" xlink:label="cprx_LiabilitiesArisingFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentInConnectionWithAssetAcquisition" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccretionOfDiscount" xlink:label="cprx_AccretionOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonCashChangeInRightOfUseAsset" xlink:label="cprx_NonCashChangeInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInProcessResearchAndDevelopment" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cprx_LiabilitiesArisingFromAssetAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="cprx_PaymentInConnectionWithAssetAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cprx_AccretionOfDiscount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cprx_NonCashChangeInRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cprx_AcquiredInProcessResearchAndDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/Investments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/Inventory" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:label="us-gaap_OperatingLeasesLeaseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/Agreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementsDisclosureTextBlock" xlink:label="cprx_AgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="cprx_AgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareRepurchases" xlink:label="cprx_ShareRepurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltiesExpensePolicyTextBlock" xlink:label="cprx_RoyaltiesExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cprx_ShareRepurchases" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cprx_RoyaltiesExpensePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" xlink:label="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_GainLossOnInvestmentsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InventoryTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:label="us-gaap_OperatingLeasesLeaseIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" xlink:label="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesLeaseIncomeAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PublicOfferingMember" xlink:label="cprx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cprx_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SharePurchaseProgramMember" xlink:label="cprx_SharePurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyalty" xlink:label="cprx_MinimumRoyalty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="cprx_SharePurchaseProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_ShareRepurchaseProgramAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MinimumRoyalty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShortTermInvestments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FirdapseMember" xlink:label="cprx_FirdapseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FycompaMember" xlink:label="cprx_FycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgamreeMember" xlink:label="cprx_AgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_FirdapseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_FycompaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_AgamreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerAMember" xlink:label="cprx_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerBMember" xlink:label="cprx_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomersMember" xlink:label="cprx_CustomersMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomerAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomerBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomersMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_SellingExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidManufacturingExpense" xlink:label="cprx_PrepaidManufacturingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidSubscriptionFees" xlink:label="cprx_PrepaidSubscriptionFees"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidResearchFee" xlink:label="cprx_PrepaidResearchFee"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCommercialExpenses" xlink:label="cprx_PrepaidCommercialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DueFromCollaborativeAndLicencingArrangements" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidConferenceAndTravelExpenses" xlink:label="cprx_PrepaidConferenceAndTravelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCopayAssistanceProgram" xlink:label="cprx_PrepaidCopayAssistanceProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidManufacturingExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidSubscriptionFees" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidResearchFee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidCommercialExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_DueFromCollaborativeAndLicencingArrangements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidConferenceAndTravelExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="cprx_PrepaidCopayAssistanceProgram" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DisclosureOfOperatingLeasesAbstract" xlink:label="cprx_DisclosureOfOperatingLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_BeforeAgreementOfCompanyLeasedSpaces" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AfterAgreementOfCompanyLeasedSpaces" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_DisclosureOfOperatingLeasesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cprx_BeforeAgreementOfCompanyLeasedSpaces" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cprx_AfterAgreementOfCompanyLeasedSpaces" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DisclosureOfOperatingLeasesAbstract" xlink:label="cprx_DisclosureOfOperatingLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RightOfUseAssetsObtainedAbstract" xlink:label="cprx_RightOfUseAssetsObtainedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_DisclosureOfOperatingLeasesAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RightOfUseAssetsObtainedAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_DisclosureOfOperatingLeasesAbstract" xlink:to="cprx_RightOfUseAssetsObtainedAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedNonClinicalAndClinicalTrialExpenses" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedLicenseFeesCurrent" xlink:label="cprx_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedPurchasesCurrent" xlink:label="cprx_AccruedPurchasesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedVariableConsideration" xlink:label="cprx_AccruedVariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedGrossToNetRevenueLiabilities" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorCurrent" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorNoncurrent" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AccruedNonClinicalAndClinicalTrialExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AccruedLicenseFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AccruedPurchasesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AccruedVariableConsideration" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AccruedGrossToNetRevenueLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AssetAcquisationDueToLicensorCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_AssetAcquisationDueToLicensorNoncurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementAxis" xlink:label="cprx_CollaborationAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementDomain" xlink:label="cprx_CollaborationAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationArrangementDisclosureAbstract" xlink:label="cprx_CollaborationArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_KyePharmaceuticalsMember" xlink:label="cprx_KyePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedAxis" xlink:label="cprx_ComponentsOfRevenueRecognizedAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedDomain" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MilestonePaymentMember" xlink:label="cprx_MilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonRefundableUpfrontLicenseFeesMember" xlink:label="cprx_NonRefundableUpfrontLicenseFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RegulatoryFilingMilestoneMember" xlink:label="cprx_RegulatoryFilingMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DydoPharmaIncMember" xlink:label="cprx_DydoPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CollaborationAgreementAxis" xlink:to="cprx_CollaborationAgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CollaborationArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cprx_KyePharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ComponentsOfRevenueRecognizedAxis" xlink:to="cprx_ComponentsOfRevenueRecognizedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CollaborationAgreementDomain" xlink:to="cprx_MilestonePaymentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ComponentsOfRevenueRecognizedDomain" xlink:to="cprx_NonRefundableUpfrontLicenseFeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_RegulatoryFilingMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cprx_DydoPharmaIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="cprx_CollaborationAgreementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="cprx_ComponentsOfRevenueRecognizedAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementAxis" xlink:label="cprx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementDomain" xlink:label="cprx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsTable" xlink:label="cprx_CommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodAxis" xlink:label="cprx_PeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYears2022Through2025Member" xlink:label="cprx_CalendarYears2022Through2025Member"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementMember" xlink:label="cprx_LicenseAndAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsLineItems" xlink:label="cprx_CommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceOfAnAssetAcquisition" xlink:label="cprx_PurchasePriceOfAnAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYear2026Member" xlink:label="cprx_CalendarYear2026Member"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyaltyAmount" xlink:label="cprx_MinimumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPayment" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPayment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_AgreementAxis" xlink:to="cprx_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cprx_CommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_PeriodDomain" xlink:to="cprx_CalendarYears2022Through2025Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_AgreementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_AgreementDomain" xlink:to="cprx_LicenseAndAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PurchasePriceOfAnAssetAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_PeriodDomain" xlink:to="cprx_CalendarYear2026Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_PeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_CommitmentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_MinimumRoyaltyAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementWithBioMarinMember" xlink:label="cprx_LicenseAgreementWithBioMarinMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementLineItems" xlink:label="cprx_LicenseAgreementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementDate" xlink:label="cprx_LicenseAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementTable" xlink:label="cprx_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitDomain" xlink:label="cprx_RoyaltyThresholdLimitDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitAxis" xlink:label="cprx_RoyaltyThresholdLimitAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodAxis" xlink:label="cprx_PeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageAxis" xlink:label="cprx_ThresholdNetSalesPercentageAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageDomain" xlink:label="cprx_ThresholdNetSalesPercentageDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyAgreementTerm" xlink:label="cprx_RoyaltyAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgamreeMember" xlink:label="cprx_AgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanHundredMillionMember" xlink:label="cprx_RoyaltyLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesRoyaltyThreshold" xlink:label="cprx_NetSalesRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesBasedMilestoneToRoyaltyThreshold" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyalty" xlink:label="cprx_MinimumRoyalty"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" xlink:label="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" xlink:label="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" xlink:label="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UpFrontPayment" xlink:label="cprx_UpFrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPurchasePriceConsideration" xlink:label="cprx_AssetAcquisitionPurchasePriceConsideration"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMinimumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMaximumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForSantheraSalesBasedMilestonesMember" xlink:label="cprx_RoyaltyForSantheraSalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInvestmentSharePrice" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ClosingMarketPrice" xlink:label="cprx_ClosingMarketPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborativeArrangementMilestonePaymentObligation" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOnMilestonePayment" xlink:label="cprx_PaymentOnMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementWithBioMarinMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_LicenseAgreementDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_RoyaltyAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitAxis" xlink:to="cprx_RoyaltyThresholdLimitDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cprx_LicenseAgreementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ThresholdNetSalesPercentageAxis" xlink:to="cprx_ThresholdNetSalesPercentageDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_RoyaltyAgreementTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfRoyaltyPayableToNetSales" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_AgamreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyLessThanHundredMillionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_NetSalesRoyaltyThreshold" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_PeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_NetSalesBasedMilestoneToRoyaltyThreshold" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanThreeHundredMillionMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_MinimumRoyalty" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_ThresholdNetSalesPercentageAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_RoyaltyThresholdLimitAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_UpFrontPayment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionPurchasePriceConsideration" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_LicenseAgreementLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfMinimumRoyaltyPayableToNetSales" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTwoBillionMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfMaximumRoyaltyPayableToNetSales" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForSantheraSalesBasedMilestonesMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionInvestmentSharePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_ClosingMarketPrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_CollaborativeArrangementMilestonePaymentObligation" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PaymentOnMilestonePayment" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssetsAbstract" xlink:label="us-gaap_PaymentsToAcquireProductiveAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionValue" xlink:label="cprx_AssetAcquisitionValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquireProductiveAssetsAbstract" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_AssetAcquisitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionBaseCashPayment" xlink:label="cprx_AssetAcquisitionBaseCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ReimbursementOnBasePurchasePrice" xlink:label="cprx_ReimbursementOnBasePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionBaseCashPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ReimbursementOnBasePurchasePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInventoryCurrent" xlink:label="cprx_AssetAcquisitionInventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquistionPrepaidCommercializationFees" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPropertyAndEquipmentNet" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionInventoryCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquistionPrepaidCommercializationFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionPropertyAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureLineItems" xlink:label="cprx_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureTable" xlink:label="cprx_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cprx_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_IncomeTaxDisclosureTable" xlink:to="cprx_IncomeTaxDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxCreditsRate" xlink:label="cprx_EffectiveIncomeTaxCreditsRate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cprx_EffectiveIncomeTaxCreditsRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="cprx_DeferredTaxAssetsOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cprx_StockholdersEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="cprx_StockholdersEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SharePurchaseProgramMember" xlink:label="cprx_SharePurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramExpirationDate" xlink:label="srt_StockRepurchaseProgramExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="srt_ShareRepurchaseProgramAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cprx_StockholdersEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="cprx_SharePurchaseProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="srt_StockRepurchaseProgramExpirationDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="cprx_StockholdersEquityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cprx_StockholdersEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="cprx_TwoThousandTwentyShelfRegistrationStatementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="cprx_StockholdersEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cprx_StockholdersEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_StockholdersEquityTable" xlink:to="cprx_StockholdersEquityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandEighteenStockIncentivePlanMember" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OptionsToPurchaseCommonStockMember" xlink:label="cprx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContractualTerm" xlink:label="cprx_ContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cprx_TwoThousandEighteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cprx_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ContractualTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityTable" xlink:label="cprx_ScheduleOfRestrictedStockActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:label="cprx_ScheduleOfRestrictedStockActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cprx_ScheduleOfRestrictedStockActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityTable" xlink:to="cprx_ScheduleOfRestrictedStockActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndOtherRevenueMember" xlink:label="cprx_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizationExpensesOfIntangibleAsset" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingExpense" xlink:label="cprx_OperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_LicenseAndOtherRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="cprx_AmortizationExpensesOfIntangibleAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="cprx_OperatingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PublicOfferingMember" xlink:label="cprx_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cprx_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SharePurchaseProgramMember" xlink:label="cprx_SharePurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" xlink:label="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" xlink:label="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyalty" xlink:label="cprx_MinimumRoyalty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="cprx_SharePurchaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="srt_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_MinimumRoyalty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FirdapseMember" xlink:label="cprx_FirdapseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_FycompaMember" xlink:label="cprx_FycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgamreeMember" xlink:label="cprx_AgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_FirdapseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_FycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_AgamreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerAMember" xlink:label="cprx_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomerBMember" xlink:label="cprx_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CustomersMember" xlink:label="cprx_CustomersMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomerAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomerBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cprx_CustomersMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" xlink:label="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" xlink:label="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_BeforeAgreementOfCompanyLeasedSpaces" xlink:label="cprx_BeforeAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AfterAgreementOfCompanyLeasedSpaces" xlink:label="cprx_AfterAgreementOfCompanyLeasedSpaces"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cprx_BeforeAgreementOfCompanyLeasedSpaces" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cprx_AfterAgreementOfCompanyLeasedSpaces" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAcquiredIntangiblesForFycompaMember" xlink:label="cprx_LicenseAndAcquiredIntangiblesForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" xlink:label="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementAxis" xlink:label="cprx_CollaborationAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementDomain" xlink:label="cprx_CollaborationAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborationAgreementDomain" xlink:label="cprx_CollaborationAgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ProductRevenueNetMember" xlink:label="cprx_ProductRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_KyePharmaceuticalsMember" xlink:label="cprx_KyePharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedAxis" xlink:label="cprx_ComponentsOfRevenueRecognizedAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedDomain" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ComponentsOfRevenueRecognizedDomain" xlink:label="cprx_ComponentsOfRevenueRecognizedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MilestonePaymentMember" xlink:label="cprx_MilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonRefundableUpfrontLicenseFeesMember" xlink:label="cprx_NonRefundableUpfrontLicenseFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" xlink:label="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RegulatoryFilingMilestoneMember" xlink:label="cprx_RegulatoryFilingMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DydoPharmaIncMember" xlink:label="cprx_DydoPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_CollaborationAgreementAxis" xlink:to="cprx_CollaborationAgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_CollaborationAgreementAxis" xlink:to="cprx_CollaborationAgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_ProductRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cprx_KyePharmaceuticalsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_ComponentsOfRevenueRecognizedAxis" xlink:to="cprx_ComponentsOfRevenueRecognizedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_ComponentsOfRevenueRecognizedAxis" xlink:to="cprx_ComponentsOfRevenueRecognizedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CollaborationAgreementDomain" xlink:to="cprx_MilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ComponentsOfRevenueRecognizedDomain" xlink:to="cprx_NonRefundableUpfrontLicenseFeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cprx_RegulatoryFilingMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cprx_DydoPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="cprx_CollaborationAgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="cprx_ComponentsOfRevenueRecognizedAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsLineItems" xlink:label="cprx_CommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CommitmentsTable" xlink:label="cprx_CommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementAxis" xlink:label="cprx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementDomain" xlink:label="cprx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgreementDomain" xlink:label="cprx_AgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodAxis" xlink:label="cprx_PeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYears2022Through2025Member" xlink:label="cprx_CalendarYears2022Through2025Member"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementMember" xlink:label="cprx_LicenseAndAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceOfAnAssetAcquisition" xlink:label="cprx_PurchasePriceOfAnAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CalendarYear2026Member" xlink:label="cprx_CalendarYear2026Member"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" xlink:label="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyaltyAmount" xlink:label="cprx_MinimumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" xlink:label="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" xlink:label="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAndAssetPurchaseAgreementPayment" xlink:label="cprx_LicenseAndAssetPurchaseAgreementPayment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_CommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_AgreementAxis" xlink:to="cprx_AgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_AgreementAxis" xlink:to="cprx_AgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_PeriodDomain" xlink:to="cprx_CalendarYears2022Through2025Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_AgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_AgreementDomain" xlink:to="cprx_LicenseAndAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PurchasePriceOfAnAssetAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_PeriodDomain" xlink:to="cprx_CalendarYear2026Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_CommitmentsTable" xlink:to="cprx_PeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_CommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_MinimumRoyaltyAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_CommitmentsLineItems" xlink:to="cprx_LicenseAndAssetPurchaseAgreementPayment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementLineItems" xlink:label="cprx_LicenseAgreementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementTable" xlink:label="cprx_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementWithBioMarinMember" xlink:label="cprx_LicenseAgreementWithBioMarinMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementDate" xlink:label="cprx_LicenseAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitDomain" xlink:label="cprx_RoyaltyThresholdLimitDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitAxis" xlink:label="cprx_RoyaltyThresholdLimitAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyThresholdLimitDomain" xlink:label="cprx_RoyaltyThresholdLimitDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodAxis" xlink:label="cprx_PeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PeriodDomain" xlink:label="cprx_PeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageAxis" xlink:label="cprx_ThresholdNetSalesPercentageAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageDomain" xlink:label="cprx_ThresholdNetSalesPercentageDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ThresholdNetSalesPercentageDomain" xlink:label="cprx_ThresholdNetSalesPercentageDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyAgreementTerm" xlink:label="cprx_RoyaltyAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AgamreeMember" xlink:label="cprx_AgamreeMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" xlink:label="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanHundredMillionMember" xlink:label="cprx_RoyaltyLessThanHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesRoyaltyThreshold" xlink:label="cprx_NetSalesRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NetSalesBasedMilestoneToRoyaltyThreshold" xlink:label="cprx_NetSalesBasedMilestoneToRoyaltyThreshold"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" xlink:label="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanThreeHundredMillionMember" xlink:label="cprx_RoyaltyMoreThanThreeHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MinimumRoyalty" xlink:label="cprx_MinimumRoyalty"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" xlink:label="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" xlink:label="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" xlink:label="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" xlink:label="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_UpFrontPayment" xlink:label="cprx_UpFrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" xlink:label="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPurchasePriceConsideration" xlink:label="cprx_AssetAcquisitionPurchasePriceConsideration"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMinimumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMinimumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyMoreThanTwoBillionMember" xlink:label="cprx_RoyaltyMoreThanTwoBillionMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PercentageOfMaximumRoyaltyPayableToNetSales" xlink:label="cprx_PercentageOfMaximumRoyaltyPayableToNetSales"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForSantheraSalesBasedMilestonesMember" xlink:label="cprx_RoyaltyForSantheraSalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" xlink:label="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" xlink:label="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInvestmentSharePrice" xlink:label="cprx_AssetAcquisitionInvestmentSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ClosingMarketPrice" xlink:label="cprx_ClosingMarketPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_CollaborativeArrangementMilestonePaymentObligation" xlink:label="cprx_CollaborativeArrangementMilestonePaymentObligation"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOnMilestonePayment" xlink:label="cprx_PaymentOnMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_LicenseAgreementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementWithBioMarinMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_LicenseAgreementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_RoyaltyAgreementTermsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_RoyaltyThresholdLimitAxis" xlink:to="cprx_RoyaltyThresholdLimitDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_RoyaltyThresholdLimitAxis" xlink:to="cprx_RoyaltyThresholdLimitDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_PeriodAxis" xlink:to="cprx_PeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="cprx_ThresholdNetSalesPercentageAxis" xlink:to="cprx_ThresholdNetSalesPercentageDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="cprx_ThresholdNetSalesPercentageAxis" xlink:to="cprx_ThresholdNetSalesPercentageDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_RoyaltyAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfRoyaltyPayableToNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_AgamreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyLessThanHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_NetSalesRoyaltyThreshold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_PeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_NetSalesBasedMilestoneToRoyaltyThreshold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanThreeHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_MinimumRoyalty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_ThresholdNetSalesPercentageAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="cprx_RoyaltyThresholdLimitAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_UpFrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_LicenseAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionPurchasePriceConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfMinimumRoyaltyPayableToNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyMoreThanTwoBillionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PercentageOfMaximumRoyaltyPayableToNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForSantheraSalesBasedMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_RoyaltyThresholdLimitDomain" xlink:to="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_AssetAcquisitionInvestmentSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_ClosingMarketPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_CollaborativeArrangementMilestonePaymentObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="cprx_PaymentOnMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_LicenseAgreementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:label="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_LicenseAgreementForRuzurgiMember" xlink:label="cprx_LicenseAgreementForRuzurgiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionValue" xlink:label="cprx_AssetAcquisitionValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cprx_LicenseAgreementForRuzurgiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" xlink:to="cprx_AssetAcquisitionValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionBaseCashPayment" xlink:label="cprx_AssetAcquisitionBaseCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ReimbursementOnBasePurchasePrice" xlink:label="cprx_ReimbursementOnBasePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionBaseCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_ReimbursementOnBasePurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInventoryCurrent" xlink:label="cprx_AssetAcquisitionInventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_U.s.RightsForFycompaMember" xlink:label="cprx_U.s.RightsForFycompaMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquistionPrepaidCommercializationFees" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPropertyAndEquipmentNet" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionInventoryCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_U.s.RightsForFycompaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquistionPrepaidCommercializationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionPropertyAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_VamoroloneMember" xlink:label="cprx_VamoroloneMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="cprx_VamoroloneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureLineItems" xlink:label="cprx_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_IncomeTaxDisclosureTable" xlink:label="cprx_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="cprx_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" xlink:label="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_StockholdersEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_SharePurchaseProgramMember" xlink:label="cprx_SharePurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramExpirationDate" xlink:label="srt_StockRepurchaseProgramExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_StockholdersEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="srt_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="cprx_SharePurchaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="srt_StockRepurchaseProgramExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_TreasuryStockAcquiredAverageCostPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyShelfRegistrationStatementMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_StockholdersEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="cprx_TwoThousandTwentyShelfRegistrationStatementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityLineItems" xlink:label="cprx_StockholdersEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_StockholdersEquityTable" xlink:label="cprx_StockholdersEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" xlink:label="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" xlink:label="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_StockholdersEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementArrangementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_StockholdersEquityTable" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_TwoThousandEighteenStockIncentivePlanMember" xlink:label="cprx_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OptionsToPurchaseCommonStockMember" xlink:label="cprx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ContractualTerm" xlink:label="cprx_ContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cprx_TwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cprx_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail">
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:label="cprx_ScheduleOfRestrictedStockActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ScheduleOfRestrictedStockActivityTable" xlink:label="cprx_ScheduleOfRestrictedStockActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="cprx_ScheduleOfRestrictedStockActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cprx_ScheduleOfRestrictedStockActivityTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cprx_ScheduleOfRestrictedStockActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PresidentAndChiefExecutiveOfficerMember" xlink:label="cprx_PresidentAndChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cprx_PresidentAndChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OperatingExpense" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="cprx_OperatingExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OperatingExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OperatingExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OperatingExpense" xlink:to="cprx_AmortizationExpensesOfIntangibleAsset" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OperatingExpense" xlink:label="cprx_OperatingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AmortizationExpensesOfIntangibleAsset" xlink:label="cprx_AmortizationExpensesOfIntangibleAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cprx_AccretionOfDiscount" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="cprx_PaymentInConnectionWithAssetAcquisition" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cprx_NonCashChangeInRightOfUseAsset" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cprx_AcquiredInProcessResearchAndDevelopment" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="17" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccretionOfDiscount" xlink:label="cprx_AccretionOfDiscount"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" xlink:label="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PaymentInConnectionWithAssetAcquisition" xlink:label="cprx_PaymentInConnectionWithAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_NonCashChangeInRightOfUseAsset" xlink:label="cprx_NonCashChangeInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredInProcessResearchAndDevelopment" xlink:label="cprx_AcquiredInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidResearchFee" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidCommercialExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidSubscriptionFees" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidManufacturingExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_DueFromCollaborativeAndLicencingArrangements" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidConferenceAndTravelExpenses" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="cprx_PrepaidCopayAssistanceProgram" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidResearchFee" xlink:label="cprx_PrepaidResearchFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCommercialExpenses" xlink:label="cprx_PrepaidCommercialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidSubscriptionFees" xlink:label="cprx_PrepaidSubscriptionFees"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidManufacturingExpense" xlink:label="cprx_PrepaidManufacturingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DueFromCollaborativeAndLicencingArrangements" xlink:label="cprx_DueFromCollaborativeAndLicencingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidConferenceAndTravelExpenses" xlink:label="cprx_PrepaidConferenceAndTravelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PrepaidCopayAssistanceProgram" xlink:label="cprx_PrepaidCopayAssistanceProgram"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AccruedNonClinicalAndClinicalTrialExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:to="cprx_AssetAcquisationDueToLicensorNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AccruedLicenseFeesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AccruedVariableConsideration" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AccruedPurchasesCurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AssetAcquisationDueToLicensorCurrent" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cprx_AccruedGrossToNetRevenueLiabilities" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedNonClinicalAndClinicalTrialExpenses" xlink:label="cprx_AccruedNonClinicalAndClinicalTrialExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" xlink:label="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorNoncurrent" xlink:label="cprx_AssetAcquisationDueToLicensorNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedLicenseFeesCurrent" xlink:label="cprx_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedVariableConsideration" xlink:label="cprx_AccruedVariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedPurchasesCurrent" xlink:label="cprx_AccruedPurchasesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisationDueToLicensorCurrent" xlink:label="cprx_AssetAcquisationDueToLicensorCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AccruedGrossToNetRevenueLiabilities" xlink:label="cprx_AccruedGrossToNetRevenueLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_AssetAcquisitionValue" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="cprx_AssetAcquisitionValue" xlink:to="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionValue" xlink:label="cprx_AssetAcquisitionValue"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" xlink:label="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_ReimbursementOnBasePurchasePrice" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionBaseCashPayment" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_ReimbursementOnBasePurchasePrice" xlink:label="cprx_ReimbursementOnBasePurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" xlink:label="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionBaseCashPayment" xlink:label="cprx_AssetAcquisitionBaseCashPayment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionInventoryCurrent" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquistionPrepaidCommercializationFees" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionPropertyAndEquipmentNet" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionInventoryCurrent" xlink:label="cprx_AssetAcquisitionInventoryCurrent"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" xlink:label="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquistionPrepaidCommercializationFees" xlink:label="cprx_AssetAcquistionPrepaidCommercializationFees"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionPropertyAndEquipmentNet" xlink:label="cprx_AssetAcquisitionPropertyAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" xlink:label="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" xlink:label="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="cprx_AssetAcquisitionConsiderationTransferredInvestments" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" xlink:label="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_AssetAcquisitionConsiderationTransferredInvestments" xlink:label="cprx_AssetAcquisitionConsiderationTransferredInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cprx_EffectiveIncomeTaxCreditsRate" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxCreditsRate" xlink:label="cprx_EffectiveIncomeTaxCreditsRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" xlink:label="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cprx_DeferredTaxAssetsOperatingLeaseLiability" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory"/>
          <link:loc xlink:type="locator" xlink:href="cprx-20241231.xsd#cprx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="cprx_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" name="NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="cprx_MilestonePaymentMember" name="MilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PaymentInConnectionWithAssetAcquisition" name="PaymentInConnectionWithAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_StockholdersEquityLineItems" name="StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_CommitmentsTable" name="CommitmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAgreementWithBioMarinMember" name="LicenseAgreementWithBioMarinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AgreementsDisclosureTextBlock" name="AgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" name="LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" name="PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_RoyaltiesExpensePolicyTextBlock" name="RoyaltiesExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ContractualTerm" name="ContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_PaymentOnMilestonePayment" name="PaymentOnMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AmortizationExpensesOfIntangibleAsset" name="AmortizationExpensesOfIntangibleAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_CustomersMember" name="CustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_SharePurchaseProgramMember" name="SharePurchaseProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_DueFromCollaborativeAndLicencingArrangements" name="DueFromCollaborativeAndLicencingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_NonRefundableUpfrontLicenseFeesMember" name="NonRefundableUpfrontLicenseFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_CollaborativeArrangementMilestonePaymentObligation" name="CollaborativeArrangementMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_ThresholdNetSalesPercentageAxis" name="ThresholdNetSalesPercentageAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition" name="PaymentOfLiabilitiesArisingFromAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_AssetAcquisationDueToLicensorCurrent" name="AssetAcquisationDueToLicensorCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ComponentsOfRevenueRecognizedDomain" name="ComponentsOfRevenueRecognizedDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" name="AmountOfMinimumRoyaltyPayableMaturityTermsNotMet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AccruedVariableConsideration" name="AccruedVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_RightOfUseAssetsObtainedAbstract" name="RightOfUseAssetsObtainedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_MinimumRoyalty" name="MinimumRoyalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" name="AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_UsTreasuryBondSecuritiesCashEquivalentsMember" name="UsTreasuryBondSecuritiesCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_VamoroloneMember" name="VamoroloneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PrepaidResearchFee" name="PrepaidResearchFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_RoyaltyThresholdLimitDomain" name="RoyaltyThresholdLimitDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AgreementDomain" name="AgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" name="ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" name="AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember" name="LicenseAndAcquiredIntangiblesForRUZURGIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" name="LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" name="SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PurchasePriceOfAnAssetAcquisition" name="PurchasePriceOfAnAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" name="RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_BeforeAgreementOfCompanyLeasedSpaces" name="BeforeAgreementOfCompanyLeasedSpaces" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ThresholdNetSalesPercentageDomain" name="ThresholdNetSalesPercentageDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ClosingMarketPrice" name="ClosingMarketPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_LicensedAndAcquiredIntangiblesForAgamreeMember" name="LicensedAndAcquiredIntangiblesForAgamreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_TwoThousandTwentyShelfRegistrationStatementMember" name="TwoThousandTwentyShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAgreementTable" name="LicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" name="ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_MinimumRoyaltyAmount" name="MinimumRoyaltyAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_LiabilitiesArisingFromAssetAcquisition" name="LiabilitiesArisingFromAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_CalendarYears2022Through2025Member" name="CalendarYears2022Through2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities" name="OtherNoncurrentAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_CalendarYear2026Member" name="CalendarYear2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" name="MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" name="OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_EffectiveIncomeTaxCreditsRate" name="EffectiveIncomeTaxCreditsRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_AssetAcquisitionInventoryCurrent" name="AssetAcquisitionInventoryCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_KyePharmaceuticalsMember" name="KyePharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" name="RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AfterAgreementOfCompanyLeasedSpaces" name="AfterAgreementOfCompanyLeasedSpaces" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ProductRevenueNetMember" name="ProductRevenueNetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_NetSalesBasedMilestoneToRoyaltyThreshold" name="NetSalesBasedMilestoneToRoyaltyThreshold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_CollaborationArrangementDisclosureAbstract" name="CollaborationArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PercentageOfRoyaltyPayableToNetSales" name="PercentageOfRoyaltyPayableToNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_CommitmentsLineItems" name="CommitmentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyLessThanTwoHundredFiftyMillionMember" name="RoyaltyLessThanTwoHundredFiftyMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AssetAcquisitionPurchasePriceConsideration" name="AssetAcquisitionPurchasePriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AssetAcquisationDueToLicensorNoncurrent" name="AssetAcquisationDueToLicensorNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_LicenseAndAssetPurchaseAgreementPayment" name="LicenseAndAssetPurchaseAgreementPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" name="SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_MaximumMaturityPeriodOfCashAndCashEquivalent" name="MaximumMaturityPeriodOfCashAndCashEquivalent" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ReimbursementOnBasePurchasePrice" name="ReimbursementOnBasePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AccretionOfDiscount" name="AccretionOfDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_AmortizedCostBeforeUnrealizedGainsAndLosses" name="AmortizedCostBeforeUnrealizedGainsAndLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" name="RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AssetAcquisitionInvestmentSharePrice" name="AssetAcquisitionInvestmentSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_CollaborationAgreementDomain" name="CollaborationAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" name="RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" name="AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_CollaborationAgreementAxis" name="CollaborationAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAgreementLineItems" name="LicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" name="ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AccruedLicenseFeesCurrent" name="AccruedLicenseFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" name="AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AccruedNonClinicalAndClinicalTrialExpenses" name="AccruedNonClinicalAndClinicalTrialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments" name="EffectiveIncomeTaxRateReconciliationWindfallAdjustments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" name="AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_AccruedGrossToNetRevenueLiabilities" name="AccruedGrossToNetRevenueLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_AssetAcquisitionBaseCashPayment" name="AssetAcquisitionBaseCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_RoyaltyForSantheraSalesBasedMilestonesMember" name="RoyaltyForSantheraSalesBasedMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanThreeHundredMillionMember" name="RoyaltyMoreThanThreeHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition" name="AcquiredInventorySamplesExpensedFromAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_ScheduleOfRestrictedStockActivityLineItems" name="ScheduleOfRestrictedStockActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AgamreeMember" name="AgamreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember" name="TwoThousandTwentyThreeShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAndOtherRevenueMember" name="LicenseAndOtherRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PeriodDomain" name="PeriodDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanTwoBillionMember" name="RoyaltyMoreThanTwoBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_OperatingExpense" name="OperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" name="ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_AgreementAxis" name="AgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAndAcquiredIntangiblesForFycompaMember" name="LicenseAndAcquiredIntangiblesForFycompaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired" name="PurchasePriceConsiderationForIntangibleAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales" name="PercentageOfAnnualRoyaltyOnTheCompanysNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_FirdapseMember" name="FirdapseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_UpFrontPayment" name="UpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_ExpensesIncurredInConnectionWithCollaborationAgreement" name="ExpensesIncurredInConnectionWithCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_RoyaltyLessThanHundredMillionMember" name="RoyaltyLessThanHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PercentageOfMinimumRoyaltyPayableToNetSales" name="PercentageOfMinimumRoyaltyPayableToNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_PresidentAndChiefExecutiveOfficerMember" name="PresidentAndChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" name="AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_PrepaidCommercialExpenses" name="PrepaidCommercialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" name="RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PrepaidConferenceAndTravelExpenses" name="PrepaidConferenceAndTravelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_DydoPharmaIncMember" name="DydoPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ScheduleOfRestrictedStockActivityTable" name="ScheduleOfRestrictedStockActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares" name="AssetAcquisitionPercentageOfOutstandingOrdinaryShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" name="ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" name="LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_RoyaltyAgreementTerm" name="RoyaltyAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_PrepaidSubscriptionFees" name="PrepaidSubscriptionFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_RegulatoryFilingMilestoneMember" name="RegulatoryFilingMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAgreementDate" name="LicenseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_PercentageOfMaximumRoyaltyPayableToNetSales" name="PercentageOfMaximumRoyaltyPayableToNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" name="RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" name="AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_AssetAcquisitionValue" name="AssetAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter" name="NumberOfTradingDaysFromReceiptOfTheNoticeLetter" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_ShareRepurchases" name="ShareRepurchases" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" name="MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" name="RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_NonCashChangeInRightOfUseAsset" name="NonCashChangeInRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_PrepaidCopayAssistanceProgram" name="PrepaidCopayAssistanceProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_U.s.RightsForFycompaMember" name="U.s.RightsForFycompaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PeriodAxis" name="PeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAgreementForRuzurgiMember" name="LicenseAgreementForRuzurgiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ComponentsOfRevenueRecognizedAxis" name="ComponentsOfRevenueRecognizedAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone" name="PercentageOfRoyaltyPayableToSalesBasedMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_StockholdersEquityTable" name="StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_LicenseAndAssetPurchaseAgreementMember" name="LicenseAndAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember" name="RoyaltyForAdditionalIndicationsAndMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AccruedPurchasesCurrent" name="AccruedPurchasesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_AssetAcquisitionPropertyAndEquipmentNet" name="AssetAcquisitionPropertyAndEquipmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AssetAcquistionPrepaidCommercializationFees" name="AssetAcquistionPrepaidCommercializationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses" name="AssetAcquisitionCashPaidForProRatedPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember" name="RoyaltyMoreThanHundredAndTwentyFiveMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_NetSalesRoyaltyThreshold" name="NetSalesRoyaltyThreshold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_DisclosureOfOperatingLeasesAbstract" name="DisclosureOfOperatingLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_PrepaidManufacturingExpense" name="PrepaidManufacturingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="cprx_FycompaMember" name="FycompaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" name="RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_ContingentConsiderationArrangementsContingentConsiderationLiability" name="ContingentConsiderationArrangementsContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" name="RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_RoyaltyThresholdLimitAxis" name="RoyaltyThresholdLimitAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="cprx_AssetAcquisitionConsiderationTransferredInvestments" name="AssetAcquisitionConsiderationTransferredInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386870016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CATALYST PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001369568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,449,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0837053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">355 Alhambra Circle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Coral Gables<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">420-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,720,853,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the Definitive Proxy Statement to be filed for Catalyst Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on internal control over financial reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Catalyst Pharmaceuticals, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by COSO.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the Company as of and for the year ended December 31, 2024, and our report dated February 26, 2025 expressed an unqualified opinion on those financial statements.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392300704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 517,553<span></span>
</td>
<td class="nump">$ 137,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">65,476<span></span>
</td>
<td class="nump">53,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">19,541<span></span>
</td>
<td class="nump">15,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">21,039<span></span>
</td>
<td class="nump">12,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">623,609<span></span>
</td>
<td class="nump">219,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">2,230<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">License and acquired intangibles, net</a></td>
<td class="nump">156,672<span></span>
</td>
<td class="nump">194,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">45,982<span></span>
</td>
<td class="nump">36,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Investment in equity securities</a></td>
<td class="nump">21,564<span></span>
</td>
<td class="nump">16,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">851,411<span></span>
</td>
<td class="nump">470,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,593<span></span>
</td>
<td class="nump">14,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">104,085<span></span>
</td>
<td class="nump">61,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">120,678<span></span>
</td>
<td class="nump">76,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">123,779<span></span>
</td>
<td class="nump">82,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized; 120,879,099 shares and 107,121,549 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">442,286<span></span>
</td>
<td class="nump">266,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">285,161<span></span>
</td>
<td class="nump">121,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (Note 4)</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">727,632<span></span>
</td>
<td class="nump">387,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 851,411<span></span>
</td>
<td class="nump">$ 470,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230481964864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">120,879,099<span></span>
</td>
<td class="nump">107,121,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">120,879,099<span></span>
</td>
<td class="nump">107,121,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392969072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 491,734<span></span>
</td>
<td class="nump">$ 398,204<span></span>
</td>
<td class="nump">$ 214,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">68,845<span></span>
</td>
<td class="nump">51,967<span></span>
</td>
<td class="nump">34,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,648<span></span>
</td>
<td class="nump">93,150<span></span>
</td>
<td class="nump">19,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">177,740<span></span>
</td>
<td class="nump">133,710<span></span>
</td>
<td class="nump">57,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AmortizationExpensesOfIntangibleAsset', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,377<span></span>
</td>
<td class="nump">32,565<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_OperatingExpense', window );">Total operating costs and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">296,610<span></span>
</td>
<td class="nump">311,392<span></span>
</td>
<td class="nump">112,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195,124<span></span>
</td>
<td class="nump">86,812<span></span>
</td>
<td class="nump">101,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,139<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216,263<span></span>
</td>
<td class="nump">94,511<span></span>
</td>
<td class="nump">104,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,374<span></span>
</td>
<td class="nump">23,101<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 163,889<span></span>
</td>
<td class="nump">$ 71,410<span></span>
</td>
<td class="nump">$ 83,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,457,673<span></span>
</td>
<td class="nump">106,279,736<span></span>
</td>
<td class="nump">103,374,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">124,943,603<span></span>
</td>
<td class="nump">113,753,154<span></span>
</td>
<td class="nump">111,375,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 163,889<span></span>
</td>
<td class="nump">$ 71,410<span></span>
</td>
<td class="nump">$ 83,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (Note 4):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities, net of tax of ($20), $4 and ($54), respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">163,939<span></span>
</td>
<td class="nump">71,400<span></span>
</td>
<td class="nump">83,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember', window );">Product revenue, net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">489,327<span></span>
</td>
<td class="nump">396,502<span></span>
</td>
<td class="nump">213,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_LicenseAndOtherRevenueMember', window );">License and other revenue [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">$ 1,702<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AmortizationExpensesOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AmortizationExpensesOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_LicenseAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_LicenseAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230387622960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net of tax impact</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392823248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit) [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 206,831<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 233,186<span></span>
</td>
<td class="num">$ (26,310)<span></span>
</td>
<td class="num">$ (148)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for common stock</a></td>
<td class="nump">9,569<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net</a></td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(6,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">83,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">300,421<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">250,430<span></span>
</td>
<td class="nump">49,862<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for common stock</a></td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net</a></td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">71,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">387,881<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">266,488<span></span>
</td>
<td class="nump">121,272<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">140,714<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">140,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for common stock</a></td>
<td class="nump">$ 13,515<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">13,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for common stock (shares)</a></td>
<td class="nump">3,429,184<span></span>
</td>
<td class="nump">3,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net</a></td>
<td class="num">$ (668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units, net (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">163,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 727,632<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 442,286<span></span>
</td>
<td class="nump">$ 285,161<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230387107440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 163,889<span></span>
</td>
<td class="nump">$ 71,410<span></span>
</td>
<td class="nump">$ 83,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">22,251<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="nump">7,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">37,377<span></span>
</td>
<td class="nump">32,565<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="num">(9,388)<span></span>
</td>
<td class="num">(17,818)<span></span>
</td>
<td class="nump">4,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AccretionOfDiscount', window );">Accretion of discount</a></td>
<td class="num">(835)<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NonCashChangeInRightOfUseAsset', window );">Reduction in the carrying amount of right-of-use asset</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on sale of available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition', window );">Acquired research and development inventory expensed from asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition', window );">Acquired inventory samples expensed from asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,513<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="num">(5,075)<span></span>
</td>
<td class="num">(3,024)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(11,962)<span></span>
</td>
<td class="num">(43,075)<span></span>
</td>
<td class="num">(3,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,897)<span></span>
</td>
<td class="num">(4,739)<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(8,504)<span></span>
</td>
<td class="num">(5,792)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">10,820<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">53,848<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">16,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">239,808<span></span>
</td>
<td class="nump">143,600<span></span>
</td>
<td class="nump">116,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale of&#160;available-for-sale&#160;securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PaymentInConnectionWithAssetAcquisition', window );">Payments in connection with asset acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,293)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquisition of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(81,513)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,465)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(293,502)<span></span>
</td>
<td class="nump">9,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding tax related to stock-based compensation</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">13,515<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">9,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition', window );">Payment of liabilities arising from asset acquisition</a></td>
<td class="num">(12,886)<span></span>
</td>
<td class="num">(12,667)<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of fees in connection with issuance of common stock</a></td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">140,665<span></span>
</td>
<td class="num">(10,857)<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">379,917<span></span>
</td>
<td class="num">(160,759)<span></span>
</td>
<td class="nump">126,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8211; beginning of period</a></td>
<td class="nump">137,636<span></span>
</td>
<td class="nump">298,395<span></span>
</td>
<td class="nump">171,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8211; end of period</a></td>
<td class="nump">517,553<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
<td class="nump">298,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes, net</a></td>
<td class="nump">68,451<span></span>
</td>
<td class="nump">50,458<span></span>
</td>
<td class="nump">7,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LiabilitiesArisingFromAssetAcquisition', window );">Liabilities arising from asset acquisition</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,915<span></span>
</td>
<td class="nump">$ 27,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AccretionOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents accretion of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AccretionOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired inventory samples expensed from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired research and development inventory expenses from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LiabilitiesArisingFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities arising from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LiabilitiesArisingFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_NonCashChangeInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash change in right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_NonCashChangeInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PaymentInConnectionWithAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment in connection with asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PaymentInConnectionWithAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of liabilities arising from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230484498928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;1C. Cybe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rsecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are a part of our decision-making processes at every level. Our risk management team works closely with our Information Technology (IT) team including our IT and cybersecurity vendors to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Engage Third Parties on Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recognizing the complexity and evolving nature of cybersecurity threats, we </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a range of external experts in evaluating and testing our risk management systems. These partnerships enable us to leverage specialized knowledge and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insights, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third parties includes regular audits, threat assessments, and consultation on security enhancements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oversee Third Party Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are aware of the risks associated with third party service providers, we implement stringent processes to oversee and manage these risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We conduct thorough security assessments of all third party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes quarterly assessments by our Chief Legal and Compliance Officer (CLCO) and our Chief Operating Officer (COO) and on an ongoing basis by our IT professionals. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not encountered, to date, cybersecurity challenges that have materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impaired our operations or financial standing.</span></p></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats. The Board has established robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats because we recognize the significance of these threats to our operational integrity and stakeholder confidence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with our CLCO, our COO, and our IT personnel. In their time with our company, our CLCO and our COO have become increasingly involved in investigating, responding to, and mitigating cybersecurity incidents and intrusion attempts. Their in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CLCO and our COO oversee our governance programs, test our compliance with standards, remediate known risks, and oversee or lead our employee training program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO regularly inform our CEO and CFO of all aspects related to cybersecurity risks and incidents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This ensures that the highest levels of management are kept abreast of the cybersecurity posture and potential risks facing our company. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitor Cybersecurity Incidents</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CLCO, our COO, and our IT personnel are periodically informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CLCO and COO implement and oversee processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the CLCO and COO, along with our IT personnel, are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These briefings encompass a broad range of topics, including:</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Current cybersecurity landscape and emerging threats;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Status of ongoing cybersecurity initiatives and strategies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Incident reports and learnings from any cybersecurity events; and</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Compliance with regulatory requirements and industry standards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, at regular meetings of the Board, the Board members, including the CEO, and the CLCO and COO maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The Board members actively participate in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives. The Board of Directors conducts an annual review of the company&#8217;s cybersecurity posture and the effectiveness of its risk management strategies. This review helps in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board has delegated to the Audit Committee the primary responsibility of overseeing risk management relating to cybersecurity.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Managing Material Risks &amp; Integrated Overall Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are a part of our decision-making processes at every level. Our risk management team works closely with our Information Technology (IT) team including our IT and cybersecurity vendors to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Engage Third Parties on Risk Management</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recognizing the complexity and evolving nature of cybersecurity threats, we </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a range of external experts in evaluating and testing our risk management systems. These partnerships enable us to leverage specialized knowledge and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insights, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third parties includes regular audits, threat assessments, and consultation on security enhancements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oversee Third Party Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are aware of the risks associated with third party service providers, we implement stringent processes to oversee and manage these risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We conduct thorough security assessments of all third party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes quarterly assessments by our Chief Legal and Compliance Officer (CLCO) and our Chief Operating Officer (COO) and on an ongoing basis by our IT professionals. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not encountered, to date, cybersecurity challenges that have materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impaired our operations or financial standing.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks from Cybersecurity Threats</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not encountered, to date, cybersecurity challenges that have materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impaired our operations or financial standing.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors Oversight</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board has delegated to the Audit Committee the primary responsibility of overseeing risk management relating to cybersecurity.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Role Managing Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These briefings encompass a broad range of topics, including:</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Current cybersecurity landscape and emerging threats;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Status of ongoing cybersecurity initiatives and strategies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Incident reports and learnings from any cybersecurity events; and</span></p><p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9679;	Compliance with regulatory requirements and industry standards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, at regular meetings of the Board, the Board members, including the CEO, and the CLCO and COO maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The Board members actively participate in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives. The Board of Directors conducts an annual review of the company&#8217;s cybersecurity posture and the effectiveness of its risk management strategies. This review helps in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with our CLCO, our COO, and our IT personnel. In their time with our company, our CLCO and our COO have become increasingly involved in investigating, responding to, and mitigating cybersecurity incidents and intrusion attempts. Their in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CLCO and our COO oversee our governance programs, test our compliance with standards, remediate known risks, and oversee or lead our employee training program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CLCO, our COO, and our IT personnel are periodically informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CLCO and COO implement and oversee processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the CLCO and COO, along with our IT personnel, are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478470560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 163,889<span></span>
</td>
<td class="nump">$ 71,410<span></span>
</td>
<td class="nump">$ 83,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230394053600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478564544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company currently markets three drug products, FIRDAPSE&#174; (amifampridine), FYCOMPA&#174; (perampanel), and AGAMREE&#174; (vamorolone). The Company is currently seeking to further expand its drug portfolio, with a focus on acquiring the rights to late-stage products to treat orphan, rare disease across therapeutic areas. With an unwavering patient focus embedded in everything it does, the Company is committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s New Drug Application (NDA) for FIRDAPSE&#174; (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food &amp; Drug Administration (FDA), and FIRDAPSE&#174; is commercially available in the U.S. as a treatment for adults with LEMS. Further, Canada&#8217;s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE&#174; for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE&#174; is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals, Inc. (KYE). In the third quarter of 2022, the FDA approved the Company&#8217;s supplemental New Drug Application approving an expansion of the FIRDAPSE&#174; label to include pediatric patients (ages six and older). In the second quarter of 2024, the FDA approved the Company&#8217;s supplemental New Drug Application increasing the indicated maximum daily dose of FIRDAPSE&#174; (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of LEMS.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA&#174; (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of the U.S. rights to FYCOMPA&#174; on January 24, 2023 and is now marketing FYCOMPA&#174; in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company completed its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an exclusive license for North America for AGAMREE&#174; (vamorolone), a treatment for patients suffering from Duchenne muscular dystrophy (DMD). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in that jurisdiction. Additionally, the Company holds the North American rights for any future approved indications of AGAMREE&#174;. AGAMREE&#174; previously received FDA Orphan Drug and Fast Track designations and on October 26, 2023, the FDA approved AGAMREE&#174; oral suspension 40 mg/ml for the treatment of DMD in patients aged two years and older. On March 13, 2024, the Company commercially launched AGAMREE&#174; in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has devoted substantially all its efforts since inception to selling its products, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and research and development. The Company has been able to fund its cash needs to date through profits generated from sales of its products and offerings of its securities. See Note 15 (Stockholders&#8217; Equity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Company's current financial condition, including its profitability, cash flows generated from operations and forecasts of available cash, the Company believes it has sufficient funds to support operations for at least the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Description of Business (continued).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#8217;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 9, 2024, the Company completed a public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, raising net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The proceeds of the offering will be used to acquire new products and for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478413728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRINCIPLES OF CONSOLIDATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The consolidated financial statements include the Company&#8217;s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.</span></div></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF ESTIMATES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CASH AND CASH EQUIVALENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company primarily invests in high credit-quality instruments in order to obtain higher yields on its cash equivalents. The Company considers all highly liquid instruments, purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has its cash and cash equivalents deposited with two financial institutions.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At December 31, 2024 and 2023, investments consisted of U.S. Treasuries and an investment in equity securities. Such investments are not insured by the U.S. Federal Deposit Insurance Corporation.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Treasuries held at December 31, 2024 and 2023 were classified as available-for-sale securities. The Company classifies U.S. Treasuries with stated maturities of greater than three months and less than one year in short-term investments. U.S. Treasuries with stated maturities greater than one year are classified as non-current investments in its consolidated balance sheets.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (in stockholders&#8217; equity). Realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statements of operations and comprehensive income. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of its available-for-sale securities are judged to be as a result of a credit loss. The Company considers various factors in determining whether to recognize an allowance for credit losses including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. If the unrealized loss of an available-for-sale debt security is determined to be a result of a credit loss the Company would recognize an allowance and the corresponding credit loss would be included in the consolidated statements of operations and comprehensive income. The Company has not recorded an allowance for credit loss on its available-for-sale securities. See Note 3 (Investments).</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company made a strategic equity investment into Santhera by acquiring </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Santhera&#8217;s  ordinary shares (representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction). The investment is denominated in Swiss Francs. The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera&#8217;s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes resulting from movements in foreign exchange rates, in other income, net in the consolidated statements of operations and comprehensive income.</span></p></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCOUNTS RECEIVABLE, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounts receivable are recorded net of customer allowances for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed. At December 31, 2024 and 2023, the Company determined that an allowance for expected credit losses was not required. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts were written off during the periods presented.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVENTORY</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; are also used in clinical programs to assess the safety and efficacy of the products for usage in treating diseases that have not been approved by the FDA or other regulatory authorities. The forms of FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; utilized for both commercial and clinical programs are identical and, as a result, the inventories have an &#8220;alternative future use&#8221; as defined in authoritative guidance. Raw materials associated with clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221;.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, and patient usage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PREPAID EXPENSES AND OTHER CURRENT ASSETS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements, and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company&#8217;s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing costs consist of advances for the Company&#8217;s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. </span></div></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">h.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROPERTY AND EQUIPMENT,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af1f8375-788a-4903-85b9-db67fcf6e271;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computer equipment and software, from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af087444-9da2-4e54-b835-1802f923ce72;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment, and from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion of the Company&#8217;s exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico, which the Company accounted for as an asset acquisition under ASC 805-50. See Note 13 (Agreements) for further discussion on the Company&#8217;s acquisitions of the U.S. rights to FYCOMPA&#174; from Eisai, and on the exclusive license for North America acquired from Santhera for AGAMREE&#174;, both of which the Company accounted for as asset acquisitions under ASC 805-50.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">j.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTANGIBLE ASSETS, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">k.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE OF FINANCIAL INSTRUMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and certain components of accrued expenses and other liabilities. At December 31, 2024 and December 31, 2023, the fair value of these instruments approximated their carrying value as a result of their respective short-term duration. </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">l.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE MEASUREMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity&#8217;s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). </span></div></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity&#8217;s own assumptions, as there is little, if any, related market activity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.984%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.791%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using (in thousands)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.188%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.943999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of<br/>December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">m.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OPERATING LEASES. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, net, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">n.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHARE REPURCHASES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In March 2021, the Company&#8217;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock. The share repurchase program currently expires in March 2025. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock&#8217;s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.</span></p></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE RECOGNITION. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenues:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (ASC) Topic 606 &#8211; Revenue from Contracts with Customers (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue when its customers obtain title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. For FIRDAPSE&#174; and AGAMREE&#174;, subsequent to receiving FDA approvals, the Company entered into an arrangement with one distributor (the Customer), which is the exclusive distributor of FIRDAPSE&#174; and AGAMREE&#174; in the U.S. The Customer subsequently resells FIRDAPSE&#174; and AGAMREE&#174; to a small group of exclusive specialty pharmacies (SPs) whose dispensing activities for patients with specific payors may result in government-mandated or privately negotiated rebate obligations for the Company with respect to the purchase of FIRDAPSE&#174; and AGAMREE&#174;.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; in the U.S. commercial market through a Transition Service Agreement with a U.S. subsidiary of Eisai to major wholesalers and specialty pharmaceutical distributors. These sales are often subject to contracts held with managed care organizations and government agencies. The distribution services under the Transition Services Agreement ended on December 31, 2023, and beginning on January 1, 2024, the Company commenced direct sales of FYCOMPA&#174; in the U.S.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Revenue, Net:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company recognizes revenue on product sales when its customers obtain control of the Company&#8217;s products, which occur at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company&#8217;s payment terms range between 15 and 60 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, substantially all of the Company&#8217;s product revenues were from sales to customers in the U.S.</span></p></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net product revenue disaggregated by product (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,035</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,426</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;+</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,251</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AGAMREE&#174;*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">489,327</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396,502</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#174; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></p></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves for Variable Consideration:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, prompt payment discounts, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers relating to the Company&#8217;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to its customers) or a current liability (if the amount is payable to a party other than its customers).</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2024 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Discounts, Allowances and Wholesaler Fees:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with a discount that is explicitly stated in its contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. To the extent the services received are distinct from the sale of products to its customers, these payments are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income. However, if the Company has determined such services received are not distinct from the Company&#8217;s sale of products to its customers, these payments have been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive income through December 31, 2024, 2023 and 2022, as well as a reduction to accounts receivable, net on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prompt Payment Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual invoice sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funded Co-pay Assistance Program:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company contracts with a third party to manage the co-pay assistance program intended to provide financial assistance to qualified commercially-insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with its products, that have been recognized as revenue, but remains in the distribution channel at the end of each reporting period. These payments are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution or master agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. Return payments related to the sale of products are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provider Chargebacks and Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to the customer, who directly purchases the product from the Company. The customer charges the Company for the difference between what they paid for the product and the ultimate selling price to the qualified healthcare providers. The Company also participates in programs with government entities and other parties, including covered entities under the 340B Drug Pricing Program, whereby pricing on FYCOMPA&#174; is extended below wholesaler list price to participating entities (the FYCOMPA&#174; Participants). These entities purchase FYCOMPA&#174; through wholesalers at the lower program price and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue, net and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by the customer or at the time of a resale to a FYCOMPA&#174; Participant by a wholesaler, and the Company generally issues credits for such amounts within a few weeks of the customer or wholesalers&#8217; notification to the Company of the resale. Reserves for chargebacks consist primarily of chargebacks that the customer or wholesalers have claimed, but for which the Company has not yet issued a credit, as well as an estimate of chargeback claims that the Company expects to receive associated with its products, that have been recognized as revenue but remains in the distribution channel at the end of each reporting period.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Rebates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company is subject to discount obligations under state Medicaid, Medicare and other government programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For reserves related to the sale of its products, there is an establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the coverage gap program is sunsetting in 2024 and is being replaced with the Inflation Reduction Act (IRA) program. While most components of this program will begin 2025, the inflation penalty portion is effective as of 2024. Specifically, the program imposes manufacturer rebates on certain Part B and Part D drugs when prices rise faster than the rate of inflation. The Company has estimated this potential impact and has accounted for these inflation-related rebates as a reduction of product revenue in 2024 to the extent they apply to its drug portfolio. Similar to the coverage gap rebates, the associated reserve is accrued for as a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payor Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balances sheets.</span></p></div><div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bridge and Patient Assistance Programs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides FIRDAPSE&#174; and AGAMREE&#174; free of charge to uninsured patients who satisfy pre-established criteria for either the Bridge Program or the Patient Assistance Program. Patients who meet the Bridge Program eligibility criteria and are transitioning from investigational product while they are waiting for a coverage determination, or later, for patients whose access is threatened by the complications arising from a change of insurer may receive a temporary supply of free FIRDAPSE&#174; or AGAMREE&#174; while the Company is determining the patient&#8217;s third party insurance, prescription drug benefit or other third party coverage for FIRDAPSE&#174; or AGAMREE&#174;. The Patient Assistance Program provides FIRDAPSE&#174; or AGAMREE&#174; free of charge for longer periods of time for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#174; or AGAMREE&#174; because they are unable to obtain coverage from their payor despite having health insurance, to the extent allowed by applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company provides FYCOMPA&#174; free of charge to uninsured patients who satisfy pre-established criteria through a Patient Assistance Program. In addition, Catalyst provides programs to assist patients through the process for obtaining reimbursement approval for their FYCOMPA&#174; prescriptions from their insurers. Catalyst also provides support for patients using FYCOMPA&#174; through an Instant Savings Card Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues from Collaboration and Licensing Arrangements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration (Topic 808), to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. Revenue is included in product revenue, net in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes sales-based royalties or net profit-sharing when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments to and from the collaborator are presented in the statements of operations based on the nature of the Company&#8217;s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 11 (Collaborative and Licensing Arrangements), for further discussion on the Company&#8217;s collaborative and licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">p.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESEARCH AND DEVELOPMENT.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research-related services for the Company.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records upfront and milestone payments made to third parties under licensing and collaboration arrangements that occur before a compound receives regulatory approval as acquired in-process research and development (IPR&amp;D). IPR&amp;D acquired as part of an asset acquisition with no alternative future use is expensed immediately to research and development. Milestone payments made after regulatory approval are capitalized as a developed asset and unless the asset is determined to have an indefinite life, the Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">q.</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADVERTISING EXPENSE. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in advertising costs during the years ended December 31, 2024, 2023 and 2022, respectively, which are included in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">r.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK-BASED COMPENSATION. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">s.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONCENTRATION OF RISK. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sells its products, FIRDAPSE&#174; and AGAMREE&#174;, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to these products. The Company sells its product, FYCOMPA&#174;, directly to major wholesalers and specialty pharmaceutical distributors and indirectly to managed care organizations and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE&#174;. The Company expects sales of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; to constitute virtually all of the Company&#8217;s product revenue for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE&#174;. The Company relies on the same third party manufacturers for FYCOMPA&#174; as utilized by Eisai prior to the Company&#8217;s acquisition of the U.S. rights to the product in January 2023. It also relies on Santhera and its supplier as its sole source of supply for AGAMREE&#174;. If the Company is unable to continue its relationships with one or more of these third party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third party contractors to manufacture the commercial supply of its drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates the approximate percentage of the Company&#8217;s total net product revenue attributed to the Company&#8217;s largest customers for the periods presented:</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">t.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROYALTIES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Royalties incurred in connection with the Company&#8217;s license agreement for FIRDAPSE&#174; and AGAMREE&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. </span></div></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties incurred in connection with the Company&#8217;s license agreement for RUZURGI&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized for any royalties in excess of the minimum annual royalty payment from July 11, 2022 (the Effective Date) through 2025. The minimum royalty payment that exists annually for calendar years from the Effective Date through 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are included in the purchase price of the agreement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">u.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCOME TAXES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2021. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">v.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPREHENSIVE INCOME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders&#8217; equity. The Company&#8217;s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2024, 2023 and 2022, and is comprised of net unrealized gains (losses) on the Company&#8217;s available-for-sale securities.</span></div></div></div><div style="font-size:12pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">w.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET INCOME PER COMMON SHARE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles basic and diluted weighted average common shares:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.726%;box-sizing:content-box;"></td>
          <td style="width:1.683%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.407%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.43%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.642%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,457,673</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,279,736</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,374,606</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of dilutive securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,485,930</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,473,418</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,001,025</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,943,603</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,753,154</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,375,631</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding common stock equivalents totaling approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were excluded from the calculation of diluted net income per common share for the years ended December 31, 2024, 2023 and 2022, respectively, as their effect would be anti-dilutive. Potentially dilutive options to purchase common stock as of December 31, 2024, 2023 and 2022 had exercise prices ranging from</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">x.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEGMENT INFORMATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management has determined that the Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is the development and commercialization of drug products. The Company's chief operating decision maker (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fc95014e-239d-4684-9334-a50e46b93483;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">president and chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who reviews financial information presented on a consolidated basis.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These financial metrics are used by the CODM t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating margin and the allocation of budget between cost of revenues, selling, research and development, and general and administrative expenses.</span></div></div><p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates information about significant segment expenses:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,648</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,150</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,789</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,746</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative (a)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,994</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,210</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,388</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,860</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,874</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     (a)     </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">y.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECLASSIFICATIONS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">z.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECENTLY ISSUED ACCOUNTING STANDARDS. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ASU 2023-07) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 during the year ended December 31, 2024. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires significant disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance will be applied prospectively and is effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the impact of the standard on the Company&#8217;s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income&#8212; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385210592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments by security type were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses from available-for-sale securities for the years ended December 31, 2024 or 2023. There were realized losses from sale of available-for-sale securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair values of available-for-sale securities at December 31, 2024, by contractual maturity, are summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net gains (losses) recognized during the period on<br/>&#160;&#160;&#160;equity securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized net gains (losses) recognized during the<br/>&#160;&#160;&#160;period on equity securities still held at the reporting<br/>&#160;&#160;&#160;date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no sales of equity securities during the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385961856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Income. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes in accumulated other comprehensive income, net of tax from unrealized gains (losses) on available-for-sale securities, the Company&#8217;s only component of accumulated other comprehensive income for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount reclassified out of accumulated other comprehensive income, net of tax and into net income during the year ended December 31, 2022, was solely due to a realized loss from sale of available-for-sale securities. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no reclassifications out of accumulated other comprehensive income during the years ended December 31, 2024 or 2023. </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"></td>
        <td style="width:2.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478987776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,910</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,445</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,161</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,541</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,644</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478487760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,038</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due from collaborative and licensing arrangements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid conference and travel expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid co-pay assistance program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,030</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,039</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the carrying amount as of the balance sheet date of expenditures made in advance of the timing of recognition of expenses which are expected to be charged against earnings within one year or the normal operating cycle, if longer. Includes, but is not limited to, prepaid research, prepaid product development activities and prepaid insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478490496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesLeaseIncomeAbstract', window );"><strong>Operating Lease, Lease Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Leases. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease agreement for its corporate office. The lease includes an option to extend the lease for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and options to terminate the lease within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6d7694a8-4fef-4d34-ad3f-97f73cebc1d8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> obligations under finance leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement in May 2020 that amended its lease for its office facilities. Under the amended lease, the Company&#8217;s leased space increased from approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,800</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space. The amended lease commenced in March 2021 when construction of the asset was completed and space became available for use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for lease<br/>&#160;&#160;&#160;obligations:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental balance sheet information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="-sec-ix-hidden:F_e02f321f-c2da-4a31-b171-0bb073d6f3b4;"><span style="-sec-ix-hidden:F_af9bf51b-92c5-4e0c-beca-6ed527c2962a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;liabilities, net of current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The weighted average discount rate used to determine the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.51</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% as of December 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remaining payments of lease liabilities as of December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesLeaseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesLeaseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478464896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,354</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230481914080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Acquired Intangibles, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License and Acquired Intangibles, Net</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Acquired Intangibles, Net. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,040</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,418</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,049</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life. The estimated useful life used for this purpose for RUZURGI&#174;, FYCOMPA&#174; and AGAMREE&#174; was approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in amortization expense related to the licensed and acquired intangibles for RUZURGI&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within selling, general and administrative expenses in the consolidated statements of operations and comprehensive income. The Company recorded approximately</span><span style="color:#ed7d31;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in amortization expense related to the licensed and acquired intangibles for FYCOMPA&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income. The Company recorded approximately</span><span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in amortization expense related to the licensed and acquired intangibles for AGAMREE&#174; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Acquired Intangibles, Net (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future amortization expense the Company expects for its intangible assets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,705</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and December 31, 2023, the weighted average amortization period remaining for intangible assets was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges recognized on definite-lived intangibles for the years ended December 31, 2024, 2023 or 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478429792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Liabilities. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,011</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,730</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued purchases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net revenue liabilities*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">729</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,031</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">417</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,101</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a 3PL organization under the Company's contracts.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385521104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Licensing Arrangements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative and Licensing Arrangements. </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Endo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, the Company entered into a collaboration and license agreement (Collaboration) with Endo, Inc. (formerly, Endo International plc) (Endo), for the further development and commercialization of generic Sabril&#174; (vigabatrin) tablets through Endo&#8217;s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical, Inc. (Par). Under the Collaboration, Endo assumed all development, manufacturing, clinical, regulatory, sales and marketing costs under the collaboration, while the Company was responsible for exercising commercially reasonable efforts to develop, or cause the development of, a final finished, stable dosage form of generic Sabril&#174; tablets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, a termination and mutual release agreement was finalized between Endo and the Company that discontinued work on the collaboration for development and commercialization of vigabatrin. The end of the collaboration does not have a material impact on the Company's consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">KYE Pharmaceuticals Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, the Company entered into a collaboration and license agreement with KYE, for the commercialization of FIRDAPSE&#174; in Canada.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, Catalyst granted KYE an exclusive license to commercialize and market FIRDAPSE&#174; in Canada. KYE assumes all selling and marketing costs under the collaboration, while the Company is responsible for supply of FIRDAPSE&#174; based on the collaboration partner&#8217;s purchase orders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company received an up-front payment, has received payment upon transfer of Marketing Authorization and delivery of commercial product, received payment for supply of FIRDAPSE&#174;, and will receive milestone payments and a sharing of defined net profits upon commercialization from KYE consisting of a mid-double-digit percent of net sales of FIRDAPSE&#174;. The Company has also agreed to the sharing of certain development expenses. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the date that is ten years following the commercial launch of the product in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collaborative agreement included a nonrefundable upfront license fee that was recognized upon transfer of the license based on a determination that the right is provided as the intellectual property existed at the point in time in which the license was granted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into a license, supply and commercialization agreement with KYE, for the commercialization of AGAMREE&#174; in Canada granting KYE the exclusive Canadian commercial rights to market AGAMREE&#174; in Canada for DMD and other indications.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, KYE will be responsible for obtaining regulatory approval of the product from Health Canada and the Company will supply product to KYE. Further, the Company received an upfront payment from KYE and will be eligible to receive further reimbursement, sales milestones and sales royalties for AGAMREE&#174;.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These agreements are in form identified as collaborative agreements and the Company has concluded for accounting purposes that they also represent contracts with a customer. This is because the Company grants to KYE a license and provides supply of FIRDAPSE&#174; and AGAMREE&#174; in exchange for consideration, which are outputs of the Company&#8217;s ongoing activities. Accordingly, the Company has concluded that these collaborative arrangements will be accounted for pursuant to Topic 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sales by KYE is recognized in the quarter in which the sales occurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from the arrangements with KYE for the years ended December 31, 2024, 2023 and 2022 were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material. Revenue is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income. Expenses incurred, net have been included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative and Licensing Arrangements (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DyDo Pharma, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2021, the Company entered into a license agreement with DyDo Pharma, Inc. (DyDo), for the development and commercialization of FIRDAPSE&#174; in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, DyDo has joint rights to develop FIRDAPSE&#174;, and exclusive rights to commercialize the product, in Japan. DyDo is responsible for funding all clinical, regulatory, marketing and commercialization activities in Japan, while the Company is responsible for clinical and commercial supply based on purchase orders, as well as providing support to DyDo in its efforts to obtain regulatory approval for the product from the Japanese regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, the Company has earned an up-front payment and certain regulatory milestones and may earn sales-based milestones for FIRDAPSE&#174;, as well as revenue on product supplied to DyDo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has concluded that this license agreement will be accounted for pursuant to Topic 606. The agreement included a nonrefundable upfront license fee that was recognized upon the effective date of the agreement as the intellectual property existed at the point in time in which the right to the license was granted. The Company determined the granting of the right to the license is distinct from the supply of FIRDAPSE&#174; and represents a separate performance obligation in the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement includes milestones that are considered a sales-based royalty in which the license is deemed to be the predominant item to which these milestones relate. Revenue will be recognized when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty has been allocated has been satisfied. Additionally, the agreement includes regulatory milestone payments which represent variable consideration, and due to uncertainty are fully constrained and only recognized when the uncertainty is subsequently resolved. For clinical and commercial supply of the product, the Company will recognize revenue when the Customer obtains control of the Company&#8217;s product, which will occur at a point in time which is generally at time of shipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were revenues of</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the arrangement with DyDo for the year ended December 31, 2024, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million is included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to a milestone payment earned upon DyDo receiving regulatory approval to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS in Japan, which is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the arrangement with DyDo for the year ended December 31, 2023, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to a regulatory filing milestone in Japan, which was included in licensing and other revenue in the accompanying consolidated statements of operations and comprehensive income. There were revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the arrangement with DyDo for the year ended December 31, 2022, which was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, on September 24, 2024, DyDo advised the Company that the Ministry of Health, Labour and Welfare (MHLW) had approved DyDo's Japan NDA to commercialize FIRDAPSE&#174; for the treatment of patients with LEMS. See Note 18 (Subsequent Events).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385478880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the FDA approved a NDA for RUZURGI&#174;, Jacobus Pharmaceuticals&#8217; version of amifampridine (3,4-DAP), for the treatment of pediatric LEMS patients (ages 6 to under 17). In June 2019 the Company filed suit against the FDA and several related parties challenging this approval and related drug labeling. Jacobus later intervened in the case. The Company ultimately prevailed in its litigation in September 2021 when the U.S. Court of Appeals for the 11th Circuit determined that the FDA's approval of RUZURGI&#174; violated the Company's rights to Orphan Drug Exclusivity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2022, the Company settled certain of its disputes with Jacobus. In connection with the settlement, the Company licensed the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico (the Territory). Simultaneously, the Company purchased, among other intellectual property rights, Jacobus&#8217; U.S. patents related to RUZURGI&#174;, its new drug applications in the U.S. for RUZURGI&#174;, and certain RUZURGI&#174; inventory previously manufactured by Jacobus. At the same time, the Company received a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#174;. Further, the Company settled its patent case against Jacobus, which was dismissed without prejudice. Finally, Jacobus agreed that until the later of (i) the expiration of the royalty term or (ii) December 31, 2034, Jacobus and its affiliates, will not, directly or indirectly, research, develop, manufacture, commercialize, distribute, use or otherwise exploit any product competitive to FIRDAPSE&#174; or RUZURGI&#174; in the Territory, and Laura Jacobus, the sole shareholder of Jacobus, and two of Jacobus&#8217; other officers, also signed individual non-competition agreements containing the same terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the settlement with Jacobus, the Company paid the following consideration to Jacobus:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid at the closing of the settlement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid on the first anniversary of the closing, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid on the second anniversary of the closing; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An annual royalty on the Company's net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the U.S. equal to: (a) for calendar years 2022 through 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (with a minimum annual royalty of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year), and (b) for calendar years 2026 through the expiration of the last to expire of the Company&#8217;s FIRDAPSE&#174; patents in the U.S., </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (with a minimum annual royalty of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva), Hetero USA, Inc. (Hetero), and Lupin Pharmaceuticals, Inc. (Lupin)) advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE&#174; in the U.S. The notice letters each alleged that the six patents listed in the FDA Orange Book covering FIRDAPSE&#174; are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, the Company had 45 days from receipt of the notice letters to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court to trigger a stay precluding the FDA from approving any ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, the Company filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified the Company of their ANDA submissions, thus triggering the stay.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, Lupin converted five of its Paragraph IV Certifications in its ANDA to Paragraph III certifications acknowledging the validity and their ANDA&#8217;s infringement of five of those patents, the latest ending in 2034. The Company subsequently dismissed all of its claims against Lupin related to those five patents but maintains its claims against Lupin for the remaining Paragraph IV certification for U.S. Patent No. 10,626,088 which is the patent expiring in 2037, so the litigation continues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on January 8, 2025, the Company reached a settlement with Teva in which Teva agreed not to market a generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the settlement agreement, the parties terminated all ongoing patent litigation between the Company and Teva regarding FIRDAPSE&#174; patents pending in the U.S. District Court for the District of New Jersey. See Note 18 (Subsequent Events).</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#174;&#8217;s Orange Book-listed patents) and Lupin (only for FIRDAPSE&#174; patent expiring in 2037), remains ongoing, and there can be no assurance as to whether the currently ongoing litigation with Hetero and Lupin will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to February 25, 2035.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, in October 2023, the Company received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer (Inventia Life Science Pty Ltd (Inventia)), and the Company filed a similar lawsuit against that manufacturer in November 2023. On July 30, 2024, the Company settled its patent litigation with Inventia for FIRDAPSE&#174;. In that settlement, Inventia acknowledged both the validity of the Company's FIRDAPSE&#174; patents and also the infringement by the ANDA filer's product of the Company's patents. As part of the settlement, Inventia also agreed not to commercialize its product until the earlier of all FIRDAPSE&#174; patents expiration scheduled for February 2037, or the earlier entry into the market of another ANDA product meeting certain conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance that the Company will prevail in these litigations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 20, 2023, the Company received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA&#174;. The same company sent a similar letter to the Company later in February with a similar certification for the tablet formulation for FYCOMPA&#174;. Similar to the actions with the FIRDAPSE&#174; Paragraph IV Certifications described above, after due diligence the Company filed lawsuits on April 5, 2023, in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified the Company of their ANDA submissions for both FYCOMPA&#174; formulations, thus triggering the 30-month stay for each application. This lawsuit was settled in June 2024. As part of this settlement, this Paragraph IV filer agreed not to commercialize their proposed ANDA products for both the oral suspension formulation of FYCOMPA&#174; and for FYCOMPA&#174; tablets until at least December 15, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, from time to time the Company may become involved in legal proceedings arising in the ordinary course of business. Except as set forth above, the Company believes that there is no other litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition, or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478448000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AgreementsDisclosureTextBlock', window );">Agreements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR FIRDAPSE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 26, 2012</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to FIRDAPSE&#174;. Under the license agreement, the Company pays: (i) royalties to the licensor for seven years from the first commercial sale of FIRDAPSE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales in North America in any calendar year in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the first commercial sale of FIRDAPSE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement between BioMarin and the third party licensor) in any calendar year for the duration of any regulatory exclusivity within a territory and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for territories in any calendar year in territories without regulatory exclusivity.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 29, 2019, the Company and BioMarin entered into an amendment to the Company&#8217;s license agreement for FIRDAPSE&#174;. Under the amendment, the Company has expanded its commercial territory for FIRDAPSE&#174;, which originally was comprised of North America, to include Japan. Additionally, the Company&#8217;s commercial territory was expanded under the license agreement in December 2023 to include most of Asia, as well as Latin America, upon the acceptance by the Pharmaceuticals and Medical Devices Agency (PMDA) of a Japan MAA for FIRDAPSE&#174; for LEMS. Under the amendment, the Company will pay royalties to its licensor on net sales in Japan of a similar percentage to the royalties that the Company is currently paying under its original license agreement for North America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2020, the Company was advised that BioMarin has transferred substantially all of its rights under the license agreement to SERB S.A. (SERB), and SERB is now the Company&#8217;s licensor under the license agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR RUZURGI&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 11, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the Effective Date), the Company entered into an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the license agreement, the Company paid Jacobus a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million up-front payment on the Effective Date, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the first annual anniversary of the Effective Date (July 11, 2023), and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the second annual anniversary of the Effective Date (July 11, 2024). The Company is also obligated to pay tiered royalty payments on net sales (as defined in the license agreement) of all of the Company&#8217;s amifampridine products in the U.S. that range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on whether there is a competing product or generic version of FIRDAPSE&#174; being marketed or sold in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A minimum royalty payment exists annually for calendar years from the Effective Date through 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, provided that such minimum annual royalty payment shall be prorated in the first calendar year of the agreement. As these minimum payments are both probable and estimable, they are included in the purchase price of the agreement and any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. A minimum royalty payment exists annually for calendar years from 2026 through the expiration of the royalty term (which ends when there is no valid claim under the Company&#8217;s FIRDAPSE&#174; patents in the U.S.) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unless a competing product or generic version of FIRDAPSE&#174; is being marketed or sold in the U.S. If these minimum payments become probable in the future, the Company would recognize a contingent liability at that time with an offset to the value of the intangible asset acquired. Any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. Royalties over the minimum, if any, will be paid based on the agreement terms on a quarterly basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets acquired as part of the license agreement include among other intellectual property rights, Jacobus&#8217; U.S. patents related to RUZURGI&#174;, its new drug applications in the U.S. for RUZURGI&#174;, its U.S. Trademark for RUZURGI&#174;, the Orphan Drug Designation for RUZURGI&#174; and a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#174;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company also purchased from Jacobus approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of RUZURGI&#174; inventory previously manufactured by Jacobus, which was recorded as an expense in research and development expenses in the consolidated statements of operations and comprehensive income for 2022.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under business combination guidance, the screen test states that if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and is accounted for as an asset acquisition. The Company has determined that the screen test was not met. However, the Company determined that the acquisition did not meet the definition of a business under ASC 805, Business Combination. The Company believes that the licensing agreement and other assets acquired from Jacobus are similar and considered them all to be intangible assets with the exception of the inventory acquired. As the screen test was not met, further determination was required to determine that the Company had not acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business, and therefore, determined that this was an asset acquisition. The Company accounted for the Jacobus license agreement as an asset acquisition under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired research and development inventory expensed<br/>&#160;&#160;&#160;from asset acquisition</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACQUISITION OF U.S. RIGHTS FOR FYCOMPA&#174;. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 24, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company acquired the U.S. Rights for FYCOMPA&#174; (perampanel) CIII a commercial stage epilepsy asset, from Eisai. The aggregate consideration for the acquisition was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash, including the reimbursement of certain liabilities and the payment of transaction costs.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eisai was eligible to receive a contingent payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million if a certain regulatory milestone was met. As meeting the regulatory milestone was not probable, the Company did not recognize any amount related to the milestone payments in the purchase price. Additionally, after the loss of patent exclusivity for FYCOMPA&#174;, the Company may be obligated to pay certain royalties to Eisai on net sales of FYCOMPA&#174;. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize the royalty payments in cost of sales as revenue from product sales is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales of greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million prior to the date of generic entry. Royalties equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales of greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on net sales greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after the date of generic entry.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA&#174; (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Base cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for pro-rated prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reimbursement on base purchase price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(ii)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </span></div></div></div><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acquisition of FYCOMPA&#174; has been accounted for as an asset acquisition in accordance with FASB ASC 805-50. The Company accounted for the acquisition of FYCOMPA&#174; as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the FYCOMPA&#174; product rights. The FYCOMPA&#174; product rights consist of certain patents and trademarks, at-market contracts and regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets (samples)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT FOR AGAMREE&#174; (VAMOROLONE). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company completed its acquisition from Santhera of an exclusive license for North America for AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vamorolone), a treatment for patients suffering with DMD which was approved by the FDA on October 26, 2023. On March 13, 2024, the Company announced the U.S. commercial launch of AGAMREE&#174; for the treatment of DMD in patients aged two years or older. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in those jurisdictions. Additionally, the Company will hold North American rights for any future approved indications of AGAMREE&#174;. The Company made an all-cash initial payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at the closing of the acquisition to acquire the license.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreement, the Company pays: (i) royalties to the licensor until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any calendar year for sales equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (prior to December 31, 2025 only), </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#174; equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales (as defined in the license agreement) in North America for any single calendar year for sales equal to or less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of net sales for sales in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Furthermore, the Company may be obligated to pay Santhera sales-based milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as well as up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% percent royalties for all additional indications and milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the first three additional indications.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simultaneously, the Company made a strategic equity investment into Santhera by acquiring </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Santhera&#8217;s post reverse-split ordinary shares (representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction), which are traded on the SIX Swiss Exchange, at an investment price of CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.477</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the funds invested into Santhera to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE&#174;.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the strategic equity investment (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction has been accounted for as an asset acquisition in accordance with ASC 805-50. The Company accounted for the transaction as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the rights to develop, commercialize and manufacture AGAMREE&#174;. The AGAMREE&#174; rights consist of certain licenses and regulatory approvals and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. Additionally, the Company did not acquire a substantive process. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-financial assets based on relative fair values.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174; (vamorolone) (IPR&amp;D)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the investment in Santhera was determined based on the closing market price (CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of Santhera shares and the exchange rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1537</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of CHF to USD on the date the shares were transferred, July 19, 2023. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with FASB ASC 730-10-25, as AGAMREE&#174; (vamorolone) had not achieved regulatory approval when acquired, the portion of the purchase price allocated to the IPR&amp;D asset acquired (which includes all transaction costs related to the transactions with Santhera) was immediately expensed to research and development. Milestone payments made are either expensed as research and development or capitalized as a developed asset based on when regulatory approval is obtained. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize all sales-based milestone and royalty payments in cost of sales as revenue from product sales is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the approval of the NDA for AGAMREE&#174; on October 26, 2023, the Company became obligated to make a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Santhera. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment was made during the fourth quarter of 2023. The Company capitalized the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment which is being amortized using the straight-line method over the product&#8217;s estimated useful life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strategic equity investment in Santhera is accounted for as an investment in equity securities, and is recognized as a non-current asset, as the Company does not intend to sell the shares within 12 months. Since Santhera shares have a readily determinable fair value, the investment will be measured quarterly at fair value with changes reported in earnings in other income, net in the accompanying consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements (continued). </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company has entered into agreements with contract manufacturers for the manufacture of commercial drug and drug and study placebo for the Company&#8217;s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company&#8217;s trials and studies and with various entities for laboratories and other testing related to the Company&#8217;s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386760544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to income taxes in the U.S. federal jurisdiction and various states jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax expense for the years ended December 31, 2024, 2023 and 2022 consists of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,876</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,011</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,101</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of income tax expense computed at the statutory federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to amounts included in the statements of operations is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation windfall</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryovers and the temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets/(liabilities) as of December 31, 2024 and 2023 are as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,058</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">759</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December 31, 2024, the Company determined that there is sufficient positive evidence to conclude that it is more likely than not that the above deferred taxes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are realizable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has received several orphan drug designations by the FDA for products currently under development. The orphan drug designations allow the Company to claim increased federal tax credits for certain research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An immaterial amount of interest and penalties were accrued through December 31, 2024 and 2023. The Company&#8217;s policy is to recognize any related interest or penalties in income tax expense. The Company is not currently under income tax examinations by any tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478475488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of authorized preferred stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value per share. At December 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock were outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of authorized common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. At December 31, 2024 and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,879,099</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,121,549</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of common stock were issued and outstanding. Each holder of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote of each share of common stock held of record on all matters on which stockholders generally are entitled to vote.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Repurchases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, the Company&#8217;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock, pursuant to a repurchase plan under Rule 10b-18 of the Securities Act. The share repurchase program commenced on March 22, 2021 and currently expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 22, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were repurchased during the years ended December 31, 2024 and 2023. During the year ended December 31, 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were repurchased for an aggregate purchase price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> average price per share).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity (continued). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 8, 2023, the Company filed a shelf registration statement with the SEC to sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the 2023 Shelf Registration Statement). The 2023 Shelf Registration Statement (file no. 333-274427) became effective upon filing. On January 9, 2024, the Company completed a public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, raising net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Company&#8217;s 2023 Shelf Registration Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385477520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,779</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,729</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,769</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,178</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may issue stock options, restricted stock, stock appreciation rights and restricted stock units (collectively, the Awards) to employees, directors, and consultants of the Company under the 2014 and 2018 Stock Incentive Plans (the 2014 Plan and the 2018 Plan or collectively, the Plans). At December 31, 2024, no shares remain available for future issuance under the 2014 Plan. Under the 2018 Plan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,000,000</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares are reserved for issuance and as of December 31, 2024,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,254,102</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares remain available for future issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has granted stock options to employees, officers, directors, and consultants generally at exercise prices equal to the market price of the common stock at grant date. Option awards generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of continuous service and have contractual terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Certain awards provide for accelerated vesting if there is a change in control. The Company issues new shares as shares are required to be delivered upon exercise of outstanding stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, options to purchase</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,429,184</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,651,345</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,172,342</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company&#8217;s common stock were exercised with gross proceeds to the Company of approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. During the years ended December 31, 2024, 2023 and 2022, no options to purchase shares of the Company&#8217;s common stock were exercised on a &#8220;cashless&#8221; basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022 the Company recorded non-cash stock-based compensation expense related to stock options totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options to purchase an aggregate</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,476,946</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,598,535</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,386,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of the Company&#8217;s common stock to certain of the Company&#8217;s officers, employees, directors, and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation (continued). </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the Company&#8217;s Plans for the year ended December 31, 2024 is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.352%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.658000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.798%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,177,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,476,946</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised or released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,429,184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,076,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,353,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.93</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,449</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information pertaining to stock option activity during the years ended December 31, 2024, 2023 and 2022 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted&#8211;average fair value of granted stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of vested stock options (in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intrinsic value of exercised stock options<br/>&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation expense related to non-vested stock option awards granted under the Plans. That cost is expected to be recognized over a weighted average period of approximately</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.72</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to the expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of the Company&#8217;s common stock. The Company estimates the expected option life for options granted to employees and directors based upon the simplified method. Under this method, the expected life is presumed to be the mid-point between the vesting date and the end of the contractual term. The Company will continue to use the simplified method until it has sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the estimated life of the stock option awards. The expected dividend rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumptions used during the years ended December 31, 2024, 2023 and 2022 were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.928%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.92</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected forfeiture rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Compensation (continued). </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2018 Plan, participants may be granted restricted stock units, each of which represents a conditional right to receive shares of common stock in the future. The restricted stock units granted under this plan generally vest ratably over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. Upon vesting, the restricted stock units will convert into an equivalent number of shares of common stock. The amount of expense relating to the restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant and is amortized on a straight-line basis over the requisite service period. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity for the year ended December 31, 2024 was as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded non-cash stock-based compensation expense related to restricted stock units totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230396263312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit Plan. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code covering all eligible employees. Subject to certain dollar limits, eligible employees may contribute up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their pre-tax annual compensation to the plan. The Company has elected to make discretionary matching contributions of employee contributions up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s gross salary. For the years ended December 31, 2024, 2023 and 2022, the Company&#8217;s matching contributions were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478477872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent Events. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company announced that it and its licensor, SERB have entered into a Settlement Agreement with Teva. This agreement resolves the patent litigation brought by the Company and SERB in response to Teva&#8217;s ANDA seeking approval to market a generic version of FIRDAPSE&#174; (amifampridine) 10 mg tablets prior to the expiration of the applicable patents.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the settlement agreement, Teva has agreed not to market its generic version of FIRDAPSE&#174; in the U.S. any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of settlements occur. In accordance with the Agreement, the Company/SERB and Teva have terminated all ongoing patent litigation between them that is currently pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE&#174; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#174;&#8217;s Orange Book-listed patents) and Lupin (only for Catalyst&#8217;s FIRDAPSE&#174; patent expiring in 2037) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of FIRDAPSE&#174; to be marketed in the U.S. prior to February 25, 2035.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 17, 2025, Charles B. O&#8217;Keeffe, an independent member of the Board of Directors (Board) of the Company, advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company&#8217;s stockholders. Mr. O&#8217;Keeffe will continue to serve as a member of the Board until the 2025 annual meeting, when his current term will expire. Mr. O&#8217;Keeffe has been a member of the Board since December 2004 and currently serves as the Board&#8217;s Lead Independent Director. Mr. O&#8217;Keeffe&#8217;s intention to retire from the Board was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 21, 2025, the Company reported that its sub-licensee in Japan, DyDo, has launched FIRDAPSE&#174; Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with LEMS.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386840928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRINCIPLES OF CONSOLIDATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The consolidated financial statements include the Company&#8217;s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USE OF ESTIMATES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CASH AND CASH EQUIVALENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company primarily invests in high credit-quality instruments in order to obtain higher yields on its cash equivalents. The Company considers all highly liquid instruments, purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has its cash and cash equivalents deposited with two financial institutions.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">INVESTMENTS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At December 31, 2024 and 2023, investments consisted of U.S. Treasuries and an investment in equity securities. Such investments are not insured by the U.S. Federal Deposit Insurance Corporation.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Treasuries held at December 31, 2024 and 2023 were classified as available-for-sale securities. The Company classifies U.S. Treasuries with stated maturities of greater than three months and less than one year in short-term investments. U.S. Treasuries with stated maturities greater than one year are classified as non-current investments in its consolidated balance sheets.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (in stockholders&#8217; equity). Realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statements of operations and comprehensive income. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of its available-for-sale securities are judged to be as a result of a credit loss. The Company considers various factors in determining whether to recognize an allowance for credit losses including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. If the unrealized loss of an available-for-sale debt security is determined to be a result of a credit loss the Company would recognize an allowance and the corresponding credit loss would be included in the consolidated statements of operations and comprehensive income. The Company has not recorded an allowance for credit loss on its available-for-sale securities. See Note 3 (Investments).</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the Company made a strategic equity investment into Santhera by acquiring </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Santhera&#8217;s  ordinary shares (representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Santhera&#8217;s outstanding ordinary shares immediately following the transaction). The investment is denominated in Swiss Francs. The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera&#8217;s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes resulting from movements in foreign exchange rates, in other income, net in the consolidated statements of operations and comprehensive income.</span></p><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCOUNTS RECEIVABLE, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounts receivable are recorded net of customer allowances for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed. At December 31, 2024 and 2023, the Company determined that an allowance for expected credit losses was not required. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts were written off during the periods presented.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVENTORY</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; are also used in clinical programs to assess the safety and efficacy of the products for usage in treating diseases that have not been approved by the FDA or other regulatory authorities. The forms of FIRDAPSE&#174;, FYCOMPA&#174; and AGAMREE&#174; utilized for both commercial and clinical programs are identical and, as a result, the inventories have an &#8220;alternative future use&#8221; as defined in authoritative guidance. Raw materials associated with clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221;.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, and patient usage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">g.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PREPAID EXPENSES AND OTHER CURRENT ASSETS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements, and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company&#8217;s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing costs consist of advances for the Company&#8217;s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROPERTY AND EQUIPMENT,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af1f8375-788a-4903-85b9-db67fcf6e271;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for computer equipment and software, from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_af087444-9da2-4e54-b835-1802f923ce72;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for furniture and equipment, and from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion of the Company&#8217;s exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#174; in the U.S. and Mexico, which the Company accounted for as an asset acquisition under ASC 805-50. See Note 13 (Agreements) for further discussion on the Company&#8217;s acquisitions of the U.S. rights to FYCOMPA&#174; from Eisai, and on the exclusive license for North America acquired from Santhera for AGAMREE&#174;, both of which the Company accounted for as asset acquisitions under ASC 805-50.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">j.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INTANGIBLE ASSETS, NET.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">k.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE OF FINANCIAL INSTRUMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and certain components of accrued expenses and other liabilities. At December 31, 2024 and December 31, 2023, the fair value of these instruments approximated their carrying value as a result of their respective short-term duration. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">l.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE MEASUREMENTS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity&#8217;s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). </span></div></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity&#8217;s own assumptions, as there is little, if any, related market activity.</span><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.984%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.791%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using (in thousands)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.188%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.943999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of<br/>December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">m.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OPERATING LEASES. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, net, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#8217;s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ShareRepurchases', window );">SHARE REPURCHASES</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">n.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHARE REPURCHASES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In March 2021, the Company&#8217;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock. The share repurchase program currently expires in March 2025. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock&#8217;s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE RECOGNITION. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenues:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (ASC) Topic 606 &#8211; Revenue from Contracts with Customers (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue when its customers obtain title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. For FIRDAPSE&#174; and AGAMREE&#174;, subsequent to receiving FDA approvals, the Company entered into an arrangement with one distributor (the Customer), which is the exclusive distributor of FIRDAPSE&#174; and AGAMREE&#174; in the U.S. The Customer subsequently resells FIRDAPSE&#174; and AGAMREE&#174; to a small group of exclusive specialty pharmacies (SPs) whose dispensing activities for patients with specific payors may result in government-mandated or privately negotiated rebate obligations for the Company with respect to the purchase of FIRDAPSE&#174; and AGAMREE&#174;.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; in the U.S. commercial market through a Transition Service Agreement with a U.S. subsidiary of Eisai to major wholesalers and specialty pharmaceutical distributors. These sales are often subject to contracts held with managed care organizations and government agencies. The distribution services under the Transition Services Agreement ended on December 31, 2023, and beginning on January 1, 2024, the Company commenced direct sales of FYCOMPA&#174; in the U.S.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Revenue, Net:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company recognizes revenue on product sales when its customers obtain control of the Company&#8217;s products, which occur at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company&#8217;s payment terms range between 15 and 60 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, substantially all of the Company&#8217;s product revenues were from sales to customers in the U.S.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net product revenue disaggregated by product (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,035</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,426</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;+</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,251</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AGAMREE&#174;*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">489,327</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396,502</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#174; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></p></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves for Variable Consideration:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, prompt payment discounts, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers relating to the Company&#8217;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to its customers) or a current liability (if the amount is payable to a party other than its customers).</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#8217;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2024 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade Discounts, Allowances and Wholesaler Fees:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with a discount that is explicitly stated in its contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. To the extent the services received are distinct from the sale of products to its customers, these payments are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income. However, if the Company has determined such services received are not distinct from the Company&#8217;s sale of products to its customers, these payments have been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive income through December 31, 2024, 2023 and 2022, as well as a reduction to accounts receivable, net on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prompt Payment Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual invoice sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funded Co-pay Assistance Program:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company contracts with a third party to manage the co-pay assistance program intended to provide financial assistance to qualified commercially-insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with its products, that have been recognized as revenue, but remains in the distribution channel at the end of each reporting period. These payments are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution or master agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. Return payments related to the sale of products are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provider Chargebacks and Discounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to the customer, who directly purchases the product from the Company. The customer charges the Company for the difference between what they paid for the product and the ultimate selling price to the qualified healthcare providers. The Company also participates in programs with government entities and other parties, including covered entities under the 340B Drug Pricing Program, whereby pricing on FYCOMPA&#174; is extended below wholesaler list price to participating entities (the FYCOMPA&#174; Participants). These entities purchase FYCOMPA&#174; through wholesalers at the lower program price and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue, net and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by the customer or at the time of a resale to a FYCOMPA&#174; Participant by a wholesaler, and the Company generally issues credits for such amounts within a few weeks of the customer or wholesalers&#8217; notification to the Company of the resale. Reserves for chargebacks consist primarily of chargebacks that the customer or wholesalers have claimed, but for which the Company has not yet issued a credit, as well as an estimate of chargeback claims that the Company expects to receive associated with its products, that have been recognized as revenue but remains in the distribution channel at the end of each reporting period.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Rebates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company is subject to discount obligations under state Medicaid, Medicare and other government programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For reserves related to the sale of its products, there is an establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the coverage gap program is sunsetting in 2024 and is being replaced with the Inflation Reduction Act (IRA) program. While most components of this program will begin 2025, the inflation penalty portion is effective as of 2024. Specifically, the program imposes manufacturer rebates on certain Part B and Part D drugs when prices rise faster than the rate of inflation. The Company has estimated this potential impact and has accounted for these inflation-related rebates as a reduction of product revenue in 2024 to the extent they apply to its drug portfolio. Similar to the coverage gap rebates, the associated reserve is accrued for as a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payor Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balances sheets.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bridge and Patient Assistance Programs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company provides FIRDAPSE&#174; and AGAMREE&#174; free of charge to uninsured patients who satisfy pre-established criteria for either the Bridge Program or the Patient Assistance Program. Patients who meet the Bridge Program eligibility criteria and are transitioning from investigational product while they are waiting for a coverage determination, or later, for patients whose access is threatened by the complications arising from a change of insurer may receive a temporary supply of free FIRDAPSE&#174; or AGAMREE&#174; while the Company is determining the patient&#8217;s third party insurance, prescription drug benefit or other third party coverage for FIRDAPSE&#174; or AGAMREE&#174;. The Patient Assistance Program provides FIRDAPSE&#174; or AGAMREE&#174; free of charge for longer periods of time for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#174; or AGAMREE&#174; because they are unable to obtain coverage from their payor despite having health insurance, to the extent allowed by applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company provides FYCOMPA&#174; free of charge to uninsured patients who satisfy pre-established criteria through a Patient Assistance Program. In addition, Catalyst provides programs to assist patients through the process for obtaining reimbursement approval for their FYCOMPA&#174; prescriptions from their insurers. Catalyst also provides support for patients using FYCOMPA&#174; through an Instant Savings Card Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenues from Collaboration and Licensing Arrangements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration (Topic 808), to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. Revenue is included in product revenue, net in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation and Significant Accounting Policies (continued).</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes sales-based royalties or net profit-sharing when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Revenue is included in license and other revenue in the Company&#8217;s consolidated statements of operations and comprehensive income.</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments to and from the collaborator are presented in the statements of operations based on the nature of the Company&#8217;s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 11 (Collaborative and Licensing Arrangements), for further discussion on the Company&#8217;s collaborative and licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">p.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESEARCH AND DEVELOPMENT.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research-related services for the Company.</span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records upfront and milestone payments made to third parties under licensing and collaboration arrangements that occur before a compound receives regulatory approval as acquired in-process research and development (IPR&amp;D). IPR&amp;D acquired as part of an asset acquisition with no alternative future use is expensed immediately to research and development. Milestone payments made after regulatory approval are capitalized as a developed asset and unless the asset is determined to have an indefinite life, the Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">ADVERTISING EXPENSE</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADVERTISING EXPENSE. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising costs are expensed as incurred. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in advertising costs during the years ended December 31, 2024, 2023 and 2022, respectively, which are included in selling, general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive income.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">r.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK-BASED COMPENSATION. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">CONCENTRATION OF RISK</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">s.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONCENTRATION OF RISK. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sells its products, FIRDAPSE&#174; and AGAMREE&#174;, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to these products. The Company sells its product, FYCOMPA&#174;, directly to major wholesalers and specialty pharmaceutical distributors and indirectly to managed care organizations and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE&#174;. The Company expects sales of FIRDAPSE&#174;, FYCOMPA&#174;, and AGAMREE&#174; to constitute virtually all of the Company&#8217;s product revenue for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE&#174;. The Company relies on the same third party manufacturers for FYCOMPA&#174; as utilized by Eisai prior to the Company&#8217;s acquisition of the U.S. rights to the product in January 2023. It also relies on Santhera and its supplier as its sole source of supply for AGAMREE&#174;. If the Company is unable to continue its relationships with one or more of these third party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third party contractors to manufacture the commercial supply of its drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates the approximate percentage of the Company&#8217;s total net product revenue attributed to the Company&#8217;s largest customers for the periods presented:</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_RoyaltiesExpensePolicyTextBlock', window );">ROYALTIES</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">t.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROYALTIES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Royalties incurred in connection with the Company&#8217;s license agreement for FIRDAPSE&#174; and AGAMREE&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. </span></div></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties incurred in connection with the Company&#8217;s license agreement for RUZURGI&#174;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized for any royalties in excess of the minimum annual royalty payment from July 11, 2022 (the Effective Date) through 2025. The minimum royalty payment that exists annually for calendar years from the Effective Date through 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are included in the purchase price of the agreement.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">u.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCOME TAXES.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2021. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">COMPREHENSIVE INCOME</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">v.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPREHENSIVE INCOME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders&#8217; equity. The Company&#8217;s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2024, 2023 and 2022, and is comprised of net unrealized gains (losses) on the Company&#8217;s available-for-sale securities.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET INCOME PER COMMON SHARE</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">w.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NET INCOME PER COMMON SHARE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles basic and diluted weighted average common shares:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.726%;box-sizing:content-box;"></td>
          <td style="width:1.683%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.407%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.43%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.642%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,457,673</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,279,736</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,374,606</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of dilutive securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,485,930</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,473,418</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,001,025</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,943,603</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,753,154</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,375,631</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding common stock equivalents totaling approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were excluded from the calculation of diluted net income per common share for the years ended December 31, 2024, 2023 and 2022, respectively, as their effect would be anti-dilutive. Potentially dilutive options to purchase common stock as of December 31, 2024, 2023 and 2022 had exercise prices ranging from</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">x.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEGMENT INFORMATION.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management has determined that the Company operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is the development and commercialization of drug products. The Company's chief operating decision maker (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fc95014e-239d-4684-9334-a50e46b93483;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">president and chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who reviews financial information presented on a consolidated basis.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These financial metrics are used by the CODM t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating margin and the allocation of budget between cost of revenues, selling, research and development, and general and administrative expenses.</span></div></div><p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates information about significant segment expenses:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,648</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,150</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,789</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,746</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative (a)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,994</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,210</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,388</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,860</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,874</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     (a)     </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">RECLASSIFICATIONS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">y.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECLASSIFICATIONS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">RECENTLY ISSUED ACCOUNTING STANDARDS</a></td>
<td class="text"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">z.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECENTLY ISSUED ACCOUNTING STANDARDS. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ASU 2023-07) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 during the year ended December 31, 2024. </span></div></div><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires significant disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance will be applied prospectively and is effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the impact of the standard on the Company&#8217;s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income&#8212; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaid expenses and other current assets. This disclosure may include the types of prepaid expenses and other current assets and how these are recognize in expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltiesExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltiesExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ShareRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for share repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ShareRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478398032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurement Specific to Assets or Liability</a></td>
<td class="text">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.984%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.436%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.479%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.791%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using (in thousands)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31,<br/>2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,947</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,564</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.188%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.594999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:11.943999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of<br/>December 31,<br/>2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets/<br/>Liabilities<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,256</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Investment in equity securities:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregated Product Revenue</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net product revenue disaggregated by product (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIRDAPSE&#174;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,035</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,426</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FYCOMPA&#174;+</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,251</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,076</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AGAMREE&#174;*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total product revenue, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">489,327</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396,502</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#174; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of the Company's Total Net Product Revenue</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates the approximate percentage of the Company&#8217;s total net product revenue attributed to the Company&#8217;s largest customers for the periods presented:</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.72%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer A</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Customer B*</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Basic and Dilutive Weighted Average Common Shares</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles basic and diluted weighted average common shares:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:50.726%;box-sizing:content-box;"></td>
          <td style="width:1.683%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.407%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.056999999999999%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.43%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.642%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,457,673</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,279,736</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,374,606</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of dilutive securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,485,930</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,473,418</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,001,025</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted weighted average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,943,603</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,753,154</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,375,631</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Segment Expenses</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table illustrates information about significant segment expenses:</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.24%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.26%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,648</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,150</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,789</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,746</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,500</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative (a)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,994</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,210</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,041</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,388</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,860</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,874</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     (a)     </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</span></span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478520912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Investments by Security type</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available-for-sale investments by security type were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,373</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasuries - Cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,523</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock', window );">Estimated Fair Values of Available for Sale Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair values of available-for-sale securities at December 31, 2024, by contractual maturity, are summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Summary Of Net Gains And Losses On Equity Securities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net gains (losses) recognized during the period on<br/>&#160;&#160;&#160;equity securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized net gains (losses) recognized during the<br/>&#160;&#160;&#160;period on equity securities still held at the reporting<br/>&#160;&#160;&#160;date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities by amortized cost unrealized gains or losses and fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385904688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Reclassifications out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no reclassifications out of accumulated other comprehensive income during the years ended December 31, 2024 or 2023. </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.7%;box-sizing:content-box;"></td>
        <td style="width:2.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.099999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain (loss) before<br/>&#160;&#160;&#160;reclassifications</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net current period other comprehensive gain</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385284032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of current inventory</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,910</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,445</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,161</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,541</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,644</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478461552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid manufacturing costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,299</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,038</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due from collaborative and licensing arrangements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid conference and travel expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid co-pay assistance program</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,030</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,039</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,535</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385512960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesLeaseIncomeAbstract', window );"><strong>Operating Lease, Lease Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related To Lease</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for lease<br/>&#160;&#160;&#160;obligations:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock', window );">Schedule of Supplemental Balance Sheet related To Lease</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental balance sheet information related to lease was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span><span style="-sec-ix-hidden:F_e02f321f-c2da-4a31-b171-0bb073d6f3b4;"><span style="-sec-ix-hidden:F_af9bf51b-92c5-4e0c-beca-6ed527c2962a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;liabilities, net of current portion</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remaining payments of lease liabilities as of December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">553</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">835</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabulor Disclosure of Supplemental balance Sheet Information Related To Lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesLeaseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesLeaseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478525216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">723</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,354</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478451824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Acquired Intangibles, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2024 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,301</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,040</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company&#8217;s intangible assets at December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net<br/>Carrying<br/>Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for RUZURGI&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,418</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,049</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived, Future Amortization Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future amortization expense the Company expects for its intangible assets (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,705</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,083</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478413728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,011</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,730</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,883</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,991</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,437</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued purchases</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued gross-to-net revenue liabilities*</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">729</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,582</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,031</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">417</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,085</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due to licensor &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other &#8211; non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,101</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a 3PL organization under the Company's contracts.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478302128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock', window );">Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,569</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired research and development inventory expensed<br/>&#160;&#160;&#160;from asset acquisition</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase price</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,699</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Aggregate Amount Paid for the Assets Acquired</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA&#174; (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Base cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for pro-rated prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reimbursement on base purchase price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,238</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(ii)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,870</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </span></div></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock', window );">Summary of Total Purchase Price Allocated to Acquired Assets</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets (samples)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid commercialization expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,576</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for FYCOMPA&#174;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued preclinical and clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,208</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember', window );">Vamorolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Aggregate Amount Paid for the Assets Acquired</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of AGAMREE&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the strategic equity investment (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial cash payment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock', window );">Summary of Total Purchase Price Allocated to Acquired Assets</a></td>
<td class="text"><p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and acquired intangibles for AGAMREE&#174; (vamorolone) (IPR&amp;D)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment in Santhera</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total purchase consideration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of total purchase price was allocated to acquire assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478519920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The income tax expense for the years ended December 31, 2024, 2023 and 2022 consists of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,876</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,951</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - Federal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,442</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred - State</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,011</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,712</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,374</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,101</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,640</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of income tax expense computed at the statutory federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to amounts included in the statements of operations is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation windfall</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,755</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,058</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">759</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,982</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,544</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385478384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,779</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,729</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,769</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,178</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under the Company's Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock option activity under the Company&#8217;s Plans for the year ended December 31, 2024 is summarized as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.352%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.658000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.258%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.798%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,177,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.73</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,476,946</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised or released</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,429,184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,337</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.47</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,076,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,353,893</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.93</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,449</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Schedule of Other Information Pertaining to Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other information pertaining to stock option activity during the years ended December 31, 2024, 2023 and 2022 was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted&#8211;average fair value of granted stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of vested stock options (in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intrinsic value of exercised stock options<br/>&#160;&#160;&#160;(in thousands)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,230</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Stock Options Awards Based on Certain Assumptions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumptions used during the years ended December 31, 2024, 2023 and 2022 were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.928%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
        <td style="width:1.68%;box-sizing:content-box;"></td>
        <td style="width:18.344%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.92</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected forfeiture rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock unit activity for the year ended December 31, 2024 was as follows: </span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.48</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,667</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nonvested balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (d)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478374928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Detail) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cprx_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 140,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cprx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cprx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230388055504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MaximumMaturityPeriodOfCashAndCashEquivalent', window );">Maximum maturity period of cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three months <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis', window );">Maximum amortization period of compensation cost on straight line basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise price range, Minimum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise price range, Maximum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.23<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential equivalent common stock excluded | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">President and Chief Executive Officer [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Asset acquisition equity interests issued or issuable number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares', window );">Asset acquisition percentage of outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Allowance for expected credit losses, written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember', window );">Share Purchase Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember', window );">License Agreement For RUZURGI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MinimumRoyalty', window );">Minimum royalty</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition equity interests issued or issuable number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition percentage of outstanding ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time in which compensation cost from stock options is amortized on a straight line basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MaximumMaturityPeriodOfCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum length of time to maturity for instruments included as cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MaximumMaturityPeriodOfCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MinimumRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MinimumRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of basis of presentation and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230383355360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">$ 21,564<span></span>
</td>
<td class="nump">$ 16,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">329,457<span></span>
</td>
<td class="nump">94,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">109,947<span></span>
</td>
<td class="nump">18,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">21,564<span></span>
</td>
<td class="nump">16,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">329,457<span></span>
</td>
<td class="nump">94,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 109,947<span></span>
</td>
<td class="nump">$ 18,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230387371568">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 491,734<span></span>
</td>
<td class="nump">$ 398,204<span></span>
</td>
<td class="nump">$ 214,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_FirdapseMember', window );">FIRDAPSE [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">306,035<span></span>
</td>
<td class="nump">258,426<span></span>
</td>
<td class="nump">213,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_FycompaMember', window );">FYCOMPA [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">137,251<span></span>
</td>
<td class="nump">138,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_AgamreeMember', window );">AGAMREE [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">46,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember', window );">Product revenue, net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 489,327<span></span>
</td>
<td class="nump">$ 396,502<span></span>
</td>
<td class="nump">$ 213,938<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#174; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#174; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_FirdapseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_FirdapseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_FycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_FycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_AgamreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_AgamreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230387612736">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">65.20%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer B [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">34.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customers [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#174; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#174; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cprx_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cprx_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cprx_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cprx_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cprx_CustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cprx_CustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385497344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
<td class="nump">118,457,673<span></span>
</td>
<td class="nump">106,279,736<span></span>
</td>
<td class="nump">103,374,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities</a></td>
<td class="nump">6,485,930<span></span>
</td>
<td class="nump">7,473,418<span></span>
</td>
<td class="nump">8,001,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
<td class="nump">124,943,603<span></span>
</td>
<td class="nump">113,753,154<span></span>
</td>
<td class="nump">111,375,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385269584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,648<span></span>
</td>
<td class="nump">$ 93,150<span></span>
</td>
<td class="nump">$ 19,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,746<span></span>
</td>
<td class="nump">91,500<span></span>
</td>
<td class="nump">31,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,994<span></span>
</td>
<td class="nump">42,210<span></span>
</td>
<td class="nump">26,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 190,388<span></span>
</td>
<td class="nump">$ 226,860<span></span>
</td>
<td class="nump">$ 76,874<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386908368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Summary of Available-for-Sale Investments by Security type (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 329,457<span></span>
</td>
<td class="nump">$ 94,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">329,373<span></span>
</td>
<td class="nump">94,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cprx_UsTreasuryBondSecuritiesCashEquivalentsMember', window );">U.S. Treasuries - Cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">329,457<span></span>
</td>
<td class="nump">94,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 329,373<span></span>
</td>
<td class="nump">$ 94,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cprx_UsTreasuryBondSecuritiesCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cprx_UsTreasuryBondSecuritiesCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386599648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains losses from available for sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses from sale of&#160;available-for-sale&#160;securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 762,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230388639216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Estimated Fair Values of Available for Sale Securities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 329,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478351456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Summary Of Net Gains And Losses On Equity Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">$ 5,075<span></span>
</td>
<td class="nump">$ 3,024<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gains (losses) recognized during the period on equity securities still held at the reporting date</a></td>
<td class="nump">$ 5,075<span></span>
</td>
<td class="nump">$ 3,024<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230483854384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning balance</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive gain (loss) before reclassifications</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net current period other comprehensive gain</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending balance</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385251072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Summary of current inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 6,518<span></span>
</td>
<td class="nump">$ 1,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9,578<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,541<span></span>
</td>
<td class="nump">$ 15,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230388607568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidManufacturingExpense', window );">Prepaid manufacturing costs</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid tax</a></td>
<td class="nump">7,959<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">1,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidSubscriptionFees', window );">Prepaid subscriptions fees</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidResearchFee', window );">Prepaid research fees</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidCommercialExpenses', window );">Prepaid commercialization expenses</a></td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_DueFromCollaborativeAndLicencingArrangements', window );">Due from collaborative and licensing arrangements</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidConferenceAndTravelExpenses', window );">Prepaid conference and travel expenses</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PrepaidCopayAssistanceProgram', window );">Prepaid co-pay assistance program</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 21,039<span></span>
</td>
<td class="nump">$ 12,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_DueFromCollaborativeAndLicencingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for pre-commercialization fees that provide economic benefits with a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_DueFromCollaborativeAndLicencingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidCommercialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid commercial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidCommercialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidConferenceAndTravelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid conference and travel expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidConferenceAndTravelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidCopayAssistanceProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid copay assistance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidCopayAssistanceProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidResearchFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and product development activities that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidResearchFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PrepaidSubscriptionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for subscription fees that provides economic benefits within a future period of one year of the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PrepaidSubscriptionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392513328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases  - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_BeforeAgreementOfCompanyLeasedSpaces', window );">Before agreement of company leased spaces | ft&#178;</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AfterAgreementOfCompanyLeasedSpaces', window );">After agreement of company leased spaces | ft&#178;</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense | $</a></td>
<td class="nump">$ 431,000<span></span>
</td>
<td class="nump">$ 431,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">7.6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AfterAgreementOfCompanyLeasedSpaces">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After agreement of company leased spaces.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AfterAgreementOfCompanyLeasedSpaces</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_BeforeAgreementOfCompanyLeasedSpaces">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Before agreement of company leased spaces.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_BeforeAgreementOfCompanyLeasedSpaces</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392094976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230481922448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_RightOfUseAssetsObtainedAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RightOfUseAssetsObtainedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use Assets Obtained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RightOfUseAssetsObtainedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386907200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Assets and Liabilities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Liabilities, Current<span></span>
</td>
<td class="text">Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 2,786<span></span>
</td>
<td class="nump">$ 3,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">$ 3,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230481943888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">$ 3,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230482715488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">$ (1,120)<span></span>
</td>
<td class="num">$ (723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230394100672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 227,712<span></span>
</td>
<td class="nump">$ 227,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">71,040<span></span>
</td>
<td class="nump">33,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">156,672<span></span>
</td>
<td class="nump">194,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember', window );">License and Acquired Intangibles for RUZURGI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">33,569<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,739<span></span>
</td>
<td class="nump">3,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">27,830<span></span>
</td>
<td class="nump">30,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember', window );">License and Acquired Intangibles for FYCOMPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">158,143<span></span>
</td>
<td class="nump">158,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">61,301<span></span>
</td>
<td class="nump">29,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">96,842<span></span>
</td>
<td class="nump">128,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember', window );">Licensed And Acquired Intangibles For AGAMREE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 35,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386970816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 37,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">37,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">37,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">7,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">31,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 156,672<span></span>
</td>
<td class="nump">$ 194,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392936944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Acquired Intangibles, Net - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 37,377,000<span></span>
</td>
<td class="nump">$ 32,565,000<span></span>
</td>
<td class="nump">$ 1,098,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment charges recognized on definite-lived intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember', window );">License and Acquired Intangibles for RUZURGI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">14 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember', window );">License and Acquired Intangibles for FYCOMPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 31,600,000<span></span>
</td>
<td class="nump">29,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember', window );">Licensed And Acquired Intangibles For AGAMREE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicenseAndAcquiredIntangiblesForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cprx_LicensedAndAcquiredIntangiblesForAgamreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392939120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AccruedNonClinicalAndClinicalTrialExpenses', window );">Accrued preclinical and clinical trial expenses</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">11,011<span></span>
</td>
<td class="nump">4,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">10,746<span></span>
</td>
<td class="nump">8,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AccruedLicenseFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">30,991<span></span>
</td>
<td class="nump">24,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AccruedPurchasesCurrent', window );">Accrued purchases</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AccruedGrossToNetRevenueLiabilities', window );">Accrued gross-to-net revenue liabilities</a></td>
<td class="nump">44,939<span></span>
</td>
<td class="nump">6,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income tax</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisationDueToLicensorCurrent', window );">Due to licensor</a></td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">12,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Current accrued expenses and other liabilities</a></td>
<td class="nump">104,085<span></span>
</td>
<td class="nump">61,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability &#8211; non-current</a></td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisationDueToLicensorNoncurrent', window );">Due to licensor &#8211; non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other &#8211; non-current</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities', window );">Non-current accrued expenses and other liabilities</a></td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 107,186<span></span>
</td>
<td class="nump">$ 67,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AccruedGrossToNetRevenueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued gross-to-net revenue liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AccruedGrossToNetRevenueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AccruedLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AccruedLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AccruedNonClinicalAndClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable pertaining to non clinical and clinical trial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AccruedNonClinicalAndClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AccruedPurchasesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued purchases current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AccruedPurchasesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisationDueToLicensorCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisation due to licensor current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisationDueToLicensorCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisationDueToLicensorNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisation due to licensor noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisationDueToLicensorNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other noncurrent accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230391235408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cprx_KyePharmaceuticalsMember', window );">KYE Pharmaceuticals [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ExpensesIncurredInConnectionWithCollaborationAgreement', window );">Expenses incurred in connection with collaboration agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Product revenue, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Regulatory Filing Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Dydo Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Milestone Payment [Member] | Product revenue, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ExpensesIncurredInConnectionWithCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses Incurred In Connection With Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ExpensesIncurredInConnectionWithCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cprx_KyePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cprx_KyePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_ProductRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cprx_RegulatoryFilingMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cprx_RegulatoryFilingMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cprx_DydoPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cprx_DydoPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_CollaborationAgreementAxis=cprx_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_CollaborationAgreementAxis=cprx_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230388195888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Jul. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear', window );">License and asset purchase agreement payment made in first year</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear', window );">License and asset purchase agreement payment made in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear', window );">License and asset purchase agreement payment made in third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AgreementAxis=cprx_LicenseAndAssetPurchaseAgreementMember', window );">License and Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PurchasePriceOfAnAssetAcquisition', window );">Purchase price of an asset acquisition</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AgreementAxis=cprx_LicenseAndAssetPurchaseAgreementMember', window );">License and Asset Purchase Agreement [Member] | Calendar Years 2022 Through 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales', window );">Percentage of annual royalty on the Company's net sales</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MinimumRoyaltyAmount', window );">Minimum royalty amount</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AgreementAxis=cprx_LicenseAndAssetPurchaseAgreementMember', window );">License and Asset Purchase Agreement [Member] | Calendar Year 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_CommitmentsLineItems', window );"><strong>Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales', window );">Percentage of annual royalty on the Company's net sales</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MinimumRoyaltyAmount', window );">Minimum royalty amount</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_CommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_CommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and asset purchase agreement payment made in first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and asset purchase agreement payment made in second year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and asset purchase agreement payment made in third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MinimumRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum royalty amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MinimumRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual royalty on the company's net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PurchasePriceOfAnAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PurchasePriceOfAnAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AgreementAxis=cprx_LicenseAndAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AgreementAxis=cprx_LicenseAndAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PeriodAxis=cprx_CalendarYears2022Through2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PeriodAxis=cprx_CalendarYears2022Through2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PeriodAxis=cprx_CalendarYear2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PeriodAxis=cprx_CalendarYear2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230372465056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 26, 2012</div></th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,150<span></span>
</td>
<td class="nump">$ 19,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Asset acquisition equity interests issued or issuable number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares', window );">Asset Acquisition Percentage Of Outstanding Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementDate', window );">Date on which strategic collaboration is entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 24,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ContingentConsiderationArrangementsContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred And Twenty Five Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred And Twenty Five Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember', window );">Vamorolone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Asset acquisition equity interests issued or issuable number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares', window );">Asset Acquisition Percentage Of Outstanding Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionInvestmentSharePrice', window );">Asset Acquisition Investment Share Price | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ClosingMarketPrice', window );">Closing Market Price | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign Currency Exchange Rate, Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_CollaborativeArrangementMilestonePaymentObligation', window );">Collaborative arrangement, milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PaymentOnMilestonePayment', window );">Payment on milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty Less Than Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than Hundred Million And Less Than Two Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than Two Hundred Million And Less Than Three Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than Three Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty Less Than Two Hundred Fifty Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Two Hundred And Fifty Million And Less Than Five Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than Five Hundred Million And Less Than Seven Hundred Fifty Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than One Billion And Less Than Two Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty More Than Two Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty For Santhera Sales Based Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesBasedMilestoneToRoyaltyThreshold', window );">Net sales based milestone to royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty For Additional Indications And Milestones Of Up To Fifty Million More [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone', window );">Percentage of royalty payable to sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember', window );">AGAMREE [Member] | Royalty For Additional Indications And Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ContingentConsiderationArrangementsContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred And Twenty Five Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than Hundred Million And Less Than Two Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than Two Hundred Million And Less Than Three Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than Three Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Two Hundred And Fifty Million And Less Than Five Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than Five Hundred Million And Less Than Seven Hundred Fifty Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than One Billion And Less Than Two Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AGAMREE [Member] | Royalty More Than Two Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Ten Million And Less Than Hundred Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | U.S. Rights for FYCOMPA [Member] | Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty Less Than Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Than Hundred Million And Less Than Two Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Than Two Hundred Million And Less Than Three Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty Less Than Two Hundred Fifty Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Two Hundred And Fifty Million And Less Than Five Hundred Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Than Five Hundred Million And Less Than Seven Hundred Fifty Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AGAMREE [Member] | Royalty More Than One Billion And Less Than Two Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementWithBioMarinMember', window );">License Agreement with BioMarin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementDate', window );">Date on which strategic collaboration is entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 26,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NetSalesRoyaltyThreshold', window );">Net sales royalty threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementWithBioMarinMember', window );">License Agreement with BioMarin [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_RoyaltyAgreementTerm', window );">Royalty agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementWithBioMarinMember', window );">License Agreement with BioMarin [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfRoyaltyPayableToNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember', window );">License Agreement For RUZURGI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementDate', window );">Date on which strategic collaboration is entered into</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 11,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MinimumRoyalty', window );">Minimum royalty</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet', window );">Amount of minimum royalty payable maturity terms not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_UpFrontPayment', window );">Up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPurchasePriceConsideration', window );">Asset acquisition purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember', window );">License Agreement For RUZURGI [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfMinimumRoyaltyPayableToNetSales', window );">Percentage of minimum royalty payable to net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember', window );">License Agreement For RUZURGI [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PercentageOfMinimumRoyaltyPayableToNetSales', window );">Percentage of minimum royalty payable to net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum royalty payable maturity terms not met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition equity interests issued or issuable number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionInvestmentSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition investment share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionInvestmentSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition percentage of outstanding ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ClosingMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing market price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ClosingMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_CollaborativeArrangementMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_CollaborativeArrangementMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ContingentConsiderationArrangementsContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Arrangements Contingent Consideration Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ContingentConsiderationArrangementsContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LicenseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LicenseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MinimumRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MinimumRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_NetSalesBasedMilestoneToRoyaltyThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales based milestone to royalty threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_NetSalesBasedMilestoneToRoyaltyThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_NetSalesRoyaltyThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount used to determine the percentage of royalties for the period from the first commercial sale equal to the minimum percentage of net sales in North America for any calendar year for sales up to the amount, and maximum percentage of net sales in North America in any calendar year in excess of the amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_NetSalesRoyaltyThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PaymentOnMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PaymentOnMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PercentageOfMinimumRoyaltyPayableToNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum royalty payable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PercentageOfMinimumRoyaltyPayableToNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PercentageOfRoyaltyPayableToNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage applied to net sales to determine the amount payable as part of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PercentageOfRoyaltyPayableToNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable to sales based milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the royalty payments from the first commercial sale of product under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front&#160;payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_AgamreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyLessThanHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyLessThanHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanThreeHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanThreeHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyLessThanTwoHundredFiftyMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyLessThanTwoHundredFiftyMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTwoBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyMoreThanTwoBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForSantheraSalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForSantheraSalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_RoyaltyThresholdLimitAxis=cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementWithBioMarinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementWithBioMarinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230372537408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail) - License Agreement For RUZURGI [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems', window );"><strong>Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired', window );">License and acquired intangibles</a></td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition', window );">Acquired research and development inventory expensed from asset acquisition</a></td>
<td class="nump">4,130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionValue', window );">Total purchase price</a></td>
<td class="nump">$ 37,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired research and development inventory expensed from asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price consideration for intangible assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cprx_LicenseAgreementForRuzurgiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392422256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail) - U.S. Rights for FYCOMPA [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionBaseCashPayment', window );">Base cash payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses', window );">Cash paid for pro-rated prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ReimbursementOnBasePurchasePrice', window );">Reimbursement on base purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,238)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 164,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionBaseCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition base cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionBaseCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition cash paid for pro rated prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ReimbursementOnBasePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement on base purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ReimbursementOnBasePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385490816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember', window );">U.S. Rights for FYCOMPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction expenses</a></td>
<td class="nump">$ 5,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,900<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230384690800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail) - U.S. Rights for FYCOMPA [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionInventoryCurrent', window );">Inventory</a></td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets (samples)</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquistionPrepaidCommercializationFees', window );">Prepaid commercialization expenses</a></td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionPropertyAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa', window );">License and acquired intangibles for FYCOMPA</a></td>
<td class="nump">158,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses', window );">Accrued preclinical and clinical trial expenses</a></td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 164,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, accrued preclinical and clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, inventory current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, license and acquired intangibles for FYCOMPA&#174;.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition,, prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionPropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, property and equipment, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionPropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquistionPrepaidCommercializationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquistion, prepaid commercialization fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquistionPrepaidCommercializationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_U.s.RightsForFycompaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478514528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Summary of aggregate amount paid for the assets (Detail) - Vamorolone [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Initial cash payment</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionConsiderationTransferredInvestments', window );">Investment in Santhera</a></td>
<td class="nump">13,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">6,513<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 94,978<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the investment in Santhera was determined based on the closing market price (CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of Santhera shares and the exchange rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1537</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of CHF to USD on the date the shares were transferred, July 19, 2023. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionConsiderationTransferredInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionConsiderationTransferredInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478296640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Summary of total purchase price allocated (Detail) - Vamorolone [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired', window );">License and acquired intangibles for vamorolone (IPR&amp;D)</a></td>
<td class="nump">$ 81,513<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_AssetAcquisitionConsiderationTransferredInvestments', window );">Investment in Santhera</a></td>
<td class="nump">13,465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 94,978<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the investment in Santhera was determined based on the closing market price (CHF </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of Santhera shares and the exchange rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1537</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of CHF to USD on the date the shares were transferred, July 19, 2023. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_AssetAcquisitionConsiderationTransferredInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_AssetAcquisitionConsiderationTransferredInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price consideration for intangible assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cprx_VamoroloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385263280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current - Federal</a></td>
<td class="nump">$ 52,876<span></span>
</td>
<td class="nump">$ 34,975<span></span>
</td>
<td class="nump">$ 12,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current&#160;- State</a></td>
<td class="nump">8,951<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">3,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred&#160;- Federal</a></td>
<td class="num">(8,442)<span></span>
</td>
<td class="num">(16,093)<span></span>
</td>
<td class="nump">4,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred - State</a></td>
<td class="num">(1,011)<span></span>
</td>
<td class="num">(1,712)<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 52,374<span></span>
</td>
<td class="nump">$ 23,101<span></span>
</td>
<td class="nump">$ 21,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230483907104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 45,982<span></span>
</td>
<td class="nump">$ 36,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386907184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary', window );">Executive compensation limitation</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_EffectiveIncomeTaxCreditsRate', window );">Tax credit</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments', window );">Stock compensation windfall</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(5.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Reconciliation of income tax expense</a></td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_EffectiveIncomeTaxCreditsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax credits rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_EffectiveIncomeTaxCreditsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense share based compensation cost including salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation windfall adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230386739424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred compensation</a></td>
<td class="nump">$ 7,950<span></span>
</td>
<td class="nump">$ 6,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">29,167<span></span>
</td>
<td class="nump">24,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research</a></td>
<td class="nump">5,755<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">49,058<span></span>
</td>
<td class="nump">38,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(1,096)<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of use asset</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,076)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 45,982<span></span>
</td>
<td class="nump">$ 36,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230392113968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">120,879,099<span></span>
</td>
<td class="nump">107,121,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">120,879,099<span></span>
</td>
<td class="nump">107,121,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders', window );">Number of votes entitled for each share of common stock | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitlement for Each Share Held by Common Stock Holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385601712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Aggregate share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember', window );">Share Purchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramExpirationDate', window );">Share repurchase program, expiration date</a></td>
<td class="text">Mar. 22,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember', window );">Share Purchase Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorised</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date for purchase of share under share repurchase plan, in YYYY-MM-DD format. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=cprx_SharePurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385904688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember', window );">2023 Shelf Registration Statement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement', window );">Maximum dollar amount of common stock to be issued under shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 140,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum dollar amount of common stock to be issued under shelf registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230478516800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 22,251<span></span>
</td>
<td class="nump">$ 14,250<span></span>
</td>
<td class="nump">$ 7,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 20,472<span></span>
</td>
<td class="nump">$ 12,769<span></span>
</td>
<td class="nump">$ 6,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230388554320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options exercised</a></td>
<td class="nump">3,429,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 13,515<span></span>
</td>
<td class="nump">$ 2,792<span></span>
</td>
<td class="nump">$ 9,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock unit granted</a></td>
<td class="nump">2,476,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ContractualTerm', window );">Stock option contractual term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cprx_TwoThousandEighteenStockIncentivePlanMember', window );">Two Thousand Eighteen Stock Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance under the Plan</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Common stock shares available for future issuance under the Plan</a></td>
<td class="nump">2,254,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cprx_TwoThousandEighteenStockIncentivePlanMember', window );">Two Thousand Eighteen Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cprx_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options exercised</a></td>
<td class="nump">3,429,184<span></span>
</td>
<td class="nump">1,651,345<span></span>
</td>
<td class="nump">3,172,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm', window );">Stock option granted, contractual term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock unit granted</a></td>
<td class="nump">2,476,946<span></span>
</td>
<td class="nump">3,598,535<span></span>
</td>
<td class="nump">1,386,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected remaining weighted average vesting period</a></td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of contractual term of option awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cprx_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cprx_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cprx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cprx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230387598880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year | shares</a></td>
<td class="nump">14,177,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">2,476,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised or released | shares</a></td>
<td class="num">(3,429,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited or cancelled | shares</a></td>
<td class="num">(137,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options, Expired | shares</a></td>
<td class="num">(11,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at end of year | shares</a></td>
<td class="nump">13,076,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable at end of year | shares</a></td>
<td class="nump">7,353,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of year | $ / shares</a></td>
<td class="nump">$ 7.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">18.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised or released | $ / shares</a></td>
<td class="nump">3.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited or cancelled | $ / shares</a></td>
<td class="nump">15.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired | $ / shares</a></td>
<td class="nump">16.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year | $ / shares</a></td>
<td class="nump">10.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable at end of year | $ / shares</a></td>
<td class="nump">$ 6.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding at end of year</a></td>
<td class="text">4 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable at end of year</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic value, Outstanding at end of year | $</a></td>
<td class="nump">$ 132,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic value, Exercisable at end of year | $</a></td>
<td class="nump">$ 105,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385522160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of granted stock options</a></td>
<td class="nump">$ 9.53<span></span>
</td>
<td class="nump">$ 8.66<span></span>
</td>
<td class="nump">$ 8.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of vested stock options</a></td>
<td class="nump">$ 12,860<span></span>
</td>
<td class="nump">$ 8,278<span></span>
</td>
<td class="nump">$ 6,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of exercised stock options</a></td>
<td class="nump">$ 53,230<span></span>
</td>
<td class="nump">$ 22,265<span></span>
</td>
<td class="nump">$ 31,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230383395760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">1.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">54.10%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">68.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">61.50%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">69.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230483854384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cprx_ScheduleOfRestrictedStockActivityLineItems', window );"><strong>Schedule Of Restricted Stock Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested balance at beginning of year | shares</a></td>
<td class="nump">854,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">228,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(364,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(8,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested balance at end of year | shares</a></td>
<td class="nump">708,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested Weighted Average Grant Date Fair Value balance at beginning of year | $ / shares</a></td>
<td class="nump">$ 12.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">20.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">11.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">18.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested Weighted Average Grant Date Fair Value balance at end of year | $ / shares</a></td>
<td class="nump">$ 15.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cprx_ScheduleOfRestrictedStockActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Restricted Stock Activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cprx_ScheduleOfRestrictedStockActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45230385520080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees contribution of pre-tax annual compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Discretionary matching contributions of employee contributions of an employee's gross salary</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ/U6IK(PC6#ZY]D=[-/G X12J'\44$>V3_;=9GM4Y# &;2M QX=7D_<B'PX
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M< :PC0"\7PM(D?K&'#@W_V"8_P-02P,$%     @ JX!:6K;S) 'K @  XPD
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M^01N;L.[\_M+"0#GUQ,POKFZO0L_A]?3RZ\AN+R6UR$X @_3"=C?.P![($K
M_9)M.$GF_'0H9..R1PQG94/&14-01T,@ E<L$4L.PF1.YTT'0\FJHH9>J8V1
MT>.$SHX!AH< 6<C6-&CR?G.L,0_?;XX,;'#543CWASO\W=$M33:4G^A"6YC:
M>M-LKCGA:S*C9P,YF7":;NE@]/=?T+7^T86E3V=A3\X:(;.KD-DF[Z-[)D@L
M9[,B<+JX%?9N;I]-J=N1'4 /RVS9[D9$A>' 1U8+%JHP!&UDX0K68.%4+!QC
MQ]^L:4I$E"S C''!@1Q>@+[(A8)W)(/39S+TZ2SLR5DCC&X51M>8#&,9/,">
M ">Q-A<NS.;?X0]=K LC9Z?+7=^WG5;^J"@'!J[72A\5A6T<=&2/5]'VC.V^
MDX$DZ6R9I\U<#H68K>4Z+W1D/*4!$+FVWR*CH@(,':M%1N,K\/Q 3\:OR/A&
M,E.I)^1 . 0+FLA!$>>DR%PNBQ$7V2#94EW/FIUV]*RO$O \SV[QG&A@&'NP
M'0X5YGB6[^C#$53A"(PM/U^Q5$2_2:ZX9&I'B2#)(GJ,*2"<4Z&=\@(URSSL
MM7)QHD$AQVWE=:BBH!7X>E+0JA6)]8YIFQFF/:VZL)3&H,!UVSTQT> PA#A
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MI;$'7-?V?6D=H2F'"2:R"1CJRNVQ&TAG-Q 0NT$?+5"[@>CL!@\3S3(<E#@
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MS (7D-.S<M$0-#,MXY7SK4$W?14SC>('(,E!4$& A:X=5I330HF&+4W^MB2
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M/4UTKM<%BM?6!^ZXTJYBEX7^4( P"?I\R;G:!*; \.E)_@%02P,$%     @
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M"+;DK]C[ 1MZ /<S"QIN?I""[G\H)_\%4$L#!!0    ( *N 6EK=MFZ+:R@
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M0VD@ND_H$;32U=;=$#FB/6E'WH77352EVU'9&TA<N&GP I@T>>51$(E?8"\
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MT2SL]*O@R->RT^ 4@D<Z$#'WJ^UPI: [U]\:"%8N<V*2C)I0G0WAS?$A)DR
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M&B,(F5-PK8A(C-[M#_N[)19T3_MXTM'Q_EOU#@?L74KW[J6=>4CM?I1-XS\
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MY</4DA[L@?9@L6%<L*7 $SKC)X8)!/ZP#\L=F#I0.["[-<(6-0(SD"M!1]K
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M84'/&-1.@/9SI>S]Q!EH'T;S_P%02P,$%     @ JX!:6EMZ^9!7 P  QP@
M !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULI5;-;MLX$+[G*0;JHF@
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MX\TJ7%4+X^GB"\V*_C30\@3Z7AKC-QTFZ/]=9C\!4$L#!!0    ( *N 6EI
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MC)9O?TO'R?L3(H>]R.$I]E^KT$GJYX6/S^'5+I^@> S5 <KW4!:@P#7=9.M
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M<2V$9 LD.>8$&,1^&@6]6*XJ!\/;3D%65BBQ$);$ S^-$\C\+#MP*D7NC+:
M4>!/)@S"V(^C]&"XUOF6.V)QG *;A(/;'6HR0&$HD0[ZB#U"'(00)9->=Z.5
M,2=6G4CJRAKO4=9X'. /A.E/H@DD?I8>3 I);B!8_@#9)(8TG PN2=&JCJ^B
MB/OC+ 06^N,X.-*S2/EJ8=>6!$39Q(4Q8H,V!V*60IR,!Q>UUB@MM=(WI0$+
M8C_(QI P/TRRP?577K]_EX6,G8%4\B3OD$,_S1)BR;+L/]R?DV_VPC/2BR=I
MQ_8YN8B-(<[&@Y^/]M[H!9$)&$6:I<'@L[(N"]^F2*D8I.1)0E])2LF1P0>X
MK+7+ )?A?E,<%Y1Y7#Z"4>4:/OY^<7NS7%#/2.,S.M:JWFR!PV?-J:*:Y+RC
MMD(1@<5&(U;.C[VP6[@2AHLA7!4%-G,.?N*RIBD+7</TO\(6AE+<,6GL.@?6
M5+%:K&I+GATL1\MKH)'/I?B[+8Z:VKD^9OYM4^]-SS3#Y_K<Z&@Z5:@WS0QV
M2K6T[:#J=_LQOVBGVT&\_4>XX7HCI*$"*D@U&*9C#W0[=]N%5;MFUJV4I<G9
M?&[I5P6U$Z#S0BG[M' &^I^?^3]02P,$%     @ JX!:6M@9PU<="P  3B,
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M\;E&SQ"*1,M.L6!E66TM$5.4Z8)0SLA5_0*]-.P22H*B1P?MY)B&?_Y_Q/[
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M5F& ..?9K1N0=S8-3=_B:')4F+$) 5C&WZK02&7&:.-"XB9F3\#L\,A*(\?
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MIE0?;D&\F^FJ20_ QSV@35TF%CP01X,A^:IHGKRLM9V=+J/;=N[N.B$U*/5
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M;AC*+^VS5XVN.=WSQK9.,+,0=>="C]QM0'K%LNU+;9"CPT<>1;82[1YV:-[
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M1PSBG(T,<'"IA T!OT+\MK? .E"U,V(<Q)TS'J$LX]  _#-9B?;"UC;&X=)
ME3S[!I85J/\$NCSL]*J@8+81(H'842ZS @F46:E@CH=5C"F&@6PSK377 IG'
M6C(HZ%L1#2169A78N&A!U#&1FK&+-,9Q"I03[(",B1X0.1?"Q PSAJ)BV&IB
M/,!N@:7?1W(1:!&0PABB=EA8WV*[6NM+$;=L[@+(0[B@*(N;2L//>0EK0Q*E
M*:NB'&L !3@EC8Q).D"C&@-[,D)<YJ&MF.<9&LN:]F"RDJ68W#BOBFE/.D=[
M%L-C.9.\LB]H5\$KK,@^F.1H<Y@R>,,$<@$%$13&D;Y66T8"HBF*(K1%*"Q8
M4R*N>>9,D:"%T=Z"XC4T$Q2RN1S,)Q7* JZ]%!  _)JM@=]Y**I-$+PE60P6
M2D,0^B6%B-(54:J=:+\VOCME1]U1FYW8YZ<54\,-3$4B 2$O?=2ZBNXH#"&T
MP:KS+50K4%'+#2V4CMHP>4ER 5H]W708NCIC7#RF[IZ'K_3/\RKJ.3)#0E3F
MA*ZEK!9GK94&<TJ2#-TWD^<%UR2O!#1=E846%; =Z,(LT1;\46B6&>^)OBL7
M&'QF98&SG%4@[^NX:%!Q*EWQL6WK:[D 403UVY00D-?UJT0TE&I<U[)KTT5M
M 1B*U=ZH:S=D=J JB<U1<% /@0Y4E&N !O3Q(I"Z&X6-VT!$DM]7Y5+4/#2%
M!L8_;"Q+[IJ<")I"SP"1X[:H&V^LG) :BP=S# &+K$"G'$;71/,DR2+?17DQ
M &W&QQ56;\!%415KE@&D-9AC,O?@6&#SJO7NS1?+&'2>E0!:E5&8Q S:HX/C
M-V/[=JM+J;3'.)>8#=N]0??-?=/V /!A^^#XF B AS\8B>SA$0KJU2(C.UF:
M C4$,GF!/ SBG2TXTX9CJ:(D4]J^7V6@(<=LU]^MV\_$GWDE"O!3$:C]Z3\_
M3.XF]Y/K*W9]H8.5V\GG7^_O].',OYU>7]Z,;6QP[16MAKH*4#N:<8BZL.A6
M5U"HV.=#8[OH;W&62%KL=#*9Z'C?E=VI*"=6,A$K]:0%H:VMX[E47&J1XG-0
M-:P*U*3.:J:O)2AI;UGO8-CIN]@$J!9QM6@;Z46AUX9$+J=EKK02@R6)((SD
M,#A0)%.Q=X67F2[-<7W6BRH%42TAJXNVB=0&6JNK0 $.T@4/T%O6K](A#+ =
M!EZQ'=Z#G<Y2K43D#<>*K&&UCRV#T1+;]*;F.HUK] P*\E4G%?5(TL%TJ5-C
M"EV/*OFLL'7#3&<N.@@/CBLV)";$<\G1UVY6A1R=_+*P9D)0&,*L,91NXP)]
M'KXVAC'VG 3^\WA\TU"JKNCI)]D^W7Y(>D8:E$8H ("6)6^=KH*#80M+*W&9
M.ZGQ*P#NG*O7QX,NGX1S\LG(2*!)4 <DGX-ADGOE'17V#NN  ,,-6,\ \U0#
MW_5?1,R; /*(ID'+;TPAQ<Q5%#!8?O*IZ39_\(/V?D35P!^X^5[O.S9?Z=V6
MG:-)U3Z49($"?]TJ W)F@A)G<8U-H'3?V=M:\&'.BEPM%Z4\34TWC(M0?4VJ
MZ^6&+S]!LX)&V]E+-.K==K?;?7.J'QN$0&7V=/(#F1P]=>E@KSTZ/'AS&YKY
ME.*,N@?'X_M=-FCW!T>L]>:^;N'UZ?2H?72X$0&$+HE<3[O?/2*(MS:7E>DF
M=E5V8,Z;+%VE.XS3!$4N!2GME"=T1J>;J;@[8 B2'V)>&M>\'+J%64G9)I8X
M=)H-TW\KP;X/NMK==_1VQ_3&G2[:;IFV*9.!N7O+1IUC)WB8U4TQL:!]&J?[
M?!)]_Y)<.)BOL]!2#\PI_=:B=S&^._%B\)>B_&>QV;;L5$0<:S+?D<]_3R9O
MPB*<%N)CW86N?.FM/3=""ZL*@AU;&:- QU:P,.XL]G1AE8(7[&=21IY<M$'U
M(-@5C-9#*?TU)81*O'5%QSS"9#<H)_A[1 )[!7OQK<!SU&F"31+I5\I@#2-[
MW;T1L'-<)23<3VMMNF).*OY4Q>6OK+5LI'.P_UKA15< JF37T>(?Z>3?)YV<
MN!3P+>9^X'AN7FW"=Q4D/>"G6PQS1CO//U'6&ZVYJAM;RJ9#+-C.2A\3H]\?
M#@8O9[B;"5AO=-3N#0>0\D9YJ9UD!,I$!^-4;+)?0-7@KT-H%R*X(;K"UWF[
M_X.);[RM-6'\>7P)WVWD\?OX\OKV^LOUU7E+=VS@,36ZP3"^1V><T#&3M)IB
M-(DB]SLP*B (7+=G-?0J;+2'T),:+H](HRR!9 L/WH$G$.6YYA*PU)),M2IG
M,T'*1A[N[/+,JY]KHUQ%91=G8U2"L-L2?3PU;F'MHS?P'7O5NI6":XS\+-]+
MW!,.[Q;47!3LP+K1"G,,(0!![6DT_IR.JM:9.;/$)IX$9$HKO*67U-)<$=);
MW7@S[V"FS4YYRF/>]MHQ@I:GPO9Y($+ZU#D5\PP<@0T<=..06E"UT;%SA1T=
M@LZH((A6"PD&?;4"/I:IM&=S(.B \']!;J5B25&C>NZ(A3+%!1Y4-C>CVM9,
M?1)9,52FL3N3JA,^#&N6' _,4K21>Q1$4]F;)V'QX=#+&71I%96-DLK->!+U
M5RN;K[X_N$T60C&9Z$>4W5!2ZQ]=VW#&3W6II_'U'9ZAO+K<;_07]=6Z!>')
ME@22[;K\M1Y\CT"5DR>P#1O]J-4*VQMM23=L8V_?SUB/7PVNOP7<($C^>Z^&
M-_@K^H!_HES]Z'YM$W!^KWCU1YOUB=?Q>]3,[U' [XV>\*WP1EODY]!'4%>A
M7@7O< M^/39UT :O5Q8[*U25X&GO.XAG)W;8A3Y:6V;UWI)M)4[G@0CRGHYF
M72V6%JAZ]#U+7KD\_9ITT73 >GI%\H3CG)L*_ MNM'DQC][6V6N=*!8@O5O@
M==B=7)8)Q&B"&@'J)$!W1?%C(>98J )'0ZG+(R!@SF.PD=629/KD)1R]]K W
M;!\<'2&6=HAK3%IADH(UUER)/;6"? 94(Y8I'F^H!<>T:1?"<SP(2G7^&C0Y
M]'J=_H'F]P;HK"PPEZ3SA#I,"?8AEAJ&5VL+*\\MFP9AND>YM\NM[B;_RN[6
M$@3I_!M$WNE<8$:./MTCBNM<._WU@AUWAH>'R&B- M99("51JTPC2)=HEF6A
M.\?(TL3L,4L@K=M;TXTRS)R 3'@@HP$[+X2=*@ #T;7%O%F)S6(:%]NBZ]BC
M4U4*^Z>>(*.XW% 6,?D=F%W&)GS"\!#EK3I]KL[A,)INEM"-Z/GE2M//+WJ&
M3L*>+3TG^)M9J8[D:K71PQ&51B>^QE24APA_>#!J*&L>M$>]P4LYWO&P?7RH
M4SS_V.1_7YI[?57.7_?G%^$V^L7;M69QLIY> U9#J!Y*PO;RG(D-MM?>_E%5
M^\%5M:UYFSTTM7D0K_;]*&Q[R_^#LMSG+(LIAS7=8=49Y=9=V69J$QR%8/VK
M+J[Q=%-R4E$T2<]&'3#-TCT(K\',H)VL%P.;RH _N]+XJK+>]DH1VYW<W/["
MEZOW9RTPUT<],NI;7 $FX-8=O,KLXX3[1H;(YA7687-?*)NFP&!.%LS9&X8O
M1WB7HN7'63:4LEY2F$"(Y72;A/4ZO='@4,]!","<A[LSNU*L;S$("V4M<N%+
M6MM<1SJVY;#),T='AX,NVL;^B-CX#">J_K<%]@<V6FS=8F_YK$T,%I2\WKV:
M$&X(H.-WK6_<=O)7YAM;!S>\?JW!PQM@&@HM"UK$3#^6==U09*>:FZ<Z['*S
M943'^, #(2G(<X"H!6)+%Q;=;UC)@KRJ[@BV[ZWV!9=NTD9Z@Y'(INA,O1;(
MOWO_!U*^,7/3COS'=H9<!!F&V[B1IJNS<8,%::@)AQO">&I92TR7_"OZO8V6
M(%/+.7"IH9<.:.L:O+6SJ*,)!</K2YEEF ;8BP,(6.NG'R#Z0E%L!:Y5P=X2
ML:</D-8KNU;CB85S08;D+M_3MXH*@B!F)=X!G9$Q['4[(UTGZKB#D.V);&7@
MM@A>.-J 4"("&J'7;]O&:\_ODF:@XPO.H=JV\.TBF$QHEXT7*%+BJ,)B@6\G
M]?WQ7I\MZ1<W,'-'@UBWRM2^BZ$$CV52]6)3#%:YBG;=4=CK(TO!%5T"J"Z(
M0"CI^1BR0]K@XT[10.KX LB,R2BIC+T-@FW[^I3LQ=Z)[[X.\'Q:B5UO]G!)
M=U.>W3Y\9I?CJX>+\>G]P^WDZG.;G9W_?O[E^@8'M=G-[?GIE\G5Y'3\A8VO
MSIC[<G?_<#8YO]MLE0\OPE:8:!J9TWD_X<B5RYQJ]T"\PJ6^Z((6UW[ G!QL
M4L(C,<T<A/I5+SHH5&X"262(B;/G63[GJ3GK!,*=WEZW]!6EE&P9I4E9BC?>
M7[D2?:;%'B%QAPA*Q[6VH)7P*5XOU#]<4!W.8NZ"@E#S>R\OIUEA]U7J&_K5
MA5Z/%8 .9 O3LM"7[DWL[[(X'C]B6*'\\EQU$2VX1:4C!VM4JQJ<*R&23JE@
M=4K_<($DT4E00=$VWD/32%DC'E@#<N&F.<@:/,SK\NH(BFZRH1>FN $4HLQU
MWV]UM] VF7DW!CJLZ<=J]KW?#@(9G-,O)&$N /9/_XR0>^I^A&FL?WNH&JY_
MP>F2YW,)$I6(&4SM=@Y'.SJ%ME^*;$6_1#3-BB);TL<%6"J1XP!X/\NRPG[!
M!=Q/4WWZ'U!+ P04    " "K@%I:5:+(YH8&  #G#@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6R%5UMOVS84?O>O(-QV2 #-MBZ6Y#0)D"8MUH>A
M1=-N#\,>:(FVV4JB1E)VLE^_[U"R+#=.]B)1U+E?OD->[I3^839"6/90%I6Y
M&F^LK2^F4Y-M1,G-1-6BPI^5TB6W^-3KJ:FUX+EC*HMI,)O%TY++:GQ]Z?8^
MZ^M+U=A"5N*S9J8I2ZX?WXE"[:[&_GB_\46N-Y8VIM>7-5^+>V&_U9\UOJ:]
ME%R6HC)254R+U=7XQK]X%Q&](_A#BIT9K!EYLE3J!WU\S*_&,S)(%"*S)('C
MM16WHBA($,SXIY,Y[E42XW"]E_[!^0Y?EMR(6U7\*7.[N1JG8Y:+%6\*^T7M
M?A.=/W.2EZG"N"?;M;1A.&998ZPJ.V984,JJ??.'+@X#AG3V#$/0,03.[E:1
ML_*.6WY]J=6.::*&-%HX5QTWC),5)>7>:OR5X+/7'ZM,E8)]Y0_"7$XM)-+^
M-.NXW[7<P3/<?L!^5Y7=&/:^RD5^+& *4WI[@KT][X(7)=Z);,)"WV/!+(A>
MD!?V_H5.7OB__K$[:;)"F48+]M?-TEB-BOC[E,^MQ.BT1.J2"U/S3%R-T09&
MZ*T87__RRH]G;U^P-^KMC5Z2_K_Y>)'[M&U^-&%#L1/V=2/8K2IK7CTR:="0
MR^]H$F85DRV=)3I\, O*;Y/["5N)7&A>L.^-EB:774M5.=MR+54#(99;\ S_
M=YH.,IEX )@8P0 F3O2CX-HP0;7#D'E1+H7NL^^>H5."1< R2)3&&J96[,S9
M!KWX:\XO1D3?DA/IZ+;16E26_<H^=':_9O/ 2Y,8BS#R%LD<"Q\[\W1 ?$\^
ML-1;S'TV]Q:AST+P)*,[L1*@R0?RSD 610$[Q\J/O=DBQ#+RDG QI&X%@L*;
M^7Y+ZR4^<?EQ/'(VA4D$4X+0\V<^+7POCF8N;EK XTP6DKM@P^L3D<1&W5@H
MX]9%E-+06*4?^XP-F#19 SF!S]Y0MGFIFLI2HK.BH1QT&7>Y!/*VL<8 T,X$
M0\7"#;)7 ,O-DZC?][J=HL"?S*#GZ#5J(T+&!),4V^'$WS]'[Q]$UA!(.Z_@
M7NMX(4MIVV7DJ(-)['CP'%%C9PBVM CN#+_/W[!?7J6!'[RE:$\6V(!2E?TX
M%KJ35;[B!24R:KEH$;6+.42#[1-BH2%T[G229K<>!=$DH"VBQVLV2?#ZN<O8
M&;)G9=6(_'S"^IH@S[DQ J&EPD9RE\BPE6# ."I<&R(#%<:Q2_-JA2V7!MKJ
M4E&M&8"LE6 / <BXUH]J*W3W!W*0QEII3%N62XA"G6?0M!1V)T2;:\=$$O?%
M %7/&$A=NY(51U&BKK2 9&?+7ME>0F/@*!$/2J]N=*T,@<^]7%=R)3..EJ.4
MJ&I?:/8 2RZ%R5M# _;GP$W/!D:=4T&"]PEZ['$#  + /U3M\] Q.I&DB\/F
M4?F\9@E08H9W[$5)./I8;>$%E?X\]ED4I=BQO%K+92'VX0P6GA\G*!LOC9+1
M399IU,:^D0W (XU#EJ3IZ-,ARP('CCX'CRR) Y;.H]$MK]$2A?P7 @CGN<XV
M0*QD/H>819",OBK\/A4\%BV\V3QE8>J%87+L\B"L%Z//R"^7 _L<BBWB#L4H
ML.<C=X;[%>%'REL%^!G'J2-*YFB^KHF()?0[N$2[G3)P6&IG0-Y9LE>6$+J>
M2H_GNN(UBX#6:4#8'GOS*#H:<!OD7FQYT7""2:HQ%*)T,$,E4HDU=Q]B*W-J
M#W0'1AJ"WZ T'3T.NPCU/@>$P_9D84[8S>E:](:E#4XK-(YRSIH6ME&A;@ZO
MT!>29E%O8F\5X)K& >%TRX:&!T^I-!7(#U$\TG;%*F5[L8PO 0='IHJVP>M:
MJP>)0RWQ(7XQSI9%X6:Z/CA<B,F34&(J"1B6,R.V;KXH79/>7#=K:#+H[FY8
M+!^=#1_N;AP80&/>$)9E[;R%X@:#7X-IB[M!3?.F5?>L1$X=?!1+BDK!94E0
MHZE9\G[N'8"Q1:Y,:(M+RJ%?*/L#W>T%P94?$EDQ65)X-$%="VSM!,:6,-8Q
MHS%XX<IU1QGD74?;C5;->O,")!U%M8>Z6A4R<P<R>$7#'SCY+Q4IYJDH7/7V
MZBF>O78X]?1D\.241X7Q<^B/V#AJ\I Z%UTJ[09@J;NPG#K@3@>7CU+HM;MB
M(<L4LO8>TN_VM[B;]O)R(&^O@+]SO9907X@56#%7YV.FVVM5^V%5[:XR2V5Q
M,7++#6ZB0A,!_J^4LOL/4M#?;:__ U!+ P04    " "K@%I:.;2O*-T$   B
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R-5]MNXS80_96!=[%-
M *\LR79NFQC(K>@6V#9(>GDH^D!+8XD(16I)RD[Z]1V2LBPGCK,/242*Y\SM
M<#0Y7RG]:$I$"T^5D.9B4%I;GXU&)BNQ8B92-4IZLU"Z8I:6NAB96B/+/:@2
MHS2.CT85XW(P._=[=WIVKAHKN,0[#::I*J:?KU"HU<4@&:PW[GE16K<QFIW7
MK, 'M'_6=YI6HXXEYQ5*PY4$C8N+P65R=C5QY_V!OSBN3.\97"1SI1[=XFM^
M,8B=0R@PLXZ!T9\E7J,0CHC<^-YR#CJ3#MA_7K/_[&.G6.;,X+42?_/<EA>#
MDP'DN&"-L/=J]0NV\4P=7Z:$\;]A%<ZF9#%KC%55"Z9UQ67XRY[://0 )_$;
M@+0%I-[O8,A[><,LFYUKM0+M3A.;>_"A>C0YQZ4KRH/5])83SLX>K,H>2R5R
MU.8GN/W></M\/K+$[-Z/LI;E*K"D;[ D*7Q3TI8&;F6.^3;!B%SJ_$K7?EVE
M>QEO,(M@G PAC=/)'KYQ%^?8\XW?X N1P3^7<V,U2>'?74$&BLEN"G<]SDS-
M,KP8D/X-ZB4.9I\^)$?QEST.3CH')_O8?[@0>UEV^YA,(^C3?_IPDB;'7UHC
M$=S114"M,0^GX(\2X5I5-9//4#(#TV$<Q^X'3,F(%=0"6&-+I?E_!*H[N''P
M(7R$.(KC!&JF8<E$@U"C#M@(+BU0;;&:T]:ZOL!D_FIW/ 2I>A9?F($5:@1J
M,\82FLLB<CY7=-%W!Y&&$-X.(POH-H:-[UTT/Q!#<#M)X^')\>DP/CWUNTE\
M/$S29#B=G+:FA]3/3(V^(XGGH?.D;S[$QHUIR"_'L!7F+<M*"*5\!>0&4%IN
M!0&M B41ELJB.X<.YLV_0I4H<K>I,5.:GJA9"D%=QEI2BUNN2N[ /0U!@1(U
M'7L&Q]@WZ@R2X+RE>ZP;G5'^*=U?)7QCM'!9HJ3938%:01JX4DQ[3VXX^6(5
MV6%UK=72Y:%U7G>4) E5:%81%;.;4AI/W3M&?$WM//L(DYB:J!#N>T"[NUQX
M(8-&FX9)Z]!LR[1@$AKI:G#?"*0:SS\G)VO2!\P:S2TG7RXS&WDQONF]LX@R
M0Y_X-D.I%U7BBT]4FO)+F<:GFGOAOC@WA0A^Z^Z*%\_&3@XY^2(+[]@S,NTD
M0DUZCX0CN-F&O($@Z\G+2_7*.@T.1 RL*#06C+382P#/?'5\C9\X"8YN U7I
M*#KMRG3@EY2))<FM6(.ZRW@8P?[V!@<9?9FXI*M$9UUT)$T4"Y)FP=VWP \'
M#Y9L4Q4L_$X+K&V(\V3=B7I*@047K1P=C>[3F(YFQ6T9I'![[<1#<XCH5#B-
MMV3X0G(OV^F*:4T2- [;Y6X;D^/<DHE.=*Z0C>36R9GF)V-=,<F2ZP=4CDJ%
M)F :=ZLWL /G\+LI.@QZ?C^5!RY3U,3I0SX>?TZ/)Y/T^!#FF+&*.L9B$?H?
M9850=-0W-TK_KTPV-!_":5#E=O(I[EJ@]06HF[G@&05"^6H#3#:)W33YD(=^
MOC3CQB$D3;TDO0PQ-[N$F$SBZ+AC#-=]5]-X-Q<1[!H11KVYK4)=^.G4^=I(
M&T:X;K<;@"_#W+<Y'J9GZ@<%EP8$+@A*7D\'H,-$&A96U7X*G"M+,Z5_+&F(
M1^T.T/N%HK;=+IR![M^"V?]02P,$%     @ JX!:6@M<0/Y'"@  _AP  !D
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MG^'SAFM*MM029N0T V0%,.W(?.&G(Z2A*OZ'2HXM*O694ZG/MJK4H_/S#Y]
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M5 T!+0XEJVZX$ =P>(*_P/I+Y3A?>MM'<P(MCC,U1'!J\@VGJ(5P<V4"^,0
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ME<:"X^X2?01EKXJNHHX:5-4G7GH8KS9+[(W< =3M6W/?T;RF\D>B(3B6TY=
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M^ T(N;.7SR92'A>%X.G12?1R&!_O[V/K^T='S][V3QNS68[/XI<OCZ*C@_@
M.-H!W7<HD0KL8#\^/,,^#^"7LQ/L]!0^G![1NQ[?@WX8?0DG&7L-R/$V1GCF
M&>'9(_D(Y^]&D\GEF\MS8E[=/L>M;72KQAM,1&BT#6:6+\$E1K<#:G5!/#O-
MNJ *IR_0P=%'0O^[3#4&?% W*Y55NUV(^%R.@\=R.1!_]^XOT>5D\FE\$8W.
MSS]\NOJ(P.?)Q]'5Q>CFHGLYMS?[-UJY1UNFT@Y7Q3V3OH]R484.J98ZFGR"
M1P;TZ][^:1Q=+@F1X$"M-U[<3.2L77!8@2"4.]B O+RK*WCYFR]2;K%#<-D
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M[&!0$P69D]QY<ZLQP&9@ L7 )J'EAY[E.Q&!&F0[ENU.!F??9>@N)&#@U/=
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MTA<)VB50O$"T6\-MT'^ZZ1]02P,$%     @ JX!:6ACDH*HN P  "P<  !D
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M<ZHS3;_1G7;=VE73I'P5;UJ]6Z:W7!IR=$.JT?F$BJUNVJ=F8U7E6Y:5LM0
M^65!'2=J)T#?-TK9_<89Z'K8Q=]02P,$%     @ JX!:6C9ILY*E @  [@4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULA51-;]LP#+WG5Q#>,#1
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MK\P+0'(%81CNG96O*T"YT;\:WU[8C_YM53D+4= ;]/=F7&3SPEBO<M1F<U_
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M.M>-E%AK^ 1?<(F2EW ",?.R-"$CC+Q)&I,1T$B<#9P?-=<(F3>) XB]21A
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MDNVMJOW08FMO,@NAZ5YDS0U=1%$:!YI?":'W'R9!?[6=_PU02P,$%     @
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MN$+E9S-_";A;$IDX(0H>"HF3>0D,(!QU"$?_CC!\WIA(,UVM2O4 7Q$"<7S
MOTBXKF@M^P ?#- /N(W*-X<:J:,V3Z.^?I$2/SEK8R-N!YH\QQ(H95OKR[]Q
M_8#VZ>A38S3Y KZ;LHG+G3!;+@5;4L5&GQLE%0*'0 )5,&?+LJ[U .U,8,3
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MU1RHYD(U#ZKY**T=H4W9AZZ^C\=]3N=%3.)H7A8 R[^IX)VUOFIG[RB#EFY
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M@QEELH'X]WF6\9=?Y (>,_:M'/;%_P!02P,$%     @ JX!:6ND/E4,$!
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M'9D%IV:.[3F66YLU4N[5*?<Z4_YP<S>?+I8!NK^%] %8:[5T0KRV6G2"!9K
M&M3Y-77^&ZG/U\FG3K! $UB#SW[-9_][JJ^<K'<H*\NWW-Z1^D[-G-[ <_PC
M];68V>[0';2K;U"G/.A6WU^SWV\7TT[Q=2*\MEAT@@6:P!K,#6OFAF\DOJ%.
M/G6"!9K &GS:UGZ/:'U'^5W_RVSW=NOB5%Z'.K/=OM.SCU3;:C>P^L>R[8[B
MOW)ZL.^V.[.<?IS>W@7=7Z[=$*\M2*UH@2ZT)GW.GC[GC41> >LB52=:H NM
M2>K^S&!W;J&UZ[Q[MGNG?7W<$_UZON6=R%SKT4(76I/X_>'"[CY=[ [,K%R
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M5#W-/!;J,P6X#E#O<\;D;J 3=!\^R3]02P,$%     @ JX!:6H2%-25L P
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MZF'%1-&_%A/%YZ8%G'"%#:49QMCS@] !^'S*N7J>Z VJ_R*"OU!+ P04
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MIRX(;8#W,\[5:J,==',\_@M02P,$%     @ JX!:6D80(:XP @  9 0  !D
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MJ&:V$$2K$<WBE D?94:.=Q7CJ+@Q*_3$ITP>OL"E)\5.L8(KJ1P\2-VA![N
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M(2UP<[WV_M%Q-UQF1.&Y8#]HJK.1]]Z#%.>D9/I6K#YCS<<EF BFW"^L:MO
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MUP%J?L68W'7T M43SOL#4$L#!!0    ( *N 6EIS]XD=BP(  .(&   9
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MIMJ@5&V@5>VK"FN$.'@CUNH21"0F8SVY9O.=38B:-.FDQ_;R98K:*,F/;7>
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M'9+ G!9<WXKU%ZCRZ1J^6'!E?\FZBO4<$A=*B[0"HX*49>4_?:I\V +X[0,
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M6>\@S2$X0[8Y0)9A#5ODLX_+[;=R72:GRI!59<C*_>QW_#Z2#D'1$M "DW"
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+5774_;,!3]*U:&)I"
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M'?>5AO#B9KAH2+;*[TKOF)0LS1^70&+@VD!]GS,F'QNZ@^I^?OP_4$L#!!0
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M>A]$?<):-Q0O[9GC/5>*4WN9@ZZ2A>F@GZ\Y5X\-<XS9GG/'_P-02P,$%
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M0+42U2RJ.53SJ!8HK1O#3:]J<DXO]-&Z%*JEJ"903:):AFH*U32J&53+4:U
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M.C:(<\,3E:URH9Q@.<ER&<LIEM,L9U@NWW/ML<'YP4L-T.V6+&=9SK&<9[F
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M6PKW%(JZ*O*#%5C $$CMXNY-'HQ<L\/1%[DCNR.*^B([\/UA"J^E\(Y21+
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M@+S)*ANS.I(P[21,1R4 4F3O\KZ!ZDI]^$<<GO?<=YM%??]'S8X$))V 9%#
MS1[RVEP(2&>U*31-"6*TI,H.7<(2IRMQ?U_<9F'2$^8VBQ*WL%DG;#8HS)S/
M7$!!E4O!,/8,3P+\WE4[ES-'%O7TC' 'DXM7W$<*SSN%YR.YQ_/'XVW;T:I8
M$<9<DH?)SN*3DD>!L1N8C0"GDV0X$!==("X&F;ZK#0B7Y MG9N%I+T_=9J\*
MR"C;D?,!?ND+\*#[KV]_VEPQNJP@:&Y_YS6.70Z%<=B3=\HN[ND[88=G/8'^
M00]4@EC;7E+J1*PKU30%W6K7KU[9+JVW?FWZ6-M;O= T3? W(M:TDHC!2E/B
MR4P7/]'TE<U$\:WMM!ZXTGV;'6YT+P["&.CO*\[5\\3\H.ONTU]02P,$%
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M6R*NHY6:/C'>F&Q5#<WT:[R17-VE*D\&-Y*%]S%+(N#B+?KX4%#YA-Y-E9?
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M[_.Y^#CG3'9<W,D,0*'[(F=RZF1*E>>N*Y,,"B+/> E,[ZRX*(C24[%V92F
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MS&O*0/X^HU0\GZ@!ZE[VR?]02P,$%     @ JX!:6L,$G.=J!   JQ   !D
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M315M.E:M?%VY49:JE&^6].&!V@70_$(I^]!Q+^@^9;*_4$L#!!0    ( *N
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ JX!:6OA$C!",!@  ]SD   \
M  !X;"]W;W)K8F]O:RYX;6S%FUMOVDH0@/_*BI?3(S4'\+U54XD0VB#1@ +J
MZ]%B+["*+W37IDU__1F;IHR#.SHO0YX(MF,^9M?[S>PN'[X7YG%=%(_B1Y;F
M]KJW*\O]^W[?QCN52?M/L5<YG-D4)I,EO#7;OMT;)1.[4ZK,TKXS& 3]3.J\
M]_'#\[T6IH_?%*6*2UWD<+ ^\%6K[_9TOGXK#MKJM4YU^73=:_Y.54]D.M>9
M_JF2Z]Z@)^RN^'Y7&/VSR$N9+F-3I.EU;W@\\5694L=GAY<UY$JN;7.DE.L'
M"2#7O6  -]QH8\OFBN;^$A@/"BX^OJO*XI-.2V5N9:D^FZ+:ZWQ;WP:^11]]
MC28.SZ_'(+XW_R>,Q6:C8W5;Q%6F\O(81Z/2&C"W.[VW/9'+3%WWQL5!&;&0
M6U5_*?B4:7+\@B60H7"9]QI.F&G2,#+RS.^7\]GT=K2:W(J;T6QT/YZ(Y=UD
MLEHB0(< =%X-4+Q92 3I$I#N!2&7*WCY,KD'P/DG,5],'A"D1T!ZKPCYKX,@
M?0+2?S7(\=WH'D$&!&3P>I"CY1V"# G(D!GR::V,57%E8" 6#]H^BB\RAX&G
M_K^W D%&!&3$"[F03^)@Q4*9YM_S6(E;;>.TL)7!(^0[ O$=+^(TMSJ!,7ME
M9 +6$"-C9'Z,HL5C^( :Q >\C'.SE;G^V9P0,D_$K;*QT?OF?;'!F*1KF&5S
M(ZVVP",61EFX],2[U-M<8TS*.$-FY4SS@[+E60-3?ADR"V84PR45G%")F)<[
MZ([C(H/4;:>@=QY:N01EF"&S8NK(Y65AGC 099,ALTZ@H^VE3L3D!]S$*MMT
MME\!K(S!F)1/ALQ"F>^5@:,PNLR4!$S,12EDR.P02/>!#/11AVWRK=+[HSSN
M58D1*8$,F0TR@\N@91O"40R(!AZ1*8PM^?9(<L*D)#)DM@@\P*92G1UQIN4:
MY]J42!QFD8RAX)+KHNZ,AV-,C_'])3Z,28G$X:Y:BBS3QQ&Z@1Q#&0F(*H]U
MZ^%QR,*%62.CK5%G:8)#6<1AML@TCXM,B97\T8X2I0R'61G+LH@?=T4**9;]
MJQEC2FP/A[*'PVR/AJTQ+3P"S6E,1@G#81;&C<K51I=BD<H6$R4+AUD6RVIM
MU;<*+A*3P\MN3RG"858$F7:V"E^'4H3#K @:T\4S'90B7&9%H.Q8O%E)^'#[
M-V:CO. R>X%,DULM[5)F<"]08#1I<F< R7DL9D.0^7([@)0T7&9IO,R7.^-(
MF<-EKSO^F#C7K!B3THC+K!$R>6XW-V46E]DL9/+<QJ0\XS)[YI3P=?9'RBTN
M^R36*?/K@O,HHWC,1CE/LSH1*;%XS&(A)]A:/="CQ.(QBX5.(3R,25G&8[8,
MC>EC3'*]A-DR-&: ,2G7>,RNH3%#C$FYQN,N64C,"&-2KO&874-COL.8E&L\
M9M?@+/Q*+*LLDY!. O;H('6*$PR/\H['[AV,.4H275\B4T@RZOOA-4?*0/X%
M:YHK,;&ESIH:XI/41GS%T?0I"_G,%NIN]/FF22L_MS I"_G<$U]D%88+69^R
MD,\^&_9<A;4>H+@RII[#P)B4A7QF"]$E62N:Y+H]LX7.2K+V\XXQ*0OY%UYI
M 4I\"&-2%O*9+=2!N83;)E6JZCZ*,2D+^<P6(C';6THH"_G,%NK G"EKE7K;
M-#[>5$)9*&"V$#5I<"46&).R4,!L(7K2  ]( 66A@-E"-":NA0+*0@&SA6A,
M7 L%E(4"9@O14S"M1J<L%'!O'Z/6+UL#4D#N'^/>0$:M7XHKC$E9*.">=SM-
M:'4D[SC?#"@+!9>;=T/^@;18K(I2IAB3LE# O06@A8DJMBV<V.)HAI2%0F8+
MD9BM1RBD+!1R+_7\ ;-I\I8L0\I"X<4V ;0Q91--/&Z&E(5"[OUE?\ LZVBV
M&YVR4,B^OPQ-8[=3XOH4QJ0L%#);Z 7FRY$38U(6"IDM1$3S0;6C2>YC9K;0
M"\QZ+J'(FZX*H+>X9 LI"X7,%NK:R"+>0/6^409R.HQ)62ADME WIECNI%'0
M[ @SHBP476)-Z S3&3@NH"KL](BR4,1LH8ZE*WB0ZH-7-U!I8DS*0A&SA3HQ
M3\,2QJ0L%#%;J#N:OVV$,2D+19?8LG:&^7OTQ)B4A:*+[UY#T6PY/:(L%#%;
MB,;$&5)$62CB7A=".^YHIT?D[VD:"_6;B^W'#PG<,U?)/7R$A>.Q3..%$?5+
M?:>AX_GUKN5-E:9C.#;/9X5,GG^W^/R;RX__ 5!+ P04    " "K@%I:PR79
M2)0"  #?,P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-;J-
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M_)^D>KS<6VZ/ORZ_3Z*$JRO.]7W%\/074$L#!!0    ( *N 6EJ-G,NK- (
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MSY:_D]S\ E!+ 0(4 Q0    ( *N 6EH'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ JX!:6OW?QVON
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ JX!:6IE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "K@%I:E@CIVD0*  !].@
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ JX!:6J)^3P<@!@  ;!@  !@              ("!AQ(  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *N 6EJV\R0!ZP(
M .,)   8              " @=T8  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "K@%I:@>>[:@D'  "M(0  &               @('^
M&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ JX!:6MH'
MO?>D @  O08  !@              ("!/2,  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( *N 6EH#@6#:W <  /D]   8
M  " @1<F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "K
M@%I::3NDBZ )  "I,   &               @($I+@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ JX!:6EQ#N7ME#0  D4,  !@
M         ("!_S<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( *N 6EI+9K.790(  (8&   8              " @9I%  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "K@%I:!@+JRT0"  "+!@
M&0              @($U2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( *N 6EH2:VR#10H  $\9   9              " @;!*  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ JX!:6MVV;HMK
M*   Z88  !D              ("!+%4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "K@%I:/#%(T)P#   D"0  &0
M@('.?0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *N
M6EI;>OF05P,  ,<(   9              " @:&!  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ JX!:6D!SO )Z @  <@4  !D
M         ("!+X4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "K@%I:WO."KRD#   P!P  &0              @('@AP  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *N 6EI]SI.E%04  (,,
M   9              " @4"+  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ JX!:6L_POS2A @  !08  !D              ("!C)
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "K@%I:\%;)
MI#0%  "Q#P  &0              @(%DDP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( *N 6EH4[4\&!P0   @)   9
M  " @<^8  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MJX!:6M@9PU<="P  3B,  !D              ("!#9T  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "K@%I:Y>4\#)T-  #,)   &0
M            @(%AJ   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( *N 6EIXC%>%5A4  *9*   9              " @36V  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ JX!:6E6BR.:&!@
MYPX  !D              ("!PLL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "K@%I:.;2O*-T$   B#   &0              @(%_
MT@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *N 6EH+
M7$#^1PH  /X<   9              " @9/7  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ JX!:6DL)_WT? P  ]08  !D
M     ("!$>(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *N 6EJC]?.9N (  ,<&   9              "
M@<XS 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ JX!:
M6BU1//J( @  @ 4  !D              ("!O38! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "K@%I:&.2@JBX#   +!P  &0
M        @(%\.0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( *N 6EJN>+@?]@,  ,\*   9              " @>$\ 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ JX!:6C9ILY*E @  [@4
M !D              ("!#D$! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "K@%I:0>!2DI0#  "?"0  &0              @('J0P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *N 6EI :1%;
M$@0  /$(   9              " @;5' 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ JX!:6EJN$GU,!0  P!   !D
M ("!_DL! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "K
M@%I:.['<]JH$  #F"@  &0              @(&!40$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *N 6EI5A+7LIP4  .4.   9
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M970T-2YX;6Q02P$"% ,4    " "K@%I:R,@]L!T$   4$0  &0
M    @('%= $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M *N 6EH=1^D+*P,   0)   9              " @1EY 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ JX!:6H2%-25L P  3PH  !D
M             ("!>WP! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "K@%I:M^>:<VD#  !1#   &0              @($>@ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *N 6EJ[9:-!L@(
M -,'   9              " @;Z# 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ JX!:6D80(:XP @  9 0  !D              ("!
MIX8! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "K@%I:
M)Z(\W=\"   4"   &0              @($.B0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( *N 6EJ0(Y(I% ,  ,X)   9
M      " @22, 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ JX!:6G/WB1V+ @  X@8  !D              ("!;X\! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "K@%I:OZB[T*L#   <#
M&0              @($QD@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( *N 6EH%7 XT,@0  *(5   9              " @1.6 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ JX!:6AJ"<UAF
M @  B@8  !D              ("!?)H! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "K@%I:SEH.A]P"  "^!P  &0
M@($9G0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *N
M6EH1!],Q! ,  (@(   9              " @2R@ 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ JX!:6G"!?U4+ P  /PL  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( *N 6EJB+83\0 0  "(0   9
M  " @0:V 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MJX!:6G3-_^0@!   21<  !D              ("!?;H! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "K@%I:M(M^R_P#  #S%@  &0
M            @('4O@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( *N 6EK][V-])2T  %G( P 9              " @0?# 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ JX!:6M8>9Y>X @
M/ 8  !D              ("!8_ ! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " "K@%I:@FTWL/T#  #W"P  &0              @(%2
M\P$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *N 6EHR
M%4<'"P,  &X(   9              " @8;W 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ JX!:6EEE^FY# P  40@  !D
M     ("!R/H! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *N 6EK,7LGD90,  .D+   9              "
M@;4+ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ JX!:
M6I%7(V^M P  # T  !D              ("!40\" 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " "K@%I:1@-7>Q@#  "("@  &0
M        @($U$P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( *N 6EJ23$:Y#@0  $P7   9              " @806 @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ JX!:6E7'!--B P  < T
M !D              ("!R1H" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    " "K@%I:JQ4VRV@#   W#@  &0              @(%B'@(
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( *N 6EHR'I%\
MVP8  -<N   9              " @0$B @!X;"]W;W)K<VAE971S+W-H965T
M.#,N>&UL4$L! A0#%     @ JX!:6L,$G.=J!   JQ   !D
M ("!$RD" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "K
M@%I:V0S^.R$#  #6"   &0              @(&T+0( >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( *N 6EHV\5BM$00  .43   9
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M @!X;"]S='EL97,N>&UL4$L! A0#%     @ JX!:6I>*NQS     $P(   L
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64$L%!@    !@ &  5QH  %Y, @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>213</ContextCount>
  <ElementCount>434</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - License and Acquired Intangibles, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet</Role>
      <ShortName>License and Acquired Intangibles, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Collaborative and Licensing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements</Role>
      <ShortName>Collaborative and Licensing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/Agreements</Role>
      <ShortName>Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/Investments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995715 - Disclosure - License and Acquired Intangibles, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables</Role>
      <ShortName>License and Acquired Intangibles, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables</Role>
      <ShortName>Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/Agreements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Stock Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables</Role>
      <ShortName>Stock Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/StockCompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Organization and Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Investments - Summary of Available-for-Sale Investments by Security type (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail</Role>
      <ShortName>Investments - Summary of Available-for-Sale Investments by Security type (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Investments - Estimated Fair Values of Available for Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Investments - Estimated Fair Values of Available for Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Investments - Summary Of Net Gains And Losses On Equity Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail</Role>
      <ShortName>Investments - Summary Of Net Gains And Losses On Equity Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Inventory - Summary of current inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail</Role>
      <ShortName>Inventory - Summary of current inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Operating Leases  - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail</Role>
      <ShortName>Operating Leases  - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Operating Leases - Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail</Role>
      <ShortName>Operating Leases - Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail</Role>
      <ShortName>Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail</Role>
      <ShortName>Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail</Role>
      <ShortName>Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995965 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail</Role>
      <ShortName>License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995975 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail</Role>
      <ShortName>License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995985 - Disclosure - License and Acquired Intangibles, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail</Role>
      <ShortName>License and Acquired Intangibles, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Collaborative and Licensing Arrangements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail</Role>
      <ShortName>Collaborative and Licensing Arrangements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail</Role>
      <ShortName>Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail</Role>
      <ShortName>Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail</Role>
      <ShortName>Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail</Role>
      <ShortName>Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail</Role>
      <ShortName>Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Agreements - Summary of aggregate amount paid for the assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail</Role>
      <ShortName>Agreements - Summary of aggregate amount paid for the assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Agreements - Summary of total purchase price allocated (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail</Role>
      <ShortName>Agreements - Summary of total purchase price allocated (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996175 - Disclosure - Stock Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Stock Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail</Role>
      <ShortName>Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail</Role>
      <ShortName>Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail</Role>
      <ShortName>Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Stock Compensation - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail</Role>
      <ShortName>Stock Compensation - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="cprx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996235 - Disclosure - Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cprx-20241231.htm">cprx-20241231.htm</File>
    <File>cprx-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img136052313_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="765">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cprx-20241231.htm": {
   "nsprefix": "cprx",
   "nsuri": "http://catalystpharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "cprx-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "cprx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 349,
   "keyCustom": 85,
   "axisStandard": 24,
   "axisCustom": 4,
   "memberStandard": 21,
   "memberCustom": 44,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2024": 9,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 213,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 791,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 765,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 16,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c24bf7e7-9d65-4eec-b363-d92095897f82",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c24bf7e7-9d65-4eec-b363-d92095897f82",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/Investments",
     "longName": "995475 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome",
     "longName": "995485 - Disclosure - Accumulated Other Comprehensive Income",
     "shortName": "Accumulated Other Comprehensive Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/Inventory",
     "longName": "995495 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "995505 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases",
     "longName": "995515 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet",
     "longName": "995525 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet",
     "longName": "995535 - Disclosure - License and Acquired Intangibles, Net",
     "shortName": "License and Acquired Intangibles, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities",
     "longName": "995545 - Disclosure - Accrued Expenses and Other Liabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements",
     "longName": "995555 - Disclosure - Collaborative and Licensing Arrangements",
     "shortName": "Collaborative and Licensing Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995565 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/Agreements",
     "longName": "995575 - Disclosure - Agreements",
     "shortName": "Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:AgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:AgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes",
     "longName": "995585 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity",
     "longName": "995595 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensation",
     "longName": "995605 - Disclosure - Stock Compensation",
     "shortName": "Stock Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan",
     "longName": "995615 - Disclosure - Benefit Plan",
     "shortName": "Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents",
     "longName": "995625 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "longName": "995635 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables",
     "longName": "995645 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables",
     "longName": "995655 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables",
     "longName": "995665 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InventoryTables",
     "longName": "995675 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995685 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables",
     "longName": "995695 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables",
     "longName": "995705 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables",
     "longName": "995715 - Disclosure - License and Acquired Intangibles, Net (Tables)",
     "shortName": "License and Acquired Intangibles, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "995725 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables",
     "longName": "995735 - Disclosure - Agreements (Tables)",
     "shortName": "Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables",
     "longName": "995745 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables",
     "longName": "995755 - Disclosure - Stock Compensation (Tables)",
     "shortName": "Stock Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
     "longName": "995765 - Disclosure - Organization and Description of Business - Additional Information (Detail)",
     "shortName": "Organization and Description of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_11716830-bd78-4cfa-b354-d95373de3afc",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:MaximumMaturityPeriodOfCashAndCashEquivalent",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "cprx:MaximumMaturityPeriodOfCashAndCashEquivalent",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail",
     "longName": "995785 - Disclosure - Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:EquitySecuritiesFVNINoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be3b877f-8d5f-446a-ab53-63009d18c5b5",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail",
     "longName": "995795 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Summary of Disaggregated Product Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cc17f402-b8b7-4846-b664-e84632ab2a8f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail",
     "longName": "995805 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Summary of Percentage of the Company's Total Net Product Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_947bd494-b761-4eb9-88a5-277a61b73354",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_947bd494-b761-4eb9-88a5-277a61b73354",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail",
     "longName": "995815 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule Of Reconcile Basic And Dilutive Weighted Average Common Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails",
     "longName": "995825 - Disclosure - Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details)",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:SellingExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail",
     "longName": "995835 - Disclosure - Investments - Summary of Available-for-Sale Investments by Security type (Detail)",
     "shortName": "Investments - Summary of Available-for-Sale Investments by Security type (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail",
     "longName": "995845 - Disclosure - Investments - Additional Information (Detail)",
     "shortName": "Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail",
     "longName": "995855 - Disclosure - Investments - Estimated Fair Values of Available for Sale Securities (Detail)",
     "shortName": "Investments - Estimated Fair Values of Available for Sale Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail",
     "longName": "995865 - Disclosure - Investments - Summary Of Net Gains And Losses On Equity Securities (Detail)",
     "shortName": "Investments - Summary Of Net Gains And Losses On Equity Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail",
     "longName": "995875 - Disclosure - Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail)",
     "shortName": "Accumulated Other Comprehensive Income - Summary of Reclassifications out of Accumulated Other Comprehensive Income (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_9966f3a4-7e1a-439f-afa1-d3b19802833e",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail",
     "longName": "995885 - Disclosure - Inventory - Summary of current inventory (Detail)",
     "shortName": "Inventory - Summary of current inventory (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995895 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "cprx:PrepaidManufacturingExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "cprx:PrepaidManufacturingExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
     "longName": "995905 - Disclosure - Operating Leases  - Additional Information (Detail)",
     "shortName": "Operating Leases  - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail",
     "longName": "995915 - Disclosure - Operating Leases - Operating Leases (Detail)",
     "shortName": "Operating Leases - Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail",
     "longName": "995925 - Disclosure - Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail)",
     "shortName": "Operating Leases - Schedule of Supplemental Cash Flow Information Related To Lease (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail",
     "longName": "995935 - Disclosure - Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail)",
     "shortName": "Operating Leases - Schedule of Supplemental Balance Sheet related To Lease (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail",
     "longName": "995945 - Disclosure - Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail)",
     "shortName": "Operating Leases - Lessee, Operating Lease, Liability, Maturity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail",
     "longName": "995955 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)",
     "shortName": "Property and Equipment, Net - Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail",
     "longName": "995965 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail)",
     "shortName": "License and Acquired Intangibles, Net - Schedule of Finite Lived Intangible Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail",
     "longName": "995975 - Disclosure - License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail)",
     "shortName": "License and Acquired Intangibles, Net - Schedule of Finite-Lived, Future Amortization Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
     "longName": "995985 - Disclosure - License and Acquired Intangibles, Net - Additional Information (Detail)",
     "shortName": "License and Acquired Intangibles, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
     "longName": "995995 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "cprx:AccruedNonClinicalAndClinicalTrialExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "cprx:AccruedNonClinicalAndClinicalTrialExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
     "longName": "996005 - Disclosure - Collaborative and Licensing Arrangements - Additional Information (Detail)",
     "shortName": "Collaborative and Licensing Arrangements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_9c7d03d5-7081-4449-bea0-40e589ce6ecc",
      "name": "cprx:ExpensesIncurredInConnectionWithCollaborationAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9c7d03d5-7081-4449-bea0-40e589ce6ecc",
      "name": "cprx:ExpensesIncurredInConnectionWithCollaborationAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "996015 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_4c43ddad-6603-484e-8db2-d46bb3b245a3",
      "name": "cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c43ddad-6603-484e-8db2-d46bb3b245a3",
      "name": "cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
     "longName": "996025 - Disclosure - Agreements - Additional Information (Detail)",
     "shortName": "Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c2b04665-c428-4f48-8bee-660378e215e7",
      "name": "cprx:LicenseAgreementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail",
     "longName": "996035 - Disclosure - Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail)",
     "shortName": "Agreements - Schedule Of  Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_2e53e13a-9358-4ded-8867-b51252e1f076",
      "name": "cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e53e13a-9358-4ded-8867-b51252e1f076",
      "name": "cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
     "longName": "996045 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail)",
     "shortName": "Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_eb22b263-4b66-4ae6-aca9-3f65ad766c21",
      "name": "cprx:AssetAcquisitionBaseCashPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb22b263-4b66-4ae6-aca9-3f65ad766c21",
      "name": "cprx:AssetAcquisitionBaseCashPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
     "longName": "996055 - Disclosure - Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail)",
     "shortName": "Agreements - Summary of Aggregate Amount Paid for the Assets Acquired (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_eb22b263-4b66-4ae6-aca9-3f65ad766c21",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail",
     "longName": "996065 - Disclosure - Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail)",
     "shortName": "Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_eb22b263-4b66-4ae6-aca9-3f65ad766c21",
      "name": "cprx:AssetAcquisitionInventoryCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb22b263-4b66-4ae6-aca9-3f65ad766c21",
      "name": "cprx:AssetAcquisitionInventoryCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
     "longName": "996075 - Disclosure - Agreements - Summary of aggregate amount paid for the assets (Detail)",
     "shortName": "Agreements - Summary of aggregate amount paid for the assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_9df3359d-d215-4d6a-884d-65563f285107",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9df3359d-d215-4d6a-884d-65563f285107",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
     "longName": "996085 - Disclosure - Agreements - Summary of total purchase price allocated (Detail)",
     "shortName": "Agreements - Summary of total purchase price allocated (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_9df3359d-d215-4d6a-884d-65563f285107",
      "name": "cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9df3359d-d215-4d6a-884d-65563f285107",
      "name": "cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail",
     "longName": "996095 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "996105 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail",
     "longName": "996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail",
     "longName": "996125 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail",
     "longName": "996135 - Disclosure - Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)",
     "shortName": "Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d4b4748-9287-4017-aa36-fd0c7a3495c3",
      "name": "cprx:NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail",
     "longName": "996145 - Disclosure - Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail)",
     "shortName": "Stockholders' Equity ( Share Repurchases ) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_709ee500-c24e-46f7-b21a-40c0f4ecc925",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
     "longName": "996165 - Disclosure - Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail)",
     "shortName": "Stockholders' Equity (2023 Shelf Registration Statement) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ca67800-b7c3-4502-9b65-2de2fc4bcd0d",
      "name": "cprx:MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail",
     "longName": "996175 - Disclosure - Stock Compensation - Stock-Based Compensation Expense (Detail)",
     "shortName": "Stock Compensation - Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_52411d29-db32-4171-9a6f-695291dabbf1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
     "longName": "996185 - Disclosure - Stock Compensation - Additional Information (Detail)",
     "shortName": "Stock Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ef0ad7eb-05bd-41b1-a942-fd05ddc204bc",
      "name": "cprx:ContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail",
     "longName": "996195 - Disclosure - Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)",
     "shortName": "Stock Compensation - Summary of Stock Option Activity Under the Company's Plan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_9966f3a4-7e1a-439f-afa1-d3b19802833e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9966f3a4-7e1a-439f-afa1-d3b19802833e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail",
     "longName": "996205 - Disclosure - Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail)",
     "shortName": "Stock Compensation - Schedule of Other Information Pertaining to Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail",
     "longName": "996215 - Disclosure - Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)",
     "shortName": "Stock Compensation - Summary of Stock Options Awards Based on Certain Assumptions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail",
     "longName": "996225 - Disclosure - Stock Compensation - Summary of Restricted Stock Unit Activity (Detail)",
     "shortName": "Stock Compensation - Summary of Restricted Stock Unit Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail",
     "longName": "996235 - Disclosure - Benefit Plan - Additional Information (Detail)",
     "shortName": "Benefit Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b9ed6e7-8979-43e3-b896-652049c5ff71",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cprx-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r61",
      "r1118"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r865"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "verboseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "cprx_AccretionOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccretionOfDiscount",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents accretion of discount.",
        "label": "Accretion Of Discount",
        "negatedLabel": "Accretion of discount"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AccruedGrossToNetRevenueLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccruedGrossToNetRevenueLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued gross-to-net revenue liabilities.",
        "label": "Accrued gross to net revenue liabilities",
        "terseLabel": "Accrued gross-to-net revenue liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued income tax",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r111"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Current accrued expenses and other liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "totalLabel": "Total accrued expenses and other liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "cprx_AccruedLicenseFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccruedLicenseFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued License Fees Current",
        "terseLabel": "Accrued license fees"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AccruedNonClinicalAndClinicalTrialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccruedNonClinicalAndClinicalTrialExpenses",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable pertaining to non clinical and clinical trial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Non Clinical And Clinical Trial Expenses",
        "terseLabel": "Accrued preclinical and clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "cprx_AccruedPurchasesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccruedPurchasesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued purchases current.",
        "label": "Accrued Purchases Current",
        "terseLabel": "Accrued purchases"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AccruedVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AccruedVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued variable consideration.",
        "label": "Accrued Variable Consideration",
        "verboseLabel": "Accrued variable consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r186",
      "r652"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Accumulated other comprehensive income (Note 4)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r75",
      "r192",
      "r648",
      "r681",
      "r682"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r17",
      "r505",
      "r508",
      "r563",
      "r677",
      "r678",
      "r1027",
      "r1028",
      "r1029",
      "r1039",
      "r1040",
      "r1041",
      "r1043"
     ]
    },
    "cprx_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in process research and development",
        "label": "Acquired in Process Research and Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AcquiredInventorySamplesExpensedFromAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AcquiredInventorySamplesExpensedFromAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired inventory samples expensed from asset acquisition.",
        "label": "Acquired Inventory Samples Expensed From Asset Acquisition",
        "terseLabel": "Acquired inventory samples expensed from asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development inventory expensed from asset acquisition.",
        "label": "Acquired Research And Development Inventory Expensed From Asset Acquisition",
        "terseLabel": "Acquired research and development inventory expensed from asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development inventory expenses from asset acquisition.",
        "label": "Acquired Research And Development Inventory Expenses From Asset Acquisition",
        "terseLabel": "Acquired research and development inventory expensed from asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r865",
      "r1193"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r1039",
      "r1040",
      "r1041",
      "r1043",
      "r1134",
      "r1194"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r412"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "ADVERTISING EXPENSE",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r849"
     ]
    },
    "cprx_AfterAgreementOfCompanyLeasedSpaces": {
     "xbrltype": "areaItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AfterAgreementOfCompanyLeasedSpaces",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After agreement of company leased spaces.",
        "label": "After Agreement Of Company Leased Spaces",
        "terseLabel": "After agreement of company leased spaces"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AgamreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AgamreeMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGAMREE.",
        "label": "AGAMREE [Member]",
        "terseLabel": "AGAMREE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r926",
      "r936",
      "r969"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r929",
      "r939",
      "r972"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "cprx_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AgreementsDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/Agreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements.",
        "label": "Agreements Disclosure [Text Block]",
        "terseLabel": "Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r964",
      "r973",
      "r977",
      "r985"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r453"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Allowance for expected credit losses, written off",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AmortizationExpensesOfIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AmortizationExpensesOfIntangibleAsset",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Expenses of Intangible Asset",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r333",
      "r340",
      "r831"
     ]
    },
    "cprx_AmortizedCostBeforeUnrealizedGainsAndLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AmortizedCostBeforeUnrealizedGainsAndLosses",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost before unrealized gains and losses.",
        "label": "Amortized Cost Before Unrealized Gains And Losses",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AmountOfMinimumRoyaltyPayableMaturityTermsNotMet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AmountOfMinimumRoyaltyPayableMaturityTermsNotMet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Of Minimum Royalty Payable Maturity Terms Not Met",
        "documentation": "Amount of minimum royalty payable maturity terms not met.",
        "terseLabel": "Amount of minimum royalty payable maturity terms not met"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potential equivalent common stock excluded",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "cprx_AssetAcquisationDueToLicensorCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisationDueToLicensorCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisation due to licensor current.",
        "label": "Asset Acquisation Due To Licensor Current",
        "terseLabel": "Due to licensor"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisationDueToLicensorNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisationDueToLicensorNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisation due to licensor noncurrent.",
        "label": "Asset Acquisation Due to Licensor Noncurrent",
        "terseLabel": "Due to licensor \u2013 non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, accrued preclinical and clinical trial expenses.",
        "label": "Asset Acquisition Accrued Preclinical And Clinical Trial Expenses",
        "terseLabel": "Accrued preclinical and clinical trial expenses",
        "negatedLabel": "Accrued preclinical and clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r1130"
     ]
    },
    "cprx_AssetAcquisitionBaseCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionBaseCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition base cash payment.",
        "label": "Asset Acquisition Base Cash Payment",
        "terseLabel": "Base cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionCashPaidForProRatedPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionCashPaidForProRatedPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition cash paid for pro rated prepaid expenses.",
        "label": "Asset Acquisition Cash Paid For Pro Rated Prepaid Expenses",
        "terseLabel": "Cash paid for pro-rated prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total purchase consideration",
        "totalLabel": "Total purchase consideration",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "cprx_AssetAcquisitionConsiderationTransferredInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionConsiderationTransferredInvestments",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition consideration transferred investments.",
        "label": "Asset Acquisition Consideration Transferred Investments",
        "terseLabel": "Investment in Santhera"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs",
        "verboseLabel": "Transaction expenses",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r1130"
     ]
    },
    "cprx_AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition equity interests issued or issuable number of shares issued.",
        "label": "Asset Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued",
        "terseLabel": "Asset acquisition equity interests issued or issuable number of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionInventoryCurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, inventory current.",
        "label": "Asset Acquisition Inventory Current",
        "terseLabel": "Inventory",
        "negatedLabel": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionInvestmentSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionInvestmentSharePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition investment share price.",
        "label": "Asset Acquisition Investment Share Price",
        "terseLabel": "Asset Acquisition Investment Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, license and acquired intangibles for FYCOMPA\u00ae.",
        "label": "Asset Acquisition License And Acquired Intangibles For Fycompa",
        "terseLabel": "License and acquired intangibles for FYCOMPA\u00ae",
        "negatedLabel": "License and acquired intangibles for FYCOMPA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "cprx_AssetAcquisitionPercentageOfOutstandingOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionPercentageOfOutstandingOrdinaryShares",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition percentage of outstanding ordinary shares.",
        "label": "Asset Acquisition Percentage Of Outstanding Ordinary Shares",
        "terseLabel": "Asset Acquisition Percentage Of Outstanding Ordinary Shares",
        "verboseLabel": "Asset acquisition percentage of outstanding ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition,, prepaid expenses and other current assets.",
        "label": "Asset Acquisition Prepaid Expenses And Other Current Assets",
        "terseLabel": "Prepaid expenses and other current assets (samples)",
        "negatedLabel": "Prepaid expenses and other current assets (samples)"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionPropertyAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionPropertyAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition, property and equipment, net.",
        "label": "Asset Acquisition Property And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "negatedLabel": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquisitionPurchasePriceConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionPurchasePriceConsideration",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition purchase price consideration.",
        "label": "Asset acquisition purchase price consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Aggregate Amount Paid for the Assets Acquired",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "cprx_AssetAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition value.",
        "label": "Asset Acquisition Value",
        "terseLabel": "Total purchase price",
        "totalLabel": "Total purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_AssetAcquistionPrepaidCommercializationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AssetAcquistionPrepaidCommercializationFees",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquistion, prepaid commercialization fees.",
        "label": "Asset Acquistion, Prepaid Commercialization Fees",
        "terseLabel": "Prepaid commercialization expenses",
        "negatedLabel": "Prepaid commercialization expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r123",
      "r188",
      "r224",
      "r254",
      "r259",
      "r271",
      "r272",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r498",
      "r502",
      "r535",
      "r644",
      "r734",
      "r822",
      "r823",
      "r865",
      "r893",
      "r1086",
      "r1087",
      "r1149"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r195",
      "r224",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r498",
      "r502",
      "r535",
      "r865",
      "r1086",
      "r1087",
      "r1149"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "terseLabel": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r322",
      "r643"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "cprx_AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities by amortized cost unrealized gains or losses and fair value",
        "label": "Available For Sale Securities By Amortized Cost Unrealized Gains Or Losses And Fair Value [Table Text Block]",
        "terseLabel": "Estimated Fair Values of Available for Sale Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsEstimatedFairValuesOfAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r640"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r322",
      "r516",
      "r635",
      "r854",
      "r857",
      "r1057",
      "r1138",
      "r1139",
      "r1140"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "verboseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r351",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "cprx_BeforeAgreementOfCompanyLeasedSpaces": {
     "xbrltype": "areaItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "BeforeAgreementOfCompanyLeasedSpaces",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Before agreement of company leased spaces.",
        "label": "Before Agreement Of Company Leased Spaces",
        "terseLabel": "Before agreement of company leased spaces"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r493",
      "r845",
      "r846"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r493",
      "r845",
      "r846"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107"
     ]
    },
    "cprx_CalendarYear2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CalendarYear2026Member",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calendar Year 2026 Member.",
        "label": "Calendar Year 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_CalendarYears2022Through2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CalendarYears2022Through2025Member",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calendar Years 2022 Through 2025 Member.",
        "label": "Calendar Years 2022 Through 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Capitalized amortized Cost",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r184",
      "r802"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "CASH AND CASH EQUIVALENTS",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents \u2013 end of period",
        "periodStartLabel": "Cash and cash equivalents \u2013 beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r87",
      "r222"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r87"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r189",
      "r190",
      "r191",
      "r224",
      "r245",
      "r246",
      "r248",
      "r250",
      "r256",
      "r257",
      "r313",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r372",
      "r373",
      "r376",
      "r379",
      "r386",
      "r535",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r722",
      "r743",
      "r761",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1008",
      "r1035",
      "r1044"
     ]
    },
    "cprx_ClosingMarketPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ClosingMarketPrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing market price.",
        "label": "Closing Market Price",
        "terseLabel": "Closing Market Price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "cprx_CollaborationAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CollaborationAgreementAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement.",
        "label": "Collaboration Agreement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_CollaborationAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CollaborationAgreementDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement.",
        "label": "Collaboration Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_CollaborationArrangementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CollaborationArrangementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement Disclosure [Abstract]",
        "label": "Collaboration Arrangements Disclosure [Abstract]",
        "terseLabel": "Collaboration Arrangement Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative and Licensing Arrangements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r145"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "cprx_CollaborativeArrangementMilestonePaymentObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CollaborativeArrangementMilestonePaymentObligation",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement milestone payment obligation.",
        "label": "Collaborative Arrangement Milestone Payment Obligation",
        "terseLabel": "Collaborative arrangement, milestone payment obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "Collaborative Arrangements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r113",
      "r645",
      "r721"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r353",
      "r354",
      "r785",
      "r1081",
      "r1083"
     ]
    },
    "cprx_CommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CommitmentsLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments.",
        "label": "Commitments [Line Items]",
        "terseLabel": "Commitments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_CommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CommitmentsTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments [Table]",
        "label": "Commitments [Table]",
        "terseLabel": "Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance under the Plan",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r887",
      "r888",
      "r889",
      "r890",
      "r1039",
      "r1040",
      "r1043",
      "r1134",
      "r1192",
      "r1194"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r722"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r722",
      "r740",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized; 120,879,099 shares and 107,121,549 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r647",
      "r865"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ComponentsOfRevenueRecognizedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ComponentsOfRevenueRecognizedAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of revenue recognized.",
        "label": "Components Of Revenue Recognized [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ComponentsOfRevenueRecognizedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ComponentsOfRevenueRecognizedDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of revenue recognized.",
        "label": "Components Of Revenue Recognized [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r201",
      "r203",
      "r210",
      "r637",
      "r659",
      "r660"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r209",
      "r636",
      "r657"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMPREHENSIVE INCOME",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r277",
      "r784"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r277",
      "r684",
      "r784"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r277",
      "r784",
      "r1012"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "CONCENTRATION OF RISK",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r137"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r277"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r51",
      "r109",
      "r784"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r277",
      "r784"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "PRINCIPLES OF CONSOLIDATION",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r812"
     ]
    },
    "cprx_ContingentConsiderationArrangementsContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ContingentConsiderationArrangementsContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Arrangements Contingent Consideration Liability.",
        "label": "Contingent Consideration Arrangements Contingent Consideration Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ContractualTerm",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term.",
        "label": "Contractual Term",
        "verboseLabel": "Stock option contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r602"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r226",
      "r227",
      "r368",
      "r374",
      "r564",
      "r584",
      "r642",
      "r809",
      "r811"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current - Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1037",
      "r1129"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current\u00a0- State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1037",
      "r1129"
     ]
    },
    "cprx_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r277"
     ]
    },
    "cprx_CustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "CustomersMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers.",
        "label": "Customers [Member]",
        "terseLabel": "Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r996"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r996"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r998"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r998"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r1000"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r998"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r992"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r992"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r993"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r995"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r995"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r996"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r999"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r997"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r905",
      "r994"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains losses from available for sale securities",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Realized loss on sale of available-for-sale securities",
        "verboseLabel": "Realized losses from sale of\u00a0available-for-sale\u00a0securities",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Investments by Security type",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance",
        "verboseLabel": "Common stock shares available for future issuance under the Plan",
        "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred\u00a0- Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross, Total",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net, Total",
        "terseLabel": "Deferred tax assets, net",
        "totalLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "cprx_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Operating Lease Liability.",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Capitalized research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Deferred compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Discretionary matching contributions of employee contributions of an employee's gross salary",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Employees contribution of pre-tax annual compensation",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Disaggregated Product Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Stock Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r414",
      "r445",
      "r446",
      "r448",
      "r848"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "verboseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_DisclosureOfOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "DisclosureOfOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Operating Leases",
        "label": "Disclosure of Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922",
      "r965"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "cprx_DueFromCollaborativeAndLicencingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "DueFromCollaborativeAndLicencingArrangements",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for pre-commercialization fees that provide economic benefits with a future period of one year or the normal operating cycle, if longer.",
        "label": "Due From Collaborative And Licencing Arrangements",
        "terseLabel": "Due from collaborative and licensing arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "cprx_DydoPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "DydoPharmaIncMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dydo pharma inc.",
        "label": "Dydo Pharma Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243",
      "r245",
      "r248",
      "r249",
      "r250",
      "r253",
      "r491",
      "r495",
      "r513",
      "r514",
      "r638",
      "r661",
      "r816"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r245",
      "r248",
      "r249",
      "r250",
      "r253",
      "r491",
      "r495",
      "r513",
      "r514",
      "r638",
      "r661",
      "r816"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "NET INCOME PER COMMON SHARE",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r252"
     ]
    },
    "cprx_EffectiveIncomeTaxCreditsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "EffectiveIncomeTaxCreditsRate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax credits rate.",
        "label": "Effective Income Tax Credits Rate",
        "terseLabel": "Tax credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Reconciliation of income tax expense",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r850"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r465",
      "r482",
      "r850"
     ]
    },
    "cprx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible expense share based compensation cost including salary.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Including Salary",
        "terseLabel": "Executive compensation limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r1038",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r850",
      "r1038",
      "r1120"
     ]
    },
    "cprx_EffectiveIncomeTaxRateReconciliationWindfallAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationWindfallAdjustments",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation windfall adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Windfall Adjustments",
        "terseLabel": "Stock compensation windfall"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected remaining weighted average vesting period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r179",
      "r205",
      "r206",
      "r207",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r255",
      "r314",
      "r315",
      "r349",
      "r387",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r494",
      "r495",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r547",
      "r563",
      "r657",
      "r677",
      "r678",
      "r679",
      "r697",
      "r761"
     ]
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Type [Axis]",
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFVNINoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Investment in equity securities",
        "verboseLabel": "Equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Net gains (losses) recognized during the period on equity securities",
        "negatedLabel": "Change in fair value of equity securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1074"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfNetGainsAndLossesOnEquitySecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gains (losses) recognized during the period on equity securities still held at the reporting date",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r1074"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r926",
      "r936",
      "r969"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "cprx_ExpensesIncurredInConnectionWithCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ExpensesIncurredInConnectionWithCollaborationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Incurred In Connection With Collaboration Agreement.",
        "label": "Expenses Incurred In Connection With Collaboration Agreement",
        "terseLabel": "Expenses incurred in connection with collaboration agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r528",
      "r854"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r528",
      "r854"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r855"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r855"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r527",
      "r528",
      "r530",
      "r571",
      "r572",
      "r573",
      "r832",
      "r833",
      "r842",
      "r843",
      "r844",
      "r854",
      "r857"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r393",
      "r398",
      "r517",
      "r528",
      "r571",
      "r842",
      "r843",
      "r844",
      "r854"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r527",
      "r528",
      "r530",
      "r571",
      "r572",
      "r573",
      "r832",
      "r833",
      "r842",
      "r843",
      "r844",
      "r854",
      "r857"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "label": "Finance Lease, Liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r560"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r370",
      "r384",
      "r510",
      "r531",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r658",
      "r828",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r866",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1135",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r330",
      "r339",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1196"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r342",
      "r343",
      "r603",
      "r604",
      "r798"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r339",
      "r604",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r339",
      "r342",
      "r343",
      "r346",
      "r603",
      "r798",
      "r831"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r342",
      "r343",
      "r798"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedFutureAmortizationExpenseDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "License and acquired intangibles, net",
        "verboseLabel": "Net Carrying Value",
        "totalLabel": "Net Carrying Value",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r1078"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "cprx_FirdapseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "FirdapseMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FIRDAPSE.",
        "label": "FIRDAPSE [Member]",
        "terseLabel": "FIRDAPSE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r973"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r973"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r973"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r973"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r973"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment [Member]",
        "verboseLabel": "Furniture and Equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_FycompaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "FycompaMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FYCOMPA.",
        "label": "FYCOMPA [Member]",
        "terseLabel": "FYCOMPA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Summary Of Net Gains And Losses On Equity Securities",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r745"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "INTANGIBLE ASSETS, NET",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r345",
      "r348"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r922"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment charges recognized on definite-lived intangibles",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r1033",
      "r1080"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r117",
      "r122",
      "r639",
      "r654",
      "r818",
      "r822",
      "r1046",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r522",
      "r526",
      "r529",
      "r674",
      "r676",
      "r746",
      "r798",
      "r856",
      "r1163"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r522",
      "r526",
      "r529",
      "r674",
      "r676",
      "r746",
      "r798",
      "r856",
      "r1163"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r465",
      "r466",
      "r472",
      "r478",
      "r850",
      "r1125"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r465",
      "r466",
      "r472",
      "r478",
      "r850",
      "r1125"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r459",
      "r465",
      "r469",
      "r470",
      "r471",
      "r473",
      "r477",
      "r483",
      "r485",
      "r486",
      "r487",
      "r695",
      "r850"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r143",
      "r240",
      "r241",
      "r254",
      "r262",
      "r272",
      "r464",
      "r465",
      "r484",
      "r665",
      "r850"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r460",
      "r461",
      "r473",
      "r474",
      "r476",
      "r479",
      "r689"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes, net",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r89",
      "r1034",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1032"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r964",
      "r973",
      "r977",
      "r985"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "License and Acquired Intangibles, Net",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r344",
      "r347",
      "r797",
      "r798"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r219",
      "r220"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r806"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r803",
      "r865"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "INVENTORY",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r183",
      "r193",
      "r326",
      "r327",
      "r328",
      "r601",
      "r813"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r808"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InventorySummaryOfCurrentInventoryDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r807"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "INVESTMENTS",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r685",
      "r686",
      "r687",
      "r688",
      "r768",
      "r769"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r147",
      "r279",
      "r280",
      "r532",
      "r533",
      "r1158"
     ]
    },
    "cprx_KyePharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "KyePharmaceuticalsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KYE Pharmaceuticals.",
        "label": "KYE Pharmaceuticals [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Lease, Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r561"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r562"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "OPERATING LEASES",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lessee, Operating Lease, Option to Terminate",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r224",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r499",
      "r502",
      "r503",
      "r535",
      "r720",
      "r817",
      "r893",
      "r1086",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r114",
      "r650",
      "r865",
      "r1036",
      "r1075",
      "r1143"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LiabilitiesArisingFromAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LiabilitiesArisingFromAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities arising from asset acquisition.",
        "label": "Liabilities Arising From Asset Acquisition",
        "terseLabel": "Liabilities arising from asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r182",
      "r224",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r499",
      "r502",
      "r503",
      "r535",
      "r865",
      "r1086",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAgreementDate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement date.",
        "label": "License Agreement Date",
        "terseLabel": "Date on which strategic collaboration is entered into"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAgreementForRuzurgiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAgreementForRuzurgiMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement for ruzurgi.",
        "label": "License Agreement For RUZURGI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAgreementLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Line Items]",
        "label": "License Agreement [Line Items]",
        "terseLabel": "License Agreement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAgreementTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Table]",
        "label": "License Agreement [Table]",
        "terseLabel": "License Agreement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAgreementWithBioMarinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAgreementWithBioMarinMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement with BioMarin.",
        "label": "License Agreement With Bio Marin [Member]",
        "terseLabel": "License Agreement with BioMarin [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAcquiredIntangiblesForFycompaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAcquiredIntangiblesForFycompaMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Acquired Intangibles For FYCOMPA [Member]",
        "terseLabel": "License and Acquired Intangibles for FYCOMPA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAcquiredIntangiblesForRUZURGIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAcquiredIntangiblesForRUZURGIMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and acquired intangibles for RUZURGI.",
        "label": "License And Acquired Intangibles For RUZURGI [Member]",
        "terseLabel": "License and Acquired Intangibles for RUZURGI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAssetPurchaseAgreementMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Asset Purchase Agreement.",
        "label": "License and Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAssetPurchaseAgreementPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAssetPurchaseAgreementPayment",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and asset purchase agreement payment.",
        "label": "License And Asset Purchase Agreement Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and asset purchase agreement payment made in first year.",
        "label": "License And Asset Purchase Agreement Payment Made in First Year",
        "terseLabel": "License and asset purchase agreement payment made in first year"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and asset purchase agreement payment made in second year",
        "documentation": "License and asset purchase agreement payment made in second year.",
        "terseLabel": "License and asset purchase agreement payment made in second year"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and asset purchase agreement payment made in third year",
        "documentation": "License and asset purchase agreement payment made in third year.",
        "terseLabel": "License and asset purchase agreement payment made in third year"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicenseAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicenseAndOtherRevenueMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and other revenue.",
        "label": "License And Other Revenue [Member]",
        "terseLabel": "License and other revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_LicensedAndAcquiredIntangiblesForAgamreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "LicensedAndAcquiredIntangiblesForAgamreeMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed and acquired intangibles for AGAMREE.",
        "label": "Licensed And Acquired Intangibles For AGAMREE [Member]",
        "verboseLabel": "Licensed And Acquired Intangibles For AGAMREE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r837",
      "r876",
      "r880",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "cprx_MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis": {
     "xbrltype": "durationItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time in which compensation cost from stock options is amortized on a straight line basis.",
        "label": "Maximum Amortization Period Of Compensation Cost On Straight Line Basis",
        "terseLabel": "Maximum amortization period of compensation cost on straight line basis"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum dollar amount of common stock to be issued under shelf registration statement.",
        "label": "Maximum Amount Of Common Stock That Can Be Issued Under Shelf Registration Statement",
        "terseLabel": "Maximum dollar amount of common stock to be issued under shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_MaximumMaturityPeriodOfCashAndCashEquivalent": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MaximumMaturityPeriodOfCashAndCashEquivalent",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum length of time to maturity for instruments included as cash equivalents.",
        "label": "Maximum Maturity Period Of Cash And Cash Equivalent",
        "terseLabel": "Maximum maturity period of cash and cash equivalent"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r152",
      "r153",
      "r155",
      "r177",
      "r178",
      "r355",
      "r356",
      "r357",
      "r358",
      "r408",
      "r454",
      "r520",
      "r600",
      "r673",
      "r675",
      "r683",
      "r712",
      "r713",
      "r766",
      "r770",
      "r772",
      "r773",
      "r775",
      "r795",
      "r796",
      "r827",
      "r834",
      "r847",
      "r857",
      "r858",
      "r862",
      "r863",
      "r877",
      "r1088",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "cprx_MilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MilestonePaymentMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment [Member]",
        "documentation": "Milestone payment member.",
        "terseLabel": "Milestone Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r152",
      "r153",
      "r155",
      "r177",
      "r178",
      "r355",
      "r356",
      "r357",
      "r358",
      "r408",
      "r454",
      "r520",
      "r600",
      "r673",
      "r675",
      "r683",
      "r712",
      "r713",
      "r766",
      "r770",
      "r772",
      "r773",
      "r775",
      "r795",
      "r796",
      "r827",
      "r834",
      "r847",
      "r857",
      "r858",
      "r862",
      "r877",
      "r1088",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "cprx_MinimumRoyalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MinimumRoyalty",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum royalty.",
        "label": "Minimum Royalty",
        "terseLabel": "Minimum royalty"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_MinimumRoyaltyAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "MinimumRoyaltyAmount",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum royalty amount.",
        "label": "Minimum Royalty Amount",
        "terseLabel": "Minimum royalty amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r837",
      "r876",
      "r880",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net income",
        "verboseLabel": "Net income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r118",
      "r180",
      "r199",
      "r202",
      "r207",
      "r224",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r247",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r491",
      "r495",
      "r514",
      "r535",
      "r656",
      "r742",
      "r759",
      "r760",
      "r891",
      "r1086"
     ]
    },
    "cprx_NetSalesBasedMilestoneToRoyaltyThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NetSalesBasedMilestoneToRoyaltyThreshold",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales based milestone to royalty threshold.",
        "label": "Net Sales Based Milestone To Royalty Threshold",
        "terseLabel": "Net sales based milestone to royalty threshold"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_NetSalesRoyaltyThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NetSalesRoyaltyThreshold",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount used to determine the percentage of royalties for the period from the first commercial sale equal to the minimum percentage of net sales in North America for any calendar year for sales up to the amount, and maximum percentage of net sales in North America in any calendar year in excess of the amount.",
        "label": "Net Sales Royalty Threshold",
        "terseLabel": "Net sales royalty threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "RECENTLY ISSUED ACCOUNTING STANDARDS",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_NonCashChangeInRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NonCashChangeInRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash change in right of use asset.",
        "label": "Non cash change in right of use asset",
        "terseLabel": "Reduction in the carrying amount of right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r964",
      "r973"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "cprx_NonRefundableUpfrontLicenseFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NonRefundableUpfrontLicenseFeesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront license fees.",
        "label": "Non Refundable Upfront License Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1047"
     ]
    },
    "cprx_NumberOfTradingDaysFromReceiptOfTheNoticeLetter": {
     "xbrltype": "durationItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NumberOfTradingDaysFromReceiptOfTheNoticeLetter",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days from receipt of the notice letter.",
        "label": "Number Of Trading Days From Receipt Of The Notice Letter",
        "terseLabel": "Number of trading days from receipt of the notice letter"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitlement for Each Share Held by Common Stock Holders.",
        "label": "Number of Votes Entitlement for Each Share Held by Common Stock Holders",
        "terseLabel": "Number of votes entitled for each share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating expense.",
        "label": "Operating Expense",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r818",
      "r1046",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "verboseLabel": "Rent expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r864"
     ]
    },
    "cprx_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities arising from obtaining right of use assets.",
        "label": "Operating Lease Liabilities Arising From Obtaining Right Of Use Assets",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Other current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability \u2013 non-current",
        "verboseLabel": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalBalanceSheetRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r864"
     ]
    },
    "us-gaap_OperatingLeasesLeaseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesLeaseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Lease Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Other \u2013 non-current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedLabel": "Other comprehensive gain (loss) before reclassifications",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r205",
      "r657"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss)",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r13",
      "r200",
      "r203",
      "r209",
      "r237",
      "r536",
      "r537",
      "r542",
      "r636",
      "r657",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive income (Note 4):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "totalLabel": "Net current period other comprehensive gain",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax of ($20), $4 and ($54), respectively",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r312"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net of tax impact",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r197"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "cprx_OtherNoncurrentAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "OtherNoncurrentAccruedExpensesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other noncurrent accrued expenses and other liabilities.",
        "label": "Other Noncurrent Accrued Expenses And Other Liabilities",
        "totalLabel": "Non-current accrued expenses and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1076"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r971"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r931",
      "r941",
      "r974"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r931",
      "r941",
      "r974"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PaymentInConnectionWithAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PaymentInConnectionWithAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment in connection with asset acquisition.",
        "label": "Payment In Connection With Asset Acquisition",
        "negatedLabel": "Payments in connection with asset acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PaymentOfLiabilitiesArisingFromAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PaymentOfLiabilitiesArisingFromAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of liabilities arising from asset acquisition.",
        "label": "Payment Of Liabilities Arising From Asset Acquisition",
        "negatedLabel": "Payment of liabilities arising from asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PaymentOnMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PaymentOnMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on milestone payment.",
        "label": "Payment on Milestone Payment",
        "terseLabel": "Payment on milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Aggregate purchase price",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of fees in connection with issuance of common stock",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding tax related to stock-based compensation",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedLabel": "Purchase of equity securities",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r216"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Acquisition of in-process research and development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets",
        "verboseLabel": "Initial cash payment",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Benefit Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r844"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "cprx_PercentageOfAnnualRoyaltyOnTheCompanysNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfAnnualRoyaltyOnTheCompanysNetSales",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual royalty on the company's net sales.",
        "label": "Percentage of Annual Royalty On The Companys Net Sales",
        "terseLabel": "Percentage of annual royalty on the Company's net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PercentageOfMaximumRoyaltyPayableToNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfMaximumRoyaltyPayableToNetSales",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty payable to net sales.",
        "label": "Percentage Of Maximum Royalty Payable To Net Sales",
        "terseLabel": "Percentage of maximum royalty payable to net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PercentageOfMinimumRoyaltyPayableToNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfMinimumRoyaltyPayableToNetSales",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum royalty payable to net sales.",
        "label": "Percentage Of Minimum Royalty Payable To Net Sales",
        "terseLabel": "Percentage of minimum royalty payable to net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PercentageOfRoyaltyPayableToNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfRoyaltyPayableToNetSales",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage applied to net sales to determine the amount payable as part of the agreement.",
        "label": "Percentage Of Royalty Payable To Net Sales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PercentageOfRoyaltyPayableToSalesBasedMilestone": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfRoyaltyPayableToSalesBasedMilestone",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payable to sales based milestone.",
        "label": "Percentage Of Royalty Payable To Sales Based Milestone",
        "terseLabel": "Percentage of royalty payable to sales based milestone"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PercentageOfTheConsiderationPaidByAThirdPartyToAcquireThatVoucher",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the consideration paid by a third party to acquire that voucher.",
        "label": "Percentage Of The Consideration Paid By A Third Party To Acquire That Voucher",
        "terseLabel": "Percentage of the consideration paid by a third party to acquire that voucher"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PeriodAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Axis.",
        "label": "Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PeriodDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Domain.",
        "label": "Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r372"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r722"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r372"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r722",
      "r740",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r646",
      "r865"
     ]
    },
    "cprx_PrepaidCommercialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidCommercialExpenses",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid commercial expenses.",
        "label": "Prepaid Commercial Expenses",
        "terseLabel": "Prepaid commercialization expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidConferenceAndTravelExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidConferenceAndTravelExpenses",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid conference and travel expenses.",
        "label": "Prepaid Conference And Travel Expenses",
        "terseLabel": "Prepaid conference and travel expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidCopayAssistanceProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidCopayAssistanceProgram",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid copay assistance program.",
        "label": "Prepaid Copay Assistance Program",
        "terseLabel": "Prepaid co-pay assistance program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "cprx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets. This disclosure may include the types of prepaid expenses and other current assets and how these are recognize in expenses.",
        "label": "Prepaid Expenses And Other Current Assets [Policy Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prepaid expenses and other current assets.",
        "label": "Prepaid expenses and other current assets [Table Text Block]",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the carrying amount as of the balance sheet date of expenditures made in advance of the timing of recognition of expenses which are expected to be charged against earnings within one year or the normal operating cycle, if longer. Includes, but is not limited to, prepaid research, prepaid product development activities and prepaid insurance.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r829",
      "r1076"
     ]
    },
    "cprx_PrepaidManufacturingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidManufacturingExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid manufacturing expense.",
        "label": "Prepaid Manufacturing Expense",
        "terseLabel": "Prepaid manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidResearchFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidResearchFee",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and product development activities that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research Fee",
        "terseLabel": "Prepaid research fees"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PrepaidSubscriptionFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PrepaidSubscriptionFees",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for subscription fees that provides economic benefits within a future period of one year of the normal operating cycle, if longer.",
        "label": "Prepaid Subscription Fees",
        "terseLabel": "Prepaid subscriptions fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid tax",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r830",
      "r1076"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "RECLASSIFICATIONS",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale of\u00a0available-for-sale\u00a0securities",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r1058"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r175",
      "r274",
      "r602",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r800",
      "r835",
      "r875",
      "r877",
      "r878",
      "r881",
      "r882",
      "r1022",
      "r1084",
      "r1085",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "cprx_ProductRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ProductRevenueNetMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue net.",
        "label": "Product Revenue Net [Member]",
        "terseLabel": "Product revenue, net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r175",
      "r274",
      "r602",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r800",
      "r835",
      "r875",
      "r877",
      "r878",
      "r881",
      "r882",
      "r1022",
      "r1084",
      "r1085",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r199",
      "r202",
      "r217",
      "r224",
      "r231",
      "r237",
      "r240",
      "r241",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r491",
      "r495",
      "r497",
      "r500",
      "r501",
      "r514",
      "r535",
      "r639",
      "r655",
      "r696",
      "r742",
      "r759",
      "r760",
      "r852",
      "r853",
      "r892",
      "r1029",
      "r1086"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r138",
      "r141",
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r185",
      "r653"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r561",
      "r641",
      "r653",
      "r865"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r138",
      "r141",
      "r651"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life of assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering.",
        "label": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PurchasePriceConsiderationForIntangibleAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PurchasePriceConsiderationForIntangibleAssetsAcquired",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price consideration for intangible assets acquired.",
        "label": "Purchase Price Consideration For Intangible Assets Acquired",
        "terseLabel": "License and acquired intangibles",
        "verboseLabel": "License and acquired intangibles for vamorolone (IPR&amp;D)"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_PurchasePriceOfAnAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "PurchasePriceOfAnAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of an asset acquisition.",
        "label": "Purchase price of an asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r152",
      "r153",
      "r155",
      "r177",
      "r178",
      "r355",
      "r356",
      "r357",
      "r358",
      "r391",
      "r408",
      "r440",
      "r441",
      "r442",
      "r454",
      "r520",
      "r574",
      "r583",
      "r600",
      "r673",
      "r675",
      "r683",
      "r712",
      "r713",
      "r766",
      "r770",
      "r772",
      "r773",
      "r775",
      "r795",
      "r796",
      "r827",
      "r834",
      "r847",
      "r857",
      "r858",
      "r862",
      "r863",
      "r877",
      "r885",
      "r1082",
      "r1088",
      "r1139",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r152",
      "r153",
      "r155",
      "r177",
      "r178",
      "r355",
      "r356",
      "r357",
      "r358",
      "r391",
      "r408",
      "r440",
      "r441",
      "r442",
      "r454",
      "r520",
      "r574",
      "r583",
      "r600",
      "r673",
      "r675",
      "r683",
      "r712",
      "r713",
      "r766",
      "r770",
      "r772",
      "r773",
      "r775",
      "r795",
      "r796",
      "r827",
      "r834",
      "r847",
      "r857",
      "r858",
      "r862",
      "r863",
      "r877",
      "r885",
      "r1082",
      "r1088",
      "r1139",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeSummaryOfReclassificationsOutOfAccumulatedOtherComprehensiveIncomeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amount reclassified from accumulated other comprehensive income (loss)",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r17",
      "r206",
      "r536",
      "r541",
      "r542",
      "r657",
      "r1027"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementArrangementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegistrationPaymentArrangementArrangementDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement, Arrangement [Domain]",
        "terseLabel": "Registration Payment Arrangement, Arrangement [Domain]",
        "documentation": "Identifies and describes the contingent obligation arising from a commitment made to the recipient of the entity's financial instruments to endeavor (a) to file a registration statement for the resale of those financial instrument (demand or \"piggyback\" rights granted to the recipient) or for the resale of equity shares that are issuable upon exercise or conversion of those financial instruments and (b) for the registration statement to be declared effective by the Securities and Exchange Commission within a specified grace period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_RegistrationPaymentArrangementByArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegistrationPaymentArrangementByArrangementAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Payment Arrangement by Arrangement [Axis]",
        "terseLabel": "Registration Payment Arrangement by Arrangement [Axis]",
        "documentation": "Information by registration payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "cprx_RegulatoryFilingMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RegulatoryFilingMilestoneMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Filing Milestone [Member]",
        "terseLabel": "Regulatory Filing Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ReimbursementOnBasePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ReimbursementOnBasePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement on base purchase price.",
        "label": "Reimbursement On Base Purchase Price",
        "negatedLabel": "Reimbursement on base purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r226",
      "r227",
      "r368",
      "r374",
      "r564",
      "r584",
      "r642",
      "r810",
      "r811"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r1119"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r1119"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r798",
      "r822",
      "r1157"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r924",
      "r934",
      "r967"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r921",
      "r932",
      "r942",
      "r975"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r99",
      "r649",
      "r680",
      "r682",
      "r694",
      "r723",
      "r865"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit) [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r314",
      "r315",
      "r349",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r494",
      "r495",
      "r504",
      "r506",
      "r507",
      "r509",
      "r512",
      "r545",
      "r547",
      "r677",
      "r679",
      "r697",
      "r1194"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfDisaggregatedProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r254",
      "r260",
      "r261",
      "r270",
      "r272",
      "r274",
      "r275",
      "r277",
      "r388",
      "r389",
      "r602"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "REVENUE RECOGNITION",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r799",
      "r814"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r208",
      "r224",
      "r254",
      "r260",
      "r261",
      "r270",
      "r272",
      "r274",
      "r275",
      "r277",
      "r313",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r535",
      "r639",
      "r822",
      "r1086"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r864"
     ]
    },
    "cprx_RightOfUseAssetsObtainedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RightOfUseAssetsObtainedAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use Assets Obtained",
        "label": "Right of Use Assets Obtained [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltiesExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltiesExpensePolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Expense",
        "label": "Royalties Expense [Policy Text Block]",
        "verboseLabel": "ROYALTIES"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyAgreementTerm",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the royalty payments from the first commercial sale of product under the agreement.",
        "label": "Royalty Agreement Term",
        "terseLabel": "Royalty agreement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyAgreementTermsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement Terms [Member]",
        "documentation": "Terms of the royalty agreement under research and development arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyForAdditionalIndicationsAndMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyForAdditionalIndicationsAndMilestonesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty for additional indications and milestones.",
        "label": "Royalty For Additional Indications And Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty for additional indications and milestones of up to fifty million more.",
        "label": "Royalty For Additional Indications And Milestones Of Up To Fifty Million More [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyForSantheraSalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyForSantheraSalesBasedMilestonesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty for santhera sales based milestones.",
        "label": "Royalty For Santhera Sales Based Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyLessThanHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyLessThanHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty less than hundred million member.",
        "label": "Royalty Less Than Hundred Million [Member]",
        "terseLabel": "Royalty Less Than Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyLessThanTwoHundredFiftyMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyLessThanTwoHundredFiftyMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty less than two hundred fifty million.",
        "label": "Royalty Less Than Two Hundred Fifty Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more seven hundred and fifty million and less than one billion member.",
        "label": "Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]",
        "terseLabel": "Royalty More Seven Hundred And Fifty Million And Less Than One Billion [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than five hundred million and less than seven hundred fifty million.",
        "label": "Royalty More Than Five Hundred Million And Less Than Seven Hundred Fifty Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanHundredAndTwentyFiveMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanHundredAndTwentyFiveMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than hundred and twenty five million.",
        "label": "Royalty More Than Hundred And Twenty Five Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than hundred million and less than hundred and twenty five million.",
        "label": "Royalty More Than Hundred Million And Less Than Hundred And Twenty Five Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than hundred million and less than two hundred million.",
        "label": "Royalty More Than Hundred Million And Less Than Two Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than one billion and less than two billion.",
        "label": "Royalty More Than One Billion And Less Than Two Billion [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than ten million and less than hundred million.",
        "label": "Royalty More Than Ten Million And Less Than Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanThreeHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanThreeHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than three hundred million.",
        "label": "Royalty More Than Three Hundred Million [Member]",
        "terseLabel": "Royalty More Than Three Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanTwoBillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanTwoBillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than two billion.",
        "label": "Royalty More Than Two Billion [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more than two hundred million and less than three hundred million.",
        "label": "Royalty More Than Two Hundred Million And Less Than Three Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty more two hundred and fifty million and less than five hundred million member.",
        "label": "Royalty More Two Hundred And Fifty Million And Less Than Five Hundred Million [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyThresholdLimitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyThresholdLimitAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty threshold limit.",
        "label": "Royalty Threshold Limit [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_RoyaltyThresholdLimitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "RoyaltyThresholdLimitDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty threshold limit.",
        "label": "Royalty Threshold Limit [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSummaryOfPercentageOfTheCompanysTotalNetProductRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r1011"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r242",
      "r409",
      "r1009",
      "r1042"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureAccumulatedOtherComprehensiveIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Reclassifications out of Accumulated Other Comprehensive Income",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r1144",
      "r1145"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related To Lease",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "verboseLabel": "Collaborative Arrangement [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax expense",
        "verboseLabel": "Schedule of Income Tax Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of deferred tax assets",
        "verboseLabel": "Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of income tax expense computed at statutory federal income tax rate",
        "verboseLabel": "Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r850",
      "r1120"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurement Specific to Assets or Liability",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1077"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of current inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Net Investment Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r658"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r561"
     ]
    },
    "cprx_ScheduleOfRestrictedStockActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfRestrictedStockActivityLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Restricted Stock Activity.",
        "label": "Schedule Of Restricted Stock Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ScheduleOfRestrictedStockActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfRestrictedStockActivityTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Restricted Stock Activity.",
        "label": "Schedule Of Restricted Stock Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Segment Expenses",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]",
        "terseLabel": "Schedule of Other Information Pertaining to Stock Option Activity",
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity Under the Company's Plans",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Stock Options Awards Based on Certain Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "cprx_ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabulor Disclosure of Supplemental balance Sheet Information Related To Lease.",
        "label": "Schedule of Supplemental Balance Sheet related To Lease [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Balance Sheet related To Lease"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of total purchase price was allocated to acquire assets.",
        "label": "Schedule Of Total Purchase Price Was Allocated To Acquire Assets [Table Text Block]",
        "terseLabel": "Summary of Total Purchase Price Allocated to Acquired Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.",
        "label": "Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.",
        "label": "Schedule of total purchase price was allocated to the acquired assets based on their relative fair values [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of total purchase price was allocated to the acquired assets based on their relative fair values.",
        "label": "Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values [Table Text Block]",
        "terseLabel": "Schedule Of Total Purchase Price Was Allocated To The Acquired Assets Based On Their Relative Fair Values"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Basic and Dilutive Weighted Average Common Shares",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived, Future Amortization Expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1079"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Percentage of the Company's Total Net Product Revenue",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r51",
      "r109"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r156",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r275",
      "r276",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r709",
      "r710",
      "r711",
      "r767",
      "r771",
      "r774",
      "r776",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r801",
      "r836",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r879",
      "r885",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r821",
      "r826"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r820",
      "r825"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r273",
      "r275",
      "r819",
      "r820",
      "r824"
     ]
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling Expense",
        "terseLabel": "Selling",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Share based compensation, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested balance at end of year",
        "periodStartLabel": "Nonvested balance at beginning of year",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested Weighted Average Grant Date Fair Value balance at end of year",
        "periodStartLabel": "Nonvested Weighted Average Grant Date Fair Value balance at beginning of year",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "cprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "terseLabel": "Expected forfeiture rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable at end of year",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of exercised stock options",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, Forfeited or cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Common stock unit granted",
        "verboseLabel": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of granted stock options",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, Outstanding at end of year",
        "periodStartLabel": "Number of options, Outstanding at beginning of year",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic value, Outstanding at end of year",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "cprx_ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of contractual term of option awards.",
        "label": "Share Based Compensation Arrangement By Share Based Payments Award Contractual Term",
        "terseLabel": "Stock option granted, contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfRestrictedStockUnitActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised or released",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited or cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r418",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "verboseLabel": "Stock option exercise price range, Minimum",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Stock option exercise price range, Maximum",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "cprx_SharePurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "SharePurchaseProgramMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase program.",
        "label": "Share Purchase Program [Member]",
        "terseLabel": "Share Purchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "cprx_ShareRepurchases": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ShareRepurchases",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for share repurchases.",
        "label": "Share Repurchases",
        "terseLabel": "SHARE REPURCHASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationSummaryOfStockOptionsAwardsBasedOnCertainAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic value, Exercisable at end of year",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable at end of year",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding at end of year",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationScheduleOfOtherInformationPertainingToStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of vested stock options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (shares)",
        "periodStartLabel": "Beginning Balance (shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r1025"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/PropertyAndEquipmentNetPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r189",
      "r190",
      "r191",
      "r224",
      "r245",
      "r246",
      "r248",
      "r250",
      "r256",
      "r257",
      "r313",
      "r359",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r372",
      "r373",
      "r376",
      "r379",
      "r386",
      "r535",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r722",
      "r743",
      "r761",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1008",
      "r1035",
      "r1044"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r179",
      "r205",
      "r206",
      "r207",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r255",
      "r314",
      "r315",
      "r349",
      "r387",
      "r480",
      "r481",
      "r488",
      "r489",
      "r490",
      "r492",
      "r494",
      "r495",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r547",
      "r563",
      "r657",
      "r677",
      "r678",
      "r679",
      "r697",
      "r761"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r156",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r275",
      "r276",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r709",
      "r710",
      "r711",
      "r767",
      "r771",
      "r774",
      "r776",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r801",
      "r836",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r879",
      "r885",
      "r1090",
      "r1160",
      "r1164",
      "r1165",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r255",
      "r547",
      "r602",
      "r685",
      "r708",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r761",
      "r886"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r242",
      "r409",
      "r1009",
      "r1010",
      "r1042"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/LicenseAndAcquiredIntangiblesNetScheduleOfFiniteLivedIntangibleAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OperatingLeasesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r255",
      "r278",
      "r547",
      "r602",
      "r685",
      "r708",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r761",
      "r886"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r927",
      "r937",
      "r970"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net (shares)",
        "verboseLabel": "Stock issued during the period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99",
      "r690",
      "r761",
      "r778"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units, net (Share)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/DisclosureStockCompensationSummaryOfStockOptionActivityUnderTheCompanysPlanDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Number of stock options exercised",
        "verboseLabel": "Exercise of stock options for common stock (shares)",
        "negatedLabel": "Number of options, Exercised or released",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99",
      "r424"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99",
      "r697",
      "r761",
      "r778",
      "r892"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units, net",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r99"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options for common stock",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r99"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorised",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "srt_StockRepurchaseProgramExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramExpirationDate",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program, Expiration Date",
        "terseLabel": "Share repurchase program, expiration date",
        "documentation": "Expiration date for purchase of share under share repurchase plan, in YYYY-MM-DD format. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Aggregate share repurchased",
        "verboseLabel": "Repurchase of common stock (shares)",
        "negatedLabel": "Repurchase of common stock (shares)",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99",
      "r693",
      "r761",
      "r780"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r99",
      "r697",
      "r761",
      "r780",
      "r892"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r93",
      "r724",
      "r740",
      "r762",
      "r763",
      "r865",
      "r893",
      "r1036",
      "r1075",
      "r1143",
      "r1194"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r223",
      "r371",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r387",
      "r511",
      "r764",
      "r765",
      "r782"
     ]
    },
    "cprx_StockholdersEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "StockholdersEquityTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityPreferredStockAndCommonStockAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity [Table]",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r567"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of basis of presentation and significant accounting policies.",
        "label": "Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "SummaryOfBasisOfPresentationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Basis Of Presentation And Significant Accounting Policies [Table]",
        "label": "Summary Of Basis Of Presentation And Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Basis Of Presentation And Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ThresholdNetSalesPercentageAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ThresholdNetSalesPercentageAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold net sales percentage.",
        "label": "Threshold Net Sales Percentage [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_ThresholdNetSalesPercentageDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "ThresholdNetSalesPercentageDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold net sales percentage.",
        "label": "Threshold Net Sales Percentage [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1148"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "verboseLabel": "ACCOUNTS RECEIVABLE, NET",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r370",
      "r384",
      "r510",
      "r531",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r658",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r866",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1135",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquityShareRepurchasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "cprx_TwoThousandEighteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Stock Incentive Plan",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "verboseLabel": "Two Thousand Eighteen Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_TwoThousandTwentyShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "TwoThousandTwentyShelfRegistrationStatementMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2020ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty shelf registration statement.",
        "label": "Two Thousand Twenty Shelf Registration Statement [Member]",
        "terseLabel": "2020 Shelf Registration Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_TwoThousandTwentyThreeShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "TwoThousandTwentyThreeShelfRegistrationStatementMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/StockholdersEquity2023ShelfRegistrationStatementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Shelf Registration Statement [Member]",
        "verboseLabel": "Two Thousand Twenty Three Shelf Registration Statement [Member]",
        "terseLabel": "2023 Shelf Registration Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/CollaborativeAndLicensingArrangementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "cprx_U.s.RightsForFycompaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "U.s.RightsForFycompaMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsAcquiredParentheticalDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedToAcquiredAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Rights for FYCOMPA.",
        "label": "U.S. Rights for FYCOMPA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r842",
      "r844",
      "r854",
      "r1159"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "cprx_UpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "UpFrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front\u00a0payment.",
        "label": "Up Front Payment",
        "terseLabel": "Up front payment"
       }
      }
     },
     "auth_ref": []
    },
    "cprx_UsTreasuryBondSecuritiesCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "UsTreasuryBondSecuritiesCashEquivalentsMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/InvestmentsSummaryOfAvailableForSaleInvestmentsBySecurityTypeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Us Treasury Bond Securities Cash Equivalents [Member]",
        "label": "Us Treasury Bond Securities Cash Equivalents [Member]",
        "terseLabel": "U.S. Treasuries - Cash equivalents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "USE OF ESTIMATES",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r134",
      "r136",
      "r139",
      "r140"
     ]
    },
    "cprx_VamoroloneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://catalystpharma.com/20241231",
     "localname": "VamoroloneMember",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfAggregateAmountPaidForTheAssetsDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsSummaryOfTotalPurchasePriceAllocatedDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vamorolone member.",
        "label": "Vamorolone [Member]",
        "terseLabel": "Vamorolone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Diluted weighted average common shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r250"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://catalystpharma.com/20241231/taxonomy/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconcileBasicAndDilutiveWeightedAverageCommonSharesDetail",
      "http://catalystpharma.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Basic weighted average common shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r250"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0000950170-25-027714-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-027714-xbrl.zip
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M<L.'HP\'KV#O-N7FL!S KJG'L/"SF<R&?LU4K W":ZM18-[#5*1'6L-;-4W
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M=/9'XEKI;738( -XE\U-#I:F@*=KRF7027L<N\JU$UUNKA6^KKP]Q\+S0S2
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MH7\YTV,UYXSW%IKKRJ^),6$""I0(X%=ID=8\("F$9(EJ0? Z'I3_ISVIZFH
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M(1C$B0(]C]J < J4!L>XTYT]$KP&:\"Z&]6E'\70HLT'4/N;_8,/3Y1\3L7
M%%*&B5R/B2%+;402:RV%5TEW-SRORR>ZJ\F<LMI:$W*DK&'9)1X-LDP;%)0E
MU >#05GO&K5Z9]6ZN)1ZC>GR;G,IFI20PR#?N/<Y.8=$1*6-# O%G3)=VVVW
MQ,9<IZD:MF+N24:U6".Y=Z#EXJRB\(AS5)G"\'20>UJI@''G+*'O.3>>LM/0
M$4P%%TC[7"?/6HF,$!1IIW%DPCO,UM%&><Q0H5L?\ZXKYSCKDF6($I)='L8B
M%R,!@P0T)9]T3+9SV0D_E'6[3HK0FFZ!9'22%*/@B(8MP  \@R;(41" 1CG#
M:&=-N6O<M^=JRF!@734)>EJX:AD*[3>"OUZ=A6H2_05FXI,\3'#8,J6C1,2J
MG)UG"-+$.T18T(82%9SMY.'/HT7]]H#< _*--Q=-.6-2(9PHZ"2<>&2C2D@1
M$Y.@@9K8.?NQ#X?MJBGKN$[418L8(P9QEQ,T5"(@[3714@K*4^<TW(Y%Q3\6
MX1++5:21MQP(YZT%>U;D WMK4C*62-XYI^UZI*#^&$4Y'HEKA9&1>H^HE@%Q
ME3"R7KE<_M$:;96SM+.5B6YZ,!1"J][9P7M;AKWAMCTM1W;P-,DI69)1<Y08
M]:"+  @Y$T"8$.&]%@FTD<ZE]_7&X2/KKUYQ+Y1%1D6=:VFV/C6*!*,N,4.L
M99USGM_6EEHLZ 'ZY&)-CP7#ZMTPWBSALMO&ZU/.O@%F-8PQC5AD&)@5 [-*
M99 13+IH'%'=*T_S'?7X/'R\M::GRM73%$^!:,M$!)IIACC1 3EA<P<SXQ61
MT8.<ZAKUN@XU?4VA54%-$)YC(1").*<VY*Y '#@V8!Z#(I@[UUE=ZLY)+.':
M+):52975Q%"Y$*3/P='8T]R,*((Y3GA 41JIE:=)=)=ZG:X0OL2<%!>9TRJ'
MD@:1P%J1%EDG&)(,8P.BP@O7.7%P1?)0NZ\6]M/LD@\'AW6TS;@^.XA^7+?]
MG-9F^Z1D+=$41'/NQ4>) TF=W022FA X5D9V[L1HXFQL)[GH1;(#D *V_D?N
MJ9;5&1#BU?CC<>Y/O90CG?D1Q]4I@9DYWH]K?VP7<E-6K]TI1&ZHW5VX]#X"
MTV-@"ZUH[N[B$;>.(Q>D1+FU'2<@3D-W/:"W22P"8;@__M>X_EAVAXQBF60,
M2OO(D" YF(XG@ZR4!$6EI> D@='5N=X:G0BF>YRS?4^Y2_GXT029>Q]&CQR3
M# 5#L1':J*17ONMN)Z;(\L24IPYS"?/VG.;VG5PC[6)$4N(<\$")^%&Z5BR%
M>2F_&?->N/1^S.M!8 B*$LT. 9]3&)T!7K;&&PJ_1-8YK.D/S;IS:/9(D"L%
M8]@X!*9ERH=F/'NP!')<>",-*#JDLUQ[*]NR;8V;_5U[)Z=U]:G5?M:FBJF7
MD@>E<EG9W'1%Y?;>V$=$L/&6"QP#[VR7C&X4:B+X$?;6C5ID=XMJ=S[M64_'
MJ->&2:+!+" YTD5QC,!>  .!1Q]LLIRPS@6\=39AZI%(:)U/+%DPZ@+L,DE=
M[I7+D65@W5%IL$BZ:R1<FRX/_>'ORK@V:9:X EYUH'?)'*F0@&NU#\8ZYE/H
M;D?)%56NN1,S/N%#.P_P19D!A3R1'!]@#=)")$2]U]&1P /M7'Q 5^/95J26
MMRJ<)TC&W ,<BX",UQAYK"(CB7O1O0KTMQ8]\XJ\UT< ?"V:>NEPOZWO"5CB
MF"*GG<KEL&1N*,)1A+\8M8Y:W3FKO!L5[AZ)7H&*P+A%)$8']/(@S1DE2"B3
M I,,0*%S9L1M@"#'3,RA>F\8RDFJ2P,8 !L^-B, ]^9=^G!Z6%W0/@$_>B2X
M'V?%)# W&E&7HZ!9E,AZ&(A2H"&:B%F(G6M0L!"Y8X>^S!S3C.KQ)4WQ0S,+
M*?B]&H;SL()MVQQGK>%3/NQ>A8NN U0-1&B.@:H,"U <"-> [Q;#"Z)CUC@M
M8^?BE-<\'FN):E\@P7J:(F(^JWTD"N0,X'ZR@7H%LL!TKVE(7].J-RT7.3BF
MJ#%#-.&(N.4!:8<]@K>H:+2FQJ[<^W"[[<LO!H7<:_M2+[#'$B7M"%AM#L/V
M%0X1R07G6B?3W9;C?<[Q]XD;@P![*<@<A^F]1T8$$*_18*4MEX%V-G"K<P[]
MQSF2#B(Q%[+U1&G*>3$:&6D24F#])BW ^@WK3L+'\'LM,50I %(:@S$R;:\T
MHB32'"P3["@)3HEDY;I[)A^TW^D2@YV#PE(1!J+<"9#LIJV.ZPG(NNBL(["M
MNI=4MG1/Q#K['%;%%MJIY!T\+N0=2W-N/ A(&:GF1MFD3><\U>O>Q>:1%"!-
MK*3"H$1%3H'6^8@1Q+-/1G+*G=>Z#R/MLFEFC!$)C!TKI,W=W2+0S\/3E7+1
M!4-,Z&2SE&^X_I^R?S:8*(.U B43<VZ>,4CG.!2AA2!@8RN".]>,;PV-R4<B
MKA4>BYR (*0'+&4@-3D-B">GM,11&BJ[2MS.Z+E=D(F.8V:40%$JH%X@%MDD
M*/(><VN,<[9[I61NHQ2OMIIBGXV_;%CQ AL?<AH:X2 S","*(!I)'3C8Z8KZ
M[C:[6H<SO4=R6T5B=>Y&0TP.):8N(J,D0<1A*QA5/)+.Q:&N3_O(9=K"R4<I
M)4;,,=A^,CADV@1?RC".T>=R"UTCU).K(-RA4KU+%<67SD[O<$2ZGC(M$NEH
M;IG+F<J-/D%ISNEC*.2*PMR#NF4[6WRQDPGSCT1&SGTBM TW B'&<J$@3Q/R
M/#++E&#2KG4@VVQ[GM>L6@AK./Q<]37S.LZ?PA$A$D9)Y21Y81FR1!"D'4D1
MQ^"EZYQWK$O'NZLY#XPB6,*#0"QXH H8V#E<62/'M(N449YL9U7?;J>^+^TH
MJ].I[X_C%8J:!T:P1,3GHGA4I!QN#P+/:<843QBGSJHL76XDV@%;/#H*"@SH
MH!QP"'';1DU;@UB2P@8EI:>=R[SNYB'8K>@'ERZ+?H8H27+3[WQ<;<%8U\I+
M% GCN35)D**SIRH=#@&B2Q3Y@4J2:Q0EJL%0X)$CC:-'WN7:["(QK#KG1.E+
MW%VD8!O$E<,#<M?![!!S6CODE!/,6".$[YRIM^XA(8\D#://BHX%Q@%R<]5V
MX^8)$9Z"T=PZW]W&&#<ZH[[:B3@]FGZ:NFO"H,=$A[!P 7'B"+*&4Y0"%B%X
MBKGK7 K*7/)]MG7XVOC8.3D=5&<QMI;ON]/14_64)NQ8<HH@D3 8RT%3I 4&
M-@H8"ZP,)K*SIW\K\91^]^T_V/%PPEXHSCT*)*E<]\'F$%YXNC1$ %8'MOKD
MG#NI5K=M"#FO+/!UAMGMFT OP[[JPQGNQ*^,>1EM0M8I#H"638%),Q,'O,HI
M9;9SQ0JZ7/I\B9FJB0D:C)((QZ1S9_&<#>4T/-V \L=C3+ZSI'G$'EH=:@#Y
M2%M:4@6\HQ%)(2$N&$56,XN\BI*X& 2EG0TB[[S%\#A&8%)*4>T$HD$!%% P
M ETR%D6M.).$.F%6KG;>#@<% JWXO#;SO7#0<L>X5$@JYD"E"A9I0Q2*3FN&
M34J6=,[7T<%C[5Z%6A7>6NULRF>G!K1];J5'SAJ-L*%.Q\ALZ&[23K</4'__
M(0Y0'TFD6!-Y=!@IAE.N(B&0R<5S52),.$$9HT\"57^@.B@="LM<4R3W3'EI
M%9C *1?M3(#D2DAD-/7,N0C;I7.I)JN+5NN+3:X%RR8K#,6("2QSUQT)EH$W
M* 7J,('?:/=@?'4'@?L?_N^'_;_L/<E3HY2[85D;D4PQ@*X))I;A5"$JG9:2
M&P'DZ2JEN]!&XG'V)R;8>N44F,,>U*R$';(Y\H(F$125C!'1V;.^I<>\WDB8
M'1S;.N['TVD<Q_NZ^EC;DP6.:2]X?_'G%0?;8K8DGRZF O/D.%(FXARWH6$3
M:XFT=XQ@+P/&G3L>ZK9/=S]^S#&250T*?,YUGQ>2>9)6&Z ()YS FU764*4'
M<<\-<*=DG#,9/#-=%O==S#Y=S>%-;OMGM)5(^ERGT!&#0$QSH)8&LYLRZF1G
M<7^- K161#R>HU891E[DOFI8*N2D#J!Y!2\(*%O,=B[*8PVREI9O<=XIV&!-
M%4FN'196("V)!T4R 98(#D]WRC-BK!"QLW& '8ZJ7F)J.I;YX-5I%+RC()MS
MP1DL' J<J'STRFCH7!?YM>EE]8.[>;!.TN7C?!SR&2B()V0I"\C11#37BJ70
MV9R86W7ZW!W7H'R,Z]CZ$+_DO]:F?"<V7@J;-/+$&01:7D"&P=.M4XHK$9+L
M7J6B;E><>B0CRRFF;,!(N)!KC&O0W0/A* 4 <0R_Q.[5,.Z0Y^0"!5O?R<TH
M>,G-<C\*FAAD5$@;E2LA1 ;6EP%C3%#,C1<IJ97#Y9H(%I>#PG0^\M*YXFAN
M9>AS!?:07&(I1L,Z5W)X'9N9=.   0=,@M TTU:!!1$"LDHI%&4@S@GC.>L<
MK-VED-[Y.60G%= ;0?D/%#Z%<T!JXAFA/0:M20MD9 +AJP*Q$K#(J\X:MM=D
M0^W'9E27?A1#>RKR 6"JV3_XL"[N+T(4D1K,5]=&F_J4&^()CH(13+$0F4V=
M]5T>C%U3AM+69SE@[5UJ"; 8 CYV\(1W*<%Z##\^R(8R-]M0%RZ]SX8B%$?.
MB4*2Y2-'ZP2R.4LX)FO!4,3,LLZ5V?G.(<^Y?[D-4YJ&(3Y)."1<)NM<1!&3
M7),:_J.Q<TAJH@1E1"2[[D;DHQ0V64TE!6)"8-KSW.;5(6Z21S8HT;8M$H8Y
MC=<N1^>^G<#ON>V - 0C*F^P[2Y?>J]MYZ453D=D:$ZVBD+DDJ(,!<EQ3"Y:
M+=>]:,E#U29;YO8*@'J8$21,3K<VBB.MP43%DGOX/E++.Q<N,8E@/P^& !/A
MBJHE\S"%]_9L&5$2W0[2^#$2[T@,BEF7D#$N6S*)()O+J*H  MU9P['OK).^
MDV54Q<UKZXCEU=:A)(CHB4$J@E7*I8A@"%D0-(F[0$ H\.ZZ\9=JD-[XK?ED
MYZT]6=SQAY^KP^-JW-AAV,EI#C%.),]>FUL#X)/O>9(H0$GTV4Q&09M\"D08
M,BD0Y!,AWHL8*.F<S%J/H[HENC@HM9$*IY!RQB/N><[9<P$1SK#!3+-H.V<C
MWXE(KZ-M8G::[H&-57UJ\?O>=4GO'&O4F:-:RJ/C1C(D;&XJDR)&-L:() L>
M3&RG>'?#LE>$MC=^_\3*V(/EA T_VFN:,=CQ=?[7ND&\,K/R@2R/93*(%(SG
MQA**9:^T3V!Y6$=S1(]11FN?5.>">1YR6W;@/(O*1)WF'+&(0=!*PY'5U"-I
M"05PEQ24M:Z1J,]@[28'/Y*J:$6P.4*!.4D09\XC+5A$"AMA&*.:X<YI(1-[
MOIWD8L9^CLX/MOY'M#6LD5Q*)'!?[77&)RZ!+2%X3NW,38_ N+"2)B2HP3KF
M1++468MTC9(\5Z1)A CJ@E((FUP36^7R-3P1I+1P)&(LM5LY\1[-@4MA@B;S
M:YXHX@&GW+J:(1^95C(HK6UGPXNVX FA'(RS_GR>C[3SQ0_&(8;=NCK)GO;Q
MJ/7QODNSD$C QC;.[O>SJQ^PP.F30JG-836#L94JRET0>)%K3MIH,RIRM4&#
M-$T8>>TBIAZ,,;...<RK4(7NE L3A]=JB4M2#'^PX"0:01\CS"*3"^H!PP:D
M=4X'$X0*&DGJ8*7\3KOT'TF!BL)$X0PB0K4Q9AII(C"BE*@4<0#EJG,G,S]2
M5=[U! >&!25<>$2L=8A3+9'E3B/G3&0Q$4^[UV_O(9O&WF4P3[&0+Z/4AX %
M8FV50)HC7!,WB%JNA%>4>=S9"-=NY@4]TGYG023% T@1KC(=08IP85#4QGMM
MO2*Z<^Z:KJ;@=H&< -W&$H&FJ2]$@C'BX3\.2\'!;E7=+7W>L9"O);I+F$C8
M&:61=#PA;G+U:FH(LE8%3*)TN'O)=X]<YNJBU%J,B+P7(208.5$FI'2*8/IP
MAS0V',4D!.9>$-S=IM"Y: RHOI=JQUS<&V^ %F=O;/U''.V"5KRT9IT/H5EU
M9[<J+ZD#GO.*<3"L)$$NIER5(DJ<C(']V]FPV?WXL6RF97ZG49@+QC*HHE=:
MS@M'[9-3M]:N.CB.@[3XP#E /\D4$^9Y")%ZY"EODQ1 $PK1(V4P5P$@FIG.
ME;SN8HK)X^2WL\"(-C(@;7/I9TQ@TV)0@4)2R0='O5]O;\AN51\ H $5;5NU
M_'?;M"Z/2<#UTH#^1_5Z@"; %=?(4#U-4+*6R=R]SBO+N!&^8^=9RY1W44E/
M&$:8:9F+L!)D;/Y((M,A1:)$Y\*"UJ?^WC()E11.@8#VFMUR'.PY9(*VR(%Z
MXI6G5G:O#]NCG:T\CACBW%BG/45&>Y-+3R1D)(]("6]9HE)+MN[V]^.W<'\<
M&<$%=9HJ $>2:U6SF)"6BB%'I?3<46.ZVQ+EQVW:L%0E[%+TXAV"%->4]27H
M/S@DL(-)[JTN! @>[T!'2M10E5*4G?5?=?+$F-W\Q)@M[\28YY MG@OVBD00
MM]DO3++#GYF4*.&>JJ<7<O?8=9$>20]Q5(/M8N%Q.N4 /8ER5C]*&AM+),5
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M1$&0S 63.0T&V9A;I086N?)"J^[MN[N$EI]' UY,*^Q#!)?"19KPB'U$B9N
M.,$!61UR7I,0S">+<>SLT?$:^3A6$PRBC#+,Y<IP0>3:X:!Y.I$3&:FP&@P)
M$T/GCB(>M<+R*MK)W 73#N/PVE29IYPGK2QAPN@<LQ2S.6,9<E[GNFN4,BLQ
M%[2S&GU7'>,W;=7"E]>J104+YJBTR N? 'R21,[R7#O7"!TE#DIU3F?L4KS1
M\@1 Y,FIJ)&6%J0 =PQIRS7R)(%%IA(FNK/2NXMI7TLLN*- ]AH)=I7!'NPJ
MT*20)L8CAF,@5#LPE#MWNMB'?7<G[/N1!'32/KGH$/<N=XB48 Z(*!%\8M1C
MIY3J;,90G^?^D,Z(,=A>+=-\.#H=U^=5J$_:_,OXV_09\.?L ;-?9I_S$ZYX
MVL%DYE\]L%W-Z8^W?&3SW^GKYXU']6;^X;;/RG%QS373G?QXRR?^9S7Z>ODF
M"@G\<LN'?3AX]=6SRJ;BE*A-^.VV3\L&=F@E=0-;"V"P]/95WDAUTP8(SM\5
MRD^PAQ<?\78,E]M15=]Q.%_=G[]\%8?523F\ZK$WI<"%1[RX./IOK\;V<3JX
M2/T[S'K[K[N=GG7Y9;..@U;*-<?E:3$HAW_L5X.+:)YOV*CJCR\HQNP%Z,SQ
M1;[N66%K7W_[XND5+Y+U(Y2J:C3,[%^,JOV8FE^?[;X]/&("?C1,@&41<,X]
MDLAZ&Q'E+$@LB?6!/RM279U,[SE2.EHI<V%08SWHP7"OTS*AZ#2SR:5\%%_L
M'FFO3 [M0C(9@CC)AZY,Y<S\R(U/."1MX3*.#4X1M+:$\XF&#@:Y7'_?$XL-
M(<E@DB^C4C)"@H3+!(Q56-#UA!,H>,<M"7!5C'!9)#'0I.E$,^<T1603#%4K
M&H0FC H=X#(%IE2T1"/J=9SVK3 $(-IB4/%QTHKX9R\Z01]8-QNBP<C'W+ZQ
MC865,3?^#@QFP84BY")]@O*,!H51;C^=TX\E,I%J1 3HR!962BN?E\HG&V@4
MB&2:<T(,,MQP9$ CX0(4Z7R4U(TU" ;F+3$0B3E@):. H#&WM!#:24M=]#Y>
M7 .MB10&;#6)N4)<6> [Z?*12X);C+-"T8Y,#@.G)P=$\C8')\#F0<YHB6"X
M'N=2(TS0BY-+L.>DPA0Y:_,=@B''(T>*2>^EH%Y1V>ZLB#7V!K7!5IQ&!@3&
M ID$CQ0N]VC)EWG%#,,Y1[8]DV)!@14E/ HR,FU8"I%WA0\HS)H1"W:WSX6A
M#,Y#!=30!!NI&(^8VXM+91P!]@;#D$>6^]QJX&]#+4K4Y+:H,JF0]P)77((V
MSC+T 0@2 R DI$'8"@(+(#W#'"X+*6', \M5(^"1P4OD JCNE.B<Y6\M8;8C
M2X6)(3@$@9*)0/S@''*1&0!"CG4D1"A\&38LM5*;G.P8<Y]8G5L"PVJ8H)W(
M*:A)N8Y,3FD2:0S HSJ+(6\!#V@*L N ';CDTK)+?. =IC9W=(DXT6QJ 8K2
M?/ *:&@ *C 170%\"[LWYOZ-/BC3%GC.K9D=$H$QDA+(0'L)["07V065VV):
MD(T8[$B3A1Y@'0@Z+P%25)[<BW9V336N?6PF'X\C")>LI(!Z\MN_%<4O^=]?
M3HMF=);GD< ,04WYK[A)\.GHY8FM/Y9#-*I.-_'+]K=D3\K!V>8A6&A-\39^
M+O:K$SN<7>BJ$9CS<&VV99 =E!^'FX.81B]!I[/%<1W3K\_^-*K\T:G]F+7;
MYM0.9Z_VU:"J-_\$-,,IO?Q\#+HQ@M]]W#RM(_I<V]/)"#['?,2PZ:I!F+PF
M1%]-' >@9,'D@#2Q:*I!&5Z&LCD=V+/-<IB_1&Y0^3]>7IKCMZ;5_O9';'UC
MF\-J&%^"EH<^EV%TO)G*$6JMMF&>WJ%U@UA4J=B>? 7J8IX<++2%_YU>7/#9
ME/^%2ACPETW$VN<>3V:&-T0Y?'E:33RH4_;\%/,:SA\R)]BI#0$&-UMY,IO0
M$F@(UCRLYNPSW:#B=%2$:@P37:1O]MO$^N4E:EY/OW9D=&D+_Q]_(A*_G*_V
MZ<7E60$_]_.]M%LQON%N71@<7]IZ?'B[=[CSJC@XW#K<.9@M2R='6O1$FRW%
MP<[VA_V]P[V=@V+K[:MBY[^V_[KU]B\[Q?:[-V_V#@[VWKWM*;E*2BY/[OW=
M@MHT_#BJAL^+5QO;&P7%@IL54&]Y0[Z6>E,J9(5ED^-_?_E@LA5OJ"Q;)SK+
M]-*Z784\C'61/9>7;UEKM;8+LBYHL#Q@W'VW_Z:X:O/?XFW/6J,,7M,Z:TO?
MNH?!H!-6)@)&CA(D'Z!YCQQ+*1_[)AM,XD: ?3L]1MG/AL;V$78F!AD5TB9;
M5BPRY+212 J*N?$B)07W#&T^30NQW'Q5^7$^ ,EG75U=8H+1W^8,=V&A?EM/
MF=FC;H^Z'4?=F0MC>1M++VTQ_M]<9JUX-XS_W_*W__)&^9 :\U74>ES>'+7.
MH2LVK!V/JADJY<'EQ\-<\N5H8,^J\?22R9L(QANP$:?7^WQ0?-K$S2:>VMJ.
MXL4MV][W++\>WE_/7OZI;$I7#LK1V>;L_NE%<%68KU;[.IY?]24O4![6=(JP
MXE]>/GMQS2U&?N^>7UZ,ZLN#FOJ]6@;X#)-#KH[VC\WVORA_<37C?DWRRX.:
MB9*6G38P*8<O/\6Z;=@[O1%^N2QP<':^3;^JIPZY]M9GJ_637@35JY6@H"2V
MFF0??8XBBCG"-R:*=)(D)$6=IFQ92M#6<#BV@_UX6M6C9T6JZA,[^O59">-M
MH@>DJ ;.#@;5"(A[1VB\X88RBLN7WU%Y6@_K*'2" \AWP.3AU/L;+?#6V[<?
MMEX7^SOOW^T?%N\_[!]\V'I[6!R^*PYVM@_WWKTM""O>[1=$_!1^+M[M%H=_
MW2D6'#ASY\W6]F'^F1C&KR++;.?#OQG?;BH&O@?-:R4(ULTT7)X"L%O5Q>@X
M%KME WNO^$>T=;$S##%\QUS\W@BNL1:Q%#8H9I"*.A< X !_'*Q%IHW7+EE!
MB%@64+YO(_EV)O%]%Y!R,\ WZ 3><IQO0\&>H3.8.8K#9TN>L.8XYR7EH!R?
M@SN4199(@F3T.F@=6.#XOA/>'M=U3K]H29@I>-,Y?S7=KG#EJ^@G$:<Y3O.!
M;.KEC?[Y:O:.)]JGS$HAIK8$GT.:.H."B1$[[+4F85E[YYR7=N&;IJ-LDJ/
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M/S48<D?C81T!(3[%<-2,;$I'.0XV^W([A4D?YJ/,I]TI>YPGH^P!ZMX,+GJ
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M*R6IHI=M./:MT @C9XA5+"9AL(7+8@SIK_ BGVM-Y$DF^=EK\IJFZ^C@U7,
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M6K4_S1UU_' 0>EOE9:);_?":9_%I.2]8:NX7KA%C6 P6HY<;/4,45NY&B?;
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M4(K'1[MK%H9#EOX@IX\.1)O.+X(; 5;;,AP*B"HAHD/D758MFHB0]*;W@PI
M:3_%0'QG">W0V/9^'$YFW+<"N QXP2<=5-_XO2CYRRUZAUB3-Q>M-\L.('[*
M6E&4VZSQ#_?FN %_XP;<9H9CY57MZL2O8=YZ%;"DY 1G"XJ79?VY#W#5Z[8*
M?F?65PQVA28T\I1CZ?R > F[AM:A1<NL/')O&RUG'IBE+&6N\X9- "WKL85@
M;]R-][H-/3=#3O8D3YWU^>K<%?FY-9E5V!R0_ZM3_U=D3?FKZL:BZ9%+D[/A
M':L-%VCK=32?*=7BI"R9IA/9([WBSAO$6WH/AE=M,O04#2^KEQ129&P'9#>]
M(<;'L27,A&_ @NXH3#/S,LN=OE+/:4NM6LV]WO%P,W1UY*ZAB; Z^3=T_T-M
MT@YJQPU/LK'GX8<'<72*LO.!(LUI\9"#M]QXO!F]_F/_9L#N@0MJ3\/!9-?-
M+MW-MA^!3#\FS-*YG.P;=)%_"-[SOIX?YE+WNGO./O"-/]A\W]\:8)Z<_87U
MX[AXU;[,S"W:M,)T+$$3T([[Z:>S(@?Y#!P_2:R8%S]%F+P4.15R-3TNQ70,
MVQJ8AVYE1@?]S+K(&#:A?B299TX/8\@[BA4H.8AT8#A>'>AXGNTO8/RQD1V^
M@99%$[T6T1XCLK?<X1;1'*?2=!UD6?0[(\)\;UT:$0C',9B):QM(KXJNR7F4
M5MVD 'B"3O\8=.?3;%+Q->JJ0)SH*#);634! _EX]/R.P>R40Q/.GMIKNWK?
M3D1H/$TI&?ZSD]-+_/>Y]"K_!WE W])XT)-]H+_CGQA(<!E'#\X/'AQ^<W5Z
M=71U]N!PZ[W4XY.;"<M:>,?GB)8EB:_'YC_(%)1B%)R->='KIG^BS7D'_SCF
MC_@_XT]\L6_I?[\Y/3T].CU]),4"=Z.'DKCH)DR!XPH=4#KJL<IN B/OF.27
M:O+@[PH20#N]D#R@J^:NUO(0IB_&(?BBNM&,_\-8!V85BWF=E*V1]?_&P3"0
M,:57,':6[YT-?=DK]#RR.&RC^,8:>UA/?1T8E=QB\BS::$P>L>.0W;XT K"+
MK[;9,HFC)G^GT00BH+E$3YS;.(Y\VJ^2M7Q^8CKGNX>OK>&.5\.-?YF\8T<O
M3< [9K)26YZ#5W*CA(S#$4<,\&."*= L<(OVQ8/HK1+W"+LD/3-#YN=W[-^_
MZ)K\2#?G)Y-+?%4U[9'STEZW';A'_J)S]6%4ZTV/9S/9=&#O<GK]3G&"E)WQ
MAG!VE[TJF67:<&_<2<VGRL!WZJG'<; E?;LTE$6V8M8785BRW(_F!*I&L_K]
M#(>HV OY:8HPC 5?3/"^_SR&*94P+V',FJ-EY4BW!$5&X08RZ\JIL;0XCP /
M!1W4K :A!I!J\OLI'=1Y6<U!0@D OTC';:9D'#4\N.NX6/!=A9YG=&AS88&Q
M1EFKX; _\#4XQ7N0=!IXJK0M7>@#P1[?6JY5+G(<?0]KI%T,_A/L3 AA%A)7
M60/)#/%N$A0RA(&.[DY>$P7/H4"IO'FNV@F?$'D]ZW_W&$;$!+JPF";AU-CC
MD2APEQ=8E:DQXF*3O&9X54M_RGI5OJ' JRNQY-MSEL-%WMRQRC>LZW21%VD-
M?D!@.'"^6(J*6U1:O"=')!!O8A #-<$D.  :H=YW2^/7CB[&E ;5.UDUW/)1
M5VD('!N;';[,9H?3D[';8>QV&+L=[GVWP\>F*J$,)U0JY"[\3"?\*Y4('].-
M>^MJ_^+4##/IE'@[E.T)2-F8TP#5#/@X6\AJ!IQ*=&&XE^ DVT)XSDV<3ZK;
M<@*FG!=KZ#LNX:BKYP*<3L/8S0I>0X5&UBP5_4&WRKK&"]&'D!G .N'E3$V1
MWJJ)'C6V@0WCJJT#K1D"INK-#R@LZ5,C_.-W8%4K]?_[%%=])D]'B=DHD(.3
M#DJ#)?1;!F-*.#T>:7^5Y4882BPRFUSZ"JFA^'[]UR^%N1U+[MF+)XV5X)C4
MREST[3"#@-6/H<X6AP"*!>28DE4))LL65^IXJG"7ZU?/-B& PL'%,IM@ZW*[
M4L5$DUJIQF85LP[:C@U19IN:KF/2<G\/U-<HW<9(J9L4&[WI)X9EH]<XGJM?
M;/..?ZD;B9]Q1^Z);]1KZ=.&WB+IRBG23F,=]0^"@/X2)J(:M (/:;:##SNY
M\&B69T5Z-&$.83KQIIQUS>H<8K%<\O3Z6G$TU<[B/I\^LXB$-*0.?\:IRD9L
M;LAFB?1HCT;XXD0&@OQJ@ZQ>$9+T*VSNIVPN9^[U=%IUY"T\9W+WNF'55SP/
MDQC# RGR)&\LN6ATG'!W!26DA.M-5PO[>7)CO4V-X$*B@U?ZI6MQBW[4"QYZ
MU)_J#FQ.('A:8/:,&[.9\FSZ09GKM<B*%9X/,"C+B]N7D+/M2N0&DPG<,[Y(
MRX*X7CH,$SR5A>)Q*L.,Z8!+59Q]X'5EKL6'65;6Y TU'$FEGIW$M)Q[E*-N
MZ"QYT"*Q+Y4ZD3AO')3K])*_JSRA[JM+A T"R5+._:37/B?7E]EM=C"7]B']
M&U%7X-"!V?6(F5WU+G>2]WM268V_F(H^D^5KSJ>U)$S6T8KE,_)$7VC30?Q#
MX6.T:;7JDM?>07=J%>Y=W>;-PD]Z$E#+VB#RYJ]:[ONPN%HC4'=>7/_]^OE/
M3QTM0X#)0&T7J]OX<[EJ,A3,=FP/F]L6K[9W=>-48$!&QE2] HME/L 4FY_+
M3F26IO3FIJP4PM'MBK;HD%YB\X9,9H$B&O9Y$_.B(>,+XN<")!333HG=I<EE
MIZ,C=>\/_G+O&56)0*4=&##)J@1:ZE,B<[Y<_V(\7;QJ+0*"8<39,6TEVI=*
ME%A]] E8FRWFY7V3@?TE,Y[WD-C_(B]">V?P*N[WUI!8M?%(1J7N=G'-EJ5B
M![]!J2,ZYQ:H(]B&DM8H.1AD&[D"F9V-:@N/=UU$!3UH1.@XH0OJYKK[LK$>
M@]P] B'*+D\34:SW*/&P_SD58#^?.+F5?VO:C,NLU#2&%)FY]@MIS!4W?S-^
M@_9T*P>-(DR:8.9L*I'[\)[2#733Y$B:T^]6F%U/;*K*3^ #E49SEACW8G77
M9753_?3NT!K*<N<=N;P'[DFS*"<(L[NL^JRESJ_B4ZB@9SZJI)/7"-<C=<.T
M34MJR:B>.,H]KX_VW3H2D;:M0^=]!T749!WKPE(AJJA-FK?LY*C;I-,EU.D1
M4Z>K8TC?GR6UMR)2<K6S'L*C+I_D>%GDS.SYD^94A'?P_A&-5#G%QR3,OMBF
M9Z7+D<5WF0F\53AC6/9X^7PVU!GY5W6>SLT;=M@"YTF)TBM^GYONF4\Z]A)S
M7CQ@+>G.).<5*U"%*<3NX1%:B[V"2,BWU";-,N[?F5R])K-D*3\!N[ZE:DQ!
MXX@<\Z2;UHPE&4 =^D)M>NJBO16Q"%Q;($YVS9?YH+GJ+QF/$PUD!<5>-X,N
M=O$!CY:0 I4B=&HTF@4]XC93GOC!C+?\N.;UTX;C@;("B\%DE,O?_L*FK,X:
M<P0&!U"0GG6='3[)6DVDH\->B[&!LA>]AK($79@6,=QH3*1:!!?*C19@7RR
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MU46B@Y]?OWKS\E :D,#G*)]]41U'IR?QU:/S^.&C\^@ UU(H'GZ6YSWLGS=
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MHNFN7GC_&\QKVW3-2G=^",\$&;R8&O1XO ,1D#+U!M1_UFZ%BJJ)Q3-]W08
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MSP+RW=25UN/0SB3O!YG>AB<T6O$6/D!K6U6B^'!Z/BK1C3$LOXDLORKJ85E
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MS(:JK W#>M.T;W']V%>%;M7)ITD3;>FY:[G0-MNV7#2T"5>T)NXTNZR*;EU
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MG<W&G(2^ )9D5F,YE[?]%75=2/9((1I(DF <SB/*^FB6K):6])JA@#RZ+2S
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MK:MU[1(P3Z"TN@V]8PNMFQ3GU2>%<" *P2K$=^BR0AN?/D#.(\I)O[FH\RG
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M;&.44YAU(*H/)6.:0@FUPN #(BLCQ"@Y3A@:DH179'*CO6OG[Q#8<H=\_B=
M]L<&R+X_ ;(G0/8$R)X V1^R#A^$KN4J4HEXD*WPX.$)61EJ.(_:!]SIM"0
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MG8LV/7C393U'$P\G.*-H6Z>C>[B!-:$.C%JFO)YZ&7\,2C@ZYMIOR&I(1S9
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M0$7$ AN3'3U]]93,IM#N[IC79-XTN%\*B>MS8JP*-Y0U%$BNJ3U&1F0/VCL
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M,^^.3V>S!.PE/J.<D45OMLH.#3A)-N6"F;N*>O>L@U5N["IX,#&_5=D)Z8G
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M^T1D$)B&,+73;'?F^\M5C%C9H\],@S*ZE8DK_U<KG[P$DRJ0QBMTFM&Q;0N
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M>!36_?;;-\?DM[]Z0\8,>)$[#@ECA+MGX/,*:L?L1^*%2C[I)Q!-E+D$1L+
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MFO$2:R<ZK8GS*AI-A*-[=[;UOBS3IT9^H2=%6X@Y(LK>S1UG3'VI8\CVZ=M
M6T> 4*PY#VTV L(W:^"HWB%O"XFA5?DQM042_ICWBH3RR.BSM5)U(>6#>V](
M6:1!T;*^SDR8YV0KS.6FESK-7@PM[B*DI#:PT0S>TZ\"= TH;2T(3>T)Z0%H
M%SXSLKGI:OHC6$D_:#6$JNYI(64YKYA=#^?ACV(=_?2V\-=^^9^< DSY 'J@
MCY0L@DB+?EH.%6X@1*:T_K1B<BL^Y0AP=8.VZ96#&@-1->1TXSS[,&SCH9=N
M3=I25G&=]!>8LUNF(L17%@TSBY$*8E<6=CLT9\^U_DI[K!ZOU%WF^!9XX:Z=
M1RP]+>A+VZY7]@"T@04D%!7 >A^QG[O-8%QO*EIR1; V?+.@O%:[,URUC71L
MT@[M2M0$QXO>F,F4P"<N 7^NX&T;O7W(JE=PK'GMN3Y7EZ=:ICUGOQ^ #F&-
M;YA8 &?7FZK9.DFS&^M=S7!6N;-Z:_U9NTK> I<HVNEH])&9$>@C)?MG-ZM&
MK@%\9*&7+K\!\T=;T92RC?)ER5%H??_"PK,<W(1;K)P)I=0VD-0:&B<NJVFY
M^_'"S617.<P\7PGQ>>T&,&EWN%2$&I-_8Q4%)E6R:JN&A1>^G8*"V$%:(3ZM
M50,%MRHBI[Z56='IJ,577,J]I&%3>=/I:CD4O?1]3?[,K!7>O_M,_/<PS[XA
M>_0J>SUT7</<?]+?P4S/OU_F ,EQ;D)NHE!ZCI+<5>EV__ ]&IQ,?<X.V=]]
MKEH/T>IE64U>[N$>VPNV"OS)18V$G-P;=.]>9&>/S\(EEF=GYU]JHX<U:W($
MR-"W("3,8E)F^OS9OH^_Y@YXST:?M3 C&KWM^]8W_*V+$>WS3PI\%C_/*HZ4
ML@(M(+77$N@F3T(_I(H[UO&-1)<L[1?:Q?%E)*;$[2_%/)P,=,&'P@4OK9NN
M#=9<6,L]7&(SD@>M< L!.TS=;"P,)9@6FMRJW(191 _@RSO,'32G33/561RP
M(GP:69*\?U^K,3EIQ(/5B-_+T0_[MEF55=,U&_(XRJ3FELO$ZT64U[/R/_X^
M6*?%?6*6C)+LGOFJAF6\W==@JJP7M! M>*,!4+JQ431[QGX4ZPR#930[$[48
M%J,8E.(&_+&.P>_K (J7B)STJK6WN?%-9J3]G)4)9/#PDC=:E^^XC',LW.(?
MY=XY"KE-Y=./ROP1F$S4FWA0Z?MHPQV-<1FU\DD\%\0'$>'B5$YNH4;REY@2
M@E-:33V8 ]+US?PM^8D\/*T56N;P<_W<_!H:!9QY4=V&UJ7A-"V[WA4<(N87
MQ\#7)?M=ZB'._5U T\_)^5[*8EP\TXO/$P#(K5=D#^Z=';T]9G8";>^#]F?2
M'567J!6XB7;92GH!='[^TV5PN)<!Y.PGLC!(,DDLOVG(;)FN@8.]!B+C##P4
M=)9)T=SX[0.#8UN*YM;F7=TP!QVWA<^@ Y#D+:0-0<4Z-+0O!)V"[_V*W(I1
M(!1BAKKZNFR;6ML?:V%3:FWV3'+//)<MD(A*@7)5*XOW'%T]D&M&U4;O RSS
M>=,N0O]0:&)T%*=7009#&JG_%$?E>*J.<2+-TG'<A=YZ9Y8&6.0&\^S?8VCH
MX4[ZW;1%UPGB#V",5KH V.4Q(_L<^9M#5F!30<E'5E!R_]Y44#(5E$P%)5-!
MR8>L@WIJ45HIE'5W[AT<BW")B>%>,Y/N6ECJ8%]%42GV@!2^'U)3VV#/JZ$0
M+MI0&L]7YXHCWVU@8XVP]ALZC S^PQT.8F[AKN0<$T^=%Q&7/TK'I8_]NSR3
M"Y<C6O1K^JWK5S4-!(.!?17/H+;-[9T;Y)YZ#=)=.08A6'==H^7F)%4KM@%W
M0>6^;?@-ELH#6^EWUR#5Y;TN^J%#"4++N6?[MR!<HU\H8#^TBQ_82^L]I4UJ
MO(@_M_:9[*QWQ5K*$Q+C"4FUN=IB[ITTL5?R,60HLA5)2M?S HFW)]XLFU+(
MKX*LA_L,CX3F-+N@K0O/$K+G!?OT3(6&'O","AHZ4J!=YT?B.>)ILL.Q=TQR
M5R]F3?/6*MS)E)P!CF-LZQGG TD U+L&9&33,@73S*'38--ZZ&9P_EN!]* *
MRE4;[C7#YIDU)\ZU'"HWYWG#6]%O-_P&>ZRX<#YD'\CF:8>R%ZMO5;:<.M1L
MI%9'M6+WYJ.T*\]V<0T[U;KX>2R0H'U4^$A$(G>?I/9M656:Q8XSISOG1$0Y
MU_,"$;:S\*F2E?_R*"9ZM,W#-C^OKWX%H,CDP?[6'NRRF0^,/G=^P_9F%KH8
M[U'8QQ>IO_O6;?>YNEICE7J_535SRIT\BO(EG>[531;S.:M(P1EK"QJ.,W)#
ML>DT;WR$>26ON'WAP+?!<NEQ 0QZ\-H^\(A6$VWW 2N7;S5H_!/)3&T"](;9
M_B?=<K"Z!0A8"_=+:X;<GWS>Q9WT:"F%1F2(P ;V$2U.,U][%5#6UZXSUD0N
M <$SRWI@XVG1D!/*QK4E+78SI*,Z*0EQB6IB\^L:F8)^*Y2EAGTBL[-R[X3\
M5].L9 DQ/WD*^I*7"Z@O+<<+^0/)5Z-"-.4=5XO5+M#.H>R)C>PF>@$0-O)R
M;%PA7)FT 3R=N>Q*QA9:4CJJ=2W(;!<WZ.R!R!L'YZPO+#ZG<$!='3+9:DYL
MXY5.6%5/-L].YA:V[M.A IKZ$UV<GX,X3:+7:*FA(+X -)S+6H5 ,*P/L=AQ
M)*Y$X,G@KVG:K02G#009>5=\P,4]&YUO6!\S@#L$Y@$4); B%?R)+O&IQ(_*
MX^>NAW[@5J?\$)I'4SGA]A9S08"FL/[9<WFJ;MK7-N33R$U[+FY:YR2;":YD
M\\=;MS3PIY"S71?5H+K)E$'HIRG4:U?L\UOA0X5D0&>.)1]XJR G/R[T2,':
MV&,E,:Q9!%APVB6B(8^*U&;36H\(_@(7:2+"$%8.@\4HE[O"&Z%S6!T\5/2.
M[=N2^WS1>[)#'9& ?@P'YS<'KE]X8H*7H67!!+4_8,7'@/2(*1&I+4 ?I'.5
M1+ZL,!='Z,;-NK(7N^1"L BOI?D,??8%CM+9O9/_S+/_\E6SKZW_6OC[?^5T
M[4AY^/BOCT_^4TD>JPR)Q84T3O'LBM;-#;S$C0#!0=O>U#1]G$N$$"54)@S.
M6AL&[0,("IISDV9B9+=TXBHKN('L,K;PM&KIKJ5.WQLQ8XQZ\OD[6ICZ"M29
M:X.B'[UY_O185.I+I(; 9D@.(&*%>-XOE/[W92E^$WFXN;DYG6MQ@H!W3DE?
M'Y)O*:5I^F\6ST@FI6(LI_^A?5]Q:^B2*387 "0N!.^3"^'0!@LKX56ZT+0X
MG N/N:A+Q.P/4NY9N?C__@_(D/[GK/B?MNS>_@]*WIJV.U2U_Y+FBOOWWMF3
MLXO3[/5!:WQ:S^R%K.=!S_.CNIE^\]5X'6U;]F98TZO\2^&3:?M^7W=3?2QQ
M$*S^>-F@JP9G'V5'K4P72B]3I<?:7O(XBI/W9H9$2U>%=9XA2V"AR3TQ(C@L
M4NIOU F(QC9"+/!'B5-&5\/0ANAK,W^[(@E1PA.@'H&RWT:84X;=WS%?ODW"
MA'U]'O)/+<(TG,T*K0_BSG1IMSX\0ZP0]&?@(F\I X0S.N?;;@[&,)XZ2J3%
M%R27E2=_C>4U0ZC2*(J@\@%I\1^%%61_0I&>-&]=T'NRZZL?^[T"SH<:NL2G
M#T-[_L(5>LW2]-I55F++??$8?JQIC0NKRK]4OH$_2MW^VC*@.PE(RE\?G3[^
M0C82&)JZ_^O)_=,O'S_ZPN/5^%/W3Q]\,9[VKX&*.3!W\"]_^NK1EU\]^;?O
MHP38PJ%?4&=EUOIKP0>$,MLT9*/RPI72'.%YUWOX)#Z@'9Z-UDB;=X;QN$V]
M/2?GKUC<*X]"N[Z;D,761'_1)#:NU>XXUK,E4GSP:SZ6YBV_NJA^%";&SQ;6
M5*"0#0 KI)2CHUV[M;6[TNB&E%FP>;"1QLGD!H96KKFG 0#K3-DNF+QEBW*8
MN(6!CV!JO01+L""@:@?IQ8TK'&R^SD[EVE N-WQMUZ"TH5E6/HL1B_PDJ9^0
MI')S<7>UE<)-]U9) HJY)+FX=<$)W7/@7$NH"U!9)1T,Z<96R#EZ>+55*:BQ
M*R4?C+!'H=:G&?JNE'"_- >+*0VL01NOA6\J-XN5_22#GX@,?NW$1V N8H1X
M>]-UV:;9^(:5_S][[[;DQI%DBSZ?OX#-V.PMF25K)/5%/:,GBI):G!FU>"3U
MENWSE@ "A6P"F>B\5!']]<=]N7N$1V:B6+HUJXKYTBT6@+QZ>/AE^5KLM;YZ
M^=T7SU]]_^7_^M>//_W]9S+>]>?GWWSW9?P+2P@>:4\%S$5@@)L]$#9,:@C\
M&F,CQ=EV>YN84SI" R2K,B%CW)[%:TD$ECZBD*4BIW!,,-=MTV%VCE[&XBZ?
MFJER:TY2WZYK-B(K*'J.0@KTU?]]\>TWKYZ+4=+6W8!YASVE<?FHQ P9'!E1
M*93AF(&0 :,$&LL.Q?Z5?PE>585H,"'W0[:O97[GL<WO?+S,[RSS.\O\SF\Y
MO_.NRC,/J>:U/)U+-<\O7+[$5<]4BO^"TZE7L4Q%D>O+2 JZ%$/?GT#T*U52
M8>QJP\)+ )<Q8P:R;JUZ3I+OL&/@W)*//!4S^!$9Q%DJX5845!Y.FW"39#4\
MVU#H@6I-UP]; P_-_K'GJK0.<U6HSIP9!<X5&!WZTH9ALZ:'4T:)H0$3+:Y8
M8W) FET+IW)YF/87HPM;+//I6";Z''50YHW&310X8M0(GZ40.?+L&&Y7E9W(
MRYVDA0[EB)RTS50AEL+@4[0AP1#0ZY4F1!+CO:G*'$+!C+Q<=UY<R!-Z_4*Z
MS=U>!ZV45H0P8[=]S4TOWE#4 (1:,RN:3<K$%S&4RUNYSUOA'1ZH)*Y:85BT
MXBD4544""P#P&DS.W3:W8*=SK<5R"UXGILK;[6S>9+95OBSE)V(TKQAYSOF*
M29WIYCYN99LX&%@QHM999/XP74B;K:ND%6,[@00"\6>03=&N#3=M:E6Z9!Y^
MGM^1HKN-!Y784GC<(((YFJ%G'9'%"O_IX+/?LMU=82!"H!&G ?,8YZX/1V$]
MD8D.C2FBU"A3JI0M:X2Z:2UE#,$8/(_IW] VU0@6PS$&%PG[@4V*)^OC).J*
MZ^&;?>@2Q0A[2)4F5749G1.A +D=3A[4% ?O5"?5M25G6^[OJ2$_12B<8P<7
MI2'6Y>ZG=-6R55\+H2OK-\2J@ *&V(]"BA=$1S=(L3P%$UT1QB.KQ%W8AFMN
MRC?MV1'@.+D_3$?=,\3Z]'>_FWG!OWO?]TL-LG8,?O&XA2TEOAC8%_=TN7@#
M?4-&)O 4L-L?E1K(:<H8I_$=QQ()9E51B;]4H-E=/]1JD!:-WINQU%^K%?#G
MI)3VG:RY=SBYNA3Y_^E>(/%];(3A0KG*JP[H),Q\P"R8DJP;UG_C9 HX$AYK
MEP&*"ZY:?/^(@3:*4"DX1<#5<E@*.88ZTK?)Q"E\ ,*I$SN'2$I7@[U(F,;
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M-(<;[O +'6YB*^<5?K7ZOVX91QT2MZ O"X1L ZO8KYG/(QR:VR+JJVE29)M
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ML0?]#W\Q=9225.*E%\HO0!Q3P1LZ7501.8ZRV7GU.3+4E\F)/A)=P_?!@_R
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MLF#5WKV1XQIUH4,(J5#H#F,WAT/9'LYW_KYDLF99<L_P(;.F5.&P?;8&"37
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M'.X7'YN#$!^K;MU:;)J0F]\;!O!P.(^/+)2-M""9R*P_\*L&(@]WF&'T"J?
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MQ/X@FF)(2R*KSKD]0S*82<5]+:)Q<AT<]<Q=27X)O6K&3>FY(HW)'4VTQV!
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M)AEYTTE8B]?D>4\+C>[FAOI@2#ZW2[%WW)CG08I0KEY1V$=7<-JO7OZ?%>L
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M#X'F5=?VS)*>$K"_C7C^.4.L.B'W#D)"M&V"#%P#>L]1/Z<]&J[PNSJ$K<-
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MIA6+*5"HJ"C>DG^Q_Z '3N'(X:@/G1L@[<"[BP#@1G=>,"FQ\,L[7^38]W1
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M4<O;]6% MQ_Z+:,\1T,'?GXCXTBE@W[RT2>_=V2I+@R\+3LK+M+?!.1<IG/
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M]^R?XG'&,,C(P^<:"VRJM'EL>=2O,6AE#)!P4NUC_^1NYH6 RX_R*(E2WCX
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M-SQ&%+FM-AJ%1PM[&I2?U*U=$ >/*"1]H3 L3FM\'RC:Q"VG(((D"!Y-7&2
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M+,Q6*S+"'A<=:_J6<41I<W*0<<E)BLSI)*-TI5/PR4RVGJS\*FM_-@V350U
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MP[<P0H(JC:4_EW_!-(>%O,[R]\+ O* ^G*:N%E^) :>$,IZ8[+CI;0@;B8O
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M%@%^DZ0V:W:V0'6B2N7B0)<!->DK4' SJF5;9"FV/Z1H3"8A4H[)Q)00L\'
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MF_FGCP9YM8VS44=YN98&H9D"BA7P;8)(\#/:%G$ED$'U7@L]A0%GA;H- S2
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M0;+!(]P3'U!;!$K#W9GD,9Z'L^(FSTF.3WA^O*@6P11IG'0:4J$S)@Z%?(E
M'B'9=,1$W0OV8'),CU4S#9@$A<.\P(;MW'G5EH& THQ#O^7)3QLU;DOT_U&B
M_W/A.ZYO*+"Y(M*I'$XUC8[%D-_9KB#MRG_"RE^6JJR8;%;\K*:]#^>.<B6M
MSH9NU_\^K/^%\[HPNLR+G,!AD9+VY=YW2$Q8DPIRE.J]7MJ)_T25VT@;L=<.
MY_NJUI>KWF#<H4GO8TCSTSN$J-+%5KS>+M9NZG@FE#2S\(-39(4^DW!8,Y[A
M(, >6#:*59+-*BW-VO%7]ES,_!8&FTS3X&TVTQAS[QCV3>Y(4"VY)0[%(5:U
M6'PSSK8>]H\R'&<MFBY?;#U3%T+'2 H">2DZ)HW)R86XTCY,Q?3]X NQEPJ"
M<86M-$Z]-( +^V]+U"!/^533R&S 7MIW<@L3:C2"G>G\L\8&P2CM3(&O3V.E
M<'P@ZW0:;OB.K\'__)JG(0CS@JC.T[1"+T5?Q2"Y)@O#"14[V]NS,K7@)/-%
M3 .,S:T5*'O9:9H'>>-<)TL2@]@1\^'7*@YHQ0N<4A>0K(F$HZU8"W'"F$CU
MFQ(A$AA,PFWE'=FWA/062&!;^;R/E<_#MO*YK7QN*Y^_6^7SEY8PKZ<Z]&1P
M>H0AYM/AJ#N:3,9=I893>/_A:#R:#$]"_?5CJW34OYK:@]Z6$K8YCVUEBNO&
MD9VT[^Z.?+D43@Z/!\?#:-I5D^DI FR'W=/!8=2=#,:GA_V1GDP/C^Y&"FU$
M_U5^64U"\R\_O)_EMY#/73B=MUC1"L.WLSRKE@&9L_;+R'!U#LI&MCIV@B?4
M2Y$ZO6P'V=:>5*+IS/[1OJ0%O#J!2"?45LEBJ,XPD1]88;EI*C"<QV@$4Q[@
MF_%\+G(A:VVV-YKU7[ZSHI/II(\["XZ727=TJDZZIT=*=\=C'0T'ZG0R/M'?
M B]T[S;;-I\UIJ:F8 =I^L.DYM23EP?G-TZ7$&AA;RX;%>DTY:7#F!RB6^10
M"9=EZ8X .L3%7/AEY9MVL?5]D]7']N-GN7+?Z.!Q'/+#=]A^6%.A\J[6?7G\
M\<->\#K?:5IV,YD[/<B'WBG)M3+B:C!=YT"-TV#0[XS[_:! 9@,XX;6FXSC1
MBA42\A$$-%B\^#S#/LZ_H&-8=(+G\%EQI(3!1M*2-NY&Y+AT\*4P=GF$T!-\
MB+'L%4;U _B( 7QF MIA9P-5WT5?';Y#DR)Y1PA%C<I^']3682]XL=,*@<@Y
M7KLYW>G!WE?M]9E.[6N5JQF\;QY<_#MXK?"WP0N+#_Y&VN,SQWY?E_)V#9VI
MAWT$5GD>+RUTVQU-DK"KK6]B%]9/5SV_>//T[/7EL[__;3 >/>D$:+ZBZAGV
MGZ 6"@:]X&=SN%&69_"$ A^4DC&_J#^D1_?#K]% SZJ2"BIA?$L6,&\<9(W7
M!FD9':0TG<+0C79XF$345 PS@:,PP]K2*N?4&@''KN>49\0B;VK<A]!F%2=\
M>,)#W0!Z]U2&/I>JC::M50#[H "(*PJ+FS$^0D7.FKJXV_IE5[),9D_@F3V!
M I>46;@XXXFY? RDA&#+%K17C4$+IB@)!>$I87L58,UBOG2.(-0K36QK$YW$
M^DK;2K:<S%+8F-Y.7VHNDJ8KX*\\=$IF4\M.K'U#< +UXJRH_H9RXIR]-4VV
M.XC[-.U:5"1>/#G6IB=IKI&>D3%=EDVEXW&I8$J;JV?@!=1Q=)IDUT5K*_NV
M\N@=#$V_P\Y$Y>I=%!?8D*+*/S?T\RT-YE$O>!GOM!&:ZN"2)C9X:B=VIP?\
MH#7M;]BN>+F$LVGGN^^V:(Y]0W,<MFB.%LW1HCD^&\UQEQ]M5 5918@!?1?'
MC3F@JY%5L< DVT_5$BQ.,"GUDYTYNE^?;3JP=G_<;]X&%Q?[.?0[MY:V%;\Z
M\_WH'=SQ7I?O8([>898W2]]AMG(O&CT?@0&O=MH>QJDEP(5C5;4 Z'.:[> 9
MS78'KN!(VR4<@>^%(/ ED\I0+.L".5KRX'65AW.%K EPGO"]P27GC_<V(5BK
M>AD<]0Y/CAIE+X/#WN'AX4V5+Y^MO'>=D/0E[4^_K>-#]K$NYRK7MGCEG&L*
M_D$X#MQ,!6X>*FR O19IXG#'"W]31:3^"L[5$H.'@<PI681,ZKE:P H&C\Y?
MO_F_CZC&(<<X&?S/8!SP9J27(A4HHTAN>CU=^EQ/\@I#9<-1)QCVAT=[%4*^
M<[%^BN$[\$.*?9J5.ZGU9R$B+%N*C?2"I8JC(#+S@R*,Q2]U$8,#(<IT067L
M<*B8HB.*D\8E9S.B##P=$QG%Y@V%UN2),&=+*X^--J*8<KI4":N7W].<CFQD
M%=]PP.[#G'W]^%;:"DU#:):W,L?V8;)::;ES#UOG9,-A_OD73&/OI[6^BVMW
M%P?S-$N2[)K(^;R%8_Q!@> #.GPGR#J'#&D&"X'!Q3 FW+A)0!J4 ]+<97B'
M7#J-$QV9/]JJTLMGYQUX="XO*2KL)^3QWTT(A)SERXSK=B<(:Y_".<5T]_ &
M-">$EPU>@2-QEJY33L%92'C#P>GA(0[-^\NS#TBO/]/>)6#$8I,BJE!8@%V"
MO3;TAQ#I5@5WC]V&D9@039!KZ04\M0R)=L!HGJP/F;Z2!\LEQCS/5#2<"[M?
M6"TJCFT&1UTDZH$W$QN2AD]-<1B%\YT+8_J?-^N.?3O*!$O--WBO\)]M'0[C
M1Q!J'(01W+)(?[!5R_+GG^/,0<'Y$OXH8^L5.J%^+!^YR38AP"GCU#G/!,6!
M<0H3(O_%7W$8Q^6L&< NQI\E1H!_PR8*Y_[,2'%$[("J4N7-DQ\7C!FJS75F
MZ,T9^&ZX"94L% L/O Q7";,-,MWP)N192BJL;>$':,_4[5"HA,1,YIMI-JEG
M0[4P1>T_#/K]X%H5@7T"#.>_54K>UH"<K7Z'>EU[3[I)##I?MK9"-.4F)&#E
M[-Q/[AU&;,6\2NR'QO^I8XMV0?-]6[7ODFSQ8A84>?BO1_##X/"X?S0\'!R^
MZ_?^7,X>!2HI-__!9!CH0^ ORP]/)"TR.AS!/Q[]LTUY[FW*<]2F/-N49YOR
MW,F4YQ9[_6/?/;R[[\8O+DGJ-I!KT<ZO:WS\'KR\"QLBJ^02?A/8%[W^C^9Z
MZ@^]+/1/A09S",PC,R\Y"2/=]PA?#^^W6NDJ-D6F/YG[Y2*X*JJ?6X>G/>3Y
M\H17/I.E]Y];;AM\DUN.>Z>C71U;^SGMY[2?\\UN&?=&=_$Y__7/,F^J3SGH
M3^"XF*CP/3(BI%%73*(I_=^3:U#/;,C]Q.8<_F*SH;2N>>NF1G\ YL05UM2&
M*I$3CD^]->,>[0[Y52[&"-V]P2#8</Z>?,GQ6SMVX+7]T_&P]G_U87R9-;\6
M7_P,CK$RNOMY__[S_&GVW^<:=?Y<PAKB7_[U:/CH:\RK-96-^[HLV5\(C)BT
M$K]UJ0;#?PY.[U+J=W=U/CKS=[L+[G9N^9#I'[9:I]4Z.ZEUAOU6Z[1:I]4Z
M]T6N]T3K#%JMTVJ=5NO<%[G>$ZTS;+5.JW5:K7-?Y'I/M,YAJW5:K=-JG?LB
MUWNB=4:MUOFV6N>&!"3A9=8SD"%HD&FX)0-YJV3CQH]IK")<_H5IL"^#^WP%
MS76WN^5<E2I9%67P>J[R!3RUHNDK.L%%&O8^8QO=9E6^2G[RNR_,]SK"_?>F
MV8[.[T?F[AM/TU<2Q(WZ]7N+)EWWC8]8!/=]3NZD%=U6A[8Z]$$+8JM#>4U.
M3GO]<2NY>R2Y.R"GK0IM!;%5H=8,/>GWCCXGP-R*;JM#6QWZH 6QU:&\)J/3
MX]:5WR_1W0%!;75H*XBM#K4Z='32&[:^_#Z)[@X(:JM#6T%L=:AEJCDZ;GWY
M;XO N+$&O$5@?"O)_^WL\NG9_^LXTW9#+^WH4K0'9'M [H!HMIB+5G1;'=H*
MXIX(8JM#18>.1KW3SZF#:T6WU:&M#GW0@MCJ4-&AXW&O?]R*[AZ)[@X(:JM#
M6T%L=:C5H8/3WNBH%=T]$MT=$-16A[:"V.I09X<.>^,6=+%/HKL#@MKJT%80
M6QUJUF0X/.R=M#JTI;W80:U\MY+_IBH*G23!RSC,LW.UW V]M*-+T1Z0[0&Y
M Z+9@BY:T6UU:"N(>R*(K0XU?'S]WFF;,-PGT=T!06UU:"N(K0[U@6N';<)P
MGT1W!P2UU:&M(+8ZU($NAKWCU@[=)]'= 4%M=6@KB*T.=;[\86_0)@SW271W
M0%!;'=H*8JM#G2\/PVI]^9;I8@>U\C=ANO@YSDH=SE-XUVRU&[II1Y>C/23;
M0W('1+,%7K2BV^K05A#W1!!;'6J"-<>]4<MVL4^BNP."VNK05A!;'5K3H6VP
M9I]$=P<$M=6AK2"V.M0!+PY[QZT.W2?1W0%!;75H*XBM#G4Z]*2MU-XOT=T!
M06UU:"N(K0[U=>BPS2E].? "_JLFB:8?[_([_JR*,IZN;J_!^/5#>/U-;_R"
MJ?A.7WS;?>$&\]'OIR?_%)?PWO 39N3M7,.@LO!]L,SC4 =+G4^S')X*/\=I
MF%21CN"'H)S'13"#@<T#^"'-RB#5H2X*E<.(X(((-D\97^D@FP;3JJSRK8_M
MF>G?S0D)/ETZCC\RG+N3CS6]^0GS<ZO9N-1AE<=E#+>?5>4\R^'Y40!+&5P4
M14524J61SH-G?U5QN:*F-SHM0!2R-'B=J+3XDM6^\\_;J\7^VA^/6W^:)4EV
M#9<&= + ;M4%_+6 '4W[E=91%;BKG\)^7TQ@J0\'G6#8'XZ"Z[B<!W##4H=E
M4&9!Z"_^$A=?A .^*9P'Q5S!Q?BHK,KQXD66BI)8J%4P 84#,J6C;Z4@[DI"
M[MGQR((A8Y'1HT'RDZK*[,DDRV&%:73X>/@>O+R;J%56R27\IA,PE7XTE\-J
M)FI9Z)\*O52Y*G7=VJ3;'C4AH5=Q$4_B!-3,3^;^#5A/?MOHJ#<<GN+[/N L
MX=#D,V'F/SQY],\M]PV^S2U'O</^X;=Y56_T;=XSZHV/O]$G[?<:W8!V/OET
ML/-&Y7 K!/17\T&-=[)!-9Y\0P?4N<+?S@,-/L/YO M/\UO.\[>/0<$:XE_^
M]6C0?_0U)E8.(?.;WM&R#(HLB:/ R$DK\EO7:INA'UPXB_$N=\7N+MY'%^;.
M=LG>'2F?N8C??\=]^QH;VEOG8"+/LOQSBFN^QIJPN/0/]VE5OM&1-&Q/I.]]
M(OU645@BF_[7)/_G_RE<Q*K,Z#<VL!!42SB;\%?Z@\[#N-#T#PI(E$6I4IQA
M_M42C[&B0_^X5GFNTK+H!' %_89FHVA/N6][RK6*KE5T#UK1_4%WZ:BK8+[5
M3-=4F21:1 NV"JU5:*U":Q7:;BNT;98;ZR2]4'%J%)BZ4G&"J07Z%R8@-04B
MZ)]^XHE^L?0SCZTZ^^Y1B+9WRK<),7Q*!&]#ME8MEWEV!8[2A/<5K[7_O[)'
M5\$<=KK.B^#CN5J<L.ZH=WQRZO\?;)B/97&/>V.X:)D5,0[QIUPGA##YA"\]
M&#S>#<3>CHI5"QUMH:,[()I?!!V]'5+TL-,?'W?&)Z>MM.Z1M.Z ;+9J\^L*
M8GU;WW[2?M@-B7RH^K/?&[=,VZWJW''5>;O83JL6OI9:&':&1Z/.H#_<;2]P
MN"->X+>1DH])P [%?UH:U]V*_V!9SZ?'@'9C<^WHRNVCK_!5T5D/VS;[\CS!
M0[(G_OZWD^%@V(K[?13WS\E$M]J[%><=%>=6>[?:^P&)>ZN]6W&^1^+<:N]6
M>W]'OIT6(;5G15AOLU(E;9SKGIVU]TFUW-=LQAZPT+78HGT4WQT0UE:/WCFV
MZ/.V= LVVBT-VZ*/6N7:*M=6$%L5^KDJ= VIU4KO9T=O-K(E-[Y]8#@9O_C3
M#C$NU(B2C6V8K"YZX\/>X>'ACU^;<_1CE*>WG]PFFV847P5AHHKB7X]@!(MN
M$A=E5R=Z@9QY.(JESBV4,XJ+9:)6/TT3_<&?3>2_E,\TKZ)KND6I\O()S4,7
M'U_\-%&%3N)4K^]@.^!1[^AP?)LI+'.5%DAY]5,!.T$?]'O'X\=/;C&QC<U3
M5/"1WFR//S+;]KW=#%8]INA=0#)_TSK(9WF!Q/=:+V$(R1,SKW&*4].EZ;UA
M/FME=;B YG!E^L-^_\?&$[](]KXBE>L%TUD71#\[[ ]&P261S\+OX0+DKB:N
M)95&YHJ3S5=8(8:OE__]:L+<;T7YFXKR<"]%^8VIC3>DRO _098F*R%<_BSY
M_4;DUT$<\09Y=_P.1%B'I8[>3>-4I6&LDG>1*M6NLJ%?P*@Q3]8?/#GN!9<[
M36TN,QL\-S,;/(69W>DA/V@V]M\8>YV .@7C<J<YT+V#;JEFNEOG ']44Z7_
MZ<:@D3[\U#U\0HHWBG.02ZSD@*^I%NF3VD'8]"!Z1^ NX+ D2XJF+_QFHTK7
M:;2A3,3C8K96](=;>B!?(%Q?QJ;RM1?PJ-ZLL:[VYS85+=\CAR<=D4S%7O\#
M3#3_FA>?\M%J"I_[DTJNU:H0HNO_HM=\"T=/!?-<3__UZ&]PV+W#06V?=JPV
MN96"H]=$.LQR*I#XB<Y5_'SQNQJ6QB2!<_9N%N\M\>]GT^"<?^7J+92WGF9?
M;G3C<<]X&W%]0WW=??-5/?=OMTLV>/Z?8!I]X4<[JVC\#FX (4:WX1V(65@5
M!2S-._!+X/]5LGJW!^;1N!>\Y*_8:8L#_I=P3^,G1?#43C6Y@&<XU45,_4J<
M#05[,(I+<\T;751)29>\ L^'-$7;\&;/NE^Y%CANLYDF-=8M"<+:PN=NX3.[
M\."+954282,;.!.CH,QFNIQC^QOLDP,_H?30Z:'JAOEE";]84-L=?GA"%Z19
MJ0O7A$LGA;Z&QVG;CNLL32NX_8U>9GD)[E_P'%SI8-#O_D\O>(L71'615D:D
ML=T.3@+XD-C+Z5J!)YUDV7MR*-U@RKDJX65760*>8PBN/EZ?Q\5[9(XLBFK!
MI)+T["J5"YAY%^\,:39"514Z4&&)0S7S5F8PMND4YF8!;\MA$L!UG>;9 N[,
MX/)X 88P?'.6!Y$NPCR>4$$B3>+V ?>"Y]QYS+R&1[#U3=J?(!HRRT)!#:Y
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M.A;?%KSU'=7U9P(WZQMAGR;KJQ]E:? ;J"9JI#L\Z5#9'PEUKD,=8R,'[N@
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M C*]8"U3L*PS.'2+58$X:%@&_QQWQSVEX0I*31G9*.&S: >@7'R@K!E(Z6C
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M=T?'!;I?%(US.11XCN:J5//9M--CPY7HYMLL ,:*78P(TRGB*V/GFB6NB?X
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MU--F+\)>+7'2UO.%6S2UIV*IJ >A9)Q&)#7=-/-R&E, 2AJC%:3]4DK+81"
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M2-7.QK+*BTK[3*(-GM)8*!=@$^<QHO0V="VDH '2&=' &I/HIH4:C%<$EK!
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M]4A'3D1N1JF6*T;332P-J;#W8XMD-Y46DI8Q!J543!),.7>P3R(H,>-_RW
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M5>:J,D'U\NJ525E:5+5*HFJG,&5'E:# >^"'6-8Z3]PX2WTLO8R5*T"0Q#-
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MYDT4Z;Q/&]&Z13E6V;^9\V9SOJ^K#AN"0"I:@5_I8KSNY7E>W28\).]1"=9
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M9<^VG#/XR 2^ZO3.ADZO=]8U>^.^Z %9W>&/CO2W*'PFNG9,V^T,0,[WNT.
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M!;F>ZR$'.!F\_2QP%E&F;I%?LDRS;;[,[X>U#)QY(BX261]:Y$2)R?I-S[W
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M]O1S!I-P$F&4D2UC&361!ZV\]Q/'-]Y&[9;Q*?5D1QRL>:PB+/*HEZ7.&-:
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MT::[TK%]Z< <#<^]_F PL#QQUSEXH?8G^\Z?.-)M!!5[YP]NU#T9UP$W4&?
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MY]&Q/6#E'NX_TN]^7\-Z 3D\-I682<0D:H)3[[E(=@A/*&S:^,M?7@Q>[(*
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MQM\!XK3R4&L*,:UH=-1>_-.R-#64,#J8.G2B!P.%@<) 8: P4!@H#!0]",-
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MQ_]QC[]]:(]_->'^,DE$:GS.8$8.7+HW\?[!.(!-//N<C*^O8?=D? ?LFF?
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MVPC9 =R@_-W7XEVO$GE]$DP?L@!]D@< I<= >=$IWNV0$\ (8 0P ACU0TX
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M(AQVEGA!D%!,($:\0\H3CT1.;"8P)9FP772_+)TB,CR0?.WK^4$S^R8HH @
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M .IF '7]L 1["3 $>PE W0R@KA^68"\!AF O :B; =3UPQ+L)< 0["4 =3.
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MB7M9PN'<9\X1E!*=A^@@4T@P05&:4<VELCAE=B'?Q+A76COD4ARNB7^(5.O
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M!F^;W',F(48)8-\KL+=5#3D%S0U@WGDP@^8&S?ULP Z:&\"\-V &S0V:^]F
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M^[5C)$Y5[9KC^:R9J4E<H2O>59,^O=G!.GK_]KO%C7R$"1P+L<LB"DP!,!P
M#($I;F4*:QDFF!,4U#M#S.L2::(QXJ4S$N/2"XPWPA3Q**'3Z=BZNCG\U[R:
M76XH$!=H BABAV43* )@.  8 D7<2A&2$4F,)4A1SA$KL$6R(!1)I:C!1@CN
M['6*,#HGA$J&I,<Y8EI))(K"(V*,<!I;9HE[,HH@93EB0@!-[+!\ DT # <
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M30Q3>:.W%"T\9]_,ZS#8#ZZNIK;-  YSFCYJ[IS_>X>\KE&8,_"A=EAJ@3P
MA@. (9#'[>3!E2B-HT@K6\8]>XND+')DJ?.X8*2PQC\B>?Q-C>?N9NYX2$(P
MD,8.2RN0!L!P # $TKA]!]_8PE$=2",W+A! 3-^23B#GC<^%H$5)U\X!IM06
MGC.+ JMPQ(@02+!"(B>D,4(9CL5:VY8G)0V6CW@.._N[+++ ' ## < 08OL
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M3%$P2HT7 C&58\2(ETA1;!$5RCK,2BY+O(FHX:,R!6:!*:#4;)=%%)@"8#@
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M.P?/2)O-[31!Q/K$3ELU)JS(;!B*>)BS#_8 V ,#M0?VWH,E+'>6>(>,B]E
MKI!(X5(A0G1.*.?*B@<=>FK.ZZ\_+S3BL7_3Z<.-G54$R3_@J0(S#0^/P$Q[
MYJFZP!(,XS)J?8J8,11)%4.?1'I"A&?8\(?$.A_.%'=S2O&($JA,WV4A!:X
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M4CJ4!]_ RT+FJA0/#C@^#5<PB#E"QN3@R6?#,<=PHW\[FXVG39,%H6Z"X,1
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MZ6+SL.TQ%1SG\.59T@G+R$O\_55&TVY<!?75Q AP5%?1E KN21I>4%9)/<4
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M<?/OGN+',!N50@P[)3=HL!Y(BX25&)2O)K&\H$L$?Q'LL#:!+K4!N9+I/7S
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M)RR#C;"C-L(?^V$CO#TX^IC][>#=[X?9\=OL[='[@_>OCP[>94?O3SY]_'V
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MN][_/WOOVATWCJ0)?W[G5_"XNW;MV406[Q>YN\Y1V7*W9ZMLKV7W;+]?ZH
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M0S#S-O.^]Y<ZT\3W'G#>AW"0Y?9))E=T&7]0O6C/S>-O>=S%,JEK!YZZ-M1
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M4T)!ZA$G#<(,_L_ULA&EOGM). 'A:F29D65&EAE99F39DY5E%*15&#@Q">P
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M(PMAIYZI=:S!6"L6&]"U+-0\BDNM&,!3D2=YCCJ34GJW 60W_ZGU%I4+^19
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MZ%_HX&T;$F7YUQ8ENM_A<=M;+$R[MDQKP:JM0;#[-3['M-4?,ZW&T,#0P-#
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ME@VBS[;^4YYM/=DXVWK_V^/6!;\?8 $?&X*,<#'"Q0B76PD7U\B6QY8M6(+
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M1T:QHS1*W<4BQQM@6;.5U^;-\*?H)J?#\'<[_F=LW<:?@=I-+M]'P$28^MC
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M-Q8YUQJ0B7!OL\O,D#5*(BS! ><"&QUL%X5OZ\+HOEB!"G 5X Y4M"O /3^
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M4:]CIP'CVM3G(%2S $6L6%$%LF+%^@*R7!CI'$=4.[#[6E-DI=:(QTBE$B&
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M"8_63NAVU)Q9XPUE&!D&<\>YALDAD2#*C"964V'X2OJCMIP1'B*2A+.\EF*
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M6LJL:RW2<AI=-4S5,%7#=(CRO0>&Z6V<5+Y4E%G:0LYMIR[Y,]K=VQY^TI_
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MJNOU?"[>3L_CN._A[]#_]-S: ]=>V(MVUST[X[%PI?ZD =U.K5U @VP8UO3
MGC;]W#[[+#=5'MNL)W#H,/;.X^1L%(YZ\!+^K-=OLH5J^J!Q<)5\M(O-I ?_
M@UV8Q-XH]2(<,#KO>_AF"#>='/5&H,OM0RP."W"WF*:#WJ"?XG$O/_7:K_+O
MH4V^GIS!G2^FXXM1$U=KXA[=K"G1YG'?2-?N?;9-SUY<C$=?VKL,+J^ZFJZH
MY\/FY,K*S]5M;N0E-E8SC<%64X>X8P)I9P5*AAC&N".>LMM&GKJDC1$<N>3S
M4B(+X C1A 0U6$<1%$WLX4;^]W;X?H'1NV'"41/]29B.+Z,=%R*L!-3R2G5O
MVZ[5R=E9L_4\9,W1E@0F&!N5!&?7I%P(21J+-%8>>9U2P-1[JU<"NB(X:EQR
MR!)O$.? #[3A#GGXH5,47F)UB *S/]+26J#M"(SPFD0K.2*.@L X2Y&C0B-F
M+&'8&47,2B&,G&#'L1"(1&RSA>'(<A"W@'D,BF#NW&%:&+Q7%F8<FXL(//H3
MX--Q40_X>(8E[WF8_>188R [X'V$6]SB/Q^I^D_@C4J.+68L(6,-!;:2,813
M, Z:6(-#5(:M9.3*$&ERDB#'.9@>X3!R2@)6$8>3YA'+)&^;D>5HZKMTVR&]
MTQN5-[Q1<=\RXO'=P=421*8'YP_@H8[V03( $I)D&" B"H9XU )9 SPV<:6E
MYDXYO!*-ETY9+TE PH2\14D99'$RR#,MI$WP%5]A)%4REB2C)0Q[(!PJ*8\#
M^#?260_4$RL@KDFAJ'Q2%&9:IY4=\,DG*PQ07":P!(&*,GLZ!J5 '2;P':5F
M)\)!CN\NVEF4</2'"V^^'9!>_'+1[E<>QW;%JC<9M:[X8+:-.7Q#-YD>$+:%
MWS]CKG&8\>RGZ..Y [>=D:,>Q92W/UE[9?B%WB0K1[W/??#08< B//#PXU'O
M(_C^8SN8/4F %^SGJ$(^>O'P37ZK?-L<3\@9GNV;-!/XYQQ>O\FAA-%%'+=O
M/"/4'E!W',_@['R=_A#^GD</OH['7YE3H+^!D5U0J1($; \,3DH"$PP\)?*\
M?8C)7'*#!2 >R6-!=2)^)<_:1)E8H PT/>5(>P"?FFE@.1P<(2RT3H'LQ. P
M<BSWPN+L!5&A7$=I@7\RJV!RC=)(.Y 4QHUGSD;GQ I1B8$+8P"U'(D$/&$)
M%%9K!^+D!'C01@B_&RRBYECMA6CL"U/AGF"KG$7 9<$($ &NCJ' 5 QU5HKD
MM%H)K 6ELUUQ*%?R@7. LU@/)\I(-<B73=JLQ$F^53JN90+?(Q)W[Y$O0AXZ
M)24WX_?=DA(_:B:9331V4 CK$,X $E764:SQD$9:@@$<L-46> /\9K/Q<)0Q
M[Z5UGJSQ@4VT2CCP:S)3<> #FPC4(X%1(09(C/=X-ZSCF)=M21:DHVK,_FJ,
MX(IZ*T'ZF>+ TQ5!Q@//(L(1@-O B?.W-89KKQ3/M?!$ C*6"P)HHH'%,9,2
M)=Q3]6BXW4AC\)[0]'WA8MA)HD7*3IP'T^C!-#H#Q#TP&C"GR0FS4L$(NR@)
MD#3@]" 28$YSK7<N40C))99B-*NI3Y6+=<'%;F9.E,_%BIJ)&QE;ZQ*R_J/7
M^S/\V_,#VS0Y&>YC1/,4MOR < ?0HGS _$W^W2ZQ?3E![&4:Q"\HP)RU$G@"
M[S@]'[X,_>9B8"]/\K<K^7''HC]L'W:^G1@?J_S)?$EM\>#MN0@F]N7%J.FW
M%V\E!P;YI1M]R:.4W_PJT^[+ W/G'K'H=YTO6L*TOD8E"1GE-Z2L3?.[DJVS
MJQWD\]'M#W,>%P*]&D].['0R>GGS"YCVV<<S46RWD=L$@W]B!Y_M9?/RQ8\+
MH7V:A$G;.QMG(_VGR<C_D1_J;B'(Y5+O'/;/,Y%WHT&8W29D/ZVU)B=3T*EQ
MF]_66IXK)9J/B1N,_#^WM'R<DS6S:7LU^ZBYFDN[-)\+*[$V939K\))96%7O
M;K6XTPS8I].2-1FT:T9VZ=;WI:7.V$V^07\XM4OT)J8(-)81%#T%'DM\1"9%
MC(1*"BM#G7;I#S(WZW.[#Z-PC@;]9H+BH(6[=B0 [5XLGNR&7;]E5-?:[U;#
M7[9#C_+EFQ-GFYCE>35E_FK,<N*&^J[#=(MEK>MH7N?/N%3LXI\Q7L#C#F[K
M;3M67QF<%W\Q5W1A20AFMR$8?W?K@@4-PMT5BT\71.Z:\#9'<-5)[_NYL,;P
MP_$U,[G&BT<IPDIF6O3"8DD5$@)3Q+46K2>'*+41!\.CL2L15^Q,##("RS?@
M%' 6&7+:2"0%Q=QX\!G4RE+->W\6PW001^DK6QU>3R?3<5QV"'Z><>+6_GZ
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MWJ=%C8G)#4WF2J"QDFK,'SY4*W.K91A8DC4=K:IH(E9\VH-,?!3JYHN/#E8
M/LM]7&\I4_SZ^-MXE)O=K;^['/%345*19JG(2TFSC._)F41UQ/+'W\*A_ FS
MRYGU/E>9(M0[3H0K*)%:>I)GAC+A"P&V8#T6Y"S+J1>2>(:$,L()(E-GB-&8
M6YYYGA9#>L$W#7A[ XZ8>^W/IF< "19GYA_+*H;P[G@HF=^6<WXDF;#8#T'5
M%\>5^B.8\48:2U*N,HP %J2494IHF?JBH)FE?".73!C!K566Y'G*,5W($6DU
M(U;D6G/-1*;X0%(B3XP[F]H@(JW@=#2,;V*ZYDMEW8OI\VI>+_X;(-F>Q(<>
MB?@@L ZVMG&_,9+:JVOM>W%'(%>42J5259(LSPLB2B^(\H4E-,N]UJ4K,[?1
M4KF@S&J>Y21G5($&DHQHK4%K.9!%XUR9\Z^0JW<.GF9_9L%JJKH];C#P$*;8
MZ:96\ZYNL9&XDXZC?.XN&Z!_!!*7YBJ5HG2D,"(EPE),FY><&%.@R3.EU1M9
M9)8Z[R0H,>931X02%NQD:@A+6>%**5FIQ)=+W/N+:CX*'*HNW'F?D+A0<K\M
M[C["]A&V[TL\S[##US1T56WB2ALM2%>=L1Y@E*OIP]5$9'[K56V$S9^TNS_I
MMG_7D+5KQH=7-][QP\V#CB9&-(Q!NG\L0RW*HU#7'^B08$Q3J^8-[7L@=6^[
M,L,OV<D1L+NSDCJ; 2!0DE)0SRP%X^X+&%$!>AL0J+8;Q]/:>Z4HP("RX(P(
M1C71F0'UG+/26I$695X,79+8Y4R=!W\$%_MM7.O7H(Q=L]#U*[=XAZL\4,M7
MR[GK]#)A?<7,;TT$/NRLR5^3!TUS$*3'OEQ>;FR$H\BI%;ZTL.09 0T$QCI-
M,Z*XH@1<E)Q9SJ7W]JLEZ&6<H49LSBZ1?&=OM=-'8K_!J 9-\S B0:0.V:Z%
M\DX+;0_@@^4.5#SA+QU_T#J3Q5I$O#W*Z:G$8]!O*A7<V#PGF2HT$51J4I8^
M(]RD@OE<JHREZ]+)5&859MYPG8-.Y-H0F7% L&F9E9PSR=/T /0;&_7;MY"@
M7%BEF!6$*F^)R,%;UH6DI,BT8BEW*><;#LQG2]!7Z+?;W)/#%I)-[?:X:]5X
MDES,/F"VQTFOGV,C.X'W"_G[ @L3H+6&32B<MFX7M^9J<!O:OJ<Q&Z4]13:8
M='$)D'IJQH2CW4T=%4SJ_*8II]QZ5OY&S=4YC.$B>?&?R1.8W<HWI_J8Z0YX
M/?G-(4=6UU8)8'JD0*I,3 3HG?3"50_>NVNUGJV4_/[NK.'DQ77?=DE+V8M]
MQR)AWN0F7 @6]*^863/KW>1!_*0QKK\MKT B=MPO_/'APUAL$,];VS9P6#3@
ME+E MJK+:K&(])1G6F,F0I YG/:0>G.V2G9('IR]>GKVL,T6P$RGVKD_0D77
MH!=R5U_S/)8@#$[$FV/O.K!3=O/9R^;:I"'NG!O,<)K&M9DT:Q-> U.JSOO9
M1W7UL8,"D\@DV-P'A_0Z5/TD?Y[-_@"-"(_&5UBG\9N'1R77(.'82P9^=%/0
M8,9A&G.8_C_!:[09 KAEJZG'.\7,C<6@X^?V*5"3#M9@GLH,<R+:@W_K:C.O
M=#=P=!0Q42ZL6%V'=IW)BHST^=,G9X'U$Y1UJ%AJAA#6,)RQA W0'<A/4?Y#
MNL9[S(]XBS5\#?PZ,R'CBY92K).9VD1DB54WS98(6^EJT;[#VLJTM2=(%M>D
MAK0S%+S=B?J V7-U/WVN_N0.P\;/"99[8F)=3*4(*1++2,\+OYZ?PWPHK*<*
M:358E]5F&N#"AU''G+18AW@3)S4FEL0D1<"E,RS[:BIP_F=IS\-P,4^BO=<*
M93;BL9P.A -N@#+1"423_H)&HJ'5BW'4D'45A';NSM4<$YFP_@#-- I!^[@I
MS',=(E](66<KT+DXJ\/5B?F(W:3.,.ER#GNCJ2D?[*.G[=S%_+XVJ:_[&-X;
M%<#?8-*Q:62S/F&K-6M]JS;\<#$+ A%:6O;'&6]0S3?$&5]G6;>KV"6(P%*.
M.7_K'8M#0BJ6DT4+ '\%T0H\KY@HU*1Y[39P=9L*>M84B?4N??$B0(W>M<I@
MPAA(UWF[*$'JJ\5-BV6:U>R<LL$^A]&THP(C47>[YZ3+Y$+9BG3A,"S,RAKF
ML@XH%5?98T@MWKRIF:CJ<J5(XJ0,DMOPN6$4[=;52VQA5DTC7>+.F[1;8W68
M,9C5P4R%B\/^:E3KJ]EI0M.3G.4GJ90K.I>5"HG.[>K-BY.D;LEGNR3=MNIA
M3)&Z=5-^UR*;L7?:6/1X#Z-A<BQZ'(L>QZ+'/?=.8U_:.^W;5AV.O=/&FL-/
MUAS^U W3[F;.V\*5V2HN&+MM9>NA0?!P(V/_6FY[B-MUE/WAMZ8P!?W\$.+"
M;D:?'= */;X4F*80QH&I>N[T/ 8NLU"@ O^N_*I8LHGJ/']ZAC&'B:OK+BZ,
M\6)T=P;QX<0$8G@UAQD<\-3$6,OBYBJ2(O4*-$)\(@0FD*]F;@/9_[:D_[66
M-VV!8RP%#)Y7\-"FYS/T;QI_I^?6M-D._17H8J0Q'K(E+M?Z;U<KC_'+PAIW
MYS3Y<AF^S<9\AK=UD.[6]VS$T0K 5OGHRUF_.G?EQEOG\3PZQ"&:*/L#%)@F
MJC"\:Q?8Z$6.21-7;@3R82\@_R TB]ALR[3+Z7]XT@RL;K=+ET6)K404[A50
M- E B>4\[$=5QZ8;+M1CA5@S-CT/$9)VQ_6F(&S?YBU7PPRQ:^S(\>%.>BNV
M)(F*;A5/CP64\PKWVFQ3?8VANVW<4#!WK\UBUA1=[SJ@4G<^HFH"VR!R:.IV
MAV63!R]"U6FEDM\J[Y)W "!0G-XL;I+?%G;UYX</5WF\PP SV$8P-!,U;T/-
MO?VE%L.G53C,ZZZXG)\F;<$R3UL^K%N*2=>%N!O_YNY:!=/[V>[=%U913+2C
ML\:>=9',87K)O^],+,%9"56/>/4@SMG8YA!2Q;F:_WO79V7S[LWM3I.S.EC.
M;8GZJZ'C\X9X8UA;'2:L>=2J2+8%%FC?8:?O>*%>XDV-Z&<Y:=J%K?9RB$LV
MQK2]:3P@"7U)8^EPP#_XJ&DL$@WST [JTL56C]TA]FP:6_W4HX)8LVNSY2+0
MKT8BMFU[8!B!;O@DPOD8B&<(XJR:$MUB1[H#TT&CH88Q8H435R,8UVN-?Z&W
M2T[VJ\Q-GQ@0@P4J'JI>J&O7*.-50<992Z*"'\WFH:M4?86<D?%<XA)I6]LS
MBN?__>3URS=GK=I\W]9AFTX/([Q?*?HXK&:G=P00#1?):@::-*KV:YMG(^'@
M$ -BB]N&]*ZY1_/,F!%4K]R0-5WVJ9.NU4&ZTF",VB/6P4GJ+0>I9X!O)DG6
MKN_7GZ3B)9O&^?./3,/S@BT;S%]_=G<<J_*47((87\2C<KQ-3*1897N@7&!S
MR<;*8UE&9Y][1Y!K%JRJUQA#JK5SR& 9/VG,XJMV"1%].])[X=OD'/'K8$Y0
M$6Y(6B..=6,U8:--'*:==CP1-*YZ-AZ]':H.'C8-C*E'V)H.54?X;V\CQ=RZ
M8%ZKZ75HS1>8J=UYI(HQ()3P0#"C\Y@RU6SU&88B4,5AKDGD4=%+N,#5@.">
M?33N*K0SK:-B0RT854W_V<CEY*[;'I'1),/F ',<\5+/RK>N;=O@M7D/%7)=
M)C98@),>WT9+2Q)UY?DY!D^0840E2 $UQ_PC9=&Q:YNRHE*K N%-O9RLDP[#
M)&*WR9"VU.&T@/^P0#GQX"_6(]_K>/3Y+8X^R_'H<SSZ'(\^[X'O50HP=KH@
MU"M/A"P,T9DN26J$UJ(0G+&-#I*?P_<:R@6ZRL8OX7:]PP#W=\I*Y4CN^C4'
MK?S'.&A=">SVD]2?M*+\'N;]ODK,U8\AB+^]>/+LU;MGR=E?WCY[]O+9J_?)
M\]=OUZ(>AP340F3_*XOD?MENJ72:.N7+@ECJ-5@=XX@2.25Y*C55U&A!-SB&
M:&DMET8@O1"FZ'A#E"TR[)XILY)KF:Y:L Z8.=K]_Q3\IF'!&C9JB2$3_!JQ
MZH9@'1B R@-![MV!4HX1"\HZ_;6>EGHX4C-TD(,?%!SRT&JJZW/9T2.$Z-^?
MJ]E+\,[7JY[:HJ?VSP^[4-RKX)"?A;>'5UY1U:Z?'JV*:38>O<YI>%,_"LRC
ML68O9#W,>M^$)_M0XG3MIDV]<U<2%<.UO<J@M@IH+:39\C@<0?&R@XTIM>1$
MICXCPBO8:!+[SE)>TJRP3$FQT5%29)I:E\.&]BD1129@<Y: \8PL!<L+J]GN
MXN6F_O2-ND$7X_WL<TN6V2VUJ,5!UZ+^BM+R2;*1#?E]&(]B>QLA""@*\Z N
M/XIMN.WR"H7O" J?TR+5168--N8VZ"@HHE3*22JE,S[7I2DWJ$%*R;(4.P6F
MF2E 8E,)S@7\RU DIZ.YYS8;2%\K88WDO0>_O<:"L+UQ,QT'N4-,"CA\F6 J
M54XX2XPJ.!&,"Z(+I;'1K<\*7SHN-KQ;H[SD7F#;/(U-]T".M$<:,&-+I;GQ
MUHGOII$.G+QK325M*)MP#KVN:^!#]Q$+&X^$8<'13%%+#?&I4J T*"5*:DO
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MV31RP 1-,@0_71G#ILK9EDZ]"HAU-UPGA GIPRH0S@0*A96A7.F1S5NWW8!
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MQR)[8IRUR/6,QT'M$\,I0^=<#)5J<UJ!29O_6*HY_ IJ#*ZMCJ%/S,_J&:
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M<#Y;7H6(5E/;M7E9T[$9OQ#"V8L 9#%O*O0WZ%X9@2L&SXS!Z%G3322BY5X
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MW9;[+$^/ZACM>!%<6:0IP']/F =?7YA2$^V+$OQ_6YA2^8SJC0[SWO#"Y*K
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MA)$$,."JY=36C7Q&6MB>X8>?M8NDLKH7AD!,]B8P\+_X3YBHI6TX[9"S#ST
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M!CE:?P%8ZDE#^X 5=O!W4,@VB?P_3<TIQE?;CEH;C\7]D[35*_WE@5M4=;O
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M4_<P>?#BS=M_4Y=7CY\^'*/&/VC4^%#"0<<5$1ZCO;=%>RTK=9%B^UY:2.Q
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M- [.,^/7*KGR%(5RB2+B<41<8HE,\KF\O8!):LVIQ(<!$)8+N':B%'U7Y+4
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M$_JN)R"?1B!VJ\KAL5U-G@^Y3\/FH#V:]4\837._L*XIH..JG_1HRA8#9,D
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MU<_]84AV,.B.WN_H0A1#I!@BQ1#9BVM, B:&(BQ\0IR"4:&IT4B+9)5C =-
M]Y(,^S\SU?@JY'YW32O K9LH)=>U!%X+?G6"Q@6_"GYMI=J CX90'!'1&%SA
M[%+;1 D2";"(6^D\7L.OG:33[@>_>,&O@E\%OPY/XX)?!;^V@5\A<2<9#D@&
M31#'3".CJ4,2FV2X4#HXN9>$W'W@ERCYMET,$9>$VT.%B-]-+N*X.[J_HR0_
M5F/DD0WVBKFRJWZ%S\F@N<O<$)X+0I'6(B&N60!W64FDI8V!& T^,]M7X==&
M^3W.W+@GO59TP<HX'ND_KE.G6^[K6]#MY/F[H-LS03>NL,"Y/*!C5B ><WG
MB!42PFL350*H>U(PN OH1KNQAWD\TE_0K:#;*?-W0;=G@FY1&G#3J$::L)1/
ML8 ?YHA"ENM$?"+1$K^OXK?%=^N(]'>D9L/^LHQ/(Z2Y5751E0CRL[!":(]F
M111&4S>(G=-$1VB'? -!BR6R9(DP0Y6T6B%OM,^6""A]"WXV.-Q,$&RP(6M5
MI+8717X-S^T/IS#V=U=QW)@CV_.N>8]VSP#IMN ?LX-]B[+%Q2X\7L#M>8,;
M9]();A,BBCC$$V< 69X@[K$*,7)BL=M=$'G'X-:)_.%C$OP";@7<3IW'"[@]
M'W##.+FH!/*6 E#92)'S3".AF5!>8.G7J\]O+X:\4W##/57 K4/!8_AL8=)_
MG2_*K]/+..Y[^#OT/^UVKGE;HI^N'XXE-Z__VAN?I"<W$0$H]1?X;^4'MJXS
M)WZ,:,8_>93P&IA!OF V@?^B_C#$+^>(O4R#^ 6%_C@VC'X.*SF]'+X,_?IJ
M8*_/\Z]KS-D3P&5YQ+-0/@A,_F9&K/GHFWM1'(:75Z.ZWSQ\' <VRS+P]I=,
MJCS]!9M_>2#CRGN(^Y7EO%';C]&6VU[;G]%3CHIL>S2,KW!9(UH+WKI8[-[,
MJ-L?#OI#&-C$CB?G=CH9O5S] 9:]_;IEQ68+QR8@_KD=?+;7]<L7/\Z9=C_:
MRE87XPP-?YJ,_+_SH.YF@GR"X4ZR?VY9WHT&H7T-X,:H1:#S*<C4.$^_W>);
M"-&,)FXP\G_L9O$^9 59C5+UNOVJ7JRE75K/N9;8B%=9@I?4PKIX;U>*MPH_
M!]7'&RB[]&IZSZM;^\JW]HQ=,K"2=#9[64@HQA$7Q"!M&4681:5)X-Y'\F\R
M4^LSO0]4N$2#?CU!<1#S=GI#";"07LQ'MJ+7;RG5C?J[D?"7#>E1?GQ][FP=
M,S^O6ZX+FO&>8.J[!P#I0Y7=LM1M:5UG8US::/XCQBL8[N"VW#:T^@IQ7OR5
M\-Z<)9:XH'T/P?B[6T_L$!56N;NUL:NF^W#U_8PI8_BA=[,Q?(,+-U+>K'/6
M'$"73%;VW>WA;0>^G\A$VZ;6FYCB>!Q#-;%?*I"_.*DK.PS5H&]=?P"Z$IX+
MF#, RZJ:7,1J&"?-I;%Q:>JLKO-7H]:#&7ZL!J.Z?<)DT3ZA\G8\OAZ!TS#[
M!9X#4G@%D#.^KD(?'C6.0P]O<G'R.<9A<T5S4WZBO1Q-A^VK[A@@N$)5Z@_M
MT/?M (8+3V[&,G_9_ G3&B::+^ZW/)*'"$X6@$*L>]5[6)Y^ K=F.&GJE '9
M9J_-S\A-6.SPNJD[JU[6X(NM$>['[Y<&]0-\F>]]$WV\='%<,7)644QY,RKX
MP"H[COFB-!H,1I^!5_MYXJ-I#1?4/YQWR:Y:R:G8CZ\R!ZFKO]X!2O?-;N'T
MS[R,&211&8(WB8'/'QWB-'AD&0_(<NE8D$1ZLN;S/V:W]KV_B&$ZB._27,1
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M%0XQ@4DN7T&0R4UVM6<\X:A9RA[I;C9<7S==IU[G_E%@6GRVXU#_/E.!VSJ
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M#/3'XV+N7\WS?7#,??ED3_.B70;AE\]/-"];?CO^RI&BXX[1_ZVM*=8=F>J
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M8QLZS2B\88ZSX<V(VX[J3G99,.8-1RR(_,_>>[A['&T-L-(R4^6GXT^QM1^
M5?,C\D(V@YB-:'44&^R;=D2+,2^XM1D0C*+[%CK8#\RJJ%&0DN4$<HJT(0E)
M&ITG-DG'S#;,B4='B18I>Z]N%,]<"[R9T?MW(/>*I7XU73HZC>C=9Z<;4P/,
M]9P@5L?AB[_^-XY'G;;4>Q683BGV)S!%T"SC%7,Y^\[P=YBV2SS7YJB5AHVV
MO&T4&RA&#_+P-<MA_\;,SEI8!2FX(U8A&D0$MU0J9$UPR#!I.%%),[^=\WH;
M6E@M\_;"QLZ+]-MT[$%KQNP@989O!>2&Z7?2H.IT3*LE2F5\"H_O/I6C4*7]
MU!$$4D^B_10S/4/U8YL6R<?>J7N,\_+6TC'IU*NFEXY)W4B1.($2]$? [0?N
MDE2::!2AZ*10'+)S3Q&*(A2=%(H[N\GLX/#E5@WA<OAR=2U_[]=_5.LA\0Y9
MO@>G]U$HM)+4>M]V!;6.ZI D\E((Q)7*1=:"1H%AIJ1+3IKM55K;UG9%%L^?
M03I_F0EGWJ[X1W_8OYQ>/G37@M^7V=I3=Y_QV]D:?9>W[W;^ELV<$+'AP ,$
M,44HXHD%9#U)R"I&@@W4)!^/@Q/LEVUR C\,)Q2L*5AS8EACF/*>.8&P%Q[Q
MF#"R%%OD1."<,1YTX@<]QG<PK!%WG^0[3:PA+%AN""+)!,0-ITC[7&\/3 YC
M;%2&KA4[ZB8G;!MKS-UUY@O6%*PI6//0PWI@LCIG%0I@HB(N:$#&88R<)-*"
MOY,TV5XYM2/"&M*CVSTXT7FLX3'00 $M@@=;@W,BD96$(Q.-QC1%R[ ^#D[8
M-M;@0W#"'EN!E!#I#A=RD3B>TYN+ 5$,B'T8$)NS3RTQ41I*460:M+4)!%EN
M-0R(:JQ#8ES[VQK>*POJ/Y^"](P!*OB(\N%^Q *.U'-G5-I>MXBOI5Q_ /'9
M^FFM!W$:[XD=G,#Z!B:_91/<<3P/<RLX#MERR_GT'N [&H$\EMCYI)FV:P%J
M;3DC/$0$. _W8&*0(W!WDK#8VGNN%3OQQ14]?-C%;5*$"RX47#@<+BCBN2?*
M(\6,!T4O,#+<YD;RR4AO/1CRZX?EE6.$$(RLEQ)Q&P-X"W"/8E39Z%,**9VX
MZC@.7'#1BJ0C1\H)GG%!(1T)12Y'$Y6G29(U7&!)X10(K";5L+@ *\@$;9%S
M,7FX!U9ZK1+"B2VNZ.WBV'7!A8(+QX,+W(+06T91D GGG6Z&P&(DR+"8!*<>
M.[GF+^RUU4(W5<?!<>&KJJ.DV!UI_.BFED!!A8(*)[8-Q9RWPMI<#8 G (OD
MP+'P#B6IE.<)6QS6K-1'AZ:V70W@7PO)_)9Z /?6S^>]NRM&GN0.5-YDHM@$
ME#PFL* I9\F!Y\*<D<X'Q:59:Z+PZ!#6<3"!)+U#I+P4A"D(<V((@Z,.3L6
MHM* ,(R"(>N903KK":!>"&(MT>'10:XC42ZZ]\QRM[TFQ/(D$<8Q9U8:BS06
M%$F! V %I=:O-4AX=##L.)A D8,P04&8@C GAC#$:*V5%(A8Y< 4!<O5*LR0
MMXSRJ)U284VY4"D8M^"T*.8Q.#*)YUKY%%DLC(+G^:1VFT"U<X3ASPQA A>*
M^^R%< 5,@ TR&)B 6"HH%<19L;:7!I!"N0 L"A:#-TN31<;F/[7&)@IP?5@X
M9B8PG?)A2@+=D09 5TNR%@.B&! G9D"$D%0RD:$4)6 'S2B2XU]42L^=L!RK
MT+F3I=LKB0HT^@(>=BZ$FGE24T)?=@@WBF(IBN5(%0OGBH2( ]BC%+>'?*Q*
M"H'K(8(A-/%UQ7+P8X1%L13%4A1+MQ5+$%I19S02G(H<\@"+)9]9-])3QDQ4
M/JP5<3_XF;%GHUA*JL^1>KII46B_E-,JP'&*P,%"DB2DB$0V1CE1'#FL"?)6
M"F.HQL2M'3;^%E?77XV_[ 8U;II@G"QN%+U2],J1ZA6#HZ::)61X]G0]U<AH
MBQ$E,>>&49TX?HJG6_1*T2M%KSP_O>*-C3HY#K:'28@+<%J-R/G)1BK#K+.&
MKA5]_!9'M^B5+?FY)]$#?GM]FS;H#Z#+K*6BG:U;I@R0KVEUY@>VKK,V^1C1
M:@.C%RN]T/[;$._+.6(OTR!^06V727A>;CXTO1R^#/WZ:F"OS_.O:SJG)T"L
M\YAGH0C<4_F;&;GFXV_N17$87EZ-ZJ9=[WG3^+/_*2[WU%E48__R0 WUA-YC
M3RN8ONW5_1EUJ4<84RM\ULC;@K<N%M&G&77[PT%_" .;V/&LJ]7J#[#L[=<M
M*S8A*)N ^.=V\-E>U[/V27]9%>L=R/ <U6UU,<YZ\T^3D?]W'M3=3) 311Y4
M-;]Y#6C=T;B1Q?.F6WF>?MM.8"%$,YJXW(!O-XO7-/G+?1M?MU_=G!^T2^LY
MUQ(;;8XLP4MJ85V\MRO%3U[0SFCD)<HVYL>R>I[;'Y):*D)$5,:44P,T<C)0
M% +E2DOFHH[_IC,5/=/A,*-+-.C7$Q0'C?G0S.HJCE_,9[VBHU=(NU$3-[+Z
MLB$BR@^OS_.)W,R9ZV;=8O897-5W6^S?N-9UXNDK-!OC4LC[CQBO8+B#VQ+8
M4.HKQ'GQ5R(7O4R7)&76$ [C[VX]L4-46.73IC5HM6R(5M_/6S&''WHWW<UN
M]/R-U,[8H>F%V.%6H$\A8O.J\_X$!N*_@:R_QWH"]FB.\K<4_B?8X_538/P
MD]A"-]#3Z?\Z[YD>*XJ)KG(7W;/JRF;7NP_#F]35I;W.7=+G'=K'-RS0=O;.
M+EE]5D7K+S("P]#APSCF)NL9B2N;'<O00*<=5(T+G#.<P>". *)5G7W"IO/\
M<C/YJM\V($_3[/O-.IAO?/-B8-.;[N^@H8;5QSB,8U""UTT;][P5!4;"=37Z
M!%?9I[88OZ-#LN7>2DP%,E:#JVPH0SKFHK3$4_"X)8YJ+8!'21#1$X-4S&=
MI0!+*>2@7^(N$,H8I]L[ ]K\\Z^VK?UO,/!1V%QE8M'8NQ-,.@';-:)<&&('
MI2FVWFSXJJ%KK_KG%7#SIY;69PTWW\'!G_N#06:*'/'*K8A&%<PB_F?:_V0'
M\,QJ.&TZ+^>VY!N%I14/>SF:PL7PV[Q'>6NHYF;.HZ^]'@2F;70^:F7.#\#2
MA;M B?T1)]45W-+8UOFWS&YV>-U$4=3+>E5F9_<'.VFN;P2S:1 -;X#1@4[Y
M;_L6"S>,;=8$J'$7X/5P22.9[3AA[F!L@W*(XT_Y[7.2WB.UC^QK+KCT45FP
M1Y/-=>IU/L:"#0J2*&]-PF)+F:L;^IHOR^\-NC;@VF!K*[4>_(W^Y/JKO<RK
MA7WS:O+06?V;=$3"?]_$FI6=S3MKJ$5'\KL:DE>?;;W<@+SZ!EWQXJ_+-L&2
MY?O-S+7!^WGP0AQ'>.]X.I.K@W0FE[)G'MV8G,A'WOG(VUB/[?F-/4GW^T+:
MTX]=CM+\_'DV^2S-S_>Y!0QKF7]MMNVV0-O2WO8)G/_KW-7XBQO_N&25-7]N
M"/D\OQ[%]R[04>1,E+[;14D=K9+ZG^:NF5)Z!32W'V/S^6]-Q.%-3CK/?^;$
MDJK)+"GJZC#J:@=G.!YL"&^<6#G#\77XST'(.D=AG!W8H8^5G50NPACSO3FH
MMQ*$_39I>LB"E+3)IYH R^\>CCI*XWOH=P!2;8DA2]KI<MJ'B$0':E!T6"-.
M3$2.!8N8XH)RBJ6*ZUWG@Z T\1Q-SR6EHA;(Y/KM0@5BI>?2*[NUW;"W_YGV
M)]>_#,'+F>8OZW>3BSC^<&&'[]HTU(4^;/VBE?S3=B]F.>T4WU-*2 M^QH6Y
M,_>T2/H127H'Y+I S_89<E4M/IQP?^X.9Q8,6CFJ::G6-J&H(P$\(1ZY9"T2
M0F."*1%FO3M41S%H[O;./-[&V<V^[N+\Q H\Y3!=WDB&"^IWZ56S]VG?Y VL
M<=V,9'%V G_EZ,1Z9V':X[H@V/81; >%_1[L*B_O-S<OVJ7OO+R?V[QL^>UX
M:QO=77.M_]:FJ74')CH "L6 Z:X^*G;+88N>F4AU-+D5" N(^QB1%CB@X)T+
MD7'E-;EMMUAI8N#)(1:"R64I$M+4!H13H#0XQIW>7FVB>^V61N'5OPS;--,G
MNLZ4ZC-,B^M\$H+> ;$NR%,8LB#/1N1)&DLC/4-1:$ >AQT"_UDBYXCPT6BF
M_5HV=)>1IQ-N,\4]?G<9^:(LCG*'N;C-NW>;_]6$OKH#%1T AF*[=%<=%=ME
M3[;+]P?JD*.XM(%[@10.$G'. [+8&11I)%YHIK3NN'74:M0M^>5,\C,M[^[T
M^@Q5R6-W$'_HCD[I@ 8I(%= [MF#W&8(BDD:0PTX,U*ZG%;%D.'2(ZF4X-(E
M:NA:D8$N0U G''1">J2$ESOCH)=][6-QT&<5.HN/?K+FRR,/MQRQSMHIRS[]
MK-!S,H$.Y>=SDCBVGB'A$@8_7T6DG=5(:NNY-((KO58RN5M&UD(Q;\G5UV=2
MJBY82,>CCXXK%+#E,\$%;T^>OPO>GAS>;D9#(FC0.BF$<9RAH4LB(F$CP9HS
M3=>SZ#N)AE, O6[$&W2O&R?!GI^V*8?2CRO"L/%0>AR&<AS]61E"M$>S;@JC
M:2X.>*K*:8^FT#<0M!A#2\:0=<X8%0T*G&3#QGIDE--(A"2C),Z)8&\;0\(8
M2;DA2"B:<JMAN <GCHQWB4=!*(_^6(^U*ZS/C,3=,V:*QMBMQBA1@<+:)W"(
MOJ#B5GJ7&LD(>/4H>D419P"-5@6, @:T4X%I8]>R$CJ*BMT($(B>9 53#Q\B
M6.G)N*'W8"G;WA$*'*IWP9OIN)^;;,SZ$]1W-2AH_F5-0PSX0,^6&VKD=CA9
MSD(%KT+>UA=5TP<!M9TY_'(CJY7V'O!CTTQG8V>/R2CW1H*Q_7G3+NHW$&,/
M^(%="!)KC7P*''&K)-*1)$2U5IP()OQVLMI>#08CG^FV&4C>ML1=U?#OWRQT
MN%S6X4C<H\1%[^Y#7UU@W0KN'\"@SHZ!0X26(I @$98R@(4A+-+$:*0U<XZP
M1(E/:UV,230*V IAH2)8&"PA,"T<F!G!6N<)$7JMN=)>.83UZ%%P2*.VCH!)
M,!;,)4&1U<FV9J@#=8 "85RI2(-EZV:H)H&8I')[2@),(DPV0QERA*OH+ DJ
MI8,R">G)HV"2LPQ$N7%W_U,<7/>^,L24]CW$;^@B_>V,?4=C*>XL<[F(!XO9
MOTF2(@-(AJ)C."0O(A=\&XVE?@->RT[0,#0^S6\CL ;BI#]N_:$XC$"+^DV_
MSIV]IN,[.TAMJ?]J;HY8.K ^N@.K.HT.K#.V:SI*WM-O]9FVWORP9/Y?VOYP
M O]?-ZW_+J\&H^L8J]I^@J?,^EE>3<?U-->W!WO_?=NMON*8?/_'#_/F?+_D
M&%1NLOE[_!2'T_ST$$&]@*N?G0!@QPJD[6,_>^[S=]2]ZOW4_2\\+S_7QW$>
M!;CW.7Q1#?J7;6_/M;N:KJ!Y*N.^FTYB-;W*MW??/.#2:QI$R#H5M*MC&CEA
M,=(AV<AEE-IN12._ =X?9I-@1B$801:$?]@O_<OIY:LA ,]@^<?ZMSA^.R,N
M?,SAQ!7; 1;_)HZ$Z++U\,NO/]\;2NJT]?#=C'_[XRJ_:&*_@!!D JVZO;,F
MEE>-/EF6G0L++O<@^IDO?&G_B!4H29\A<#2TXRQ=$W^11< OD[QIE3D7M=5?
MCH6=L1($N)*B8!RX-T9*9%)T"#B<T."C)6QM*W*+[#SCV/$_9O1=^?W;N/B^
M<"CO/@LO:>Y%?]2/XU%=@QX';7K=JWY>:F/YJ##1XKEW</3G.(X56&GC$>@9
M\$X&UT?ALR4-CKE*R!,+7,P]1E9HA[2/WKH0X;]F#US\9EEG+%_TJNFLNS5?
M[C@<_J,("3&GJ<4" XCG *!D"6FA%)+4,Z638I&OG=+@*0KE$D7$8^ V^?^W
M=[6];=M ^/M^!=$!0PI8COP6.W%1(*F3M5V[!$FW[[1TLHG*HD=)=KQ?O^>.
MLAPG:E>@>TF+? D<O9#'N^>.=P\I*>28&4V#*!X@DHY&_>Y1^"B1$[8__?C%
M8T+.MT(5Z?@H(1H=\=?9>T%_=)0$TQZ 0&$/\*!A$ND'D^<P/"8:A&$0=?L,
MGF083+L='?3#*$SZ%$7'W0>,\R,!S^-. K]%"FGOH]+_#H$TT,?3<-@+.MW!
M +-<$@68]L(@I&%O2(,1OXS^'_DR>3G-Z8\2XSQ?\=+X$T/TF!FBT??!$.U
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M6F_R\;-#-/SB<&KCS<L?7AS.BT7Z\B]02P,$%     @ JX!:6J#R<S1.KP$
ML,L8 !$   !C<')X+3(P,C0Q,C,Q+GAS9.R]>7/C.)8O^O_]%'@U$S/9\>S*
MI;IJNGJFYX;73,?8EJ\E9TW?BA<=M C)[*)(-4G9UGSZAW, D."^@J"RW!%=
M*4O P0Z<]7?^XW^_;ESR3(/0\;V_?/?Q^P_?$>HM?=OQUG_Y[F%^?#(_N[KZ
M[G__Y__ZC__G^)B<7U[=DEOZ0DZ6D?-,SYUPZ?KA+J#DW?SF#^2_3^^OR7SY
M1#<6.?>7NPWU(G),GJ)H^^?W[U]>7KZW5XX7^NXN8LV%WR_]S7MR?"R(GP74
M@N_)N151\N=/'S[]>/SAT_&GGQ8??O[S'W_X\X\_?__#SS]]_'\_?/CSAP]*
M-7^[#YSU4T3>+?] H!9KV_.HZ](]N70\RULZEDOFLM4C<N4MOR<GKDONH5I(
M[FE(@V=J?\^)OH;VGT,^B,@*UC2ZM38TW%I+^I?OQ%"65F2Y^S#:/EG!QL)Q
ML(;_^/'3#Q^_(U84!<[C+J*7?K YIRMKYT9_^6[G_6-GN<[*H3:;8I?"W*0*
M*#^S-?'"/]M1<!SMMS2,FX49?'T,W._]8/V>_?P>?H:6/QU_^.$8VN8UZ=(^
M#G>/<3VL$]+E]VO_^;WX$3NL5"@MG"K(YB;5FY<?L"^?/GSX^/Z_;Z[YVLO"
MKN/]5MQW5OZ']_#SHQ72>+S4*>X$^R'="?:C':7+"JH_ON<_JD6=BCZPW1BQ
M#1+W8;DOF0CV0WK&O-WF4U$7/GUX3U\CZH7.HTN/H1@-<%N'QY_@=/'J89#T
M?V6%CUB9?9EJ8Q<>KRUKFR\H?D@57FZ#UV;[4\Q,;G7$6G[\^>>?W^.OW_WG
M_R($CX.SV?I!1/BIN/:7.*"*:86_CN7<'L-7QQ\_L0WZ/2/V'?%RYZEB8=[W
MZX3<9)TZ$>_0KIV0VQ%:_[&LW<+]VZC%L.RXRD-^#']4MEMX*S1N/#/>ZKW?
M8/PUAZ?=I.3.U7OJ1B'\53DM^>/8;2WDK04?FJ]#?-=U'*MZ-?#QBF^:C3EU
MLW3;!@7O$OX=-CIW1:]:M_F7-S9\:#[_\3T_P %L<_AZ'KP?V)7O+G<N%CO^
M^'WQ)1=F3ENNEM(!R_/\"'^ K^27VZWCK7S^#?L.+L@_![Y+%VS)"'QXN+]J
M\@J]CZQ7W_,W^_=0Z?V9SUC0.VO-WF&'/<#)G[(EV99-&0/I8*\^?H#_,?92
MX32Q(H&:__$^6SY#:1=2>^;])W[>!HP#]/AHK]D7HK(H4E%1F;Y6]9)NE583
M7\K)U3#EP(@[-N.U[5/+A;=V_D1I%,HE*/NY9DD^PI+,V5Q2N2:SV_GL^NK\
M9'%Q3DY/KD]NSR[(_,O%Q6+^MD@UBY0(6+,MOH3>^IHRAB2\IF%(,U]>.]:C
MXSK1_L:*=@'[]YQ&EN-^X@LZ#*F:Q?^$YS&1"H])3)?PUMA7O,&C[$]')&[U
MB,AVR3O>,A/LWC9+UQ-]9P5L+IYHY+#1U1SO=-F:Y?ZAQ5DG[U*D__"VG"V6
M,Y[C<+82QX;]>N+99_Z&S<T3<,S/],ICY&A^@5O5KEGR/U8N^7S!_KFYN&7+
M/;LDL[N+^Y/%%2M 3F[/6<F;N_N++Q>W\ZNO%^3JEOU]\;8+-.V"FC/?G53-
M_OAQV/WQ=FL,M%_.GBQO3<,K;Q[YR]^>?->F07CQCQU[8ZMW1U7%FKWP4XN]
M</;EY/;SQ9PM._MA=O9?7V;7YQ?W\W\E%__GX6KQU[=U[[KN5OATZ?HO!6Q]
M<;&:-?VW-FMZ,O]"+J]GO[PQ^LT9_;/](SM@=(GL[[T3_G9C>4R>A=F>1^R>
MINL]NZ8_@Z#K<<UUFKMO7;]FP?^48^E3+1!H@B1M'!'9"K$\FR3MO&V!FBTP
M"]:6Y_P/]IVMT#D-EX&SA;]FJ]-=Z'A,;.*+W:ADQ;+^_/./?_SQQYRDIE#%
MM5/H$G]%).6WA:Q9R%,K=-B5>J<,G:W2W%E[SHHQ,5YTLESZ.P\DWSMV%R\=
M*M:U2\6:9?XIM\S8"*RGV@RNM](025HBLJFW=:]9]ROOF881/JA\/=4O:M;I
MWW+KI%1^F_G&KR?;M[L-C((USX2&H%0^;E>E9O7^E%L]A2A!JB1%EG"Z;PO;
MX$AYD1_LDP/%_ZQ9D)\+CQ-6?9OSFCEG[\+6<NR+URW;JQ1T OQ8[ (0Q$_"
M,+81-"I9O5(_?LBME*!*)%E\F\09XI0))_VVDG4<95K1+YC'S)<UZ_,QSR=F
M-/IORU![H'PV91&(7: WV<*;?DLC>8:*?ZQ9ED\%QX83PN,2DSHBC-C;"M6L
MT+6SA*N&K<')DLU<0.TK-@/>&KQ0PGBI:DO5K-D/N343%''))$VB$'U;O2:K
MQWBM8$=SSY"T)L;B58-R-2OXQR(^#V@6/58*W;<EK-5>NJ[UZ,.[\@P'C!\,
M]L:<! &HGQ6AJEG1FH7,:S]29'$58\)$I?RVE+5+N=DX7&Y%<Q(J$:B7:#FJ
M"M0L6UZ;H1##14N1>UNKNIMS'5#U;"E_UZQ$7E^1U'V;]EJI%H3_A?5*8T51
M\D7-Q.=5#;PRP=IO4U\S]676SW;&35B(O(I!I?&OA%-Y6Y F"P*Z,?;6X@"4
M]4A]7;T</^7U"$B"J#3>%J/.<D$]UHGHSK7$,JA?U"Q 7E$@*A.H_3;U=>=@
M]QC2?^S8L"^>DP<Y]VW-(N35 @D%PDF\K<3PYKO>9KR&YKR?\BJ$SN8\\DY^
M>G.JTK E%A8H<#IO"%&]9COD]1$]M@-O\FTSM##SJHN<_[IF\?(Z"(7$VW)H
ML?VJ"]:E8LV2YO43S>S ;ZO=VB"</7KJES6K5.QK@03>%F)(*[&Z1BW*URQ?
M7@/2V&+\MKP=3<?J2A;_5+-H>6U)+C#L;6WZV9/3IZVJ2/5:_5N12T:I;?EM
MV88R,JOKU[!LS4+F53*-#,YO2SJ<Y5E=U,:E:Y8UK^1I9H5^6]?V=K'4^F6_
MK5FGO+(FH?"V%AV,96F>/_MUS6KD=26JX>QM/3H;;-15*?NQ9FWRJI"\\>9M
MA88,)#JQ;>RDY5YY*Y\1A#\XU$+S&*,J(C4KGM>4- T_@FLT;I<H#<=0$6\;
M9'AU=NU^&9AFS?;)JW"Z*[[?]I.!_71I.<%7R]W1&R;\LQ7$\-0M74*%A<^U
M-;.8-=[WW&G=6JO9@WD]5)\]"%TDV$>B=)+(7I+(ESHL/V'J]V][M+V9H,/^
MF>\V&RO8SU:,BK5F3/P:%/IW@6_OEM$]?:;>CJI;=*S&:G9H7NG69X>*?D'M
M5,^(Z!H1?7O;D^/NR3L:+*'2FLY6BR<*/+/E[<.%S[IQ2R/=N[1+\]7[]D]Y
M!>1 ^S;I*_P5/5$BNONO(<$.H_KK;3^/QP< 8+2]<]G>N:=+WULZ+F[&)8@<
M#@!V/]-?**!T4_ODF09LY<#CV_?FK#,T[,D6#-)XS5XN<(OKLY=%C\EL1>(^
M(\4E.0&9272;R'X3T7'">TYXU]^V]#A7=/+CG*Z!GY,*6C[].4<$+6W4;-"\
M-KG7!E5*B/XD6FFQZ]Y4.&U\C.*']N29S1VHP"[]8&ZY5"ESNI\+.!YH5[T5
MAR!4LX'R:F[5CRGU_L8M'S,I^QC:3I5]W!/9/ $,Z+=KJL-^J=74-"Q;L^I%
MZG1UU=]T*H.MZ$48.1N0M&(U1I@_Q.+@.&FFJ#>5FEU0[<-X3.)&%?U&F+H)
M"-L;!&^"I.VW7=+GG6 BS&?+03#/:S]D[^[,X[%(M5ND XF:_9%7\Q>_#8R=
M!<D+&T5&EC=+9IZ(HWK;';I=8^/%9W*%:X4A<G'0_7"VB]A-44^A6+<P9M,U
MN[$@:+69>VZ*B<EUDOB[".^TAKZ^;]NWI:]OO#^$-V?\0_8>:U2Z9I,4!=A*
M[^#4/E@*UU(G<1Y^6]GAG(>;E%'7?V":-;LDKUIO[H3<RF'Y;4MU<EBN]V]H
M7KYZ*_R<UU;G7)O?Y*&AUS?S9\7*%I>L6=-ZU+-"#_:WQ>RTF(D>?K[;;GEJ
M3,N5D.3*<;FGR%TM?*Q7L>C]*-9LCKS&M&!SQ)IZQBFH?2#0"0*]2-T#HA]D
MX7,2;WMIT+VDIKCIN8EJ2=7LGKRZM,WN$:T3;)X$;[MFF%W3(@=6X59I4[]F
M?^05JT.ET'K;%-T"JTJ^3@L?'6K6;(2\;K4J#*LF2.MM"PP3I)6\"9?057;(
MG]4B>;%T2((U&R:O;&T6[I5^;G@W"/9#*?LFD(ZQDRYW$:A,-WX0"5=XH2+H
MO:7J*-?LK;SJM/O>.L8.'1'>):+V26I$WK;94-NL5A'2AT#-ILFK4IMNFC=M
MB>[ U.22J"^K;A<ME&OV45[9VC#@-7W[-(V2?=MD X(VU]X_O:E4;IZ?/N35
MLTVAGM_N(9U@T TV1J>Z-=LAK]FMA)!^VP,#!M/7+GFSHC4K7 "/D(3=ORWG
M<,N9//08.W&W"Y9/5DCO G:;_F*%)Z[K+[EZ=/%$);?'Q<A3"_O,OG<"5**R
MFSCQ2RO>$KJ;J]E6E6@.:<]\$4LB>TBPBX3UD<2=!)4MZT["! OQ&GL*;D_8
M5R([FW*?>]NJ[;=J[/LLP]:8U+GSHCO+L2_] #8,SK]<CI(=V(U*S<8J2"J2
MVEB*^[1LEO!V"32,#I00RB1V4+RCWK:)]FV2RDT^S)XI(EFS@?**XH$V4#KU
M^MN&ZK&A\D^6\EZE'ZN:?=2>4LWV*0 M+=D^A<]:\J1!B'KF.7O;,MKNH'[7
M3;.M497E);TUXG!P8O&;9:O>+-;;;M!X@72_,)KM@H+LMB6[(,(+8BLOB"U>
M$%9\0;RM?VO'?07F+)%_XB\+C$/=JM;L@*)TN@IV6EK-FOST9LWI 7;7((ZO
M4=GJI?V85X]FEO9-7S+8DN;Q!AP<4OY80N#(#F 'HCF;K1U$%UQ2FP:PP*+D
M/;M22[:#KG9JME)>M5IQ2Z1[5G)OR.X1*R)Q!XGHH5H!.OFV)3ML29AAWX.7
M?+8ZIRL:,.:=_9!G,5O6J=DJ>1UM9JLD;2#>D&@%U_I-M.B;\NXN$/.)/Z%Q
M!6%-\*^Z9V<X<C5[)*]P+4JP1][%S0O04&[#X6@G\,4?WAXQ#7L(@63NJ>3U
MZ]F5?B1J]DI>AUJ\5SC^#5$:)6_;0\?V8 4_S)^HRSB0M1-& 0X+GG 4&SML
MENX$:[9."?9P;NM !PCV@*A=('$?WC:2IHWTP] ;J2/!FHV4UZ.6;J0?WC;2
M&!M)A0_'+]"ZJGY;H$#I5+-F:^3UJ 7XYN++8VX"3OWTID?IN_S-+HJF-6J6
M.Z\P+5SNMS,^E)8T?V:E\AM_F2&(_,DR<I[9#?S@L?M802J%],3%&M2AR-9L
MEY),XKG;(=&S\]]Y^T1V@& /,JBFT(NW'=7]U8@U:>@GK!S3.QJP.?4<;[WP
M"W9#]8O2DVKU?OK4)!5Z1AO'O:#56RCI"=AUBS?<V[[JO*\*+I+PY,4*;.FK
M=L;G_R0,=QO^<_66ZDZP9C?EM;IM;J>0\$X(QS965/2#*!UYVTC]-](]98*$
MLXR$%NZ!=;397=2<0,U&*<@]7[-1DB9%46CT[7IIC[M-/=:)"-[Z^CPMS<K6
MK'5!'GI.ES,<;[QM[X.^>PSI/W8 Y_S<R'6^386:Q2U0IL;$":?^>U]A^,\C
MN+C U+O>;[DIM8(EU+RG*R(^JOO@]3%PO_>#]7O'B][;SN:]*//><MEROB*%
MIX"NX@HO+R_?QY4^??CP(Y*PHV/X_/UK:/^34A.@D__R7>ALMB[][OU /6.?
M(43*]X[9W%D[-^K8SU(ZNGOM;QC7T;_3*3)Z^HQ-'&_HYI$&73M<1$-+;Y\8
MT6"Y>Z3'\21U[',%I3X]AX9IR&Y;N@O\+?R#+;]G-\XJ'L6+PT3G8\\* O^E
MR:2[01#7!>+'X@\VFH]_.O[X\?C31QQ3,=W.PPG5E0 ]<MR)$+@JN,^.G8AN
M\@,(\TO :BO7Y_''[WF7BRE5=UGVMT^@H!?ZKF.#GZ"*L!2FA[+<!J_'D@1V
MM[:B[IXG#V5W3*!/=:,<M)$QUS(V:H2SE>BE[_%XSAR(;YNE[D+7U+@E[%RK
MO5Q)0/=(C"7RJ9X?P]T:[R;1DVNFZ16CL_7QYG!4R/.F4VN@4[IGO#E*=_4D
MM:6C>UQ#8U17CUY/:[KG:"#LS>JI&;21D6>D%:YDJVGH0%GWV ?%SJN># U-
M37)V:O'@-$Q3PS9USY<>"*OJ^=+9IO;Y&@^7HV82Q^[(B#/;$4:B\83UHF]@
M'CJ$M;>>B\YM3&]?Z-H/QL?=(#IYR'4W)9>WBL9M*A-V(*I?IM,?LU@G#8[5
M@Q'GLE&P7>-Y:4%-O^;SF09WUKJ!"C=3T)A=(85MT]G(4$AEJOKUSD/NW8@Q
MS?L3@'F&5UX^#*2S+KZ>Y'COT=G^D;4N4B;?.^%O-Y9G<?32.825T#6D'O@,
MA\Z#3=O\4>I*6;M^)5A;GA!+08=/PV7@;/ES<+H+'8^&M9KN-C0F:&G18"49
M4U<LDK\V40=GBD[*=C"HSG]T77UC9?R4M.U#Z- -Z8%;*G?'F_7"_#3U$UU9
MS;0FM:]6=#H:SO[ZRO$XL 8H[O4\5PLB^D=4"C]>/X[:JN/I:)IK7@Q(Q"W$
MW;%ZUUY4,"<)Y*(Y&G6UJ()V/C<).ZCE7_-%M<]CQGF^=AI+RD]06M H-8PM
M/73HXL*"-UW#V-.$1Y2;FHVHM,*D9*AF8^E!<C1YJOFJ%!2?@FS5; #M*8TL
M9S4;1F4E0S)7TP5H4-FT_-5L*.VHF)?%FHVJ+9WQY("&_2\I/Z),T/0N+:DP
M.L_=K+\UU::@-Z^,,>VO4F] ?H(<9(])T=/:!.<H=LRZ8>\IX]/02K2E2ZBP
M\#E;,(OOP(;^KF/W8]K1'=(IAE&)4RW8C!NP=\OHGC*V<M?:[V24;AS&K-[1
M8 F5UN"JF$ XH0<23^-N:)Y[=&Q$F31Q4WMF'8!W[=(/YI9+E3*G^[FP)D,T
M??.0D(&:&'$V>KP8[:B,.*:+,'(V<-83']S\4HC9;^QM/11]$SN=';[/EH-.
M,-<^>UC"F2= C;M/0G?B(TO9?1C%UI1&'EOFSTZCJJ0QB9@L&5&LS+JVT*R6
M;1G2OY1\W31ZKSM-T]J:'H=Y -*3L$OWF(*AZ!NT9O<:?1^JX^F^>@RQ%9'I
M19Q49BK5%994T=B(>L1>?'@;*N-[)'1.X-+6D:%G0^//3*NT)&UGHP/Q\6?@
M4_?,&VWGHW=31F:G:SJ)#K/3KZG1+1F-<B2T-'.TH#GZ>/LN=TM:X^E"!\/#
M;ZKC'+C!\7=^7YSWMJ=BF/;&GZ<>N.5MIZAW4^9FIP$8=]?9:$QZ1(_./C;2
M5E3&]@/M\T"T)]5M="LK?$1$SUUXO+:L+1\)I?;F_<5K!,J(1Y=>>+N-B-N\
M9KQ(QELA!2V:HP?#>D_=*(1O@'B((\510C,#=3\,(MYU]N%X@.X#O:3K0+2@
M[Q_[=3X+:OLS'X''[:+7UB-M .<,6+)J-4#$_?GXXZ?CCS]A/XNHZ>@N&A6'
M[7.>9'7'72AZS3Z)TM!$:>]_X#V @C%U)X(*,9ETJQ3VDTUM!:P[;MA?IHHB
MSH1?  3<\)C -\E.$U_\[2[PEVS7A9>!OP&#%I.G)5)7E;5+]@*']9?O^E)[
M;VKXL>S#EH9>L8]E(RLH:*[3(//GY!<.#WJRBY[\P/D?:B-+JS J\)Z%%Z\T
M6#H"N^0>M,'7@ +-/SD;)RH;OLXF!YG(D"Z_7_O/[Y=[F\\A^Y!,'?OC;[GX
M\5.?<6[@.!+0)2,>SI[9[P"\NF#'\I0U^5MF-KI2,;934 >**M 07WI $ #X
M;^[M%[#5$1@=\-%:\B)AV2;H2LW8\*^\9<"M>?S?*T_XM83W=$F=9[B,2L;:
MJ*JQ@<'!NK4V]#P%_9^]C-.%NG8VST?"-[G-T";261ZGSG0&'HMB- 3Z$N I
MMC;<I'(6J+UO6'/HN5]%-(C;F*V$U@(MU_9\:RUS#W3C:H/>Q39U^&YF'Y)-
MS/[XVX7'^*(]$T#8^Q'>L4O"<O^OLSWS[>QYK"EL[ 1*#V(VAX^.Q]%GT%5N
M7W(:*RH8??^XO32B=!8P^7 I_V(R_=;GD@YCUWJ\C%WIFWTST<\I"9#@R+8G
MCZ R7U8^C]45C0VJ+#8-?+E.*1/^:0[:>V&]E@RT(S%C@\^@Z=_NX$Y&J'UV
M[2$+.]M%[%;Q;'"2L/^^X\YO):/O2LW8\&/_Q:(-*MS2[9EW#R<W@#Y[]JWO
M!?)/]!5>5+!*P]$?]?&!/1ML?<4&=@;\7;"O?(6J:PW\SM^"6]IJY]DP.P_;
M5>"#_(D<QR6%N2UC2YI5-+8CA7-X6'.AYHH9%"08YT1#]"Y1T%AR,D.ZU,"[
M01MT<9GN8ZQ6A^:.>;SCYX ]1PO_ELI8A ((FA1WW*":L0W(7YD8ZM!;BY0F
M9>JJ\O+FGJ%RU/L"8/>_4BNX]'?9VZTGL8FI[!2'S--]4N3.VJ,[!A@6A9%1
M*-'@.L_P'RGU6BOMW?"MFYU>E>^JFHA4.6-=SL'CYO#M,GVOJ&">M3S=QQ^_
M.&QGL$=B?\WN3_?DU2F[HQI6'OQUD&[A:*P(0R:)4F@28X19H_ZV@/EO574D
M-O9D9SN,!JCX"MA5]5?CFSP+>2WN96%IK]GP-94/[TZOM37U)SPTZYGS)*SF
M&2N*#RTB"49G$5APGY];>S0^HI)^&V&$ZJT?L<?IFD91B;#4DH2Q#5>47RDL
MT\@UK&1L,!5Q&HD/7]W@6A(9>.^=[RALE,)XFV4)1*2Z\5K5-V@B9U-W%89,
M-CK?@<+FC@:.;^-SG?'\PDN(24ZSU:4?K*@#29O*#>H]R0X[(7G7G'@BV!]_
M$U'MLV!.@V=(^Y%G:TJ+35'B.MW?6'_W@S/0TE:Q:"THF%/8JV%MJ%NTDF\4
M6W2QOJPK%;/G,8GX2)T>+M]4G;CJBN8,VIR+">/L2>(DP8U89#IN7L^4<2U)
M3B"$!4C0$-%U@,JR-F:TAI0&?MSN_;WE1OL;/Z!S4(1]V7DV:/8\^])9L>\=
MU^6H(<!@+)XL;^;14_YEN5ZZ/U&#_(H'L"=<\8_6S3V30)9/&ROXK>(&K:UF
M[LAQ1XL4D''.G4\I8O;"2TD3C!VGS9G$YO5'92D6X!@*":-LY]FQ=U:1JJ2\
MG+G7-N/%>4X?H\23$[7G#UY +1<< L$B7/;>MJ9C;@-:B!\!VPC4*2@I2G:@
MT@.K046#-CC)8P,8!DA/[!\X'L^LT^Q%+?ZVDH7J1=*@;4^H47_Q@]]BU1Z*
M&Z#?"YY+K\<F-0=^E5/FMY3_)3M&.4N(T%<6O<3="$U0E'D(Z6KG7CNK4O>$
M)E7-[S[N"U;WEI46']5UX@PY&I<]2?3UOVC68%%>[O!4M<( IN@=KCPN,6DR
MM16U-*X]8;9E!\;WRG9B54E-;KG28[52YUQ>V!RK9#_3('( >D?8+,IXH7S!
MZ<@Y5:Y?)84U.'10: %!/M$+O\R!(UM,M]-[Z2O:R-6]O+91M;Q 2. Z(:ZB
MK="_%Y4V=]''WDH7FZWK[RD5FMB2>YE[+^&>@4R^:P^D#7[M0NA*I=^CGK8.
M[XU4_3]EU#O<!9?L)I8N<9#C^(:]%IO=9NB'LVWS$XI&$OH5:>@6=[\,>:E4
M?'8D9G+P_H8F4#/5GI]EI4U$IV O9@&3[IX=+^=B55M\0MLM,0(G+HWU"]&&
MB.'M!6HB;E$%0_".=3))#<T#$Q04M8M7UF<_L!W/"O;(*=XR;H;5#'R7=6TM
M[X[*+:JGQ0DQ?X!:7:7BJJHQJCJ56R-W8<1F.RBR:984,C?7HANY&:S4L=75
M,N[JA:S,F;5U(JZZ%<]2^AU2\F=5WS]]J6J62(O8PXJ"FGOSBQ,]G3K^C14X
M%3:X!K4FJ.8K<^M>L);;:_ZJJ1ET\&)/+&SUFE.1+V=6:GBL9]L?ZUW+V1JQ
M+1@Z2^3F/U;)"7H:'/AXIGWN5'8I0%4/\ VS1X&L=@]N];/50UCL[S  P:$M
M$4WR[I6Y.;0G,!+G?^8_L]>D^/3E?S=WZM)(7F6*T=KBYI@?*WS*V %SUL/T
M%TI)KC/)BB87KTMW9Z,*=?D$EP$(_1>K%2V]1D?NA$F=7C94FYN/FMF<&E<W
M-L +*X K#]9$ZHB<9<EHBLM.RJ>;OU0+'\'FRE2O#2J:0QM(>YM?<\T!;)P:
MQJ9!1=T:?26[E1(G-A-2>Z&#90]"YFQ3KNN_6$R&O/2#<W_W&*UV;A[AZ)>
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M#0>Z<.?6.'6U)G>P=T(Z#+4J6EQ'2U/#0*AYB.MJF5>#"]AXCJ]NS[Q[8))
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M^BO3 W>E8E[Q>N5M&>-T#;$T'RL9RJH:(_'P,OD6) [W@RV ^8#3R3U@=U
MWBQ9G79U)Z:':2))-8D02V%8=#43#]@#<YHYQ7J3A[DN4]555QI<W12#5;'I
MEW)%N7M)97F3GE>01,YRKSS&4.]*9*>ZT@=KCU $TLQ!N*>P,)A7AP<K[BP7
MQ*M/FDP577HRA<CRLJ!_B.^_I=%L!;D%JN6]KM0F$Y32S+I75\N@^Y^J]\9@
M@T8#JJ]G#FHL#N_@Z#5)@C?<9HA_FSN.==["/8E.0,]<!K 8<GOZLN1GS MO
MH:MZ84(.C0T9C:_+7$*W?E3*OC:N-H%=T/"^K12FAJ*JT8OOACV:?;+1U50W
MA1=_[[LI)/=6J/#EE37%9DD^%P![=_^S"]9.?3A6:1US_,ZSY;BP_JQ+L/H)
M;-$Y?8R2O\H8G*;533)TF1Q)]3Q;684)W' E,)()8F28@D1M?LEU)FPR1"H;
M\5H?%%5:P^ P1*+!>^OEAKTQ 1-"N40 :#/!<^G9:U#1;%A'"LZD#N2AO()>
MG?_,HZ=%GOFG+77\S>CH&0N[?)-DT%=,TN;9,8 EC5.AAK/5PW;A7SHKUF?1
M)];UVO'UIVTT_ ; 0H M9Q^3N$" OT!UCQHCV!Q=HB_9P?T497BPN _FUF;K
MQK%X=E-DG$YTS*,85HIMZ4+F.IO):,VU"<UT$<WJ3L_>V]DE7#OG+BQC0LG3
M!$2AH/Q40-PJMW]148,[1:#<M_$LJ:ED& Z_++5UK76Y<?71X^NX6UNI4Z)2
MQ&10-R#18A)<&8K=0$<C+.'<."A5[J4*X &;F(PVOX:Q*2T^1?2$@BBXDQ4[
M3N .#>!FY7:^SA3-K>-J13&Q52S  NY_&H\ 61T0/5@/W+A<J?#8BZ1Y6;F%
MR%]>PSSO.EO%=N<[7\#<U\G)#:J:=Y%-M.)UGK!*2?T(:J4)ADK+ZA'8\P@
M*=FY3B9O5'VZCD1=$IY\]=G#B^%_8Z=:R;1L4I$-,8;*/5P#9%5:?E)J;'49
MXNROP.O+8$J0#V%M^%HFZ]-9OSU4BZ.RYO,GZKIU$4.I0J8W*I/O5^R>0KTA
M0#DVVJUEE4:=:W98KFS KI#<?XU,5%;>,,Y=G9UK(C!P\=VK<#2)$UYUML9F
M=4?=/&+'QNHZ8-AV12DY*HL?K-NA\+*%F[*ALY\NA(0N/3'GU96REF>MZO<B
MR9#,+E3FQ=6.R,"LK<S>BU@,J; /QJI&9Y9W2KF>B^<X9$_52H95Q\)F04Z>
M86GK\Y1.I_65EC&9;>#1==9%N 9=J1C4O273*@]=TF/E8TT>E794)L"Q"K>0
M4+A+(2POLBQ*%&=[O[*V),U-A+^*7@!W/DE[4YT^IK3\]"Q5BLS?U6951&(J
M%J(Z1K"T^)34?'4K4UEEW!!D;J_]3"&6>/O$1 *W//ZXM.S(,6T)*-LE^Z:(
M72TK.2;4354(4GVUB1@^JY*T%94<>()K4ZE?5V69:%%[DD:CQ(2G6GLZV(I*
M"!D;=%'"W'+S<UGIL4 CP;TOH-:9;Q<"1:H_&SRUCA]P2V[6&GQB_WT71OCN
MTW 9.-N*3=2:S-#G?;?96,%^MD(DR=F*73$A! *(W$ASA]V1T"'&S^0<GZNO
M@D$(3X"SE_Y\:IZQA(MHR]2WHS:%]#;5BMF"@N;YPMO2#'BI(I,VV)]$E]2F
M@>6BR@^ZG"K<PVY?1]F<>3A86YYX*I-D"?R^4*\/19L;JV[JI)AA:(_T *)'
MQ=T3XUA+30NY(A-A7W-P9RT<]]1:YHPCL3?[G>4PQN[,VCKLCBZSDI24UH,U
M>\OV+BL,<B#;MO+C B([)*Y+L>=VX]I#]SOC#Y[V:PRSCHUIS#S^:^& !B!K
M/BY)^*D6)F6O*6R^\\V<TTN+&P6O<R(9D0T6'G;;4&_9*L*C%8V!C]1_[>D=
MV\<;:TEW$1S@8J3-ZK+&IG\1(*3]7B@%>$2)L+L!C(#T+2V9^<;5)Q,PFS&Z
M<64 ATQ P:CL76E+9C*I,QK)0S65)B#UG0OV!*[>@LP,+:6^=M2&SR2"9M'"
MN/X;)@+ LP(&[O#6CVY*DXJTHV'>QS2=%:!:BJVI9-#N'^\;%0TV#>57:NYO
M4M<\)Q%S-I4FX=+B!DW=$6N?VC(LHM+>65+8G- F,'H6OGA%2TV79?);<P)#
M(YW$:+P.X(>>>(URS]96&MFBAH _#@=1 M^N"I-:KNC $PIRH14^G3V!5\65
M=P_.4+/50UB>8JJFQKCV5& %<QC-20P@?[FR7F1M:DX*+#U^FQ1(<+"V+E[\
M,@UM2RIZHFKMTD35)VMK$]#Z.-NF%*8;V%"'3RHA2(V"I+;KA$' BF&@*4QO
MFAR.]!G;WDX$GTJU#^4UC#.J"9LFTU#7<*<%%49ZB4]V;-;\X-()-E=9+6/^
M]U'?-"%E%>[P_.]32 11G<8X5\Z<Y4T&]-#@F=U?);>EBXVC-2AQ$^*W(6)=
M7M<D=1RZ%=/H:)4NJ,V=\+I2F^Z+7O.6\BR,( R)8,&%#U\I=JZ3]3J@:RMB
M7'04.(S-7U;Y?YGKS_!HE6R7E^4J4GX=N-V'[\/O45H!MO%ROX18N'(^HJ+T
MX6U):2.+HY\0I *AR?CF8$+=,^Z/#,.'J/F0B#>.IAIZ=P[9M:G9C2L?QNHZ
MVN"-D-62&I$8=%2LR(UEL\//N)XP HFP0B!K2VG4.+M?J.O^E^>_>',F[S)&
MWT:S;WF09EEY+1=?N:-RZG>#>UEZ'H8+7SH/4<:;*VC&/FB [@+_V;$A5<E#
M"+Q\K&5( .[JPDQU-*7/BP&OM/,=7?C\$/@!P/Q59/YM6'5X-WEIH2[%M,B5
M,6>R:9#[@!\,]CU8@.DYY?_6.7WU)VS8/A+[H%T+6:&!D:2LSN3UF+>,XU^\
M4/>9WOA>]%0F774F-W1$:\H66IBPO+R<V<.6M@+6V$;+*PP^H>F UG+.O*3D
MT/=^?6ZCR:0S2GP-8A=GL4HM715JJ@\\Q>=[V^<N2NSN*E_OHF)#JY[31JQP
M]L@MMB5/3+,ZQK;#9]^W7QP7'#VSL4F-W=S:T1@712.;4+;<X;AAI<&%K5BC
M=1(X(6NA*<QRPYHF^9(4IW3EY95X$A(W>:.3W\I9EWYD369<LH363.AR,;ZT
M3D=<6VV2 9)Y#,R&3%M/HIK]TD$EA4(F9R>:^)QGJXSK], $2(O)+0]>N*5+
M9^64!#]7EQVURPLGXNR%S:1U>V>YOSC1$R80 PW?D[-=^/R:+AU(6PJ#<X,U
M?@I3<4-(L7)<M\(%0^X^)!U;PM/]&1,4UXS5J[NK>I&<@GFR2FV=*S8M5^HV
M'M0FY[IWVKNZ33AH$\8=)4I,)'"E)1=<%L_^T@]DXO0:MXK>Y(U?7_ZJ@F6X
MW$4@>^09AU;"[B!-F(R[W*+5B(EA%3LB5TR7DJ2!(T"#"D:S 4$T%_L'[)'/
ME@M=C V+25_+KJ?&]:<6&M$N)F*J((B-3GXK$E.,4:S@8<IJF(_PH"&8M^L"
M.T2IH9W;1=92=#J(U<8+7VCC%ZQR"'GE"MW<F]8=N,_QR1,O3E'?<F6,+7/&
M)T,&6Y\[[@[0GQKB ;2E8IP_F:VRF;>NO)4?;)!5.-V+'UL D+>B-O".B[>R
MW/))/N R)ZVZ*L9]%N_IDK)G^!&]"6K1Q<NK& PP"ZD5+(&K4& R%6Y>XA,O
M?#;WL%O8.X8*TK VP=0PM"=O4>YI09Z2EEW:Y=JHT-4Z@]IG6F3M5E)N/SF!
M?6<%T?["6[/O[$O7RCX'G4A,[>G+O58UAK;69*83K7+*F,RGC17\5NF74EO-
MO$B$'O?",QH"H^L\BVKKF33?@)S?2,8K+CLP<]$$D^P7Q[-7ENLJ[H!%3$=7
M4N/F8MFPUB6$9JDU.EU*LWU+!F>K<=GYV*Q65<V_)ZQG2WC(,004_@5CN<BT
MLN<)E[$P^PC,JA6%I7HI?0T-[=C)MC3;^,%IN1DJ6\0@_XH6[7(65/P\M",/
M=3:/.[:4F!,![;2IZ/]"1YZZ.GKPW(0C?7GZHYK"QI;V81XC,<7:M,I(AXH*
M T_M)>,0K6U88:?-E#"G20"3(T>C.V=3XJVY*S)G^[+XV1 G@R[+[ Y:40=L
M$Z76VMYTIQO=5!^]OG4XFVDXB+Y=-X96((*@GD07B LD9E&%&U6Y4U9'(I,Q
MG / JV-3O@)H .96T8:V]-+JQ@8(ZJB"&!@!5=LBW*8#H>E>!C6'4)&<==P!
M [4^=( 9-_=*_1[C%HK.=D&IR2M1A"D@,:2B)\= JI4:XN:$>6D_/MWC+74&
M&0(J]+KEY?7L,W95LKN1>DN(!F57Y3.M1")N4,N<N))VYI>^_%?>Q>L2@:Y
M ][*@MZ'XM!I'G2D/DY8Q@)$^M&:-:\[Q*4K2R*)/U8ELFQ-QMR#G,D$5FO<
M+"T_M%:$W=ELCFZLX#<:E0KY!:4&#[L5CA=1BH54!8>2(F57R6!D)Z"N\SEW
M'<X"[JX2411'M]!A<,)I;0UJ1-&X'5J@W32S0&<*ZPL+OZ[*W5-8;FB7@Q=_
M\>3O0L9_+5Y82_ORM*SEJISV1 RR%^%O(#4_,*XG $:@@;1676=,E(,J]623
M>L-SGW#)(=#LV9-#5TRF6N[ ,#1;K5C30?F6:5JUJ,= AKQN7/;)6__E.^H=
M/\R_2PV"$?=W084SKK^DU XAI ^<9M!RP,&S9ZNL.V*B*?V;^Q@G( E\E_+M
MR';CR\O+][@C83-^^O#AA_?P\WML];O_E*V1%6N. $G"#@J1+1)_1< ADB0-
M'9&X$\<K/SB&.O_Q/AG) <])!*_(=='$A# Q_NI?_NGC3Q_^W4J-'W[BWX=Q
MP[KG(X%OD%=OQ^6/"9%?@11!6O_?]+NOKI2A,12*+=EP"9Y,'+3H7.4#R-=A
M2KES#_S9M?]" _[)8:]JU\6$QH\QF3T1@A)1&, CPOMP1&0'"/: 8,-'!#O!
M_R#8C=_3%#)1ZM%7MA1KCOC8'J%RMK8X6P&?+8'8H6N."MG:4Q]TAZMS)V!"
MKA^$,];K$&3!6&KJN'-2+1%HBF!;>/W+UDC<'/D5&B38HO:#UE3SK@1Q@<--
MQYG UHC2W!%)-4B4%H^(TB:!1K^1N5!O5W6(2W!D^D;&F#[PZBBI4#/J'F@A
MG$'&Q[CC+I:DR3M)_ _$\8BD3Y(&#FJ0/_-!>H@^:HNEBP<5Q 2/B$>UGT5X
MAVZM#>7NB5W9;T:$ !7R*Z>C_3KMU^T4ASQ:WTN<SE)9:J2Q64B3/$"S[?!L
MD4Z#9^(6CX&E/ 9'C G 9N-; L4E'UHFP@I.+&S[^X.?C;(GD8C&B&R-L.8(
MMD=$@X2W>/!3D)8(&ZX\>1=:FZU+PS\<[O@+K]JIS4 =R"Q7T_2\!$0C.%9^
M%&0[)&Y([UG7,TQQNIL,C_S*F]!\P:_8:8O;G*U *+2\/5JU[/G66K97Z&3O
M<VB!6/&PF'2SY(T0%ULA(3:C^>H>?ISRIL;Q)<LV6Q%!G'#JA),_M.&IMW#3
M-=0UQL0[_\2V69GPC@D?EOM_G>V9;W?EUSE!(B@>$4Z3,*($J.KF"66( 5NJ
M1\?C/HD\&V_'\4B"1*5(.$GRJ_AW1!W"< -4M^+IP_SJ]F(^)V>SF].KVY/%
MU>QV3DYNS\G)?'ZQ("=G_^?A:GZ%7X^O)XK-G;-@OGM<RK]4VZ<?Z-<@Q=T@
M?D#4CA"E)V3%?C2H7LKD6N6QG]*(UH=MYBR20OJ(<.+D5TE>^PBK$*Y/*9MY
M"(X"'S!G)=-?+:S7CJ,64H#:&N'-D7?0X!_((S9)<FT>$=;J@<]%(=?,IV29
MFI(U$Y?).U>=D"#;L.ZY*/1[+ -32"+E.FX,V1H1S1'>'A$-$MXB49HD29O?
MR%2HCP</4P3VQ89V8%.,9S]47>=RM]\-!N%0>^;=0X<"'KUVZWN!_!/3B2]Z
MZ">A?8(=.")Q(WA5JLVP=P#:T'Y!&IL-=3\D4T)$D^A;8W)^$E87+LE@ZRON
M,F>@<PWV_7G>%.DC@L2!51 -:.5_9:+:>[K:>3;,Y<-V%?A@EX[CZ ;1(; V
MV/TN&R$[W@IQA>R]HKIE3BV#% L)@TN($T&=2,4"T->N0,@&C/;DW229$;FT
MOCU7[Q))Z\_ZK3NL61I&@,IU2[O.MJ1"@ QX)RS='3( (M<5> $060B\&(0S
M-$DBD28^4'5Q(+:*H!H5A!Y'$-9Z^A,$J87/YC,5MOR+%8HLDY#J;_%$9?YD
M_ABB>\;,8]\[ <=1?DXRJ26>GSWO1]E!8(<BZ"*1&;>%T\6+Q20IV4U6A#">
MFAMF6$^ETIE[OK#;*(+>L@N7=Y>LX&E]Q@[KO66G-\_BA,7S.UL1[%JBY.4N
M0*QW).X>*T)81XCLH3#F$.PCF7D$>TED-TG"NH2CN&"I$>^? \S^Q<YD#(X?
MLVY]M<6\!;*&)HXC_]BC$=M4V I[NN-F-&N+AQ^G5%"HXX,S53*^0QM>2EO<
M< UUOQ\RJ#!^NP1:7]>U$\(SNRZ3UU"2/)BQJ N5#,B/!Q2.-*!V>2<@3^4E
M(]=5],7&CK$UDC3'[]@C(@/8B-KR$8%&";3Z;<R%NO*?/GSZDQE/T^:!VL+=
M%.2;JD#M ?QVU?ZISKOD<4\*_7NAE]*S-XQ=>[D75$[GEG;\_9W.NKKYXAFR
MQ REG7U3\TFLB% /?6+W;-^/,GNJWK'/[F([0Z$T^:YO$0[EPI,J] NN$#ZU
M7("B(^]";$";<\G XYA'5A!)FR%=.YYG8C R[</">N7W>9S%K^/&D@3!;B-$
MA",2$SV<X:CWP6C=5T 8XH]?''8',;%L?PUPNX#(T%N]3F*:7'M\\I7\"H3'
MTZD/.KX2A?G8@Q22"Y>.KSR!_5>,E]Q;"!4RN..Q)PG;8?(+;PA':R=-'>)P
M8UDT&::@3^[589X?]C#3,FD\UF-32PJFG9.=[;"K#CRXNZX:IX!.X&/=]Y<4
M8D'<&-Q52"*GU*.KSI%S\5,FJ$N7!7C91 /DG6ABM(=ZV)&J.U"VP,-6C^6H
M)RL/]%9_]A6P)A!9JG.:4M&T!S%77-T.49J07H)U'W"'HWWG&<C:(Q3*_THH
MTM9L.AAN+'+3*Q0))WF02Y,.]5;79>Q!2<7G(K 0#\[:(R !!K)M(_;]$[WU
M(P>PTJ.HO\] K!&->'O$9@UR.(* -XD_/E'B8:O$Q68U.Q+HG8.T>ANL56+L
MT!"!EHAH"G]D8^>M$=[<(0^]6!O>;NUU/TU%25'"SJ[#Z1#<Q)#!R1[66,3&
MY415'P5.=U27YHI,;P7I%+LZ?">-H-"2:H8D[7Q#(T]Y<50-7^LU=+ZC<.VD
M4]UZ'/H=X7D5R+>^R@?,V PW#7I8<(\*[G^Q3($BH#L+$]TM^QEUFN#9LF7L
M(3C[@_X<?'AX27!U8_>6%8$V _"%"23F\#?.DCQRP28D+T[$!&&RPNRJA.M0
MT3+(GGG0O(-[(+_Z@@V3U1*#X7*_!+.'LR*NSZ9 \U.H<R&D7+JC_-%+-8+A
MMG$S*F-^N#LO)9ZR4>-3E\K7C,>,>TRB,^P(HZY!RT?E8Q.P_#X</.'M$MXP
MX2T?)<[3LG7"2PM[(.L!G!BE#]_:'*6T]B(CM0@&W+![)L39V&W91\A&#U/'
M?@R2Z1(%/ >L%AKA(L(@ O@R>[>,9L&<!L]L!_=0[0M2>!@$M;$T^N6> :?[
M&^OO?A #2>MPC0A!Z8#-$&SG\$>=,F9,<.CJ=<Y#'I0[5P',Z><]GGG9%"43
M1J0K?_,X*L8[>)GG<"SH%,T3DK(1*$W)N(]CI345>2H<;0+P]KZGTC>W('5,
MKY=.H9Q][CCUPQM?:DW7ZP # PE:_-EC%#=T> -+R^X)Z=P3/)JOQG!#+(SB
MG, 09=;9A2],B((9 #:\#\"/I MRG:!,$M*:H7RT#2X%W:.,4$0-@/PI1V@=
MY@C39_"*<1!,T"9+'E^RUVHJ;Y@,$<)FU@&&/ R/+Y"T1^(&2=+B*(HGGAG0
MWUMNM+_Q SH'U_(O.\^&P [/OG16['O'=<& QR1EUL<%XU]F'CWE7PX272C:
M)QL((P^A!^2)=P%9AQ5T@FQX@UR*!I<#9*1 I?(H?ME@7_3J3$:?*K%]Y!1!
MPP1;)J)I5*9@XT2TSM4K,$70 <)Z0$07QL%!&GV.4J&#AS%1Y5FC]W'>Z!Z2
M:(JL0#.19$>2O@36VL)Z[8'MSN':D,:4^UN$LA?I!P/)&ZEO_8@.9R(IM%9#
M$Z;,(]H&7&>CUZE<6S@11%Q>>;;S[-@[JX_C+-("_CZAIOFX#S:"%&;SZ,.(
M52297 R0.R+)QX!1?@]>0'E,-X#N=';8J\Q) 3D9CDC2$H&F#G?LA0(I$LR.
M<00=B05[%0\YN'VB.X341/6"0I[S%!O"CC&62BLQ34!</AB-V3]P:3VS[D#2
MK,)O^VD\04!#FS%\4*A^DX/.01\8'7D<W_&+'_P6^WBC+0H<O8/GSLQ63/F(
M &W%D3VVQLD6#G"0J9@Y1O4X\5W7*@NE(!12F0#8)9L+4!6.]3W%Z1@:@4-/
MI#T=!&:'M,\(Y F)1*%7>!YE,J3LD,:'2.? 8,T5&*EDBX<_!^IN5_&1K21R
M0S;T#6S_M!JQ;KQX IZMC<_J@O;HW=7=_;]8F^V_GVO7?Y?;8A]"NMJYU\ZJ
M,R!==50^IT^@@4,<9(&EV<619F^R([+C(W5'&&G\3'$DWK[2MO( FP,:'FI,
M*>^6VZ\7MXO9_5_UX_R=H=++96(C??TOVC4P6"#["6($J1%&;K*!,P)O0/%&
M8EP36@XG@.B@] J92NS7MSR5A=*NB@^3GAB _ K($OR_7%<?]Z%$3,ZV[ [U
MO;X7EHR>%.3&LU?)?!(20_]ZH*@IR3HH>2.N1PK-&6Q(;IH+.N2A%'&QXXXG
MUHS9C,>,'/#;%4&L78],0DC&Y4Z_[RD?(&4 =)P!Y$QD?8";"PQCFD&(8Y0X
M"DU"\LL0\[WUO*L@=,SBX0T!W4+X/7K:R78X+C=O23^^7\^AR<,1=WZV(I+6
M9/M>ELLO/__C)M$JE;B'SB67A3A-Z9E&3AXWV*#E5FPUV#&BP@"VG#%6W!.0
MARGT"'QC T)RTC'U2$1I',A(LH%LTI/QB'NF,CGCD$:3UE\9'$\"_WNQV;K^
MGE(1H5$B37&\7;P^[^G27WM@QN/"$F2T[95AH387N&!F;&&/B8&VCXB(^ALI
M^<(D)BWEOZ!@4<LNQ:$V98+]$4DZQDT]LFM"8,?TT.%HD]I5?%=38>PV7-(&
M+N^2B0T2 _V>/=@B^[DY]8B"_J5T]8BSI-#;&#">0'^UYVN?^LQG_/5AEE8P
M2Q)_G@1CSE(^*[1P^Y+(1.)VDCE,>[FWER3#SB2QQ7N0AQB-X_"N>0[Z)7 =
M8?#^AF*R%SP!_=)U"+2NF-P(:3MR:2"Q\5EP!U'M7F<HX&PBR#@=CJ0[_JY,
M$#(2N/3^ZU5T(A70C*2I$5.PZ!U[&F943H"M3, (Z5IDKCL>QP^0%3LV.C%,
M]N+P''@QY!P-+U[98/W =CPKV*.V\-9GOWH1&Q-K8BV?IGXG5Z0&7'&H ]DM
MDO1+)LE+</E Z$IW)7[Q?T?3B,E2I(F$B=P.GQ\Q6^*O: S_[[R:D=7JY1!8
MH&L$FMI]Q< EET=V[Y@4N6''MD\D@: QDO^M;"ZW&OT\%N4@BM2_8T5Z##NR
ME ID L.33!^*B8HX+CBV-!.8>.SW?(ACW%-L]BBM!Q!-'^4XXU3X@O;7N= H
MUDG*KS=7CF#*&&0DY5;*0QE!C7'2P#!^<:*G4\>_L0)GF+#,V),N'A8"6\DV
M]*KXAQ]=Z9[[18R*(/%Q8B2''U[UADRMW&B/0OMD/(LGUN/Q,Q-AL]_(;&1R
M$_V;?AQ*)O[!^]OS+4<Z1_B2CR@SHS+SL5[?^5B?XX<M*CM<H;-$->C'";C>
MI9(IQ=WC:N??S\1FD_$D.#;)E#QS.+KQLR7A:Y &<55U-0&ZVH"8/GN,F-#(
M_KB'C$^SU4/8$74C\\HG2BL7-3I*4D%B\>:Y7L.7'2 !]  F9A?*"!*]S,"H
M\R/.808!-Z72$\UR:,NX88(M@_/*0Z@;=6;\:5&?E:Y[YMA?'2=[1F_D"1?^
MQ&,:2OGSC%L)^!1T=H M\,5B?P$HCYU(EBN!\KJT@F"/B)_<+FV%$OKZ4630
M"I\HC8B-FO(5MVW8PF%Z8]E4!:85-2-G$R-"HJ%6VFUCP\C+DP/96 **7RT%
MZNTCZPZ[=-=@-E^SE6%/+;O;8($X:JWC=0"I!:6FN[-!H?FXBX@3 J8WVQ,;
MA[=Z!%"Z:+8)1):8Y!L!8J2FC"%6G!4;)7=9E/5V%\ D: Y2T[EQW+092S:"
M0"1<0R':D9J*T7RJM0Z["!_C0C7A%8U=I^7KS'^F04]^%6F,R:GN'D/ZCQV;
MH(OG 3S$$W($Z8V;(F:@L:3\7DP." +",^'FN2#U]!=*2>YAD[7>7;S"K8IN
MV^S.9C<M>$]<K%:T^XYES1[E8M=3(,QQA'OVNU0%X1)48 8%%EITF\A^HP,+
MX3W_?:]#@;6KP(S*$?!@$? #33HX@D,C>VV? *'\65C_>!Q@SVC C(?C[.;N
M_N++Q>W\ZNL%N;IE?U\<ZLCBMT A+XR\)L,X+P13QW:T]-9REEU=.B2#R(AQ
MK<,107H',0CUA1BEUT5I6;A*8^%?O$:,M1\V-8M4]P![S^D?W@A3NNNI##.3
M6>>:>]3 R>[)..9&QA4,PC5D)(-D+H2"!F ZMM9TME(21L^$RT<WD.7Z$)*X
M58R,3=HETM=$>,"/'$^B8S+$ZO-)4!HC26N@.U+:([)!S?#AX\U!*I3P]SP1
M:8ZHQ\'0'C[JNOX+:%TN_>#<WSU&JYU[LL2XMA SQSV#LOR7P(G8]*PZ'PI!
MD20D>43"2YR.Z2R@MA,A2-P1P?;\U>K 1Y\Z#JG1QDJ[)1^VB]AX1^2%-<4>
M/Z)Q[* ?.1<7]XGG[2SWGF[]H+.+CB!%."W"B6E?N,PA[N$!E[^GQG&% RB6
MD&=H R1&)KAR+-($DK&W%W/<P!%!0$J0.07,:]+*J [,NH:<=EZ>RKCQO5%R
MP;!]*CTVNFS8#+N5(ISX@NAEI88;32Q:%XY"\R'$L8A@(@$IWG,U!#$2<&IZ
M5Z%?S\7,RQX+*A/NL'JZ,_,\!H>PA BEXL"Y?G A38-@#W.0J83!OG>,VDZ,
M>Q9#7JKN+R.AC2@ )^A3/(Q^4(5-X0Y.X^L$!QY9BG<]_WIQO[B:7]U^)A?_
M?7=Q.]>FT!6.#^@BM/ E\(,2B3^(ZZMH )1-,?"#FC))M[O+T,.+-4]\6 N?
MQ/BH*AS$.+ZOPP\O[9L2+YV9,28@U>#[0FVIQF9RXVZSPP3$YW3E+)VN?+LD
M3&+-_#N%-A'$M:.9#C^^5!X7.4CIGS)6RAI(!7/I/%.1-2:?K4;-::,FM!D^
M%1)F.%J!14FF0RI.@I1.F91*ES1:-J21ITT>!37;#R;Q@3[$&7^*\_RDLP*E
M,P*-=3G<L8J0?J!/)EU&@@"-L1+Z].ARR@%HI'[SE-^Q/]YLE3'H=%4E9$ZL
M$DOFK[)6*\WYS(<?G%3:50YJ;/?\'CBNBL*>([!.P"M?Z=,1X;WZYJ<QZX-?
M (>KVGO&\;V?V.S,(RN(&L_/(UT[GB>\@,>8)1Z_NUP&.VHKON:  \#]-KL*
M)3PREQ-6W>PY/@*G?7"#2XDD.,)_^:<_??KX\=^)!ZJ.<4;%'6FE#V^_)X'3
M.HJ==,=[ P8913I>7O4SUHY:HHBW(CZ=VXSO>2X;^](/+G?@[@_P@59W[)TT
ML*-H2EC,9>X>&ZV+O#DBVSOX"2C#@Y3PB8$Z>$<T0I@ 0'F, ["D6CFU+B],
MB$\,H+/ ?M]9[H(&K6'3LN(E^N-B_N^8+&&SMTE>&F)!LYH=;HS-A\K.D=-J
M=NY4L'.B7)R#&_M!E(X0Z,FW.5^YQ)AREZQ9TQ&@;&1WTEA (POK57FH^^*'
M,&H9UH-J?YU[CB0-D+=07,OQ,['EV"(V-B5"3^]&C=%0L1,I8.9?K# V)"W\
MQ1.5"9_X.XQ[=^:Q[YW@GKH6Y)6/024Y+.I0 7LJ1"KZY&?AG5^LD%BRKZ!*
MAE<BSB8EDJ9Q*0]<4J'+[)'A?28K@/;$@&+=M^@T)UO>L7*29RO"=V0F)QOK
M(HG["#8)B*.4W90!</SNG7D$NTID7Q7\5 E*.X8M;<K37H@!K'ON==^1[!J&
M(!U$C[2I?;I_" $](]9(G<2QHAUW*83A8("3; *T..^@%>)X?U!47TE+ASOF
M;/P16MRWZL!W<N!)O*\UVL [ZV&X[]:5QT1#O.9#E+A!V9]/Y_0+A4AT=B"?
MV0#7]#/P,>?L%,3'T)R&4+B@*>,0@;%HY2E*J'5$Y'"(& _! 1$8D7).WU:N
M-BELHWE4DG;I1&^\XU'Q$(4M@-O#7DB4@AZ:#242_%@9BQ6S,(\HST?B@4\W
M9O=EG'!W!_+8 "Z"R0M"\@1.:YS0F+5WX,//ZM4ON'Y8($M\$X-3U>*GL=+[
MVQAARHE*V<("TCRUA048[KM;GUU)?]3NWI'#*;WN"3A0!$YZ/5Z$/KL#V7Z*
M]J#KDY[EB#?"UJ[[M8HDCU"!F+B1;[ESY@@JA"$'E0;IX'1Q2#09DG=80TI'
M67%!:&MN:$6!LU+SLY=:N_,=0O]=,D)#!PK';1T)+* [A,=%!$1H[]#'GT$^
M_--XX2K#98#F]$RG@!YD5-D<T//%S<7M8CX=\;FG1;2#ZF!$JZG^:2A&A$OH
M:C.L\H@1ZQ7B/&ZL".*U]AR[9;82&"]I9)>^H3N\*<)(K:,G5!H[D); )QO1
M.C<L*G*[PR'10%><0W'1'/JC<5[$QI?S(=N0>$"S%3\/)UX.-.A@AYP*+1+C
MCE>="RAH3RV![!DO^YR:?XNBZD Q*MVPIW87@.KY'N(; W90 0QE8$4_FP=5
M52*TR# K*GBF[ M83N+>(*+,F)K\24R@NKF4A'"B,50-SK=TZ:R<)=PV8D+9
M51-S3:,B(0C_J+N +EE99VFY<+S$QT7@6*X$]1L:*.0(,QN#?]@V:9R?-_E'
M!.W'^)?CXH7HFQBIWLK%H$M_.:5-?N_*/[#9&&7Q&YF.C+ZDS8XX]!DHS3<]
M@3DH</2ZLX)9@-G?;+S4)(C7(+YM=QR>EI,7EV:,3G: @RS/9[RUA"O! 8ZJ
M*J^Q]G$M]_;?SO:/,+$(Z+#'5$N69W%[U)W/#VHX Y7N!D!5T!]Q"WF]!^")
M4DUS96?2.(E;AUV<M$^4#HR'_"OND*\6NRI8PX/FC!?7T[.@/6J.^ &'Y:9O
M6TF3G(V1!7[PT62PIRK7:!2_^P*CRH,74)['ZXOO@DGKL^5X8&F9>0H8#(>:
M/]\!.\ZEOIYFQ :FPZ1Y)N$\6XX+DW;,Y/_CN06H54G/B>@Z@;[+%)$R=0#O
MM)"<&7N[8F_ &/;(J4QXSA5%^.1+D;K   : ];^;Z5$X F5'K7$GN;B3P%4[
MM?]"MO](J&Q/CUNYP?^3_?/NGS]]8/OWG_^('.*[?_[QC^PO-AT -,;&Z6J'
M2LDF/4J"#/LKSM/)GM(9_D;5G0\^Q**\7K" L;->TJ9>MV7^#LD==^D'<-\E
MF_]T+Y)8\1R0R::%D\+8K&M$L&-B4*QG&=2E-^X8JF(S1P$4\Y;L';M5PHCL
MTH<*.3$.LH>SF_CP_DZF4[(X\31>@H %TZ@@HIWN2=PKCF.CW$W8,3(+".\:
M:B,4I=;(3KK3F5GU %^$D;-!H57U7V:7<WK[9N9=]ZVU""R;QAE:<_"6W PX
M'+*G":.FEB%F&.FSL]G#[6).[B_.+JZ^GIQ>7[#[^&*A78,-DCK<A-SB<>GZ
M+WTMFS%)V)IHR4&J(U@OP?OQ#!:'!ELKB/8],3)44F-B99QXD6,[[@X8J^0<
M0P=Z^7&J9%.""!_:6!Z= P\NI=0U.L("!,O$A;E_TNIJ?$[%37S\_-3Z!AV?
MQ)+!FLC&K6^T:4WN)-8W?B>HZX+@2CT:H#WBQ-XXGA.B1^8SE0:)7GA,HHTC
M(EKADDJJG23QUUA82UH'GN8!FHQ?][ !O_N"7:/1OM=;PTEHOW+[]C;%78_3
MY8+X72[M?_9]^\5Q88ME%0%#Q"=+! [9#&ZNG.KCD$>=1NF.!Z8W76B.C^8Q
M2: $]#V,H^_.?XJ(KH362/SGH&-)';&1!Y1<#R>VS<J$XI]KQ^N<85M<$X+2
MD?Q @":9>=I-K1>;K>OO*<5XVA3<T%DO("5)]SC@A-. !F?C0 X-/K@BEX\4
M,#3<@H_LN5TY(]P1VN(<,=PPO/*XV6#R,:B\NY"LD'?X]SKQZN[\S"%11O5H
MN O\);N[+OW@REOY 62%/O41]D4X%<R"^>YQ*?]2' Q8E1EC7D,(>]7@[2 Z
MANK,N&L$^Y9X/* 3C]*]E ,$U(Q[.*H51_J$AK-5*FAMMH*AG>+$7S*1S0^&
M 6O8;3:0T,E?J1FP1*9OV.Z6M__74. X@*U4AO/> Y#M",'=^J=#WE^R)=0[
MIN(%V1?0SA%<7[C!>(L&/(9A179L_>+ M%X2LZ26! Z.)A</-)"<FY>I\91&
M#E[WC%RMC/.<1A!KYR$617V:'V<F/_B"U>DAA>4R@P.]L22Q8492F>A\A.&@
MVE2X'\0YF  <HZ<.//9HB/,ZV8RH7L_ (88A=I;L?I*6"HA-OO?J;D*$$_;
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MH?<=&7-^)%<TS+Q\,]-2[![YC'-#>=,V3@R%B>&1@Q AJ;@BC\ <+BFUP\O
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M8>98:>@BF>D'-!QW[E(0\SNP_##.CF*Z49#N7*J?>ZVXM^XIN!JPY5!36/#
MTH^:?#[B)E.9.T9*9CW25+3Q_S R'ZBQ%5?RXHD5>O)=^QJL-]T<7C)::7G9
M1Y(TMPSI54 /.)S,FQ63)$C33$!8 NZ"?&>G ._:^+ $[T58FS'69]R L2$&
M6BI@)<2%K5=KX+^V\:74JH8'68 ")3VO7^5WPC8-L1O!<PK+:PC$*WF5PN?X
MASCUE6PT!?<U4D:L<>8D':?":- $%L<XID49I 7/*GKE,;D5[R2.%[9XLCP!
M=O&5[6%XI@MQ+CY#:AG@&_LRM0/ XXC\J,I0U*CO&).$CZ<2C@1'A>RPPD>_
MK6 ;N)+*J92+H#]/7/@$_X<9>F8BA@?LI530P _LL*>_4$IV3I$7/AT1^"]1
MB*4T:+P(7(.9+]4:W]3<;''G77@24! '"Q. <. T(4S^Y9_^].GCQW\G%%#$
M5F0[BCAB8"[FD15$C6?CD:X=#X63T>;DU'(!3&C^1&D$N=[P,NINB1?D"-(C
MDJ!FFW.< KJOR5PD@)YN9^4K6I9K>Q1_APJI7I6I!<.%ZAQ65H=^XPC93KQ7
MU9:%<NMRA/RYX\R%ND<_??CTLW8>A6)VHG[Y2 61L3+^]NMSRL[#*>F/=@NC
MV>JS[]L@C,R95,*DQG#NNUWA]M%IFCT<2))K?@51 E0/9SS9V#T^+$S'HU5U
M@*:\)Y[F@7/;G7()9M0^*E4IO(R137"@T<1/SD&/(G6^QQ]*"P5%2BKT;)FM
M0+_B)B6.P^TAF_YV)J4P ;$:4C%NTB6XV89*&S5*VO+>O4]!)<5#<($<AE5-
M?P19+RK&=6L.,<1K4( 7YXUE/.!0C3N:>?,HL$ _<^UXH$9J+V9D7C#1.+$V
M_L[#MSAR-FA;?7ERED\%T7'<FTQ-@4.<$.I#[P'#EMTP)!3=)"YX6CQ"1_6:
M/L:=1'%2Y>05F!LAZV(^[&T&T!)B9J!Q@JU_0Q.C7@+*UDIFAVL^1!:LS,Y"
M%(?<OM'^1%6DFN[KE%>7<WI,;SLMXRSQH5/: B5_.H&/[H%>0])AFGX.9#*5
MO?24&61Y>4L EIYYL>/F$L\= RL^PD2HZ]]F-@SJ;CX'W?WIZSQ0D/:AC4U=
M0R1 SJP@V,,"CF(UPX=FMKH#.$#!EX"2P5E[SLI96EYTLEP"<\(ZA. B#@W[
M'EQL$BXJM5'A4!<W2Y)VB6QXU&"A,2<F&R?3:7;T:@L2;_'==LN3>EJN:N.X
MIRZ\-PL?[YU^%UN&36;$=JX?J*",$#JE=(0Q*ZIYA,>@\9D3_8*LV]@SO9SP
MN/,D54A*K%EJ5M)&HR S$R,^B@;FIAS-I<44':[/ OH-E&57.4"O$SZ>WY/7
MB>85[.)U@E_K=SNYV&Q=?T^I,'443_&MC]Z!;$9@-D-T@\O*U+=^]%>X598^
M>SG_A\T_3N6E'XBOH%Q7__#:D*^X@W*GHQ*"=8GL:4223AU)I05$3RL=^WW/
M<AJE1]BB@]C'_"6;U@EZ"3_H=>Y0';1O_(#"<?VR\^R VC>.ZW(>$40QY0?V
MS>*%[8@]&*A%J4'R^DBW[@WK"+\MGWB+9,-;0:X1(C/2O\*W$?:(K"#@1Y0>
MQ:M]_$D3QU5.%G2 0$-$M$0$=81D@5ZD?X5O>4_0[2$N/18F2,Z&HV2FO:5=
MK1R%UJM;\/LPXT[<;U"%UB? I+/$R#RJW0 R]) 4=&=30[HOS% @#(<<:;0S
MQ(Z2>T!-T1#;3,V!JVH8=<H3[F)^<7)_]H6<W)Z3\XNO%]>S.P!6U3TLCKZ'
MH&0PG@$\$@4P84QR+*=$#2-2%\CTL(2[;,9)MD^.-^D=F_60/K@!I2#5#8^*
M7_)]XKG&0?EH/\FYA%DCII]^K!>D'YLD0982 \3F#R'@#9QP.A9HH'^_GXDM
ME.DBC5/ )0^ZWKD6)#2Z9/R8MV8</),5?8_V1 F45 DG2V*ZX^0O'7A8:0 G
MPV-KB,%Y8]GTREL\.8$-#N ](3F;0(^2#6L2E) 1-(KH!]_ 1/3 8BV8D$G
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M'V5%SNI1^PW@+Y+UR5$QI=NR($<V2,_NC=AW]&+#:Z-V$KW3=]CZ/>9P[$4
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MSJ)05"WG1Q)L1>$[^EC0#J6-A:S88$#GR.'00E9,1L"]GFRB)7FA,5U%3-R
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MP;J )B)FEN>\&1\$.&+R"E7G68NBLBF\/",],1"[DN91AH&T\I=,PME"]O(
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M(^153XDV1N[G1JE&#A/QQ/_N)MHP=<DI">64["-JO_RR=W-2>JHJLY):W"B
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M!:+U=7OI?5\0HW>4J VIR$AK*(;@P+,$.C"B<CR^)7$_6"Z.08)T'*7VU&'
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MS,L/,!'Z8>BY+VRZ"&[BG+T(?Z+K]1_CY"-^HD&6Q#1$M*%3%Y_3)$#T\U^
M*I%D.<J2"\UID.);0B/AM%QH3[WR4:3^Y"AAHZB D2T2B>-+'VC._69W2<9^
M#]&@CVGR'H4TO-P#%. T5F%FHD80H KT@Z?1A@(F$348\!9*)^(G&-!/\&=$
M>Y># F'\$T(41O%/6F1>,3:'519]F%+S$3?F-57S&K-YC?B\ A8D^Q?&'6_U
M2=W)22WP&0,UNG]W!;2&)_EZ1Q<)OX23E(F=R]/R#UO0^;B2!Y"5;#[6HB<
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ML#DIT,;=W%LEJ(=L]L)1BTY5J,OI>A+'XCE36+.RB[/B2ZQ1&S^N0/2'9LV
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M>C6GKU$F '>>V,; NV>0&'O6'\E%AR3''B$[: W1O46?)).=6H:UM,V]V)_
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M?$2_7DQP'2P*KX6,TL(J23'M5B8A-AC3CR'A!=NM297U\3,M'WC!DI0.%$8
M6P; OX2KF(D2<.9K-W4=MZ?2\F(B^IY=,YF_$:_#0C=>3%\#R$S;ZW_@$R_8
MTM,VH=(++X42SN(Y"&M@ST,LDN<X>0$ 2A!/I_%VEYOAW9=[_!Q+Q+14F+'4
MEQ<3^9@F3#UAVL@Z0'L$R'AX&3:>E/8OO& * B62=13R ++#"5=M[;U@Z&G'
MMM9?=_!&O0LK3/-^;6SL!2N:/3KKL#0MS<>7WI^S18JWP?XR <Q Z;\KV6H:
MQ/>COAX=KA,5P3G=FN%Z18 )0.+H+';]9OQ5%.!S//SNDC()EYK.UPQCD;*Z
M#.TCOO7B],FHL0+CDCU?6-4OB"'!7(O_AWLCJ_]3\]TS)'TO)NQ0Z8C3)40!
M(V5JD?UK65@=T/B'M1Q.#^ZCD^+PFS[T8]>Q)SP*HR#=@T5'6.&:DD$:&WO!
MR@.3>=F#QN[^]RBDX>7^.8.(51ZS"J4,>(F5J#U>Z7@J7C O-6\$+Y//((9^
MR[J<;?IZ\U?>G$.CW$K3F3,:C3_TXTH98QVU@<LCU]+T8L,*79_7CN/!7& I
MDM7J>6TY.&\@T61H):RWKQU-9OQ](<%UIMPCSZX7-O88<L23&$=?U'YFSZS<
MTY6M<!H9+U9?\_OPI'CP.U>Q+#JZCKJ0\()M!0#0L0AX6WLO&"IDQ"X@!\?(
MG,?3.SMG<-WN[D/'BQU1@=R:RL3*^A>K32SI2F/\&UWAIVT#L+Y&4/M\*<T0
ME8N[M;47JRB*;'RC,4V#-<#8A)LH%E%S[_1P>8X#7_K!I&DTJH;GUC\[!S[R
M@C4FT-/H->;1?TLF#;+!,ET=KE TG*R#1G3ECI^.?^9DJ'BYPEOEN#4U]&.E
MFN'[&S"+V[\8?UW*]H^/Y/(H>TFIO1>KQ.&9FJ)KZU:I_0LOF&*25<JC]?E_
MI[$  \S8 ]R$Z'7P(R]8TV)+3$3O5G?TH8_&/UN51&TP53%1@EW:3'R .SH4
MPD4CU.OQ)$:/OS/@',5_[J*8?BW'WS4V]&)3:IL*G!9'!4IV_7;\+2HV#]B*
M90[0+6V&'"ZW\V*E9"+D3"NNVHZWT?[%Z"=(!J9R.?6&:4\E)VIC(R_6H\$H
M+SQZNE'^")-^S=<>G!XM2Q+3(C4@#KBE+_>3 LM(Z<=,;LI_2W;+MQKQJC?%
MT3?O=+E*!=[D),_9X<*QEY%=VEMZL8WK;5I@MX[B';BOMV)=CH 1K?O:"V8G
M;%QAM-[!B(N0$VZ0YWX)L-;N<A'[=Q.D4&\\8]L5?<D<%[9N'@8A//Y)?]ZR
MH2HDX&K,CO%G/U:T@*=E]T08HO@8K.$2F3(Q<AOEP;J^/,:<<G%3EFSB+XQ6
M9:G1W&*[3S\F]AC%TF^=LFLBVF25TW2(C#:#D!=34(?_PF2/592#@"B">G]-
M/D *T1+EZXVI)Y$:_W+3A0Y1>568>8258)%T HHX\*T'C)JJ,M/-."Z_2+M&
MJUQ+\.FI-#Q@G!_!6:SROYI>LL:67IQ6)4P=!HUK:.H%&Q)4F5V&;(XYW,@L
M14AS.#&M8=Q=OQU_TY5M5RK<I>:][/2!%VL'4@L[%8A$7TF*:S,*=?IP=/5M
MD080@?.TW[PD:YV-RA_]6(T@>[M=)Q]*]"C, UPF:5V1KA][P6K5C-CH\31:
M>3'XRH9OS".J;SG^;?:TVVR"=#];G5+-NNR?&8:B%RL[W3!Q*)6A7::'DSL_
MU^#\K'VBNWWJ!9N-Z6V7>WASFX*P.WSF!7LHP^I^M%;DHN;67C!3GP'!TQL
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M,A5@&L-]S5_'-CC+;I]ZP68+ M7M#N) =)E7*+U%(5(X?D^[Y9)2K F$I=)
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M7K!2YT#05T8694;516:-@[8,R\67MUBRT_P5 W7GB7KQ]$;7Z]9L0;V%%WM
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M,8B8^'D5;"-VV=<ZQNJ;CB\B" O< SL3[$^@8+/C(']<0.J71,ZJR '=/_6
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M"B#$>"^)MB%=M1D@M+P&FY0>0!+H^+D7J]P;BUO";8^'!G[4",;?8\? _0R
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MXKH^AC%VHN8<'%9+RD2;EB\M]L6CAY^Y?_3WX3F_S#E&DFK;ZE6_)C:F! 8
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M>8.LZ=$@]CI>!)HFW@9,9^=%I./4\PA0N.L6@:HFR9[+)18!Y&62O5J4@%9
MW16J-,NE<F$)"\%V+)%*%""Q9-XP4!_+"\]8"/4:EP6H,MJR,E%+"@1CQ]<8
MV80D\R*7-L&0DX'07TPKN.ZRC[$N/\GHH(6@?MDM."QZ:=G0*I*K2KR4D4(!
MKK'A4>]",Y@Z6OO)T 5'#_C2BJN[3,#TK<8.65L(P/HUY(P .A.,P.7DW6.P
MUU__9J8^BY/YOO6P5Y500".E;UR3!T;AL*(HQD44&=*K,:.'46H%TMU;2Y7+
M2KO/F"C7Y!PACN>E+!\HNPC@]7  E=!<(["Z=H4-D;DN<VQ:1!FRD=Y>&H*U
MK]NA>SO4(LH744=N9/SEK!IZ:M$M%7*Y^/Q1R]A9*15UON)N3^^8" @0I]<P
M_>VK%WL[<KF^(?@RL#LA2OR2? "(+\IST?;1:TBA2?ZP2S[^Y)^"(@4#^L,Y
M\P+ZRZ^]M=PD'@RPC@\"'PV>KM$J4OP4W:"9W43]/$]#1]&2:&+H K'6+<PR
M -;P+7_WJ[\A1G),XC0L!/ +ECYT?%N@""CXJ5L]C@> ]%CV%UO>'P"[UN ;
M.\4&Q<< _1)N3X6P2QJC/V[0MSW$8E5(0<^'[,-$W4=&I82+AG)TJ1M*)9OA
MX]A?9$V-..QIAR<:/$3>;B!)=P:QM;QR/NB %4HK=)1,LWK=GW22,B[E>+21
M;"WT%0ERZ^UYDDIK8W>VOV^;?0B#%P]FI_MXA_YMP'FF#V%_:2])\8).U[ ^
M5VGS**ES+ID1;2W\O TU@T!W2"DJA#YY-9RE"<FUJP_J_KX/Y4O2P]J#( ,P
M]*+HM"*NKR!8PU?@I>@%_1Z=GL+?0'3:)-U6KV 78BDJSN0/A(;OV*<3K'6#
M69BV>//E="(_[%3I1!$871]S2#X\;ZP.'G/9!^P?)!%G? 7'!&:;A(BX^F_=
M_O!V]:L7:L>(MEJ__LE$&JO( 6VV%JT4$W--&I\K^&SUCP3V/-W*0J'5H(!4
M(?JNOF=1J&O@W=IU3"928CB[ =K8N<Q.7I'5SZL;.[10>*WQZZ52M@:FS5'Z
MFDA"X"R48U,Q0R>]*,PUD*^J)MQ$G+RS^(Y#TP-T\HO:A5&IO,^^M8;+.0OR
M6.Q;A_%A41NCE?H5K!DFXL&<!7D:U+_4W3&C6E$QSYB(X9DSW!>9?4R$DO3
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MCFW$ IO9=MPI%T5GFY-@ \UL:P?E-_24\V"8B!!NM1MWJN67O\7I$?B(C8.
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MTYLP^>K!,!:[F'!Z&9YG[[#QIO=DRM&D^Z$[+Z,Z<E';&9X+TZN,WO":F7P
M!^BH\S@SIS9U9N)<QUU&XVO-B.G5C+CZK+OILRXB*LSNJ+=Q]]=1IU6^.ID3
M:_^N._UP\=;=H$;I/HF"IQ#)X6R78EYS,S/[FI!'9+P!\=<PBC#/CX,GD*;X
M'_^5QP$2X,L?.!F3AXXU/GTR6/+Y-SOE*MZ0L(/$TD14JJ+5;MRIEE_^%J='
MX(?;D%'-@-_68L;J%*#'\AY1Y!WX %%R)(+964;#3BK8&V63O "(7WP/"20E
M'U,A_]4SMCUH2GU<+6D#>."_!GD]-+.I;S^D/[R&NWV6(LP>3C[6K;(9$:?U
M&(R=%:/";GR-3!JZ 4N,"JH)J#(MG)7&+"!$7<:;(1LR<:<I7ALW)\&[0\_8
MAO4SZ).O^>\YW(7R>K9>'S.\MW7]<-ANN]VX;P_OD__V:/UN5L)O"^!]R1S]
MR^8[0NGT$'X 59'_@L$UK_IG[Y# ).)6>.FU,1CE4@)55M'>)+)Q0LQ^6@@X
M!?X/N^3C3P$("_I%?SB3+OK+KT]@YT7WZ$I'!ZC/PV@M1B%?'51J@!@5P2U0
MH]Z(O9^UA\][!\0/V9BU&XQX,@AYWW@I82-%1DS50T(;P@Q9#E21&-&&L*+0
M2H[1?7W0IL=L:^E.VGQ/!BJ?E(<TA'J;"C>)RBX(^QK6!7:1:J*(!@)#]8*#
MQM6> :!\IF8M%YNF@9O1Y"GTWL,(,6;:4G4,:WA7+]FYL7:G[2)&FUFGA5GN
M?J;8AW"+X%#D\MSNNN]UXDZWWK;Q*6_&KUZ68S\=HJA[3K*O@!JZJSR&08JM
MH4-,HHE>@V=@\6T(05\RM&.:B#(=NY*&H>ICEMWT$6S ^X:3^ TY63I&UZVA
M/C[@0@V<B/A."W.X-Q?.INUU#&X4X!XXJ&[VUG'O: 6MM>Y3*F.3[VWV5)QA
M:DNF*ALB/X[!QQOUBI#7;HBZ&Q=P50$?%=M"*S@86T%W,]@^)/#-B[%VVJ.\
M83BESY7Z6[M^2^:=UI[W9;)?G @5,Q>6DE_<S]AV-%V8@[!(]8P-=6=0U]MO
MQTW2NB(1N<MLU85C&[X<[M&?LM,C]DE#LTD?TS0'P1KB_^*S4 4(O.T]]'OQ
MJ\RM,618B[NK9Q]'NLX;_&N=9VGFQ3AV8PW1_WKP5$ J=;-+#61X-8_Q!T*/
M^.O@[Q$I0V;RU'ZZ]1]1DN*B0Q[\#63,F5%:66.]B$Q!N(MO<;VIV#_=?R+1
M+=Z!5R\#)/(@(E3[(X,!R_;6KF9B%!COE!Q<OT?ACBFW#AA%MUQ2?B#N?I(J
MA3 ;V_-S\8YAYD4X47QE3K]-TFQU2& 6_DX#7J6GO3.!Y.<,/"&J"-!]A,@B
M1!<082??4K#-HZ=PRU(*2'5U(XW4P-BE7D0;+VQH_JFEA$%)3+R*0*'E(32P
M1MH\$9()(VI54&=$[<PUAY H\*>J#J,0<S-7J*Y)-Z4K9/9C:2HZZL2S+(+W
M<*,O6\Q'56*8-7QLYW-6:=K!04&S/XQ4EMX\I;.F)&&P4EW#CQTF-%<2,1)B
MU"HARPO0F3NJ_"#PFG/QXH3F"I$@MHC!W.D7P5PQTI.1FO% G#7+[\91=3%9
M4%IJR;BK&AJ)**BYXF4D<*I=3UW++3MW_'6K3OMQ8+/.^RNO,Z4'H\T_M:]0
M9]IY.<T:$9'*IAT&.&LH+M4Y7!*F.%>6I/@6ZH= SI_BY!FV7'#F_#-H"QDX
M-0IT_KA<SKLD6)16_%Q@49R0X8J6VD&O%1 _S//UK,BR.U&Y\S]E>O@U-61X
M_DGJI61ONDW:!#@N\)^AK%O*JK4@4F*?0W8X^?S+&P@/7$]9:@*3*9^SX1'_
MLT92_?B)\PK,OZ"&U/W',%>;0,<9<KK$UV-8TH=9PRE_.K5DE9A__19I1UNZ
MLZD)@)PAMDO.KO!\+HBFV(>TFUQD_G5_Y.16H7G;!%!3/G=RZ6%FC9K\J5-/
M3&.BOM3$SJ5L<52S-;@F="0OSQDT:T2ECJMDJJ$2J)]T O4!X'LRI0,J\KTT
M 9(SU'2!J'I16JA9@RI_HW8S3E76_7E:TM0N3$U^AT8@=8;4!I[?H>G%%DB?
M''%8(9%9!=SL')H4[E@.LD;@<8NN+KAI)5/-+8O&V.=2*;E=!=J,'30N,R4P
MB&QV;D^7$)DHRU\%VHR]#P80F62>02/@38OB%%(75FC-V(5C&*E=FD/1"+#3
M(D-]&1HK,&?LV6"*2KOTN'1[_<#\DQ5\5W.J=-;+"K(%65G9D-&2;U8 +<C<
MQ157I--]5L!I50=/$+C!^4:K*(.K7HZ?Z+3":<9Z)J43*I53M0)MQBH2-;8F
ME;&U0FV$-___^5,/-+2 WQH-J+^72VLAB"1.+SJEV1'=^P?O!S\Y_*G*)/RG
MS/M,XN1P*J928Y6^^7L0Y!&2MS8)ZMU2@__BI:N(),X%P2;9[$'Y< V*]RIY
M\J]C].\A? 4187D/7@A_]J(<I'<@\\*HWH(PPQ/MKN(/+>( GQF( _3$T)L[
MV=@2>X06%60PUE=UYYAFFD"0+- Y+&DU8]K2APUD+8GSP!P=Y8J'CK+ @M'&
MCD3+9#7*(2R^:(UDN8DX.X1);^MN!9=N]J_.<N3[ZZXN49('W;4!O[IC--2I
M],\*'I" TGV:TTA4Q["&ZV@0DJ?.G=K0 9%PO"O__' 9=GO..G?=Z%FPYNDG
M-,Z]:2G!O@LH3S._M4O(*=_J]=DV3=QS1=[6/:=%#)I_(JSQ>/9HA##7M&[6
M3A)=S#:2= BOR3G58WXX>/"$+MP=^K<=0K>(47OQP@!)>!CGEK!L0:-XN6Z)
M4ZVGJT"B-;6G%.,FS!),O6SLS.0%*@5F<V<60%-P\=LZ,W66DES<WK!6 [/M
M6R_=<PHIBKKH+F'/*9[0GQRGM6'D"@@(DT9B/O8("%X@.*)_*:4^J1*Q$J/H
MKMH+PL-[CJ3$PL*,=[-US]-F+>SCS$%KZ9S(&[00$!K/46P>ECR&LJ,YO_P+
MU^O(^_I:]4\1'XJZ07"Y+@TB^8=)[Z9<AM+Z6O%(%:)A>:06 X_\B9.1L&:M
M0[N8PA:@MU(G,[$ K%7Y]%.!54QT.X'+9$6%[&)!>]9IBXU":2B9\1RTH"]D
M1_8@"WTONJI$KRK1JTK4=97HC1=YL0_>]@!D3TD1%\BA>F9SIQ; I7Y.!VN+
MP#(UUX.WT< 9*A]?>[YPO:0%U;P#0MM5G7A5)RI")+K4FA#Q[H\EXL2N,=^\
MI!:I937Z$M<*I4.Y4J\J:_T*139_NT(DH]5?C+KU I6TV3QLKBBV^@Z5#6_*
MMBOE59]UU6==]5FNZ[/L*RDD'=7J:(0BBXV4CU^OSX0T"3JQZ]B;5W% TG.7
MJ%09"\5X2HUC;BV-*=PFAP. ?HA3IA2!F4#HJ2CL;GP7DB. V0G!AG/UD1B;
M9R!%R*RNAF=<Q6K&076UGX-?&T0LLP+9H0RO:.7[,"<.&#[JC,UN:$:WY1\W
M$!&$BMNKPFC.,/BK;^55&7I5AAKQ].J+*%JQFHX+SE5794@1LQAXY ^=G&RK
M59$UG8-X=;'41&KBI\?5VU)X4!G/'ZVNE7-$3OH9IM71<HY(JCS_M)9AGSB8
M@WU^]69UG[+/[]4<8G'B5W/(U1PR$7.(^:2<C*6(^VG6S?[L'1+$3),8L&TF
MO3:FTR$P+K1S(0ZY? @2PSA#X]-RZKTJQ*\*\:M"W-D7@GQEO*L#)^,67*2O
M\%4?KBO=@(P$<\TW<%6&C^^R/\^Z1>,HTO0F'G!:D<;Q,;XJT:Y*M*L2[:I$
M&ZCMF6A5K*O^;)+ZLZL"Z:I NBJ0E!ZS#A5>NFJ4)O[^NFJ4KAHE5TCLJE'2
MI :9:R65NS#UHR3-(7B,43.P\3Y!HYYS_8^E>]H4]2#U&LYK%3S*>3WLI1XK
M',L? ";3Z+PE-R &VY"U%%$OV\MYR[#C6AS@[!BJBQ+TM;:TNY(7E*!WSQ!_
M;9*=K2^N!?ZP)4H-86VA:FM2F+Z%NU&"!;822(E8S2+D^F&@B1C:(N151>AD
M&>8BS'D#L9/CQXO()JZ(H BLN:8/;PC\JR (B_4\QML$]2-:GO%E?8:RG[*A
MO===4ZO/;6]=<D+S*O2(3Z'W'D8(>)#VTW'(]K(O'UE]5LE3#,V.R6]K']I5
MGNT)X^'8[AF-'9H\UW[/;&YM ??;+2!^H_74<.V<5^ GL8\.7G&35<(QOG9S
MG'JAU9BQ5ATC.U#F6(8=TT04)N.[/B<ZFG V^YJKM4"*:U.EM@Z/G"M <G<#
M'Z&YF\8'<2<M['[6KWKILRF!_RA6*-O/J;/]I$U&?7O*;7(XYAD(5EE-65TE
M"":PJ]GE*@W*2H/NP$)72?4R'&H94O/[468NSPD^7SC$#+'!\CR_(38!<$E$
MG*T'_XM7!2.@@:(\"./=FQ=Y\$1[B)K_J'&4;A'/#K.40O42'2SLX2]A'&R]
M*%H%_\XY;J)#AW+Z>))T9>R%7S248PN_3>(LC'-T$-;'TLE#;;G4 1Q[$,AI
MNW6*N]<'NR*P[!MQU@^((2J0$6[@JSE1B'GK/K\:#P?0*%7",&)9G"B2EXDL
M6I/ES1I)N@PT\W1YC3L67P=)C*EFO>U9)*:H8&DLHFU0$:A9Q/U<,)$WIM;)
MM*RTK&Y?>_ZN//(3[)A<7Q=VK9@2YE3EOS7TG)4LAN3?TL5&8BM5!W0!A ;Y
M/0$O11QW!:$7[P#OF2W?WX4E%MM2UQV0W<=S!Q<6T<"9"!9*.U/T<&$9!;1?
MDB3X'D8XKW W7E%V=WA#N+#0!OI*6^7$Y%F,[!7)&/"#U \@2:*]Z *N2!M,
MLU:U-XM2FHQWF%>!"G:J@ENZKU,;5KR!;ST(3]L$?O=@D&*<D?B^5]@IWBCN
M+/<+3%)Y?D$:NS-Y4_Z4%EY\TK(]P\^*)STOI#:0DL#-=5=3$&<7H1C72)Q4
M^7@A-7/T$6A##E^$'4$C 9:"_T**Z.@C.>YS8Q&&%8U$:+04T8:JC9T%$4J^
MIA9AMU)&5?$UMPB3E5;2Y+X;%V&WTGC=%._2\:Q5$T>-=2.5 /[C2G:7!"K]
M<Z;6TK<L\7_;)Q%:9(I+)6:GEVHIY"=<LRXY'+ ?$_Z;VT'#_<4\\6*&><WM
ME51JP4]<F](RFN=W9IY/02>]BTEAUE@(^MMY$>@OO[[B9STE>+7]V_A3HB:N
M[?ZJ67/>IS!F2#*KJ3VW6C()@9FZT\B14_/BP34DCI?!SUZ4@Q< R9F0.CW,
MSHXLKCC=ZSQ+T1L<^S8J\(1F+YMN$=5](LG>>#U<6(8BO<GT=&%9!=:/:9K+
M[TS9VIWIBP\*MXOF"^$YQ]?,>OMSDH'T/B;"$E:!/R3PWO/WY/O_ E%P<VK,
MZE_%K4"[-2X:SX$04PF)K57Q2R <S3PY,U6\POCTA)Q9&Z5D1*L6*N;2!#B#
M"5]JJY5_3-1FG1_@(B[#OMQ-&-X<XC:RQTP,\5SS4.NZPEHRB@E+FOM4Q<6,
M^V(P8>J9#UY"[J75NC,?W-IO'Q.FF[EA16-B6JTV$P5,P[MO/!..(S8(@L<K
M.)8E>EQ/5NJLW4&@%R<3.</\ I,=] [GRW5U2/(X^Y&B,Y?M:4T/1*X\?,(*
M@,_V04Y:37X?RXKX>C;<U)KTMBYHXZCF%W:[N1MB1">SS0"K\T6WJG$:+]AZ
M- AAZN$2-M=-K/A;+^TOL<MN<EH[<)G<?Q[#(O+\KI\@2KJ;Q6ND-;O@+H=(
MOD6/J# )"K&7>9<(.]JS)WHGXG:/A,_S#-?;!A-FF13%':TM:@.!E^;P5/BI
ME.4:5^C-X.T 3@4CL,E)=Y_.PT-)PEN$<EQ**&REU:"+7G-5EDM)G PE@$G+
MDPO8J!B=>-+;7/&Y&J#8-ENQ-,^GG+GS'5EY_$Q%' EYUC>9GON_*Y3/.H)0
MEG%+"@E76Z;2(V?>@8':3>1:89HJ6<F\3V<=X#<$-/GW[WAA?8Y8DU##_WK;
M@VC["G8AEDOKO+R8S*ZVI8$S^^I]AH?\4*@06L=SL_>R6R^^ 87]_!N"!;(W
M@+8,;6//W8Z@H"%K E2RV$82CIM3XR\<(YGJ* NV0&C;F\8?N=8_U5$T'X[-
M]V2S3_+4BX/-=_25$_M<LLT9ZH-,YZ[6S#:7^-)E/MN4N=NLT7-1&^<<. ,O
M1'FJH_#M*[#LVZPFRP$7R:QQ==L3W_6WWU^N;[_KVV]<KY'\/07_R;$.&6?I
MVZ!/\=P.&:U=FC[WV<%N?WU]S_$Y.CM5P;1>W[K/-]<SE][6M.)@@YH#+=H#
MN9'L^A<6MUG?>/8,OI.?N#Z&XLX6\Y8D/@!!^H"$6#P7+_;EW R%_9P4QZ\J
M'UUN>GSQJ66!9HLJ<W664?9G8*$Y5X"NNJ^K[LLIYL7VGV5(8HL 2KN24%)H
MG#6X@[VX)&30:[H3+0:G17E9<@E/XGUP]1ZTYCWHFEJ_68"'_$.OXG=9$&"*
MA5W?_#T(\@B1__WA&"4G=)$!^!'ZC-KFJXA, _UIO<7EDG<Q#N8J^#9V]DMI
M>E&SW[*F92CJ_=;7_%,Y68Y>DM?#M65P-8[\/O:JM-4EJPDWKRGI%40X#Q$A
M&D)K[YC6*F]?40GCRP:UI_?7<L9Z]VC7<*#Y*_84HM29LS@9O;%%.T)1ZV,5
M!W?@ T3)D<21%-<25\TNT]/>GH (#;?[ F( /5S^:14<PK@4?C] 56:0;T=0
M&L.-%ZK12[DI"'.OL%F_5Q4N<0G %J5HTG/+MA0!9NA]$;MAZ)IO;0_C:EP$
MOE+B<5L](W$7+P*ZT:XQ[6=@UAJSP92M*(Z-J;9U0SODBE?GY0X4D1<_>P>^
M]UVGD3G7G/MPM\\ *)1OB&H1<(C<\.>E_'&$W1U[<[:4^><FE:H?%W<4O<HU
M#.Q"ZL9;[QBBPU@8A,IRJ\%# A_R#$F?E>:>@8'Z.*-FK=M@1K#>/L9!^!$&
M.>*G]!R+]'9VI_I+F.V)M(^(*MV'QTURCS,+GYA)#%5'L.<Y5O(TCA*WU<3:
M1%<(KB",<LS*WH"?PZ)PI(AG"[MIYN)K<L^GFZ3*F2-*S"K;ZYK?=W[Y?:T7
M4QPTK:](!#[D]#RI_=\=8QCWGWZ4(TD36\+QYN99^4*Z]V",9/VTRMYQ<Z(/
MP*%ZDU^<?6%1Y6/\&*,')DBSPI]F#8E4@][+PB :Z>XN2(0C)?/6:%87BN(I
M2Q:7,Z5?.O[56.N$L99["&].@D@^Z>YNQIN0'TNA[_X30#],F84_!PPTKCA0
MA%RPQ8'6[TZ$R*C +^YG3\(A3(U_4-IMW%7\,)GV>0%Q(*6E,_(I$W4'%-55
M*9G>;1(3SIU[T0;  ^TQJ6]P^ZX\YP/'%838[=VE>!85EOSE"VJ8I8]QP>V_
MP"35KOOD?,FF8T\&0S\KJS9^B\,L?7W[)G+IX?2Q3\0\(]US$G^@Z8."^:2;
M)/.BYN]8@'M.LO\!V=F$=XEGVJ#OS0_"@M9)VE/R3[A=M_J6I4G8$R<*>S$(
MZ"LLK9TL.4.NL[W'5VET9;!(K)X_*^N[I4_1%@EL+]J&G]Y]1?[G9T3[]=.$
M=9"T?D*S1"8A5SDC'0W&\<$+(:E-NT+D=JC>,4> K\X[3)P@#E[[Q:/&^ZX;
M?B+T9P8M'%)LJ#?A]^10*)]^PSZCZ(VL97S6?F9",WI5C$+9@#UKV'BV[E:4
M9.?<+P(46;MZS?YD+-R+0,[E&F?.@,6P8U>,JF-+GGNBE!%LTDV"$Y_M9= >
M[8IL$>7<Z4[58K[0RH/&C-GB0ZF)!\SZ/(\1CW7QAB]B!U2M]WTI2(87S9[-
M&'DT#W$\F'7XCT@$;?LOS+7JX"AW6_N%/6NJ,GN();Q59IVPB>OB(@[5O=2Q
MI,+VAWE?XV;EW/;6F2#7V2O"=3L+S;J6YQB^9M0@[+Z34H7SE7\,YQ]RU:$7
M3LK#7@@F7-/&JW7K\GYH8BT"+[@*:[WLQ<7;U 2#X5A1KT0\F*D8]'8L=^5O
M\]X5DW>IO+[.!-9.J3^F1?P,/]5RE_Y^/1%#F'_#)F@"R/F3NZRG<(GN/ZYD
M.O@1I&'_EK$+1@A=G]=XN0G_G+O [M:#E>J;7F[%3]>M4-5$LO2)/\[^'>H6
M6<O[\5<;--^<A&=GD'[MBOQP\. )7<QG#>W*SQ! V8G4_]OLL?/JT8M/*=;)
M3#%QX36IA,:8VW6>I9F'+O1X]YSS4JQK_\YD(5MHF/)\LGN,2"M((-Z"$,?K
MU-MHB%9H7YHL;.AF#XOB9Z9AHWUILK!98^:__FVZH)5<!JLCC(+6_\YD(6OL
M_R^ Q(,&*R0A>SM0L>P7&#(#Q\?ZNKOP,I5BU'O?!,0:9S!=F*MU6$5:;1+3
M!9LBG]B 6W4:TP6<(MG8H6^U:;@+^!PNQ5]__/-T$6Y(4!80EOVZ77C?Q0M\
M5R:A5X"]MM"_=[3A?^9!/?),)@L[FZY8B^4F&QIY)I-E)C\7?BEQ4%D1-@G^
MIP;IK78["'9>!A[1FL,X#7UB@##$7H;/9PZ4WU[2" 3>_: ;1C<#8;[Z54HF
M8E2/A0HX\V#FDA'4O?W@.:*/8O&<UVX,#QS6$]7U4P%V3/AZ,'.P3=A2M,;$
M7'?C0A.-UF""ZVY<9I$QXMA>7-3W\74_5(U*BW!@=V\GI-5R)GR&KV*M"9.7
M"<?BZTG2;B\SX71\W28#EC8C+LW7G3)@HC/BVWS=*9W6M7J/M*9]N8K=>BV$
MU2;-.Y>&H0T:V\98;=:\<Q2XMUF#+)/59LT[=8%[K.\">V:U95I5$TNZL0S9
M0*M],:"2H.V+E5BV?@1;'5N^SO8 /L;;! V!?T$"<E9PG4U""6^[AK(M/)2-
MJT(B/]ZA]=>!I*/$;(EG,5GOC>+"J19:+\B4[P;S<Y.EUYXZC:3'&<792.K3
ML[ZRQ^0SB\B/[YYHQ690B\C2[=[!D6-XXR7Y=D3@I:1L*'(9IP3(=7Q;"+Z-
MS!=3E'4'4\]3-Z&(KLOP//#T9 A:/I37,/WM 0)0)3W$^5#*:F.ZH5/]O%Z
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MB2,FK9AN0L13_9K HR_%6Y9=)5";* YJ-S9?T3Y1"'3<7K6N?N(8&&2H;$/
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MBM/9,8%++YP.]JF @)T2B>!'?G4:3@_'6%0]U;LPQ2]!1'!*'(O6W_Y.-<^
MG.37:6]_"=-F.?9Y=Z&T.G.1AY^?']&S!:\*,).&"SI-+INET==VRRM<WQO5
MY8 HH:')V)N="K;@M>LRDI+APDKO>BI&<B_)B4#%#0\>!ZO91"[J>.TT462]
M7YV&2>H4BA^W31PNPW4B:/$.XGAPS>8LFI9ZFX#SWJ1S@5%%?4J]"6A/W;F
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M-.G&FK\/W60UMPM7=%"RC4/_(:!:LCRE4S5\G)T]QMPLBU8X>@S"D/'\R'_
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MY9ET\U<H1)&'7[<8IP]Q7@&@P+QT."@ E">@F' .0%3/$LSX#'6R5>8ZU0:
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M!]+_Q\[T X7<-YE>(T(.0;1QEF 5,"\\+\XHE,_HP.P.-\]4!-ARSY6J:/.
M48)?& S+]5N"^8RZIP,T?&9\YCK>[>)(P%2A@]>'J8I&N0>NGF3+P8>G./):
MUQ(ZH%I66[*=%^QARF@IYWG":9OY0(?2F,.2#/L*P0D=3CF3?28QI=GTP"K6
MF/G [N.>N::>:CSV)^#@F;&=8Y[L,PK\^^@:[0-JBC@#91]6R^1*D)816O9<
M%F5../+J^JQ#< MY+LO\KHT1,%OH$&J9[7W$_,HQ.;AT*^5,IWQV\#ZBUC]>
MH>_YT#IP?P8.G-GU>V%9^!'V;Q&)Z,5+J"3)=FR?V*<X"+S '8"U-/I,\)[R
MU>+!3<IM^,44.T/< %8$Y1USB5'-[H-1;XJB#7, =\GW_P 'T%!B'LF5'R8K
MTB%XR]S>'SB_O ]QP@!?KNDM=@9Z^?'FN'C%5()P87+W]>E>(%!^M@-PP@(*
M9:W'W-4=FD!7<\Q\6=?2N]%.N>X.G&W30L>L<->BD1""H$J=5AX2%4^# )!^
M[R"V.43P>9I-&WIWA7"8S9V//4J<N&(^*1X\V^8UCEHA#.HY\Y%8QP\KIJ;V
M,""X%WH<#? OFC?[71![%I4W0CAE3D!D?D,9%)+Q,ZH5*O>@1+]03)GO+&3.
M/_%)2$;/RI>D?CPIBY+-F(];*7QU8C8EGS ;$$UGG'#;C2&S;53E9A-N6S%A
MQB<.]"XT(3 &$^>TUO2^,IGUIITY&U@ZYY@0(LVD.:6WG?-+)M.M5ID-7)WG
M2PB=9E(WI["5-3A#4N%-D+!<SHS@I@J</&!*<UBB%S^BE(%8/$CT$X0$1.5^
MBUY)R4TF+$0PG?M$D;[ZAL,/_$@5B*U#.7 3(.=?&)'5M]B9)(#)<$(Y$G8F
M2CD55N[BC#@3_YH,*50(.A,UF@(IBW6*20<S(,--MNAH.Y9-IX,'L"LD3P*X
MLQQX!%2"\"2XRU7< #>7<:<#S-=Q N1<@)T,,5_&#8 Y"SX=8+8,>(!;@N<D
MJ)MK030"ZY5EKRG]W[R'[+J C?[*?:8=4QV"W7=T&MS1O^>.W8P>QW'O5W@=
M$UPY\7!R^STEB.H2083(@7>V8D8ZG4D_2K^PN8_H@>%$F-95'??QN\Y8@4\X
MK>^Z"]RHN'0$20(R;_NTZBAKX=01((54W 7N!7_@*,,E,;!B=5:*>YTE*9U%
M;K][849/?L/<D_3__'K2&U04\ KA"O["<2S.%4_HL7^)8Y\GU6#R$7@X>8U#
M'SR,<_%&YM&EP^,F=54X=L0Q9,@F*;H*R*YPA->!L/SECR AM.1Q,D_]6T0P
M"H/?L?\+O17TO+^@(&)(6T9''_B"! G]Z8;^9[3)WP#H),A"IP@-NY2P%.C4
M8,P)7W!"M5>/)8S=4(D0QCQ_P95K;0SF*^8<[@N]S02%%-B%OPNB@#5I8;TC
MVO!"]>1JX>4#%KN8I,'O?)%B3,):;C0BCGT=M%,E'HPNW3IY#.-]<?Z4N2YS
MDR7)U4;.MFVAE&YMN#EFSFPEG;CM9BM)9\R8>M+#&I#DHMBO-'";)1F#K/=3
MZHR9D8+DMHB$@*03YLUV4Y@'8IZCGC2S\!'8  K!T1T][UF,HM++3W&,S\W(
M#)4ZL83MJ>;,5^!EJ/<*83*</##W-M1>NRS=;*)+/GI6PG,7QM] =(%CFVG5
M%!W?P2MJCII_J(W,KS9E#(1%4FYP_O\K98#^8\L:Q;Y0V&_7:RQNG,D*'>BR
MSR3^""C2KPYO"4NDK$1Y\0Z?2PW,;$#J(H1.HY+&*>^T!. [:D-%GA[@(O+&
M&T92W3&F<H)IE]M<PMS%1/S,H@@]L!PV&OS<\\=FC?&SBHL.[-(*%7<P I;O
M",\$N,-L&+YS@ZFRYP7-J^4HR*:<A\0>QCYW#O%BR.+QU=OOF'A!@GUG\ #V
M/@E/ KA#=IC[I!%:C@)O*=.I\'[!^XS:4!015/<]UAV+$ %35ITHO>L\AMXW
M>A'+8HSE>O&!@I"5^S(EA_YXM*%=IQ/-)<EM.X]R&K;\<LVJ6E@%M"B X115
M:.Y'WNX\OQS+=;T-2.XS8532?FC$>9QH;DH=)_<1-9LCS)]=8S; V>'"4'BT
MA?%]U&T1("H\< H7/;2T^R3)6!]]L2B!7H$QL!UX'W'4)(G83^D\??2^*V7Y
M>EV._NPH$BP5KN6:7XGRGK"PDOLXZ'M!.N6]'T^!\\CH?2N*TONR28*P!+_"
MSE\^&W9:3:DJ1/S539ER"AY:37Q*"CD63@@>%?G;)T-3I]5(#1=_/\^[P_7T
MISCBOB;N$;J/I*]:.!JRZ$T/DJJB(T*@>Q!/0T@]3-L)S]8\Z.?IS3BZT-_3
M6AI$R[GS4F1.-$)[?X)>2G^2?X=K8;[8/*EZ3)5A?:7OXT^.VG8V>*HP\HIV
M^Y"EHG+$^&K$6!;7NXD8,T/W3W\Y2UR4LT7F3)E_=<3!7RVUC^EZWTX?H!(T
MT9UP$W.F6EN263</VW2!.5M[5GDR0B!J Z"=A,*I8W82H@7F.XG>"3SB<^N[
M'+135KBMS$Y9M,#LIVR2AJ0\5X,%9FPY6D^"$8+1&#(G]].EKLB8HF;>?&G-
M-DP"&@LP27A0W@K%1!A$9I.[H"<]B]6&3D4791TT-BP=-O!.K/, NKNT76(<
M"/11>^G.M5/G+!@R",$+*=UH*HA;+8FG:^^O>-[LW-<\-&ZFH>B6 42<C9BW
M(576Y\Q^=N+(M?*<A%-F!T03?C:C/.%<0.1F%DPVI$.CQ0 !WXD56TJ!<AXL
MD*S"ON80VRP+""'" *\AU**Y VM>NCAL5^'2S "$>FDLU1#]LOGS/<6@B8X*
MX=),FM%%8A[DE#A0C!<8W/0;(" I,A5/7W8D2.U"BG+0K-89#18;G=YJ*IQ7
M2QHA/>'U44Z!6 A_A9* JNI4R4LHKO-H:^2_!ILH6 <><_WF:A%K%A&' 7OA
MZ]7;8C\+J7E)#>8X\H*0^?H"CQU;$&:L4<&O/,:)_<4'9?8;7)BAS"N8Y(^<
M0"BO;VWR*=N]4\UGS6' ?K[;998FE+>ST(8HZ"M9HC.7X\>9BO&Q$"-;8.'_
M3Y:DS60!B"W2>N*EQ2)L5X$&KHRX;8"5K $+5!-R-0?:8#6(\N'XHE4?27'\
M\15O:NUY"BD HLM*NR^9I'>S2=-.Z(S="-2B!Y$K#4FM8!NI&^G$K27;$,H:
M2U;C+GV]!NOK9=2_:_;-]NL^9M%V#*!\,G@,\Y7Q$7+@ADN(DH3+)IYA007R
M<FVP ASK9>R>@TWIUT07=RSHD54\&2MI4PZ^#=*4&%8]WYIW0>Z0K*3E.Z"T
MXDM;S)/%YY#W3B)M!_P$.$K371\K.M(L!E$Z'CW#I>0K#J[Z 8Y :SQK+V"1
MU>\OZ-LCI4T2H#!_VIIIC.3#H1Z4QJ#^&I/?*O>X&%;H=IDQK.RI]F2+?=YF
M6PPK2+-,!& G"EH;,O]&%1=(O7WYQ/F!4ET5-52*F?.#I;H5:K 4,R&*JB+-
MJ/19E)DHA;S*X^HF8^ (M.9NFPE3Q9;K##%/O,WGE#Z0.^R.<]$2W-:T^XC:
M\"Q/T!G!=L+QLG@HJ^A X=&5YTA'P1.@?LW>$X\$'!I*V(FH7=RYP?R(HFR-
MO)2;E6TO,_2J^9XWFH]JSJU&]WMS'CKD_,1ORB=X0BJ1X]QS2F<^!![.BT$)
M8<E]/)-8U,GI'!#1FM;LO .]6=-)##U:8SK 8]-6!'W@+F>'WH3I)/#WZ$!'
M!BRH[;'2T0U!.U'+)3AFFP6XG5(;_<RA2[D$:F%C;[)1<Z.WIM:I<'D<-@[B
M1 J7%'^"P>/LJJL02??4&3K.CL3JBG17PN'S.H$E>H?<T2N>,#!Z[72#+KZM
MYL]]YU7E&(TA8]UUA2Q67'KYK+'V*1::BBT*)T!TYC2+/&H9PZ_9?A]R.D7A
M%0H9'*];C-.JG<A#7BT"Q8>CJ79IF#WBH6W3![H;YW2(V9.\+:!!IO/:53*!
MJUO2T9L-%*>*O;& J9.2#3RU>0ZPQP?V+"^6@%)VX8##$Y7;+6NEJ<8B8AG*
MN6^17S3S8&7&+!JSV#7>'8'..T_!C+9'+406:@MPZ_8:3X<)H)Q>[:&5K@6-
M)?<7CV#8+S>;N.?F6()8%O"R2.E1764QU)1"\U$? BW.J-BD).=",>,+<>EM
MTT%!KZ6]U<N[@2=9FJ&@=5LUDR "4Q"F+3CY-(@ 2<G-%D390F?#>N^RE.7W
M=Q\;/U,>+(#TB>)_]0V''_@QCM+M9^707<3\"R.R^A8[DS4R"3XH\^I=RW:6
M&+F+,^),NLDD"*%CG<E#&1LABW6*20<KECDJL^L39Z7M&8E :T7)8%%'D%&)
MO0%P4*[E$NBYA!L*>+Z:0^#GXFP@Z/EB+@'/F?10P+/%' &^):8&P$!S18CV
M8M&BLIWQ7VM+>;08]6/AV(O=UIME$4/D=X->C<?<9#.=,0D5$!S!K=J\TY&L
M.2;](?!X;X+RGRLBRI^'"CR'A]/C\7CU!'M:U!TJ+OI?@KY8=,0Y8'0S6H/9
M0THX23@0+#.PS0V@PGSZA<A9Q+&_)?_23897<>YEC,GIF2BP2>!VMP_C \9%
M]I1")D!U @W(%GD2=@=[ A* BHO>\K%PJHMN/W1?EQ6Y&V;807=G69_O5T15
M':K'7\=1$O@<![6P)/1:JCY"K=:;O7VZT"NF["A:S+3:,$.OG+*FZ.?B*:T.
MI-"+I"P@52DF;; M*Z1@@ET.OH]23'"2%@]I=!129\T2&37S'(-5_,32V#]P
ME&&A[0$R@<_.!&L_@F V&1YPMO",\<J=J5^CL5/;V0/ON[>B7M^^_2+04B"'
MS4J?Y4Y(O0:JBR&;-/3M,#7I!5?#<.I\3TKH+7;A">CGS5MVJ3:\Q9=$.V\<
MKBNREJ5,5C 8&C>:I>!'C6*)P2K%LGC\W#Q29(2JV*-@/+1+:5 //;42U#4%
MI632&3JEX%%MSV3>C*WDQ.:8D 0D@\<Y>K7=)"4#Y3200>P-P7EM_C%8O8KI
M[)*@GPDEEE]1L@@Y%ED=]&J+RPSI/'S/GU-?1O3O >%:0/"![U! OJ(P@Q#9
M;M\$_MH8WUS';&Z W>#Y=S'I9K?G6  ?U;1 @-V;=)+WX,:L2M$SR"YT$HY8
M&SAT'X5^9-3=;;^%9GW^T/J-P%.6!<Y3R];6BPW]VX:RS[QR\AD%/CT_QD@;
M!S<_JZSTQA:B&Z2W(BA*\I=JA8$2P[G\G\C+AR0.Y8;TP TG^!<<[-XSDG#B
M6$9,;#;N=V_&Z0X*.A-1LBUNPS.)7YB"T>JDZTYL?"B<,+K(\7)H/#QH&3"?
MR""UA+IMGYI.!P]@AYN=!&][M8$ENIX3=<6U=L[(&IT)J]"K>P:KC Q'YWKK
M-]V>XHC6TS4D:U9DTX1T6_,1'EJEP"J2H,]<NILTQ?]<2D\-*\=>GD7E0Z/Q
M^$^? 1L%D<1[3-(#I0[V1#DW_GC!8%?M.7-,*#L04(%U=Z#\=X]$V81GCIDJ
MRHN]T+#:XN<QG$]GKRX;ZC!=V:978CIS1MZCF?#1[]MHG?%@T4L,)0C:Z:.?
M@H2[FR!>/'7D'1MS83T$IDN-#)$-]]0#9;&:(W:*QCOKMFU2SBU[%E:6%[U>
M?N;Q=MU-1?QL_:^F$YFD2M+F:RC@B[-F=-B#?/L0NJ9U>DM[_8460J:?-[8C
MS^3:&7CR#)8!3WV3>8TARU^%G]!MV3M 2LDYRIV3A?%%X S'G<\L506$K '#
M;&^"Q OC)".XE@%\S/2K_@BN:6E[9U<XPNM 6--W@_.S>$V9!1?Y#Y1<0NE\
M1VR<'O#?84:@6LBA"Q0+R L77./@Y8!#SQ^Q![PX<3G((#-&-'!VLK[%HV?;
MOAV[$<)DM<3L@.KXBA)$S>39@#-D'4+8S.;.#9J<.:B DLZ"J-T(=9H7[,61
M%X0!_W17Q[F.=_N,]:/G!YBQ@%2;2%E6$!Q5Z':]QMP[T]@?U4C3(,J":%.4
MT5$-520JQ+.;2%J4QUYAI#'8&:5I?$R).;9#;=SZH8C;1-VIUY3!!VG2H!'H
M6M;X-)*7*OK_D[6]%M ;7@U*&UV\/,6,Y3-'\WN("V;\2GD\YN5CC"W3OZ#2
M=TD7"C.??O45A8@<1#DOGQ&)OP:1OT9A**(OD%WA[?'1;B]@O@ P("V%K 7T
M=BN#1HM<HO;&AW3)@7V-&H'8]2JJ)X ^IJY0ZWT\G:5&/Y;!99')T0[]T1FP
M)!0V_6 7+07<I&0'$D=LI\MUZ<Z@/T#+":IM3=.&5CQ25FX'W=CK'$F]48_X
MZ9W.%+=>E#SUI%F;'<I/%H2@:(/=2F\Z[;0U#==A)L_+J-6 KND_RK_5O%ZE
M=*&J4>'5<_+\>]$^5SJ<<5*<</15EOT9 <NUC,XPW:ODT-TMI]WOW'*X1H0<
MUC'YAHB?E'TTG/&5G("!+W'L?PM"EGK>3BUQIOOXH R>'3[YX.4I/$$?A4=$
M6/8EGS:\*.;HDG!B:S"PS:O+T>WF0@!-I6G)@1+.@@..ZK%NR6 (F]?I\1:D
M)IH/ 41KW=7L#,T7A("$KLYJ<;+Y# A@=)11L[,Z3AC8W66N/7;]6\9SX2!>
MIR :WQS5*G# 56J#AIQ>L00<0 WUOKZ,4;28L9>V^)7]SSN]%OF?__DCA><?
M:+\/HG7,_E3\(8KBE*_ _\;^A$,NBOXC\(MK]Y3MWC%9KK_&*4YNHS1(\Q%W
M,;E%WI9[SG_!H7]U8(7-+.P3>[_]$H=4Y:4HB-".'LMI:^1'RTXO^$<0I7B#
MR3W5YE?TSW_XCR1[3^AZ&0."J@G9OAJ9*_S\WY11!+&_XNL$44+IBBI0$24S
MUL'V__XA):Q'):(+$>11[7Q-$5X$@L0X>0Q"G*1QA(LBKD?,X"NAE?V:P^&G
MY(_L7\D__'B'@N@$4/RL[)LMAX7_MP*48H_W++<^PEX>)$BWW<:1.6S&P^N'
M1D\4IX@<1@8U/[9B\CL*4>3141YGG2H4<&K;YM3&*MS3 [U/F&VV(F#ED#JH
M="]4(,U\INP2!7ET9\56**'H_KW'UOWT'UOZ._&R=XZ T8#(Z!W:87+5O%R=
M/X.\567'@;+(CMV1JR!^1!3%37A,1H($\5A >*QN6>'OZ165P;^5T&D&M0%+
MRY\FX10&YQ?E?='*FJH*G)*S(Q_?1W<!25+V1G;[3&UG#\PSC26=/<M\IO>?
M_@%M6)_R;;/,C/5MN#HL5MN ^,^(I(>JPGFU1>G7./.V1_(?8*$V$>WS)><F
MH9?X@$)F#19*W7,<!MZA<T.TP\#>$9;[Q892]72%R>XH9%I_KE-U^>&Y]U[<
MP&74UM5:>HYH !C-QL?OZENZV,4D+9H,E1Y-EHG?L*LJ5FTVV!WH31I&22YE
MKZEP+VJA,B5B32H!K69PV_!8TQQO"-HUX5"-  G23899$_WKF"T0L_4^>)XD
MTQJ\CD<Y!])N#A1%0GM'G^+H!:^SR&>KONW7A J/VH-:S8,V' SRS)L'=SRL
MMGA9OH?!IOQ:(4_M9T(Y?[TBN=H2G###^@FGKXA"=%0(%]^#BORUP_H9LGY
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M,KI>ATRL66W\3IGTW=M\[QF]U=VK_E]02P,$%     @ JX!:6LC\O-XU"
M/34   \   !C<')X+65X,S%?,2YH=&WM6UUOX[82?>^OX,VB10)82>PDFZV<
M+G"[28&]%V@7BS[<5TH:V;RA1)6D_-%?WS.4%#N.DSA;+QJWSD,22</A<#B'
M<X:BKL:^T.^_$5=CDAG^BBNOO*;W-_^+SOK'_:N3YA(")ZW$56*RN7!^KNF'
M@TIFF2I'\;MJ-BRD':DREK4W_U)%9:R7I1\>!*69FG1-?H]4F=$LCLZ&A2JC
M,:G1V,=]50XKXY17IHPM:>G5A-#XZ@1-@XJJ4Y";TD=._4YQ_[3R;;>1-U5\
M.@S/<EDH/8]_504Y\3--Q6=3R+(33(SWIH"LIYF/I%8C=,@V<&_<ONLG-=K8
M^,UI^!E.Q\I3Y"J94EQ9BJ965DUWTV8$B='9<,6VI\P)SV[)ENR_TI04W#%5
MF1_'N?)1BN<4''@S&ZM$>=%,"+>#6ZI-G3(X?\:0)_R2P@"RK]8Q'\AZE:M4
M<M0(DXM/5I6IJJ06-S-*:XXA\4L.";(O=UQ_\.6.TY1_<3QMVTL?>^*S2L?2
M9N(_Q^):ZGE/I,%S<^''TL<KKF&LIEHZ]\,!3"PBK9R/2%-!/*<PLR)[T TJ
M4Z[2<A[GFF;+SGL+\_]?.^ZD,R7(1,Y+ZX?!2Q&K=W$B'6G% UCQYV) Y\<7
M9Y??;LO!7R$N6P.GQF918DG>QK=$%6S5P\Y#JN1!1L%13WCFX'W_N)N0I56S
MZ:9_>OKMBL)7$V5B+($V2Q-%4\H06<H)698UP&B)LX$ 1G\RMA#]T^B_C-8/
MTB,8G1>?$)P%3 1@4ZE=3WPLT^/A75AR!ECD@7UX_K7A.=C)\/P1LYAQ!!9S
M<5N:J:9L1+TF2MOPS QTE\8+;B55B>B=B[KTMB98+WV(,(Y;*0I<687(SF6*
M6U:8 OG9FT;N@4!)*3DG[9Q%"GE+Z'=)I\.]#,:@2\U3SWVP0*IL6A<0*]$<
MEF1D!3R6CH6K^=>B_90LM4IX (5R&F0-3A%3Y<<8H*LH#0:R7@!$F0S#G*!9
M)I+YLAOVL'N=L#O[>\&.1*Y*!#9C9!'(/6 .XGALEYZK,D?::$@>^)VN,^@$
M6):BM@>@*:OG L-Q#%.&K]8+'+80<"M=P](LU!P]EJ@U!  ^@U@.W;E@3RK=
M6.3:3%V'3$LCA+]%?2,DWVSLAI6])8"YSI@'UNXQ]CHQ=KZ3&/OU7D!^]V8V
M..U_/W0MC%JFS[G -)50B-6/0EH*J$"4JT031Z\@>")!U(U9G,4*Y$'.A7R-
MT:?:N!KMN'-K= ./RIJ4,MQVXA!HR CP:D+^9H:RHQR1^#>2S^=:0Z)_)J/^
MQ2$=A:;]BZRY:BX55YME TO6+SA#+:&U00_;LG%'^;V.<G3$XUS%,"28O<;;
MP&6+)88)!^?@W2)N=@FJVT#FY<6@?_GN[?GW@[/+\\O!Q99@*H]V$:;7Y# G
MB-= WIX'4X]Y92IKMWD3)G@) 1AM3PUE-+6% H3H1+F0Z2!%9=##Y?\B1R[G
MV68+#DAK.>,"+;TV!_-#A7P)6YS1*I,^&)HXE2EI%0] -<PV9/Z2-=6.V698
MF%R@IB$O&D<PR",/<Z,*DZS26DM.YQA6,&+!6M&BX<#+U!W_)<2"F$*TIVPK
M&7:/Y*^-Y.1O@.2-D]8#0&^>[C;&-=:"B<H8KM*94G)>1[#7EDM(QK"T68<G
M(%S)1&GEYTQKUW7+JTN 7D#5W2[K.N;>T(=9.Z"JMA50[0(-3U.$2C @%*,C
M*L&N-<"-)U3QJL$B*+0; (<=7&3P/81W L+I3D+X9B)U'3(6QS?E.6I#-4%D
MNC4UWH)2;Y""F\OU=5^ +!HB?;JFNDQ,[1\W81.2(.^DB4OG_/D='I%T17E8
MA:AQ!>P9LO(]ZG8!==E.HNZZB>>'N."=UK:""T_6H^\%^9)YK4G3VG+X+Y'(
M=6H+XSP>\+M.*',I-/U6P\W0??A8FQQ(1BZ[+W[4]#N6[HY3<Y8+R*8LI/\P
MY#8USX56MZ3;3>$5^=Z?]\+Q?I?I5>XR7?R3=IG"2\&LPWUOD7LX%2XC;Y&&
M.(F]@%0_*% 7MDE4J=Y8=T=DPPWH+ KE/=%3J?Y'PR_,(7"M8&'0<@@  QN.
M,S?^<K'<K2OT6ZTP@+"$U&4:]HZ/]MM).Y%+=W,[B=]N<#D8SK_ '-X-314!
M'BT)O=O6F<(]S"J;<BSPRE!(AO>6W9N.%X&NW8%I=I#79#.9H:&CNV3V.$#;
M^A-M #),9J_AM@[$UM4%@A->"Z-IB<+:ET)[WKHS6-O-#1^FI[E%\N@A\BDD
M/& GO&EO0=9KJ)\J)T9/B/E?*4?M@0';YD@J*FWFA*?3L6D2H[P'84!N._SW
M,>;W#SKT=HV)B<5/E-B:SUT,WO;$X'1P\?)3@%]\IG2=-YX;_W/.WWS\W[WI
MOST=K@S7APW!UI8$>"8;C&%ML)V?1D"?J7TXQ3ML%X/38R"S%<=\:EDYBEVS
M)4C- 5_HMIUBWHYLUO6XDVZ%()6M 7UB9CQ^MJ(= !PZ"X=_?=9H/_%VM9ON
MX##/5R+3VY$U=9E%;<#EX6=]P"VM9.%WQ#?6F-@>;F["0)7#"9-<U'OM!./V
ML!/I @!2,'OK8=4ZO[O&ZEPAIOBMB^B@M24<;A1<)^YD]4CI4J3M9VV[2^-&
M4[*?CE<U'9\L*'9&[=F"#V-%^9-'TO>3]!=,TN$3GPL</34Y^,NY\FM0B'=H
M^B=)Q/9(U%H2L5115>"XT7T><?#^D6]]0AF0A;T4_L0'$UD7Y4IY=?]SH+6%
M!)79$]\)+:CNV*X4=6V)$@J1AMW<?P#%S>UF4 $M,@?ACJ6>RKD+J+DZX8^?
MWG]S=1(^F_H#4$L#!!0    ( *N 6EJ)ABLH0 @  $TU   /    8W!R>"UE
M>#,Q7S(N:'1M[5MM;^,V$O[>7\'+HD4"6$GL))NMG :X[F:!17%WBZ*XNZ^4
M-+)YH425I/S27W_/4%+L.$[B;+UHW#H?DD@:#H?#>3C/4-35V!?Z^AMQ-2:9
MX:^X\LIKNK[Y;W36/QY<G327$#AI):X2D\V%\W--/QQ4,LM4.8K?5;-A(>U(
ME;&LO?F;*BICO2S]\" HS=2D:_);I,J,9G%T-BQ4&8U)C<8^[JMR6!FGO#)E
M;$E+KR:$QE<G:!I45)V"W)0^<NHWBONGE6^[C;RIXM-A>);+0NEY_(LJR(E_
MTE3\; I9=H*)\=X4D/4T\Y'4:H0.V0;NC=MW_:1&&QN_.0T_P^E8>8I<)5.*
M*TO1U,JJZ6[:C" Q.ANNV/:4.>'9+=F2_5>:DH([IBKSXSA7/DKQG((#;V9C
ME2@OF@GA=G!+M:E3!N?/&/*$7U(80/;5.N8]6:]RE4J.&F%R\=FJ,E65U.*C
M*B7^Q7__RB%!]N6.ZP^^W'&:\B^.IVU[Z5-/_$.E8TE:_.=8_"1UTA-I\-Q<
M^+'T\8IK&*NIEL[]<  3BT@KYR/25!#/*<RLR!YT@\J4J[2<Q[FFV;+SWL+\
M_]6..^E,"3*1\]+Z8?!2Q.I=G$A'6O$ 5ORY&-#Y\<79Y;?;<O!7B,O6P*FQ
M6918DK?Q+5$%6_6P\Y J>9!1<-03GCFX[A]W$[*T:C;=]$]/OUU1^&JB3(SE
MA(2EB:(I98@LY80LRQH0M,390 "C'XTM1/\T^HG1^EYZJ>?.B\]C:0N86'M@
M6;N>^%2FQ\.[L.0,L,@#^_#\8\-SL)/A^2-F,>,(+.;BMC133=F(>DV4MN&9
M&>@NC1?<2JH2T3L7=>EM3;!>^A!A'+=2%+BRG%QRF>*6%:9 ?O:FD7L@4%)*
MSDD[9Y%"WA+Z7=+I<"^#,>A2\]1S'RR0*IO6!<1*-(<E&5D!CZ5CX6K^M6@_
M)4NM$AY H9P&68-3Q%3Y,0;H*DJ#@:P7 %$FPS G:):)9+[LACWL7B?LSOY<
ML".1WS&T12#W@#F(X[%=>J[*'&FC(7G@=[K.H!-@68K:'H"FK)X+#,<Q3!F^
M6B]PV$+ K70-2[-0<_18HM80 /@,8CETYX(]J71CD6LS=1TR+8T0_A;UC9!\
ML[$;5O:6 .8Z8QY8N\?8Z\38^4YB[)=[ ?G=F]G@M/_]T+4P:ID^YP+35$(A
M5C\):2F@ E&N$DT<O8+@B011-V9Q%BN0!SD7\C5&GVKC:K3CSJW1#3PJ:U+*
M<-N)0Z A(\"K"?F;&<J.<D3B[T@^/]<:$OTS&?4O#NDH-.U?9,U5<ZFXVBP;
M6+)^P1EJ":T->MB6C3O*[W64HR,>YRJ&(<'L-=X&+ELL,4PX. ?O%G&S2U#=
M!C(O+P;]RW=OS[\?G%V>7PXNM@13>;2+,/U #G."> WD[7DP]9A7IK)VFS=A
M@I<0@-'VU%!&4ULH0(A.E N9#E)4!CU<_B]RY'*>;;;@@+26,R[0TFMS,#]4
MR)>PQ1FM,NF#H8E3F9)6\0!4PVQ#YB]94^V8;8:%R05J&O*B<02#//(P-ZHP
MR2JMM>1TCF$%(Q:L%2T:#KQ,W?%?0BR(*41[RK:28?=(_MI(3OX$2-XX:3T
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M&TY'!9V(L:ZJ[N135A.[@\8_CBQ]+MW*[LCOK:L5)B9GF_HKR0@(S'Q+ZD/
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MMB:YCI7U"?V&A:.6&4V5[V+LR[:^U3G6E-9CZ/_G\EMWK.12P,<JJ?YE\28
M)T*(MM*,K,)5#:+M;QIS)I23G$!<+SJUN)OC[EK#Q]_BKEO2P/>XKAE-B"FT
M<*&*/XPU3VM,<#B'DKEJQ**0D=..(7<W8?(P0"Q&:M#]\Q$U/V.# !DBHV/J
M8GYID]6[;B &P]IX1=+!G#<:F^"W.(WFLS$1==,Q]E>F0^]B>@G* RX5@UD!
M1UI'ZJ2!_/8Q4*\LOXB, 1.7:$\I0 CNA]NR5-<;?ITFP, %[H1_$I$I"V45
MB;1W$C$@NX.+<C'R8X\<YP?T$S(YW&PCG\+(^D1LYG*;J#X=Q'8_>G&('BN@
M9G+HV<Q]R6H9W^KLO 3;^:\PWY$$3IW]J5G9O(<$\46,IARUE+,301*#130Q
M,P0H9#^ :KI6^BKXBSK$B%,CSF[\#Y3#3)KOV))+DGM'VK%ANSR+HPQB?6VB
ME<W1EM:.!F9+X3Y1W/T<8LA6][/P2R[@AH5V;D/XJ?(Q68:S'AA_LF/DC.P^
MV4A&Y6>*=O-SMZ8.+N"TETH=-VP!RTHJ>IL6RO0@VJ,L$N%!K68>SI?]#%2Y
M&1L7;^ULGK);CMI$G9P0)T'5DA.D$PV0%1#0_978)/"E\[BY)G9OF;LOGH_U
M(#1!3D!)GQRUP=GG460+T.N\0LVB2W?PC'^;ZKYV2,MVY4W'MM)'+XX%CR;*
M$-&7JO$3W+['0V:9HB$^-@O>,LK0E_V+;)6'XR<A<YP_^;S]%J0/2UT+P'6#
MOZ3][1!J"AVO>X_6>;?>*L[.:7'=2X$<I1;5IP*>&-FNLA)!Z23C/FK0@*,T
MR29#-DQ+,)2C'/&071A\/$]B2GG'EGC*4?-[I*?I2\B+U,68(%PVCI=#:RW*
M8KH\F>5\N4&'7[<:CF?6S1JTK!3^_ Y2916_761S<OB[T;YMS>P1AOH.7GMC
M!Z,P.+DFZF&9JLD./>J/*<2,&LS7?\5/&L&(9SD><E1@D> CBE(_INNW7YFR
MF@U<CI=NM %M>#,]:'U*YU[V6;S1G,DJD))1=W;DWUM:',6NB=N3"/,<8Z2X
M#AQOA=R \AY_!U6'#(:/DW='#B&+93.B!J7YCG[A 1DW'D<:EN4*,MO@#RQ'
MDM]3" -X"PWZ2OW?^'AX0P< NL"@U]@;GRU]'E_KK,"W(O06%5YR7??2NF[I
MWB:/3LZ;=>MV$_@WOTF/(/HS\O*E:H*/@'(+TYS9=]9,7'YE0@=/EWI";.&9
M.*SUQI*2ZJUCSCX"_4*WDNQW;Z[>A0$5#N6IAU2; *LI(Q'F"ZID?\=-WN';
M5PFQZ"C#]T]_GF!$]&B0I[HH&LTT+>Z?=NI3/L']H:9_#@@(>FW1_FTMU?>)
MH=P>V"IC\&CKV.+2'XWM.5_PH_1;." R7JHG1_$)J?'.87P96GP5$EZNFB5P
M)LBJD N8Y%?4-[#QUY#3H:<FD132<48#@U[C=L%[ZZ[#K]]^[S@R<ZSLT_C(
M09^@+QZIN*5_9+^SP]GI[(: A3'@LC@$LBD/CIQ&04Z\.HNNMJ0[\<8=;]JK
M>S>T@=A;=N4;XILA:E_9UN=CI),"B[X+,741 1U_:MYZS/8\J@(]A+O8P#'\
M5#>LJBS9SPTEF2,?DJI?YN,-/GQ&A G[ C9[B)@_R%]$Y)/AY]G0S4!KSV"&
MX\V5!(Y#SH+A>(HU3BMPZC/+"6#\?<S][!/.9F;3<SDJE V9<T7]0":LAI68
MDW;(:LGJ>%M70RC[T4N3=G[*P<B/$V03Z)M[D<2ICX:6NG]\=&:N;,.XH(QC
M,9IA$9+D><<;W/8G_5&,(PGA"YI<X%KFP@$>11%Q@SA*QI2JWP_\? VIQ$Y4
M39(FQ'>E1>G5FIB!'C=M@[&:)&O0__[9G=92KT3^7N= ?JDO3/Q[V= \36H1
M'7Y^Y+HQ6KI!1W)D?A=Q1CPAHR9:'8;GNU?H-YE:$B^BC=?5"[$V;F-2E]IN
MH%]P4L;<M\L]69",UY7N3)U]X74AL\N_?.84OE"AE]()$+X2V&?B):;(6N&^
MVP+AE'TXP)<&;6&+D+11]OQYZ&T"OS)$=Z<0NKGJSGX51+?>VT2NP(3&:W^6
M6!KA%1O]TC(V/M;:4/RAUJ_8:^ANV)WE\]J7"4.M4@P2B682\6HYJA$'ELM1
MQ_&K Q!>OCH+GL8U9"YD2_;!$],;98]Q2+*E4A3L%@VD,8!]*S_65$"C+J%5
MH@WA@C!>8&V\G=7.J5/M+85?WW# PO$HOG_^OK_RLN*V*WX=@3<C'"SU)>7M
M70#A*.B6G]N.KR3]L&H*<J-^! 6.4\)QT';\0J;$@W0:H'7&X#(HJUGVD$<_
MV;[M+6MWY,ITP^H;Y:=?6BT47[FSFJ;+21\N1UMS]FD]<EZM)ZN0H[KG*;P"
MI!H4T"=_WB(SE?(CBG"4_)K;PEZ@2LY2NB(0W=T@.2S%R.[C^"%R5!<B?%2Y
MTIW4C9%E-@@E\(:U%T5<Z#"NE=U07T]IHK2R^>M!M)C N9+2)#'R^YJ44AAR
M'X,?<M=5^#&#+'LD]!X7@8>V$4238(93Y]EJ*%A\%GH>P2_IXBN9V(%)-[^C
ME8EZ7_V^XF^1W!\\IL:%6YJN3>^F0W_!KVF-_2(-R1DI J?I;I(])#,POH^2
M37EG6)6#3V-NB%+^5%]F/+2U*??DV#_>);FG3!L;BHXVY$2%AO>T_GKX09G[
M<;B4#20-]G&ADVP  4Y-XBJCP2W?Q+=D]UW72K?'1')C>U8B,NG?J7G+7V./
M;=6_=)ID.E)77]'_A\G*..<X7)AM#B#$1&G+SV_:DG21WX=)1&A&<H3D!>T3
M#N:5.8*$%]\ "C\IG6160TSJON9.EVYU=09HN4S$5EIOT!3A0^3.%M;J(<NE
MYPGQ:L3;7Q8^S.DW5=*BO_KL5?D3\4DJCM=(6*+&<Q"7**U@Y"ALC 0A4VD>
M[+,XSC<Q!DJ2Q,\BDN0%SH2D.DK>0ASA77C *\%OY 0&>0N\L>LB*3JQC(&\
MO8&$T$RJ#RU@9,OS/>M?,?YQ<EOE">"O4X!DZL)'(7I]% <K,I)HDXY"1GPG
MV4'U'=(H8$8@S@3_B6R9T-@8X3_N[/18Z@C95+?0PDV;6\'(WV**'S=F?QQI
M?NT+]%>]E!5*UT$? :KX+H3G4?(IJT@I_,5LKBJ\-?)W8EHGRQ[HY7*6Z@B^
M=_])/;%S5F^:5CW;^C0DZMIT]I/@P!C'=4WAE/(8?WW#BKP/CS:9T$,#P'X>
MO3N>XX"0VQ[Z=3EJ/<DF0HC.P.@SC>HAG3YX(VO]ST.E V%6>=S)&;^94]'^
M9><(489UY1Z41]$MXT&5-&>#\2O?/.;^0"#TY\ZJCQQUAI##!KSI4P0!8:%?
M&%SJ&PYDU,0BQ3R-JW4N/\16>@ Z61?R?IKD"J55X"]N]DYQ?]A4X@4J72/E
MZ:<)2Q5[KFTUV--R9X:]DDWI9.& $_-X:*?!@AF?JDF<.LU@RJI8JZRI0)68
M.C+05YS?4!\T^\49 X;7^84A]*7I0=2WZ.7+P5-342!1^ OXAEHYU1M6/O4%
MI$+[CL.J6VC ,<J[-XL";%>\!I*4HDL2JU,Q9$?HE[:4ED1J=NB:758S/;C4
M-T.F RE)]>\"S;.DBA>'\'N@;VXC2T[[F@?0ZXD9"*L?M(#7I"$Y9@^J2+7;
MQ0!@T!?K.W_B#B\ICX--IS2WIL<>^\2;PZDG?C@\^AXJ'#ERR^8T5,ZO;- H
MRK/5S= ;Q1[_98QIH?&ZCI9CMX6'F46R764-LHA^(C;O3\+3@%R2.Z_T-W4,
M)T;X=LQ5"W[C?ZFMI;P\AI-1II(+6VS=W%U1U45;%VI\H>N+9UQM2?^US!L)
M>8<YP<;G>/0?F3^?;L3Q2MG:.-X33,MR-VVRO;O(D%&486<T2[H*S@N<(Y=O
M0RK\U9F/ P>$\;H#ER\9]_P&Y?K?7AGI-M'*^7X^TP]LS5K:F[@Z%Y\L&8B/
M01+P(S+J+XD_A3];]$,8GSV]_ME8/6LU44V 1Q:C$8&*0PX/ Z"KCZ*;^LJL
M8C<4F%%[,7K??\0Q"13%P/J:J+,4/G?-!R\BRZ#Q#SGJ8974J!I)O,(69.PS
MY-Z@N >@^?Y6AJP684[J*2H"\_Z!FJPMCO346.4_[A"->+=/5XJ>2AU'OEN\
M)!WY_:6M TXS<5"OV:!UQ:4R?2L*8TKI',&HD3$D-63 =9/2#9 ?/\^IDZ+A
M:D#RDQ4SU7GQ:K/;7YY]0 SK=@AH\R^HZAJVO?,&# H^C/"ABC+QRL?*CHYG
MS]K+HA[)47OEJ'?'Q;J0#/&S/B2K(K\F-/F7\E.."\C5?(HVQ!H>Z87-6H"R
M6QR'FZ('[6,?OB<_BTBWUMX@W+4_[(-3^(E4"YDE(O$7L3_<XO-P"SQ7)3EJ
M]MM).I\+:S3*ZB@1E'=5L%H2GY!/8*![/F#YYETEZ#2:@;/#5:%QF#=HTA"^
MNE5@M:6+>_AI#%8]DO.E=IC@HUO0OR5*I!3N57;JC]3]KKER5)8;^R>.F9$0
MH=$M>D#YVDB%;CK!ZF9RU,& %VBI*\= CK*PD'0@E_[.YF43ELA("4)T%9?T
MJQPU0_"0'D(JGM(1.:I\&:+(41D2(1) CBNH3\CL/\1#YC,BA+@IC<NN,ZB3
M7#%MA&1>0?+JD-V'MT@]4B<Z63O^#^+>/2RF]?T?'SMTDM%!46H<(J3&H;15
M9B$DR2"D4K/M-AU&9E-I,,U2Z:32)FH+#9*0&G0BF66:#@C30:5)S<E&)ZV%
MIJ59L^:[YOW^\[._O^OWNZ[O]?W]-\U,SSSK>>[[=;]>SW,_]U.%</_BK%(P
M3#BT]A]/@O=4)/4OK#L%38]BNM[(X2S^Z^D*<Q+ +GW+G8$%H_'(D!P\S77A
M+$#6\K-ILS@[X/(<)6L26OVJ>]?#"L0JI6Y]N"V>4]H;.&09=/QNM,G8U3;Q
M'#?5ZOR=I5,*^MVF>(<H*#,B"LU;7<4SV?G^%6V>:^37*/[(5.C^X"HG >]6
M1('KQ8ESI7>E^X&6*==2LBO'XU>YM5BL\"BT:-6'"4:A7XI_2/T>I"D 9(6A
M,[HF5;?)KJ@*T&YFY+%]M+O< G$2S>2+5?U4QM(0@,"UE$Q%M*_OLY49BFY/
MJU+[&7\[.5Q!@U%_Q*,)G$);S'%'F^'/ ?GKT$2XI)EF@6;+LH_8-ODY-'*-
MNY=Q-LDUZ_<$3DOJWM-1=HB=N?15>MM#R2>!2/,,BF110*$?*+L)VN">D>Y'
M^.7L-%4.VE]+J0<,'U!+1?(E<2: ?%Q(T=MD_"K,^EI^\K#G@NNO'_Y]X$EG
MWJ>/WJ:/#U*J0?A8"6;Z703!VW5T2>A)F\MQ;AMN/C/&Z%&*P(KXIF?QFZN6
M#TQ(1V;"^3Z90>\$\Z..>1Y=.<B;5=D'AM15)JXW)(N>?D."KQ6R]2?V<IN@
M2FDR>%C:$R CC_C)+%,XKDB+'$RI.V5RQNV7@3J@=+" $ZG(,0S93C*+"C5!
MMEF+4USW3W,N*0JY;N^\'1HYJ"4M>JCVU9)Z((QXW1FG<,?70K(65N]UME06
MT"PES"IS+,89@KU"6.<@_3+G$JH+9(S/&UP>R3.M]%MMTOM;1QT%6?)#:KK?
M-K'D'<WIK?#JQGI@V$%%0$WN/AVK&I;B*[6DP5K$E@2F@$F>\^YCZY&2,YY3
MY TU^0TT-V1SHMS$R.-)5U>77WA#;=7MS.+B-QU3@YGQ@F>)AZY=RIO5LF6]
MT29P*X08Q&.6OO@9_FD*FE!)Q?<&?/^N=@J1O.=V\"JNC8V]>78I.[\9/.,6
MGY\?XQW-C&1&(_JBCOW[/WS8]G*:);PA9UG'UH$Y.XL\'MV[ 'S0QZU;5/L(
MA\K7\ A'^X:Y:TF?SIT&7AJK6HAH& _)[FE)#\3UV:"RI(E\.B@\G3L#I;6H
M?9OP7U$_72HIMJD:WEM .5S+SZA;6SPX WW;O*%R_YM[[ M4D_UHS*8:_Z/W
M!R6<3;:" J+!8Z#L(60#'@!ZC66CPR-*,#UT+D(9CD2TI.8"2OVH%>=7Q/GA
M_2B!-1J@8%"8RP=HMB@?_K[]PJF_/>?=B<27O(O]KGP<F[GB@()OM#^J9,^#
MVFX7J<F@Q&U<30#@#@)1'X#"M> AZ+U(=99&TQ31#+!U")#-G8YM@?63:8:H
MHT(_U1-4\C+L'!!^XMB(U2;X,S:?:]KIFA"^'>Z_&W-J)C_=,[@T>!\[?'U'
MN76"]^[4P.&RKUK2RWC5#-1129<XJEHU>5Q#C-9>=8W1R#"E>6"K6H=EK?-/
MQ#G:KN7LN2U%TQJ6ODR,/"AG3.\9[%_4&;>DP"/$86L[-<[CR8VJRH+=! ;&
MGM7E?>'^H.P?.NJL>DI@5R>\.5'MA+<$W;X(' :S<,O'B.4-16_I%M<(D&#>
M*?G?!MU=<[*N=Y1?"%DYK@#.C@7;;I8^+^#>G7ZCY$OUR=4EBH136PN7<%8Q
MR\"]>W![*1P 27R#=+%*=IM7W=RD"=Y=VWD_3BS1UPW#3*<>D01;B;+NB^'/
M\G.%#Y+"JM4.IS%'.?HYE7*>3^OP<*GP6]9.8G)?\!XX8!8!N+$-PF^:2!-"
MT]A#RM'L[#'!0R13R6^DS]Y/GAYA5?#X8D\_9P-:H@S^^?%I5]7B$4*@K:]\
MW(4%WPT*_" N_A*_USWN0S54#%;J8]9AQ*1Q4'-X=!>:<9OM(.MN?A\;O:(J
M.E@H)0GLHPH7HLG13-.I@XYD(U0L+"0]038715L.0(\X%+?T.-].?\M+X6#L
MKCZHM04WB%'/9P,J9\(&]G-?,*9QUMP(CB1T9EH]=2H6C=:PJS-8=X<@*]H*
M-FL+ F4=B2O-,APSYI$%)0=ET4L'A\R]Y#F&7]Q/-D^VW-';./%F'46A"_R$
M1$[B<]\1_N$SFC-!SQ&8HSFA[VBS0]"S3>1S4$5UU=W]P6R*(C\M^DA1=5>E
MNL]99=P"&K,GFMXN*8*;<V(U:SW7R_LV+QXI;RJ5MUR+$9V$U//QMU([KBW^
MCO$+S93;!AI6S:YBI!+2%+=#@Q7>R>7ERB23S6MM&H/\JN].Y=T/ZOT0TGB
M'TD^NBB7/Y 9YQ%9\.:2BF?/7UA1@.EIB@%9)Q]U8(R$J<,Y!S0/N,O8^<K4
M:UJ2<4[#7KL5W5QCSLKNNGDR>AH(Y]/.W^YA/]U?!S&F#M&6UUYIMNZ\-)Y9
MU58\)*!<17/V=Y:W#[3'90/QP$%Z#T,&#OO#E.=0!7U8*2>04@^S08]:5E#.
M<)SNH%!3J-L57]K\[C'Z3.;]VO%S8UJ2&?-K07[ZV#-& '/U.ZCB?@E48.+\
MMK[Q0&6Z'I9$6*) 2_IVF4HH5<W5J0^UI-MKIT+O6+@!H9<7$R$_Z3B!Q@\X
MGEI2^Q(F]@3X__#U"+TQ+B2Z@AL1/' )H?.3DL&>4;Q32YH0<!(87U<QY+KD
M*U<MZ>)Y77$-:'A<2XK2DC0,&NTZ6>6NVXD!7[D!,AZ@^H/R* V_PR)U_R2D
MG3!62_IG.0#OI*K7$.P$G B>"99U8^:.^$[".B;_U)(JYFHN F->[*G02RO<
MN(3X^42BM0RP1XQY$3U[?T>/BAL\5/NTJ(E(ND=+^IV559O=4+ ]NQB+;>7:
MHE]]TYC[ACU-D22/T63!FKIW!\ZO8_^@D-F]N[H*)+'3:H)V.Z?:_'VC@*HJ
MXR.ZY<-*_"U5O1KO *=_[#A\Q0_^W,SH,5;]JBGV7/PE5;\6S)!6?$X,;G8_
M^VC*M XLM%4P_U+!J@MA4S>KU^5!744J>TT59P7"QPU38+)J .FJF..^^H9Z
M202AL6C.@X/U$3^>Q3_GZA> 61]I\D_E:;H\_-H/3__NIS\TG[_QG_/K@#<>
M^/2[FMOFJ@RB.PV<R%:7WD\"6#S<(9,2Q*PB+TFQ[D"P=%ID3>AJY(./V2K[
MF'V8#Z)+.@_\@*O\;S7](2F=LQ.WY[Y:C."=0,4?QQP7E(SHP7&VMEMKW;'-
M\."C1P^F!&Z9=_'T^LFFYQE'N<)0 X2*6?3BQE1XOKCY>%G9(*]R=(3GT$3/
MS,NIA:7LWUESHJ1SN"N;GW1,A^#4 3NGGF7G?ZZ8?_]1PX'-YP0>FD(MZ>,/
MFCYA,V+,A0CX93=;]2=&_FWI=B4==<O$_;V)"=;5_W@DO <./D&>@;>EF)42
MW]%#6)(A\?:D4H(NCZ_G?]?EE;&A?UQ F*XEJ9=9E^"E/)M6?;53P'<10>7\
MM:17TT$F3ST+.#2JB>2?B=.0_S>?Q$["YOW[HBYX2XI9UN [*<2/$UVL6(?*
MM:0[V^\R/KW4DJ;>!U\=A?Y@J:UTB6*:0XS,2W@N" =)?VX$,0LF_D9/F8;?
M<"\F@1>IF*DOOHOXW\F$6JJ 4**]N]7YC)$8AD*75;&+\)#'H' -.#R*$T,U
M&%W<K=[_WT,Z#"7QX/H+N!_25(1@3BKE'.^,-?DMBF<$A5]6:BYS+32%'S]$
M=@R QE6VV\ESF*IC&Z5A3S,)A>5*F1,UP;T;/<M-8)TK^LMS?.>^WM?2 <*C
MI_REJ=8UQB$>^E<@4BK9WKSSG*A9XIUXQ-,4/NI[YS%/26FX["_DD<O+?EN6
MS1;,[G*-0\I+F3:W<JZSPP+._Y'SRAGZAT%T'=!D$9$RZ30HW D<HB1)\,()
M+>GT?>PX- M?;3-VJL67GTHQNL9A*<K<]I]O>=75[_'L00?-KDHH=5#E9)79
M]NEYOICT 11"8(V/)A&0W9%6B!O*8@*M@7K>6>LG&AYMM<]:875'$7H"^7U\
M>WOT6-_>7<<;2]A6S:O[IZ&)"4M\*,.AEK4UZVBM#6!I,V;!D]%SB!D9?6^L
MJM=<PV<&#\2#9EP7KIAGSIW#MNL.?J=HJ\S _!0\$T;DR6U!>:4K?2QYA\9C
MFBKZ7MK<,O!]]-<*QL<;Q#B]UF2 \D105@)5:DG/-90M^$LT^CXJQ)=C5F=G
M>6:[<):@-9_8T+IVE[BE61-@8I5C'TM^]U*KE0 .&3!9&5W(^*&SY21CO$_O
M/ZOGDX6::[3ES)-/.@5+V)0-P"\"-Q^73\H=X%F*X<CA6,<WK#T7*[Z^XYR0
M1WHN01;)?K%<I9QGL#OBLH4>2OXW30<1[QZAOP>5S9AYBRJY&SI$EWC1X;>7
M$;KH)#D%\[DK8?LV'.]?VN:_#>'F6E85>;HWWE_NY2(.6^G:,'_Y;W_]_?["
M*L;7>,9'@H+J'R9\(P)?3K@K!9VD)=W[O/TZ^6_P (2ZU?PWI=U$PW.A2%@J
M%MQ='TV7AV>XCEJP8[8]15B-:ZGUM1U1W!F=M]OB+E[Q?OJP,.* [Y>0Z$\K
M9Q8NVW)=[RR>!LC2I/"1 ,SBJ4JWMGJ3^QJHBA_1DX-GK./KJ2D,N!:4.]7!
M-8W7'!HDPP!\%1<#EER;+\"!-J?[\PK'7R- ELN^\NJMT*&*4YG5'_*&2U1J
MW&01X3_.'#L=:""Z\=Z[NHC1/D8"#4"8P\ N0*@#2W.1+/'0DG:*S\S\QL)F
MQ\@H1IP @F3([D+&G!/%7N4H14%_+DVVFX3DI1W5DNPFQ"F>84>1&I%@?CNA
MWK87W8IRRSNF1!=%3;3@9$)?7P@@IG.$^,U$M3<XN 9.$A B.=D6^'@/%&Z$
MAGGX6V#B/,:X3E:>4CW0\+!XM06W2SH'"J>;A@Q:VKEJ"FDKV7SAZEK-DRM^
M=0*& 9IZ5$ZWB5S9^/%#<#":XYWIC1Q)B:/D+G[T;OC(CHT?"?,)9Z"+6".L
M,'4<+@0>-8_LF?*FN(F/A,L=TEA8C.W99MMR'N(K&J">$3A&KH8;CHNBB['-
MK1QZ6$1*6%CXE+K4Q0V)^C 1$/4+N4WZ<M9(/ARLZH"[<C^BX:IB]#C'5#DT
M%!&8BUN."VVBJ9NKH7>?]Y@*W=(%EE$"@PX7MCWM8#M;+[A@Y5#TXIP?^?BT
M8LTC0+X47:C>P:T7+.SD] 7+W3(K"<(K3[CVNO>K/4QMV#?"<43(VSIN]JFO
M.=0+5K?6N95M*YX4[:](>9WD37XTE_QUK\^"U#4+\S:>77S^5E[@[%V_*C<M
M^[9E>,/-^4FO7V^XE^1#,F<H='5&#VOXMS1/ 5D16%4RXAI]I[I$3I_#V=<5
MFY,:\[,<UI+J;Z'@S!K1:,JC]::TD%(&:B6RMBP#ISR>45UV)\K*ICA/$4B
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MY +_UC8)GTLHAPXMZ:<??Y@@DW]H2:ITXB.*\J26%'Q/2[)GH"X$"/LSU6O
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MV>C-A%7;,K?[Q-EN<#+?)+CPJM[-A^J\UR/V8.0D2GO\_S1!#1#PG="+^B?
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MUB0H(4)+*BJVF/1S#P$]99K'YO]=)'^GN0U%^%'WA% 57NS5C%1PBM'6!<_
M+,#"F.TMK,V[FO7+AS>R)DB 9IZ*"EU%RY:-[-RU?M%SZ4?=;8*OT!C83=$]
M\EV]G,U0W4 OR:@I8(6$LZ>M[@!2T@19>/K>1AGU%#B1/6,_6\F NTKN#WYO
M_"4$Q9TFL\VWK3M8&.+?4%U6T1)X,&="ES7=KB4=\5>RSD$$T<2(::QWAZY<
MYYCI[A2CLK(L\RHJUE.)T4S/<[.FB\K,_6N633Z9GRRP*2]1.(8;[ WQ4'P
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M)/3G2DUR8,<BGD_GB*>X(B0T\(5:2WI7@9M4$08,H438O*9>C#[=@([&W/Y
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M C,D\U\FR*CI[AMRYS0I11)9FGK[VWY%6]6H2<B08-:3)SGT;JH7"?R%]R
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MKJZF *@(P,R'9/G)P&'I^SQQ(\T(#7=H6$N1IS7F)(?.0PX]498YBHZAY>+
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MEL+>+N!,;'&FX+5!ZMEOG</Y*>[6[3@,\/8"\-8>Q]Z+4_"&C)9VA\E\[UV
M[ O, ?)?=*4GEDR25%EOO?8W2X]:!G;?F:J09SEMMWM\KR?]^"UZQ;HYG&_Z
M3U=LGQU2)%IA&4Z(:&^3415_\SS/FJ,;W\%[)B2$%C5]T]QG3^!<R-WM.325
MQ+2]##I;ZEV ET^W4>*O"QL^V<HIZE[#=^>?<Q^OQ $WB8AA.1;_N3 &7F<
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M<_1 ;@K&%^,RE[@9[8 &$GJ<>KFG>3[X5J-?GH.7[OB=7]?D.R6NRGVR/>[
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MD B;TA'M'I<N*^'0 AD5XC>0-> DA66V<4O1(Y@HP5\)M;H3DOE-<RF=P+2
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MT*OY.[:Y-8FT8GQF0<,L-\MV7&_6F.':7/VG@)@T>9+2A\G/0O1H%O0=?;-
MPD$KW*5%U"$*HK<-55?ZY\*_9$BM1\G7:OQO9='ENY'M<GJ3<)#3[)X:$B@
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M=T02D#11S]H%Z+7]7O/7K2"C5 E7\]W8=9ZNMCGY;0"R.@S; X%8OKN#8@L
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M0)U@AH):&0V5I#2@Q4.S"<9)P[- HO)0KV9'./(UY)=$WZE0N\OSN'BA)%N
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M"]]%3&[ M6$SQY;U4.@XLKQNH"[0I4<!,RM/E1>==\RF$V7.W_^](#RY"C5
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M#6DHCA+D!W[*KYH<7(^[*5DED-YG@;&2F;_ JH/J^X+SI'=7E%ZP#NC>/@B
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M;R:S;AO)C +:Q-D<$3;]$?[V_-I/]'WD)WL7ZW,O4\O%T2>#^%8]+@^?U_^
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MS4H2ZK<.,;Z5F$3 >.O3@#:Q.6X=_\LI[XV%+0N,99!+]F,BI',<3I!C5\9
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M&*N,R0MV(ZV,N;(MWOK7HCE@'6VHM4%9<7]B^]B4 3A[$OPHG#6A%;=WGQ*
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M01\*6@D)M@)JH(T?KQ^(S'9\R5@%#KZ 9@^@Q2F-:WM5L@]=/):3O,7O[%:
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MT]=53#L<[MC.YBC\[A9%][Q]1@YB,ASB+VVV+)U0)07.HK*9D&V)O+-"TP&
M?SU^JK!O!ZJ9;:(/E6(LO(S9$;86/%,-$F5^V140?:I%5Y:7=6*P$5,YEBTE
MZ%-7O?O%HUNK[\M/]-1TG1=X5E6!W,MLOE&4PE>3=<&D8\9)TX>M)4Y6JBR@
M<[L4%#E1,2$I>0TLAO*G#O?!SD]A+X5M"4.J,'U4%.CXZ,E8OH'_O(\3%O?8
MMXJ;^VJ^GJ&<S!:\3=YS?*'N]Q)DX/.0-$[FBN^.SE.G<",)'[X@(-(JMU0>
M@-I NY9;,*&I5J',*H]F&7C$KQ"P8_=3)_9 S)(Q@6993R5MC[/3 !Q\0E:*
M"'E221:.7=NW>N!GFZ_O+*J8FS,Z1WT;28)G0!6K773% M/&2N>:X0W@1 @H
MHZZA7&4MI)'$0&:^/\,Y=J=(7FBBJ&2P?=&'!+2M<5+<?"A'X*T & 8"PR4#
M->2MP;]B6FG1JA/:\T/B6X0ZN>:1PE6*F?SR$")*7;/#8\_*9%Z3LZA*$KQ.
M@6_"U]4=+&@5EC/3[W&LJ(*@08.W%P@9'M%BIG',KPBXCTX;N\;MXLJ#M7V*
MX//J#">*J68 8=E3PRS9@@*%KL2%\0P2'( 2I!-/:4L5_H&]'IMB\4U)CR%_
MF5U+AL?6H@G.JE?LY]^=IA9.L Q_&NJW^C?$XM@39A7SYNG,(*HW^3C0[.ZA
M]::M5^?&BX9\)!VM".-DF31:%5&'V\)<>J?Y&3Z2K]/9C@#"]T^-D"VL[^JF
MUS2M:1G>83%2\:A<&-QIV/6O_\71^W:<>NM@]+^=&D-$.?[]+Y*?,83)XY!B
M%E5^Z8F__ MLJ5V*#(;RM);&ZBP:\2D-B'51*:^J[]'B3H"=4EQF39;^MC4"
M*1X9UOF^(-"KE2S'$@.<Y):M^=)=4L/5K4+ZK8C(A[ZEU+.(<*OIBTVX\3":
M<!4 3W/A$CN-_B$$ZG4[F&JR?.=E0M,[S4*">(HTQ.E3DJ VE1'0',"-O!J+
MMZ0E5D/<$V)@.;5NUY7R,XV[%#H2#2M:@15'7ILV.TZ54YR;T$20E 432D4A
MK;\NCEZ)E-Q;I8P^[>1#/:(254JY&O1IZ*ZD":>T5E_7+ X9V<[!*?CRP N*
M+9XO[!>]*N !>O2EU(F64;OZ[,Y+#U;4]FLV0WO6Y3IM?&O;O^"4?R;J-58@
M>,W,S*=T$*\@+YCC\G6P/**(]B=T!/PA?7S[Y/=%A7V^4)K$"MM6ZU*^_O(+
M=E-%Y3+?%:BM.U\?%RC\D5D4"J9QT'H[&(/3+-)Z]EX!3\N?P5L@G-306,J0
M6T6?V:]<E""]AQ=((UO7)C3\%=13X6&KVDK=]P&*(;]=&>A<F>D_8W[(^2>9
M,!VH<HZ9\=+ZE\^K4Q>RF3F)9R'R'O7?W./<5 S!]$PE]I_Z'CE=C\[7++=V
M6GRF**V"(N=*EO>OREEWTOO,U-Q=+)=#I"_GD/^OO5AYAW8!.J9*H ^)P*/J
M1,VB)A61_I&PA!!=3FK'8\%?5SF&8_C-#6!BRWD%XYJ<%B<#](8AAB]T3#:L
MWZ#&>59!"1(".FC8NV@4 IJ5KJ:;6T\GO)$<1 OXT/I+" ]NMB"(9<PA5XW>
MCB)/.P80B1XF>]:"D?*YIQ^YY*\@!WAL PMDY!!A\(6_O-$,VK8$,%%6MO%"
M[G<R$M>5%:>\-GWL(OS*6GZC:_G9ME4^RYZ\\-QPNG+YC?IT[]4)MJ%6>R,B
M; /WKKB^H_('Y?^TMCE U][.0,A1>"F0RM$VO-E('V;-:=P%LCIF(ML!?1I9
MX96N63%Q$9M\.M[0,KBW,4'WZD/@"M[L>Z/#,\C5K_];@O<IP>FR#6PKRYV#
M4_"'F@A]]5&@N78654>!78FP$4^<^T"Z+60<T-Y0^H,KN<NQ+RBXXO(H$0#Y
M/KT2$)-1:>WEFG<3*I4D_$IQ-B0&U&]/P)IZ25.-0SHC/?Z9 XLU+1P3D ^;
MLC2+SZLK-%OI/194* 7T43H2K4?@55"2E+JG2K)HDJ,'[^FA&\!&/;@:][LV
MSU-VO^R?@HD*P9&>ZKB2&/RVS+$$]VT'.OP'_(@_UZ+6ZMU?_V3.410*=1RE
MBYKS6N>R/:Q&X//#4Y+RXO_I*!< 1!"LGT5Q7#@ITN_1!\E=\SE59:'P2O4C
MBT'I\+[\S[OPCV>XC,:848?L^-]G;AWMKAERAH0RX@M5$'#?%T73M@W=I$[E
MF/_W &0X+AM;K=L:JK^OWQEM0CWBUT\WI=Z<&?TPCEVLV3AF$?NI@\=?'I5_
M[7EG7#'_,;E]M"_(A:)#MC;A"F#7I-71%[M^;@9<1. I.WF$C)*!?<&4NZNL
MJ*I# VSD%TY69HPN4^A>;J\Z?\9R!XAMGP PEZI?UP<YY8!C''/%+QX% UUY
M,(ORGR]@GLS$;-QPL%F=#76VC5I!@ 1YH!]M,\6<# EA'D0)421F.I>^\!/L
M!:?2?W:61P8/..Y+/T$I&:OU=SUG,N^J],\Y'OZ@-MD#(2!  ;01H/48N8XU
M"]'@[JTS_.9*]-C2OX/)[MGA(0I,.\DRQHUVOO;](/F<I,M1MBOPAJM#41"\
M5/@J\\+9.6J%X =!VW>"/AAFK[[#%=_DX$#NE02'77L4KO(CBN!FH/KT3/NM
M)-N<XF*J74A/8[ "+;6TZ?$VKF5)27JTK1PHL>PUY\3+7C@N0<?KTUN;*F"_
M":S=\1C#&B:(M.[:3IJ%M)T]DQ53I^FF&D'8DH(VAS.]9DXL-)4OR6O#+N:5
MB?98G?B.:2.!UZ(.[?_ZPRNQ<KAM4< WQT4HM0=2MQ,))V91C%E4%0DVXBLC
M8W5YPDN5K7RAJZ0R>185I?4^W^!B^AQBMA:N@LKO!U,[>&ZF5<#R/S^'$B2B
M%+;<KGG&Y<X/YWO7:H,XQ0:;QMV^5<4EJFZ0%@#-#GB;KP0,("X@/*>TX@SY
M!C-GFE0VM#G>A^=G&'4$]M#-H7/;%8XY;^?:+')A2+?ACO54&,T+."QM.79U
M88M@-'X. E#KD5$NI.MJ$/UU!,C6=LQ&)XO,-"LA9_R6DFOB1G6^A_U]J@]/
MM'!R$K]*&.W&O!8?ZQ=?PQU("%W$63T6!^\%:V\_Z!!/ /KCN<(]3/-^A&<%
M..L"S<CHQ"\!/>3-:"Q!='(\BR%DRG540;0SR=%X-+RPQWE1S;^A#E/%W;$>
M%-FEG>T\OX'8QFT)TJ-N&(:3@[%/@P*=P^[T]?+J&3Z0XCOHW+7ZYYH)K96L
MR0?ZX!9-RTR>W!S\L4]=OJ*VQ_&(.*?R B*9UW/QJ\%W$'_/BYYOSE9XP4Y!
M0I)(SX.^PF)-=JEH8DGT65[BN7"#<[M)OW6@%$DGFHD,.@F3[F&OH+_K" +K
M7C-UD&C$ZL=;T;$U0R.CD)W2(46*J"W'GV^>O\-YK$,"=T;0ZKM^^U>'::9!
M5MZ:O84CK_%W;FG;':8TQ5<R4I1Y_=JS*E7J+\E[KF S*83(TFVXPP23<IIC
MKOT3GP3TY7*MW1HKXZETZ.>7+>CYM4^?43_S_785?X3=??>MBU^@OH/ B0OR
M;B(XBX'F4+P1M3.@FV952C.'D,?]4[6W6^,&&RBLBV.?CE+/JOS3OT:/VH&Y
M3U8]YP@:T:6BZ/SV/)/!TH=10=\R*J+=TK/+HS>MZ'4./:<,XJ92AK#$'@1;
M*9#'L+(1"@;SWW?N![W:IAC6C@T*.E/R5=BQK[H?OJ1RIZU2%\'^VZ;_7ICK
M>RY.X?<^:>S:FKTRSJ!9;ET#N>"/[?C76GD#-+\!E@/'B9 ]IAW]H>20FD4S
M5E1*T.D<4YA0(!:ET*V@<*DN[,1H YB B0=:?,GG-0O=U_87U!<")A0RGD(-
M;?X'0]Z6P*OZV8J'@1TG'@K)HVORVSN/_4[YOV=4T$';"X9ER !H&U]2S+KJ
ML(+[O)MF_I#:.]HK7;J!4@[M4NHJ3!LD!6Q;P3O67H5MX>UR85?MSCJWT_N6
MF/Y8K7D"B%_XG:\3@=Y\:)V!ZU]%"KO)(ZJ]8:OV+CI6WZ<QH18<?''G.+-0
M^%TX*MW2[6UT<^&;%=C46A'X%T/^%D%Z;(\'1DR!5GZ9Q,4J_*7T E#6'+9%
M_11O0^\.NE=[ \Q2)B*X.O_?<[35O=/;PML /2?2<FJZ>_:60Z]ZX8.C:Y)]
M$_?4O'K9S;$:?Q$X\0*BX)2ZR'Q]!YH15:Y=KP$QL-$OC;Z#:C,-#VU5$*5@
M3PTK;19EC+=^/>/&O4K;41)SENH8&NT$F,->T"6%<8O(B-VTF:C[=70]A CV
MVD)S1=V]!V2WA&%>64E:4X?&0 &F,R13D,T?B@4%$90%I3*^\)S,A2MU[T]>
M]HK3U%O6B)%8SHG[Z^J:0O?0U;S:0\-E[Z5&?0N3,RP)" ]M.=2A"V-4&L/?
M35>,+#N9.:)J]G]^Q:WO..?\'Z 6X/58E?7=-WI[.ED#V2R6&V5U/G^"[W$!
MT6,E&KT^52CLK4X!Q/=$-2(Y!63L!@E7-:MA#,A-F^;J?V49.8TD!8">ZM$Z
MA64S9TD#D]1'VR0EZ4X(_!1CG)5-A2-.4T;1AVU_^KUXNZ%VS*%F%M5%G/R%
M3)6V7VD/T'S, RW!Z0'-&X'P6=1E!=3Y&HN.)S.%?.5UJ#BBDIHHSLU2)+;Z
M]8947L8;1(TZ0!DK:RGHH9# $%]3;@7M@&)!Y5E'YT6T;0^I!T9Y@0J<'("7
M(S.^=I^Z:18UR8+QLZ@!"<AY18)<(B7$9+KI?Z]CA[^B84\4-R<I7+T1T=!&
ML8H1QD><4F"S&P\I[-K\$EUG&DL*LH_L 359$OY\\X5SK0@M^9?R(QR.W='Y
M,:$,T'K*:3YBJQGR-B2D["IA#$89 Z)?8\WADXU]3@@Z86LB6_)>54,GRL?#
M;#BU?1[K3%_V0H_:"S&#L'TE^0B7X4A+D!"7!1"NP+N%Y[-D@&Y VYJZBJ_8
M;BZ\#*.<AK2-'(3J//B<ZHBF^V(V3#<"JX51'"NP/<VJJ2,+OYKZ*RCG*Q2.
MT/$4N>.76C8K5&#][KOD2\/+NKZ?ES '!CUV//L8/!;D.8F,<9,(3+*[W&@?
MIUJL>2/"%"6WXZX6ZJO+_5^'60SX.3-#:\'*5G0J82F-*'VR@7(K]A\7NQ H
M6)Q4\+*GI>"-T]#+F[;."@9L15(82[%MW"&L9F&HA&DY7I?O=U>A\AS@K*+Y
M#U#@FLQ.J26\15U0HPKU/Q(P#RS_?(^B($D=.B>]5Q]+:D;==4U#J2S% M@$
MJUE,1B8RBQHVI<Q6IW./4X8H$MQDTZ6GXQA KT!VOO@OCT#%ECVUWQ^:UHZN
M5%2VL1ARF?N<M7&Z.1Y;P"^2+RFX,YKAQP'49,T/[W[38;EVX[,.QO1)B1TB
M84,@\N7(#S3[<$\A&!].&9[8%WLRRN(\4ZG"I1&,*N(O.;/'XJT6=[1J5BM<
MZAZ0A0S&JGH%.N5,_"P*0]L%1K9NTR$V#CBAS8+Y<0^C@_@_F6*2#N0ER4NF
M84'1:VML'\U.3$112=M!_V38X=%VAQJF(72D17CL,4,BU_6IF]^83=C;>SIV
MPP;IQW;W)&I_]1)OS7*">+*+X 6M4P% LQD04SDG<"@0CB)>U:RIX3;VRLA$
M(W)^)(+V6:1JA+;0K7><2XHI/*D<M."VXLP" [.>&FUW#A2S@Y_,[PU"T9$R
MU8P,4_P\#P#WHW5I:.@"&"DQ8-7@Y 6J(*CERVM2=6++(O]CL7.GCK#[&UT?
MA) Y:YD[J E-@4C(7VNTEW -J%OV-/4Z,RW(08W= 1-!$17,9V$[?F^1B80_
M-(M!" /^\E<7X5=HV@E5A&N-^I)R/9(9522N2S4=;J4[@]QT)RJ%PN9%/X((
MRBOU"CS[:5O)@5-)!#VH0+K@T:)>AX@4KX:A9\$QP'&M)Q< [N4+F<KI/.41
M=2EP7&3R==1:70F$8XW&9P2I\;Y'6DTY2_L]3IQ(K*3ZM&E,N2"0Q:[#F_1X
M4,")]D(CIG^WW.. D,"8;B LF; [JC LFL'?*AD';N4GPLMO_]=0]')771I7
M>UT5]-D6'@)^SNW^*F2T31E2P]M)\_:\,$]KG"GCX'Q=I<!K@M7XX7].8D^"
M3II%W=^.W:]C3IX.DOZ%'NO\O[%AOX(KOD, @XA:LT=X&4^[$*:914DB7XN&
M+ /5)=P(M#'-#!1-OA47.&"D=BF-<V1)+"NH0[J-D75$RIZZ1B?L^^50 OF\
M/AMCL4&(R:+I&UR\?^],>E&>:>TF30W0;,6-)4%K9E'R:A6>C'?1FD7 [B"F
MV0K+$Q8R'\,AD(F$GU8X']HF0Z<7KGY5S4GA'83Z6@#T<6L+SHM!I_(UOV&L
M--OXT.#/;4<./.?VE2?H7PK>+:CQ7?U;R[TV$?[5WOMLF$4-'5>SN#]EJ@/=
MNEJN8*0OS8--\UI8X&&1=GQ7N7\2AQJ4AZ \E1]TJT.T](NZPD-700GE/H<H
M8K11".V2(O97YFF-^6@PG 0!SO(T9FM&0KGE@0N-D;(_9PS918_'%7?&D40X
MS=4>J-[PZS(@UCK&<I:38JQ1>3*B?)>B]_.77= 6T,YS@.7#.-SO]*;F \U3
M*EH6XY=;/UIR0BS7/S+HU+2YO=.G;]HPL=U-^2C\?M3CT7D"FJ=DJID%N4QI
MCFC7BC[/HEYP%76SJ""5U):V%?F7:U"U:I?V$&8?RQ!'UZ._-Z8CXU_&/<6=
M V-?0BN1^74]_/BN+)BU&,8H=#OV#,3?=K0PHRV5$DRAE(Y_AT[_/:XQ>'5G
MLT?LAN/8LG4J9-J:1WY *^B]FX!FY!=.+H3UU5FXJQV37YPK'F':9)*]XEN'
M7'':9I#1 9Q5K.5 A&,_F#SB)5O$OIQ/(^D7'+U.O3"+.H6D?(X(#-#N+OCQ
M4_".BC5IXJYP,;^C,GFFO4!"0-CV7 ^?2X::8O%(XJ'DKV,S4PRVCF&:IDI\
M[^S4_L&?$_I-),_NA)$MP=T)7>B 'HF+GUMNY6_]610:44PI.<#87-'O!&K)
M+"IW^CL +[57GOVO;5FX1O\14E&4']3W9U''B=::-]I[RF2 03(#)">CK_^V
MDW 9'M%2WUW-I"6>[_8+LT)'PZ"\#@Z:VW\B_W/;MQ7]'L>>[EFSSNG'OCEJ
M@?\_V-HI^"X@3T0&U:RUXSA&S+(?FT'8Z,@LZA9.78$4\@]XI)"//U5$H( -
M!/ D%[Z#DY,08@W$S:*>A4L2J)C) :W/NO96&#)Q? @!_VJ@&?L!D%#D&!4M
MAHMABPQI:-"_I7(Q NV,%MP"FA58MLH0D#([?/W;":9L";6S\N.8T+;DAHR9
MQEE6%5B1@#:BLO;$W1\KM/TE@C:3-/LQRDKDB[DO$5:Q":SG(,(K97.CSOV0
M_YH$O8 /O:JJ+FBSP&7B#:BZGOV%O0OZG>0Z;=8;$9"6XHP_#(M>./_C=W'P
MD02]D'\A6K]C?NO,_&N"=1ZY@^D?=0 9"395:19;: V'H$JDL"/O4/R$^UST
M^E*2\C1T1?K!R2<[7/)W_;&F 79K[;I+YR04 YH7E*B(E!+280=I09)EZ(%9
MU-Y>_%IJV QE6;9[H"_V8![Q1<&Q/J"&A=)TSZ(6TE?3^=;&ZF?Q.//H\]RY
M, ED[(/&(F3E,9^'?7IK^.D72U(?*AJH#-++W,2Z'DDOS=TF+W_\(S_;MIRR
MJCZ!'!@'(11+U_]#8!C0C)Y%Q91FE08XVO4V^JNVDL:J?2T:<UU?T'L  Z>W
MCN6!5S:^GSG_"#C9N](@MM)QI=W)"O070AO1BOKH-0&,J,VKA(*^SXC\N.H;
M^,54TW&RR[F_1C'0+94W%2MA7=OP,>T&AY<@YBZ;.(_IO)SBFR_1]S+;<-],
MZ ]C?/['_F<_]$FQI44$[B8-Z4IN:KI("]FW[FM/;=G)L6>>NU[]%D:.?-[O
MB'/F6U#=6\+,7@W(74F!L%/W)'XE=::/5S=(7SGXJ6=P8O(B18J!E]LCW[E,
M78_?0G\/Z $GF- ZP223HOI#(^ NPF^+9IG',RUH;KFC*K%_.RG5'S"$*1);
M 6S_Q.Z:1^QIX71.0_D'SR=80VII:_V&%YW/HF>*N5=H.^Y_A$X!D[LTA@G0
M!?$L:@X2JT;<DSZS*/WHF0C.(\6J+S+_5L+R\7K:WEL0LQTC6DY?"46-6S1F
MM+TO>0216D8Q("G_M<?%Q+1XU9ZWM1^!C4AX*"EIA4N0V#^!'B+*CHWDL&91
MBWY=YI+--.9?+8H>G2DJ7 *5@EE20D8CJ5CX_,3GX9$)TD+:TDMQQNVJQ07+
M;[S%3!T6Z\SD@U_:1 P6BOLG5X\6"[&EP3A=> MT2.5"]>\8=5.XW \9CM*8
M@UQ>MJO?P)G63?8?PT*R@B-S.@Y49R:I]RE]+N%;1J7*SPMM-,<XVA,[I[GB
M>@)XS"&I0Z,]);F7CE":^8TF*D>J5VO=J'4?W473=S'UQX3;IV_Y/3Z&J6Y=
MOUJ!N=15E"6C0][SIZ["6+%('_:BS#<D'G@Q0(LPR^TX.M!4H%F<J.U2B[SX
M9BZ@]]/*D+VL"BJ53@U92GYE%K8$_IE&VQ8M[O*2[G,L_?0BPVD,2?>I[2GO
M\C9M@VO=_WX>!$5J%G5I3660A_J7WH5]WC')!BG*6.2OUD+J#S$SG6Y(=3T(
M 0IK/FEP\I8T)UNJ=L298S,/\QZ/FRI/?9%Z#G+C9#X9JZ[]ODD^W653?M=,
MYV>BTDTK!ND"P( ;2YR'/)X;05R+?4%!<B4"F\,UPSEENR(10TE+W.S:3+(2
M3>3, .EE"=X4.$EAO+>^3G&J>AG=ZKDB[TIC4OF' .C+P5H0R( MQ4.2_C,U
M_"9 7"^J3827$36+IE6X#YI![/-?/&#HB_1+,G[Y^)$.E1?UB QSF;.66M=F
M;0ZFE]IF5Z0I[%O\L6C\1II+AL<62=/^SA.R"7LU+K#A1=5@O&B9UX62KT'H
MJY^8OUV1AV\:TQH5LR#[CE2\[E?6$J[X6N%F""?E7RYT$C3ZB_E7N6BV9=>1
M5L40E;7_18W PZUZPJ+Q\%# :$P0-MVY)RXB85E5C+7UB[^NM9W,4NO1=$M$
MM/V0KG@$)R.EQ+(.0RE@"J\>:*MDC-I7U?1/CJK:Z ;5=8HO*33OQR'ZI58[
MATJX _&^?[;'Q44G+GU5][>/P34S'2GS Z#18ZE<-!^X(-$!H]'#X+*<< SL
M8IJ[V#<Q6/W P;E\KP_F]90YO*W72"7-2TOX?=MPLBKJ %=8:/F2O):--H&(
M?B"G(?RQ/37Y?;<&J9_-6O.#"FP='S;I5%Y7W]>L&F/-H\__;W?Y<'B=PC7#
MPT&,LXS1Z$.W"7)=!:;U[%46HG.SVM"*"YSEGA71089=K&S-6E(T4C-Q91Y;
M%Y1(1/,_!(^,4M,\ A\CF0B !T/U6Q#2+!>H_L= )9(UO#H _ 4;5THKY>[@
M15)VR5YV/QS\ /Z#N7W@.&< =I<FZ1^?*<E.0 _5J]K<1F]5?J!2_+=0OQR$
M+DA*@65W/4B2@B0T KREHLE@U588I;Z%A!@WF85 2H3*RAI]1;,(=,SDZ [4
MD">LPG 6@633I^4A\&Z.8D%! <YH KL$EZ#/Q,2,KJH-)Y>%C7\?#5Q8=K(V
M?2/Z2=3_VTGB___\KQ][D*E93% C'%'"X(K_%F'97;H!H?8(B5 YJ>_B3<Q*
MOCLOG&9FSIQ_&B';1B%21\Z44SPV@2]X'1>_W7TZ7'':8T?T@\\!$2^O3/PZ
M^WR:;T EMRIVZ&;0MCV TO4#+<A1"5UK>'Z9H_ZAS U+1<,?;3:[T:XIGE7C
MWGDO/ZC[0S2+6O!*TT8"WQ! [ZG4L#6"G[?[-+;TP8MI7^1;9>:V*9BG$KYE
M8  2DPN=^#5OYLE+F&ENA+3&0R9918>B9_A9T].9:VY>^%;!??@N<^$*=K(E
M.>I/K:WN'PYR<;;65G?'\H.\92>TMKK']LH\C^X^^&SNY?5!J%F4>^62,("7
M11"/[RC?:&VJ_IM N;?'_=Z.MTD.<SM><]G6G*H8@=$?A*&+QQ@M@#"+-U7:
MJ5<V54QS[7V4\T<-Q'ZSGW1T@O"]09#*G61^G$5--#7ZDH;?UXFG%D*Y24FL
MI5 P+U_=]=!,[NC<A-X_$,G._L_>GN'.2V2/ZZOWZMS.N.USN?7,Y\=X#/A6
MH)O!9\2OEAXC.M!VQF=[3&1AA[I8N<Z4:G6CW9!Y^?FL;&[D&H,+N\M1=#J2
M>R=F49^68<'#!-5FM!#A:T<1A4W^GJ(Q-)Q%_>T"X33O=61U&I;3,\T]RH:R
M:4N? L.=O4)-NW)1+&5#Y8K,\=YOPOA-791SL6X>6YJ=3O=T&CQ1O+EVK/_I
MJF=1,]99D@G;OGA#K$_WST\WO7-Y7GURIT[;W,,&+\K+_]ZXW>;ZY9-Q9I$K
M3&TR41I;KE@"_"96PI9?D)1%N#1"Z ?Y4 2I!ZVUZU@T_01HWD\0WQ-9$DX!
M>J)=);1#F\:P1AJ#D-&0X*#H/*P)WOJC3RF4N'W@6\600UD-USS(^QFT_L?1
M_("'/<:MNT*N=UKG#_Z@WX_!FX&#E4^B9VK+)7+TT8'XC-4%WOW35FM:?AWL
MLTU/>)4>BO_^>32X8-VJ5[M?9LN+,F[&!Q[-6+;QXWVTY)%F$?)PNA:P.X*(
M +P +$%@2Z.G  6RO,E/BBFE)Z@I /-XFC4-4'@964E?!45*?!9MX%B-T5>"
MRBPT;)._ITHRI2?\6KBL>[K+;H\"G8J0I6$K3%L5];:%1NG_^XAR4OV(CHBA
M 8!-FORA6J5I05C66BI!N01:I)A+P<"1VI4'Z.(V.V^+W$IR=-$XQWE WC/E
M-&*AXED; DO'2(LT6/127QG6*J;0OI\RW66_LU?^+XO'%;%:*Y-)"_!; CH>
MTXY#GB!/RBE8<LVSA+8/1*=Y)(2;9?H5KK0JR72Z=WADWA'W+K. U]Z!12'N
M1A>G]*E>+84+>AP\G,4L VI2LV;Y\RV66#04[-E'(SP,M,PHE(J%T4&^[.*T
MJD*IM]T=WESS4S<^77K_3ZO.;T]$%W :MSRDVFL6]H!?FCD654P?\$LJ-P9[
MF6Z.3)JQNV=)5#Z:Q\P4^MT.-][[C]RJ.*W(].O[?SZ%S[_SGUNJW[.H>>^0
MN#P#-..!R3>$"+3ZX.B<RA<)]W1V*JSN],&['HZY32?_DZ<?7C8V>+'XSLOL
MT/#_!)-V>:R*&O0VL5W49.JE]WJ+#GUP4-@N''WW;E3?QWWO2G9-#3O=/8D<
M3*8.KD72/>/PVA7)-GL?I-L$R+*/+3UV%#4'=OI?/<Q4)?^S7'=:T\/"_B0.
M96GTK%0&4!))09 GJ!9"[WFMN:.F8'9U3.%&!>ZR$],( : E-$(%Y,Y311:T
MCCI QQ3ZN^H$\2*]Z/-?CBBL&5)@65940BC1IZ<FB3\>-M&B,><,.GCL2I*,
MZ/T@/=\KJQ(XUF3C90$O<M;<EN;T'<D?F8J]Z5J8F'WBGHE%=.#VS5L)? !>
M/E\5_M]T8=$MU 5<,NY#]<X:B*%RA>S:+FI8JBC8O>#U173FMT=@GXCJ<PB,
MO JPVYF79-B%U*3#?>6-ER2L)1!O?P/3"ZPH31!/E.\3'GERXC5>1[OLHWN=
MWE7_BQ=*X%G;JS,0G5O &@X(+&&< 2*Y# T&K*V3^"9)DW?%Z2H/I$@;1*:[
M%+K$[C/L/U;EC.M/I5DPLWYNH=6Z<+"*X ^=0-QO!^3%QBETY:%:(SHWH -8
M L2BY_)!D?*&HN0*'D?; S%!::"\ BMYG"VKO#QJK=#E 7.Y-Q(OV):%&4)D
M*7H.Y.?@?OCE+5)O;KO#EE:R:5/TTS;LSY7(A.M& <TF@&0>)3-;1LK*)2VM
M@-V-1^$-V.JIS&%I=:/IY^\$O2[I'0=FRW#&P\:N,@/1LO>I=?OM5#2_3Q48
M1')"KGRQ )',?R%1<%!KC^<HZ,"E!O&;N6G8Y1Y;*R&L,K:;YFLU4/M 2K:Z
M^*O98O&M,H@>G.6SSL-',L40+=)8C-'U!AIC<OVLL0I*9J-7DFOZS5,]S@6^
MRW54?U;^#9PA#J$EE?(O*CO:7^J;] UE5517F5>*HP=^IJEL4=P3ZI'67$RN
M=IO?@U*\P^:&)[Y4S#(?LT!GUJ@"__4)[BQ?Y6[?-9AH_.A2J"<*N$>9=$;H
M_"HUFRL>(BVCYFD6:1N&V:L+.+8T;_5U!X\+93&L^9PM\&9V_@]BSZW6Q.PR
M\D5F,W,IQ%*AFPE&'KK2O%Q9FT"TN)*V0\PWA[!M^:RKGP8]*THO/87HV#XN
M$PM>*)E<^8AJ00:&@L4$^6K%L.Q\@X&I]2(0N.;A(.&G:PR(2V(VVQ;?KLQ(
MF,":4CO:7(]X)GCX+LB68'7)9\G5=LH0M_<Y@D/CAP!2F W(3:=%/ JC)K9;
M6W4W^DO4GO,NIJ=)?5<3!?'DK\UO<G[L'W#X5E9QT'HG7Z<BR3\/LE1&J?]#
M-YO A*V"R"H"; 0E2?4G7E&FV"(=VGK0+G4ZJW.L*#.P\@Q[F\Z.OJDSCI]R
M%]KF?HX>C;9)MXMTL%@R!_X/T-RD71$E"7^UD=@E;7S( 5$44WL&&YU5>^'P
M653J<QH6"I41%[^5\,V@"XV)X1%%$R)CMDA_Y$(0@U<0ZOZZR@=\)&%>=K9,
MNN3O QY3OEI3]?C##DS:IWHH4:/O-". C1&1MN._1E]/$!4^U<PRIQU79TX7
M8!F_+%RJB[[>@!C>X.,&"9 B+&G)&K'W=DM5"DWJF!Q+:M<DW9U*YEUD:W)G
MY/\\'XD2W!CM2 "*9U'WV2>@6SQK"T5NUB5))09*VJ7P9R3L';0B;E>LN76B
M(JK^FO>J_3=(T4'WF@:R/T8[Q;U[&C<O\\6>FRCSHY?1GWVD7V"K")7.N,8D
MJP5X'IE&=]=\Q+(C<V+7]-*7PKJ@73,VHQ!+GK(8\=P\=IW:>4BQ)J4HAO3!
M[^R*A@% ,J?/(_*9SYG2>4N$';:#3Q]K-B,94JHC_=(L@C:@X65YXCQY7 E3
MASX0MAD*+*4.2W53$[*:7'P/3'0L@0/!7UEP5*VKF_/GX@>DQ@R%A8@4\+/I
MP+1=[Z<DE>ZKYS6-+U-4O5 <2!!7-G\HJ8.\P!1)8LL;Q[37]0Q)!P\1$Y"U
M_8W$!.7$ P^Z>6]\S9V0T5G4XY!%)JD"TIC1F;PO%>\)>M"?#F=(QIZ2K@4$
MH_W%:Q3S+N(+\S\^.>YS^,5XYQG<OT=BEY__%"1.F6OSQ_>!HRA@(0#&Y3$3
ML!^(&OVW"#1U(%GW-_6'A)G3Z*-R@XPE)%Z3;NM%4:H35''&F;6,Y@&5*SK\
M%'5I-?9=IU3[0 &\)A<_!\J2E)_;W>WL>VY7W6#J80JGNHYYJ+_\ @OZHUJ:
MW0&;^FL6D50V0/-N[I^$!7"(PFM2#;K*$CL<+&7H9(]=D@9WBB4U2*AP0NL'
MT78J$M,\L%*<*8\B$:%'J3L_KRX-&O^U)=I"MS64<'3@B'<=Z[ +=E2413/7
MVA5&Y2%A(4J%G66DQ:$^E&T"!J*GHNFK>QPCJ^^><5CSLI>=%=RYJ)C]<G?A
MJ/>*R.23@7^N'S=#('T)R$J.#_!P%?/UH<06O!7[![[S/C5\-T+D3(>[.@K^
MC;YXC%U\#7]*]^ZGUPV@:^2R.? KFA52WJNXXFP\5ET Z\29"-HHZ?BU(/\R
M[/I 2.\,,X*LI)>.!(-=[=F/=CWFB2GS)H0)[+R68#G6-VEM3:5A6"CTA0>.
M1%<^[DJ*?+1?4.N'?6^7S8TF"<_)=.'EVGY=H]K[:IH/VJ9:6<!)8AJA!M<V
MBTJKUYU\*\%EQL3+PXF0^0-JNDS"8$QCC7;\]3RF?D])*975U@MQ _)">W\&
M+Z.8[2J-_I,RGUA$3@2^JB6BH1+E69"1^<TC44*XC)T'XV19K\HK'!LC)**T
ML/D]'O[GXB)L;@7RXZ16KCMJ!S[G]P9&Y H#<>;BF][6:_:<M^MCL_2@\-;#
M0T0I>G&4V^0,V7VLC^R&9SWM//Z]AK@ZT#N)XBZL8<Y;+-?9$_H@X\XM"Q.4
M9@7PO[E8OO<S94L  ^CZ4-W51O<'9'E)X\T %W91],R#JIOA2W-]MERB;*V]
ML'^)N875M<]F=<:?'N./J^MG4;&D5!%() XQ.T3LD@Y?NXYZ;@LK/8]C4*V(
M@5V[?W*70OEO/1)EH3H2#>.2Z>W2"8U%3>$;:E[KC$/Q1,7C:I[5AUS["\H7
MW;J@#U(S+:-9IHB6XX)'6$QL#3 YBXI69X"_-'J=*E.:'^0N"XRE]Y0(=TB9
M2\<T%J!KQ\*:4^QFZU69H?825JNR/Y45[?:+R?9>Y3+9N1JA!>#NJ0]WZ*])
MX'[^$* $!IP0K7.UEVJ-R^":WY8$L)<J$J6E0$ND5.UZV'8N/T%<VS])MQ8>
MZ,'=+8((^XU6;ZYV_=X5J]KNA3S<=J Y CB9Q4P5Z=%MHPC@ 1)D%^^@($E=
MBA4^^WM_CL'!TJQRP%=A/ 2E^'0GD)90Z6V<#51F<]A<T([1:*:QZ:=YN?+X
MBR%5>T5\QZ7@[3U<[GJ4Q@RO^]^#LZ>QT.H\N4!U0--) $.LR#)1.RX5[Z+P
ML*B;%*GV1W/TD+2V$/ N>LS<' OZ=N411/("PS(JH=4=>)/^>&_X&%E<&BQ:
M"F]3?&.X7'E*]?SF;'4V5!]1-I"C"#;5T3812.ZDH:%HE8YV58RSD'9$NZ@?
M3;) 8)%U%;:4[>48Q,S8BGC!5BLK%G.Q*<&MN;D<%U]2:^[WX:^C=HUN+DSQ
M)5SS"W(0_RKL8S$V> ,]Q6]'!NC:&KL<*8.89-A.UH3ZZ'D^GF!./>>EV)-S
M1KQX1;W;J;K(2R?/K%PL7=?(W+SQV])T62%1 KPF76'-.\YA0S@P7$)HL8PE
M1BIOU[7,HAAA2\!Y%HS<*1O@#*,E'W_+:O2MS<W=JIUOV2,C?_WCC=+$ >)'
MHN>)[5P4T%R.Q.*D?WA1#':99BN\6'V7<.I0Q5C8DDP5J5#F![DJ2!*[5FRF
MRR@FN=VE41#/U8-(O-%-M3T>#7OR9U%[>N05JUYD2AYFXI8C@!+^/ZVIL!VD
MRX074]KN>@? RC:FH:87X2[SJ4WL6/^@'MJZ691>26L^Z3)M3UT8)0WVC93Y
ML(Q'8H2Y*5*RKX\*=Q \D%][*TICFS%E/<CW:1H$*H-^L QA:\A+/+5D'.\
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MZM1*URH2&7!>N\ "&DC^J00S_6TXY4T\9G_[L:=O?H)&7SQA$_E6-[H46(
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M![DGD.0(Z2QA,;+SN1FAOB^:HC-JO"!_%9(J-_%:T_9)Z=:-'OT?N% +!IE
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M+]2.?VCBK,^^JR7&5@FE?S/^M>,.I6(O<5HI5/GZZJL$_6:I,HX6\_0&*32
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MO1-1'AUH/'0(X2FMD5L!]3EQEWA.QR%NR\ST9;OM$0MZ@IC*%L?]?TQ/KLN
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MF)@*)#?YBC_DMN6=6A!D>&O,$--4*M=A_4#%7(T(-T48;M,_L5;J,IPP7*5
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MM_,Z'R+UGA#JR];*/#I+.,A(YR[$EJ&T7NLHRE5P"6;,\NM^'$3;5,U)SU\
MU7)L7\XM5WI\X#^!O;,?B8<:)D/._K ];.ZNN/7JXU5MO;Y*)!22>$$U-Z7Q
M.V73"9N<].]F1Q";%$%Z71$LZ_N5ULWW>EC PJ18[[\.G_^6[76G<*W/)^G2
M)87OU/[%D<Q"HNK*>5!:1(7</#F#D7OZ3O4XKQDCS6<3D3'9HJ(86_N9W]#C
MR"59X_R68>V>Z+B\JZ+0^T@EW9.[B.YX,]5Q_VVY55F0T<?\YO62?V=PT5!P
M\VD>7H3_.\_2Z@*DN3@G\NU, 4R LY-9U,KHJ\ RE"1_R4VI:T\KLY.D^%C'
MD!.C>+IA9J0$K]@7/T2Q.Y[@(3"919&56;9@VO! $BZ;Y7O*"S]]^G$,&QVY
MMCWXVOH"]_OI!MOOXYGVFNTA/#[=W;AFO<:CNQL?$@@$_4^S!&U,$S5%VHL?
MW(1C9("(DI%[\I?%/R5I&"[4:[9(\^W%2T+E\5;':@\MK?S=8+/:C;T[+OZM
M#A^%.S%-DC(&; H#(\A7A%5$='GM$:07<I,R1!WG X\JKJ@>X[1I_JAC4*KU
M@])-]@/^ QF;6*X/F 4>70U+9&2MH:^&.*]O3_/I;)LEZ+*"2^,3),T7*?=I
M1X/83^=DPX5\<<$OJ%==_\E-IJJSW*+EI*%0Q;7N\T[SH?WV<1&45C:Q^XB1
M+:#'BNFOGG#L7_SQ3?6_-KX'H97S*?SJ 8'%U^6!?J.Q^5DRJB[M K@;6P8Y
M) C,PBH0^G,S(E1[I6''TA_O7>XR=XIF*"E1)\K/'^!WM,3Z9-)"3M]\M[64
MLO6YQ1^/;J](T[<OD4XN'LO-*J\H8P:(<@5EIW]W"WD4GFMV^V&X_84ARMHW
MU1=K:R]6G1PJ:GS5\VYWQ8%,O>__V)XZ<_&T&GH3>TZ"(HC-'W%=[T/]$5UE
M$$T#.,<9"O;HP:Q9^Y"\QP$/ZD?(@TJY3W;$PS&<W0.%X;[+!FY(6#OZ[$J'
M)C.Z_:DBAVMV0GUT#U3TJ?XA\]R7&!_,%Z<U8K#)A6V%=5(-,'.P25W(&'P
MU;8+!WN#X'7I2MOP_#6-E]33&NSNNMKS'Z-FO=&>K0E>H5Z]*,!)IR[@[],5
M\=#-?=%:#I0;G>Z0)&F<#%3/?+9Q,I69E(4#.H'XY^8XKTF6W;".'7'I7==_
M_\:@P<Y+YF\L^/0/<<PWP<FW?NU>\ZCM^&X]-82.JVNN7,%7'.AKS!)&A&+/
MY]A*U5\-+I -=;!'U&0X4'>M%K;T@C^P-YK9]CL%%[J:EO%3$QMLQ!Z]0\U;
M*>:>=LC3@ ]9/N;S;86-?.0V/F.5*E-((Z60JD%4ST0QIBIO6 'URHBMDT-N
M>-K0:M@I[;S,7=+@%CI"UF"M00R5NYB@#^0KZHZ3OW?P[HGJ8+0*G&J%SFM@
MBQKC^&H=CXC0TLZ0N^'B;Z4R\C+V8)>:J]ZA_SG^GPQ]Q% VB6QB9 I6SW7.
MC<:3"R/963<L5OTR>SEJ"ZMG8NO0$P-V 8V^K?EV\#[N$G0%;"G*]4VLSMP6
M4H@<%3EZ\;(F5O6?GSHJMPZF]IU3#/)2-T44!?XR?[HG SLBE'X!D0UN$Z6X
MWL>Z@%,!DK<C(V[HAC'>5:Z.L]47D@Z.$I(C(:Z<B%K$4E(>"XPZ[ON?0XJE
M%)/VPO@,RO(QK<]?-A2]>Z>J,HSTKE'<)W[MOZRQ_OY_#?I]]ZR5&>77'E^[
M=N]Z]Q4?'Y\%6Y]8;/U]SX*$S;0W4"JJKSGBT,(;',"6#"C#61>1'7(*XH)M
M1->J_G+>R)R636> %3^)R\%F0-ZIA?C/$@YW1S/& ;W16$FJ';4B2*0G.=7_
M,\O3Z^G0Q_>#G;JV9^9W!2BT5"F25H^18M5588@A7!W9'DFZ&J"XB.P=WNCY
M9WE!8X;,:2_++#HZW^KMZ?IKQQMTUO8=?F>UY/#)^!-IU^^W&S]:L_'^FO7'
M]AW2/WY\M\8C@L9=/'HOQ3ULUR1BR6TG(SMW8AJAREW%$UN4.S")L$K%$94X
M,>0,PB:2#EL/>V6&:T$QF6S>\_'-RM%<W_$XN2?UR=:O_<*0IUC/U@/[[DDS
M3^<H':B(%DXR'S%##]0-1$T.!2C\D.28!ZL;,IMRU9.!$"MKWQ;K\TLE@SZU
M01M4-QJ(]W=/MVT)MVB$@U*-5R2:'G@U/W*YNJ+,%;0$(1<N0@8FEBA]V+VS
M!)U9@C17"!UA),>J-TF&?&6OS#:"2\-SUV5&2I&&2R4L@%;.BI<">HCCYZ-O
MSOWL-/L2JQ?);'?I9YE'L5:/$!?18K\5T(,+9PEG1J<%5EC%>L+]C/_C* ]M
M"]+ R2!U*=UL"9(H(R]%QIKRU_ -G%=!G*O5IE8MF-' N:2*=YJ[@G?W3Y"K
MR[S[*$NW:<8-><AU6E?F.;0]!G*TMF$:AY7A[\"FWGS<S!,N>,$%X'AP,#2L
MQ1Z02E K;M+8Q_!.Y<HP4-]_$C,P1K39&P6LN$N1O$LZS(\3J;=5MU8;;W4K
MQMF,NCW8= "(H"*6-4+<I#]5JGYWM@6;[_,1&#8?678%#B(COL"2N;8,2WQN
MRNB2*YN_V.=AEHAN6V48^ NG+<B""H@8!>_>@[2SW^DI54_L[Y)ZP>;)1,D2
M9W6FC^2Y<"'; -V![)%F>A0^Y4,QS7.'5V2XDT24KSWF$5H+32?][+!T3Z'I
M;._Q"*[RC<[2_S/IT"[C.8D).T(QC0D<W,QM'C['7@BA8Y0A$RGG.5$<H"1)
MW9X#:6*U'B<UA^>4P8$6\=ETZ6 4F(K%I_#E93&R924C);:-OBWYZQ,/Y!QM
M@ ^_"7XZ8%UV+GJGG__+%[.$?<3!WA$P":2!EZD+A6$,0L=GYK81L%DR#ST&
M==$,_,I^<E<B=&_8M"Q9MML^W#C\*VEPYNK2$FN^BM_1T-V^B6)\.<Y._T?G
M1(1R']-7X:[ZD^V,];+MM@ IV$)T'=S>4C^TX>QR^ZH+LHAYTT=Z6#OHN,+^
MY*1/I3UVVE74YDSCFWKWZ_];J(]N_J\:'"?)R$;>!*Z*A?N1:.5.=C]8G8C\
MD!'3L16LXW#*/:DA0H+F/Z?;SH1>7@?[)O+*IB;GL]9#PJLCE4E>P24GSL':
MJ4<K;[R?-,:&3Y\AS!+V^EM!;=,8"<_%Q,8>-IZ1UI^9)20Y4R:H_]I._FL"
MR/+Y %G%0$-\T1S>^"2BF"6D,Z:%\JL_QJ8=_[?0-#>L</I#%%.ET^,QD*8\
M=<(:GFS59KK(*,W TD FM]6QPO6IX(XYL\RV47-O[ZLG IX<U*4;^H.I#5ON
MB]902L?$^=SBEB_3:@.($"*C>IG8,C-<M9^0JE9LU5R#<^2HK'/<6FF,,%H'
M!";=F!WJD2K* A^?'$U?*3H ^UYK\)!1,HS;TUBN%C$&,RE5#UA:R FQ;Y+3
M$(6(I+;X)_YC4%!^&8PYY@LUP9&R8M2T%K?K5U#@7'=LT@0=BE/\B_A"G_H_
MMPIUV7HG3K3"E@'.!CV/5S?"6HJRNTB[3+V9EQXC,.U-BCS@UC29UBE'QL]]
MB_:PS=0"E'O4?^[$YPN>JXN(SA6P;&1WY'!U\<\#FQN0-U#SC_U0[<1"*,&S
MO>\T%)/.C]M9?T>WQ=GHC87[IS<8"9&;DGWKH,:)#X?"+\;X>]?+)KQWE%=O
M*_FZF_3DV&%7@MY_']3; .3'$!N.J(\7X8]L53T!PAB7@\BX\C1'B,V2%(7Q
M+.&*$U5U10;JS1).A?<BO<WB@[4@Q$%Z76%2\M0N,;LHCO&![KCNWCE!3.Z3
M])&,$\\!KX>\5A+B(%0\5=T#SY.1M>U-5/$V10&2.$O0!$;(F:Q3<-X!F'@5
ME.E!;@G"ZDU.EO#15F>3+EQ#27&RSRD-:V4!E"=A=1'9.7G!]X:\HC^H[BL\
M\YZMS:>(O_ZO1?&$?W"1[<2Y0$5GMX U$E0G1V8X+H(+,/T<4:?XJ'S7MT28
M)Y) Y6Q=9B^FZ[6.G DN1+>8%BMJ6\CSF%4GH4_OB:V"514_4,N2+[Z62I<)
MZRT-U95/:PA8V</_VX)\<\]>;8GJ%2CZ595X9"\ (!]@;ELIIXV#G)@E: !G
MP33,O(N]A.F+Z7<V,]1G"<WZA6]9T<@=Z9 G9:)3C:G;C%G EMDR(3%LAL&5
MOP\.>G9S'#QW(U3XM*[NK_DS-?<S(**X?D21K=S(?D6M)DW8E3/C#L'G.4H
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M)8PXQJ+2HJ]UNU!7IS%ZWB7[6GB.K/Q <':O'@HV'9PEA%:K'@"AP-"T JQ
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MGM GZ/G"D_C<>V<)B?BT86-"<<\/;,EU7+&_(%LBE"[8F]@@(2B=3 <,;%@
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MZ0_2B$C5ALTD+J;0L&PO&,>"MZ *E02Q)#K_ EAD&2K.*NJ:!4$SUI\T-'<
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M5\6;&5>Y ),F264K%@O8W_Y3/G#[L02E&7N(8A _)&S#:<KN@ZQD7K2WAZ0
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M832730+U6'4%<1N_+#I>U<+CV+:*EM,[[11X6B+\0.$U%#FZ'ERX29+9*GZ
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M2_!KK[TLKBKD".+Z_[R\JT$!J2GAG/I*/^4>49S1; 2G&X])G-N IV\;#A4
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MI16>L@9]48'^.10Y+I<URDWOY&095N3FYEQ!74K>L8IW=JX2=DV2YK+\0ZO
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MCQM/VKZ,W;IQTEGTSOT].N5Y3GPC</7562/QJ&%I&TS_9QMTG*G;0+*A3IK
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M6/O&+\^Y2OV>_Z9763PZACAHB)D<"KH7/G4I/@%Q5>-8,$#-MXSAD)'>M,F
M=Q ]UO, <JV@A'$='-S^O,NZ'C.M>)'HSZV7K_EERL-*],_ 2MT%'%N!W_15
ME%EHO&&&Q!C_#:39FP*'JGN$<((,FP_"F +VT0[."M!\ $3?/W84CYTN-6]M
MI-=&)Z+%+@]>,WPGKWJ:AP\_$R\9"&E>__CM-P)]63N>4N4K4#O<IN?Z@U\X
M+H;6GP7Z=,R2I6GVX-M-FM 7<+HA8\EB0 M'*"+K!LNO8T*(C;_[.*I,G'7Z
M'3+,*VE)!S%M8S6SSV"0(1XIZOXALA"R50S@&*1,6F[=()!;:Y?BUH/GP(!7
MKYC/V2P:"U01^Z;4S&3,%G7JP):Q!G3JIAL(7>W4Q$\+MX']!&=A;?\W.8W[
M=JB6BP,C$.*AT)J- YM4-5;JL:)KR^]=GR&47,#AYE'\N0&&+DJ)J_YGZG&I
M'<H K4JJ!9BC*1YC('ZZ\!X<UPC,AB66B.02_%)U:%IT&2-%8:O;V-LC(P71
M(A&V^@6XI0F-@$REVM1DM7ZVUIOI\LOPR/0#PXW;8JI21>JC:7/UOU"5 FF9
M/VK9JET/EB,!:FW)HS!PZC.>/7&(./:F72-_\HF @Y(\9;G=@LP;]39^)>>+
MHO@VE#DC/733>7^V^87C=I>QLVM5]0OA$4QOR'5P#_*59#-4MV.#])0"K M&
M+60'NM!U.@9[ 2Q*%N]0068Q%F09<SG;L&"WI+AAG$LLB*&LCMU(-&)' +HZ
M+'B?I".NU7IWT?:2[4]B;.P%CZ)%F'W[:2;UR7I<9_; 1JB=H;S%3I\CIC+A
M?FRA(42D >E#]B'X=5'5K1)T>]L&;"5[-FUIS(*4#?&F ;4<9[!#X[+@&+C<
M(1\YE!,*<S/&V)Z0C^LQP)195?O^N6]H8)YAMS,)#I&"K5P:G#!:!/=J5_1(
M3_#>/)AJMK%.E[B@NT%JOELUK"W,M^]2O2C+:Z!:^)Q445.S9PB+1U'[7@\O
M[#8N$N[E:S6/P'W%=SWN_0\K6[R=2XWTBQ[>)381^\]I]W1 D:U@I?68D\Z&
MTYJ_'/'/')4LY^!I/-@!3VUKKRS=T1#NCCPM>L#V%G<&#;O8[KJ,(X(@)#AS
M\D;\D_"CT4'EMG?HAYY?J^]>M6D;OYF*+@G %I;A'#&\_3B O3J+_9%O:-5R
MY73P;>( Y@A:U51T36[K90H5K(%;-<OB=IWLD)9MD,QC_3++\F+[K5_&=;MJ
MFN7+W,S/'Y=.A^)00;871ZWS1G!EO$R-2=JL44&C23B7CX)T'#$8I47<\*-E
MD!9C))2.>*0K_YUTBW)Q#XT]IZ8G8V;L-7!3:4SCTR=DBD-,;BO7L_9SC(W+
MY&_6YKT?<U!;7$WF;@4%NCFL&SC8&RO3G0."[\ MW06LK3E$U%V<'(:CQ@%J
M:O@*9*_(.H,=N?&>9K?*'.2H>0WT)3N9YS5AB7NRQ_=T5HYY].]L$V;Y*8(0
MT]<SA$ECW/A-J/ 1WD5I)8[G^9C)N&X9I[F7.E?B"LD6<_[LS;?/5'LVC!U4
M\;)&,3-&[*.0-VBT_MY&@Z7G5*^@$'^A+0%.]0.+@'/AG^XF#WG7*G.>":TK
MPI)^H7VZMD63ND6=X9:Q]GI$QMKN ULT.Q=>;\J8?7_5Q4>/9C^Z2"#,HMV_
M2"'CK$_G_"XAZ5_.$+ZGRH.U@<CL/C_%<HHU0VZ=(G3Y9I-C,9?C$%U"2I,L
M8STZ*?^KG4576_%4I1=8ZDTMOA*^2W6 ]6]A4-XX< MMD@II]>.7Z)5.H\MU
M!]GSP2!\DVV)=$DM,!,&:2G'&BCJ;>8-IHK/)7G<1EQK<XW2W%];T]K(.3)[
M2F<I&A'-/)&4>.[1*\0I7"K,3O+<:VJD=< YM8@D;$:7X#F*(58GZ5\:JK+G
M&0[OR/)HT9#JJ>DB+W2&L$P:<<?3S^M6+W>"M/A=*"NS8<"X')Z77U84@VL]
M9SF=]>"5NW3V=EBB;E9394G;*\>)T5Z6XRD3(S5[=2H(K#="K7Z&Z@[.$$[%
M.F@/Z8NHRFLS!)'U%8XK*[3QIP$J''X+;E&/9Z+KK-(1AUT=[.W*"G5_EG68
M_K;/CD3!D>A7@ABM?WWN^$5WYX<6![LF HC+HD+R^(NITSMP5?U[G49Q40$?
M-'6JA\J,FHC A58W#M8:94B5ORKF^802N5]U3NZP:^:Q+>&I0UUQ_7J:;.H"
M+7TRR[N)3FS../*1LJP=W8Z$^:Q+>@AB_E#4T8EL_^_C[*Q:\13K(/4-I"W7
MWYHAG![OZZWCX^Q@+HNVWPALY^Y6)LUSXYD-8XMI"\( ;6]G[ /8<3 E_C79
MK\O'-U&5:)OE\?L0_WC EM*0CD /1JE7:.AM3E%/99AM0ZY?T5U6YNY.]S&3
MH^7/.^.S+$*>";O=LH+WBM/OOGS65=G_L;A"4EZ=,F";&?KPY&76[8)L#[^O
M8)(190';7I_O8QP)2Y4T&7D.NA*<*XX9<.AU&Y_#]H8'<E34A='RXLQXO7\#
MMJJZ<\+%1MZYMPSKZ(T/U0U])12E#LSQZ@^1S2NTTB*$"[<@&P5\WK-6FB6U
MHY[BO6G=#1SA!'5QD\O!;\"@YIW_L4Z.%=L783;8[?#K_,2>,T]8HWT<J7)Q
M"'[>^>33QEFBU ^?MIS(_L_W_M'SY=@?47>)JN!:*ORC%+5TJLV?"P=?,I0*
M+\+:0FZ&F\(Y7)]U5@6.W#'S6$>48]<^.G&EYI<^Z-2_V>\^9?^Y%][0\21P
MY=5=JAVD?.@TN=\6,S,QW(6@KM0RJ)X'',=YTA^HETA+)FF&5HA.A,_S<47(
M]5;V#IUNOC^Y[(Y[S=#XXTDW$?6"A<673KMG>32'(J14L:7*E][L]9O<[L%M
MTW>36>_'N>Z"B:_Q?&XQ9@;5>8WB(?<.CIMV0%?I9>2+GYB4-4#SK?YG:?2_
M/H>? LA/G'< Y"$Y:G\9WYYAOS)')K=[LGDX(>CS2+50>@4U+\H\+[S-WEH(
M?FP:.R,\<7;##.$6!,=R1S<]0??@7V$%UHVCA]ZQ>#A/#=77.&E:QTR109G-
M8"J:I!Q?PO9&"NV7(<PZZ%*UWVV-[YSOD%,Y#^CI<:4,6MY^^-/3TX.=>U_>
M7<JLS/1^?%:?MG\;J39XE*8+_.]R>*4\"%S267-ZH3+/)KI<H742(LPT<1(<
MJ5&,(L4,BF,'V[&8$7(S4&U[AW@D%@\4,@][>V11>X ZUE^5<$V V;,*ZC%R
MMWOIZ;!AF^#T Y\^\,9N((/80MP;&WD/2Q=!/PCZ(*T'*-9]Q:F;IO+8WAI%
M)MU>0CD2,QTH2CL3IPN]U>GN&[K/JMKCDMK46Y8;]&)C&2[[*YRYU<A3@9IH
MT:(:7\((T685]AVE?^1_--I)X/R$TO5I$S6>F'$@<@XSUL!6/<1R_'1&Z"[]
M3<X2XN*6B%G5W4QL'H._""4]865,_2%\%DC;U_/I='QI0O"FT(*8'.O<O//?
M!9#_8<X0Y@]@ R1ASNAN =L+9[HO"OUWHW@2_'=U,\YOL\!@S8?B!T CDS/K
M@7C__=V/7A$SV4Z>]>\.[NIQNXGX99YDGM $D-.J@[GCE60K>4Q;Q=$ACU[*
M*DR+!W!5I):GOVZ8/O4_[^O7TQMQC$,:-=5YL1YKJ_1<:<R=[[%Q36LMC>LL
M -PFBM4+1%*=3T9.\>)5 K.A"[UI;ELFZ':F$0U28\PQFF.%^*>BCO<9"?FS
MD&-!5M.78J%R_0-(J>')I[1O@:]:T,? C'-P#_V[OM*-)(]4:Z^7H)Y=E%4L
M17UY?S_;RN;U38]PIYY*HS:7C4^^1\SR"H=='^2HQU>,*(ANS#EA[Z(EY.ZO
M:@+<.AY@[];>)3:3P2H^:J'3,$>==0N'(&,J \J4K ?C2+\ZO.0AZ%=7 UFS
MQ D8!L7-"F54V]^^'ZV8ASH^!/S@[MA(6'%E(M'(YG43S_3IC2= $(*XO\ZD
M?U3T>=+0#G0U3!^;PN4@QGH5E?$YLAE"WQQUL6%=X]QJ?9'X /NPRLY?^0\#
M<T:X,M+H_)Y3<%K/I[@:ZV-T8] KDYM5L1TTJY%KW")6@OK:G8*/7H-<-IUY
M7J5[O;%3-XC;ZZ490G^>]KU>3%7^3<3CM':6_LH,X02-9VA;'&W74%>PO!NI
ME=2QE;J=48%W61=<3.JKW^4_/E$\;*UMHR9/C!,!_=CEWJ9?HBX89?H<1&R;
MIXNY<4E46;59#K-XN(U!^A&J:X2>]:93K*&Z^7C8XK]IT1X#L0A)LP2="T2Z
M+8#\70?'GF718+\)2146  <5OZ'&.A09*%6U+G@S$ESUSTCUGX/'$-._S[I?
ML6FJ_CV27OF-[32*HP-W0__LQQ!%BF'UY@SA&2^5'5@0([%#G+A0!+TO^1O$
MB#OYCC*^JV?"A;D+."J3J(?;A7><]Z4.S!"^ZXYKT25FNNR@U8@N?_KCDW'I
MTQ,947>L_[V+/Y7/-L&%-PZ\<(7Q19+K^4:<]2R^BIQ,F<^V[Q2?0/QE"B([
MM)3M!3^X%X'<T HE-64(.:ORW:I!68CE^SO7A 4#8:$QN7>>]&BKJVZ?W;S:
M4RL@:P\:;KGI,"O!4)2PP@>'WG/_SE0*_EN48/T>%C5"6<&2-9FJ!$-1 D8S
MZU,,S1 6!#6-A]&,/TY71%OUED9<J+HQ/'O .;NR>O'+O//?0%&5N -K;*TU
M3.I>$:< /@[:AT#Q$%T.!"?@T"/@X-G(0G9X#4A0Z^@ITT4J?3;'*$K=NQ=!
MIWTX2R4OO*KX4%&:BS#ZI%=6UOLT6F5_X)+$2-2Z'S,^JSN. Q.AM6&FX#P\
M';[\_<=6-5W>JCV9O(>K]J\?HZC^[L56@]"Z@XIP5L)A6,K-:KR(W/E38M>-
M'H;'U9X73PM#8Q.:.7.[)N[8UFL]IXMJNO/OZ6/Q(S?%#Z)VD4B-F$B2O20"
MAYRQ&Z2QLH1[=8Q(^(%.1G%ASL;#$BW!\NEMQI,%$? ADN6XVW*?G3_Z",R<
M+L<R/YU@A"WW.6HYIM#^9M]B&+1BV!X),?BI]$K/L?\N(\1/?"-DS25=&*=G
M$^N77AG59*.]7!,,$E1,>\ /0+B9\5*+ON9SC[:K7.@'DDP,@U2IETX+MY(E
M)&"TIZ9MLB=C*CB6N!VKP*U=/;(+$)%&JO(?:"D[#DJF6G8J;RH6NHS> PT*
M,S1<:N(H)CV#N&RO6 =P)>ZLRNF%_5<980MJJU_<9&QZ5713%^,VYY,";&G&
MC"V1'&RA":Q10F,..IOPC;=T3*R9LR:G06'Z%:_A9Q9M']*<0MK?*=XCM^:R
MMT..DAN%[&_@G*N5IL1&*3'>E+Z_?:+PCGAW<7C,OF/#N;&-Q1-E!N7"<"-+
M?C!#B%)<49A-\%+Y54[H$F=M0YF^S*UF?9A5DD4]95$ONE))3Y>L;;M?S3W4
MNR%NW!($HJ'*$><7+A%B<6>EG;7:MR@M^Q^&BQ]C;6D!'DPL#?TA^AH<N0G
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M%_I"_Y<1K)"[:GG 6[<.784T-RFNV7NT^5@J>;-9H0V<=34WCO2RJ04Q-L.
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MKOWUHO;R5TO+*E:G_?&Q<=<:[Y$1E\U_#>[K$KC$Z4RV_/!<+)$\S^CXJV?
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M!X>H1]_2@XY!"<]BM.L?5W9)JQQU/Z)ZJM_2\:Y1(A[H2<'#;%05(UTJIG1
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ML%U'[/9"]+[),7MO_ 4(9 N.CKHFS^=L201T!T9HG3F,%9E\(3Z2ETRIWOM
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MN#?/Y!0E3IP%DI4XQSF29"L9-@(4:FPN]C]K.(N4N"_"LO2W%%0=HRW7+9
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M?Q 4-XAXPC5K?6H2&(:.9<VV.H),5J0:19<^XUZ7;'\EH,G'H_Y5]#C"1'L
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MA B1DSA18I[N,;=',+4=73H8S=.ED=L,3RNO&F:ELMXW^ CW5Y[\T7MYX+&
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MOMF'(4'ZM-D)YUR>'ISLDS-JGZ$5DC2ZL8!4^7[!)Z)B(;8<.QE/B:!7@,X
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M+G!Z7D1Q,DC(/=C+P9==69U9*W5@BR=//4J4NP2WUY"0.XS7//"23P?+>#0
MUD4UY$K+<2+^5'^5[IY7Z#IZW,_(+OA.F5?9GBR%#094KXYJ-C> L<G(=NO
MS99R-EF??KAW^O3= ^-GIU(#94I]H.5G$\->C%EDPAO5Y:0XJ<7='XX'(FM5
MOU@:N7=G[>DO=FC,[""F^%D*N>7!D69N:JK\3+"A]<LM5^VGO<C>=8T)'[J^
M#:HR,"]V=ZZ5"/.U:<]KQN\8+NMLG4X:-6VH5UKREI?VG(&RV\O?Y^F=,^/
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MM\9CI]U/]S/6,!\<^6<#N7^"_-U;]S]& K<H=R!T^*C2"M&%<Y6N="H4D)W
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M(8[! [HCO(4U[N>HL.'C%],L^+7QV=Z0-R]651A9U/5(H)C%F;[[1J'X;XQ
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MG!_<TZ5K^NS9O"^\OR\I^+]$[^L<;<W&/$,^;(1J'%;JP2+90,DW[UHHKJU
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M$ S:J+*I2S!RP8.9Y(JC__@7VTWD_QAMP*1_ZU5^_J??B/P?7M '1<SBU&.
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M:QZ2+/EY<K7]4?',Q$&A=]>TI]ML\$!<;M"D =ZO)_:NBR3T@T]@'WOR8?;
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M'HVO_;WHPMG.GR7MN8Y;S\UT9G6%+KU&-WW1U6AAQTL-WP*FYSW2/&(T<S&
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M48$-"C( %'.3.M5:5*JT[5KAK716HO+&^QBWMV(1.B<QGYFD+BHGQJ,P]QD
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ML'N'D&LM7(!M6,$IAY5GFQKZ'&9:C^YR* F>:9F<")BU^73Q[BXQ?%I=BQY
MSP%!2MAWZDQ"V&O'LSD^O\71<W"LCSGF70/ WM<&3G9@HK1\I/6NX.>-TU:,
M":.2A&U\8Y,X?2_D.ZW%8=)NVA#0Y#E[36D0Z5>V35T-1.%N E_7.KH$EXQA
MCT,?<^?'")VA5HW/XW,^D]; EMJ7.>&R9<QSK\DB;VF^EM_ML=(C?Z1G $4
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MG-#2C/LK?MYM?A_L?7\\7O?N4S//>/<F%E%MD"DWN;G:\M>B^O=S@,L3U%K
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M0;X(, PQ4%>4)E!<'D^5[#WRT/\1L?9<2-1U\ZTKQIH8?ZT7O.4#G4 K'3R
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M0:UNDG R^]@W\=(A\T'V'NB#RXW-VB\XD7G+-F2Z*/(,]/* 'OR["40=K4@
M G TP4I.4 5I@BG1D^;S.,L=HT4+J)1Q7;"-&2[$K8*T%E!MB/JP-<M96.'J
MVP_C1%X4?&0I%.-9W?_3L\^:XAM(>AKB'5OS)0O_T/UQD+U@R'H=RG.)])2(
MT$++P*RE!()IXKDX>+]46T1OW;]4R2D16Q"?RO@<Z;NLU5NW6.]NY(7'7EVK
MG\FS1\\?[O5]-^Y,BO7?7R=A:+<+>@]@:&RM1;%4@&L ZPY)%D-X/[)DW##P
M.;D]+:); _KE55D85*2G.E&E04X/ZSWSFIGQV<.HZ%8 XUS X<AY]V8.Z(Z'
MS*/B3 ^#],77,)M[/KB[5,>,8D>(PN3![:$Z0P?59546<6:#MJA+AS/SYK^)
MQ@^[7K]\QG1V]99E;V!K$"NDW2IV8VF#X2)"?$G&E_'YO2QK<*[9SSC'8?1W
M0Y_6;+<^:Z/M%:EES.<GS9."OHW]:3GXGV:2QY537]Q0M1$V5;K+-<5=4] \
M_W'0N+JBB*KI^X6]0W'?R73:<ENPW3Y9(3%4)9FU;$(MW\%!<@2WA'*HKO_'
M=.C%"7S]<U:O;9-%BY]%7/=I#ZV)PX,<XK0T$%%3DI45A8N2D\NO0T20WHKL
M@'PF\'>H^Z&.">P,:279]("]GT$/O<58G]T;YF0VS6]O=>\T/ 5^O5L6Q,8,
M/B2L)0=M_LH4JU]7(BUT0(#HE6TG\!L*L>#X<R#K*EC'&5&'!AXI$CBAW2.Y
MYZ%,,/_EG-XS""/B\.[C3X.X.Q2+AR4/D;\$RZCVYX*I6)"9[J3#^NZ++_%N
M+X(F6J[/:3D'B$@:Y+!FRPHG0AT0A(;VEXM):2SM2!%A!"<SZ$4P,'ZX,/OW
M/A9)ZB.^W\US-UK]#2HN+N+;M]#5R(8O9\5&08Z=V^\IBL7%_1<'_!D^DF4$
M1E:,/JZNZB;=$.>/@;8%SG"%]'3CY<^@4+D+K"+]<6(<FX1L@G M?M8$=8B.
M/T<X"](R*#IB'X_+HRT%#F#Q^^K1$/Z9#[O<EMG6%Y?X$C[S$W.?$*B' :[I
MXK%\T)4S>DI6#I6"NV5ZBC@]V57H-0B\1'9"F6*<40BF9I'-Q1]C]3'H&,CS
M)7M3VB'IHA#K!JB<YVG05BY&ZTSE?L3^2-_%GV\>__9E?M[A7<7,UP,X39PP
M 0<ZX_@"V4-%92@@K!" 9],P!BYEO GBHHCM6JHQA5"3C5=FDGAQ73[?%_(4
MXUOQJ_RFAD*%0")5)6L4WP1BX@-K>K[6N8^A6^IE?D:]B&'0D&[!U@74@2<P
M>G%[/\!]"=0L E-W3R@*%/CT8-F.,$6:4R>J.-6*4U%R;B/[WP818XI)PX 0
M$4@_I=FZ-\:,[M_MS>X=FD-TNN.K<KJF>?-9KI$QP ,H9&MDO:( VB1-XA(8
M%EQ!(L;(:8-[!5Z(3F.O +M;\2L[Q5@TT7C=L#DXG!:1[TMTS54Z&B?8OSS8
M\^2[L>994M25%VLVQ[E)BA+%Q]$G_[_J.OP_NJI>"Q;[P.5C;P$SC>1 )4Y<
M0+7.*R[^]_]'S9$@\R3X'I9+D#]>0,W7LZ()USV; = #_6L7(8XS=V(!]3.4
M_(T]\W\Y$"RD;J*<A7Q!VI$%U.TT,:>5CH)W@K^^5U?"AZ2T))9>(:;VT>NK
M"RAMG%;(OM#<KZ81T1Q 7A00R'^J^@L0)L'KJA#5!93<G>+=!.G(G:COZ+6"
M-EJ:KK<+LJB,16K!I[ -I E?"XN" ]:6Q8KD8UKSWX]*;;ROA#'WQ4%1QP?-
M:FK&8J]E>A5V/<"03A"ZHV#=4\C:]9!RV.4 E"#$Q%%-(5,I9J*]K2H9MW83
M5%T*D5KX7Y.$A)5!XZO84HL4>%/AV/3XGL%0QX.QQJ7E4#P7,6'6]]L *D3"
MY=I^\Z:!L*>=;?DD &;\IT5:/T"B)7NS;F!G1N6FU"Z!^I&RZ'7[0I/2"&)2
M.TW_551Y<0X]\N$T8;5-?F.9;/VERV! AR-V(Y/)I'<\3UZFV#JMUEJP!>R.
MCXCA:$"<5F^]A BUY;L(Q *SP1\*M&M-^IG[18T#/QW2?"POK<KX6')_W;9:
M[00SZF7(HIU0/RLI6]2]94J[,A]@9P#Y#0I%D6T[34-/Y56PJQX<!#LFG)J4
M++NEA?_V;$/KOJH4BII_E6\Q+?E'4"0YLFH=O+=V>.;428.N1M&O3@'8\DB9
M\LL6.U?RF3Q+,8'?,4%OP:SUM1YL'X4]I-.R5*F@'6?DKO9&])61#&.+*(?K
M.7E3LO?1^YAW*+@&E:B"B(83Q(TJ\_;P1L537$ 5'^TGQ26PER!]')23/43G
M[O#Q)7>WT%<Y[83W07>KR$?XLL#ZVN=2ITQAM^:T=^*M%6.MUPZ&VI63@C=\
M-^5I.Y1O@1?E')4/RGU#J!Z&M88G0A=0,YUB>B+.P,D>CNJC6(IF=8D->C=#
M618/($RS#-E6$WKJ8)^CVP1A'5$V_[?W1X1F3J^P9B:Q#,7NZVV:CO5^_6D8
M\VW^QB]/6!.#J-?W ,(L8 /%5>Y!9LJ*AJ@.\%FI2HLZ491 2W*T%ZI  >#W
M%F_7E$BZ.M%[C/>9WN:W?8@5]3B%9>VO>_<JU=&VZ-WFP8%OT/7OIYE]/QW0
M?8)1'T1U4>_MOJ+8:=MG H,IX8*&0F8RU>QSW@I.@L1I(\5%.IM,Q9S[TF"<
M'[ZJND9ZC%X"333[:4FY?0%L9DU_&,N_>'JXP;=BP.#,75[=W[W>SU2DGZ2N
M"/JJHMC1N<IK!.D&GM&X'-5S'A7!,G $/@&E3PC2\F1UI74_6:=&1GC"]-W"
M'_O"ZI[Z_'HV);\X+.RKJJR8&R7?LO9VF)VQE/4.X4A8OB>BNEN,TT5:&M96
M@<MD'Z!>$"U2R6#I";'KIO?ADAQ#P7X_:3ZDS2-H4]>CM:$RFU!T"TXK K^*
M0.[@+DK@/O]QSH:NRULQX4N^-KDGTA?;!MO*O91&:P*>)9\ VR>PL-9WX9'2
MP U7N]$O):=D5&/; _XU.]W*1RF;TTY)[S#U=A#X[XN'*@S?"WP<F8^\A,R&
M/.PZ*'L!I7(*X&I3,?H/^X%@90J!\9R;V/P+H$"(;\M_J<]K?-3RE%S+-=8
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M7<E.6P#N!P%#U2R8SAR/5Y0T1D/.0LS(OX<=G0U=_C+D$E8?R1J:#CLFE5F
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MJ_BW@W)-NG]PQOB/W*/TL^#I7 #-LB\_(F6<'(&&VQ"]';^?W3INL?&XBB3
MQ1'TYMIVONWU&?7AF<WI:;_ZB[M<XV&65TG.H6K>NA/ECED.VTRV7MYTT!8A
MT^NZ8>,Z*8GG:<_64L1Q+E6A(1.UCEL7BBA'%(\BW:N,H3>_PKJSE^>1FFE)
MPWS[I CUJ^9D7AZ!O( 2F]-M6JT:+KU,SA>FX=_5(FNO+[:D[225P5<'$,<@
MSDK8W29JY:PL0VI)?4NH_5G'R%H6\.0<1;6'<7_E7*N=TXFQ8#%:E;)>^ONP
M;J\JYN3]XO1/*&0<%TJ#]F0CJF[RM=RRJ0*LHL@&GPYH18C"UT/N\MWU]Z4T
MGB"TSHTBL3\[;!-Z<EA4==MV?:5IQE"H0QO;$925;L@N++Y3[7)-F0E,%[O8
M++::7Z&F**><YJC@A/D+J-H*^LLI%C[2+E.4-HI>>Y[:!S!R4P*ODRLN@>,W
M'?<@*WM)V(W^9@TZG!:!\1<[3R>"#$C%*+G7O+M<'^#>Y=0R;Y7VL4[(KR%]
M3KN@V2<'>L;&*-:0=0FG&4@Z=&EG=,/9VHG0WV+#Q7JIC!=G LUG6T#*M@%N
MGHXK;:9K#ABBS=3*U:FO<-78!(X(K?B;$TA( )8Q[H7ZUPY4PCJB- =@'92Z
MA=U=#1,F\D6Q$R3],70-?U+.HVX<(A%FAN1?#5_3@E1^#<*&2L!  H1,#GB:
M8'B.<D7!0:S(:<*A_/)M;Q!;Q5-6I!B32C?P[PUK/1F;VTQ0L5%<1N0M=K([
MI@F.1A-8#=@L_EC<X 5&=>JJT O ET\R5>6(WH#P'TQU1 ,^#8X6QKK+VJ"F
M4D7!!**-X6\3_#9$42W^LG.70X>($)>CVPNMY@\6)XZ+WT%?,,E\67ZXX>M2
M<BI_:\$2A>F) SI65E81Y8;66/<:1G]$IUT?O^58_U/KA[75SZIK$ZPE5D\K
MK/L<8GS<?<@3<7S^JHG$5?Y''[FXG-']_+\K4^[ZF8YVD:IG!S<@M.+IO'"W
M#9T7G@;+\NYGNVN:;_4>DND+=QUQV_GB3HW6;W]Y7&5B5-B:XS[=P5$@4]0Y
M6#&P:_3]Z'FR:<ONT?<^7>GK>O!K&OQ=;78?Z=Q0??1IENFN?7?-,$<>W712
MLH9$#T4.[C,?%[B @G<3UG)^_5MI,BM;HKB-_5I)JN)<I(V8R&0R,;&QHX,S
MPA%^[!P<&WR;;LOK[&P=7Q-=^KP@<%%$(7ISYLC8O7^R?S:M6P+6+RIKLQ9[
MHD,98(CQIO^T3FWF_YQOSIF.?8J\QJ BW;DD0P=7U LV!#@VK^>[Z9N@JPU<
MMSVHU6Z;IH.NW=!F3/+%.*7!(7/!S-ZPG&\VU?5)\NVP =CZM*MQ50&@3L:Y
M%7S9L?=<V*4\,])]3<)D56_#=TRZWTJI:^OL;9PVU8AL(8Y*8:N16]J-5TAQ
M"92=TG E(CA2*%[L<_FB<&QJGG"'8:A^G3_MWCC 4'LM'@@5/C_J=R0^M$*6
M3P[]:7@<+51!UFZ'/BV^ %#0;!90&DCS NK9W(RVW)B<)FN7KOLS: &EY;29
M'"CLCINM "Y/^WQ*$/7\B'K6?]\6R#!H<-P:6HAA>)'-WPC/3\MR;W2.Y:3K
M?<N57UC\70L(HKT[,BWS!^<DEH5<(389P^AN3D/?R8MJR6?\"U6)NA-L.0;3
M!>@>F]EDNRRKG5-^.]FT@_E^ XY8P]<QH@Y+N;JE7U9[:_7T/G,:<A,''JZ"
M[(X(9%;0A'AVL=':+ZG];2"(Q,>V<#19^'#0]-BSQ@'6"6'W6D./Z](*7!!.
M>PS*&;)V;B7HLGPW.IF %07E.F\H>]Q;AZNV1V*3<W6CC%?,=R!J2F:U\L<B
MX%A !6/C. P+V/83O%L ;U46J'E 6;L. Z*#0/.[Q=<W,\:.4@LE^ZM?%!81
M15)LD%?? =$FY"W2A? &8$ZU@BGIEM%J#BR!#:8(M7HM=,AT&%YG<5*QJ(9:
M0Z^NO"]WH78;;\H9XL^VCAM*,:VS*E^83LM>#,J", STS-P$/<EO!Q13#F4U
M+[LBA>@O]XT_JKJZSGOXMJT/09W,?M6I,A<*SB+JC<H OX$+QB?X+8%XH(7L
M>EHK88W3IL\Y5"LPL!6=!#"4-7I_^11U2T_=JOL7 @ MRH7AK!%)J5=HI-$^
M'R,'[SY;HGN3J6=B%_+F6QMV  -M73R6M>P_O7#+D"[OJI?T#/[Q/OA@<9HB
M4#C79F30/ 1L@#=(W\K*U^Q#;MET+AE@6!_E$H,G<"M]QYR+(*9;XI;+N?BA
M",4R0B_.D2,<1T-F'(F/TLM*H+U2SDL!(U>BK4)C=!M3W#@L*!9TYWIF36-6
MLU1+@O3XB3G4+<%Y!8W%WM-\((UJ_:Z]-.1&:>(/^DR%J7OOE1\$R,WZ)TV7
M\5KTUUJ+1:VUHQQA&I\!=EP <R>PB?ZIIH:C00"& EQ=T9%K97&/Y18E-KS[
M]U;-6Z2KRPW7::MFA]/M!@%A%PTRLRN,M1TK_B3Q?>CSQD2U))A@0-EOF_XB
MPRS]SBXBH&Y[W^U.5X4CFUJX1^N56'.=R9Y3\T\?W<3]19R%=C4BJ@'AUA^&
MZ$8 R=>A.TOL0SQ'W0*CGM=4?_<:7V_BPQE))$Y5A$99!3'WW69>.WS3@_Q]
M]S%*FL_B\5S<16):4'8+O5Y/XE'LI]KBX<0L@C=+5S!RQL_?>IC:U]+LI)^C
M_[;$0@\=XT@T<-.LNWPW($E^5OGMMW&: #>#OOHKP,")%O7>4B@'>AW? @%
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M&FPX(MU$(?F(E^6!+I+-T(@XZ& ON5K%6:W%<#N4@)K[NK:_25ROZ,C09'+
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M#[J;P?W9ZO"MU2;9(>"7<'C-:=*XDT'1SMYVJS>]&3LR!K C,Y!Y.:Q?AIH
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M>KT\(KZAWT0[.562-PCPWV&AC7;UPVJJM![&2TGIS<K<FD'J:?$4IUPA+O_
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M#9O+*?9-"Q@FC3&6JC9TEG-I8HZV&K3.!GF"SXAF[JE4@5>L7=B^GRUZ0%Q
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M;^,EWYY9:?14QV&UT7<6O^O^IZQO&[LJ"-8L$GC%V[ #90 ?*WHDKF_/MVH
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ML> )/ZRP'=:RYP_"JPL$Y=.] D;\/+')XY+$1ZQX'0CL4-/:%<V/L:2]9QF
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MAH#COM,V68OCF?G7[I$/LXZ.(,%Y%>=+N1!'96&J:+-"?H,'%,G!)S-7-YM
M! YI#@..[H'NL45R'<J?[!*3*-@P+B 7>NM3S-S]TN+@*2NPIB[),,'T36'H
M)-K3)]DL_,S3>",B5U.,SEA&.8; '71?YD[9*?2*/X)"*3D++J)0VU%K4.N7
M$2<DJ%F"T,%9:"#N0NR;YFR[M8[KN8]L[#-:/&MUC>]OK9M/5?)EF6RF7+"V
M<5*C8ZC,,U<9;7%3<,F,<IN)RMZZ IME?Z2(-P#L'X0?VDQV#EV %8\ 2Q=$
M?WU:(=1%>OFP!/723)JS37 *4\$45S':<B0H>V#LFO3\*7N>J9+FSO.:$*_.
M%OI6NU[3SC5EJ%-"PK1P 3>T,(=S.AW8MP/.EQT\:2]!%3C#*E'BH]*2NX,(
M6)0(,<D+>=3UHR#RCG++J+UT'28[$P/ZT!+IX'%6(G59(U^S!4ABKA-KB/OS
M-8<'3*O!7/@$>+I?KH,1A\..WGV<9Z7DTY4!17GPK?^B*;A$<^CKWW;?Z2D)
MP6F/GAU$X<.8[(5%:1W!*5&.OMG="<$D6/A 8]F8*AO?57/)_?7!NQF_O))5
MJU^^.Z"773QG'<A@P%I=TKJ#N:NL/N/9=Z=L&C_(J^?NTC,2/9W=9D!.><[K
M4.;UIK6?L;;I)%H;7 6)H!<+,B.D &PV35/<Q:J,F@T68BF^@Q:-]ES&VM!?
M(9UC](-\SS3Q)HH[/_S6O4\C1X-C N/UYET'8&.VDFQW^Z@GSF28Q#D0,7GQ
MV*CU!&EUL+?2JSK\*&D.T;',*;YF,L">;)(3R^>!_ @)2@6.A-!@X+/\':"+
MU]M5U2P-:E_SRA$,E]BN:[D[9]K$PX1J&)HSVDZ7)[NY'ICE5 .:P9;3BR.@
MS^3;JZL ]H#S/J1G+>"-[@%G,9U8VHL-'C*%]*2HKRM_7>.>8K?=H^7-])NV
MY<!-%F1$\:QC@E%&I:(,-R\"K*: >*,(WZ./E*LGKJ@*"AJ&WNU6:786'/(,
MOR5!E24FOXM(UAI%2%"L.6(VVH,1^"31;:H#M9.. <[ADZDXOD<<W[,39P<%
MG@XN#9Y:-=1HS"OW<>IWV,&E)Q#5(NAJ7A.A2#1E)=T0=WBG[X*]DKT/7RE-
M7,%5LIMOFWU\HIKHA[1=A'_<U85.Q]<R.^B0J5PG33'4CM FTCD$W0L#61U+
MM=F7[WG!QZ"/_%R/YL=\<0/[!?9H9PV'MA(*6>RRPR;5Z'@%U-#:I[8,5.>&
M[9D6[N.KW_M3;@F+^!+PV(%'TM&=RP2/^*1N<WJ+J4#/$:U+W=SC7Q&7P3&@
M^NGGF]Q/*C]W2 ^=FX:$XM4:#R2HQYBYSO0'GR2HBL4YBT<W5IB:4C3Y)0$!
M&Q(\9&)7;8C=O>X.^BM"AV,WBX=!:KOT-*_:O""M>@#6+P\54%= JF"!KT(G
M;BVXF&9%TX3LN;<A3MA#\@KW_D:GXI!+%Z' 3NH_BLNEX3NV-E5-X/)67ZG4
M2=+LQER-B?]C/D SR<)@$#%OM9&Z^WT^9[T0A,:G3-[-"/UD!=UQN>RK_BC<
M?W#6(&UDL\5#:QW[H%Y!V/.4(KM'Q:3[K" PQ+8OV"ZO)_[+O7L=40XQU+O1
M]PQG8P*&YW+VFW]Y9/5NJ$:M(H<\Y>+$;#RAO?6BC03UB"/*AN5)PM73K)K.
M<N%^B@Y&Y1$5AY@\N3AF@#FFLWG]4//V'G8W2Y$\[\./ZJ2M(UM'.O'E$F#5
M^S-Z.LB;Q#?:;PJVC?-H&@TG+?CDR?90K)I-43_LV^H%]SB^@!/?YL;(@3((
M<'\\4ETW%%%NZOO8U?%0?<K7GGDKWTO=;OV1/OY/$FQR"4A@.(F;6Y;P982L
MRR-Y0&>%!^!HR)2?*];6YVAV$-?!UA"[CFK)C.,FQM8X@Q]39TG-&X.U/\3Q
M3'LLCP]J3+ENF3DYX'#@D9<K+L<\H)9V)/.A]\CQ>-YGG#FL#SFQ:;'$*G0[
M;3FU#Z<.I?+1/,TX2G09)1 R/'TO=$1L(:+#SAQBBI\%2$\XW[C[8=[61OT'
MGX&U%.4BZ')GC&%3?B/%\_[.+W<UFC@32IM(BC-VB],L6,>834#!AY!1T4=]
MV2P'W6:S5L&[P'"F="UR&\L=!-(;=Q9"C#;MOCI1#LZ"Z"A;R!%17TM0!X>R
MY,,\OII\*3<Z<:_.Y;H[.7-H!?BMBVK/9W2@M<G%7-MVF@:4VI6/YW<VE4*%
MG3@K_J4*@(M6A0K;8X;?UHW7/F6$QA0MVJ67/@BQO>5R,?IR] 6K;SWZ#ND'
M'KDQWQJW(P&;"Q$RBDK3($('F>Q\H$+CJ576MN"")0E*X GI&I62 C9FWK"Q
M>P+:3<=0N_*#3V>T?AGWB7X7S<[8D;[TH["#!2+N%U8N[AQPL9"6GX(@M/\@
M@?0KK]4&9P0!ZS+&)V9O/CP"H=NI.BFKM+'YW!&U]/$O'T4VTYL9>& 7YEV7
M<#UL)[K>>+%\QEQ($@\PM7'+(>I4Z':''6&@)UN7UKGSF!=*)\]MOEW[?KGT
M4,<$Y/9J3W)Q$,^EK_'"Y<LE;[LC2[T^C5/S=*8E*":K:G&V3H*23?5KOFW<
M09"FN7AQ^>'+G) 71>1!#CW%827G<FYIX[7(E1.0G. 4OZ;S3Q6N_*M15<K>
MVL$Y,VR&P1#6(BSW*&&&A;Q=" E61K=7/*\GS#8@='29BP%:<]Q!7[A7W&>K
MXFSYTE_H?X$\RL7?"%.)D'NYO_G5>8\-<F^ZKRY\[4K'LU^Q($/-Y(S/\%8$
M]X0.IZ,[-;&2L ;VA"X^_%P[V%27>3[;IMD*LN;Z[OG2JG"USFVBZZ'7U-MS
M^SV/Q=K<:%_VXR8/#1DB&M8^(-Q+UFS#Z4#*" M4!Z-F.=P9);_NHXU0:KEX
M8.9^2+[)0&!%1V<\%U@C'B@\##;_F6 ?S3!G1.A:MN:D9S_L76^72QQ[$7:7
MV8]?R62/DJ -SFF;$GB[I G)X4,0_Z*#[=9XT'/NK'"S[Z>,]Z>8*1\&!EN(
M"@M*1T[Z!%?N^4)LM_7(F)C4Z:S>F_6F+9[7"VW]QK8I_"A!M5:(F#@+R/$"
M?98)YE-405([8.C%L6D%(&>8!%;-&:T;X01N%?UQTN'Q"^WQ\H:NBWR:=*O>
M<^PX@9!Q >P6S$*ZW$^9SVL 77@+?[ZMU(@V%WZMF-:V]+'#L/;B&?TGF]?7
M';08F[V>H.;S X4O(,D"+<5$<"]+:=V[$2!P/@EQ*+^[6$U03@L=*0&5Z4'W
M:_9ONI;+64QM7"UV:GQ ND,N<DEX>C.+R^4^=PZBGR!;BI6FI<71(:4[86BQ
MO! \ TWH.*[CY[%H5/TR'9-71W[,\-&=?B8^=Z;;)U-O_C)DT%['_>#NB>E0
M0#Q4"1X\R;K:\Y&B#GT&;18*7UR'547%.%-(]OW>;];OXL1;Z(F (B^%4!,L
ML#SYX*1#V"7!MB[SKK$/^?UQ AEIX6,)*M#]&S(V@(F+/GW?[X2;L<&ZN0D.
M)F5)ZY?$D2]N7<^\L[O2J-^P$8OR%\.GUB:%VI:;%UV8WC-M^ 0E02$]AR@!
MRV3G8M :&&@/P*:S*J(2BJ^%#4<J60K.0-@UC,W5?_2&&HY43RE<\1:$1B=G
MR<]C W,V__)BPP9E 2$>-N8098)J\[5!8@(%ST&O>1/-/-7G@"T,'I=-#?BX
M?]!5X&IZH+:ZHO;;_:@LHI',-X-+-[^^.B!!;0.@<"SD@!=$M(:*%45/K2?U
MGBD#QDGX,Q@Y2G#_#>T0&6PIN;.-34HEF=TY6Z)_I1FO^J:VS(P<VL!Z_/+W
M ](Z%6>DW]. P(;<RW@:L (G-WV=H'YO"*\#G.M-(2I91]\N<L^P]W+ \N83
M1FK'_THMG/Y\?N"S9A:?8%3R-;CNP%D9C5V8SY^=@+S$-A:$T^2=R_F=T0%
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M(;9#HA/8>^E@B.P88_10&. ZI!0[E6OO>*GV_L;?PL)NM+Q2#ON^Q60%_L!
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M*-BM8W;P 4+%G/HC2$J?M<.O<2:-#_5%F&N_9+GV?W?5:!UU&; JMWMM&#N
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M1$&8H>QAZ=I ]?"UYHW4(7PM-O5<FM<]XNIIYDI8(?#"+XW;]NHI$3A8FL7
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M/&)RK?#O7E!72U"3SHA_JN&]%%;^F^1+/^6G_*<*+-URU2%!O:B$-,7==0G
M A$F,$:V_.WU.^A+?_OAA"(MW]XG0=TRA$PEJ$B,!.4Q2C/]\O*_G0O^E/][
MY7\$S_\I/^5?RT]R^U/^^>4I49L\TX)1@G=>X<XG4;>"C*N-F^^;7'%I%UOQ
MU]SDD-#!GQQ_"9T+/=E8,1BF]L!>-O_#+WNVOE;C/6!\VX-0A#_]X #DEW0Q
MN%-#@@(/,;7AL)'FM=(S7 IB(S*=8WNMVCDT-4^US88I+]8,;7: Z+PKIBWU
MZ87W@O4V0*7\+<(VL4%_HSU7J_S=$YIC$YB96GN/,[FLXXW<HC2KRBS2?H'X
M!1,\UAL?15<'SC'40GYM*2;3?, /A6QTDBN'B*8<'Z0[NN[\,,* E0K)C/;Q
M>'HB5H*J/N-KZODD:SLI7R?3B6C\0:3"^"JM8TL!6C3Q[+OX:NPL4V@/M#CA
MV;?U3$8MFG=\8E9C.K HJ.S0('4CV9BC40'>;M9[0[[H+OV(K03U=N#,P+[1
M:KJ*4N QD)GBL%FI]MX5Q;)37[U#<>M'(Y]$H.>_B5>G2E K945W 78>$]RW
MTT?P)W3K'N39AJ]]O]C*BJ<K9+OV&PQ2'-D]"@(ZE';Z/AGHH.J#7]XU#EB'
MR;5$;>81DJ:T!AES\U8BMXFVF/"TLO%N4F24+HKZDDSGTMLP,M-+A$0XD(]Y
M1E4>K9G_L>Q3OC$?2*S6)7J+/F9*4"IYMNY#8=A(S-1-S-)Z2^JW=\*WGM'$
M]Q?^%W^+H^"#B)!Y\>P$GR=>O9)O+V .-6+Y^ Z6<F-D 8PG)>%4AG$FH41M
MRF5.D^6AH4BF*NPHK364;A7FV):/&8)WES!BRTD/OS/50CQ4@Y<>/1P/?1,T
M3DTM%Q<!+7< T U()_#CN'18I5=PE1_.Y.(5R2[/M#^F 8$3: V_G@?3=(4%
M9D*]*"&1C^:LH0'ZOB>[.*%SIB<DJ.NWG/KR9X/R-9Z X0T:R>M7M+OM8F-8
M(NG^/JKT6\T9">K=&$5!@@J8:,,O,<3&HS/J?_^//KD&X&]BK6;5_V\;@_[C
M0J2SZJ+F:%SBF/8@)ZTWT4'G+KFI,?H"%[(8]6$.F3E=!=_ZZ63(UMIL.73_
MW4Q&\M[&#;$[Z=$E*[[+IGPCQ.'L&B Z>(M#;[\L5+ABL=A%70G6I89_GS@0
MD#/2^I'8_W!A1[GY^S_EBV*G7+)2C/^(OI&B +>/WNO[^T2T_Q%1_Q$M_%7,
MHF)%?U"-R&>?Y>N!<@FP5S"#K-';446<L<LO#;A(NGB1 24ZA^[G51Q3W541
MU'](ETGVSW'";RE'4>_VN\]^M+7)JC.[Z\V=DG\9N_^8F<O&(P2#Y6]DONXJ
M^Z_(J$GU@D]),WY ;9SBN?A[XAX;/+K1NO133.*-9@UR .P:53K]^W1_"W_Y
M1.NW*5_SHBWG7XU'CW[P\3?V+YC"VF;%H$2'"OY+: )<!6)A-;E./7-1-8D9
M,$%/G-*N[@O#;:0X@6>@^TJ$XU=\YRCJI[F7NWU&JFY2VXV;PF35GMS 6%@_
M^;WK):+/^_\U64BI7N)V/'@$LXXZ3%>'=X/?VC&(SCCVYCJ<+^6\[36Z.L>&
ML>'WZP<;#W!V*ID5I2SL=9&Y24X)'G?"G<H8-\28-OV78?N/BR?(0NSS(F(&
MH_ AK!OXFG@6K%8FEJ>5OKC(3_2K!Q=3<8:P6;_#!<TV0K*W9SMK9?"(C;=G
M!S-6;#FT4(YV%@\,54]J'LKV!CFC%.M'8^1<5[OYA$<.SI>YE\MM]XK?F4*:
M4(L$):< M#CBV7\106_&>O%K)GAD+ESWF$ ?9+;WK@M^_ DG#V'9::;MB)];
M[G!A3;'QL_DT/=W1V>_O^=CD"<<J>EM]W8V(26Q[MDOTA6+R?&M?\ !$/U0W
M,/L,KRA!L6E,\%?&G ]BU&]!T1Q:W"AK9:,^'Q#8\SW;"6O)G5=,O?IK&*O(
MWT-L!X)M]';40T3^GH$+'-&>K_UA9GJ+^_BVB91CP>KO+@FV3I$OD SK&9^*
MQ6NJ1*5B7?$H$=Q+?'-6D +IEOM.XU>)\<AH4'2(+FB:[@A\N'LMI"!T+!*O
MXYMG9DXNY#UB<G9>%GKNXGMDJHM$C_*X>;+<*9TR9H53!/"GJ00UD2@X0H!L
M;[4R'Z^<:^I* T)[7 0LOF8G@ [N(Y/<74C7<4IU%0/GW_/C>U,M9LN_Y^:Y
M="Z%AHB5!ALM[_A-U_4&7RD)R?FN?>B2]^8A">H><YP@EB?QN43(ZAC;MB7L
M<HO=9%=7[]B?QG/%MFVEYDJCR=^OH-LE*-5F,VBFPWOU"91%=0^IA25#W3XS
MOI@4H<(H;2F%+GOUC0]-OZI]L&Q)*$')WO/V0O39LA9Q(3_*_3WS):A.8G7
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M'41:" 5:73&)O(DZL3)>410W2WSC-5F_.(</Z32';_2(]($V<_$KYO=P^G(
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M"X.S T1\XF52?61#M>EU1E[V88;YI=RO[S:7EUGX]H5KKR[L"P\TF7-,L3X
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M4SDL2W^!9.\9=,K5HQH%(*'/\$#(%]Z.6HXK@UM4*(-M [6+8/BSNAR>37D
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M9U37*.[(!;.)?S4G6 S18#ZY$CICM8ENA! 5O"3'\0)3_A/TAP%F>=6'LY:
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MTT+@X,HP I1]QO&[:2?%.9CSI[0RKJG!17U76Q@3Z&% (XV,<VP:>H3F*'G
M?9\N_0NF)W@.?2R4IK%CE1U9#LJ?P#Z!1R$=B6K?4SL84U(TJ*K^<X9&/,DY
MB=HMW!@"&?3$>8*9.UG.1+X5H\:?#R%Q,I+A[WW,STBT')>Q5#WAE@AL5=^G
MG&"[5G.=ZQQG1DY-KO+=^LKX R.+^(AK1T#82_#Y@.,,*Z9;,REC(BYD]4&(
MBIK,49&MQT$SS /=C?!=VGBI/*M84@K)!,]65H;\-?R9BY/EFO93<UN_ $2V
M'3_2/%R4<+&E[E #I%@QX^$[NSNW:6ZE64[RDTW[8>H*4*:F2FCJ*P.HO68S
M]M>5$PN9XJWQ8=FUYV]$7BF.%%573]5"I?)+#;+9KG(!56%7(O)Z',0^,;"Y
M2^!YNF#MOK_GZ*)QCXM'JVJ>@5#_0-$B;3_;#GD$S1.4<2+Z(O04<DR11\9%
MKCYG,T+;#;=?8P<__.N?T?P-$)CF.)[@M[_?_J<G)K!]Y]TW-)OJON]"_#L_
M!80,#W_8X[@=BP2:P@'9$VP9#F0^G#;,!AD%H@M8I4K/C(JSD.W$1P@,R!^?
M$+H@]R]'?*THY =$9E]RK406-]Y;A!Y1YF98:+=ZY^YTG"?H#C%R/%/=_1Z\
MSV=@RS_*R_>HM^*#;L7^[-#0QO6A$>H-L/+\$YBF2"Y6CA[SIAH(+,NC.'9(
M331ZR')OSD'$MNG*3'Y>0O'[%B=]>\>B7OYZ\R1!%U=6KWX#9^/ @>Q,40[B
MPE,][N7N):.]8V KAO!:/0';-F=X#U\P\0U@IDS;QQ]%@F7O)FU<3*E0)<61
M=<<;2)6:A&>&4%-0TN,.^<4RLII^]7$= ?N3*GNO0K:1%NZ%+V4AH9I#K$'U
M'8C:""Z) I>BER%-,V9:BY#D/!+"H(&]J+]<91@ER92@(1Y(+NSP:>P?B[RM
M'[8][JV8+K&^]LE_<NK,F=O4T65@,A79/HL=($[B9!F6* .Q LX._M2O___W
MU/F_?>8)W],0#P [ZJEQ H9^8^%0X"=N'YLG^-1AZT'9)S&R,1LUL<-T3V@B
M4!.D0V/-W@*U<]T7R\ A0"1=*=CUE &88):(^:?!-G.@%<@(V5KW+.,G&$B-
MR=H]MJ2;[?<P2$\3?WG;B/=]^YY0#\&7JZ0A53/S7QM GSK!0USF"4<ZG<$,
M$K)3A1FL@;DBNBDK&UMQ'^>*\8&90/!F3KD$I2*S<&GC]81C+1R# ?:>6B_F
M-7#IVYL.L2LHVT(Z$TSO*\0FD5LE_.O,*;/F_-7#N.N9Q!4EGMC!O#7;.!Y(
MH'H'DO*8(\ZQ2>9K?")XE=FICK3$'(>"IQ&7S+W1R&HD[D(ALB[*M>)5+%..
M3)>2UCKD700\M)*3':'1WT7J_OD*#Q79 &AZ085^(28*-X[B((1N@"1$7;9_
M#_L@MJ-':(N$JZN0P ?LW3THW>;OG$2DU ?.OP.;][9<LK)F_%O8X/JAJ-#@
M\?F/MY63%$;E;\11*:8OQE$M]HPVF?ZC]B48';VUX[B6/Y-GKOCO4NRPV\/'
M>ZEGM78MEU9)Q@)J7B48OP\8IYK'YFW&*T&8TW:YBO?-J)\D_VY8;"DCX&X_
M=N<Y+DNSL6X&U(NMX$.]:J"7O_(*'@\WS6XD"F<.VJH7%JH44&>Z0TIB73^]
MRGG\3KAR$#G\T'9_DH_T/V\J6\^1\-]:+O35O@9TB[%!O/JJ]1FXM9KD2'"J
M\ -DV3SH, GYUA,U\<966$0_02U>P7X3@9IM2*#<X(G&$_4=P+:Q;2[1UXYA
ME*X9L81XB&(\(-S0"MNUFKGR;E#6LBSVFZOOR^U_MO?S[?^<\P/9OJRB^ 'Q
M"ZY!VC4_M&HV<9J %Z0)V;F!]F.(MX:*.D*#Z8J3:($+-U#DZUK<XOW5=%%:
M-<TRRFICW\CF]W##L+4@LW#X:R]F$#%/^'T=]D&J)B_<JAS(0>SI]?W_'L$+
MO5Y[3[B#(P$A;YZ$K_Y9FX]ZG%: F523*FZR<_[*+B>J8830]'E?."1N4R7G
M._4/*$/@U5-YCR(54M&(17]%-Y^YP?_C-?O3Y ONVU_JR,3H6AQ -NMI_.8)
M0]+WP-@?2# =#U53 B"[!T(T)K+%LEW$1P)Y-69-]'=*]6LH.*LX$5N+2-N$
MKLB%\%@E;262$OR<YX-<5C)30C;#<3<$>Q0?*#X,_UL"G8L/QN;.ES]DC&Q]
MQ8B8&0X^ZV.J\L;TLW!P_04;H$(^Y*$=2E4S3Z)JE)"OH@RE6+*9F1IBWEM%
MLT"\VWUG\TV!9.%22#+268)0??LGSGURK4DI:5+;/5'4K="E?;S\?<ODUW9T
M72Q>;P2D%H_15KP& <E7]<Y!@5T1IY>JCYHQH=E6[!OXO(!M&0:[-9LOJWR*
M<)L"BF^P3]ZC%7\!5[EO+V5(.C.HZ<R8!K.@+@?'QPMM$7Y\!>7E50@6(3KX
ML%X+79+9"5K<-<GR@55@)'>X ]/=HZ1)?L:_>4Q9B@1J-J(&M3"IQ8/>-.>7
M*DB =S0'+(']QX#5Z)Y28=KC+_.$E1OA[/1")$%&UAO]!H\S41+DHTB+B3;]
MI_>XMA"OI&\Q<T8(27N-&BE.-\\2U-316[B2A\%Z(NS7N@2A6"X5D9;:JY^<
M6_N-]YDY?@8_YF[^#Z18=59)X(O] T-W_J&WT*%]9.0'_-S"GJ*VR,)=?E.D
MH(2U0T82Z1_4FW1KG2>LY;BPC9&LHDC//U_V\MU]<#Q8A/!;*5L0'KQ1ZIFC
M[M@W@-EX198( @H'<LDW'0,M:;Y_  F\9_.$B8M0AGH)GH>&V&MPB3TY%"(V
MTXA>1;N>CDTR;5/=_17ZQP[7#[(#E?15[P-$3"8%5$B-HZX4O2JQKS(\.>2A
MB*P+KLZ_&QH:?G[13.Q"DXG_Y0-DVZ*K0S%?#32KS9\GH*N&YPDGBB< ^I@+
MO;EX4H6GA3L^<YGL.#RX:8X \BU51+\A-!V@AG70)(EJ8R27FG4>LT-=>IR2
M(*!1M01[6T=N8<"R3EK+I9&MD=-9>^2J])^KGP5_.Q+5$;:R[IS+]A&)XP/2
M!^^Z_5F;,DM2RZ:FFHX8[3I[]NSZK25+*E<1"+=_L4/QR98)J% 0+U,*'5%E
MK0*:;/!O[JJ%W\+@5318,2HT0_? Q2(_%RL;;0G[Q,JO34]9BQNO)/T'%IV&
MK+TT-A.8'7R\MB:'R3VWS4G?\TC?-LKJR-DXC@/6@8_TC$JD,L!,.G0(E-!D
MX@FG@N%QH(K61M;%D7VEX[(Z."X%)5K=D:G6,B0A=^!CQ[@M(9OZ8P(M+#XA
MX2[IT^5;3Y(5??8SP8?^4K\.\0XB?FU&]N&<TX]7OXA>.9LY*;1&ET&QLTWD
MU$N^+G-A/"[%B/,.-.!8L-[V^O2?UC@_*0[$G0IH[!C\JY[E0>FLF?H6W:;A
M;VK=RYM[_XU8K,&'NXX[G>6"A;NXV4A8"?L@<C?A,7N7MEKH@/S<>P#)509O
M$^!HPI![59R+O<\Q9+ODL^3YJH/!(:)#0IB;89LL4;:YOKU5Y&YZR=R96S0,
M_NV"6DXJ/M#52=H'@.RN%/I)M81^0+@9Z89/(1W^SS/8_^QYPO:&LY.%WZ ;
M^@;:OM\K#/Y4 (=Y=UBLVWMTF>[@CVBI9CO0]!TH&^<OQWIXE8/IV/><'E+U
M^5(H141:QS%FI2@JLLOP0/P4RS6--,\6)9BUURTK5.;J^S7WL"_T&;?417].
MMJ_VCE<1&Y+^83B_\"YVROOSU7?@N*J%AFQF3M9KO("F3KS  28MD[1DGO""
M>IH\5-PT9W 7 A24 MA:;O6$FL9$]:'L "$D,,U?U(W&/V4?Z';G2ZP59FGH
ML7 'OJR38E3\9?>G*>\MU7:73A''+(DB[E7ZBI_-)/=2((V<W,1->=9ZH91Q
M):GFCER\%/5 $N1]:?S8X$.PK*IW&B B<5Y?SZO.GTG78WA[YOCNW>WY;P70
M=)@J*^95?T;7!6J"6!>Q%;WX_'R"^.F@/'M2</AL3]6OLQQ+JAE5;M$7C5.N
M4M7>L+> OIR]'F+?'AX3KH;:RKC:__1$YKSE%T>!1C/TE:Q0$?B.A*[ST7S/
M&:'7I$P8@"\&)RSDEM06;#U2#A]KSH"KQBA4B"OZ,B@;3(IV HQ]'NYYPN('
M=?6,^0 *_91K^A^K,P<W*_?U.B50YCZ4S:Q=A&WF+ >:ZG"C_ZOM1&?I.&>]
M-K<,#=90QC&;WM/= L\*MJ&V5F &/?(;G,Y@%#;4]E0W>#<"JV/T/OCY7)\Q
MG;*P&/U<G3[J*]_H_^,OB[1?@"8+0/8;;^G"RE92Y>^X\V"OY>1[((.PS33=
MD-,%F)_?EI4EOHGZ/ X8V??XRY6E-[C;ZD@B\=(L/[]JZ&;&MLI@04X^OV*L
MTNOIN)\7$8J[_#.O<A:U1$:5O\0<B,49\^\K;V@7R4-=NS3[QK=4L!RFO,[G
M.WE'^Y+3S?7?_=R\N:;!:O^7G.^ 4%!VEP0=DB(_A,L^HR9$]3DD6Q/-9FL+
MV8$:>Y9?R\CF>J1>+K4 FG;-T#,PT[[I>#!%2.YU9%4#R;.D-0)/8OKIC%8_
MB?X;9^Y#>H;WR^B9#>NBS]AF3%"1G9Z8OA2YB^/_(J08-Y;#V6H2?"E#3I5T
MB.9H-ZJ(%BPS^N!F*#JEI0-8]G8C%'=3L 7^9HLS:X\B+O&<\:&>6[';PQ\Q
MKAAD/>J(KF#%!T#3%Y _%N,$F/A.$/KP)%X>KM2SY)2O[W$V;9'6\%/8H84!
MIH>_?LE?BJR%17L'ITZL>-_!2("-14=V?+NU"%YL&+QCSAK'F$J6SE&(C!K9
MJ@_S3M0PW$!+!FD=RK[7L\_Q6);+2>0CK$/K=@A;]1_7L8#-W.*HFMO-IFMC
M-..>B_+RAO_]C8:L]T37K<4O;2_2#]W&N:X!OJ1IHNH(3;PN%P0BTG; E&.(
M'H--,V2:6X6O%7K<9"L"XJ309WH*X93,0<^><RJVIS*#1QS+[HFL"<A.Y\=N
M?WPR<A#X$@N%R\VN"@FH-1(.N<G/IIDE8Q;H1L@V2;B.9;$G+9,W)#2#+F6$
M/_@RT!OTW:J0X R+-2%S6,*@RRS78[+W]07WBD:K[/^U^P_]TPJ\)O&ZO/N:
M8@T,+;QJWW02G%FF?6&GI8PC#&TZ59:*U\414B()^M4L$\_GAU)#BC%"/ZC]
M?88KD:HQY/EI908S'32(]3E+7\*^ M5.;BA$=_3E-KD"J17N_JO;GE^&S9IO
M?1CMB;1+>%0^W1/U2T#AW>&]B[0U+&G;B!'"D$EQZ0+/$U*G 1W$HG'$<@#G
M=>)J)'E.?\=N2)K,]BA^'U7WZ559E(O#/77 ^>PBR?N1D: WX^N^VSW5_@WX
MAH_IGL:GR5Z+*P?9W\1A/1$)H@&(+9C$IC$T#N]8^8&@ >O\)_S8"F^EZH>(
MK HT>SE=<[]?>)._&@F7'W,T3TER)Y>T_U*WX56OPU35)$-QMEJN7>R%-8$R
M)7'HHEJMK:&>MG13G]0FHJ0BY-%Q7,4$BORHZX:/(8ER4@K,NR$D5O8)/*,?
M>,8K.N-WIVLT<0I+_G7^^?*)D8D:GEQ3'_CGT@;U&&9'P:5>4ST(_4J;>/V$
M(1%/#.MD@N&=H:W.SCGA:3/,:_.$VH4V'F,AUKWG'#;5/^^M'E<M8OMV.53'
M6]@]"7M55=5G\[*V]N5MKX*L39=^7J2= )JL%IZO+\8/O$H>:D=>Y$/*PG:P
M?PPV"](^P%Q"_!.XQY$,18.#9'1;3(-5YXB_.Q52->L_B;J7KP=UY?C;*\&^
MV+P Q2Q]H#IP",P1(UM5MS0<H*D/9W_@73,)R661U<&]F!E2JC#-U$R=VU_\
M, M0UR+7&"4/IY)[Q"W@2K8;)!4-+AKX(>PVZZ%FU^U/;W=6_7^'/U-TQ&80
M-791?^BBRNJHT&'<@VT!)XLA&K::E\A9WPY316"E_ML%'B3=K-8/W06'<ZOT
M]9KJLM]1UK%FVUQK4U3N9,BNT=4OQ>$A;)]_PX:^6LQDG/L:$+0+#ZL]IP>L
M2FF2#IG)Z"U\B9M2E;E-H _QY+04!W<O12<'6AMF^/A60*1D_ZV?;P0QK*QA
M@_*+H0\0QIY*8D+Y>-U-7N'0_EF7(T_F"3OH6:0U>'X^P.OIDLODO\7H)L3E
M<11)#SBCNB&YU1]CJ1.0,P8DSQ,JYPFBX?$GTZ\Y#NCI^I[W_DB[DIZU[92@
MJLN=>MH]V_A ;8@A%%-#L>@5A"NW $^(R ^?U3C[7[^'YY67.U&S UVL31=:
M?<'UCXN<:L@2*8"VQ%+T*$2ZZN<+SS04Y<FER::;.UJ%-MWGG>SH!E\D7"[_
MX_: #_Y.G\#3MKF6 _^Y#OY!O4Z"?N0A/XC59WN<0"+6*9EM)0W-_@@[%!I4
M*CR(LI3)&;DJR7P_6#H<4'Y76%H^*ER,@ _\H^I^-SU0\YN4OLNCS_=IS>C6
MEF\(Q.F]^!GB KF)0@V7(IOC)CKDY"&N.JZ[8GU73-KC0312:1_^9VX;R03;
M&.5[R5FX 4E2NKU;M;-HP.E,;UG9Y+;HT(R?NASMJ5Z0FLMD%D5>>DY\Q4#^
MQH<UXHBH$)TW-*B6]+,!' O(N%";;<=C^5BZ6'!9/FZOIZ!/UI=@7?F6M#1S
M;JH[\:(\=QI:/=A*7M-J4,@LC,0VW1QN67S K_=A_J=W(;N=OKD#A,8LPD[Q
MH# :6NBB_*S]0Z>5JHW@#_F"O5-@,H@XAV/+N?A_+2RN.,<9(9ER?L &Y@DK
M4+*,EF)EI[WM?AGB[>V?IN'HR+X8=U&9$*<D-=+71-:=RZ'=<-]7.N:K_AI!
M60+;]([M&+;)_-Z_-7K;^(6XZ'7@^\+_>;. BYC]/.&67PMN\,>I<^=?\;]N
MPCEU*_!Q"TBB3C12MLP3QO=Q_JK&_I._O@HW-;L&)J*/>W1.W7H2$%@0]N/7
M]T.=*P\&IQ[7MR[9UK(U\?:/2P;AA;<ZW^ S:+1 !+BOY@Z+%.)VJD0JIR:A
M*R!E*_#"DTLQ_I(C3(/]Y.*;YZ?8S HT%-%3ZKOXW/&"4E*K$PZ.C$3K-.9O
MJDO8'W_F>;+WSO+"O/,.DX]^7ZQ9HRVA1O(3J<_%C?0TH(HWN4@Q3E^"?HL<
MDP]S#9%<_[R]L]D6(6[!Y%U=,3*XLYSUJ*6NNO5>HCQ/MT_+/SGHI&=)6>DN
MST;%PLWL0_BTX.35-$2O[2/I"]>>'*/K F=X-^8>NU;D%8SYN60#NO.$<&I*
MW&#<E3/ *J'-ZU#[ZFPNQ0T9:/8X.+RG)_I,L/>)?#=<OB$A/L0F<W*ZP"M,
M2P6:Q !$ Y$MV:A)L8A7:=LH?B>2?TI1J*Z'Z/2[GX;=%%(UV$I*P1:;@RW%
MU\4B.M'^\7,82)V.'T;8=O(.T"*HU;Z\JL:>FL'-M7L_M'L]%H8MQ\]U,57V
MF3Z4NV^ [:)Q05(4O FM7&HT=FL\?T,793DFS2<A1QZ.U_7YWCJYKW3<E7X5
M(W]Q=BUZ8IGYW9!G"5YNDH!]JU^\V9!E2  >QJ'&4O5R9&&9X#MM-JJOL>>(
M)6%](6N@=EX9ZU'KE?9;MNF8#;JK7U9%6UB.E=0ON"!R?E7Q.BQRI>] =WOQ
MEQR;Y%OR#YLM$FP//+]._=M/'66(PS0H@TD26P7?'!1)W]DVY[OUQOQQUOYB
M<< X::G X@&GD_QSY?/M"17$+)XA2E=F.8PL-K9ONV/?7#8>&K<-/ (TZ8,_
M2Y&=>NI@;2FV&:4M/"-D']0^X.Q 5].&,A2^7!D/5X!&U/-[8*GG@-#QM4*<
M/->>:!\S3]##;9,XK2J8& 1V5]%,(TTIV_O*8S3VYO8'IR0JOQ?5?47&\4S4
M K>%2X3:%]2?04-L!*CB3N*X*R0F2ZNHDYZPK6A'Y#VR4IP,&/(=V#]$)RA)
M5JSAE@MC^/@X#N59_44T0Y3M1_9<*(ZZ(@BHS94-QQ>_N#D0&)_;2'S/0[YM
M1TUL9;:H,5E-A[,G/>#9H_>G\U8_[!(09<$;XX_#<:WTU)S'9M^SXAJMC*Z/
M7G<N*,D-S)T\=O2N58<HW[)WAFLT]N.[T8NX3LWC3ORK<5G8> "OJG'N,*^%
M3A*Z(3Q?)$QCRW8:S-TS*#A1[!E+%8FOAQB^<I:4US9*KYJ;EG":%+1TUY$_
MZL)FTV.'_RAD %7^B%1A,E5+,8 J:C4+C][M@:9O%]Z\)T''J1)0?ARL9#;S
M]9%*=0A"@O+U;9MXDGG"&N$:9.<(Z@,7E<>6LG^"U^40T] 316.CCG.7\F3
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MOGG^Q3.5!5"QB*<JH$5FO-_J=T/J'P_GMX>V9+;_T]+']MSZNT?LB= I\+X
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M]_3R Q*5!=_+VWLV$_/^ZK>3#8>^+MIQ_$K?GW?]:*29>])/I3BJB$&A*Y"
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M]T$O<S(;F#G4Q>#"^-U106DGE8 ]$A C/?0@,[A9PE]S,LV[A3M@:BP<HOV
M<'5^^#.7<MPY@X('9/$3HB6K1;U+_QL["LI4O2I6"N:RAG<]A6+%W'R!>8-
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MO0%^HJAH*K\CK&T[]*2A=%\/_TSMCML,,.8Q#.9X_6)6%0TF 4T&@N:NZ@6
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M_T7JM'3J)]78UMZU_+ 4Q_,[XN\,(<1VW[E%26KD#([*V^%BU,9$.:QY0"[
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M5@50_=P*E[Y!_E UE;QW#-0\'/I=BV]C4;_\GV6XXP+6*G#:F2&*_^JY^(A
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M!?W\,6J/DX;3*P5BJ+"14%4+*<%@%5E[](ENHGE&6 GIRG);F1(S/>:=T>4
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MINK?H$5,!^K]G#N96:IK_3$OL^0)HOQ_9]FL($*ISI6=N4I\AJ>O>#ID.=2
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MXJ358_4E!VQ3#1HY%0%1B?'*Y*?RO_D<B/2_2NX\PQEJCV4M8FHY;3TC/JI
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M*=8N8LCH)254R/F;,F%J.ARL4M5I>/S-3"!+@6N7IHPZ0GH 1;ZW)N=G^G[
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M1^H0QP@=B=U)=6#O8(OKLT6$"UP[]I9W3$#I(QUW9>N4M&;Y"F1/=2>1B,'
MY1.5'JG<A2-AC9YQ;]YO]O-X;,M;7+?4>]/U-27Q/E-8\)B7 O(N(X9.454&
M+G68VB)8T=^X2B4W8[^F+:AA+(7#I784PT[MI2-V3=GI->^(-96,O;V5&@\O
MER/5=QWM&^S'0]PJ/P9=B[[><V$.,@<0?0,H;A' PSS8E8%8E:/VX:C)<E"H
M\L^B+(A O#O9&Y!4.!VBBE+:FQOPE_L<E_&[^T7R>>PE,".HJG/*+UPLRRJ\
M'TTQ>=%#]K",'EH(IYY(\QB^G"_-4^H< )VAJYT>,^UJ;/R7:M$_4H(OH81Q
M.T(6-89X4> DA#-!PC'(*2]&J?EQ^&AW<1<2 W9+"OX5E#P=1LE6-VWO_O9Y
M]O?\VA/E<+78T;)>R)@(X8?\I>\SS/ATK1]V5BR]BYB X@+J -$F>(_1UP42
MK'!9V<]/B]H%XC6K0&]5<"YBK*0MI0<> V+I\D44)V0S1,O8Q.>9P[FA=;KX
M>_3[L%I*,>E)6NA!?V/A0(SH]:@,4C^ #2^?1(8.+8"H65ZKYVJ\= FPO\H9
M^RX]>;K +%N"OUI$!>=/-L?9[H,#E>,#3R90:_2-  >9Y165JI;;V7^(;/7N
M/3.1Q#4;]>S5\E18:*@(A-9*WSNNG,4%IJPW^D=GZ! ,B#PQZ,CA")_FBQG9
M0M#7T(_72AC5GC.+J[:NS+JK,+0-,*%L@UL5K9F";<C*+A:QG!E+S$CNGW&^
M@GC<>\-CGI:+4;L>MGT$_+?6;\%;/VI(QR>&^TU55'_BY,<U6A)VBDE,6Z>I
MF-$7Q@$G>+)MVGGP+>@^8^[XS%L.^"42'E42KE$LX7NE'YC<[WN3F*PM#Y@U
MT?4?>5(S(UULVIYI4?=ND['J&(OVLAC!^IY&:MSOTONSN-(/V%RC49]-(I94
MU,0# Q!B[&(5G,%)[6-]P11UH$+AD\/> MNJZEH *SH7G\3+%"SM17:"@WX@
M7W 1 PW43'*,%R\727X$B_> MW.5=\-;M,_&9OPRIE.&<QO]*U]5VD<8A:!Y
M5 4X>6D6MTSP#6"(/U&<Q8@U[ \1#<Q%[NV#+LVR3Z6&31U#\R ?B1G#OW,5
MO!9J\R\,%6#AO#2V7UMP-'@F,_/7@DQIX[G+R6E19[H7/3GN@]9@*.GO:=0L
M$ Z%=BHFL5JRV=$4?@$.MW)-R2>,6_WS4JX.6<(<)7X)DR#I&)V>>7MG;=[7
M>OSE&@WQZ+6W4TN'NCYJ]MJN?]S1D.D$+).#(8R!9.U'PP-S0!0GV,@>9,^%
MUZB] '$P@9\DU'! 6]4C%A7RR467,#$E1D*W.)(6L#4GB8H_\$Q,N:PVU7B+
M*&Y@Z:<ZI7SIL?#=^GMEI65Y/#@YJ'X6%UR/90Y9NM)'@U6/QBZ889=07+BR
M.B4A"X@2#IJ*J#6M.>0 G9MW$JA6D41"W ?J19:EHJ'2)MS7/\>3<P4)?  [
MM\Y0.>PUK!T-T(_C=D-Y<:I4)G\#NS=949%KA:8(CU/A#23$)AU=:*IDY%"K
M:->$QS'$?U.IF;XZY9<JCL3#<K!==34L*AU)?OA[=Y*?KS)*PIGWG6 %E'RI
M\?OD,E':^?*1L/(<A/0X-BAAW-&B+[&B*9S6V#N+ZQDS/'?TE,-K\5C5CA77
M5I.HB?-YW6GD'-R@"T=;A56?^)"+'YP/%<B](48+\0)FB[1B.#3QC;TOO!ST
M5YKS>#F(=_'0J*<U)YW(\CM_ZDDHS/#N3LH[(7'<TBM877E+T(1>.1JP:[[5
MO^7?\F_YM_Q;_BW_EG_+O^7?\E\IKYRN+?OK=JC%^OO[;X2>/&6@A*]^M>:9
M2<X5TVU;3!XM<L+YL=-@(6KR!JLKA:!M[DF0>!50W",\J[VH:J-+NJ?,'&=Q
MVESX:'5TO^;GOKQ3JD5J:.]MMD-]W9V#3>G'GG=_?'JALG=,%#N^!:<WOO]<
MB%6_%A0')!0LRU<+,]E>($W2;C1^]DX-;3E661S*5E--8J$-<TJ[D'W*-HWO
M >%5BSFIOJ^.6FP]_Z3K?WXUZH*5;#'"O)G@B39#DW>@YEK#O3%'YTYJ5/O%
M69P-A33N:-<5'_=XBK9DE&9"-N;!7PYW?&UK>!GGFF06UKVKH/GUWR/VT6[Q
M:V[_]&.0-7(>D#"H5>WZ9=.MLSCD&ZZY\!_'"]0ZF0M\NW,6IYCV?X>F]G)H
M^EQAC->V0UO^"!OW@:*:]3]__1;W^?H98I(_?E?GBS]N!#YTV8]S65RB8$\!
MHFU"Q7/Y4Q_$.G):XFBM_U<C34U8S H#!;^@:_H$BUBGP(_9Z>RUSEFKB_JZ
MU)+ZO9YN0I5\(5R\OUK06%?=\Q<HS$W*_6 3JG'JFT@<3//Q*P"-IM#_-</^
M3]A(*P'P;+^(!CO5:3R4[0.%*L*$'/)1#36HJ.D"6UAL?!FQ50D7C:3XU1:J
M.-;,\>;:&??:E+_\F=-]=8[S&QH*$JE13(:F<P'\L7U$J'EAX&\ ?28,_5\G
M#:O9LN%R)>]*(T/1AC=!K*! 9&>'1]R:0Q#Y]BS.#O%5 &8QYW(?C:V7'2[<
MRVVUJ2-]"CXE"2(M8F3?(./8-SII' +HPX,W$<4,>).SF'&59D&Q1QR@5M$@
M(5WP30=KZ<,8 :F_QB%E/+2^/]&V_Y[@6>'NO5FFS%7>#*=DW!]=2UZ?ZY_P
MPED%?[1%K,=1DSI0AR["ZZ@(!9[%0?9*ZE4!<606MX2])08P?HQ0%7?I>SOX
MKCN/])*MU8!=Z^/W'^@/M%7OI'1%;H7SI95N=JJ9H7V48S]'?2Y$%^FQ^I3&
M_I-65ZY)!4]H]W<+3PMSJ0L]>'D%+77*=CQSLL5Q"WB:IVS#+XE!+?L;#Q;'
M!&O#]IX=(Y*N$+^&L+:4>@C ^K>\\D6WXF2A:W!HY8/'FA/!W61JR5B!MBXM
MKG1$MNYN:L78S-V)BOE%=\MB:KN&:/*(/__:M+WO]M.VL^3'>UJMXO]2V*'.
M1$ Q31O88]_V_,PL[D>.;*ZVR^6.BM](\8)38^,UQ;>Z3(OCG-RT?ZM65OWF
M\$%)_%B]Y<@!8^WH/E:;S@7M]K35!.C6&>C9O^(7QPY9@],MPG3!<EA<"ON&
M-%8W]=7XD22R>6&(G8=^ZI=P^]SQD%,VG]OC[W_X./^7.)Z8"J_E(2M>@234
MY+HN)(90!5P0GO:_,HLS)7M7P(26(A)'6D2$@ R/NW;VM/D#X9$?0IINYUG0
M/*1CQS;N7EV7;[]AZ^*ENPC='O_G &0]++1&-[$\8&M0W4*S1;<PU6+ #%V&
M>'5\0@ZJ_5<P&P+KNLA4I<;NS_6W/Z$S'V\9^6[Z118:MF=M4T^2:6[$3O^Z
M>F%#;5T^/*DO%2JFN -&RO[<*9X9^B>W2B@5RH+W=;E%5=="D[FLN%(6#JR[
M7+2\^&@/BW0J53&+NUSDCDI>9+2Y-J+KP?Q,?B54$NQ(J MEC;RD\C>ZP*/Z
M:]A\^CR+>P>H.7DU_G/1;KF1P G]PX)Y1=M]J!K2,2O\X'ZPW*>A@;G*!\K.
M<>>8,2U;/!?\*_Y4]%L> YP.Z=ZD\*\;#_;<=^7]L7#@!SOSIGO,BCV=K !E
M&OT@Y)S5>+!D5#:=S=KW^]CVE)9,7G28]%^>6=<KH^L%7(\6[J,8SS+N649:
M>>QVDN6 /+3=[$U-EWCC3AS]OP'[P?\[.2;,)3,4PCDA(;$"3PC(1&Q+QP0K
MP5E<QM<F7VD!>E/99N8KC=S4&U=#-&6>;OX2TE!=UP@97TYJ&_2R%\]X--Z(
M]7Q;D1Q7'M/73[HI-9TRG/AGU H27D*2Z14T)D&*VD*W;J>K_ !1_<?A3 ^]
MLR2HGI2+;'CPIA@N;Z[GMUQ//F]^5^5O%MOW930%S6:"8RF4XGE]87F5_#_]
M+2XD6?T?V *L FBORQ&K;:CY0[UA;U814.O3 KP;;N%6E;<0<]AK8&R2CCL$
MM[!M(>ZEFC>6H93-\'DE(>?<YYB9<Y6V@PJ;H$BWNNZR\#MS;H^]C0FXO=P2
M1^B-L/Z+BF-[LK;JRU 3A*C_76#&O":7 J8H$29Z0_)+_'?;7=Z/R#3_2@X8
MI UNNE%[MS(FP5T6)"Q^O[FQ,ZG!P?N@X #O3/EEZDIL5,^$8 0W8Q8'^OA;
M(,:@7,*[2%A*V>H/J;TA[8N2]S!!4F37\6/'CZ#9+"[S#'%E3R M;^AOO]U(
M(&-M=?CQ'\,/9KQP^W6.CK^/-:Q;A7:F$#7).B++2/^ O$/Y)K#9#M^*I6QS
MN+R$&1[>4"/H_6I&;?'TJGT65QH;?'O.F4^,3>H7(5$%/0M/)KDN,]F72KC&
MHBN!K"$3*%M"LQ^W*7($:1=8KBJ\'2RD"0&W5F]0F)E8V)1,ZR.>Q/U:T^U>
M:-HPF"\:7&S^[IO?S<NNH!Z4)8!HF/O,L(C^JMQ,L(Q.JYILD6<[+H,O0O;-
M@@5-\%T5;1G31+T/#,I7<98,1-/  N;-;Y^>:[!SR[3^/&XW84,*)@7-)/$'
M:FRKI2L"@5.)N("0HK40,9NU7/DA58JZ]2=R3.' 9MGV<A71DIDOL<LKNWZ/
M">SJ/%/6DY1'#^ME?+S4^EU731-%IIH^+&PLL@_?>6#M\Z(05=YO@ .-#R".
MV3HK9 WTI$XQ.9"N388K=$'O1DBD<T3(\B@45 @2E,,YGRK?KJX'$V=:,Q%
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M&/;2Q0DCTR07JYOR8Z]Q5,'_M*#YOZ.X_#-LZ*<+Q!!AE_R)89"JB)O%(1:
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MC57OAG_H86Z'=X+7NXQS7I;H%GA-V_I6_SMT%NC*C-7[0=>;UL;?V?,XWWJ
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M@R.4?N)&QT+)6[FWY9<)IA%HF?WHRR+FI^= 9:WD-M."3>Y=F5<Z_B=N@DL
M EH=.__N"1P)%%O/FQK]]6OK"OV'=_U+<P]5B]>=*B?<==VY9<>ES0<=X61D
M& ?0/T_9J8GP65 ;99#A>=F,B";Y.M)V_5;^B1K00\C<V4TTAVT'ZFPOA<_T
MO;K^B5L"%5/ U(*07WAA2[?MX2T+Q)OE;]?E\<WZZT97!^I=4O>S9(\$P$E*
MQMCWZ"+]MVIX%<WN\7)I-JZ6/-6D)M!M1/Q-W8.V.EM!5/>:0MKRL@[7[.\E
MI:.6(\'=7Q'K;-<I?M#@?9.'5&.NN.4?@_,=T-+HPB7V) @N2=D=JL<:+D*
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M/K2?*SVI*' Q.2?W4=QAF0 <H\_AB]*'UBW6MX,Y/K BU:4/[0K#\[?W4[;
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MH_ZRH6H4Y15Q1.KHTPG- [MNHO.MATRD$XJ'@*"6#?Z\A#"$;=6,'3H=T#8
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M-O^5_9UG4+;,1OG>10/\UFH8MMH.AAB>#@V+N)ES?L,1.MD4K7[E;E)VZ[C
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MJZL1^P_IO2AR-[WNOJ7R^(/6/1;W/0W-VTVO/GUP?,3#S_W4YG,>9TZM,]7
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M(55Q_O@)KD'SA#%QJ.+7_'>^# G!E%[BZ5S3F)J/_T/K$%+<I53?_3K755$
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M3O;*PYV(PD!,ZX,Q]/"B"SU& !@/C;',NYEN1EE/:GGZ=+DK!-/'U;"Z$].
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M^18C[>Z[T2="MV"K-WW[&^L@*KS.3?/VW[TP89"+-MDX*V'<I8<N9):J?*\
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M05"2@:YEMJZI%^73(-/6[^Y..#M H==%!P5PANJ2K_*]^,4H45P6$M(KJF#
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M[(<D0(N*E-4+%/,#ITF!%QZTWXV*O/)\(MG?LT+?SZ,=PX*J JBCM/'R"6#
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MDU^C\+-;\>:LPS -BL>0;0F#9 )%J4S;1O1$Q6S[-H;8X]YXI#!;#2QC;1C
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MKI>)NMHGMMA_?T([)=S19E(:L9IV#UTS3*_6 /+@QZ7MSV"@C;B2X0%^?AL
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MAT"#'<$JI4M,7N3?#];8I$T_PV:I*U2<J-OE-0*:#O%WH2*\!;H5\8)SI?&
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M^)7$'SVVVYO]-:2^U.]I\]8E\6)WE%MRT?/N2..S_362)&>SLR<"!MN*#U+
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MD>Z=5Y8VNI"?.9[XWCH4RI%*A 2QN8S$0I<R+H'7'RATA7%-W'>6P<0V:]S
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M2!X>#-["DM/TO6_@$G-:/-?<:<E6%RD$.&V&:( "*O:"\WK)2&#IAIXWQ.(
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MH5_Y,MDB3N24LE?LATI$;'B'.6*NCQH\=DE@V@-- <0?B#>#=VA9T1VKFY[
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MN3>*FOYCV&@$#G1((FR?UCU9?EJX1\4UX3D&G"5?OP X842T.0PUF*X!6B(
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MF>6E#*N.5"5GLAP<NRK95?\X2U;$2MU=TB)QW=S44XT;G-6AQ+<37S,"P)/
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MVU@^_\GH(D QA3>(*7+58GA1<8%M,CA5+.P61FH"D:-@N?@,Y"L_T^W*O[R
M>[SL5EJ4V^SQ#:38^R/?7OZAFUL?\#<*S:7582, _\$Z4XF:G4 +C4S3[$,L
M!T3F,$-]65O&<AAEI,^75U<S X)S.]@6CZ#&:>*#B#BU"3-::OFV\])W1YB]
M$H+1RL9EMQ)>5.VJ/-/CD_ ;$?R%.+59<T0GP4U$3 )4E*GW(#T4+E;PA[CJ
MFU!%GLB3+@L6*)VVR)4?,P64RY1:MV>151-NZ 9H66[:?<G94H0,W9F0W)5-
M-.XK-&_U/W/CV%&_7Q=INC4,G/QQ\C3SX6(']HL%'#%C,RX=W\JU^&8YV=AO
MB<UR_@<N:I2R 7MS.._MZ?Z&HS.R=YLV_%:"&AOI/_):]N'4\]$-1:6#LXLT
MP<P :01%6P#$DKYA^NPO"(.P7+$(.0$69'Z)V=B0GD:31MC"YU5.Q-V]ZXK^
MIM/W1HG[^$[5D?D3*L.8D8.?.U?MO /H XH+V 2[3_MK-@ M:[TWH9WR^I!6
MIT@EM_UM:CNE/JNL%-;[:8#L\"".T.#M I[AEL,12E?\2KKL959N%2V,RC#H
M?. +UD?57%_^YU/<URIT12O(N>2B6WYM PACZ@&&JFLU^AHPB1=&/7 2U$Z$
MD;>"7<JE? Z9<C9UM?OV\:;#627GJF,'"AQ->SZW>4@'H&_%^?["811_J*<^
ME_&Z0NT"J?\3*&ZC&:!#%H4A%UT]K4Y/#GCX-H.W5<L$JNVEM+;;SWX<L06C
M)2\X#8UZT\GY*:<[-</+'50\>$/RU! 6X[Y@;KL1,1M U\$TM357?0\^!)6T
MAR(ZN?H3[? UA6Y#YR0<I9(OE\5:>*^&)8JN56,A;$KO;!I)A<\*@(%#CU[5
M Q83>6>5PZL3 8-8_XI8RY$JM3I'8Z:K28]%/GDC;>K]/_LZ!RBGWCJH;;27
M*">]SE L6=]IKR>*5P_#O2I\&V#QIJM\,ME?-?.XYC:PP;*\43FS0L;L#8.P
M,+=T581^+Z%%M )DR?*;57*+UD6?!Q'KNK-059NXGH*8F"D;.5_PR[I4)',D
M 'K?P?G"L#[V%\^ Y0-5_01U3'7<?3UFXW'6JX%L52*/LP@N[/Q=E'X2E%]V
M/?=1<LTU[2.&PPL0&RQI[[Z-ZF.8,\,)8[9%X6SLUY9$0'&]%V@) :)F5C C
ME1VY7[JR  'A.64-+T=<5R!-B_@<TIMPV^C,!ZL FAGL&=&?X) Z';V[FQP>
M7Q'3",$9OKV?9N/UVMBKP"+^BA +M\)\'O U0\'[YWAC.!BDK+D%^HV2$.,Y
M*<UF 1<32/!I!@?N:'Q@!U5S64'KS*JXE"64GVLAWA6$A+T4/-PKF7,/?5#6
M4/9 4LX*@\]'JP+^($6]PC"+D<^6\:9?L">!;1F(621J(  7HP9_:'Y$Y;1&
M8CHEFJ<W1A0P6OB$&+%Q_<Q%]/NP:3/4(F_NBF@5G.L_4,];[O6A"HA)7 ("
M.6=F YXUGU!O["/[5 5:MI)^SL(7B15]7<MBS=AO:&"X./N<;RU=ECQMJ^0M
MBZU;_9M7^;5J5H2VTK7SC.N_/]TL.-3\BNS=:;KZVH%\KGU1%V%(K#MMF24'
M QG#0>HT.%,3R!Z1@S]2<PHL/TZG:2(F!@L(/#VAUZ@^LE.!SXA8U9^82S2+
MRP]DE$T,HLMM-O6Y>E%VOZI_2VK-JXH960)2+R7D$?9 !^Z[OCW52_T;>V[W
M#-VJ)A#)EQFB!E]5&% (P:@>R)< ]2'3#DJ:%8O0[QI/;PVMC_ $!9P\<8SV
MQ\\ACW(EWM\.?#J]+EW27K3Z24SB$Y<7Y>&AY@%)UZU*+RR>S^9OAL607 %,
MS2FSA0QH;I34RKN(KGC21_#/:),3,!_R4U9DV?5'O/Q\,'";$]!>V)Y;YG_?
M*XL'L!K\DP:=HB//_VK[W?#^\8G^KYA=+;V@0XS,9-2@6+.2M4>;GT@T:5&(
MUXA*REB^L/LH_77IDQZA$Y3:TC!?R(R8H:4;TE\T@NV"J*K)"!-H=U-:]<NJ
M*.6,R43R?&#SRXK86,8FO31-,-""<6X%3]RH?GH7V:E]@ &9Q:R409>9Q7L4
M709PQ=%!<M@2&2.]9M9*;K*'H<12E@&SQ"^72DB>%PS<+?QP_55<HTF709[_
M]''!5=+[%Z@^^,_Y[VM$\&Q$&9;S<^ 0R$]E+R6]#E%?A^E\ID;);Y5;,Z]K
MVAXA9GT%2F*N]_;QT/SLZ-2G];>G24%8R)W!T8X=K2D@7$:<5$YZ-.AF0\7#
ML91@/GT*J.N:_HP%FA7L%KD>F:A9P\)0:KH;7*'^'9*WAIO*E042HBQ2V=CV
M.4H!F#'=6RWC&VXIC8(ZDBV)Z<+S99-SOXQ!1\*<GSV 2Y2^@IJCPSZ$;)<
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M^/43/^-JO:>_>]O'!E(?$>,T/\_C7BR"Q^9Q9P%E!'KOTBA@(P/#;Y16C!/
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M5/G*,>J'T3CA&P9%^X"I2\<\RU4@RV@J>EV"[H+"ISNG\:'T):'0]L+[]J\
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M)N( .)WI02JG4(/4_)H)TZ)]6?<C):$-S2TEU943+0N; &-O5YP0.(_.:*=
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M;]2@Y->+M'6!7Q8>(8+8>$W4$I?"A2=K.Q9J?#OER"1XM4);$=-(2 -,*V#
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MOHM%=CZF^P>PR<_@B IZP:SR7+W2-J<K\%+LLYBY68T>?0Q=(:H!!.$T()P
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M'Z W*!XB 7[$]]0F@A&4*\.;TL1- KU]')3#+/T<L;6+AS>'0K_N!1F\Q]$
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M4G)KAF-XXN2']T)':1B]%QT(U<*DZRA!$TA.J^G0:<U.9$!@SM^F\6 ,"9;
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M!S@B6,:4#> A^[@FZI!(1LUDDKE#YT0_0A, 29;=VFE*MT>12"3.@B)1PO;
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MXE"O^4,"2A%%$M(O!:)'IQ:1-<&HR(^@^E)#JFG++2%%S1-%W-42^'B72WB
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MG6)YRCM$[XSHW]LZQ_1>%R!0T_5GIJ-1\0@><J9.,0$+Q>@4!:Q3D#*=^(Z
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MU.;PT6A ;.'P?#/+".OH4?Q^/KIM%CX*O.E8#B?3-<-SR##0)%J25\>2WU[
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M%6?Q?BS5_/NB'MB%8PP;RJLOEMB-%9[H=2W?O-$]WJG/? '3X]X<"#E@)_,
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M+(I[IFM\H 8093X;H$SE,-%/4$<)V-LNS";8]3F[X)8N8,B2]DODTF%HQVY
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M   /              "  45O!@!C<')X+65X,S)?,2YH=&U02P$"% ,4
M" "K@%I:JI(O*/,$   !&@  #P              @ %== 8 8W!R>"UE>#,R
M7S(N:'1M4$L! A0#%     @ JX!:6O%HQ:31Y@8 JV<( !(
M ( !?7D& &EM9S$S-C U,C,Q,U\P+FIP9U!+!08     "  ( .\!  !^8 T
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>cprx-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cprx="http://catalystpharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cprx-20241231.xsd" xlink:type="simple"/>
    <context id="C_83103e7b-d556-4ade-a0c3-b0b5be918a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_890414d1-43e4-4730-a09e-a3e88bcc0421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a4314de-6143-4019-b113-f6c338cc4873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8ad02f07-3470-4aaa-a47f-2bdce2375aba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8b7f00ee-4559-46ef-9b02-67895013d0e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8be25042-7914-4b7c-bafc-23e4b7ab7fdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8dddeb9f-3b04-4e8a-baf5-72e1456394e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_91a9fa46-f095-4873-a0df-54c2ea98d1e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_933bcf2c-5622-4455-af40-79b259c772ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_947bd494-b761-4eb9-88a5-277a61b73354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_96caeb09-9772-4554-9b52-38246d8f8c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9825031d-05c7-4f08-b508-c1c43d16f3d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98bd37e3-3099-4a59-86c5-e3462fe02fee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99496368-5345-4bb0-94b5-aed58a22c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9966f3a4-7e1a-439f-afa1-d3b19802833e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a4f3e35-a536-4dd5-b66f-0ae66fd2a87b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a567032-9b5a-41d1-86f5-591b8c5517a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9b391f02-52d4-4024-84bb-8903cbcabfc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9b84b239-460f-4343-8a55-dd9c8d160502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9c7d03d5-7081-4449-bea0-40e589ce6ecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9deb4c05-1297-4d5e-8b6d-c26fba201c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9df3359d-d215-4d6a-884d-65563f285107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_9e517535-208d-4e79-a8f2-94a3fbd26bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9e6f3d23-def3-4cda-8382-44bd50588fd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0a9bef3-9a5a-46af-831b-722f42e564bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a3c97892-bfc1-4d8c-9b02-7eb288071f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a45b1de6-43f0-4754-959c-bc894267db20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a4930a59-5dbe-484a-931a-7075307c98cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a5b8f9f5-4c42-49ac-89f4-7c6e0c290f71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a6b7ed37-7935-4f83-a2ae-608865c7f8d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a8aa9d09-9937-4de9-a389-d7a12cd901f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a964cbf4-04fb-4e05-a570-316b7877d00d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ab102545-8c8a-4aa6-9552-8b80e35cb031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanThreeHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_abbabfa3-211e-489a-bee1-41937cf8efae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_af98f620-db18-4836-9d81-b2bf497b9325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:DydoPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b0a378e6-1a77-4f91-81cb-13d89217dba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b2fd37e7-0f2e-441c-ae7f-719ef52d29e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b48f2bea-3319-4b24-87f1-db81866524fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b4f3694a-ca49-4caa-8b5c-bca9ff9a1642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b63f6e84-f32c-44aa-b9da-315cc85f2d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:DydoPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bc74c57a-97e8-4b7a-bee2-532bf391aa3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bc793338-3e30-4b0a-b679-9536be9b17ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bd18a35e-b683-418d-b5ad-979c716ec315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bdd6ca59-0c27-40ea-814d-e69687c2f5b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be3b877f-8d5f-446a-ab53-63009d18c5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bffaa182-9732-421b-b5cc-2629dd407967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cprx:PeriodAxis">cprx:CalendarYears2022Through2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_c0079872-347c-4ab4-bd66-e2c441bd5d42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2025-07-11</endDate>
        </period>
    </context>
    <context id="C_c0d78ce3-51fb-44f9-a661-e786541f4b0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c24bf7e7-9d65-4eec-b363-d92095897f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c2b04665-c428-4f48-8bee-660378e215e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="C_c2c87252-f283-4c4a-9b97-9a9c92725e3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c653309b-c27f-47f4-9795-b45c969d5d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c664d775-b622-4767-80ce-109ca450ed44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c8936189-a149-4740-8ce1-e4ecdafa4139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cabcf3fa-e7d3-462b-b114-a34b026905f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_caf83f47-b1bf-467a-bf14-8cd9ab3cfde4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cb022394-9f10-4ba9-855f-2cc8eb1d4d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb97f1c1-6e70-405d-9c80-c07e31f4c5c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc17f402-b8b7-4846-b664-e84632ab2a8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cd25d34a-1eeb-48ca-b321-579fd363c809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cef50498-2b2c-43e6-ac01-77fde9e03dec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d1584098-3050-4148-b6a0-12eb3a9b86ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d1dac2fe-3c70-41e5-b9eb-fad2c7cd29cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d1efe803-2f0e-4a4d-8b0c-2027e98829a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="C_d2c50c06-f8b1-40b0-b95b-16454488f954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d2ced546-d65f-4ccc-95d8-be9078a46d22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d5f3bd21-522f-4b08-969f-7e84f85ab2d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d6459900-9ea0-4176-84e6-0b21db75fa6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d706713c-2b5e-4983-a2c1-f8ebab1d21ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForAdditionalIndicationsAndMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d78b7fcb-31d0-4120-ac5f-6e28497af893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d81a6259-f258-4b87-b123-cf96424bc887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d9995f07-a56a-4e7e-b1c2-377bebd919d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da5c0563-d56c-4b30-a42d-4fb7860e6926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db403975-e67d-4d1a-af52-cc04a99bba23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dc509cd1-e714-4010-a518-68d402172ccd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_de1a8f83-1949-42be-9761-1b0a53274e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dfce6660-3b34-46db-9ab4-b2300eecbdd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e16b26af-4376-4363-969d-d2fd34caf5aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e44cf128-2b29-4334-ac2f-c4e3a37536a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e5da14d5-3dc8-44d1-b668-b38be2324fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e84d3106-1c0a-425f-b8b4-ab83374f00fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_eb917612-49d0-4a60-87c6-e1340f2ed65b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed261f48-f289-44e4-80ec-cbc85f5f3076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_ed459907-b1e1-4660-b88b-b7b539a955c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eecd310a-1107-4709-994f-14fd984abc2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ef0ad7eb-05bd-41b1-a942-fd05ddc204bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0b3fb71-5f08-4d82-8502-0d005079016d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0c5744c-d1f7-4baa-a2c2-36915bc2d3a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f33c6eaf-ab74-4de4-8b0a-b6b2d34223af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f352d976-0ef8-419c-95b8-31914f4eefcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f627f358-1fdf-4532-a83a-c7e61bed5227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f77728b5-2d78-4209-bf9a-e8743612b59d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="C_fa4b3467-673b-4bda-8917-eb88309ffa19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fa8bafc8-49aa-4a6c-ba98-092b8ee3ad87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa9e4eb0-730f-4a45-9ce1-7f135b523329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fc37c6a7-8bf0-4bfc-b756-982c3bbeeb03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fcfa5920-3506-4ee6-bfc9-fd2b01fa5229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd78caae-6fed-4925-9427-26b866495956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cprx:SharePurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_02504fb4-79e0-4668-9486-8cb310c6d004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:RegulatoryFilingMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_02c41411-07f0-46c6-b493-3634436dc399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_037898a6-6cb1-4b19-b864-b48e4e232b6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_044a6030-c57f-4067-b68d-6fdc516643ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanThreeHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_048b05a5-861c-4ff4-b542-3b7c319a55ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_06627fb8-dcb2-4630-a05b-d4177e6132d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_08f6bfdf-0d3b-44a6-a23d-b2f184873fd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_09c65af8-c1b9-4e2d-9312-ab77475df623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b737ad0-5bd1-4089-bd14-fd61307aded2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">cprx:SharePurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0b9ed6e7-8979-43e3-b896-652049c5ff71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0be61b87-8b88-4b7a-bc46-ddfbf3fee93e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d01d582-ddf7-4fdd-a777-e6d1bb59c432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanTwoHundredFiftyMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11716830-bd78-4cfa-b354-d95373de3afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cprx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-09</endDate>
        </period>
    </context>
    <context id="C_120e4417-63cf-4ab5-a1e1-efaa73f03a30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_146fabbe-e017-4017-80bb-681752315fa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_19dd38c4-484b-49fc-ad75-95d8593b80cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementWithBioMarinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-10-26</startDate>
            <endDate>2012-10-26</endDate>
        </period>
    </context>
    <context id="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d817031-5908-4974-887a-064c703e2a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:CollaborationAgreementAxis">cprx:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1ed73abf-99b0-4ef1-a69d-7dabbba940c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-11</startDate>
            <endDate>2025-07-11</endDate>
        </period>
    </context>
    <context id="C_21d5ec19-7e43-465e-bda0-2f4bd1233423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cprx:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21ec373d-d899-4e13-9fd1-cf11cc5ed214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22ae25b7-7b9c-4c4c-babd-143090383ea0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cprx:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_26534ab4-73c0-4cf4-8ab2-a0597988cf75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_26f2b844-3e09-4694-a82c-6a12e2562d12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2a5da979-3b61-43bc-853e-709593328300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:AgreementAxis">cprx:LicenseAndAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cprx:PeriodAxis">cprx:CalendarYear2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_2bf89954-bfc4-463d-a62f-52908e5d72f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2de88c77-0912-47da-84f1-785b1e0068b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2e00963d-e006-4d0f-ac53-ce3876d788ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2e484187-8b25-4de9-82f0-c8be02c5a796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2e53e13a-9358-4ded-8867-b51252e1f076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_2e59e5b9-1570-4e88-8150-2217fe0d9951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3052145c-1aab-4286-a4b8-bb9e3ef1c2a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_322cdd05-3fc8-4285-9f49-2a475c723c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_33d5f74d-1547-4288-8459-e89cc8ac7180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_345c9a15-8b88-4b16-82c6-8b06540097af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_35f0b978-6b4f-4932-a291-aa7d01e6b0d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-26</instant>
        </period>
    </context>
    <context id="C_36b51e6f-78fe-4d4b-8094-ef5504c510aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37c62b10-c734-4e61-bef2-3be60f99493b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-09</endDate>
        </period>
    </context>
    <context id="C_3c4dde2c-c247-4018-8dec-79047db0d397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d31896d-8a0f-4011-b088-df7fcdb2cc51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyForSantheraSalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3e76c130-0386-4921-9a30-01e38dfe1755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cprx:UsTreasuryBondSecuritiesCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_449ab8c2-98c9-4b7f-964e-75ca3f26863f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_452b8271-91ed-43ef-8673-b266c4b29987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_465c30df-be19-4455-9dcb-aaf2927ffe62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <context id="C_48c77464-b5f1-4ac6-8188-839ff214c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4c43ddad-6603-484e-8db2-d46bb3b245a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="C_4ebf61f1-ea81-43ad-81d4-337230acd6fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:FirdapseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_50617df4-5ae4-4936-8bfe-fce589850662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_509d007d-642a-4644-91a4-d006a95ed40e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_517f0446-4af8-4ed4-a041-177e495d6020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_52411d29-db32-4171-9a6f-695291dabbf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5402459a-da02-42fa-9a9a-d8809e5bcd3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_556226bc-36cb-4e4c-af68-b7221da14303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_55e052ff-760b-4233-875b-b80e5e4fd436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cprx:KyePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_578e3acb-13d3-45de-b073-1b8543855c9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_581d19f7-26e1-4059-90f3-b147eba1d7ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_586a96db-2895-433b-86b3-59a27d4ec21f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_59962491-572f-40ec-90f4-9cbf4e5124ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5a58400b-bc1f-4635-913c-4ad5f983a455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5ce2a22a-eacd-4fc1-b3cc-795c49539d41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5d47ea25-4a27-4ac3-92dc-45b3e93e5aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5f8fe6ab-7ff7-4826-aac8-a94da76c2e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61b5027c-b632-4929-9a07-a51a4a172615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_61e41641-345f-41a7-b190-b0f5bedca153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_62b69186-a8bb-4324-acc0-f14d726a9dc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_63b514b4-d04f-4c24-ae2c-3f68c86bc2cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_641f77d8-a8c4-4ee2-9594-6cbd48dc0f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_64ac5d48-5a11-4212-bd0e-58e8990dba06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_65b685f1-a56a-4c6a-bfd2-43a03bc5ac14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67b31110-ac66-4aed-a6af-7327aecffdff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_67dce2a2-937e-4e9c-8d05-52a8de7df49a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_685da0b4-944b-4ee5-98c3-1fd7acde1f9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_699b6fb2-eaae-4c2e-8078-429b64ad536a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6b652f70-c405-4c0f-89a3-daf7d3f4fbaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-19</instant>
        </period>
    </context>
    <context id="C_6b7ac61d-59d7-4f79-a0f9-c3856afc6147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6b9ea75b-fd6f-4b79-9eda-f78b19010cc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicensedAndAcquiredIntangiblesForAgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cprx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6c1acb2b-a004-4627-8c8b-62b043c6ae4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ca67800-b7c3-4502-9b65-2de2fc4bcd0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="C_6d644c95-287a-423b-b6e2-b8baaa08fec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6de2fb61-b44d-45b0-b76c-c1b0f84e06f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e1efb3e-07db-484f-b24b-35978abd908b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6e28630c-cb40-4a69-9fd0-0723bffc77c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyLessThanTwoHundredFiftyMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7063df84-df92-4d68-82de-908875303ee3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_709ee500-c24e-46f7-b21a-40c0f4ecc925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_712db356-621a-4482-bbbf-6e0f7cee9633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <instant>2023-07-11</instant>
        </period>
    </context>
    <context id="C_71521487-ca68-4307-8394-188717a68617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_71e97608-057e-403f-bf4b-90daabc11583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_76b5439a-53d8-49ab-af66-1b56f6f623fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_76b8de51-684e-42d9-ae4d-1d3e47c58783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:AgamreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_79793b06-4d51-4322-b5ab-725a80889edf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cprx:RoyaltyThresholdLimitAxis">cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:U.s.RightsForFycompaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7a13598e-80ea-44a3-bc8f-76223a604527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cprx:LicenseAgreementForRuzurgiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="C_7da21a6a-c5cf-4df6-ba41-9a958e60d77d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cprx:VamoroloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7e4fb7e8-86a6-44b3-8a48-c1f6087f018a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7edf969a-90c8-4fa0-819c-30ed128b4031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cprx:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7f8cfbeb-4cb9-4b6d-a5e6-cb932c0b7774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cprx:ProductRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>cprx:Segment</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Vote">
        <measure>cprx:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_ChfShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_6f442802-8468-425d-9746-5b60fb75bf18">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_976ffb6e-1622-4f8b-8b42-d45554c6fd59">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0ac0f068-c902-46ee-b0dd-ac58c27ab466">0001369568</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      id="F_b3227f7e-05ef-4816-b5f7-7b8eae6c5421"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      id="F_aad5c8a8-d3cc-486c-8887-82ff44fbcbeb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_509d007d-642a-4644-91a4-d006a95ed40e"
      id="F_af1f8375-788a-4903-85b9-db67fcf6e271">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_61b5027c-b632-4929-9a07-a51a4a172615"
      id="F_af087444-9da2-4e54-b835-1802f923ce72">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_22ae25b7-7b9c-4c4c-babd-143090383ea0"
      id="F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_fc95014e-239d-4684-9334-a50e46b93483">http://catalystpharma.com/20241231#PresidentAndChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1"
      id="F_6d7694a8-4fef-4d34-ad3f-97f73cebc1d8">6 years</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      id="F_e02f321f-c2da-4a31-b171-0bb073d6f3b4">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      id="F_af9bf51b-92c5-4e0c-beca-6ed527c2962a">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c5a6f12f-751b-4ccc-b3ff-819fad9f4951">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d760a810-9deb-4ea3-bef2-8f61df72b823">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_065ad739-7e82-4d47-84ff-389c8bfa5115">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_840725af-ebc6-417a-a161-6ec8d88d3d40">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c18cf5af-def4-462b-82b9-d9ee0b0c881d">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c885e8e0-f239-4c2a-b520-f95cf69760b0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_78d82ede-c24c-4251-a5ca-ed3860bd80fb">001-33057</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_bbfc45b2-a2ec-4933-b040-be7b636d54c5">CATALYST PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f72043d0-7c67-403a-a2fb-322920f52d03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_a54ce2e5-ac36-4b1a-8e52-5e5eef0faf22">76-0837053</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_265c654e-f64f-40c6-992c-38c88ffc38ec">355 Alhambra Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_1e8c2a49-56ff-423a-9357-92bfb1e6a5ea">Suite 801</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0be43a8e-84ea-44a1-8eee-e71a37426933">Coral Gables</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_514b4ddf-a04e-4ed7-bb2c-af078e644911">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c1199ee4-118f-4a36-a74a-d16521e08efe">33134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_3bce18b0-f920-46a1-83b3-ee9d54ebaec7">305</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_52170c9e-76ff-46d4-9508-103ce5510700">420-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_e2ba1ce6-94f0-4d76-996b-6f7ee9fd3290">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_10fbf918-e176-4614-81f9-0ad7365e092e">CPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_203731f4-9147-4929-8a6f-0dfe6dab04c6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_6a9d303d-25fd-44ab-81e9-bebe04d0837b">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_ff2981c8-73ed-42f8-a56a-a157a7a241ce">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_992b9046-7306-4ec0-ad0f-1b33d31f552b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_9b1d4d9e-d1c0-421a-bc65-a7bb616c6bb2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7460aeed-ff98-488b-8e86-4abf6d929e8e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7d7ba637-02bb-4732-91fa-3acf33ccc27c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_fedf6815-883b-4270-a88e-b2e09f33138e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c309d910-3f60-4523-bd5b-e7f865957687">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_e0425172-645d-40a8-9c48-259ebb4a7bac">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_42eed31c-6f07-49f7-9cd6-598234c5d545">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_7063df84-df92-4d68-82de-908875303ee3"
      decimals="0"
      id="F_f5fe6ad4-b7db-4c73-8f2f-25829841b832"
      unitRef="U_USD">1720853867</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_f77728b5-2d78-4209-bf9a-e8743612b59d"
      decimals="INF"
      id="F_6e094710-234a-4e4c-b46f-5cb21e8456ce"
      unitRef="U_shares">121449655</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0b127b13-d185-4f54-9a97-272fafc5deaf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the Definitive Proxy Statement to be filed for Catalyst Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f0243950-fca9-4165-b731-4d4a48419984">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item&#x2009;1C. Cybe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rsecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Managing Material Risks &amp;amp; Integrated Overall Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are a part of our decision-making processes at every level. Our risk management team works closely with our Information Technology (IT) team including our IT and cybersecurity vendors to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Engage Third Parties on Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recognizing the complexity and evolving nature of cybersecurity threats, we &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a range of external experts in evaluating and testing our risk management systems. These partnerships enable us to leverage specialized knowledge and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;insights, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third parties includes regular audits, threat assessments, and consultation on security enhancements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Oversee Third Party Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because we are aware of the risks associated with third party service providers, we implement stringent processes to oversee and manage these risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We conduct thorough security assessments of all third party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes quarterly assessments by our Chief Legal and Compliance Officer (CLCO) and our Chief Operating Officer (COO) and on an ongoing basis by our IT professionals. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks from Cybersecurity Threats&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not encountered, to date, cybersecurity challenges that have materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impaired our operations or financial standing.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats. The Board has established robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats because we recognize the significance of these threats to our operational integrity and stakeholder confidence.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with our CLCO, our COO, and our IT personnel. In their time with our company, our CLCO and our COO have become increasingly involved in investigating, responding to, and mitigating cybersecurity incidents and intrusion attempts. Their in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CLCO and our COO oversee our governance programs, test our compliance with standards, remediate known risks, and oversee or lead our employee training program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CLCO and the COO regularly inform our CEO and CFO of all aspects related to cybersecurity risks and incidents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; This ensures that the highest levels of management are kept abreast of the cybersecurity posture and potential risks facing our company. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Monitor Cybersecurity Incidents&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CLCO, our COO, and our IT personnel are periodically informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CLCO and COO implement and oversee processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the CLCO and COO, along with our IT personnel, are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s Role Managing Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These briefings encompass a broad range of topics, including:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, at regular meetings of the Board, the Board members, including the CEO, and the CLCO and COO maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#x2019;s oversight is proactive and responsive. The Board members actively participate in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives. The Board of Directors conducts an annual review of the company&#x2019;s cybersecurity posture and the effectiveness of its risk management strategies. This review helps in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Board of Directors Oversight&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Board has delegated to the Audit Committee the primary responsibility of overseeing risk management relating to cybersecurity.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_02e736a0-8c14-4da0-aab0-ef6588b0ebda">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Managing Material Risks &amp;amp; Integrated Overall Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are a part of our decision-making processes at every level. Our risk management team works closely with our Information Technology (IT) team including our IT and cybersecurity vendors to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Engage Third Parties on Risk Management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recognizing the complexity and evolving nature of cybersecurity threats, we &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a range of external experts in evaluating and testing our risk management systems. These partnerships enable us to leverage specialized knowledge and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;insights, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our collaboration with these third parties includes regular audits, threat assessments, and consultation on security enhancements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Oversee Third Party Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because we are aware of the risks associated with third party service providers, we implement stringent processes to oversee and manage these risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We conduct thorough security assessments of all third party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes quarterly assessments by our Chief Legal and Compliance Officer (CLCO) and our Chief Operating Officer (COO) and on an ongoing basis by our IT professionals. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks from Cybersecurity Threats&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not encountered, to date, cybersecurity challenges that have materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impaired our operations or financial standing.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7cfb89a2-d5cf-4560-9d56-d8b277c1fc76">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_68c28609-501c-44e1-9d8e-d86b77f5de4f">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_367e7154-f62c-46a0-98c2-3617ba0b9707">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_54540c53-1bee-4b55-a27e-e231190fb534">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks from Cybersecurity Threats&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not encountered, to date, cybersecurity challenges that have materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impaired our operations or financial standing.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_41db1c65-efde-4b4d-b6e3-09f8ffdcba0c">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f7f0079b-9de0-4ee5-86da-4967e9e88bf1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with our CLCO, our COO, and our IT personnel. In their time with our company, our CLCO and our COO have become increasingly involved in investigating, responding to, and mitigating cybersecurity incidents and intrusion attempts. Their in-depth knowledge and experience are instrumental in developing and executing our cybersecurity strategies. Our CLCO and our COO oversee our governance programs, test our compliance with standards, remediate known risks, and oversee or lead our employee training program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c0ab7ba8-4dd2-4927-ba4d-72f55cb8c1a4">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f54c55b4-77bf-468d-85c1-2dd8e48d364b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CLCO, our COO, and our IT personnel are periodically informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques. This ongoing knowledge acquisition is crucial for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CLCO and COO implement and oversee processes for the regular monitoring of our information systems. This includes the deployment of advanced security measures and regular system audits to identify potential vulnerabilities. In the event of a cybersecurity incident, the CLCO and COO, along with our IT personnel, are equipped with a well-defined incident response plan. This plan includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7a218015-8410-4f76-a941-7e5b883ccd3c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Management&#x2019;s Role Managing Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These briefings encompass a broad range of topics, including:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.8%;text-indent:-3.786%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x25cf;	Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, at regular meetings of the Board, the Board members, including the CEO, and the CLCO and COO maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#x2019;s oversight is proactive and responsive. The Board members actively participate in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into our broader strategic objectives. The Board of Directors conducts an annual review of the company&#x2019;s cybersecurity posture and the effectiveness of its risk management strategies. This review helps in identifying areas for improvement and ensuring the alignment of cybersecurity efforts with the overall risk management framework.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_469be272-d0dd-4810-a448-3db29258a44a">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CLCO and the COO play a pivotal role in informing the Board of Directors about cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; They provide comprehensive briefings to the Board of Directors, with a minimum frequency of not less than once per year. &lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2b2d3229-e6b8-4ce8-96fd-614762bcbf06">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7eb19572-d924-4bb7-aa2f-413474b28ce6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Board of Directors Oversight&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Board has delegated to the Audit Committee the primary responsibility of overseeing risk management relating to cybersecurity.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_b36162df-abf9-4ee2-913d-b179304ebf35">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Directors as a group is responsible for oversight of cybersecurity risks and bears the primary responsibility for oversight of this domain.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d8fb02df-f02b-49a8-95ae-77ed21a9b78e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Board of Directors is composed of board members with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_e4da62ba-83f6-4a39-b05d-307494796743">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_5d1f462e-214a-47bc-b531-cbcfe8ae6531">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_162e521a-204f-43a5-8a55-405b6e5479c8">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_302c3710-6486-495f-9b5e-aa3db0142e2d">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_9bf538da-0d39-4a2a-b5ca-ba180369a17f">248</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_86670336-559f-4511-9c99-d392af708c7f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on internal control over financial reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the internal control over financial reporting of Catalyst Pharmaceuticals, Inc. (a Delaware corporation) and subsidiary (the &#x201c;Company&#x201d;) as of December 31, 2024, based on criteria established in the 2013 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control&#x2014;Integrated Framework&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the 2013 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control&#x2014;Integrated Framework &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;issued by COSO.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;), the consolidated financial statements of the Company as of and for the year ended December 31, 2024, and our report dated February 26, 2025 expressed an unqualified opinion on those financial statements.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_efe92fcd-6d33-4d76-9ee4-2a7d8919550e">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_a92a76fc-bdbb-4476-9f74-f52367efc4b8">Miami, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_af8f61f4-21b3-4a32-86fc-3aa20d18735d"
      unitRef="U_USD">517553000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_74f9db9a-ca72-48ff-a973-e13f7ab069c6"
      unitRef="U_USD">137636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_8c718ec8-adf2-4d81-8d65-978c6d68909c"
      unitRef="U_USD">65476000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_4646e103-93e0-487c-ae76-d35965d209c2"
      unitRef="U_USD">53514000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_f2dd1ceb-3cee-4ec5-a4f2-c3a1b5be45d8"
      unitRef="U_USD">19541000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_23d8557e-7610-4c33-a4e8-d58175acce8b"
      unitRef="U_USD">15644000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_87d0ad7a-9378-4d47-938b-d1ba8426f659"
      unitRef="U_USD">21039000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d77b3dd7-513c-4b7f-9fd2-cf7fd3c46d29"
      unitRef="U_USD">12535000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_bfbd13b0-e282-4498-bd4b-f6f3ab1493fa"
      unitRef="U_USD">623609000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_e9987dba-d676-4a74-af34-12179bc2ef11"
      unitRef="U_USD">219329000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_97f03a24-24ee-4b78-b52f-43647c79d68a"
      unitRef="U_USD">2230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_11aa4101-d764-4d02-a6b2-03c8e297d3ef"
      unitRef="U_USD">2508000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_9cb2bc01-2851-475d-8ef7-4e44e219b4ab"
      unitRef="U_USD">1354000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d0d9092f-05e1-4f11-ac3a-30f1513cbcae"
      unitRef="U_USD">1195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e3e4fa4b-bff7-4420-a323-90ea290a61ad"
      unitRef="U_USD">156672000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_2cd7a551-2227-42b2-be92-14ffcc3f09a6"
      unitRef="U_USD">194049000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_c1c72821-5ff1-4c6e-8066-2c422a0b2914"
      unitRef="U_USD">45982000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_c231c7b3-9e3f-4071-aa54-db1bd746c861"
      unitRef="U_USD">36544000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_8f8f767b-6506-4a3c-94f6-1c3d908034e7"
      unitRef="U_USD">21564000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_db5789ed-611a-4f82-b461-e913a26854ec"
      unitRef="U_USD">16489000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:Assets
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_8ecee4a4-1ad4-4691-963d-af4891bb7339"
      unitRef="U_USD">851411000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_a9784148-63f2-494a-8843-1de77d5b5231"
      unitRef="U_USD">470114000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_cee26d8f-5233-4fc3-85aa-f359d61f8bbb"
      unitRef="U_USD">16593000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_e42b6457-0abd-4e0e-b9f0-0d1485f255d1"
      unitRef="U_USD">14795000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_a4bb061b-9f4c-43f3-ade4-91cd71f9a13d"
      unitRef="U_USD">104085000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f1b6f8d5-cba5-43d2-b5fc-dc247f12a6d1"
      unitRef="U_USD">61268000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_590956e0-8ec1-4a09-b1c7-fd0124485f7e"
      unitRef="U_USD">120678000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_feebfd3d-16ab-480d-92db-12c88f443c77"
      unitRef="U_USD">76063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_5b469d3d-f8ca-4911-ba0a-163b698b5c4b"
      unitRef="U_USD">2786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_8337f159-0423-49b4-b6d0-a9acaf3797da"
      unitRef="U_USD">3188000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_ac71413a-aecf-40f0-bad0-771ba51f2726"
      unitRef="U_USD">315000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f4eb36ca-8375-4a59-9be9-8649bcd76033"
      unitRef="U_USD">2982000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_89033a6f-e720-4f8f-8083-43e797e9c767"
      unitRef="U_USD">123779000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d250cb3b-06bc-41b1-b893-1c5722f9c7aa"
      unitRef="U_USD">82233000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_b4b145ec-62c4-442c-a36f-5970e1c7cef4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_f859dd2b-51d8-4ec3-9ff1-43c4741727ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_f2257958-8b13-40e4-b769-034d5b963381"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_efdad824-02ef-4d2e-8442-865bee88f55a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_93179275-28b1-4c3f-b037-9d5ea00580de"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_b162b43a-ad3e-479b-8503-fefee4c6d33a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_d436d2a7-f541-40bb-9486-ffc2bd719976"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_42edb062-8b7a-4d5d-956c-3bfe8b972139"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_eeed3a0d-6ae6-4b4f-83e9-0565100df9c5"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_0a5d6722-3b76-4508-b4f3-f3b28ebea50e"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_23b02162-bcda-497c-88d8-6294cd2b6423"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_ad9af219-d1eb-4418-81f9-9a84223470f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_c3f13661-7693-48b6-af0c-564f80bffe56"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_ab0e594d-1d0e-46b4-aec2-2cfc5222f879"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_1b2b45a7-8b40-43cd-be73-ec1c27921083"
      unitRef="U_shares">120879099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_d75aec02-6757-468a-9566-d355d57a8eb2"
      unitRef="U_shares">120879099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_f66958d3-65eb-4177-86eb-788feb1cafb4"
      unitRef="U_shares">107121549</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_eb652236-a973-4cbd-80ca-db120e6ba943"
      unitRef="U_shares">107121549</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_630e3887-c9a3-4588-901b-a9c94f248ed6"
      unitRef="U_USD">121000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_86c5f227-2a50-4043-b7e4-4096e1237e9a"
      unitRef="U_USD">107000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4a47861d-8f27-4a88-bdbf-88f0567fe8e6"
      unitRef="U_USD">442286000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_23274f95-0336-4e8b-81af-8525bdb755c5"
      unitRef="U_USD">266488000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_942f954e-99ee-4ae9-907f-d06801b7898b"
      unitRef="U_USD">285161000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_79d45dff-d314-48f0-9b8c-14f5e316f1b9"
      unitRef="U_USD">121272000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d776a50e-32e5-4f9a-a842-2222066697b0"
      unitRef="U_USD">64000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_6eadf7cb-2b15-4fa5-8181-d9fa0f919ae2"
      unitRef="U_USD">14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_0479fa45-8683-4b5a-aa3c-dfcd56163631"
      unitRef="U_USD">727632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f2a1c2d0-7b3b-4af2-afa0-01971762aad2"
      unitRef="U_USD">387881000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_447152b4-f0c5-45f3-8e26-e1e9855d901f"
      unitRef="U_USD">851411000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_1044fa63-bd80-47e8-b845-eeb627be8978"
      unitRef="U_USD">470114000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9b84b239-460f-4343-8a55-dd9c8d160502"
      decimals="-3"
      id="F_7d84f130-0ab2-4d0d-80a7-cf65bee8a739"
      unitRef="U_USD">489327000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_76b5439a-53d8-49ab-af66-1b56f6f623fd"
      decimals="-3"
      id="F_b964b3e0-8459-409d-8e48-919fe26f5a9a"
      unitRef="U_USD">396502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b48f2bea-3319-4b24-87f1-db81866524fe"
      decimals="-3"
      id="F_3c820fe1-5663-4d92-8dbd-6606831639fb"
      unitRef="U_USD">213938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_120e4417-63cf-4ab5-a1e1-efaa73f03a30"
      decimals="-3"
      id="F_d3675dbd-9cf6-4e2e-9399-bbd0bc553a66"
      unitRef="U_USD">2407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3c4dde2c-c247-4018-8dec-79047db0d397"
      decimals="-3"
      id="F_2d886aec-fb83-40b9-8d04-4673cd793c6c"
      unitRef="U_USD">1702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bc793338-3e30-4b0a-b679-9536be9b17ee"
      decimals="-3"
      id="F_1903216b-edfc-454c-bead-03541967507a"
      unitRef="U_USD">265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_1b80566b-682b-4d24-912c-29d44fd48e94"
      unitRef="U_USD">491734000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_4d16489d-ec9e-43d3-9ce3-c8f1ff7c90f9"
      unitRef="U_USD">398204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_65f1ff7e-296e-41a6-ac23-30bf116ee8bb"
      unitRef="U_USD">214203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a"
      unitRef="U_USD">68845000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_e1ed2f82-8a48-42fe-af2f-872d5813258d"
      unitRef="U_USD">51967000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_4090fec8-f07e-48d9-bf06-c1a0911f901a"
      unitRef="U_USD">34393000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_7d7bcec3-1fee-418e-b3c1-ba9969689260"
      unitRef="U_USD">12648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_c10a8b95-2022-44bd-920a-d67d0528455f"
      unitRef="U_USD">93150000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_d249fca2-2d41-41fa-aa9d-d85acd64557a"
      unitRef="U_USD">19789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_75cfea18-2c8e-42fa-9913-1a0fb70f871c"
      unitRef="U_USD">177740000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_78ea662f-49ac-4435-b86f-eb83afbf77c0"
      unitRef="U_USD">133710000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_266311d6-f055-45aa-95b5-dcb4a1d901ee"
      unitRef="U_USD">57085000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <cprx:AmortizationExpensesOfIntangibleAsset
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_031f85ad-c0bb-4cfc-a82c-d201e112aaa0"
      unitRef="U_USD">37377000</cprx:AmortizationExpensesOfIntangibleAsset>
    <cprx:AmortizationExpensesOfIntangibleAsset
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_e6c38add-4acf-40c1-9a27-e56bcb8cff33"
      unitRef="U_USD">32565000</cprx:AmortizationExpensesOfIntangibleAsset>
    <cprx:AmortizationExpensesOfIntangibleAsset
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_1d9450a1-2497-48a3-9107-8500b63abb7f"
      unitRef="U_USD">1098000</cprx:AmortizationExpensesOfIntangibleAsset>
    <cprx:OperatingExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_81f01372-76fd-4b6f-b82a-24c96989417c"
      unitRef="U_USD">296610000</cprx:OperatingExpense>
    <cprx:OperatingExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_3ba873a8-ed0a-434c-856e-ee3ca263eaa8"
      unitRef="U_USD">311392000</cprx:OperatingExpense>
    <cprx:OperatingExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_524fdb93-7595-453e-b461-bde90f8e2e23"
      unitRef="U_USD">112365000</cprx:OperatingExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_dd86fc2f-e228-4517-b797-17456e62fba0"
      unitRef="U_USD">195124000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2f59ab16-1d8e-4ee6-ac8b-defc21d45854"
      unitRef="U_USD">86812000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_366642d8-9eca-4994-8d03-591c0c7fe190"
      unitRef="U_USD">101838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_0b3198ce-8876-4bfe-95c1-4620bf8d3a15"
      unitRef="U_USD">21139000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_0e1297ac-d75c-4a3f-ae2c-b1b0b66dbb61"
      unitRef="U_USD">7699000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_389bb83e-3a01-4cc0-9d9a-6849f9ce100d"
      unitRef="U_USD">2881000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_d737d514-29e3-435f-82f7-ab84839f838f"
      unitRef="U_USD">216263000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_abd90bb1-b752-4c64-be3a-3609e0281a3f"
      unitRef="U_USD">94511000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_326bd90e-bb1a-4fd8-aa57-fd8294984ca2"
      unitRef="U_USD">104719000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_e1891ea1-1f1d-43f7-af44-e0a6de57c395"
      unitRef="U_USD">52374000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_01aaa8d7-122f-41d4-9d0c-b9534774910d"
      unitRef="U_USD">23101000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_339c90f1-f237-4be5-ad04-0985c9e0826e"
      unitRef="U_USD">21640000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_1dbdadad-2c28-47aa-9b8a-b2aa30115307"
      unitRef="U_USD">163889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_f0020963-13dd-4fdb-bfb3-dee998e9615f"
      unitRef="U_USD">71410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_676d591d-a320-4790-b439-fbcde2afa393"
      unitRef="U_USD">83079000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_d239254c-94a0-43af-b9d6-3e50a26a7532"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_dd91cce6-38fa-4a58-9e1e-cc872ca57027"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_e942226c-f203-4963-bddf-11b5443f2058"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_65dda079-ac6e-4346-80a9-0e6ed10cd0e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_2d74d96d-4c9b-4920-b2d2-28b5bfd8d6f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_e5a34421-4d19-42ca-b326-bb11d613ddc4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_b059198f-ec07-4e35-9d88-388e1df40318"
      unitRef="U_shares">118457673</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="0"
      id="F_241019d1-ee22-4ae5-b4ce-7483b4ed06fa"
      unitRef="U_shares">106279736</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="0"
      id="F_d69fe632-c8d5-40b5-857c-9a55ed0bdc7a"
      unitRef="U_shares">103374606</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_7f1ea5c3-ad62-4a49-9868-e2ebca964fa1"
      unitRef="U_shares">124943603</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="0"
      id="F_3a8de5ee-6cdf-4e2c-b7cb-eed1c3d3f083"
      unitRef="U_shares">113753154</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="0"
      id="F_3457157f-10fc-4c18-8f01-a42ee8b5b9e3"
      unitRef="U_shares">111375631</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_b62ebb3f-f55a-402a-b97c-fdd44718cb1d"
      unitRef="U_USD">163889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_5693295c-0886-41a9-b94f-2aac834b3091"
      unitRef="U_USD">71410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_c0f3f39e-32bc-4ab4-a46b-1fa6aa6b3485"
      unitRef="U_USD">83079000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_2e62c929-8868-4d2d-a8e1-95b4bbd534f6"
      unitRef="U_USD">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_14939732-c473-440d-9df2-577f48e3f37e"
      unitRef="U_USD">4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_39dbcc16-a04a-4ee1-b611-462d52a4ec08"
      unitRef="U_USD">-54000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_714cf9f6-8fb3-462d-853b-2a24e6e3b8e8"
      unitRef="U_USD">50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_f4b6ca6b-c291-4f17-8962-35910bca0c3b"
      unitRef="U_USD">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_6bf5e0e3-b348-407a-8c8f-d2ace8234d18"
      unitRef="U_USD">172000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_a5919c02-3834-45df-8dea-e2dd41ee0703"
      unitRef="U_USD">163939000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_e96c7e57-c162-4ae5-86b8-22e14a23af42"
      unitRef="U_USD">71400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_0faf0998-ac38-4fb4-99a5-8813f952e83e"
      unitRef="U_USD">83251000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0"
      decimals="INF"
      id="F_29cae9c2-fb7f-45f0-a1a1-5676d94e9a11"
      unitRef="U_shares">102993000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e5b155f0-f728-45a3-a151-8b1fe0edc6b0"
      decimals="-3"
      id="F_995203ea-3fd1-4cf7-9331-2647975cddc2"
      unitRef="U_USD">103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d5f3bd21-522f-4b08-969f-7e84f85ab2d2"
      decimals="-3"
      id="F_45ee5290-d92e-4f03-afcc-4ab6261261c7"
      unitRef="U_USD">233186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e4fb7e8-86a6-44b3-8a48-c1f6087f018a"
      decimals="-3"
      id="F_593d37d8-a234-41e7-97c6-aa6222219982"
      unitRef="U_USD">-26310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a58400b-bc1f-4635-913c-4ad5f983a455"
      decimals="-3"
      id="F_89e0aaf2-c8ba-4937-81b1-72b867c52da5"
      unitRef="U_USD">-148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c24bf7e7-9d65-4eec-b363-d92095897f82"
      decimals="-3"
      id="F_56e4c098-ccc6-4a22-9306-57605860b8e6"
      unitRef="U_USD">206831000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a"
      decimals="-3"
      id="F_e75c4524-5e20-464d-9769-2a0bc6ebd203"
      unitRef="U_USD">7907000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_2eb71450-020f-401c-a8a6-600b38a39e5a"
      unitRef="U_USD">7907000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"
      decimals="-3"
      id="F_b78799b1-3c1a-49f9-a2ce-c69d326c2c94"
      unitRef="U_shares">3172000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"
      decimals="-3"
      id="F_5eb11a22-564d-4885-ba6e-2b54feef21e9"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a"
      decimals="-3"
      id="F_675fd159-b575-49c7-b87e-631c131b5111"
      unitRef="U_USD">9567000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_2b7f3915-7e57-4f41-bbac-a26774cd2e93"
      unitRef="U_USD">9569000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"
      decimals="-3"
      id="F_c732d32a-376d-439f-b674-89f8b8e14994"
      unitRef="U_shares">98000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_b596e2cc-286d-47f0-ac7b-678a98a7ba2a"
      decimals="-3"
      id="F_629cd6cd-c44e-42ac-96f3-21c6092a0179"
      unitRef="U_USD">-230000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_3203f47c-91cf-4e0d-acec-610d9c57bc9e"
      unitRef="U_USD">-230000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"
      decimals="-3"
      id="F_8c661528-4c5f-4ead-9ba7-471be9e28c17"
      unitRef="U_shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_da5c0563-d56c-4b30-a42d-4fb7860e6926"
      decimals="-3"
      id="F_6f2278e6-5f4d-4846-a3fc-8d007c71f68f"
      unitRef="U_USD">6907000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_d09fbc89-668c-4a07-98cf-da395a1386c6"
      unitRef="U_USD">6907000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9a567032-9b5a-41d1-86f5-591b8c5517a5"
      decimals="-3"
      id="F_990f9984-3329-4043-84f0-d0ca28daff6e"
      unitRef="U_USD">172000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_897dc2de-5754-40bc-8b29-d4105f8d54db"
      unitRef="U_USD">172000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_da5c0563-d56c-4b30-a42d-4fb7860e6926"
      decimals="-3"
      id="F_5c9228d0-d2f2-4c29-8dc0-fc3f6792cee1"
      unitRef="U_USD">83079000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_affbc5e7-3c4a-4830-8428-a1f9de569bb5"
      unitRef="U_USD">83079000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b"
      decimals="INF"
      id="F_fc35ccf7-3ef3-4600-959c-8c4558956e17"
      unitRef="U_shares">105263000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1c6a5b8e-92f8-4e55-b233-d640efbea86b"
      decimals="-3"
      id="F_f5957310-0cb0-47d0-8a69-ad09eebd3fb0"
      unitRef="U_USD">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb917612-49d0-4a60-87c6-e1340f2ed65b"
      decimals="-3"
      id="F_1c6c0a21-db44-4133-8656-625cdf92962f"
      unitRef="U_USD">250430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_63b514b4-d04f-4c24-ae2c-3f68c86bc2cf"
      decimals="-3"
      id="F_330a0651-f75c-40d0-a95e-680d48cc335e"
      unitRef="U_USD">49862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_146fabbe-e017-4017-80bb-681752315fa3"
      decimals="-3"
      id="F_e17f5ee2-02b7-495a-8483-053b69ad104d"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3"
      decimals="-3"
      id="F_66061dac-b317-4099-b4a6-7277ff759377"
      unitRef="U_USD">300421000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e"
      decimals="-3"
      id="F_0d72b149-2779-4f17-8010-52224283e1b8"
      unitRef="U_USD">14250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_6eb4010b-e679-4c06-a9a7-4636b95e4b20"
      unitRef="U_USD">14250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22"
      decimals="-3"
      id="F_c768b748-620e-4b21-9327-4df525a85264"
      unitRef="U_shares">1652000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22"
      decimals="-3"
      id="F_5cd34d37-7234-47cb-8f86-ce1bcd907a99"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e"
      decimals="-3"
      id="F_e968a474-5157-40c2-bb74-f399728e76ba"
      unitRef="U_USD">2790000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2f59245e-270b-43af-88a1-40c9b151d4b4"
      unitRef="U_USD">2792000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22"
      decimals="-3"
      id="F_e5a7559a-ec01-4289-a139-7f0fc000cd14"
      unitRef="U_shares">207000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_54c80768-0f06-4000-8e57-fa7dbdba9f5e"
      decimals="-3"
      id="F_060029bc-138e-4999-b508-4e41de532269"
      unitRef="U_USD">-982000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_3afa04f3-1208-46d6-bd7d-60a48fa62f12"
      unitRef="U_USD">-982000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e84d3106-1c0a-425f-b8b4-ab83374f00fa"
      decimals="-3"
      id="F_8ebd6de2-f020-44af-983c-47eb340d9692"
      unitRef="U_USD">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2216e08e-0812-4ccb-a869-ca09ec7ba2f4"
      unitRef="U_USD">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c65af8-c1b9-4e2d-9312-ab77475df623"
      decimals="-3"
      id="F_f9fcf92e-a2af-4f53-b81d-35fbc53d4f8a"
      unitRef="U_USD">71410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2bd98324-a31d-41a2-ab97-ef3f46d4a7b5"
      unitRef="U_USD">71410000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_586a96db-2895-433b-86b3-59a27d4ec21f"
      decimals="INF"
      id="F_fca285ce-17c3-4e1e-888a-0d2c968ffd4a"
      unitRef="U_shares">107122000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_586a96db-2895-433b-86b3-59a27d4ec21f"
      decimals="-3"
      id="F_dd412172-c214-4fb6-b2b1-76ec9116f811"
      unitRef="U_USD">107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb022394-9f10-4ba9-855f-2cc8eb1d4d2e"
      decimals="-3"
      id="F_94292cd2-a377-451d-9523-9aa3c1c887ed"
      unitRef="U_USD">266488000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a4f3e35-a536-4dd5-b66f-0ae66fd2a87b"
      decimals="-3"
      id="F_06118ec1-c1ba-48f1-833a-67fd13ae5ed9"
      unitRef="U_USD">121272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8dddeb9f-3b04-4e8a-baf5-72e1456394e4"
      decimals="-3"
      id="F_a3973b4a-8fd2-42c3-81f8-58330ea095a0"
      unitRef="U_USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_5cc9f91e-cae6-43ca-8db6-6609ed7efc26"
      unitRef="U_USD">387881000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="-3"
      id="F_c0a11324-8102-4fd1-af54-8cad212281f0"
      unitRef="U_shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="-3"
      id="F_c7a86ce3-bad6-48fd-9950-d3ef15425dcf"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180"
      decimals="-3"
      id="F_acd5e3b3-b0ce-4735-a9e8-efcf08835632"
      unitRef="U_USD">140704000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_6b1af070-4ccf-4f96-9a60-0e3ce8f76c1f"
      unitRef="U_USD">140714000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180"
      decimals="-3"
      id="F_4513717e-12d9-4a48-a59a-59cdce3618a9"
      unitRef="U_USD">22251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_15d75696-50cd-47f0-99fb-a83bac4c785d"
      unitRef="U_USD">22251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="-3"
      id="F_fc80dbec-0645-48c0-88d9-529d96369f2e"
      unitRef="U_shares">3429000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="-3"
      id="F_c1935635-56e1-40e9-bb85-29d7eff5f13d"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180"
      decimals="-3"
      id="F_aabc5493-2d2b-4a81-a8da-6d9d865e40f0"
      unitRef="U_USD">13511000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_1fbcc1d3-5e5f-44aa-ae33-8290b03137d3"
      unitRef="U_USD">13515000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="-3"
      id="F_88580a19-ea62-442e-ad7b-b271837b4cd1"
      unitRef="U_shares">328000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_33d5f74d-1547-4288-8459-e89cc8ac7180"
      decimals="-3"
      id="F_6831634f-2310-4144-9ef0-74e53538709c"
      unitRef="U_USD">-668000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_3c2af574-5ce5-42d3-b6ae-dd1765e7dc12"
      unitRef="U_USD">-668000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_449ab8c2-98c9-4b7f-964e-75ca3f26863f"
      decimals="-3"
      id="F_d61a3964-0946-4307-9c08-273de1aa8105"
      unitRef="U_USD">50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_b612d1b7-7a89-462b-b97a-d7a59c7ad080"
      unitRef="U_USD">50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_322cdd05-3fc8-4285-9f49-2a475c723c0a"
      decimals="-3"
      id="F_c2715388-892b-4336-8d9c-e08bf4f83bac"
      unitRef="U_USD">163889000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_ad3c79c7-fe23-43af-b903-bb791ee82696"
      unitRef="U_USD">163889000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_345c9a15-8b88-4b16-82c6-8b06540097af"
      decimals="INF"
      id="F_c7505a09-56d7-4a47-afe2-9b35c8face5c"
      unitRef="U_shares">120879000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_345c9a15-8b88-4b16-82c6-8b06540097af"
      decimals="-3"
      id="F_1ac4d197-c604-44ed-9956-e8bcb370453c"
      unitRef="U_USD">121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_048b05a5-861c-4ff4-b542-3b7c319a55ea"
      decimals="-3"
      id="F_1ce233f8-f2f9-4395-8802-f5e378a8223b"
      unitRef="U_USD">442286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6459900-9ea0-4176-84e6-0b21db75fa6e"
      decimals="-3"
      id="F_634015bc-ceb3-4126-890a-b711f8fb3c6d"
      unitRef="U_USD">285161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a6b7ed37-7935-4f83-a2ae-608865c7f8d5"
      decimals="-3"
      id="F_eb9dabbb-7026-4dc0-98e6-1eab338a22e7"
      unitRef="U_USD">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_0604e773-3c7b-4b60-9d16-45ec8cbaa365"
      unitRef="U_USD">727632000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_1844fa84-68ba-4d45-aed7-a67bd467e33d"
      unitRef="U_USD">163889000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_6039807c-58f4-431b-bb85-5f50d64af615"
      unitRef="U_USD">71410000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_e3842b3f-7633-4028-9206-b80ca17ac26f"
      unitRef="U_USD">83079000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_d75c07f9-d51f-488b-a863-99b2fb35b645"
      unitRef="U_USD">397000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_04261232-5e9f-45bf-9e47-27ec018e521e"
      unitRef="U_USD">316000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_955556a8-3575-49a8-ba21-759c1a1d7b0a"
      unitRef="U_USD">141000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_a1072a55-b409-4831-ac2f-5a8bc4c2b60f"
      unitRef="U_USD">22251000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_5433cf88-4a01-42f9-a31d-38ade1467961"
      unitRef="U_USD">14250000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_12984851-b2a1-432b-ba20-65494d7d7ad3"
      unitRef="U_USD">7907000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_9e4c4d1f-233e-4aa7-9fbb-d55a28b18f8c"
      unitRef="U_USD">37377000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_ea450243-9b95-4f15-b311-f8fe934c8084"
      unitRef="U_USD">32565000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_a5e555e2-cf0a-4b37-bdea-f80cb5b8861d"
      unitRef="U_USD">1098000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_8e5e3e72-df19-4870-b748-a3d5e6ac3725"
      unitRef="U_USD">9388000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_76f1b685-3c91-44f2-80a1-3ccb7769ce16"
      unitRef="U_USD">17818000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_8a7f04dc-28b6-4751-8bc2-90da6bfe6cfe"
      unitRef="U_USD">-4937000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <cprx:AccretionOfDiscount
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_240ed2fe-ce95-4e59-a16a-22b02377ad8d"
      unitRef="U_USD">835000</cprx:AccretionOfDiscount>
    <cprx:AccretionOfDiscount
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_e2fe4116-8973-4cc3-9a85-329f228f41c7"
      unitRef="U_USD">-1320000</cprx:AccretionOfDiscount>
    <cprx:AccretionOfDiscount
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_88038fec-ba8b-48b0-b0e5-6c4674f67d1a"
      unitRef="U_USD">-17000</cprx:AccretionOfDiscount>
    <cprx:NonCashChangeInRightOfUseAsset
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_4c0414b2-0c7d-478a-acde-c3cb8ba74edd"
      unitRef="U_USD">278000</cprx:NonCashChangeInRightOfUseAsset>
    <cprx:NonCashChangeInRightOfUseAsset
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_983f8e54-a417-44c9-af4d-09d5ad07dcab"
      unitRef="U_USD">262000</cprx:NonCashChangeInRightOfUseAsset>
    <cprx:NonCashChangeInRightOfUseAsset
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_9c01e411-d642-41ab-a69e-0f71f9590a68"
      unitRef="U_USD">247000</cprx:NonCashChangeInRightOfUseAsset>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_436bd015-a7fa-4607-8990-8c34398b6765"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_69feb187-b6b7-4ec2-a845-16023ce43c58"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_ab9e4d9a-7c16-40c2-ab17-69905ebebccc"
      unitRef="U_USD">762000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_23e2f3dd-50ca-44b1-9fb9-9383f86cbf1f"
      unitRef="U_USD">0</cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition>
    <cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_a1a47c84-a47d-4b86-bbce-7acf965f6759"
      unitRef="U_USD">0</cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition>
    <cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_425d81cb-acd7-4eb7-861f-c3b3359d1767"
      unitRef="U_USD">4130000</cprx:AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition>
    <cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_8b6a240f-ccec-411e-830d-2e865744ae92"
      unitRef="U_USD">0</cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition>
    <cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_584bda6a-660e-48f8-8e68-85e58f5a2035"
      unitRef="U_USD">130000</cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition>
    <cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_2b74b6f4-7090-47b4-9993-3c6cb357f447"
      unitRef="U_USD">0</cprx:AcquiredInventorySamplesExpensedFromAssetAcquisition>
    <cprx:AcquiredInProcessResearchAndDevelopment
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_45709ed8-2617-40b9-aa5e-1bba891fa637"
      unitRef="U_USD">0</cprx:AcquiredInProcessResearchAndDevelopment>
    <cprx:AcquiredInProcessResearchAndDevelopment
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_85aa3e86-9c48-4100-872a-752c82becd43"
      unitRef="U_USD">81513000</cprx:AcquiredInProcessResearchAndDevelopment>
    <cprx:AcquiredInProcessResearchAndDevelopment
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_7d523daa-0001-4a21-acaa-9209291f711e"
      unitRef="U_USD">0</cprx:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_93bcf038-e723-4830-a450-c2f27e03df1e"
      unitRef="U_USD">5075000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_6ddf755e-9815-4060-a58f-5bc815fe000e"
      unitRef="U_USD">3024000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_5436104f-150b-42b6-bc6e-f5cbdec485a8"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_b4048c0f-8dae-4651-80ef-ad5513f510e7"
      unitRef="U_USD">11962000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_86169d8a-0e56-4d2f-befb-2452a18c709b"
      unitRef="U_USD">43075000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_58e67829-bdfb-4c0c-a625-eb941cda0bad"
      unitRef="U_USD">3820000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_7419ad70-0c56-4458-ad71-689f46a725ba"
      unitRef="U_USD">3897000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_1e979fdb-7162-46fa-a22d-3d094d0202cb"
      unitRef="U_USD">4739000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_89768cc6-e40c-4932-b649-8a0f2342cd57"
      unitRef="U_USD">-1065000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_711a6a9f-75c3-454d-ac82-dfa2a5ca56b9"
      unitRef="U_USD">8504000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_5dba83fa-46b3-4d81-bf22-c99682c1cb66"
      unitRef="U_USD">5792000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_3dd94b15-2b40-494e-b1a4-a6bf6328d62a"
      unitRef="U_USD">807000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_1c6c078e-cef6-4a43-8451-2e1d2ee5bcc8"
      unitRef="U_USD">1798000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_fa9d4d16-e99e-472f-b300-002d7cb0fb3b"
      unitRef="U_USD">10820000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_9158f862-b674-45cd-9f04-5a51c7754f68"
      unitRef="U_USD">1207000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_6df11b9b-1cd2-4c34-ba94-1a2b3c1457b6"
      unitRef="U_USD">53848000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_940c171b-2824-4f8a-b299-6c739943bea0"
      unitRef="U_USD">5800000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_b3379355-7c8a-474b-a1f7-c30e9456981f"
      unitRef="U_USD">16391000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_9a779198-971a-4f57-b1a6-f92c8d4cbbf9"
      unitRef="U_USD">-369000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_8f7e619b-3b70-4919-9bc4-158677e57220"
      unitRef="U_USD">-338000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_5754f629-5b20-4a1f-98ee-17ec5322e32f"
      unitRef="U_USD">-307000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_3b56090c-3b06-4243-b8e0-79117ab335a7"
      unitRef="U_USD">239808000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_3ff47a10-a924-4b8b-a7a4-b974f79b527e"
      unitRef="U_USD">143600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_a0a1ce94-52dc-4338-9ab8-8ef74096867e"
      unitRef="U_USD">116047000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_93a1357e-8f57-4963-b092-c32b5a33b196"
      unitRef="U_USD">556000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_932082ca-1cfe-4503-8acf-d3f7976f18e4"
      unitRef="U_USD">231000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_557891ac-f6ee-4530-af36-cbe60ef0bea6"
      unitRef="U_USD">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_4e2d5ed4-f59c-4366-a674-9a4dec478614"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_faa881d1-ee96-47b4-9b47-4cd35c45e01d"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_325b9058-65d6-4129-b112-f7e37d505db3"
      unitRef="U_USD">19238000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <cprx:PaymentInConnectionWithAssetAcquisition
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_21983441-3cb6-488a-9ee7-c09022ebdd1f"
      unitRef="U_USD">0</cprx:PaymentInConnectionWithAssetAcquisition>
    <cprx:PaymentInConnectionWithAssetAcquisition
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_aac34b99-7f9d-41ca-a8e8-84de3b77bc0d"
      unitRef="U_USD">198293000</cprx:PaymentInConnectionWithAssetAcquisition>
    <cprx:PaymentInConnectionWithAssetAcquisition
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_7129c5a8-c663-449a-b463-6078b2337150"
      unitRef="U_USD">10000000</cprx:PaymentInConnectionWithAssetAcquisition>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_50f3235a-820d-4212-90cc-65911cc0bb11"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_510e449f-9a0c-43b7-a0af-662df03246e5"
      unitRef="U_USD">81513000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_d091eac1-2dc2-473e-9961-3fb7ff4a91a9"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_213fbdd4-4736-4b6a-b3c8-3600ef47450f"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_4bcf1675-bff5-4143-b2bb-7b9380e99ca5"
      unitRef="U_USD">13465000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_315bdf3b-4bdb-4e15-9f2a-cac0dd12048e"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_90c9d9a1-58e7-4f16-986a-04e9257e676b"
      unitRef="U_USD">-556000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2b6ff9f0-366c-4c46-9bd8-abb4c8d3e9a4"
      unitRef="U_USD">-293502000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_890f9626-8912-4fc2-851f-fb7cd782714a"
      unitRef="U_USD">9209000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_94534026-2b02-4d0f-8e40-e30a4212df14"
      unitRef="U_USD">668000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_b1b7b19a-3ef3-4307-9e1f-c98ee842671f"
      unitRef="U_USD">982000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_a6e8b7a8-e121-4156-ba5e-4febc75c6cff"
      unitRef="U_USD">230000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_011a3f93-df58-408c-b106-3d8cdf695279"
      unitRef="U_USD">13515000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_4fe199fe-9397-436c-be7b-fca67c714364"
      unitRef="U_USD">2792000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_c05173d6-109b-4bc7-9b34-a597cc3e4f60"
      unitRef="U_USD">9569000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_d56118fc-e87e-4a8b-9b8c-ac6b627cffba"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_63e85cd3-f7d9-4438-aece-38c0e8a0c1aa"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_db1319c4-c481-4261-bbf3-fa60b67e5f1e"
      unitRef="U_USD">6907000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_a109b77a-d2f9-4be5-986c-6b374802623a"
      unitRef="U_USD">12886000</cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition>
    <cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_b48af94f-9788-4707-96bf-42c81eadc89d"
      unitRef="U_USD">12667000</cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition>
    <cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_9a048760-abd6-4ea6-a2f3-370031c89746"
      unitRef="U_USD">738000</cprx:PaymentOfLiabilitiesArisingFromAssetAcquisition>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_52fb793a-c2b2-4eaf-999b-10ded39f5e99"
      unitRef="U_USD">141000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_13a7245d-dff0-4320-972f-62dc8c410808"
      unitRef="U_USD">296000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_5697f370-b9cb-4c26-bb6c-5d0e680b6ed8"
      unitRef="U_USD">140665000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_a798c0c5-d808-4826-9134-560c47b86fb7"
      unitRef="U_USD">-10857000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_f1c364b8-356b-41e2-aa36-b1db2d27093b"
      unitRef="U_USD">1694000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_99e4c05c-8f97-4fac-ade1-239dc11dad77"
      unitRef="U_USD">379917000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_d1281410-4379-4097-b190-b900473d782e"
      unitRef="U_USD">-160759000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_c3e65930-929b-4816-b8cf-4f4b40d7fe22"
      unitRef="U_USD">126950000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f503dc1e-ab49-4c22-b859-437f6e50a5a9"
      unitRef="U_USD">137636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3"
      decimals="-3"
      id="F_850d61f4-7734-433e-80b0-d9d176bd6e12"
      unitRef="U_USD">298395000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c24bf7e7-9d65-4eec-b363-d92095897f82"
      decimals="-3"
      id="F_37ef5ecd-b479-48e6-8b7f-96d2d3596ed8"
      unitRef="U_USD">171445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d8c485ce-1bbb-4713-89d6-12b84df2ab18"
      unitRef="U_USD">517553000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_5e0bc677-9f53-4383-afc6-439c7ad3b744"
      unitRef="U_USD">137636000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3"
      decimals="-3"
      id="F_e308ec81-8b0c-47d1-bf96-20564a4a89d3"
      unitRef="U_USD">298395000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_b188c8d2-a282-41b8-a1ae-6e0f16a4add0"
      unitRef="U_USD">68451000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_31a11dc4-824d-40eb-9e42-9237e47bf5ad"
      unitRef="U_USD">50458000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_ad0b57c3-5a9f-44a7-901e-334317ae9f37"
      unitRef="U_USD">7667000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_5b395b61-4cc1-42bf-9e45-15298d10d905"
      unitRef="U_USD">1395000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_07518736-45bc-4679-8d82-3d539d1fffab"
      unitRef="U_USD">705000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_c67ac53e-843a-4eea-ac05-bbc3150ec228"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <cprx:LiabilitiesArisingFromAssetAcquisition
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_8d71edce-295f-444d-88d5-587952c3e9ee"
      unitRef="U_USD">0</cprx:LiabilitiesArisingFromAssetAcquisition>
    <cprx:LiabilitiesArisingFromAssetAcquisition
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_d8c0245e-c40c-4331-8bc5-f8ee51df1d7d"
      unitRef="U_USD">1915000</cprx:LiabilitiesArisingFromAssetAcquisition>
    <cprx:LiabilitiesArisingFromAssetAcquisition
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_b174a279-6743-4ec7-b264-3ebc53a9bf17"
      unitRef="U_USD">27699000</cprx:LiabilitiesArisingFromAssetAcquisition>
    <us-gaap:NatureOfOperations
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c1566db8-5b9a-4ec7-80a6-9f65122f690e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization and Description of Business. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company currently markets three drug products, FIRDAPSE&#xae; (amifampridine), FYCOMPA&#xae; (perampanel), and AGAMREE&#xae; (vamorolone). The Company is currently seeking to further expand its drug portfolio, with a focus on acquiring the rights to late-stage products to treat orphan, rare disease across therapeutic areas. With an unwavering patient focus embedded in everything it does, the Company is committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s New Drug Application (NDA) for FIRDAPSE&#xae; (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food &amp;amp; Drug Administration (FDA), and FIRDAPSE&#xae; is commercially available in the U.S. as a treatment for adults with LEMS. Further, Canada&#x2019;s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE&#xae; for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE&#xae; is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals, Inc. (KYE). In the third quarter of 2022, the FDA approved the Company&#x2019;s supplemental New Drug Application approving an expansion of the FIRDAPSE&#xae; label to include pediatric patients (ages six and older). In the second quarter of 2024, the FDA approved the Company&#x2019;s supplemental New Drug Application increasing the indicated maximum daily dose of FIRDAPSE&#xae; (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of LEMS.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA&#xae; (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of the U.S. rights to FYCOMPA&#xae; on January 24, 2023 and is now marketing FYCOMPA&#xae; in the U.S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2023, the Company completed its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an exclusive license for North America for AGAMREE&#xae; (vamorolone), a treatment for patients suffering from Duchenne muscular dystrophy (DMD). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in that jurisdiction. Additionally, the Company holds the North American rights for any future approved indications of AGAMREE&#xae;. AGAMREE&#xae; previously received FDA Orphan Drug and Fast Track designations and on October 26, 2023, the FDA approved AGAMREE&#xae; oral suspension 40 mg/ml for the treatment of DMD in patients aged two years and older. On March 13, 2024, the Company commercially launched AGAMREE&#xae; in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has devoted substantially all its efforts since inception to selling its products, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and research and development. The Company has been able to fund its cash needs to date through profits generated from sales of its products and offerings of its securities. See Note 15 (Stockholders&#x2019; Equity).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capital Resources&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the Company's current financial condition, including its profitability, cash flows generated from operations and forecasts of available cash, the Company believes it has sufficient funds to support operations for at least the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization and Description of Business (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#x2019;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 9, 2024, the Company completed a public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock, raising net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The proceeds of the offering will be used to acquire new products and for general corporate purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_11716830-bd78-4cfa-b354-d95373de3afc"
      decimals="-6"
      id="F_1f385ce9-3dd6-44b9-bb08-efca2a9db265"
      unitRef="U_shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_11716830-bd78-4cfa-b354-d95373de3afc"
      decimals="-5"
      id="F_e0263344-b780-446d-8678-8fb78d96984a"
      unitRef="U_USD">140700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_92af92d3-b1c2-4d70-a8c8-00dcb7ce4c0a">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;a.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PRINCIPLES OF CONSOLIDATION.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;b.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;USE OF ESTIMATES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;c.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CASH AND CASH EQUIVALENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company primarily invests in high credit-quality instruments in order to obtain higher yields on its cash equivalents. The Company considers all highly liquid instruments, purchased with an original maturity of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has its cash and cash equivalents deposited with two financial institutions.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;d.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVESTMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; At December 31, 2024 and 2023, investments consisted of U.S. Treasuries and an investment in equity securities. Such investments are not insured by the U.S. Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries held at December 31, 2024 and 2023 were classified as available-for-sale securities. The Company classifies U.S. Treasuries with stated maturities of greater than three months and less than one year in short-term investments. U.S. Treasuries with stated maturities greater than one year are classified as non-current investments in its consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (in stockholders&#x2019; equity). Realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statements of operations and comprehensive income. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of its available-for-sale securities are judged to be as a result of a credit loss. The Company considers various factors in determining whether to recognize an allowance for credit losses including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. If the unrealized loss of an available-for-sale debt security is determined to be a result of a credit loss the Company would recognize an allowance and the corresponding credit loss would be included in the consolidated statements of operations and comprehensive income. The Company has not recorded an allowance for credit loss on its available-for-sale securities. See Note 3 (Investments).&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2023, the Company made a strategic equity investment into Santhera by acquiring &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Santhera&#x2019;s  ordinary shares (representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of Santhera&#x2019;s outstanding ordinary shares immediately following the transaction). The investment is denominated in Swiss Francs. The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera&#x2019;s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes resulting from movements in foreign exchange rates, in other income, net in the consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;e.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ACCOUNTS RECEIVABLE, NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Accounts receivable are recorded net of customer allowances for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed. At December 31, 2024 and 2023, the Company determined that an allowance for expected credit losses was not required. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts were written off during the periods presented.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;f.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVENTORY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE&#xae;, FYCOMPA&#xae; and AGAMREE&#xae; are also used in clinical programs to assess the safety and efficacy of the products for usage in treating diseases that have not been approved by the FDA or other regulatory authorities. The forms of FIRDAPSE&#xae;, FYCOMPA&#xae; and AGAMREE&#xae; utilized for both commercial and clinical programs are identical and, as a result, the inventories have an &#x201c;alternative future use&#x201d; as defined in authoritative guidance. Raw materials associated with clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an &#x201c;alternative future use&#x201d;.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, and patient usage.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;g.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements, and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company&#x2019;s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing costs consist of advances for the Company&#x2019;s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;h.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PROPERTY AND EQUIPMENT,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_af1f8375-788a-4903-85b9-db67fcf6e271;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for computer equipment and software, from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_af087444-9da2-4e54-b835-1802f923ce72;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for furniture and equipment, and from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;i.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BUSINESS COMBINATIONS AND ASSET ACQUISITIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion of the Company&#x2019;s exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#xae; in the U.S. and Mexico, which the Company accounted for as an asset acquisition under ASC 805-50. See Note 13 (Agreements) for further discussion on the Company&#x2019;s acquisitions of the U.S. rights to FYCOMPA&#xae; from Eisai, and on the exclusive license for North America acquired from Santhera for AGAMREE&#xae;, both of which the Company accounted for as asset acquisitions under ASC 805-50.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;j.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INTANGIBLE ASSETS, NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;k.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company&#x2019;s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and certain components of accrued expenses and other liabilities. At December 31, 2024 and December 31, 2023, the fair value of these instruments approximated their carrying value as a result of their respective short-term duration. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;l.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FAIR VALUE MEASUREMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity&#x2019;s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity&#x2019;s own assumptions, as there is little, if any, related market activity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.984%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.188%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.943999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;m.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;OPERATING LEASES. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, net, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company&#x2019;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;n.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SHARE REPURCHASES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In March 2021, the Company&#x2019;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock. The share repurchase program currently expires in March 2025. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock&#x2019;s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;REVENUE RECOGNITION. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Revenues:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (ASC) Topic 606 &#x2013; Revenue from Contracts with Customers (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue when its customers obtain title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. For FIRDAPSE&#xae; and AGAMREE&#xae;, subsequent to receiving FDA approvals, the Company entered into an arrangement with one distributor (the Customer), which is the exclusive distributor of FIRDAPSE&#xae; and AGAMREE&#xae; in the U.S. The Customer subsequently resells FIRDAPSE&#xae; and AGAMREE&#xae; to a small group of exclusive specialty pharmacies (SPs) whose dispensing activities for patients with specific payors may result in government-mandated or privately negotiated rebate obligations for the Company with respect to the purchase of FIRDAPSE&#xae; and AGAMREE&#xae;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company sold FYCOMPA&#xae; in the U.S. commercial market through a Transition Service Agreement with a U.S. subsidiary of Eisai to major wholesalers and specialty pharmaceutical distributors. These sales are often subject to contracts held with managed care organizations and government agencies. The distribution services under the Transition Services Agreement ended on December 31, 2023, and beginning on January 1, 2024, the Company commenced direct sales of FYCOMPA&#xae; in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product Revenue, Net:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company recognizes revenue on product sales when its customers obtain control of the Company&#x2019;s products, which occur at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company&#x2019;s payment terms range between 15 and 60 days.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, substantially all of the Company&#x2019;s product revenues were from sales to customers in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net product revenue disaggregated by product (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FIRDAPSE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FYCOMPA&#xae;+&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;489,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;+ FYCOMPA&#xae; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves for Variable Consideration:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, prompt payment discounts, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers relating to the Company&#x2019;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to its customers) or a current liability (if the amount is payable to a party other than its customers).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#x2019;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2024 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade Discounts, Allowances and Wholesaler Fees:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides its customers with a discount that is explicitly stated in its contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. To the extent the services received are distinct from the sale of products to its customers, these payments are classified in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income. However, if the Company has determined such services received are not distinct from the Company&#x2019;s sale of products to its customers, these payments have been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive income through December 31, 2024, 2023 and 2022, as well as a reduction to accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prompt Payment Discounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual invoice sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Funded Co-pay Assistance Program:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company contracts with a third party to manage the co-pay assistance program intended to provide financial assistance to qualified commercially-insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with its products, that have been recognized as revenue, but remains in the distribution channel at the end of each reporting period. These payments are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution or master agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. Return payments related to the sale of products are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provider Chargebacks and Discounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to the customer, who directly purchases the product from the Company. The customer charges the Company for the difference between what they paid for the product and the ultimate selling price to the qualified healthcare providers. The Company also participates in programs with government entities and other parties, including covered entities under the 340B Drug Pricing Program, whereby pricing on FYCOMPA&#xae; is extended below wholesaler list price to participating entities (the FYCOMPA&#xae; Participants). These entities purchase FYCOMPA&#xae; through wholesalers at the lower program price and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue, net and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by the customer or at the time of a resale to a FYCOMPA&#xae; Participant by a wholesaler, and the Company generally issues credits for such amounts within a few weeks of the customer or wholesalers&#x2019; notification to the Company of the resale. Reserves for chargebacks consist primarily of chargebacks that the customer or wholesalers have claimed, but for which the Company has not yet issued a credit, as well as an estimate of chargeback claims that the Company expects to receive associated with its products, that have been recognized as revenue but remains in the distribution channel at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Government Rebates:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company is subject to discount obligations under state Medicaid, Medicare and other government programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For reserves related to the sale of its products, there is an establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the coverage gap program is sunsetting in 2024 and is being replaced with the Inflation Reduction Act (IRA) program. While most components of this program will begin 2025, the inflation penalty portion is effective as of 2024. Specifically, the program imposes manufacturer rebates on certain Part B and Part D drugs when prices rise faster than the rate of inflation. The Company has estimated this potential impact and has accounted for these inflation-related rebates as a reduction of product revenue in 2024 to the extent they apply to its drug portfolio. Similar to the coverage gap rebates, the associated reserve is accrued for as a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payor Rebates: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balances sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Bridge and Patient Assistance Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides FIRDAPSE&#xae; and AGAMREE&#xae; free of charge to uninsured patients who satisfy pre-established criteria for either the Bridge Program or the Patient Assistance Program. Patients who meet the Bridge Program eligibility criteria and are transitioning from investigational product while they are waiting for a coverage determination, or later, for patients whose access is threatened by the complications arising from a change of insurer may receive a temporary supply of free FIRDAPSE&#xae; or AGAMREE&#xae; while the Company is determining the patient&#x2019;s third party insurance, prescription drug benefit or other third party coverage for FIRDAPSE&#xae; or AGAMREE&#xae;. The Patient Assistance Program provides FIRDAPSE&#xae; or AGAMREE&#xae; free of charge for longer periods of time for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#xae; or AGAMREE&#xae; because they are unable to obtain coverage from their payor despite having health insurance, to the extent allowed by applicable law.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company provides FYCOMPA&#xae; free of charge to uninsured patients who satisfy pre-established criteria through a Patient Assistance Program. In addition, Catalyst provides programs to assist patients through the process for obtaining reimbursement approval for their FYCOMPA&#xae; prescriptions from their insurers. Catalyst also provides support for patients using FYCOMPA&#xae; through an Instant Savings Card Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenues from Collaboration and Licensing Arrangements:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration (Topic 808), to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. Revenue is included in product revenue, net in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. Revenue is included in license and other revenue in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes sales-based royalties or net profit-sharing when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Revenue is included in license and other revenue in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments to and from the collaborator are presented in the statements of operations based on the nature of the Company&#x2019;s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 11 (Collaborative and Licensing Arrangements), for further discussion on the Company&#x2019;s collaborative and licensing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;p.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RESEARCH AND DEVELOPMENT.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research-related services for the Company.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records upfront and milestone payments made to third parties under licensing and collaboration arrangements that occur before a compound receives regulatory approval as acquired in-process research and development (IPR&amp;amp;D). IPR&amp;amp;D acquired as part of an asset acquisition with no alternative future use is expensed immediately to research and development. Milestone payments made after regulatory approval are capitalized as a developed asset and unless the asset is determined to have an indefinite life, the Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over their estimated useful lives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;q.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ADVERTISING EXPENSE. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. The Company incurred approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in advertising costs during the years ended December 31, 2024, 2023 and 2022, respectively, which are included in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;r.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;STOCK-BASED COMPENSATION. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;s.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CONCENTRATION OF RISK. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company sells its products, FIRDAPSE&#xae; and AGAMREE&#xae;, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to these products. The Company sells its product, FYCOMPA&#xae;, directly to major wholesalers and specialty pharmaceutical distributors and indirectly to managed care organizations and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE&#xae;. The Company expects sales of FIRDAPSE&#xae;, FYCOMPA&#xae;, and AGAMREE&#xae; to constitute virtually all of the Company&#x2019;s product revenue for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE&#xae;. The Company relies on the same third party manufacturers for FYCOMPA&#xae; as utilized by Eisai prior to the Company&#x2019;s acquisition of the U.S. rights to the product in January 2023. It also relies on Santhera and its supplier as its sole source of supply for AGAMREE&#xae;. If the Company is unable to continue its relationships with one or more of these third party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third party contractors to manufacture the commercial supply of its drugs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates the approximate percentage of the Company&#x2019;s total net product revenue attributed to the Company&#x2019;s largest customers for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;t.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ROYALTIES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Royalties incurred in connection with the Company&#x2019;s license agreement for FIRDAPSE&#xae; and AGAMREE&#xae;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalties incurred in connection with the Company&#x2019;s license agreement for RUZURGI&#xae;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized for any royalties in excess of the minimum annual royalty payment from July 11, 2022 (the Effective Date) through 2025. The minimum royalty payment that exists annually for calendar years from the Effective Date through 2025 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are included in the purchase price of the agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;u.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INCOME TAXES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2021. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;v.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;COMPREHENSIVE INCOME.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders&#x2019; equity. The Company&#x2019;s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2024, 2023 and 2022, and is comprised of net unrealized gains (losses) on the Company&#x2019;s available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;w.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NET INCOME PER COMMON SHARE.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles basic and diluted weighted average common shares:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.726%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.407%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.43%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,457,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,279,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,374,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,485,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,473,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,001,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,943,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,753,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,375,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Outstanding common stock equivalents totaling approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, were excluded from the calculation of diluted net income per common share for the years ended December 31, 2024, 2023 and 2022, respectively, as their effect would be anti-dilutive. Potentially dilutive options to purchase common stock as of December 31, 2024, 2023 and 2022 had exercise prices ranging from&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;x.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SEGMENT INFORMATION.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Management has determined that the Company operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which is the development and commercialization of drug products. The Company's chief operating decision maker (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM) is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fc95014e-239d-4684-9334-a50e46b93483;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;president and chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who reviews financial information presented on a consolidated basis.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These financial metrics are used by the CODM t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;o make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating margin and the allocation of budget between cost of revenues, selling, research and development, and general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 	&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates information about significant segment expenses:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;     (a)     &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;exclusive of amortization of intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;y.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RECLASSIFICATIONS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;z.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RECENTLY ISSUED ACCOUNTING STANDARDS. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (ASU 2023-07) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 during the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which requires significant disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance will be applied prospectively and is effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the impact of the standard on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement: Reporting Comprehensive Income&#x2014; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0e0bd480-23a8-4b40-ab05-03ea49652432">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;a.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PRINCIPLES OF CONSOLIDATION.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_fd8fa3f7-f05b-4e26-8a82-d8d6bceaa7ad">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;USE OF ESTIMATES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_bc789707-9c93-4134-879c-5f062456f71b">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;c.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CASH AND CASH EQUIVALENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company primarily invests in high credit-quality instruments in order to obtain higher yields on its cash equivalents. The Company considers all highly liquid instruments, purchased with an original maturity of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has its cash and cash equivalents deposited with two financial institutions.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cprx:MaximumMaturityPeriodOfCashAndCashEquivalent
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_80d75849-92b4-4257-a24d-b293e7ed355d">three months </cprx:MaximumMaturityPeriodOfCashAndCashEquivalent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_37d75c48-6e30-4f99-8b01-0ab0e8590dcd">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;d.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVESTMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; At December 31, 2024 and 2023, investments consisted of U.S. Treasuries and an investment in equity securities. Such investments are not insured by the U.S. Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries held at December 31, 2024 and 2023 were classified as available-for-sale securities. The Company classifies U.S. Treasuries with stated maturities of greater than three months and less than one year in short-term investments. U.S. Treasuries with stated maturities greater than one year are classified as non-current investments in its consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (in stockholders&#x2019; equity). Realized gains and losses are included in other income, net in the consolidated statements of operations and comprehensive income and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statements of operations and comprehensive income. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of its available-for-sale securities are judged to be as a result of a credit loss. The Company considers various factors in determining whether to recognize an allowance for credit losses including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. If the unrealized loss of an available-for-sale debt security is determined to be a result of a credit loss the Company would recognize an allowance and the corresponding credit loss would be included in the consolidated statements of operations and comprehensive income. The Company has not recorded an allowance for credit loss on its available-for-sale securities. See Note 3 (Investments).&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2023, the Company made a strategic equity investment into Santhera by acquiring &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Santhera&#x2019;s  ordinary shares (representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of Santhera&#x2019;s outstanding ordinary shares immediately following the transaction). The investment is denominated in Swiss Francs. The Company has determined that it does not have significant influence over the operations of Santhera and accordingly the investment in Santhera&#x2019;s ordinary shares is recorded under ASC 321, Equity Securities, with changes in fair value, inclusive of changes resulting from movements in foreign exchange rates, in other income, net in the consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;</us-gaap:InvestmentPolicyTextBlock>
    <cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c"
      decimals="0"
      id="F_6b80c94d-f884-40f4-9193-1774de86ceec"
      unitRef="U_shares">1414688</cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares
      contextRef="C_546d356a-6c67-4823-bd4c-e714e8e5ae8c"
      decimals="4"
      id="F_0b4a33eb-9a51-4ca1-a89b-928f26707931"
      unitRef="U_pure">0.1126</cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_cc25b986-982e-42d3-af6a-0a3aeb6cb475">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;e.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ACCOUNTS RECEIVABLE, NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Accounts receivable are recorded net of customer allowances for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed. At December 31, 2024 and 2023, the Company determined that an allowance for expected credit losses was not required. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts were written off during the periods presented.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_8d9c27e4-ff1b-45e4-bcc3-ace8dd046bae"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="INF"
      id="F_2042e2e3-ece0-4663-a828-748e7e623613"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0697907b-9bb1-41bb-a761-1bd65b74884e">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;f.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVENTORY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Products that have been approved by the FDA or other regulatory authorities, such as FIRDAPSE&#xae;, FYCOMPA&#xae; and AGAMREE&#xae; are also used in clinical programs to assess the safety and efficacy of the products for usage in treating diseases that have not been approved by the FDA or other regulatory authorities. The forms of FIRDAPSE&#xae;, FYCOMPA&#xae; and AGAMREE&#xae; utilized for both commercial and clinical programs are identical and, as a result, the inventories have an &#x201c;alternative future use&#x201d; as defined in authoritative guidance. Raw materials associated with clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an &#x201c;alternative future use&#x201d;.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance, and patient usage.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <cprx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f7e477f2-c544-485d-bec9-c6435f61314f">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;g.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements, and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company&#x2019;s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing costs consist of advances for the Company&#x2019;s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cprx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_703ca658-c6b2-47ce-94f6-d49fc13062bf">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PROPERTY AND EQUIPMENT,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_af1f8375-788a-4903-85b9-db67fcf6e271;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for computer equipment and software, from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_af087444-9da2-4e54-b835-1802f923ce72;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for furniture and equipment, and from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d3b52a8a-08b8-4367-8b90-1a1091dc96d4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_517f0446-4af8-4ed4-a041-177e495d6020"
      id="F_daa7bfa4-20db-4163-8534-ad53d70f1dc3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6c1acb2b-a004-4627-8c8b-62b043c6ae4f"
      id="F_eb036f14-81e0-407c-9ed3-79cbc9712152">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_578e3acb-13d3-45de-b073-1b8543855c9c"
      id="F_9f2e1209-d796-4a49-b827-fc1504335963">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_7633232e-9a4a-4cf3-a99b-84c53c0d3bf8">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;i.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BUSINESS COMBINATIONS AND ASSET ACQUISITIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Notes 12 (Commitments and Contingencies) and 13 (Agreements) for further discussion of the Company&#x2019;s exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#xae; in the U.S. and Mexico, which the Company accounted for as an asset acquisition under ASC 805-50. See Note 13 (Agreements) for further discussion on the Company&#x2019;s acquisitions of the U.S. rights to FYCOMPA&#xae; from Eisai, and on the exclusive license for North America acquired from Santhera for AGAMREE&#xae;, both of which the Company accounted for as asset acquisitions under ASC 805-50.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d0d2ca7c-cc2c-46f8-a631-8576e3c74337">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;j.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INTANGIBLE ASSETS, NET.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, the Company would estimate the fair value of the assets and record an impairment loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_89a06719-2093-49f5-b3ac-9c17e66466c0">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;k.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company&#x2019;s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and certain components of accrued expenses and other liabilities. At December 31, 2024 and December 31, 2023, the fair value of these instruments approximated their carrying value as a result of their respective short-term duration. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_77fd132f-e8d3-43c6-ba49-3b3ba5df480e">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;l.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FAIR VALUE MEASUREMENTS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity&#x2019;s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity&#x2019;s own assumptions, as there is little, if any, related market activity.&lt;/span&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.984%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.188%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.943999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_988d19f3-86a8-4466-ad73-3b20009287e5">
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.984%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.436%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.479%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.791%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.188%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.594999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:11.943999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balances as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets/&lt;br/&gt;Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investment in equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_556226bc-36cb-4e4c-af68-b7221da14303"
      decimals="-3"
      id="F_0fd654fd-13e5-4a20-8b48-7b6a8e7dedd5"
      unitRef="U_USD">109947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_36b51e6f-78fe-4d4b-8094-ef5504c510aa"
      decimals="-3"
      id="F_b5c1218a-86a0-438d-b0e5-942ebf99c3e1"
      unitRef="U_USD">109947000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_be3b877f-8d5f-446a-ab53-63009d18c5b5"
      decimals="-3"
      id="F_4bfdbfdf-491e-4f32-99be-b721eca088b8"
      unitRef="U_USD">329457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_641f77d8-a8c4-4ee2-9594-6cbd48dc0f85"
      decimals="-3"
      id="F_bc205fea-d817-424d-9ffb-417692743bd4"
      unitRef="U_USD">329457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d3e62045-09fe-46e4-b7c0-83bcc9562e17"
      unitRef="U_USD">21564000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_de1a8f83-1949-42be-9761-1b0a53274e18"
      decimals="-3"
      id="F_9658a8d2-3066-41a1-a3a0-039a996968ea"
      unitRef="U_USD">21564000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_685da0b4-944b-4ee5-98c3-1fd7acde1f9b"
      decimals="-3"
      id="F_f2cfe5ff-3f1a-489e-aa4b-e80f97b3c329"
      unitRef="U_USD">18256000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5f8fe6ab-7ff7-4826-aac8-a94da76c2e7b"
      decimals="-3"
      id="F_879e66c5-cc22-4a34-85b0-c417c3134b1b"
      unitRef="U_USD">18256000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f33c6eaf-ab74-4de4-8b0a-b6b2d34223af"
      decimals="-3"
      id="F_270e7833-c226-4aad-9a73-182bfe627026"
      unitRef="U_USD">94523000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3052145c-1aab-4286-a4b8-bb9e3ef1c2a9"
      decimals="-3"
      id="F_4a0ba6ee-3944-4543-9727-8b93c351b11e"
      unitRef="U_USD">94523000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_ff2e2217-c088-4f62-9f30-3cfff5ef481d"
      unitRef="U_USD">16489000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="C_a0a9bef3-9a5a-46af-831b-722f42e564bd"
      decimals="-3"
      id="F_babac47e-4e30-4e82-a1f9-4d1fab47268b"
      unitRef="U_USD">16489000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2419c74a-d34c-4d8d-86bd-4ef4acf8067b">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;m.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;OPERATING LEASES. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, net, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company&#x2019;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company&#x2019;s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <cprx:ShareRepurchases
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f2c645bf-ecf2-4bcb-91d0-1e40bdefd2c3">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;n.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SHARE REPURCHASES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In March 2021, the Company&#x2019;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock. The share repurchase program currently expires in March 2025. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock&#x2019;s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.&lt;/span&gt;&lt;/p&gt;</cprx:ShareRepurchases>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c"
      decimals="-6"
      id="F_c4e231ed-dc19-4830-85ae-9a92752a49b7"
      unitRef="U_USD">40000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_6259e4bd-b209-4b77-9fec-ed7ac3436f2d">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;REVENUE RECOGNITION. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Revenues:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (ASC) Topic 606 &#x2013; Revenue from Contracts with Customers (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for product revenue, see Product Revenue, Net below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also may generate revenues from payments received under collaborative and license agreements. Collaborative and license agreement payments may include nonrefundable fees at the inception of the agreements, contingent payments for specific achievements designated in the agreements, and/or net profit-sharing payments on sales of products resulting from the collaborative and license arrangements. For a complete discussion of accounting for collaborative and licensing arrangements, see Revenues from Collaboration and Licensing Arrangements below.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue when its customers obtain title of the promised goods, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for these goods. For FIRDAPSE&#xae; and AGAMREE&#xae;, subsequent to receiving FDA approvals, the Company entered into an arrangement with one distributor (the Customer), which is the exclusive distributor of FIRDAPSE&#xae; and AGAMREE&#xae; in the U.S. The Customer subsequently resells FIRDAPSE&#xae; and AGAMREE&#xae; to a small group of exclusive specialty pharmacies (SPs) whose dispensing activities for patients with specific payors may result in government-mandated or privately negotiated rebate obligations for the Company with respect to the purchase of FIRDAPSE&#xae; and AGAMREE&#xae;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company sold FYCOMPA&#xae; in the U.S. commercial market through a Transition Service Agreement with a U.S. subsidiary of Eisai to major wholesalers and specialty pharmaceutical distributors. These sales are often subject to contracts held with managed care organizations and government agencies. The distribution services under the Transition Services Agreement ended on December 31, 2023, and beginning on January 1, 2024, the Company commenced direct sales of FYCOMPA&#xae; in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product Revenue, Net:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company recognizes revenue on product sales when its customers obtain control of the Company&#x2019;s products, which occur at a point in time (upon delivery or upon dispense to patient). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company&#x2019;s payment terms range between 15 and 60 days.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If taxes should be collected from the Customer relating to product sales and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, substantially all of the Company&#x2019;s product revenues were from sales to customers in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net product revenue disaggregated by product (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FIRDAPSE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FYCOMPA&#xae;+&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;489,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;+ FYCOMPA&#xae; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves for Variable Consideration:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, prompt payment discounts, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers relating to the Company&#x2019;s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to its customers) or a current liability (if the amount is payable to a party other than its customers).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company&#x2019;s analyses also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of December 31, 2024 and, therefore, the transaction price was not reduced further during the years ended December 31, 2024, 2023 and 2022. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade Discounts, Allowances and Wholesaler Fees:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides its customers with a discount that is explicitly stated in its contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. To the extent the services received are distinct from the sale of products to its customers, these payments are classified in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income. However, if the Company has determined such services received are not distinct from the Company&#x2019;s sale of products to its customers, these payments have been recorded as a reduction of revenue within the consolidated statements of operations and comprehensive income through December 31, 2024, 2023 and 2022, as well as a reduction to accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prompt Payment Discounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual invoice sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Funded Co-pay Assistance Program:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company contracts with a third party to manage the co-pay assistance program intended to provide financial assistance to qualified commercially-insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with its products, that have been recognized as revenue, but remains in the distribution channel at the end of each reporting period. These payments are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution or master agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. Return payments related to the sale of products are considered payable to the third party vendor and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provider Chargebacks and Discounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to the customer, who directly purchases the product from the Company. The customer charges the Company for the difference between what they paid for the product and the ultimate selling price to the qualified healthcare providers. The Company also participates in programs with government entities and other parties, including covered entities under the 340B Drug Pricing Program, whereby pricing on FYCOMPA&#xae; is extended below wholesaler list price to participating entities (the FYCOMPA&#xae; Participants). These entities purchase FYCOMPA&#xae; through wholesalers at the lower program price and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue, net and accounts receivable, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by the customer or at the time of a resale to a FYCOMPA&#xae; Participant by a wholesaler, and the Company generally issues credits for such amounts within a few weeks of the customer or wholesalers&#x2019; notification to the Company of the resale. Reserves for chargebacks consist primarily of chargebacks that the customer or wholesalers have claimed, but for which the Company has not yet issued a credit, as well as an estimate of chargeback claims that the Company expects to receive associated with its products, that have been recognized as revenue but remains in the distribution channel at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Government Rebates:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company is subject to discount obligations under state Medicaid, Medicare and other government programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For reserves related to the sale of its products, there is an establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the coverage gap program is sunsetting in 2024 and is being replaced with the Inflation Reduction Act (IRA) program. While most components of this program will begin 2025, the inflation penalty portion is effective as of 2024. Specifically, the program imposes manufacturer rebates on certain Part B and Part D drugs when prices rise faster than the rate of inflation. The Company has estimated this potential impact and has accounted for these inflation-related rebates as a reduction of product revenue in 2024 to the extent they apply to its drug portfolio. Similar to the coverage gap rebates, the associated reserve is accrued for as a current liability, which is included in accrued expenses and other liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payor Rebates: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses and other liabilities on the consolidated balances sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Bridge and Patient Assistance Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company provides FIRDAPSE&#xae; and AGAMREE&#xae; free of charge to uninsured patients who satisfy pre-established criteria for either the Bridge Program or the Patient Assistance Program. Patients who meet the Bridge Program eligibility criteria and are transitioning from investigational product while they are waiting for a coverage determination, or later, for patients whose access is threatened by the complications arising from a change of insurer may receive a temporary supply of free FIRDAPSE&#xae; or AGAMREE&#xae; while the Company is determining the patient&#x2019;s third party insurance, prescription drug benefit or other third party coverage for FIRDAPSE&#xae; or AGAMREE&#xae;. The Patient Assistance Program provides FIRDAPSE&#xae; or AGAMREE&#xae; free of charge for longer periods of time for those who are uninsured or functionally uninsured with respect to FIRDAPSE&#xae; or AGAMREE&#xae; because they are unable to obtain coverage from their payor despite having health insurance, to the extent allowed by applicable law.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company provides FYCOMPA&#xae; free of charge to uninsured patients who satisfy pre-established criteria through a Patient Assistance Program. In addition, Catalyst provides programs to assist patients through the process for obtaining reimbursement approval for their FYCOMPA&#xae; prescriptions from their insurers. Catalyst also provides support for patients using FYCOMPA&#xae; through an Instant Savings Card Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenues from Collaboration and Licensing Arrangements:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes license and collaboration arrangements pursuant to FASB ASC Topic 808, Collaborative Arrangement Guidance and Consideration (Topic 808), to assess whether such arrangements, or transactions between arrangement participants, involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities or are more akin to a vendor-customer relationship. In making this evaluation, the Company considers whether the activities of the collaboration are considered to be distinct and deemed to be within the scope of the collaborative arrangement guidance or if they are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For elements of collaboration arrangements that are not accounted for pursuant to guidance in Topic 606, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. Revenue is included in product revenue, net in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Significant Accounting Policies (continued).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The agreements provide for milestone payments upon achievement of development and regulatory events. The Company accounts for milestone payments as variable consideration in accordance with Topic 606. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and, if so, these options are considered performance obligations. Revenue is included in license and other revenue in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the overall transaction price is allocated to the performance obligations based on the same methodology used at contract inception.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes sales-based royalties or net profit-sharing when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty or net profit-sharing has been allocated has been satisfied. Revenue is included in license and other revenue in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments to and from the collaborator are presented in the statements of operations based on the nature of the Company&#x2019;s business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 11 (Collaborative and Licensing Arrangements), for further discussion on the Company&#x2019;s collaborative and licensing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2c65f616-7cf6-4de2-b929-51ed569a5b95">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net product revenue disaggregated by product (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FIRDAPSE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;FYCOMPA&#xae;+&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;489,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;+ FYCOMPA&#xae; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AGAMREE&#xae; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cc17f402-b8b7-4846-b664-e84632ab2a8f"
      decimals="-3"
      id="F_527373f0-fe09-4389-814b-2c1e7f6a378f"
      unitRef="U_USD">306035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a3c97892-bfc1-4d8c-9b02-7eb288071f27"
      decimals="-3"
      id="F_7ec06c76-37e7-46d8-a932-efdea2ba7b2d"
      unitRef="U_USD">258426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4ebf61f1-ea81-43ad-81d4-337230acd6fc"
      decimals="-3"
      id="F_d5036a41-7b9d-42b6-97f7-bfd841abc0c9"
      unitRef="U_USD">213938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a964cbf4-04fb-4e05-a570-316b7877d00d"
      decimals="-3"
      id="F_d7c32d70-ab8c-43a6-9e28-15f96a90187c"
      unitRef="U_USD">137251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c0d78ce3-51fb-44f9-a661-e786541f4b0f"
      decimals="-3"
      id="F_ecfad2e5-1ee6-4119-9494-9beb4590c583"
      unitRef="U_USD">138076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d9995f07-a56a-4e7e-b1c2-377bebd919d0"
      decimals="-3"
      id="F_881659e8-6047-47a8-a6b8-49f8b69ba572"
      unitRef="U_USD">46041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9b84b239-460f-4343-8a55-dd9c8d160502"
      decimals="-3"
      id="F_6c5d0700-7421-4049-b16a-80c252f66e08"
      unitRef="U_USD">489327000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_76b5439a-53d8-49ab-af66-1b56f6f623fd"
      decimals="-3"
      id="F_563bce81-0e82-4a35-be19-58b53bd70d2d"
      unitRef="U_USD">396502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b48f2bea-3319-4b24-87f1-db81866524fe"
      decimals="-3"
      id="F_a70d6518-5059-43f9-b4b9-a4a34893c8c1"
      unitRef="U_USD">213938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_dbce71a2-04aa-4911-9cef-5c8a3f5b09f8">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;p.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RESEARCH AND DEVELOPMENT.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research-related services for the Company.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records upfront and milestone payments made to third parties under licensing and collaboration arrangements that occur before a compound receives regulatory approval as acquired in-process research and development (IPR&amp;amp;D). IPR&amp;amp;D acquired as part of an asset acquisition with no alternative future use is expensed immediately to research and development. Milestone payments made after regulatory approval are capitalized as a developed asset and unless the asset is determined to have an indefinite life, the Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over their estimated useful lives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_17a19bba-8ad7-4f72-bf88-d96a21a877b3">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ADVERTISING EXPENSE. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. The Company incurred approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in advertising costs during the years ended December 31, 2024, 2023 and 2022, respectively, which are included in selling, general and administrative expenses in the Company&#x2019;s consolidated statements of operations and comprehensive income.&lt;/span&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b"
      decimals="-5"
      id="F_5573d2a4-5bdc-416d-8289-3ca90ab77489"
      unitRef="U_USD">10000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_96caeb09-9772-4554-9b52-38246d8f8c0e"
      decimals="-5"
      id="F_4b0813a6-ba6f-4652-8269-e424cf51dab9"
      unitRef="U_USD">9100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_d2c50c06-f8b1-40b0-b95b-16454488f954"
      decimals="-5"
      id="F_91adc952-2099-4122-9cf2-47f573877621"
      unitRef="U_USD">3300000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_4af32751-f5e0-41a9-818c-d554f8eeeefa">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;r.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;STOCK-BASED COMPENSATION. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cprx:MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f3cdd42e-bab3-4c40-b1fc-16720c714e44">P3Y</cprx:MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_43fb9923-93c1-4a5e-ae6c-31970646798a">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;s.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CONCENTRATION OF RISK. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company sells its products, FIRDAPSE&#xae; and AGAMREE&#xae;, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to these products. The Company sells its product, FYCOMPA&#xae;, directly to major wholesalers and specialty pharmaceutical distributors and indirectly to managed care organizations and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE&#xae;. The Company expects sales of FIRDAPSE&#xae;, FYCOMPA&#xae;, and AGAMREE&#xae; to constitute virtually all of the Company&#x2019;s product revenue for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE&#xae;. The Company relies on the same third party manufacturers for FYCOMPA&#xae; as utilized by Eisai prior to the Company&#x2019;s acquisition of the U.S. rights to the product in January 2023. It also relies on Santhera and its supplier as its sole source of supply for AGAMREE&#xae;. If the Company is unable to continue its relationships with one or more of these third party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third party contractors to manufacture the commercial supply of its drugs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates the approximate percentage of the Company&#x2019;s total net product revenue attributed to the Company&#x2019;s largest customers for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d7404b0b-9e2d-4158-9d74-9f99092cd454">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates the approximate percentage of the Company&#x2019;s total net product revenue attributed to the Company&#x2019;s largest customers for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Customer B*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_947bd494-b761-4eb9-88a5-277a61b73354"
      decimals="3"
      id="F_8908ec4d-2383-4836-8dcd-80320f5e65ad"
      unitRef="U_pure">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c2c87252-f283-4c4a-9b97-9a9c92725e3f"
      decimals="3"
      id="F_b0c538b0-cfea-4451-8254-55093e56403c"
      unitRef="U_pure">0.652</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b4f3694a-ca49-4caa-8b5c-bca9ff9a1642"
      decimals="3"
      id="F_b5e1ce43-d1b7-468c-b054-fbe2ce905ded"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_99496368-5345-4bb0-94b5-aed58a22c466"
      decimals="2"
      id="F_f4436702-baa2-4753-b4e4-736cc652c726"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fa8bafc8-49aa-4a6c-ba98-092b8ee3ad87"
      decimals="3"
      id="F_c7393005-53d8-43d7-905c-d6e3893fde43"
      unitRef="U_pure">0.348</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8b7f00ee-4559-46ef-9b02-67895013d0e5"
      decimals="2"
      id="F_40e080c9-fb3e-42e3-9405-9f5355bd8806"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_7edf969a-90c8-4fa0-819c-30ed128b4031"
      decimals="3"
      id="F_867ff943-6113-4987-8b30-5d5fe1321be2"
      unitRef="U_pure">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_67dce2a2-937e-4e9c-8d05-52a8de7df49a"
      decimals="3"
      id="F_090701e8-fa71-4bb0-8e45-228ef6ca16b6"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e5da14d5-3dc8-44d1-b668-b38be2324fa8"
      decimals="3"
      id="F_cd68d0cc-15b6-4c99-a1e1-fee5d2dd1c04"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <cprx:RoyaltiesExpensePolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_76e3bc2d-e130-41ed-b91e-a22e8f02cddf">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;t.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ROYALTIES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Royalties incurred in connection with the Company&#x2019;s license agreement for FIRDAPSE&#xae; and AGAMREE&#xae;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalties incurred in connection with the Company&#x2019;s license agreement for RUZURGI&#xae;, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized for any royalties in excess of the minimum annual royalty payment from July 11, 2022 (the Effective Date) through 2025. The minimum royalty payment that exists annually for calendar years from the Effective Date through 2025 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are included in the purchase price of the agreement.&lt;/span&gt;</cprx:RoyaltiesExpensePolicyTextBlock>
    <cprx:MinimumRoyalty
      contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527"
      decimals="-6"
      id="F_80ad1668-9b29-45c7-b3a4-2ec072b4ebb3"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <cprx:MinimumRoyalty
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-6"
      id="F_a2ba0ac3-ff5f-4bd6-bdc3-c6bdb52c1f0a"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <cprx:MinimumRoyalty
      contextRef="C_465c30df-be19-4455-9dcb-aaf2927ffe62"
      decimals="-6"
      id="F_69e1ea1d-55a8-4a61-85be-38d4109950b7"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2108d1f7-3f04-4790-80ec-75e342b4deda">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;u.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INCOME TAXES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2021. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2defd399-c51a-41b3-980d-0b6038a8f47a">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;v.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;COMPREHENSIVE INCOME.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders&#x2019; equity. The Company&#x2019;s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2024, 2023 and 2022, and is comprised of net unrealized gains (losses) on the Company&#x2019;s available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_6cb2b66d-96e8-4793-9970-891557c5efed">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;w.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NET INCOME PER COMMON SHARE.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net income per common share is computed by dividing net income by the weighted average number of common shares outstanding, increased by the assumed conversion of other potentially dilutive securities during the period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles basic and diluted weighted average common shares:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.726%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.407%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.43%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,457,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,279,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,374,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,485,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,473,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,001,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,943,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,753,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,375,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Outstanding common stock equivalents totaling approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, were excluded from the calculation of diluted net income per common share for the years ended December 31, 2024, 2023 and 2022, respectively, as their effect would be anti-dilutive. Potentially dilutive options to purchase common stock as of December 31, 2024, 2023 and 2022 had exercise prices ranging from&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_a4c2d510-2468-4841-8807-304dc18adb5e">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles basic and diluted weighted average common shares:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:50.726%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.407%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.056999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.43%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,457,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,279,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,374,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,485,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,473,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,001,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,943,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,753,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,375,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_2b6ef366-0b1b-4908-9e8b-40c9d6698d72"
      unitRef="U_shares">118457673</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="0"
      id="F_a3262111-397f-45a9-b321-fd067fffbbbf"
      unitRef="U_shares">106279736</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="0"
      id="F_0d1da843-5ee0-4eb3-a91a-7fd514c67cc2"
      unitRef="U_shares">103374606</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_539d46e9-9abf-4388-91c3-caa8d62a5bd0"
      unitRef="U_shares">6485930</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="0"
      id="F_7f05a079-d164-43dc-a530-def693f091a6"
      unitRef="U_shares">7473418</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="0"
      id="F_c896b767-ff37-4362-9cfa-36d3678ce571"
      unitRef="U_shares">8001025</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_6eb8bfec-3c19-4904-8cb8-75e2e0b77ec1"
      unitRef="U_shares">124943603</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="0"
      id="F_b546c6f8-8347-4d1d-9f52-3ab375dc1735"
      unitRef="U_shares">113753154</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="0"
      id="F_76f82f3a-47cc-4f2d-bbd8-ba1ab8c79c3f"
      unitRef="U_shares">111375631</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-5"
      id="F_1038229d-d94e-4c6c-8d0e-a5df5b0b1a1c"
      unitRef="U_shares">6700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-5"
      id="F_98c1b411-8104-42a3-8b38-f6c60f93f316"
      unitRef="U_shares">4500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-5"
      id="F_dea675f7-a616-4e76-a2de-00845537edee"
      unitRef="U_shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_b251cbf9-0aa1-4c79-b133-5f199fbc5b0e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_56a9e9e1-38fd-4a38-8858-3de1a219f9ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.23</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="INF"
      id="F_7cfa0353-3610-4c89-a4d5-fa1ef61a0478"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="INF"
      id="F_ced02898-031d-4787-9537-faa3ebf09601"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="INF"
      id="F_3c1a18e2-2dda-4073-a268-2e5f93e4f6b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="INF"
      id="F_6c2a79f2-cc6c-4587-a177-958b2cc152d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_37aac078-d9ee-4e9d-92b7-745043d79426">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;x.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SEGMENT INFORMATION.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Management has determined that the Company operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which is the development and commercialization of drug products. The Company's chief operating decision maker (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM) is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fc95014e-239d-4684-9334-a50e46b93483;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;president and chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who reviews financial information presented on a consolidated basis.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These financial metrics are used by the CODM t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;o make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating margin and the allocation of budget between cost of revenues, selling, research and development, and general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 	&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates information about significant segment expenses:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;     (a)     &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;exclusive of amortization of intangible assets&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_bcbca938-e9c6-4aa2-a8a9-e2e94c0bf6d3"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_fa879947-85b8-4e47-82c9-2c689588da85">The CODM uses consolidated operating margin (operating income divided by product revenue, net) and net income to assess financial performance and allocate resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_4863c748-930f-4527-b4a7-da7852f1b269">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table illustrates information about significant segment expenses:&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;     (a)     &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;exclusive of amortization of intangible assets&lt;/span&gt;&lt;/span&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_47328395-c4f5-425e-bb09-324a5ab788d2"
      unitRef="U_USD">12648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_7f81251e-b40d-4bb2-82f1-a6adb05c1e9e"
      unitRef="U_USD">93150000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_bcbf119a-b622-4420-8a6f-74ce61be9e81"
      unitRef="U_USD">19789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_85ab21a8-799b-4419-bd5b-239ca0c0f306"
      unitRef="U_USD">118746000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_4026ab61-faa8-4cdc-a928-6a4591a5603f"
      unitRef="U_USD">91500000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_4ed55be4-b8ef-4d9d-8e0a-9f0a159e4bc9"
      unitRef="U_USD">31044000</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc"
      unitRef="U_USD">58994000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a"
      unitRef="U_USD">42210000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_47467f83-aca0-4199-b569-0a51fde6c304"
      unitRef="U_USD">26041000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_528907b0-46ca-4b1a-8a8c-c3e72ac6a5b9"
      unitRef="U_USD">190388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_f793012c-28ba-4338-8950-71ad3ca54999"
      unitRef="U_USD">226860000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_59bdc1c3-9499-448d-b279-f0147ab5a2fe"
      unitRef="U_USD">76874000</us-gaap:OperatingExpenses>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_b6dc836d-a789-4812-86ea-9ee5e179f012">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;y.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RECLASSIFICATIONS.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_733dd2ce-a4b1-48fe-a0d1-138664c9cf76">&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;z.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RECENTLY ISSUED ACCOUNTING STANDARDS. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (ASU 2023-07) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU 2023-07 and all existing segment disclosures in Topic 280. The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 during the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which requires significant disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance will be applied prospectively and is effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the impact of the standard on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement: Reporting Comprehensive Income&#x2014; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_9a843c46-dc1e-424a-a8f9-00e320b22e68">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries - Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries - Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; realized gains or losses from available-for-sale securities for the years ended December 31, 2024 or 2023. There were realized losses from sale of available-for-sale securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair values of available-for-sale securities at December 31, 2024, by contractual maturity, are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net gains (losses) recognized during the period on&lt;br/&gt;&#160;&#160;&#160;equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized net gains (losses) recognized during the&lt;br/&gt;&#160;&#160;&#160;period on equity securities still held at the reporting&lt;br/&gt;&#160;&#160;&#160;date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no sales of equity securities during the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f306df02-b09c-4dad-b5aa-63059ed63440">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Available-for-sale investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries - Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasuries - Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3e76c130-0386-4921-9a30-01e38dfe1755"
      decimals="-3"
      id="F_a65adb53-a039-4e2c-8283-c26880d4eac8"
      unitRef="U_USD">329457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_cef50498-2b2c-43e6-ac01-77fde9e03dec"
      decimals="-3"
      id="F_c4fa20d4-0e63-43e0-a8ef-8066f455d26d"
      unitRef="U_USD">84000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_cef50498-2b2c-43e6-ac01-77fde9e03dec"
      decimals="-3"
      id="F_8a45a72d-29bc-41b7-9624-e71c2410eba8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3e76c130-0386-4921-9a30-01e38dfe1755"
      decimals="-3"
      id="F_256f2d8c-84dd-4e4b-b9cb-145c2e99f1d1"
      unitRef="U_USD">329373000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_6dc3705c-5bd6-408e-8be4-9b73835c084c"
      unitRef="U_USD">329457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_3e448836-14ca-4923-a976-0625645098da"
      unitRef="U_USD">84000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_431f588f-b724-44dd-8093-aa0273c81afa"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_0278696e-47cb-4d2b-a5a1-7e2150fea8f8"
      unitRef="U_USD">329373000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_02c41411-07f0-46c6-b493-3634436dc399"
      decimals="-3"
      id="F_0276b4b7-1019-4ef2-ac4d-efebcbb31cc5"
      unitRef="U_USD">94523000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_dc509cd1-e714-4010-a518-68d402172ccd"
      decimals="-3"
      id="F_4fa7d420-687c-4858-892f-38d8c6dcdcb7"
      unitRef="U_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_dc509cd1-e714-4010-a518-68d402172ccd"
      decimals="-3"
      id="F_0108b4c7-0eac-4d8c-a45f-3f7ed9b80329"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_02c41411-07f0-46c6-b493-3634436dc399"
      decimals="-3"
      id="F_dba24fda-9cdb-4674-a069-9b34d11cae15"
      unitRef="U_USD">94505000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_b0e4a5bc-3bce-4a66-8a76-5773e926c8cd"
      unitRef="U_USD">94523000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_23b9b961-b95d-43c0-b691-1314e518b0ba"
      unitRef="U_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_8072bd19-e049-4eb2-82ad-62725490e256"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_cf2f9f07-7a29-4c79-b99c-97e68e3ead85"
      unitRef="U_USD">94505000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_ebc9756d-2a7a-477e-9bea-c31661dbb676"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="INF"
      id="F_a20942c1-a52b-4a98-9ed7-b5dda0f622d6"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_4ded9671-2bb2-4056-839b-ce5b77acac98"
      unitRef="U_USD">762000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <cprx:AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_61d619b5-9fa6-4229-9a8a-5b638bc83a01">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair values of available-for-sale securities at December 31, 2024, by contractual maturity, are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:AvailableForSaleSecuritiesByAmortizedCostUnrealizedGainsOrLossesAndFairValueTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_3492c3cd-0010-4f7a-987e-b8b4c457460f"
      unitRef="U_USD">329457000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_73ee862e-61ec-4678-ab2a-d5379af6cfb3">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net gains (losses) recognized during the period on&lt;br/&gt;&#160;&#160;&#160;equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized net gains (losses) recognized during the&lt;br/&gt;&#160;&#160;&#160;period on equity securities still held at the reporting&lt;br/&gt;&#160;&#160;&#160;date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_a276d4e2-7e44-4143-a755-b8a7aa1c68d3"
      unitRef="U_USD">5075000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_0d3ba64f-3f4f-4dae-b922-79a15aa72b44"
      unitRef="U_USD">3024000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_251e05d4-6df5-4b73-9b19-64161c8286de"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_fab98bf8-9b3e-4c87-b8ff-ab03992db07b"
      unitRef="U_USD">5075000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_9ba4da10-38d0-4844-9a86-db83813231ab"
      unitRef="U_USD">3024000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_74816607-e4d9-431c-a23d-4413efc2a3fc"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_5cf18c36-fe7d-4c49-8c09-15091b7de8ee">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated Other Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the changes in accumulated other comprehensive income, net of tax from unrealized gains (losses) on available-for-sale securities, the Company&#x2019;s only component of accumulated other comprehensive income for the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amount reclassified out of accumulated other comprehensive income, net of tax and into net income during the year ended December 31, 2022, was solely due to a realized loss from sale of available-for-sale securities. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no reclassifications out of accumulated other comprehensive income during the years ended December 31, 2024 or 2023. &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other comprehensive gain (loss) before&lt;br/&gt;&#160;&#160;&#160;reclassifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net current period other comprehensive gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other comprehensive gain (loss) before&lt;br/&gt;&#160;&#160;&#160;reclassifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net current period other comprehensive gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_52d5b900-3755-4f80-8421-4e081b39e418">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no reclassifications out of accumulated other comprehensive income during the years ended December 31, 2024 or 2023. &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.099999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other comprehensive gain (loss) before&lt;br/&gt;&#160;&#160;&#160;reclassifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net current period other comprehensive gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other comprehensive gain (loss) before&lt;br/&gt;&#160;&#160;&#160;reclassifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net current period other comprehensive gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2de88c77-0912-47da-84f1-785b1e0068b3"
      decimals="-3"
      id="F_3c53a2c0-943e-468a-bf4b-06b08f90802d"
      unitRef="U_USD">24000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_42eeb380-9665-41f1-b5ab-a9c3c4f0f8ac"
      unitRef="U_USD">10000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_bdf799e9-a892-4565-a856-2e37b7d498a5"
      unitRef="U_USD">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_8f261079-9206-4e8a-a15c-61f240834707"
      unitRef="U_USD">14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_4d2a5277-95db-486c-9256-00ef2caafd87"
      unitRef="U_USD">-50000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_d2daf9a2-e277-480b-8231-cbb56936f32f"
      unitRef="U_USD">50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_519632fa-a949-4952-8f1e-e60cbe4e3444"
      unitRef="U_USD">64000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_16ba1629-bcaf-4a12-b926-b8ce14dfdf75">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d4a39a54-1dff-45c0-9178-3b18d5dab1c9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_6f88f268-5885-40ca-9fa9-49966a60e7ea"
      unitRef="U_USD">6518000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_6b63dd53-a2c6-4cb6-a08e-4efe8fdb8bc4"
      unitRef="U_USD">1910000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_db7817a2-e1dd-4500-9330-fadae57e9bd2"
      unitRef="U_USD">3445000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_052519f6-4fa4-446b-8a49-be1d9649a40e"
      unitRef="U_USD">4573000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_662c472b-84b2-4a4d-b4d3-6913e788559d"
      unitRef="U_USD">9578000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_40368b01-6b8f-4aab-945c-cac14188e956"
      unitRef="U_USD">9161000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_2d6379a3-f281-44ff-9a2e-ee3c508771ff"
      unitRef="U_USD">19541000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_cd30948e-0165-4163-b5ba-ec3101e0df26"
      unitRef="U_USD">15644000</us-gaap:InventoryNet>
    <cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_9ce7cae7-0dab-414e-a5b2-5a60d15efaa0">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid subscriptions fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid commercialization expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due from collaborative and licensing arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid conference and travel expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid co-pay assistance program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</cprx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_3b7ddfd1-cc5f-4c59-902f-d99e3852738b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid subscriptions fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid commercialization expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due from collaborative and licensing arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid conference and travel expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid co-pay assistance program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <cprx:PrepaidManufacturingExpense
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_6e132074-ea47-47a3-aaef-6e643a559c4c"
      unitRef="U_USD">206000</cprx:PrepaidManufacturingExpense>
    <cprx:PrepaidManufacturingExpense
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_af9623a4-5849-4824-9e69-2a1981d57bca"
      unitRef="U_USD">2005000</cprx:PrepaidManufacturingExpense>
    <us-gaap:PrepaidTaxes
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e9843bc0-fad9-4e6c-9440-27112a3b5ac6"
      unitRef="U_USD">7959000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_e6e26ab8-29f4-490c-a837-2df3e4a24641"
      unitRef="U_USD">1238000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidInsurance
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_7d66996a-ddf6-4d03-93c9-bfd9a54e1b02"
      unitRef="U_USD">1660000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_66c803da-f8b9-4b67-9c3b-ceda150e181b"
      unitRef="U_USD">1332000</us-gaap:PrepaidInsurance>
    <cprx:PrepaidSubscriptionFees
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4fb86897-637b-4b0d-b162-7d35dfe05a72"
      unitRef="U_USD">1233000</cprx:PrepaidSubscriptionFees>
    <cprx:PrepaidSubscriptionFees
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_24596bb4-28b7-4882-a688-4ee2675dd66c"
      unitRef="U_USD">1299000</cprx:PrepaidSubscriptionFees>
    <cprx:PrepaidResearchFee
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_be785ae2-5099-4e1b-8ee4-7d42b6a470e0"
      unitRef="U_USD">1135000</cprx:PrepaidResearchFee>
    <cprx:PrepaidResearchFee
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_81a51d74-ec3e-4999-a5df-21b893541116"
      unitRef="U_USD">1500000</cprx:PrepaidResearchFee>
    <cprx:PrepaidCommercialExpenses
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4b5f0340-776e-4298-bb28-41e7509825c5"
      unitRef="U_USD">4957000</cprx:PrepaidCommercialExpenses>
    <cprx:PrepaidCommercialExpenses
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_40ccef85-44c7-4387-8d14-1695aa41cf30"
      unitRef="U_USD">3038000</cprx:PrepaidCommercialExpenses>
    <cprx:DueFromCollaborativeAndLicencingArrangements
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_da113539-3b13-4db6-9923-2fd853158489"
      unitRef="U_USD">11000</cprx:DueFromCollaborativeAndLicencingArrangements>
    <cprx:DueFromCollaborativeAndLicencingArrangements
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_6fa13f15-d8eb-4de1-90c1-b24b5ab9aba5"
      unitRef="U_USD">138000</cprx:DueFromCollaborativeAndLicencingArrangements>
    <cprx:PrepaidConferenceAndTravelExpenses
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e60f4796-0018-42d0-801c-2b6d27d53a13"
      unitRef="U_USD">1287000</cprx:PrepaidConferenceAndTravelExpenses>
    <cprx:PrepaidConferenceAndTravelExpenses
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_975f3bb3-ab3c-4a66-96e5-3e03e9466c97"
      unitRef="U_USD">771000</cprx:PrepaidConferenceAndTravelExpenses>
    <cprx:PrepaidCopayAssistanceProgram
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_72606b51-e171-4db1-923f-9206bfa2ad3e"
      unitRef="U_USD">1561000</cprx:PrepaidCopayAssistanceProgram>
    <cprx:PrepaidCopayAssistanceProgram
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_de1a7ed7-44b9-4ae3-b1a6-b32dce50eef4"
      unitRef="U_USD">863000</cprx:PrepaidCopayAssistanceProgram>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_c761f971-3b5f-4606-abeb-15826f8512d2"
      unitRef="U_USD">1030000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_97131aa3-e44f-4bb7-a8fa-0ccdf1d9d0b6"
      unitRef="U_USD">351000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_fda468e7-f362-4390-9728-10fe950d0283"
      unitRef="U_USD">21039000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_7db3d015-3778-4285-963d-b650d2fba1fa"
      unitRef="U_USD">12535000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_1217525a-830f-4218-b1d9-66cb0231b78c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating Leases. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an operating lease agreement for its corporate office. The lease includes an option to extend the lease for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and options to terminate the lease within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6d7694a8-4fef-4d34-ad3f-97f73cebc1d8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.6 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; obligations under finance leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into an agreement in May 2020 that amended its lease for its office facilities. Under the amended lease, the Company&#x2019;s leased space increased from approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,800&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of space to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of space. The amended lease commenced in March 2021 when construction of the asset was completed and space became available for use.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to lease was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease&lt;br/&gt;&#160;&#160;&#160;obligations:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental balance sheet information related to lease was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e02f321f-c2da-4a31-b171-0bb073d6f3b4;"&gt;&lt;span style="-sec-ix-hidden:F_af9bf51b-92c5-4e0c-beca-6ed527c2962a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. The weighted average discount rate used to determine the operating lease liabilities was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% as of December 31, 2024 and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Remaining payments of lease liabilities as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rent expense was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_01ff7144-37b2-4380-8791-4d225c3f2d2a">5 years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873"
      id="F_3a9c9230-93ec-448f-91e1-23981a825942">7.6 years</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_5bcf7c57-e542-473c-9ea7-4b3750e7fee1"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <cprx:BeforeAgreementOfCompanyLeasedSpaces
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_bd68f933-d891-43ab-8b41-e4575e5e31ee"
      unitRef="U_sqft">7800</cprx:BeforeAgreementOfCompanyLeasedSpaces>
    <cprx:AfterAgreementOfCompanyLeasedSpaces
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="0"
      id="F_cf52e313-84a4-4fce-a410-309ea189f103"
      unitRef="U_sqft">10700</cprx:AfterAgreementOfCompanyLeasedSpaces>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_4d1ef844-0842-4a44-a87e-18b4e52b84dc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_77052ced-25bd-4e0c-b542-dc5ec51cca0e"
      unitRef="U_USD">431000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_a6738010-894f-4185-905e-dc1ed93cc16c"
      unitRef="U_USD">431000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_560fce43-d991-466a-ba09-de4cdbfe5fe7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to lease was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease&lt;br/&gt;&#160;&#160;&#160;obligations:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_4c2bac6f-e112-4959-bff1-d70e7cabbbcc"
      unitRef="U_USD">522000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_cd8553e5-d317-48b7-b717-40c0f52592ac"
      unitRef="U_USD">506000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_68b033a5-ef96-4999-a12d-d40cdcc7fc44"
      unitRef="U_USD">89000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_2df50425-d007-4d54-9432-e592360edaed"
      unitRef="U_USD">89000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cprx:ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0416301c-deb8-4032-9118-715a37b185f8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental balance sheet information related to lease was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e02f321f-c2da-4a31-b171-0bb073d6f3b4;"&gt;&lt;span style="-sec-ix-hidden:F_af9bf51b-92c5-4e0c-beca-6ed527c2962a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:ScheduleOfSupplementalBalanceSheetRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4c876b0c-2634-4df2-bb49-a6d0516c6638"
      unitRef="U_USD">2230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_5dc8674b-fb7b-4b34-a351-885e72b25197"
      unitRef="U_USD">2508000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_21a3de6d-dd63-426d-8792-9eac3aaf6b81"
      unitRef="U_USD">402000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_13ac50da-f17d-4e87-891e-cc0343cecd7f"
      unitRef="U_USD">369000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_aaedfc00-ab29-4be0-a259-c8c8ae74d580"
      unitRef="U_USD">2786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_8a78092b-ce24-4471-8b25-50593e5b3b60"
      unitRef="U_USD">3188000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_3177b4a3-a949-4a38-89eb-04ad32f70b0d"
      unitRef="U_USD">3188000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_1f18ff05-b040-4fd4-b757-cd3cc661a682"
      unitRef="U_USD">3557000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      id="F_694c5d1f-825d-4f23-a5d6-b42284bbceae">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      id="F_1b3aaaf9-1223-4556-8d69-561f1686a855">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="4"
      id="F_80cbe385-d130-4137-8d1b-e5b6a8e6e8de"
      unitRef="U_pure">0.0451</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_570934e5-4138-4723-8ec3-a1b1f5eb430d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Remaining payments of lease liabilities as of December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_235ebffc-272e-44c6-a0dd-de27a47d84b3"
      unitRef="U_USD">537000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_78144d54-1808-4153-b82c-3e67a2650fbb"
      unitRef="U_USD">553000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_114bf220-2310-4112-a2b9-80d281beda41"
      unitRef="U_USD">570000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_c823eeb2-828e-48d2-aeaa-3e5f6c59c4cc"
      unitRef="U_USD">587000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_479f1861-744a-40bf-b509-96a8c0b21005"
      unitRef="U_USD">605000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4958980f-bda3-433d-9345-77a945a672b7"
      unitRef="U_USD">835000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_6d6810e6-2711-4597-bda1-e72090d923a2"
      unitRef="U_USD">3687000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_339f0073-f878-42a1-b043-6e0db92d48a5"
      unitRef="U_USD">499000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_5b514792-f2b6-4f72-882c-d79283acf0f8"
      unitRef="U_USD">3188000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-5"
      id="F_74fef29d-efe0-4fe6-adb4-e3eca0bd9171"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-5"
      id="F_2ddf6c3c-72b5-437e-984d-5641fc26cc59"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-5"
      id="F_44a67fa3-e784-4d9a-b355-72bc19f9079f"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseCost>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2ca2413e-4e40-419f-8e3d-a6bc5a5a3c6b">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_43b2f010-f632-43f4-8b10-5c2314b89740">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_08f6bfdf-0d3b-44a6-a23d-b2f184873fd1"
      decimals="-3"
      id="F_e144b8bf-0e0c-4993-8fcb-d89a96ae4a6d"
      unitRef="U_USD">1050000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_21ec373d-d899-4e13-9fd1-cf11cc5ed214"
      decimals="-3"
      id="F_50c408b1-6acc-4c73-a279-a0fd14555064"
      unitRef="U_USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_71521487-ca68-4307-8394-188717a68617"
      decimals="-3"
      id="F_6c275858-f32e-4b28-a94f-c90071542bab"
      unitRef="U_USD">991000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c653309b-c27f-47f4-9795-b45c969d5d1f"
      decimals="-3"
      id="F_989cc69f-32f4-4b26-8339-ff7088e76dbc"
      unitRef="U_USD">991000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8be25042-7914-4b7c-bafc-23e4b7ab7fdf"
      decimals="-3"
      id="F_2e6c0787-42ed-44a0-883e-49076309eae1"
      unitRef="U_USD">433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bdd6ca59-0c27-40ea-814d-e69687c2f5b3"
      decimals="-3"
      id="F_ce233c55-0c83-4fb4-88e2-e8fc43b1edb1"
      unitRef="U_USD">433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d653073f-0351-4a50-b69d-5235f2e0b915"
      unitRef="U_USD">1120000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_daab077e-40c8-4486-9280-c845081aeee4"
      unitRef="U_USD">723000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_bcd6c46a-6afc-48bb-becf-7b64e75112d3"
      unitRef="U_USD">1354000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_bd1cfa4b-4f4c-4a79-bbf2-f8fa3050e3ca"
      unitRef="U_USD">1195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_efe74631-ec21-41ce-9fe0-57f70792b8bf">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License and Acquired Intangibles, Net. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s intangible assets at December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for RUZURGI&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s intangible assets at December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for RUZURGI&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company amortizes its definite-lived intangible assets using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life. The estimated useful life used for this purpose for RUZURGI&#xae;, FYCOMPA&#xae; and AGAMREE&#xae; was approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in amortization expense related to the licensed and acquired intangibles for RUZURGI&#xae; during the years ended December 31, 2024, 2023 and 2022, respectively, within selling, general and administrative expenses in the consolidated statements of operations and comprehensive income. The Company recorded approximately&lt;/span&gt;&lt;span style="color:#ed7d31;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in amortization expense related to the licensed and acquired intangibles for FYCOMPA&#xae; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income. The Company recorded approximately&lt;/span&gt;&lt;span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="color:#5b9bd5;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in amortization expense related to the licensed and acquired intangibles for AGAMREE&#xae; during the years ended December 31, 2024, 2023 and 2022, respectively, within cost of sales in the consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License and Acquired Intangibles, Net (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents future amortization expense the Company expects for its intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024 and December 31, 2023, the weighted average amortization period remaining for intangible assets was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment charges recognized on definite-lived intangibles for the years ended December 31, 2024, 2023 or 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_5bf1fa46-ae4d-4568-b5f8-e4dfdab0be9a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s intangible assets at December 31, 2024 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for RUZURGI&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s intangible assets at December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for RUZURGI&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3"
      decimals="-3"
      id="F_ae9fd2db-4b2c-4ab6-8746-52180f83eb9e"
      unitRef="U_USD">33569000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3"
      decimals="-3"
      id="F_13d86d01-741d-422f-8db4-a1940731865c"
      unitRef="U_USD">5739000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3"
      decimals="-3"
      id="F_6c5096bf-ff54-44c6-a719-8e6de79f8198"
      unitRef="U_USD">27830000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607"
      decimals="-3"
      id="F_88cca80e-3509-430c-89df-b0d75b686919"
      unitRef="U_USD">158143000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607"
      decimals="-3"
      id="F_d7887ebd-b730-4587-8ef6-65cc659eb6f8"
      unitRef="U_USD">61301000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607"
      decimals="-3"
      id="F_a662cfa6-4dc8-4988-8331-80463c6b5877"
      unitRef="U_USD">96842000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3"
      decimals="-3"
      id="F_74bb9ba1-2b6f-46b7-80da-049b87167c3d"
      unitRef="U_USD">36000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3"
      decimals="-3"
      id="F_9613bff9-0fb4-4944-b761-477164e65a21"
      unitRef="U_USD">4000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3"
      decimals="-3"
      id="F_34589d9e-ff85-4f86-9106-55a7b675a9d4"
      unitRef="U_USD">32000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_37aff173-00f9-4685-a0af-86a088422d8d"
      unitRef="U_USD">227712000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_231ede08-c006-413e-8af9-e4dfc63c3ad2"
      unitRef="U_USD">71040000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_7faaec86-6ff2-42df-8702-6e8b5a94c90b"
      unitRef="U_USD">156672000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea"
      decimals="-3"
      id="F_a5f18caf-278d-4cee-8ae0-11512e7e3d27"
      unitRef="U_USD">33569000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea"
      decimals="-3"
      id="F_453b59f9-ebd6-4225-a11b-5a79afb9c116"
      unitRef="U_USD">3418000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_7814e0ce-f49d-410d-a8d7-a5553cfa00ea"
      decimals="-3"
      id="F_81e6638c-e38d-4e1a-95db-dcfc3496c2e5"
      unitRef="U_USD">30151000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c"
      decimals="-3"
      id="F_1de6a19d-94d1-495c-923a-bce9724461ed"
      unitRef="U_USD">158143000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c"
      decimals="-3"
      id="F_21dcc5b7-8766-40d8-8a2d-b4ee35886d10"
      unitRef="U_USD">29673000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_037898a6-6cb1-4b19-b864-b48e4e232b6c"
      decimals="-3"
      id="F_cb4465b5-5d42-4d75-90d3-cd3b6f531d0b"
      unitRef="U_USD">128470000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed"
      decimals="-3"
      id="F_d2de23ca-a7a7-4f12-9db7-cf098cd326b8"
      unitRef="U_USD">36000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed"
      decimals="-3"
      id="F_c01b316f-418e-4226-9ac6-00d8f3bd5c72"
      unitRef="U_USD">572000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_d1584098-3050-4148-b6a0-12eb3a9b86ed"
      decimals="-3"
      id="F_8367d4f3-f264-4628-a028-19e13dc8df14"
      unitRef="U_USD">35428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f8e83007-f262-40c6-8846-970f69ed2d57"
      unitRef="U_USD">227712000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_574589ce-a61f-49bc-9420-e53242143385"
      unitRef="U_USD">33663000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_330f3f51-1913-4cb5-9d08-c20765c51e31"
      unitRef="U_USD">194049000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_2bf89954-bfc4-463d-a62f-52908e5d72f3"
      id="F_609a8380-432b-4b35-8ba5-f919334b1c23">P14Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_5db29bfb-a1c9-44a4-894b-c94b8fe5c607"
      id="F_d9ae7620-9f8d-469a-807c-c8ffd02cca87">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_bd5c4055-1e0a-4634-a48d-d04ed7104bb3"
      id="F_5c81ea64-1b2d-4ba2-b258-39a130b9719d">P10Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6de2fb61-b44d-45b0-b76c-c1b0f84e06f6"
      decimals="-5"
      id="F_640a033f-9a92-43a4-842a-481a90de7932"
      unitRef="U_USD">2300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6b7ac61d-59d7-4f79-a0f9-c3856afc6147"
      decimals="-5"
      id="F_4edf6304-ae53-4e85-a935-f478684b7b05"
      unitRef="U_USD">2300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_fcfa5920-3506-4ee6-bfc9-fd2b01fa5229"
      decimals="-5"
      id="F_7f7c0d80-6bac-4407-9ff7-e7cf72afc8fb"
      unitRef="U_USD">1100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_9e6f3d23-def3-4cda-8382-44bd50588fd1"
      decimals="-5"
      id="F_ff50103f-e46f-4365-903d-b7fc0528f1c4"
      unitRef="U_USD">31600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ed459907-b1e1-4660-b88b-b7b539a955c9"
      decimals="-5"
      id="F_248e6a6c-3a72-4978-8b3f-349c3baebb55"
      unitRef="U_USD">29700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_d78b7fcb-31d0-4120-ac5f-6e28497af893"
      decimals="0"
      id="F_4c10a7ba-6303-415f-9927-e92ba65fb877"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6b9ea75b-fd6f-4b79-9eda-f78b19010cc0"
      decimals="-5"
      id="F_696a1060-0a8a-4460-a927-b233cc6abc15"
      unitRef="U_USD">3400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_48c77464-b5f1-4ac6-8188-839ff214c273"
      decimals="-5"
      id="F_5472ca6b-f374-4371-9c07-15b1a65d41bc"
      unitRef="U_USD">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0be61b87-8b88-4b7a-bc46-ddfbf3fee93e"
      decimals="0"
      id="F_0b6185ff-e4cf-4c79-b96c-d32d042fb598"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_ec5a0627-5502-4885-839f-22ae0d94e9a7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents future amortization expense the Company expects for its intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_6ff6b273-0e96-43d4-bcf3-5112bb1f5296"
      unitRef="U_USD">37378000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_0c864a89-f214-48cd-9f73-e7f8252a7cca"
      unitRef="U_USD">37378000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_bbba7dd4-be0b-4675-8962-aa4c8cd598b6"
      unitRef="U_USD">37378000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_37a2b0f9-fc96-43fb-a16e-e46137dfbbb3"
      unitRef="U_USD">7705000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_a83bb874-f800-4fe5-9cef-beb1a10eee8d"
      unitRef="U_USD">5750000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_b8e96971-9a4d-4273-9153-ea2b5e54cf59"
      unitRef="U_USD">31083000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_c1bef222-ccf9-4529-a74e-92f51b02281e"
      unitRef="U_USD">156672000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      id="F_f64f14c7-0871-466b-9b0d-5c8dcca04b8f">P5Y4M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      id="F_a39c75a8-418b-45ba-a3b1-6d034fcefbe2">P6Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_e3430f3f-db57-45f1-80cf-45d844523f2e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="INF"
      id="F_7bc202a5-4aac-4c70-83ca-4217230d5fd6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="INF"
      id="F_f9316b60-4a48-4e6b-9d0c-86d2c61b77db"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_b5395198-7823-4618-a4ed-c702ab3d0136">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses and Other Liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued preclinical and clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued license fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued purchases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued gross-to-net revenue liabilities*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due to licensor&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due to licensor &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*	During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a 3PL organization under the Company's contracts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_412ecaaa-f2c9-4503-a1bb-05979ba0c282">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued preclinical and clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued license fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued purchases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued gross-to-net revenue liabilities*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due to licensor&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Due to licensor &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other &#x2013; non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*	During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a 3PL organization under the Company's contracts.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <cprx:AccruedNonClinicalAndClinicalTrialExpenses
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_ed5f1971-cbc0-4ec9-9775-b27a1c53d321"
      unitRef="U_USD">267000</cprx:AccruedNonClinicalAndClinicalTrialExpenses>
    <cprx:AccruedNonClinicalAndClinicalTrialExpenses
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_e46ad2e1-2570-4947-b194-b1b50c7dff35"
      unitRef="U_USD">1015000</cprx:AccruedNonClinicalAndClinicalTrialExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_1c59ffd0-7e18-4496-ba95-591f7031e416"
      unitRef="U_USD">11011000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_251a5adb-2828-409c-ab16-fa8227563372"
      unitRef="U_USD">4730000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_8f0c76db-7a78-4463-9bbb-aa2298f9dca9"
      unitRef="U_USD">10746000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_163698d9-4dfa-4939-a37d-7491f36ce34c"
      unitRef="U_USD">8883000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cprx:AccruedLicenseFeesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_901aaf1a-70a7-4737-b3b8-1ef569307147"
      unitRef="U_USD">30991000</cprx:AccruedLicenseFeesCurrent>
    <cprx:AccruedLicenseFeesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_c81c52d5-c6d8-4058-a433-c6ebe1045b23"
      unitRef="U_USD">24437000</cprx:AccruedLicenseFeesCurrent>
    <cprx:AccruedPurchasesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e7d563d3-5fdb-4d1f-9a54-4facf8df0895"
      unitRef="U_USD">447000</cprx:AccruedPurchasesCurrent>
    <cprx:AccruedPurchasesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_4a85707e-d519-43b7-8732-d5ae3e7c5cf3"
      unitRef="U_USD">192000</cprx:AccruedPurchasesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e3282b4a-6209-4060-909f-75f1002f1451"
      unitRef="U_USD">402000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_75f3da23-c08f-451c-9668-35fbc8359508"
      unitRef="U_USD">369000</us-gaap:OperatingLeaseLiabilityCurrent>
    <cprx:AccruedGrossToNetRevenueLiabilities
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_5a00bcef-013e-4b81-9338-670783a1df9f"
      unitRef="U_USD">44939000</cprx:AccruedGrossToNetRevenueLiabilities>
    <cprx:AccruedGrossToNetRevenueLiabilities
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_6f6c9bc4-0cf1-4bc8-a3ff-9c89dd62711b"
      unitRef="U_USD">6877000</cprx:AccruedGrossToNetRevenueLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d02dfbce-a4b4-4d65-8153-552d739faa9f"
      unitRef="U_USD">894000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_b31ba04c-8e97-40d7-8160-0f2ead673482"
      unitRef="U_USD">729000</us-gaap:AccruedIncomeTaxesCurrent>
    <cprx:AssetAcquisationDueToLicensorCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_790cc8d5-32b2-4ab4-b88d-6c704e443363"
      unitRef="U_USD">3582000</cprx:AssetAcquisationDueToLicensorCurrent>
    <cprx:AssetAcquisationDueToLicensorCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d7a508d1-ca60-4889-ad0e-9fe41b3ff428"
      unitRef="U_USD">12540000</cprx:AssetAcquisationDueToLicensorCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_bb9067a7-76e2-4145-b663-be14d96eb30e"
      unitRef="U_USD">389000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_18298d8c-cf43-4de9-9ada-289b7b026449"
      unitRef="U_USD">1031000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_cf93f9f5-ac2e-4f82-aa55-dea4c17dc153"
      unitRef="U_USD">417000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_a019909a-f88d-44d2-a203-a21e1f561a37"
      unitRef="U_USD">465000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_c2ea52a6-03f9-4225-b94f-1e01314968d0"
      unitRef="U_USD">104085000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_b67e4e0d-5a3a-4f2b-8d5e-d31a5f2be4a7"
      unitRef="U_USD">61268000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_00f9d681-789f-42eb-92fb-2598a4eed137"
      unitRef="U_USD">2786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_edbef13e-563e-46a3-b2ec-5780356c9c1d"
      unitRef="U_USD">3188000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cprx:AssetAcquisationDueToLicensorNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_85c5205a-ba53-4d8d-b2b6-709519827b02"
      unitRef="U_USD">0</cprx:AssetAcquisationDueToLicensorNoncurrent>
    <cprx:AssetAcquisationDueToLicensorNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_c305b37c-1da2-49fe-a9fc-7876006f0222"
      unitRef="U_USD">2497000</cprx:AssetAcquisationDueToLicensorNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_e0369414-ffe2-4451-ac19-6e7f18de8434"
      unitRef="U_USD">315000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_eced8d9e-9d86-4022-84f1-cb780e477e11"
      unitRef="U_USD">485000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_2eeaefa7-0e31-49ad-890f-28c584a665f2"
      unitRef="U_USD">3101000</cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities>
    <cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_a2356d10-450a-40a6-85ed-d99dfdae71e6"
      unitRef="U_USD">6170000</cprx:OtherNoncurrentAccruedExpensesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_0e0e0a60-a13d-40ec-a0f7-38fc61c32de1"
      unitRef="U_USD">107186000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_c6de6f62-7aff-47fd-9d10-744197206c2f"
      unitRef="U_USD">67438000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_54a18074-6b89-4d72-ad56-c15f5cf9002e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative and Licensing Arrangements. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Endo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2018, the Company entered into a collaboration and license agreement (Collaboration) with Endo, Inc. (formerly, Endo International plc) (Endo), for the further development and commercialization of generic Sabril&#xae; (vigabatrin) tablets through Endo&#x2019;s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical, Inc. (Par). Under the Collaboration, Endo assumed all development, manufacturing, clinical, regulatory, sales and marketing costs under the collaboration, while the Company was responsible for exercising commercially reasonable efforts to develop, or cause the development of, a final finished, stable dosage form of generic Sabril&#xae; tablets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2024, a termination and mutual release agreement was finalized between Endo and the Company that discontinued work on the collaboration for development and commercialization of vigabatrin. The end of the collaboration does not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;KYE Pharmaceuticals Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2020, the Company entered into a collaboration and license agreement with KYE, for the commercialization of FIRDAPSE&#xae; in Canada.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the agreement, Catalyst granted KYE an exclusive license to commercialize and market FIRDAPSE&#xae; in Canada. KYE assumes all selling and marketing costs under the collaboration, while the Company is responsible for supply of FIRDAPSE&#xae; based on the collaboration partner&#x2019;s purchase orders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the agreement, the Company received an up-front payment, has received payment upon transfer of Marketing Authorization and delivery of commercial product, received payment for supply of FIRDAPSE&#xae;, and will receive milestone payments and a sharing of defined net profits upon commercialization from KYE consisting of a mid-double-digit percent of net sales of FIRDAPSE&#xae;. The Company has also agreed to the sharing of certain development expenses. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the date that is ten years following the commercial launch of the product in Canada.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The collaborative agreement included a nonrefundable upfront license fee that was recognized upon transfer of the license based on a determination that the right is provided as the intellectual property existed at the point in time in which the license was granted.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2024, the Company entered into a license, supply and commercialization agreement with KYE, for the commercialization of AGAMREE&#xae; in Canada granting KYE the exclusive Canadian commercial rights to market AGAMREE&#xae; in Canada for DMD and other indications.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the agreement, KYE will be responsible for obtaining regulatory approval of the product from Health Canada and the Company will supply product to KYE. Further, the Company received an upfront payment from KYE and will be eligible to receive further reimbursement, sales milestones and sales royalties for AGAMREE&#xae;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These agreements are in form identified as collaborative agreements and the Company has concluded for accounting purposes that they also represent contracts with a customer. This is because the Company grants to KYE a license and provides supply of FIRDAPSE&#xae; and AGAMREE&#xae; in exchange for consideration, which are outputs of the Company&#x2019;s ongoing activities. Accordingly, the Company has concluded that these collaborative arrangements will be accounted for pursuant to Topic 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from sales by KYE is recognized in the quarter in which the sales occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenues from the arrangements with KYE for the years ended December 31, 2024, 2023 and 2022 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material. Revenue is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income. Expenses incurred, net have been included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative and Licensing Arrangements (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;DyDo Pharma, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 28, 2021, the Company entered into a license agreement with DyDo Pharma, Inc. (DyDo), for the development and commercialization of FIRDAPSE&#xae; in Japan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the agreement, DyDo has joint rights to develop FIRDAPSE&#xae;, and exclusive rights to commercialize the product, in Japan. DyDo is responsible for funding all clinical, regulatory, marketing and commercialization activities in Japan, while the Company is responsible for clinical and commercial supply based on purchase orders, as well as providing support to DyDo in its efforts to obtain regulatory approval for the product from the Japanese regulatory authorities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the agreement, the Company has earned an up-front payment and certain regulatory milestones and may earn sales-based milestones for FIRDAPSE&#xae;, as well as revenue on product supplied to DyDo.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has concluded that this license agreement will be accounted for pursuant to Topic 606. The agreement included a nonrefundable upfront license fee that was recognized upon the effective date of the agreement as the intellectual property existed at the point in time in which the right to the license was granted. The Company determined the granting of the right to the license is distinct from the supply of FIRDAPSE&#xae; and represents a separate performance obligation in the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The agreement includes milestones that are considered a sales-based royalty in which the license is deemed to be the predominant item to which these milestones relate. Revenue will be recognized when the latter of (a) the subsequent sale occurs, or (b) the performance obligation to which the sales-based royalty has been allocated has been satisfied. Additionally, the agreement includes regulatory milestone payments which represent variable consideration, and due to uncertainty are fully constrained and only recognized when the uncertainty is subsequently resolved. For clinical and commercial supply of the product, the Company will recognize revenue when the Customer obtains control of the Company&#x2019;s product, which will occur at a point in time which is generally at time of shipment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were revenues of&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;from the arrangement with DyDo for the year ended December 31, 2024, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million is included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to a milestone payment earned upon DyDo receiving regulatory approval to commercialize FIRDAPSE&#xae; for the treatment of patients with LEMS in Japan, which is included in license and other revenue in the accompanying consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the arrangement with DyDo for the year ended December 31, 2023, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to a regulatory filing milestone in Japan, which was included in licensing and other revenue in the accompanying consolidated statements of operations and comprehensive income. There were revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the arrangement with DyDo for the year ended December 31, 2022, which was included in product revenue, net in the accompanying consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finally, on September 24, 2024, DyDo advised the Company that the Ministry of Health, Labour and Welfare (MHLW) had approved DyDo's Japan NDA to commercialize FIRDAPSE&#xae; for the treatment of patients with LEMS. See Note 18 (Subsequent Events).&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cprx:ExpensesIncurredInConnectionWithCollaborationAgreement
      contextRef="C_9c7d03d5-7081-4449-bea0-40e589ce6ecc"
      decimals="0"
      id="F_a095fd07-dde1-4ed2-8bdf-31a24b47d3a7"
      unitRef="U_USD">0</cprx:ExpensesIncurredInConnectionWithCollaborationAgreement>
    <cprx:ExpensesIncurredInConnectionWithCollaborationAgreement
      contextRef="C_55e052ff-760b-4233-875b-b80e5e4fd436"
      decimals="0"
      id="F_8ac63f63-f422-44ba-a265-75cfc41f79ea"
      unitRef="U_USD">0</cprx:ExpensesIncurredInConnectionWithCollaborationAgreement>
    <cprx:ExpensesIncurredInConnectionWithCollaborationAgreement
      contextRef="C_b2fd37e7-0f2e-441c-ae7f-719ef52d29e9"
      decimals="0"
      id="F_667628a2-4e81-41d5-a01f-8c17e2915c9a"
      unitRef="U_USD">0</cprx:ExpensesIncurredInConnectionWithCollaborationAgreement>
    <us-gaap:Revenues
      contextRef="C_b63f6e84-f32c-44aa-b9da-315cc85f2d23"
      decimals="-5"
      id="F_34dd8cce-71ba-461f-98da-760b3fb58605"
      unitRef="U_USD">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_f352d976-0ef8-419c-95b8-31914f4eefcf"
      decimals="-5"
      id="F_1376436c-f727-464e-91cf-a8d7bd3890ff"
      unitRef="U_USD">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_1d817031-5908-4974-887a-064c703e2a44"
      decimals="-5"
      id="F_9fdd39d0-f23e-43d7-95d4-6be18ca9cfea"
      unitRef="U_USD">2100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_af98f620-db18-4836-9d81-b2bf497b9325"
      decimals="-5"
      id="F_8cd16f00-f8b3-4320-8d4d-1b693dd41e6c"
      unitRef="U_USD">1900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_7f8cfbeb-4cb9-4b6d-a5e6-cb932c0b7774"
      decimals="-5"
      id="F_7f4b8b50-9090-4844-a56d-0edcd08f8581"
      unitRef="U_USD">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_02504fb4-79e0-4668-9486-8cb310c6d004"
      decimals="-5"
      id="F_3fedefc4-fa9f-431d-8990-839eea233b76"
      unitRef="U_USD">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_61e41641-345f-41a7-b190-b0f5bedca153"
      decimals="-5"
      id="F_a6710541-64cf-4639-b80a-8bf1d23e6642"
      unitRef="U_USD">500000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_9b1ead07-346b-4987-9f19-c6cc7386d442">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2019, the FDA approved a NDA for RUZURGI&#xae;, Jacobus Pharmaceuticals&#x2019; version of amifampridine (3,4-DAP), for the treatment of pediatric LEMS patients (ages 6 to under 17). In June 2019 the Company filed suit against the FDA and several related parties challenging this approval and related drug labeling. Jacobus later intervened in the case. The Company ultimately prevailed in its litigation in September 2021 when the U.S. Court of Appeals for the 11th Circuit determined that the FDA's approval of RUZURGI&#xae; violated the Company's rights to Orphan Drug Exclusivity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 11, 2022, the Company settled certain of its disputes with Jacobus. In connection with the settlement, the Company licensed the rights to develop and commercialize RUZURGI&#xae; in the U.S. and Mexico (the Territory). Simultaneously, the Company purchased, among other intellectual property rights, Jacobus&#x2019; U.S. patents related to RUZURGI&#xae;, its new drug applications in the U.S. for RUZURGI&#xae;, and certain RUZURGI&#xae; inventory previously manufactured by Jacobus. At the same time, the Company received a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#xae;. Further, the Company settled its patent case against Jacobus, which was dismissed without prejudice. Finally, Jacobus agreed that until the later of (i) the expiration of the royalty term or (ii) December 31, 2034, Jacobus and its affiliates, will not, directly or indirectly, research, develop, manufacture, commercialize, distribute, use or otherwise exploit any product competitive to FIRDAPSE&#xae; or RUZURGI&#xae; in the Territory, and Laura Jacobus, the sole shareholder of Jacobus, and two of Jacobus&#x2019; other officers, also signed individual non-competition agreements containing the same terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the settlement with Jacobus, the Company paid the following consideration to Jacobus:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was paid at the closing of the settlement, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was paid on the first anniversary of the closing, and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was paid on the second anniversary of the closing; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An annual royalty on the Company's net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the U.S. equal to: (a) for calendar years 2022 through 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (with a minimum annual royalty of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per year), and (b) for calendar years 2026 through the expiration of the last to expire of the Company&#x2019;s FIRDAPSE&#xae; patents in the U.S., &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (with a minimum annual royalty of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2023, the Company received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva), Hetero USA, Inc. (Hetero), and Lupin Pharmaceuticals, Inc. (Lupin)) advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE&#xae; in the U.S. The notice letters each alleged that the six patents listed in the FDA Orange Book covering FIRDAPSE&#xae; are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, the Company had 45 days from receipt of the notice letters to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court to trigger a stay precluding the FDA from approving any ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, the Company filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified the Company of their ANDA submissions, thus triggering the stay.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, Lupin converted five of its Paragraph IV Certifications in its ANDA to Paragraph III certifications acknowledging the validity and their ANDA&#x2019;s infringement of five of those patents, the latest ending in 2034. The Company subsequently dismissed all of its claims against Lupin related to those five patents but maintains its claims against Lupin for the remaining Paragraph IV certification for U.S. Patent No. 10,626,088 which is the patent expiring in 2037, so the litigation continues.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further, on January 8, 2025, the Company reached a settlement with Teva in which Teva agreed not to market a generic version of FIRDAPSE&#xae; in the U.S. any earlier than February 25, 2035, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the settlement agreement, the parties terminated all ongoing patent litigation between the Company and Teva regarding FIRDAPSE&#xae; patents pending in the U.S. District Court for the District of New Jersey. See Note 18 (Subsequent Events).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pending FIRDAPSE&#xae; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#xae;&#x2019;s Orange Book-listed patents) and Lupin (only for FIRDAPSE&#xae; patent expiring in 2037), remains ongoing, and there can be no assurance as to whether the currently ongoing litigation with Hetero and Lupin will allow a generic version of FIRDAPSE&#xae; to be marketed in the U.S. prior to February 25, 2035.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Finally, in October 2023, the Company received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer (Inventia Life Science Pty Ltd (Inventia)), and the Company filed a similar lawsuit against that manufacturer in November 2023. On July 30, 2024, the Company settled its patent litigation with Inventia for FIRDAPSE&#xae;. In that settlement, Inventia acknowledged both the validity of the Company's FIRDAPSE&#xae; patents and also the infringement by the ANDA filer's product of the Company's patents. As part of the settlement, Inventia also agreed not to commercialize its product until the earlier of all FIRDAPSE&#xae; patents expiration scheduled for February 2037, or the earlier entry into the market of another ANDA product meeting certain conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The outcome of patent litigation with Paragraph IV challengers is always uncertain and there can be no assurance that the Company will prevail in these litigations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 20, 2023, the Company received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA&#xae;. The same company sent a similar letter to the Company later in February with a similar certification for the tablet formulation for FYCOMPA&#xae;. Similar to the actions with the FIRDAPSE&#xae; Paragraph IV Certifications described above, after due diligence the Company filed lawsuits on April 5, 2023, in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified the Company of their ANDA submissions for both FYCOMPA&#xae; formulations, thus triggering the 30-month stay for each application. This lawsuit was settled in June 2024. As part of this settlement, this Paragraph IV filer agreed not to commercialize their proposed ANDA products for both the oral suspension formulation of FYCOMPA&#xae; and for FYCOMPA&#xae; tablets until at least December 15, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, from time to time the Company may become involved in legal proceedings arising in the ordinary course of business. Except as set forth above, the Company believes that there is no other litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cprx:PurchasePriceOfAnAssetAcquisition
      contextRef="C_ed261f48-f289-44e4-80ec-cbc85f5f3076"
      decimals="-6"
      id="F_2dff6a5a-1fe3-4e71-8b8f-65c124f74821"
      unitRef="U_USD">30000000</cprx:PurchasePriceOfAnAssetAcquisition>
    <cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear
      contextRef="C_4c43ddad-6603-484e-8db2-d46bb3b245a3"
      decimals="-6"
      id="F_42cfc8cd-03a5-43e7-9890-190f7715d13c"
      unitRef="U_USD">10000000</cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear>
    <cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear
      contextRef="C_712db356-621a-4482-bbbf-6e0f7cee9633"
      decimals="-6"
      id="F_118aa0a9-5667-49f4-af7d-156fbb9e95ee"
      unitRef="U_USD">10000000</cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear>
    <cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear
      contextRef="C_d1efe803-2f0e-4a4d-8b0c-2027e98829a4"
      decimals="-6"
      id="F_06a0849e-7c40-4d14-8883-cc724f7c9db6"
      unitRef="U_USD">10000000</cprx:LicenseAndAssetPurchaseAgreementPaymentMadeInThirdYear>
    <cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales
      contextRef="C_bffaa182-9732-421b-b5cc-2629dd407967"
      decimals="3"
      id="F_291ed5a9-a811-4d20-bbf7-fa7a088cdbd2"
      unitRef="U_pure">0.015</cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales>
    <cprx:MinimumRoyaltyAmount
      contextRef="C_bffaa182-9732-421b-b5cc-2629dd407967"
      decimals="-5"
      id="F_4f9d0795-226e-4005-a3a1-d1362d338ffd"
      unitRef="U_USD">3000000</cprx:MinimumRoyaltyAmount>
    <cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales
      contextRef="C_2a5da979-3b61-43bc-853e-709593328300"
      decimals="3"
      id="F_a043cd66-5a7b-418b-99f5-3c042f68a520"
      unitRef="U_pure">0.025</cprx:PercentageOfAnnualRoyaltyOnTheCompanysNetSales>
    <cprx:MinimumRoyaltyAmount
      contextRef="C_2a5da979-3b61-43bc-853e-709593328300"
      decimals="-6"
      id="F_64daa2d4-1afd-467d-b781-75ba203e0336"
      unitRef="U_USD">5000000</cprx:MinimumRoyaltyAmount>
    <cprx:AgreementsDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_984ceeb7-1faf-487c-b5b9-0c4bb4743225">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;a.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;LICENSE AGREEMENT FOR FIRDAPSE&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 26, 2012&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to FIRDAPSE&#xae;. Under the license agreement, the Company pays: (i) royalties to the licensor for seven years from the first commercial sale of FIRDAPSE&#xae; equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales in North America in any calendar year in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the first commercial sale of FIRDAPSE&#xae; equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales (as defined in the license agreement between BioMarin and the third party licensor) in any calendar year for the duration of any regulatory exclusivity within a territory and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for territories in any calendar year in territories without regulatory exclusivity.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 29, 2019, the Company and BioMarin entered into an amendment to the Company&#x2019;s license agreement for FIRDAPSE&#xae;. Under the amendment, the Company has expanded its commercial territory for FIRDAPSE&#xae;, which originally was comprised of North America, to include Japan. Additionally, the Company&#x2019;s commercial territory was expanded under the license agreement in December 2023 to include most of Asia, as well as Latin America, upon the acceptance by the Pharmaceuticals and Medical Devices Agency (PMDA) of a Japan MAA for FIRDAPSE&#xae; for LEMS. Under the amendment, the Company will pay royalties to its licensor on net sales in Japan of a similar percentage to the royalties that the Company is currently paying under its original license agreement for North America.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2020, the Company was advised that BioMarin has transferred substantially all of its rights under the license agreement to SERB S.A. (SERB), and SERB is now the Company&#x2019;s licensor under the license agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;b.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;LICENSE AGREEMENT FOR RUZURGI&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 11, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the Effective Date), the Company entered into an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI&#xae; in the U.S. and Mexico.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the terms of the license agreement, the Company paid Jacobus a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million up-front payment on the Effective Date, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on the first annual anniversary of the Effective Date (July 11, 2023), and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on the second annual anniversary of the Effective Date (July 11, 2024). The Company is also obligated to pay tiered royalty payments on net sales (as defined in the license agreement) of all of the Company&#x2019;s amifampridine products in the U.S. that range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% based on whether there is a competing product or generic version of FIRDAPSE&#xae; being marketed or sold in the U.S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A minimum royalty payment exists annually for calendar years from the Effective Date through 2025 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, provided that such minimum annual royalty payment shall be prorated in the first calendar year of the agreement. As these minimum payments are both probable and estimable, they are included in the purchase price of the agreement and any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. A minimum royalty payment exists annually for calendar years from 2026 through the expiration of the royalty term (which ends when there is no valid claim under the Company&#x2019;s FIRDAPSE&#xae; patents in the U.S.) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million unless a competing product or generic version of FIRDAPSE&#xae; is being marketed or sold in the U.S. If these minimum payments become probable in the future, the Company would recognize a contingent liability at that time with an offset to the value of the intangible asset acquired. Any royalties in excess of this amount will be charged to cost of sales as revenue from product sales is recognized. Royalties over the minimum, if any, will be paid based on the agreement terms on a quarterly basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets acquired as part of the license agreement include among other intellectual property rights, Jacobus&#x2019; U.S. patents related to RUZURGI&#xae;, its new drug applications in the U.S. for RUZURGI&#xae;, its U.S. Trademark for RUZURGI&#xae;, the Orphan Drug Designation for RUZURGI&#xae; and a license from Jacobus for use of its know-how related to the manufacture of RUZURGI&#xae;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company also purchased from Jacobus approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of RUZURGI&#xae; inventory previously manufactured by Jacobus, which was recorded as an expense in research and development expenses in the consolidated statements of operations and comprehensive income for 2022.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under business combination guidance, the screen test states that if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and is accounted for as an asset acquisition. The Company has determined that the screen test was not met. However, the Company determined that the acquisition did not meet the definition of a business under ASC 805, Business Combination. The Company believes that the licensing agreement and other assets acquired from Jacobus are similar and considered them all to be intangible assets with the exception of the inventory acquired. As the screen test was not met, further determination was required to determine that the Company had not acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business, and therefore, determined that this was an asset acquisition. The Company accounted for the Jacobus license agreement as an asset acquisition under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired research and development inventory expensed&lt;br/&gt;&#160;&#160;&#160;from asset acquisition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;c.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ACQUISITION OF U.S. RIGHTS FOR FYCOMPA&#xae;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 24, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company acquired the U.S. Rights for FYCOMPA&#xae; (perampanel) CIII a commercial stage epilepsy asset, from Eisai. The aggregate consideration for the acquisition was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash, including the reimbursement of certain liabilities and the payment of transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Eisai was eligible to receive a contingent payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million if a certain regulatory milestone was met. As meeting the regulatory milestone was not probable, the Company did not recognize any amount related to the milestone payments in the purchase price. Additionally, after the loss of patent exclusivity for FYCOMPA&#xae;, the Company may be obligated to pay certain royalties to Eisai on net sales of FYCOMPA&#xae;. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize the royalty payments in cost of sales as revenue from product sales is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales of greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million prior to the date of generic entry. Royalties equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales of greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on net sales greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after the date of generic entry.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA&#xae; (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Base cash payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for pro-rated prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reimbursement on base purchase price&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(ii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million has been paid in cash.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The acquisition of FYCOMPA&#xae; has been accounted for as an asset acquisition in accordance with FASB ASC 805-50. The Company accounted for the acquisition of FYCOMPA&#xae; as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the FYCOMPA&#xae; product rights. The FYCOMPA&#xae; product rights consist of certain patents and trademarks, at-market contracts and regulatory approvals, marketing assets, and other records, and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets (samples)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid commercialization expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued preclinical and clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The straight-line method is used to amortize the license and acquired intangibles, as disclosed in Note 9 (License and Acquired Intangibles, Net).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;d.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;LICENSE AGREEMENT FOR AGAMREE&#xae; (VAMOROLONE). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2023, the Company completed its acquisition from Santhera of an exclusive license for North America for AGAMREE&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(vamorolone), a treatment for patients suffering with DMD which was approved by the FDA on October 26, 2023. On March 13, 2024, the Company announced the U.S. commercial launch of AGAMREE&#xae; for the treatment of DMD in patients aged two years or older. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Japan should Santhera pursue partnership opportunities in those jurisdictions. Additionally, the Company will hold North American rights for any future approved indications of AGAMREE&#xae;. The Company made an all-cash initial payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at the closing of the acquisition to acquire the license.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the license agreement, the Company pays: (i) royalties to the licensor until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#xae; equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales (as defined in the license agreement) in North America for any calendar year for sales equal to or less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (prior to December 31, 2025 only), &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; and (ii) royalties to the third party licensor of the rights sublicensed to the Company until the later of expiration of product exclusivity or ten years from the first commercial sale of AGAMREE&#xae; equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales (as defined in the license agreement) in North America for any single calendar year for sales equal to or less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of net sales for sales in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. Furthermore, the Company may be obligated to pay Santhera sales-based milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as well as up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% percent royalties for all additional indications and milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the first three additional indications.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Simultaneously, the Company made a strategic equity investment into Santhera by acquiring &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Santhera&#x2019;s post reverse-split ordinary shares (representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of Santhera&#x2019;s outstanding ordinary shares immediately following the transaction), which are traded on the SIX Swiss Exchange, at an investment price of CHF &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.477&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the funds invested into Santhera to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE&#xae;.&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of AGAMREE&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the strategic equity investment (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial cash payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment in Santhera&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction has been accounted for as an asset acquisition in accordance with ASC 805-50. The Company accounted for the transaction as an asset acquisition because substantially all of the fair value of the assets acquired is concentrated in a single asset, the rights to develop, commercialize and manufacture AGAMREE&#xae;. The AGAMREE&#xae; rights consist of certain licenses and regulatory approvals and are considered a single asset as they are inextricably linked. ASC 805-10-55-5A includes a screen test, which provides that if substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. Additionally, the Company did not acquire a substantive process. ASC 805 requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-financial assets based on relative fair values.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae; (vamorolone) (IPR&amp;amp;D)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment in Santhera&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the investment in Santhera was determined based on the closing market price (CHF &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) of Santhera shares and the exchange rate (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1537&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) of CHF to USD on the date the shares were transferred, July 19, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with FASB ASC 730-10-25, as AGAMREE&#xae; (vamorolone) had not achieved regulatory approval when acquired, the portion of the purchase price allocated to the IPR&amp;amp;D asset acquired (which includes all transaction costs related to the transactions with Santhera) was immediately expensed to research and development. Milestone payments made are either expensed as research and development or capitalized as a developed asset based on when regulatory approval is obtained. As the transaction is accounted for as an asset acquisition under U.S. GAAP, the Company will recognize all sales-based milestone and royalty payments in cost of sales as revenue from product sales is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the approval of the NDA for AGAMREE&#xae; on October 26, 2023, the Company became obligated to make a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Santhera. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment was made during the fourth quarter of 2023. The Company capitalized the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment which is being amortized using the straight-line method over the product&#x2019;s estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The strategic equity investment in Santhera is accounted for as an investment in equity securities, and is recognized as a non-current asset, as the Company does not intend to sell the shares within 12 months. Since Santhera shares have a readily determinable fair value, the investment will be measured quarterly at fair value with changes reported in earnings in other income, net in the accompanying consolidated statements of operations and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;e.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company has entered into agreements with contract manufacturers for the manufacture of commercial drug and drug and study placebo for the Company&#x2019;s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company&#x2019;s trials and studies and with various entities for laboratories and other testing related to the Company&#x2019;s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cprx:AgreementsDisclosureTextBlock>
    <cprx:LicenseAgreementDate
      contextRef="C_19dd38c4-484b-49fc-ad75-95d8593b80cf"
      id="F_b00eaf97-d1fb-43ce-a461-608b1a1cb41c">2012-10-26</cprx:LicenseAgreementDate>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20"
      decimals="2"
      id="F_e1fb8b83-80f5-4fa5-9874-8139157d2a84"
      unitRef="U_pure">0.07</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5"
      decimals="-6"
      id="F_070b75dc-91cc-487a-aa03-088ecf6b9c92"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_caf83f47-b1bf-467a-bf14-8cd9ab3cfde4"
      decimals="2"
      id="F_2a0ae4ed-ca73-4234-b7ab-8d4f57f9e345"
      unitRef="U_pure">0.10</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5"
      decimals="-6"
      id="F_e15a1d1c-f0aa-4f11-a8bd-14090d440202"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:RoyaltyAgreementTerm
      contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20"
      id="F_60bfb03a-56ee-4ac7-947c-122f8f9e7e70">P7Y</cprx:RoyaltyAgreementTerm>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_a45b1de6-43f0-4754-959c-bc894267db20"
      decimals="2"
      id="F_c5aec280-2d11-437f-bdb2-cb0ee1d79ba2"
      unitRef="U_pure">0.07</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_9825031d-05c7-4f08-b508-c1c43d16f3d5"
      decimals="3"
      id="F_88f14e60-3503-4081-a497-fd492dc9d673"
      unitRef="U_pure">0.035</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:LicenseAgreementDate
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      id="F_6d6be30b-075a-44c4-b12d-004ed8006121">2022-07-11</cprx:LicenseAgreementDate>
    <cprx:UpFrontPayment
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-6"
      id="F_b6ea8c60-c397-4f74-be92-58a361ef9071"
      unitRef="U_USD">10000000</cprx:UpFrontPayment>
    <cprx:AssetAcquisitionPurchasePriceConsideration
      contextRef="C_465c30df-be19-4455-9dcb-aaf2927ffe62"
      decimals="-6"
      id="F_3feedd31-f415-4f7b-ba7e-7bcdd3e21a00"
      unitRef="U_USD">10000000</cprx:AssetAcquisitionPurchasePriceConsideration>
    <cprx:AssetAcquisitionPurchasePriceConsideration
      contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527"
      decimals="-6"
      id="F_5ce49bbc-ed5f-4d37-a50a-18c5ad7793ec"
      unitRef="U_USD">10000000</cprx:AssetAcquisitionPurchasePriceConsideration>
    <cprx:PercentageOfMinimumRoyaltyPayableToNetSales
      contextRef="C_6d644c95-287a-423b-b6e2-b8baaa08fec1"
      decimals="4"
      id="F_1d74e456-709e-4f0b-ba39-3e89acf2db34"
      unitRef="U_pure">0.0125</cprx:PercentageOfMinimumRoyaltyPayableToNetSales>
    <cprx:PercentageOfMinimumRoyaltyPayableToNetSales
      contextRef="C_f0b3fb71-5f08-4d82-8502-0d005079016d"
      decimals="3"
      id="F_86083284-ae6c-42ea-9a4c-7a47fb624052"
      unitRef="U_pure">0.025</cprx:PercentageOfMinimumRoyaltyPayableToNetSales>
    <cprx:MinimumRoyalty
      contextRef="C_1ed73abf-99b0-4ef1-a69d-7dabbba940c1"
      decimals="-6"
      id="F_b3c59b25-f94e-44b5-bff3-fbcf11c7c669"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <cprx:MinimumRoyalty
      contextRef="C_7a13598e-80ea-44a3-bc8f-76223a604527"
      decimals="-6"
      id="F_0d6ab4f4-74f5-4db2-91dd-4dfea837258d"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <cprx:MinimumRoyalty
      contextRef="C_c0079872-347c-4ab4-bd66-e2c441bd5d42"
      decimals="-6"
      id="F_315e2a6a-03ba-4335-97c8-a7e4c63b696d"
      unitRef="U_USD">3000000</cprx:MinimumRoyalty>
    <cprx:AmountOfMinimumRoyaltyPayableMaturityTermsNotMet
      contextRef="C_e16b26af-4376-4363-969d-d2fd34caf5aa"
      decimals="-6"
      id="F_0f686e9a-76fa-48d3-add4-04b776c64b67"
      unitRef="U_USD">5000000</cprx:AmountOfMinimumRoyaltyPayableMaturityTermsNotMet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-5"
      id="F_461fde90-42c2-4809-bb1c-53c057584c61"
      unitRef="U_USD">4100000</us-gaap:ResearchAndDevelopmentExpense>
    <cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_2a8533fc-3bf1-48f2-b1a6-83eb3d52bee6">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired research and development inventory expensed&lt;br/&gt;&#160;&#160;&#160;from asset acquisition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:ScheduleOfTotalPurchasePriceWasAllocatedToTheAcquiredAssetsBasedOnTheirRelativeFairValuesTableTextBlock>
    <cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-3"
      id="F_2a8f7fcb-6225-49b7-838e-8a32f23c0792"
      unitRef="U_USD">33569000</cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired>
    <cprx:AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-3"
      id="F_8ddc68d5-85a1-460f-bf99-3e91cf10fbc0"
      unitRef="U_USD">4130000</cprx:AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition>
    <cprx:AssetAcquisitionValue
      contextRef="C_2e53e13a-9358-4ded-8867-b51252e1f076"
      decimals="-3"
      id="F_d4871974-ebca-4c20-a465-331072168ca1"
      unitRef="U_USD">37699000</cprx:AssetAcquisitionValue>
    <cprx:LicenseAgreementDate
      contextRef="C_c2b04665-c428-4f48-8bee-660378e215e7"
      id="F_7b7d4364-0e0a-4003-9f81-dd51271b4497">2023-01-24</cprx:LicenseAgreementDate>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_d81a6259-f258-4b87-b123-cf96424bc887"
      decimals="-5"
      id="F_55548250-9aa2-4003-a3f4-86b4ead88eb1"
      unitRef="U_USD">164200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <cprx:ContingentConsiderationArrangementsContingentConsiderationLiability
      contextRef="C_8ad02f07-3470-4aaa-a47f-2bdce2375aba"
      decimals="-6"
      id="F_b0f8ebc3-f074-493b-9bd8-e226198b56a6"
      unitRef="U_USD">25000000</cprx:ContingentConsiderationArrangementsContingentConsiderationLiability>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_abbabfa3-211e-489a-bee1-41937cf8efae"
      decimals="2"
      id="F_e660084c-c4f0-4415-8466-af156f42d836"
      unitRef="U_pure">0.12</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_b0a378e6-1a77-4f91-81cb-13d89217dba7"
      decimals="-6"
      id="F_a0d73838-9023-425a-88e6-bcfbcac5faff"
      unitRef="U_USD">10000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_91a9fa46-f095-4873-a0df-54c2ea98d1e7"
      decimals="-6"
      id="F_6f349287-a878-441d-9236-834de96f5fee"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_fa9e4eb0-730f-4a45-9ce1-7f135b523329"
      decimals="2"
      id="F_ab5149ae-dcaa-4e61-967e-7f4cef089589"
      unitRef="U_pure">0.17</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_9e517535-208d-4e79-a8f2-94a3fbd26bfb"
      decimals="-6"
      id="F_cec9de70-84ee-475f-b820-a9794d129a0e"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_a8aa9d09-9937-4de9-a389-d7a12cd901f2"
      decimals="-6"
      id="F_4adf30d6-39a8-49dd-b5df-e079bd8f8735"
      unitRef="U_USD">125000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_452b8271-91ed-43ef-8673-b266c4b29987"
      decimals="2"
      id="F_480c3203-49c1-4482-b19b-4a0e2f9a55b0"
      unitRef="U_pure">0.22</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_dfce6660-3b34-46db-9ab4-b2300eecbdd6"
      decimals="-6"
      id="F_d7c8a8bf-b58f-4aff-bc98-571c47db12a5"
      unitRef="U_USD">125000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_a5b8f9f5-4c42-49ac-89f4-7c6e0c290f71"
      decimals="2"
      id="F_8b3cd620-46ca-47e6-b156-86f12672ed15"
      unitRef="U_pure">0.06</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_79793b06-4d51-4322-b5ab-725a80889edf"
      decimals="-6"
      id="F_aa557829-eb9b-4eb9-b3e3-826b9b7d53c3"
      unitRef="U_USD">10000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_2e484187-8b25-4de9-82f0-c8be02c5a796"
      decimals="-6"
      id="F_f8e8de32-0fe4-457c-9275-98cb368a50d1"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_62b69186-a8bb-4324-acc0-f14d726a9dc6"
      decimals="3"
      id="F_2e3cacae-4946-4efd-a037-a4f7f14a417c"
      unitRef="U_pure">0.085</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_26f2b844-3e09-4694-a82c-6a12e2562d12"
      decimals="-6"
      id="F_9565c2e2-0959-478e-858a-cdc63e6193f4"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_d1dac2fe-3c70-41e5-b9eb-fad2c7cd29cc"
      decimals="-6"
      id="F_5a09bf57-1019-4654-a52b-07262a8442b5"
      unitRef="U_USD">125000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_933bcf2c-5622-4455-af40-79b259c772ba"
      decimals="2"
      id="F_9ba2035f-dfe6-4bae-9fbc-64bc59a83b1b"
      unitRef="U_pure">0.11</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_933bcf2c-5622-4455-af40-79b259c772ba"
      decimals="-6"
      id="F_c03c28bd-f2ca-4df5-b8d9-4ade11f126d2"
      unitRef="U_USD">125000000</cprx:NetSalesRoyaltyThreshold>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_6600b942-c426-460f-b603-ca278e462938">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of FYCOMPA&#xae; (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Base cash payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for pro-rated prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reimbursement on base purchase price&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(ii)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:7.867%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:7.861%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.924082093358947%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million has been paid in cash.&lt;/span&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <cprx:AssetAcquisitionBaseCashPayment
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_02c9f8f7-8b09-40c4-8838-e84cb634fc7b"
      unitRef="U_USD">160000000</cprx:AssetAcquisitionBaseCashPayment>
    <cprx:AssetAcquisitionCashPaidForProRatedPrepaidExpenses
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_08ef7e31-5461-4ad3-bae0-d0d12466b9d9"
      unitRef="U_USD">1576000</cprx:AssetAcquisitionCashPaidForProRatedPrepaidExpenses>
    <cprx:ReimbursementOnBasePurchasePrice
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b"
      unitRef="U_USD">3238000</cprx:ReimbursementOnBasePurchasePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_cb02a000-e0f2-4b6b-a266-10189165015c"
      unitRef="U_USD">5870000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_712bb953-76ee-4940-ac07-9cdb394ae39f"
      unitRef="U_USD">164208000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_d81a6259-f258-4b87-b123-cf96424bc887"
      decimals="-5"
      id="F_470da26c-c0c4-4afe-850a-867899488d26"
      unitRef="U_USD">5900000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_dee76cd0-d3c8-454b-bcae-3403b1879ead">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets (samples)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid commercialization expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for FYCOMPA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued preclinical and clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock>
    <cprx:AssetAcquisitionInventoryCurrent
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_55c221f4-fdff-4564-afec-217761f75c5f"
      unitRef="U_USD">-4100000</cprx:AssetAcquisitionInventoryCurrent>
    <cprx:AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_25c39984-c81d-410c-b8cf-56a28e9cab0d"
      unitRef="U_USD">-130000</cprx:AssetAcquisitionPrepaidExpensesAndOtherCurrentAssets>
    <cprx:AssetAcquistionPrepaidCommercializationFees
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_59c34316-81a9-428f-abd8-d9f7116966b7"
      unitRef="U_USD">-1576000</cprx:AssetAcquistionPrepaidCommercializationFees>
    <cprx:AssetAcquisitionPropertyAndEquipmentNet
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_a183fa3c-b836-44ca-a7d5-6bce801f7a64"
      unitRef="U_USD">-433000</cprx:AssetAcquisitionPropertyAndEquipmentNet>
    <cprx:AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_3fc3e12d-cb1d-4a4d-b7eb-5ec767b45320"
      unitRef="U_USD">-158143000</cprx:AssetAcquisitionLicenseAndAcquiredIntangiblesForFycompa>
    <cprx:AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_b2c667bf-73be-4a9f-844d-0f0516e9cf30"
      unitRef="U_USD">174000</cprx:AssetAcquisitionAccruedPreclinicalAndClinicalTrialExpenses>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_eb22b263-4b66-4ae6-aca9-3f65ad766c21"
      decimals="-3"
      id="F_f45a1ee5-e48b-4b84-863b-ef688d43d5d7"
      unitRef="U_USD">164208000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-6"
      id="F_7d8dc6bc-eeef-41d9-88ce-8470d103da5d"
      unitRef="U_USD">75000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_6e1efb3e-07db-484f-b24b-35978abd908b"
      decimals="2"
      id="F_ff8a8ed9-fa37-4181-92ba-41e1378e95bc"
      unitRef="U_pure">0.05</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_db403975-e67d-4d1a-af52-cc04a99bba23"
      decimals="-6"
      id="F_7dcb8195-52d2-4970-8526-b7c0beb12d49"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_890414d1-43e4-4730-a09e-a3e88bcc0421"
      decimals="2"
      id="F_234467bf-e50c-4183-8097-beea939eb275"
      unitRef="U_pure">0.07</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_50617df4-5ae4-4936-8bfe-fce589850662"
      decimals="-6"
      id="F_2ad62d70-a073-4881-ab0f-7ac471c0b789"
      unitRef="U_USD">100000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_5d47ea25-4a27-4ac3-92dc-45b3e93e5aaa"
      decimals="-6"
      id="F_33a9c8d9-221b-4d5b-8653-31fd185237c3"
      unitRef="U_USD">200000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_2e59e5b9-1570-4e88-8150-2217fe0d9951"
      decimals="2"
      id="F_25edbee8-7cef-423b-8390-60c74514076d"
      unitRef="U_pure">0.09</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_9deb4c05-1297-4d5e-8b6d-c26fba201c41"
      decimals="-6"
      id="F_e75383f5-3b25-4e1f-8622-f7db2d5c687e"
      unitRef="U_USD">200000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_f0c5744c-d1f7-4baa-a2c2-36915bc2d3a4"
      decimals="-6"
      id="F_b6b6adfc-3d95-4e50-b94d-755876b7369f"
      unitRef="U_USD">300000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_ab102545-8c8a-4aa6-9552-8b80e35cb031"
      decimals="2"
      id="F_26c36d27-a1f0-49e8-b87e-e066dfb0115a"
      unitRef="U_pure">0.11</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_044a6030-c57f-4067-b68d-6fdc516643ad"
      decimals="-6"
      id="F_e12e4035-39b4-4181-aded-d7e4f3e3fab7"
      unitRef="U_USD">300000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_6e28630c-cb40-4a69-9fd0-0723bffc77c0"
      decimals="2"
      id="F_0a825508-a2aa-4f8f-8a14-36a5e1ec8210"
      unitRef="U_pure">0.07</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_0d01d582-ddf7-4fdd-a777-e6d1bb59c432"
      decimals="-6"
      id="F_665ad2b9-dede-4449-bb03-82c4a72f8585"
      unitRef="U_USD">250000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_cb97f1c1-6e70-405d-9c80-c07e31f4c5c3"
      decimals="3"
      id="F_d3e62f3b-87bb-450a-92b2-7444ca127c2c"
      unitRef="U_pure">0.085</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_fc37c6a7-8bf0-4bfc-b756-982c3bbeeb03"
      decimals="-6"
      id="F_970026cf-2f5e-4c9b-bf79-12d7c9af51b6"
      unitRef="U_USD">250000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_5ce2a22a-eacd-4fc1-b3cc-795c49539d41"
      decimals="-6"
      id="F_7f300b32-9c4f-4c60-8030-36a5e39b4a24"
      unitRef="U_USD">500000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_06627fb8-dcb2-4630-a05b-d4177e6132d5"
      decimals="2"
      id="F_9ff7767e-e730-4ed8-92d7-a7456ab6ba07"
      unitRef="U_pure">0.10</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_cabcf3fa-e7d3-462b-b114-a34b026905f8"
      decimals="-6"
      id="F_05d2d20c-159f-4599-a9a0-0e228b63da59"
      unitRef="U_USD">500000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_98bd37e3-3099-4a59-86c5-e3462fe02fee"
      decimals="-6"
      id="F_ccaaf0d7-97ae-4731-bc14-6175e2b3ef7c"
      unitRef="U_USD">750000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_64ac5d48-5a11-4212-bd0e-58e8990dba06"
      decimals="2"
      id="F_50417ad8-c333-41a6-b00c-04a7fc14fe63"
      unitRef="U_pure">0.12</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_bc74c57a-97e8-4b7a-bee2-532bf391aa3d"
      decimals="-6"
      id="F_364f53ff-6f6f-4e53-a19b-ee31740d029c"
      unitRef="U_USD">750000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_bd18a35e-b683-418d-b5ad-979c716ec315"
      decimals="-9"
      id="F_3441a6fa-ae24-469a-a492-d447d60d1937"
      unitRef="U_USD">1000000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_76b8de51-684e-42d9-ae4d-1d3e47c58783"
      decimals="2"
      id="F_75452f91-3720-499a-82bd-1f98949ff78a"
      unitRef="U_pure">0.13</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_e44cf128-2b29-4334-ac2f-c4e3a37536a9"
      decimals="-9"
      id="F_ffee60d9-b142-4e5e-a9b8-6eb1c3de24d9"
      unitRef="U_USD">1000000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_fa4b3467-673b-4bda-8917-eb88309ffa19"
      decimals="-9"
      id="F_7c45ff59-6d69-4098-82d1-f15026d0a538"
      unitRef="U_USD">2000000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToNetSales
      contextRef="C_83103e7b-d556-4ade-a0c3-b0b5be918a24"
      decimals="2"
      id="F_90c8c573-533c-45a6-b387-302b1e051254"
      unitRef="U_pure">0.15</cprx:PercentageOfRoyaltyPayableToNetSales>
    <cprx:NetSalesRoyaltyThreshold
      contextRef="C_9b391f02-52d4-4024-84bb-8903cbcabfc3"
      decimals="-9"
      id="F_e77b5972-985d-4c63-b3e7-0a6d249afa3e"
      unitRef="U_USD">2000000000</cprx:NetSalesRoyaltyThreshold>
    <cprx:NetSalesBasedMilestoneToRoyaltyThreshold
      contextRef="C_3d31896d-8a0f-4011-b088-df7fcdb2cc51"
      decimals="-6"
      id="F_ed5df5b6-6aa9-4550-80fc-3a7ba084d3d7"
      unitRef="U_USD">105000000</cprx:NetSalesBasedMilestoneToRoyaltyThreshold>
    <cprx:PercentageOfRoyaltyPayableToSalesBasedMilestone
      contextRef="C_cd25d34a-1eeb-48ca-b321-579fd363c809"
      decimals="2"
      id="F_afa39628-d26a-4ba3-8ca6-abc9fe1a9fd6"
      unitRef="U_pure">0.11</cprx:PercentageOfRoyaltyPayableToSalesBasedMilestone>
    <cprx:ContingentConsiderationArrangementsContingentConsiderationLiability
      contextRef="C_d706713c-2b5e-4983-a2c1-f8ebab1d21ee"
      decimals="-6"
      id="F_995c8603-e7fa-4b6c-93fb-a24f4166d817"
      unitRef="U_USD">50000000</cprx:ContingentConsiderationArrangementsContingentConsiderationLiability>
    <cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="0"
      id="F_7c615a6a-3262-4af0-81d7-0c3ce9549031"
      unitRef="U_shares">1414688</cprx:AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="4"
      id="F_4d0057d7-d1b7-43f4-9473-0f9b63c7ce22"
      unitRef="U_pure">0.1126</cprx:AssetAcquisitionPercentageOfOutstandingOrdinaryShares>
    <cprx:AssetAcquisitionInvestmentSharePrice
      contextRef="C_fd78caae-6fed-4925-9427-26b866495956"
      decimals="3"
      id="F_3f619cff-8561-428d-8736-165c7326349e"
      unitRef="U_ChfShares">9.477</cprx:AssetAcquisitionInvestmentSharePrice>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="C_fd78caae-6fed-4925-9427-26b866495956"
      id="F_82c75c8e-f361-4743-9da8-d0f419c02d39">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the aggregate amount paid for the assets acquired by the Company in connection with the acquisition of AGAMREE&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the strategic equity investment (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial cash payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment in Santhera&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_b209c392-3dc8-4d8f-a620-c1aa9645b385"
      unitRef="U_USD">75000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <cprx:AssetAcquisitionConsiderationTransferredInvestments
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_96b55390-ac60-4d72-9aae-2df3aa121181"
      unitRef="U_USD">13465000</cprx:AssetAcquisitionConsiderationTransferredInvestments>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_8f5a955a-292c-475b-8cbd-58b1f00f9255"
      unitRef="U_USD">6513000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_b514e827-cbec-48dc-859f-0046c78b0ef5"
      unitRef="U_USD">94978000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock
      contextRef="C_fd78caae-6fed-4925-9427-26b866495956"
      id="F_f7ca89fb-fe6d-4e58-9407-3d305a765cf8">&lt;p style="margin-left:7.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total purchase price was allocated to the acquired assets based on their relative fair values, as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and acquired intangibles for AGAMREE&#xae; (vamorolone) (IPR&amp;amp;D)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment in Santhera&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(i)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total purchase consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</cprx:ScheduleOfTotalPurchasePriceWasAllocatedToAcquireAssetsTableTextBlock>
    <cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_d29b7040-4178-4624-a8ac-3f383837d6cf"
      unitRef="U_USD">81513000</cprx:PurchasePriceConsiderationForIntangibleAssetsAcquired>
    <cprx:AssetAcquisitionConsiderationTransferredInvestments
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_6451f60b-cda5-406d-9f2f-9f875cc67c07"
      unitRef="U_USD">13465000</cprx:AssetAcquisitionConsiderationTransferredInvestments>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="-3"
      id="F_3c08d4f9-e455-44c6-9c8e-6d56cc762e10"
      unitRef="U_USD">94978000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <cprx:ClosingMarketPrice
      contextRef="C_9df3359d-d215-4d6a-884d-65563f285107"
      decimals="2"
      id="F_4cab325f-2e82-456b-ae65-fe5913f85674"
      unitRef="U_ChfShares">8.25</cprx:ClosingMarketPrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_6b652f70-c405-4c0f-89a3-daf7d3f4fbaa"
      decimals="4"
      id="F_798f1321-88b0-4562-837e-847c0094b9e6"
      unitRef="U_pure">1.1537</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <cprx:CollaborativeArrangementMilestonePaymentObligation
      contextRef="C_35f0b978-6b4f-4932-a291-aa7d01e6b0d2"
      decimals="-6"
      id="F_668b91ad-483a-4d07-bc4f-ccf6665b265c"
      unitRef="U_USD">36000000</cprx:CollaborativeArrangementMilestonePaymentObligation>
    <cprx:PaymentOnMilestonePayment
      contextRef="C_c664d775-b622-4767-80ce-109ca450ed44"
      decimals="-6"
      id="F_2e2b05b0-a74f-4de4-92e6-e5332069dc31"
      unitRef="U_USD">36000000</cprx:PaymentOnMilestonePayment>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_c664d775-b622-4767-80ce-109ca450ed44"
      decimals="-6"
      id="F_88fd1c12-855a-4218-8202-c996464eff7c"
      unitRef="U_USD">36000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_7da21a6a-c5cf-4df6-ba41-9a958e60d77d"
      id="F_0bff39c7-75ee-4043-9637-f3bd7de2de75">P10Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f6bafff0-5734-4519-8a32-03e781d4cce1">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to income taxes in the U.S. federal jurisdiction and various states jurisdictions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The income tax expense for the years ended December 31, 2024, 2023 and 2022 consists of (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current - Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current - State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred - Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred - State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of income tax expense computed at the statutory federal income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to amounts included in the statements of operations is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Executive compensation limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation windfall&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryovers and the temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets/(liabilities) as of December 31, 2024 and 2023 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December 31, 2024, the Company determined that there is sufficient positive evidence to conclude that it is more likely than not that the above deferred taxes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are realizable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has received several orphan drug designations by the FDA for products currently under development. The orphan drug designations allow the Company to claim increased federal tax credits for certain research and development activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An immaterial amount of interest and penalties were accrued through December 31, 2024 and 2023. The Company&#x2019;s policy is to recognize any related interest or penalties in income tax expense. The Company is not currently under income tax examinations by any tax authorities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_01ce9ec0-b578-40d0-829f-53c95f0315ad">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The income tax expense for the years ended December 31, 2024, 2023 and 2022 consists of (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current - Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current - State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred - Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred - State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_63e54a92-2f76-41f1-a5d9-a16f8f3e652a"
      unitRef="U_USD">52876000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_9658b5d5-ba65-49c2-885a-30380dbc39c0"
      unitRef="U_USD">34975000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_d9f04d18-a68b-4755-892e-4971c7cd7928"
      unitRef="U_USD">12858000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_e29b9ac9-f7b6-4004-9679-472559cae5d2"
      unitRef="U_USD">8951000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_f05060cd-d4ec-41b0-95b8-8b444b8bc764"
      unitRef="U_USD">5931000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_47836630-8d43-4636-8a2d-38986db06331"
      unitRef="U_USD">3877000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_e6f67c17-7eb3-44ae-92f2-1956c77de188"
      unitRef="U_USD">-8442000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_36033ce0-53a4-4f9f-be3f-6e3e045edca7"
      unitRef="U_USD">-16093000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_f4ba13cd-daa2-4bfe-92fe-28ad046ee85c"
      unitRef="U_USD">4739000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_45f82724-eb58-439e-80f8-8e9b09d0081a"
      unitRef="U_USD">-1011000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_150a3f2f-bf06-4d65-bafb-95fea0a0e523"
      unitRef="U_USD">-1712000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_7d6a3c9d-0efe-47e8-a769-a6a1e522cefd"
      unitRef="U_USD">166000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_c111e530-8061-4a58-824b-eec6368e32d3"
      unitRef="U_USD">52374000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_940c19ac-8731-4689-8423-2426d175db64"
      unitRef="U_USD">23101000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_81321662-2726-46e4-9aca-e0451657f67f"
      unitRef="U_USD">21640000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_0435e11a-5aae-4829-8c63-9f993a497f28">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of income tax expense computed at the statutory federal income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to amounts included in the statements of operations is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Executive compensation limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation windfall&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_b004fb18-aa0b-4990-b7aa-57e2a63c7e10"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_7c1654a8-cc03-43cb-b2fd-bf878ff79fcd"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_ee97cd14-4220-4626-9758-2ad2d7d19537"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_88fd8b2f-7d3c-4878-8871-2c253db5a0a0"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_44eef232-2cb8-4cf3-aa61-b196bd2a7d9d"
      unitRef="U_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_4e0a02ba-8840-4f55-9d54-c1155e663418"
      unitRef="U_pure">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_ec73657a-66f5-4b05-9c37-36b050091cd7"
      unitRef="U_pure">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_a5709391-a530-4eea-86b4-1c6937b583d8"
      unitRef="U_pure">0.041</cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary>
    <cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_0cd786fa-ce45-4f73-ac05-29dbee793565"
      unitRef="U_pure">0.026</cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary>
    <cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_50a5bddc-b470-4f69-b6a2-21482f0ab367"
      unitRef="U_pure">0.036</cprx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostIncludingSalary>
    <cprx:EffectiveIncomeTaxCreditsRate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_7107d0c1-6767-4b26-bbb4-33eb30e5ae54"
      unitRef="U_pure">-0.001</cprx:EffectiveIncomeTaxCreditsRate>
    <cprx:EffectiveIncomeTaxCreditsRate
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_7a6d0b0e-9ad7-47e4-a703-049725ad597e"
      unitRef="U_pure">0</cprx:EffectiveIncomeTaxCreditsRate>
    <cprx:EffectiveIncomeTaxCreditsRate
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_a9baeefa-6e4d-49e6-8ed0-e059515e306d"
      unitRef="U_pure">-0.019</cprx:EffectiveIncomeTaxCreditsRate>
    <cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_7a1d0192-05cf-42f7-8298-85fa7b3d02d2"
      unitRef="U_pure">-0.041</cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments>
    <cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_4ce9120e-180a-4efa-af21-5f2044a6bc02"
      unitRef="U_pure">-0.044</cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments>
    <cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_df4b630d-6d81-4038-982b-609f94578db6"
      unitRef="U_pure">-0.056</cprx:EffectiveIncomeTaxRateReconciliationWindfallAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_df5c4512-885f-483d-af76-86aed1980443"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_4705057a-b3a5-4e05-9e07-55c89e7faf72"
      unitRef="U_pure">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_e6986a28-813f-47e3-bb17-a48f1cf1ea1c"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="3"
      id="F_39276a87-c98c-47ed-ba07-e05351090917"
      unitRef="U_pure">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="3"
      id="F_436b54af-171b-4f43-89c1-4c07dee41a0b"
      unitRef="U_pure">0.244</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="3"
      id="F_400fbe75-ca2e-4ae2-bc38-58357c506c65"
      unitRef="U_pure">0.207</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_26ddc9f3-caeb-42dc-a34d-a46b3d616c15">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_4d31b189-09fb-400c-a68e-9f4666782bc8"
      unitRef="U_USD">7950000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_33751ae9-9799-4405-ba7c-3ef5b85f9f90"
      unitRef="U_USD">6473000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_93deef35-a662-4d2c-888c-b25c80e36295"
      unitRef="U_USD">561000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_e578d66d-6559-439f-ae7b-fdf2eabbb9c8"
      unitRef="U_USD">448000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_d0d0153d-ea98-47a5-a64b-20c76a125d51"
      unitRef="U_USD">29167000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d6d54e1d-fa12-4148-bfa0-fddea0da952b"
      unitRef="U_USD">24847000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_5b7d2b41-de6a-4f77-895b-f3b249d1f0f0"
      unitRef="U_USD">4863000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_12a1cb43-facd-4934-ae93-ca6b00f22096"
      unitRef="U_USD">788000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <cprx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_fbd13139-b895-4c31-b1d8-e0bf6d75d7e1"
      unitRef="U_USD">762000</cprx:DeferredTaxAssetsOperatingLeaseLiability>
    <cprx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_70bc5fd6-7723-47ed-8775-372907148607"
      unitRef="U_USD">854000</cprx:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_92979a5b-3501-4401-9a2e-8c34f0e83fc3"
      unitRef="U_USD">5755000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_6c3c0d2a-dacb-4428-be87-e8c94e019dcc"
      unitRef="U_USD">4927000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_175ad65c-e78e-4160-9302-5949af8eb6c2"
      unitRef="U_USD">49058000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_1bec3bfd-3269-4afc-902b-2b37db9ee14f"
      unitRef="U_USD">38337000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_de51a725-4d04-45c6-bd5b-f314e5926a0a"
      unitRef="U_USD">1096000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_f3c667d7-7815-4957-9080-b4e181917534"
      unitRef="U_USD">1023000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_3eeb9b43-1d1f-4529-9a23-eccbe705aef1"
      unitRef="U_USD">668000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_599a806b-f08a-458a-ace3-1775fdb1a368"
      unitRef="U_USD">759000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_38bb70e0-54c4-4cf7-a1ed-1c61b2cbdd35"
      unitRef="U_USD">1312000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_3272d849-7764-4f87-9406-dd130a370f94"
      unitRef="U_USD">11000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_50efe6a6-d9a5-49d7-9674-51bed7db2959"
      unitRef="U_USD">3076000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_d5a9aabe-d1ce-4fa3-ba90-0e09b4ee6bc5"
      unitRef="U_USD">1793000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_29006600-76e4-4dd5-8369-8d3858201e69"
      unitRef="U_USD">45982000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="-3"
      id="F_1ac8d8c9-6d2f-4cdb-b9bf-803bc1258f1f"
      unitRef="U_USD">36544000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-6"
      id="F_12e509a3-5e64-4016-9a52-2826d0170324"
      unitRef="U_USD">46000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f005b099-0914-4a81-8f26-a2478d8442a6">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of authorized preferred stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value per share. At December 31, 2024 and December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock were outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of authorized common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. At December 31, 2024 and 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,879,099&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,121,549&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of common stock were issued and outstanding. Each holder of common stock is entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote of each share of common stock held of record on all matters on which stockholders generally are entitled to vote.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share Repurchases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2021, the Company&#x2019;s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, pursuant to a repurchase plan under Rule 10b-18 of the Securities Act. The share repurchase program commenced on March 22, 2021 and currently expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 22, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were repurchased during the years ended December 31, 2024 and 2023. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were repurchased for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; average price per share).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Shelf Registration Statement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 8, 2023, the Company filed a shelf registration statement with the SEC to sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the 2023 Shelf Registration Statement). The 2023 Shelf Registration Statement (file no. 333-274427) became effective upon filing. On January 9, 2024, the Company completed a public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock, raising net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;140.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Company&#x2019;s 2023 Shelf Registration Statement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_9a7c8fa5-764c-45b7-91df-e8a9f95be610"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_f9bf7d8d-119b-4b8f-8426-9e3a241d82f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_d9f2c9f7-ba76-4803-a9a3-5b33f7d2436e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_e7c0cf6f-e019-4b91-9f32-86413e942c5c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_6266a51a-5726-4488-9372-4599560231b4"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_786d6106-03d8-4cf4-b3b6-bb95179be543"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_5bc084a0-7f09-495e-9db2-c26bf8dfa1bf"
      unitRef="U_shares">120879099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_cae69244-9ced-49c6-879c-a052521f96ad"
      unitRef="U_shares">120879099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_f09e2468-3d6e-4773-841f-ed092623fdb3"
      unitRef="U_shares">107121549</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_58136856-4d09-4bc0-b832-5e2ccb9ba909"
      unitRef="U_shares">107121549</us-gaap:CommonStockSharesIssued>
    <cprx:NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="0"
      id="F_feb5e85e-e3b7-42a0-9344-4e91fff4438f"
      unitRef="U_Vote">1</cprx:NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_010ac7b7-02cf-4f0b-af48-2f5d7263315c"
      decimals="-6"
      id="F_6ac82fd8-d47f-4335-bb0b-2364a796e976"
      unitRef="U_USD">40000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramExpirationDate
      contextRef="C_0b737ad0-5bd1-4089-bd14-fd61307aded2"
      id="F_6984d8de-e4fa-4b13-8841-bb4b0fbacf3b">2025-03-22</srt:StockRepurchaseProgramExpirationDate>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_c8936189-a149-4740-8ce1-e4ecdafa4139"
      decimals="INF"
      id="F_9f53d71f-7688-45a0-bc94-da725903a1d3"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_d2ced546-d65f-4ccc-95d8-be9078a46d22"
      decimals="INF"
      id="F_7f2cfa10-d945-4b3d-8ff1-054242820721"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_a8bfe9ff-b0fb-4cc5-af1e-26ae30574b79"
      decimals="INF"
      id="F_cc7fcbd2-5329-4344-ad5f-4aa918130527"
      unitRef="U_shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-5"
      id="F_d53c1037-ab00-4d65-8192-12ec0d1c3f6a"
      unitRef="U_USD">6900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_b320ab89-d402-4fda-ba09-8b7a2322e127"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.91</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <cprx:MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement
      contextRef="C_6ca67800-b7c3-4502-9b65-2de2fc4bcd0d"
      decimals="INF"
      id="F_9c4cce59-d277-43c9-85a1-c29965b9d189"
      unitRef="U_USD">500000000</cprx:MaximumAmountOfCommonStockThatCanBeIssuedUnderShelfRegistrationStatement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_37c62b10-c734-4e61-bef2-3be60f99493b"
      decimals="INF"
      id="F_78d8cd64-80bb-43e3-970d-090e87487fee"
      unitRef="U_shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_37c62b10-c734-4e61-bef2-3be60f99493b"
      decimals="-5"
      id="F_98894ca2-26bb-4ba3-9965-284cdff9d79c"
      unitRef="U_USD">140700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_c62a25de-26ef-42c8-b6d2-dd247863be8e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Compensation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may issue stock options, restricted stock, stock appreciation rights and restricted stock units (collectively, the Awards) to employees, directors, and consultants of the Company under the 2014 and 2018 Stock Incentive Plans (the 2014 Plan and the 2018 Plan or collectively, the Plans). At December 31, 2024, no shares remain available for future issuance under the 2014 Plan. Under the 2018 Plan, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,000,000&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;shares are reserved for issuance and as of December 31, 2024,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,254,102&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;shares remain available for future issuance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has granted stock options to employees, officers, directors, and consultants generally at exercise prices equal to the market price of the common stock at grant date. Option awards generally vest over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years of continuous service and have contractual terms of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Certain awards provide for accelerated vesting if there is a change in control. The Company issues new shares as shares are required to be delivered upon exercise of outstanding stock options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, options to purchase&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,429,184&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,651,345&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,172,342&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of the Company&#x2019;s common stock were exercised with gross proceeds to the Company of approximately&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. During the years ended December 31, 2024, 2023 and 2022, no options to purchase shares of the Company&#x2019;s common stock were exercised on a &#x201c;cashless&#x201d; basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022 the Company recorded non-cash stock-based compensation expense related to stock options totaling approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options to purchase an aggregate&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,476,946&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,598,535&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,386,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of the Company&#x2019;s common stock to certain of the Company&#x2019;s officers, employees, directors, and consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Compensation (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s Plans for the year ended December 31, 2024 is summarized as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.352%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.658000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.798%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,177,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,476,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised or released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,429,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,076,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.26&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,353,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other information pertaining to stock option activity during the years ended December 31, 2024, 2023 and 2022 was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&#x2013;average fair value of granted stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fair value of vested stock options (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total intrinsic value of exercised stock options&lt;br/&gt;&#160;&#160;&#160;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, there was approximately&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized compensation expense related to non-vested stock option awards granted under the Plans. That cost is expected to be recognized over a weighted average period of approximately&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.72&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to the expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of the Company&#x2019;s common stock. The Company estimates the expected option life for options granted to employees and directors based upon the simplified method. Under this method, the expected life is presumed to be the mid-point between the vesting date and the end of the contractual term. The Company will continue to use the simplified method until it has sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the estimated life of the stock option awards. The expected dividend rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assumptions used during the years ended December 31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.928%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected forfeiture rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Compensation (continued). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2018 Plan, participants may be granted restricted stock units, each of which represents a conditional right to receive shares of common stock in the future. The restricted stock units granted under this plan generally vest ratably over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period. Upon vesting, the restricted stock units will convert into an equivalent number of shares of common stock. The amount of expense relating to the restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant and is amortized on a straight-line basis over the requisite service period. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock unit activity for the year ended December 31, 2024 was as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, the Company recorded non-cash stock-based compensation expense related to restricted stock units totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_f7dcee78-81c0-4134-8c64-8ef572a07ac1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation expense as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_52411d29-db32-4171-9a6f-695291dabbf1"
      decimals="-3"
      id="F_5bbf1a15-e776-40f1-9791-d428d9b3234a"
      unitRef="U_USD">1779000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f627f358-1fdf-4532-a83a-c7e61bed5227"
      decimals="-3"
      id="F_614633d6-c809-48f1-9eb4-431a22a4226b"
      unitRef="U_USD">1481000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_eecd310a-1107-4709-994f-14fd984abc2a"
      decimals="-3"
      id="F_54ac9b2f-cde9-4d70-86df-73842ce651c9"
      unitRef="U_USD">1729000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d9e6daa5-f9e7-4099-87d3-58551fe8710b"
      decimals="-3"
      id="F_fe5c65c6-f5d6-4b9b-a57a-1b70fc15efda"
      unitRef="U_USD">20472000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_96caeb09-9772-4554-9b52-38246d8f8c0e"
      decimals="-3"
      id="F_c222fb97-522a-4367-8745-76f4b8150a89"
      unitRef="U_USD">12769000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d2c50c06-f8b1-40b0-b95b-16454488f954"
      decimals="-3"
      id="F_19a80902-6bae-4510-ab6f-6efd0d3e449b"
      unitRef="U_USD">6178000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_51709493-9e71-4138-a4e9-f0bb87ec1d51"
      unitRef="U_USD">22251000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_df4b41ce-3704-473e-ac96-b577ccc124b7"
      unitRef="U_USD">14250000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_d5d89a9e-fc6f-4511-8661-9d71f4d9bb33"
      unitRef="U_USD">7907000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c"
      decimals="INF"
      id="F_53651961-217e-4497-907d-32cc5e4e3fe2"
      unitRef="U_shares">21000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="C_24eb4963-5a7d-4fe0-aeee-63dc15fb745c"
      decimals="INF"
      id="F_bb3727b0-0da6-4d4b-b47a-5c1a2a969319"
      unitRef="U_shares">2254102</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_699b6fb2-eaae-4c2e-8078-429b64ad536a"
      id="F_ce97501c-17da-4c9f-8cf0-88aca3640058">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a4930a59-5dbe-484a-931a-7075307c98cd"
      id="F_f52d6b72-3723-4051-a1ce-54b6db741c57">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cprx:ContractualTerm
      contextRef="C_ef0ad7eb-05bd-41b1-a942-fd05ddc204bc"
      id="F_892b426c-124c-4e9b-a30d-cdb81a2ea86a">P7Y</cprx:ContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      decimals="INF"
      id="F_32cacc4e-a0b4-452e-aa73-2581c5769f65"
      unitRef="U_shares">3429184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"
      decimals="INF"
      id="F_5f1a7ef7-6d4e-4808-a91a-72e6ffbce9a0"
      unitRef="U_shares">1651345</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"
      decimals="INF"
      id="F_33e9fbb9-5652-472e-87a5-ffd0c06724e7"
      unitRef="U_shares">3172342</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      decimals="-5"
      id="F_eb1a8d42-fac5-4f5e-9c8c-9aeb9cbf14ae"
      unitRef="U_USD">13500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"
      decimals="-5"
      id="F_ec9ff6f6-a76e-49c9-8803-5bfb1f796acf"
      unitRef="U_USD">2800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"
      decimals="-5"
      id="F_6b5ab9f3-bce9-4bca-8bdd-0fadd4791b7a"
      unitRef="U_USD">9600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      decimals="-5"
      id="F_11fa4ac0-347e-4ae4-a358-d06ded222f65"
      unitRef="U_USD">16800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"
      decimals="-5"
      id="F_903c980a-67bc-45fe-b5db-03f137b01f7c"
      unitRef="U_USD">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"
      decimals="-5"
      id="F_19827f42-7bf0-4ba7-9dcb-ca3a8925f015"
      unitRef="U_USD">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      id="F_6eb63435-ad31-4c87-b6f4-e52566b84180">P7Y</cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm
      contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"
      id="F_248b2427-a6c3-4d83-85b8-42d4b532f4b9">P7Y</cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm
      contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"
      id="F_ab1e33bb-853d-4135-8f40-e239a8e52204">P7Y</cprx:ShareBasedCompensationArrangementByShareBasedPaymentsAwardContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      decimals="INF"
      id="F_9725914d-fefa-401b-b2f9-3ff6c66488ea"
      unitRef="U_shares">2476946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6bc48d55-9bd5-4e9b-ab23-61e04cdb0c55"
      decimals="INF"
      id="F_bf904b3e-b743-453e-9dac-59464df034cf"
      unitRef="U_shares">3598535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_4b28d0ca-318f-47d6-9dd3-f809a1620ff2"
      decimals="INF"
      id="F_0ac534e5-4943-48da-82f9-bfbd1ec3cba1"
      unitRef="U_shares">1386500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_e14b7748-122c-486f-a8ac-c2facdbf2c45">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s Plans for the year ended December 31, 2024 is summarized as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.352%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.658000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.258%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.798%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,177,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,476,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised or released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,429,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,076,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.26&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,353,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="INF"
      id="F_4bebd2bb-50c3-4275-af09-918b5bcde7ff"
      unitRef="U_shares">14177488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9966f3a4-7e1a-439f-afa1-d3b19802833e"
      decimals="2"
      id="F_285df4be-1c7e-4ec4-ae78-8d8acb12b9ef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_500a6574-4d14-40ee-9dc7-adc1d6ab95e6"
      unitRef="U_shares">2476946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_f5b7c8a2-161f-4858-be7e-da4817781278"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_47a0d939-85f1-420f-94c2-288a0eaf6343"
      unitRef="U_shares">3429184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_4e6eea53-585e-481a-9c25-3823dc7c3728"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_7717876e-538a-433e-9a2b-0f48ae67790c"
      unitRef="U_shares">137337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_263943b9-9a30-4cae-bf18-4598d46a0518"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_d78f2354-8444-4a61-a8fd-14c0176693b7"
      unitRef="U_shares">11124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_1c79c5e2-4de5-40a6-a79d-286a32924334"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_2245bdcc-3713-465b-ad28-1b57f7982892"
      unitRef="U_shares">13076789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="2"
      id="F_000a5d00-07d6-4093-8b3c-f2b454c8d74f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_a0b5778c-e71f-4d9a-a53c-2bd9176dcd13">P4Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_7151bcff-5e41-4e86-b6cf-aa88ab9406b9"
      unitRef="U_USD">132570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="INF"
      id="F_80a03a72-f380-49f3-851d-77f34c899a4b"
      unitRef="U_shares">7353893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="2"
      id="F_1cbc5751-2671-452d-9665-520e257fb56b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_b6d4f13d-723f-4050-9745-39095f0b72ae">P2Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3d4b4748-9287-4017-aa36-fd0c7a3495c3"
      decimals="-3"
      id="F_565b7d5d-1474-44c8-ab45-3f60573a0a7c"
      unitRef="U_USD">105449000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_737e0f76-a318-4b86-9922-017ac218a2dc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other information pertaining to stock option activity during the years ended December 31, 2024, 2023 and 2022 was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&#x2013;average fair value of granted stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fair value of vested stock options (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total intrinsic value of exercised stock options&lt;br/&gt;&#160;&#160;&#160;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_705e5b3e-4e27-49bb-868f-0204d978534a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_839b82f8-9218-4343-8301-8a948b0e233b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_953f1b21-155b-4384-a664-345001b59cb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_88518ae7-6c82-4ee4-b4b4-865b7e86e4f7"
      unitRef="U_USD">12860000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_a1adf263-da42-4378-beaf-98904cb56d35"
      unitRef="U_USD">8278000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_95d4b720-c91c-449b-9812-56e69c23147f"
      unitRef="U_USD">6096000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-3"
      id="F_8c99e1af-d214-4515-9ce8-8ef9403e7123"
      unitRef="U_USD">53230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-3"
      id="F_0c4d0077-de0f-48c1-8b04-a1beb497fcaa"
      unitRef="U_USD">22265000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-3"
      id="F_c5a88b40-c9d7-4750-8aba-fc6a840a2696"
      unitRef="U_USD">31881000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_65b685f1-a56a-4c6a-bfd2-43a03bc5ac14"
      decimals="-5"
      id="F_8e83966b-1c4b-42b2-a2e1-79a87ba1b5d6"
      unitRef="U_USD">41700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      id="F_fc33afd0-c4ac-433a-aca8-0c33d25168bb">P2Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2e00963d-e006-4d0f-ac53-ce3876d788ae"
      decimals="2"
      id="F_33a3a7e8-d663-4372-891f-62ebc1af6b39"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_d654b1a7-2d5e-4267-a9db-9369417f83c7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assumptions used during the years ended December 31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.928%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.344%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected forfeiture rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="4"
      id="F_2ab28df6-c655-4774-86d8-d30376bfb697"
      unitRef="U_pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="4"
      id="F_e0946551-3712-4f3d-ac1f-a731dad29fce"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="4"
      id="F_937cc3b5-0c5c-4ef0-a20a-b5d44334d8f4"
      unitRef="U_pure">0.0355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="4"
      id="F_e13da491-1f9d-4942-8c42-476b99ae792f"
      unitRef="U_pure">0.0492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="4"
      id="F_cdadbba7-db9e-452d-9b00-b616adf6f81f"
      unitRef="U_pure">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="4"
      id="F_4ed2d206-dc0a-4416-a614-9e9802fea308"
      unitRef="U_pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1"
      id="F_a19e6922-e38e-49d1-a4a8-fa2808df348c">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873"
      id="F_f04a540d-b613-43c6-ae95-c060bcf838a7">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_67b31110-ac66-4aed-a6af-7327aecffdff"
      id="F_71c4c17c-739c-4c50-94af-02f96cac4ec6">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4"
      id="F_bea5f8e4-7b54-43c7-8e12-b49427c2f617">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      id="F_4ad8aa32-d6f0-4f33-8a41-93ef542c0b6c">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c7a980d2-4c33-44ce-88b4-3d0e2c4b97f1"
      decimals="3"
      id="F_3bca5aa8-d64f-40fb-accb-f677c4f0a0d7"
      unitRef="U_pure">0.541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8a4314de-6143-4019-b113-f6c338cc4873"
      decimals="3"
      id="F_2fea209d-fc01-44f3-b8e4-3b96bcd74693"
      unitRef="U_pure">0.615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_67b31110-ac66-4aed-a6af-7327aecffdff"
      decimals="3"
      id="F_0e8db7ed-e78f-432d-bc39-8c338adddd5f"
      unitRef="U_pure">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3f70fd1f-7286-4540-9d8a-bbefc7c2a6a4"
      decimals="3"
      id="F_c811a4f6-00ec-4e9a-8052-650dcc422aca"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_26534ab4-73c0-4cf4-8ab2-a0597988cf75"
      decimals="3"
      id="F_19888765-1a7b-40e4-a703-ca324e8b77da"
      unitRef="U_pure">0.684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5402459a-da02-42fa-9a9a-d8809e5bcd3d"
      decimals="3"
      id="F_cd4574c9-b147-4009-9003-1a252251ba56"
      unitRef="U_pure">0.695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_ddf7f9e3-fe67-42c9-b8e4-266c4b5a407d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_4471de0d-4020-452d-a7f7-34a5d912f47d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_d5872b98-5425-40e9-bc5c-96c2339e7cd9"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_3df61dfe-552d-4174-b081-ca65992801b8"
      unitRef="U_pure">0</cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="2"
      id="F_90e8283f-9420-4c28-98a0-21e401928f40"
      unitRef="U_pure">0</cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="2"
      id="F_c9ae8fb4-899f-45f7-95cb-f96793aba92e"
      unitRef="U_pure">0</cprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_21d5ec19-7e43-465e-bda0-2f4bd1233423"
      id="F_a4ca6025-9a8a-4923-8e2d-91c295c60e70">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_546ce7a2-dfad-4984-8a09-d617ca9f057d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock unit activity for the year ended December 31, 2024 was as follows: &lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nonvested balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a"
      decimals="0"
      id="F_c5e18d29-eb08-419e-b3da-3745242067e7"
      unitRef="U_shares">854459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0d522f43-b8c0-4e85-96f0-57d1a6c46c7a"
      decimals="2"
      id="F_3da288af-e8e1-4e1c-bfaa-5580102159c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="0"
      id="F_49e28e93-f63d-4cee-850d-dcbbde347c81"
      unitRef="U_shares">228029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="2"
      id="F_f80696c3-e58d-4b0b-8af6-bb15ce9838cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="0"
      id="F_746ad4c5-70d6-444d-a0b9-e2e1c583788d"
      unitRef="U_shares">364861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="2"
      id="F_ef69929d-c66b-4193-946c-677546bf2920"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="0"
      id="F_41f40ac3-5bf0-447e-8ba8-68ac4695478e"
      unitRef="U_shares">8667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="2"
      id="F_152d88f7-00e0-447e-bf5e-5ae1084382c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_59962491-572f-40ec-90f4-9cbf4e5124ec"
      decimals="0"
      id="F_abb997e9-d419-41ac-97b8-5df6e61bb5da"
      unitRef="U_shares">708960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_59962491-572f-40ec-90f4-9cbf4e5124ec"
      decimals="2"
      id="F_99631b34-ec72-4319-a7d0-d040e7d389a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a69ed4fb-3dd9-417f-82ad-0fd22db34b85"
      decimals="-5"
      id="F_0bdd6088-cfd4-4a76-8e1f-288741535c20"
      unitRef="U_USD">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_71e97608-057e-403f-bf4b-90daabc11583"
      decimals="-5"
      id="F_5865d1d6-066d-435a-8198-883bb13f21cf"
      unitRef="U_USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_581d19f7-26e1-4059-90f3-b147eba1d7ff"
      decimals="-5"
      id="F_0053bf52-a8fa-4319-b0fd-d13477e2da30"
      unitRef="U_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_4ba3be93-3e2f-4f62-9535-eb30dfc5e454">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;17.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Benefit Plan. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code covering all eligible employees. Subject to certain dollar limits, eligible employees may contribute up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their pre-tax annual compensation to the plan. The Company has elected to make discretionary matching contributions of employee contributions up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of an employee&#x2019;s gross salary. For the years ended December 31, 2024, 2023 and 2022, the Company&#x2019;s matching contributions were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="INF"
      id="F_46c82d5d-b899-4b38-b5a0-8dfae46e68a4"
      unitRef="U_pure">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="2"
      id="F_07518972-d9be-4966-9feb-d5d12dcea13a"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      decimals="-5"
      id="F_0f803f7f-c1ae-44c0-a58b-8cecabde8ce9"
      unitRef="U_USD">1200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_4fe57bf2-1c0e-4606-9fcb-cd5972884260"
      decimals="-5"
      id="F_3b82a050-b5d9-463f-8577-62c378f73e4e"
      unitRef="U_USD">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_709ee500-c24e-46f7-b21a-40c0f4ecc925"
      decimals="-5"
      id="F_ad6fee86-91c3-486f-b3cb-e03bf2e7fcaa"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0b9ed6e7-8979-43e3-b896-652049c5ff71"
      id="F_45a9b073-1255-43fc-9ed0-0e737e586c46">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;18.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent Events. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 8, 2025, the Company announced that it and its licensor, SERB have entered into a Settlement Agreement with Teva. This agreement resolves the patent litigation brought by the Company and SERB in response to Teva&#x2019;s ANDA seeking approval to market a generic version of FIRDAPSE&#xae; (amifampridine) 10 mg tablets prior to the expiration of the applicable patents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the terms of the settlement agreement, Teva has agreed not to market its generic version of FIRDAPSE&#xae; in the U.S. any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of settlements occur. In accordance with the Agreement, the Company/SERB and Teva have terminated all ongoing patent litigation between them that is currently pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE&#xae; patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE&#xae;&#x2019;s Orange Book-listed patents) and Lupin (only for Catalyst&#x2019;s FIRDAPSE&#xae; patent expiring in 2037) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of FIRDAPSE&#xae; to be marketed in the U.S. prior to February 25, 2035.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 17, 2025, Charles B. O&#x2019;Keeffe, an independent member of the Board of Directors (Board) of the Company, advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company&#x2019;s stockholders. Mr. O&#x2019;Keeffe will continue to serve as a member of the Board until the 2025 annual meeting, when his current term will expire. Mr. O&#x2019;Keeffe has been a member of the Board since December 2004 and currently serves as the Board&#x2019;s Lead Independent Director. Mr. O&#x2019;Keeffe&#x2019;s intention to retire from the Board was not the result of any disagreement with the Company on any matter relating to the Company&#x2019;s operations, policies, or practices.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 21, 2025, the Company reported that its sub-licensee in Japan, DyDo, has launched FIRDAPSE&#xae; Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with LEMS.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 13, 2025, Gregg Russo was promoted from VP, Head of Human Resources to Chief Human Resources Officer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_78ea662f-49ac-4435-b86f-eb83afbf77c0"
          xlink:label="F_78ea662f-49ac-4435-b86f-eb83afbf77c0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_266311d6-f055-45aa-95b5-dcb4a1d901ee"
          xlink:label="F_266311d6-f055-45aa-95b5-dcb4a1d901ee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4090fec8-f07e-48d9-bf06-c1a0911f901a"
          xlink:label="F_4090fec8-f07e-48d9-bf06-c1a0911f901a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e1ed2f82-8a48-42fe-af2f-872d5813258d"
          xlink:label="F_e1ed2f82-8a48-42fe-af2f-872d5813258d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a"
          xlink:label="F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_75cfea18-2c8e-42fa-9913-1a0fb70f871c"
          xlink:label="F_75cfea18-2c8e-42fa-9913-1a0fb70f871c"
          xlink:type="locator"/>
        <link:footnote id="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4" xlink:label="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_78ea662f-49ac-4435-b86f-eb83afbf77c0"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_266311d6-f055-45aa-95b5-dcb4a1d901ee"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4090fec8-f07e-48d9-bf06-c1a0911f901a"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e1ed2f82-8a48-42fe-af2f-872d5813258d"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8c79aaa0-6f91-4168-8378-a8e49cf0df8a"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_75cfea18-2c8e-42fa-9913-1a0fb70f871c"
          xlink:to="FNT_35fac935-4dd0-4ee6-acae-243d6061acd4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_d7c32d70-ab8c-43a6-9e28-15f96a90187c"
          xlink:label="F_d7c32d70-ab8c-43a6-9e28-15f96a90187c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ecfad2e5-1ee6-4119-9494-9beb4590c583"
          xlink:label="F_ecfad2e5-1ee6-4119-9494-9beb4590c583"
          xlink:type="locator"/>
        <link:footnote id="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711" xlink:label="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:7.867%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ FYCOMPA&#xae; net product revenue for the year ended December 31, 2023 is for the period between January 24, 2023 (date of acquisition) and December 31, 2023.</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d7c32d70-ab8c-43a6-9e28-15f96a90187c"
          xlink:to="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ecfad2e5-1ee6-4119-9494-9beb4590c583"
          xlink:to="FNT_168ade90-ce8f-4b2b-a6ef-72d35cf45711"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_881659e8-6047-47a8-a6b8-49f8b69ba572"
          xlink:label="F_881659e8-6047-47a8-a6b8-49f8b69ba572"
          xlink:type="locator"/>
        <link:footnote id="FNT_d94b260a-93b1-497f-8e6a-658b6a2becce" xlink:label="FNT_d94b260a-93b1-497f-8e6a-658b6a2becce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGAMREE&#xae; net product revenue for the year ended December 31, 2024 is for the period between March 13, 2024 (date of commercial launch) and December 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_881659e8-6047-47a8-a6b8-49f8b69ba572"
          xlink:to="FNT_d94b260a-93b1-497f-8e6a-658b6a2becce"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c7393005-53d8-43d7-905c-d6e3893fde43"
          xlink:label="F_c7393005-53d8-43d7-905c-d6e3893fde43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f4436702-baa2-4753-b4e4-736cc652c726"
          xlink:label="F_f4436702-baa2-4753-b4e4-736cc652c726"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_40e080c9-fb3e-42e3-9405-9f5355bd8806"
          xlink:label="F_40e080c9-fb3e-42e3-9405-9f5355bd8806"
          xlink:type="locator"/>
        <link:footnote id="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352" xlink:label="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2023, the Company sold FYCOMPA&#xae; through a Transition Service Agreement with a U.S. subsidiary of Eisai. Effective January 1, 2024, FYCOMPA&#xae; is being sold and distributed through a third party logistics (3PL) organization under the Company's contracts.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c7393005-53d8-43d7-905c-d6e3893fde43"
          xlink:to="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f4436702-baa2-4753-b4e4-736cc652c726"
          xlink:to="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_40e080c9-fb3e-42e3-9405-9f5355bd8806"
          xlink:to="FNT_0c1afba6-ca92-47c0-b986-6b8c063b5352"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a"
          xlink:label="F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc"
          xlink:label="F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_47467f83-aca0-4199-b569-0a51fde6c304"
          xlink:label="F_47467f83-aca0-4199-b569-0a51fde6c304"
          xlink:type="locator"/>
        <link:footnote id="FNT_267031a3-8c5f-4907-907e-81096734e04a" xlink:label="FNT_267031a3-8c5f-4907-907e-81096734e04a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive of amortization of intangible assets</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dff004d3-5a1a-4dc6-bdb9-21843a0aa13a"
          xlink:to="FNT_267031a3-8c5f-4907-907e-81096734e04a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9b11ee9a-4e31-4a84-992a-f29b28d6f7dc"
          xlink:to="FNT_267031a3-8c5f-4907-907e-81096734e04a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_47467f83-aca0-4199-b569-0a51fde6c304"
          xlink:to="FNT_267031a3-8c5f-4907-907e-81096734e04a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b"
          xlink:label="F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b"
          xlink:type="locator"/>
        <link:footnote id="FNT_01910dd5-f9ee-4dbb-be39-87408e115701" xlink:label="FNT_01910dd5-f9ee-4dbb-be39-87408e115701" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_da2a6892-eaef-4786-81a0-9d8b5e1f9f7b"
          xlink:to="FNT_01910dd5-f9ee-4dbb-be39-87408e115701"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_cb02a000-e0f2-4b6b-a266-10189165015c"
          xlink:label="F_cb02a000-e0f2-4b6b-a266-10189165015c"
          xlink:type="locator"/>
        <link:footnote id="FNT_781e2edc-d82f-4caf-82fd-b49074646a3a" xlink:label="FNT_781e2edc-d82f-4caf-82fd-b49074646a3a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the full $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million has been paid in cash.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cb02a000-e0f2-4b6b-a266-10189165015c"
          xlink:to="FNT_781e2edc-d82f-4caf-82fd-b49074646a3a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_6451f60b-cda5-406d-9f2f-9f875cc67c07"
          xlink:label="F_6451f60b-cda5-406d-9f2f-9f875cc67c07"
          xlink:type="locator"/>
        <link:footnote id="FNT_a726e936-cd79-4ad5-818b-5d331ff1d6ae" xlink:label="FNT_a726e936-cd79-4ad5-818b-5d331ff1d6ae" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the investment in Santhera was determined based on the closing market price (CHF </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.25</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of Santhera shares and the exchange rate (</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1537</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of CHF to USD on the date the shares were transferred, July 19, 2023. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6451f60b-cda5-406d-9f2f-9f875cc67c07"
          xlink:to="FNT_a726e936-cd79-4ad5-818b-5d331ff1d6ae"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
